White	O	O
coat	O	O
effect	O	O
detected	O	O
using	O	O
self-monitoring	Physical	O
of	Physical	O
blood	Physical	O
pressure	Physical	O
at	Physical	O
home	Physical	O
:	O	O
comparison	O	O
with	O	O
ambulatory	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
home	Physical	O
blood	Physical	O
pressure	Physical	O
(	Physical	O
HBP	Physical	O
)	Physical	O
is	O	O
a	O	O
reliable	O	O
alternative	O	O
to	O	O
ambulatory	Physical	O
blood	Physical	O
pressure	Physical	O
(	Physical	O
ABP	Physical	O
)	Physical	O
for	O	O
the	O	O
detection	O	O
of	O	O
the	O	O
white	O	O
coat	O	O
effect	O	O
(	O	O
WCE	O	O
)	O	O
.	O	O

Hypertensive	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
measure	O	O
HBP	Physical	O
for	O	O
2	O	O
weeks	O	O
or	O	O
ABP	Physical	O
for	O	O
24	O	O
h.	O	O
The	O	O
alternative	O	O
measurement	O	O
was	O	O
then	O	O
performed	O	O
.	O	O

Clinic	O	O
blood	O	O
pressure	O	O
(	O	O
CBP	O	O
)	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
beginning	O	O
and	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Subjects	O	O
with	O	O
a	O	O
difference	O	O
of	O	O
>	O	O
or	O	O
=	O	O
20	O	O
mm	O	O
Hg	O	O
systolic	O	O
or	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mm	O	O
Hg	O	O
diastolic	O	O
BP	O	O
between	O	O
CBP	O	O
and	O	O
awake	O	O
ABP	Physical	O
or	O	O
CBP	O	O
and	O	O
HBP	Physical	O
,	O	O
were	O	O
classified	O	O
as	O	O
clinic	O	O
reactors	O	O
.	O	O

A	O	O
total	O	O
of	O	O
189	O	O
patients	O	O
completed	O	O
the	O	O
study	O	O
(	O	O
79	O	O
on	O	O
stable	O	O
antihypertensive	O	O
treatment	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
magnitude	O	O
of	O	O
WCE	O	O
assessed	O	O
using	O	O
the	O	O
ABP	Physical	O
or	O	O
the	O	O
HBP	Physical	O
method	O	O
(	O	O
mean	O	O
discrepancy	O	O
,	O	O
systolic	O	O
BP	O	O
:	O	O
-1.5	O	O
+/-	O	O
11.7	O	O
mm	O	O
Hg	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-3.2	O	O
,	O	O
0.2	O	O
;	O	O
diastolic	O	O
BP	O	O
:	O	O
0.9	O	O
+/-	O	O
7.0	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-0.1	O	O
,	O	O
1.9	O	O
)	O	O
.	O	O

A	O	O
strong	O	O
association	O	O
existed	O	O
between	O	O
WCE	O	O
calculated	O	O
using	O	O
the	O	O
HBP	O	O
or	O	O
the	O	O
ABP	Physical	O
method	O	O
(	O	O
r	O	O
=	O	O
0.64/0.59	O	O
systolic/diastolic	O	O
,	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
patients	O	O
classified	O	O
as	O	O
clinic	O	O
reactors	O	O
was	O	O
identical	O	O
using	O	O
the	O	O
HBP	Physical	O
or	O	O
the	O	O
ABP	Physical	O
method	O	O
(	O	O
25.9	O	O
%	O	O
)	O	O
.	O	O

Agreement	O	O
between	O	O
methods	O	O
in	O	O
the	O	O
classification	O	O
of	O	O
clinic	O	O
reactors	O	O
was	O	O
found	O	O
in	O	O
147	O	O
patients	O	O
(	O	O
78	O	O
%	O	O
)	O	O
.	O	O

The	O	O
sensitivity	O	O
and	O	O
specificity	O	O
of	O	O
the	O	O
HBP	Physical	O
method	O	O
to	O	O
classify	O	O
correctly	O	O
clinic	O	O
reactors	O	O
(	O	O
ABP	Physical	O
method	O	O
used	O	O
as	O	O
the	O	O
standard	O	O
)	O	O
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
its	O	O
positive	O	O
and	O	O
negative	O	O
predictive	O	O
value	O	O
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
HBP	Physical	O
is	O	O
not	O	O
appropriate	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
ABP	Physical	O
diagnostic	O	O
testing	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
WCE	O	O
.	O	O

Nevertheless	O	O
,	O	O
HBP	Physical	O
appears	O	O
useful	O	O
as	O	O
a	O	O
screening	O	O
test	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
this	O	O
phenomenon	O	O
.	O	O

Optimization	O	O
of	O	O
acid	O	O
suppression	O	O
for	O	O
patients	O	O
with	O	O
peptic	O	O
ulcer	O	O
bleeding	O	O
:	O	O
an	O	O
intragastric	O	O
pH-metry	O	O
study	O	O
with	O	O
omeprazole	Pharmacological	Pharmacological
.	Pharmacological	O

OBJECTIVE	O	O
To	O	O
study	O	O
whether	O	O
an	O	O
intravenous	O	Pharmacological
infusion	O	Pharmacological
dose	O	Pharmacological
of	O	Pharmacological
omeprazole	Pharmacological	Pharmacological
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
during	O	O
24	O	O
h	O	O
can	O	O
be	O	O
subsequently	O	O
reduced	O	O
with	O	O
maintained	O	O
effect	O	O
.	O	O

Second	O	O
,	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
oral	O	Pharmacological
omeprazole	Pharmacological	Pharmacological
20	O	Pharmacological
mg	O	Pharmacological
given	O	Pharmacological
once	O	Pharmacological
or	O	O
twice	O	O
daily	O	O
up	O	O
to	O	O
day	O	O
10	O	O
,	O	O
after	O	O
cessation	O	O
of	O	O
a	O	O
3-day	O	O
intravenous	O	O
infusion	O	O
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
partly	O	O
blinded	O	O
study	O	O
.	O	O

METHODS	O	O
Twelve	O	O
Helicobacter	O	O
pylori	O	O
(	O	O
+	O	O
)	O	O
patients	O	O
and	O	O
12	O	O
H.	O	O
pylori	O	O
(	O	O
-	O	O
)	O	O
subjects	O	O
were	O	O
included	O	O
.	O	O

In	O	O
part	O	O
I	O	O
the	O	O
patients	O	O
received	O	O
omeprazole	Pharmacological	Pharmacological
,	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
,	O	O
during	O	O
24	O	O
h	O	O
followed	O	O
by	O	O
8	O	O
,	O	O
4	O	O
or	O	O
2	O	O
mg/h	O	O
.	O	O

In	O	O
part	O	O
II	O	O
the	O	O
subjects	O	O
received	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
during	O	O
3	O	O
days	O	O
followed	O	O
by	O	O
20	O	O
mg	O	O
omeprazole	Pharmacological	O
orally	O	O
,	O	O
once	O	O
or	O	O
twice	O	O
daily	O	O
until	O	O
day	O	O
10	O	O
.	O	O

Intragastric	O	O
pH	O	O
was	O	O
measured	O	O
.	O	O

RESULTS	O	O
All	O	O
H.	O	O
pylori	O	O
(	O	O
+	O	O
)	O	O
patients	O	O
showed	O	O
a	O	O
rapid	O	O
increase	O	O
of	O	O
intragastric	O	O
pH	O	O
with	O	O
a	O	O
mean	O	O
intragastric	O	O
pH	O	O
of	O	O
6.7	O	O
during	O	O
the	O	O
second	O	O
half	O	O
of	O	O
the	O	O
first	O	O
day	O	O
.	O	O

After	O	O
the	O	O
subsequent	O	O
dose	O	O
reduction	O	O
,	O	O
the	O	O
mean	O	O
pH	O	O
decreased	O	O
to	O	O
6.1-6.2	O	O
.	O	O

Patients	O	O
continuing	O	O
on	O	O
8	O	O
mg/h	O	O
showed	O	O
the	O	O
best	O	O
results	O	O
.	O	O

Likewise	O	O
,	O	O
all	O	O
H.	O	O
pylori	O	O
(	O	O
-	O	O
)	O	O
subjects	O	O
showed	O	O
a	O	O
rapid	O	O
and	O	O
sustained	O	O
reduction	O	O
of	O	O
intragastric	O	O
acidity	O	O
during	O	O
the	O	O
infusion	O	O
.	O	O

Subsequent	O	O
dose	O	O
reduction	O	O
to	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
led	O	O
to	O	O
a	O	O
stable	O	O
fraction	O	O
of	O	O
time	O	O
with	O	O
pH	O	O
>	O	O
3	O	O
of	O	O
72	O	O
%	O	O
.	O	O

CONCLUSIONS	O	O
Omeprazole	Pharmacological	Pharmacological
given	O	O
as	O	O
a	O	O
continuous	O	O
infusion	O	O
of	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
for	O	O
72	O	O
h	O	O
followed	O	O
by	O	O
omeprazole	Pharmacological	Pharmacological
20	O	O
mg	O	O
once	O	O
daily	O	O
raised	O	O
the	O	O
intragastric	O	O
pH	O	O
to	O	O
and	O	O
above	O	O
levels	O	O
alleged	O	O
to	O	O
allow	O	O
haemostasis	O	O
in	O	O
patients	O	O
with	O	O
peptic	O	O
ulcer	O	O
bleeding	O	O
and	O	O
subsequent	O	O
healing	O	O
of	O	O
the	O	O
ulcer	O	O
.	O	O

Learning	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
:	O	O
does	O	O
comparing	O	O
with	O	O
inequality	O	O
symbols	O	O
help	O	O
?	O	O
This	O	O
study	O	O
investigated	O	O
whether	O	O
instruction	Other	O
that	Other	O
involves	Other	O
comparing	Other	O
the	Other	O
equal	Psychological	O
sign	Psychological	O
with	Other	O
other	Other	O
relational	Other	O
symbols	Other	O
is	O	O
more	O	O
effective	O	O
at	O	O
imparting	O	O
a	O	O
relational	O	O
interpretation	O	O
of	O	O
the	O	O
equal	Psychological	O
sign	Psychological	O
than	O	O
instruction	Other	O
about	Other	O
the	Other	O
equal	Psychological	O
sign	Psychological	O
alone	Other	O
.	O	O

Third-	O	O
and	O	O
fourth-grade	O	O
students	O	O
in	O	O
a	O	O
comparing	Educational	O
symbols	Educational	O
group	Educational	O
learned	Educational	O
about	Educational	O
the	Educational	O
greater	Educational	O
than	Educational	O
,	Educational	O
less	Educational	O
than	Educational	O
,	Educational	O
and	Educational	O
equal	Psychological	O
signs	Psychological	O
and	Educational	O
had	Educational	O
the	Educational	O
opportunity	Educational	O
to	Educational	O
compare	Educational	O
the	Educational	O
inequality	Educational	O
symbols	Educational	O
with	Educational	O
the	Educational	O
equal	Psychological	O
sign	Psychological	O
.	O	O

Students	O	O
in	O	O
an	O	O
equal	Psychological	O
sign	Psychological	O
group	Educational	O
learned	Educational	O
about	Educational	O
the	Educational	O
equal	Psychological	O
sign	Psychological	O
only	Educational	O
.	Educational	O

A	O	O
third	O	O
group	O	O
of	O	O
students	O	O
served	O	O
as	O	O
a	O	O
control	Control	O
group	Control	O
.	O	O

Three	O	O
aspects	O	O
of	O	O
students	O	O
'	O	O
knowledge	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
lesson	O	O
:	O	O
(	O	O
a	O	O
)	O	O
conceptual	O	O
understanding	O	O
of	O	O
the	O	O
equal	O	O
sign	O	O
,	O	O
(	O	O
b	O	O
)	O	O
equation	O	O
encoding	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
problem	O	O
solving	O	O
.	O	O

Students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
showed	O	O
greater	O	O
gains	O	O
in	O	O
conceptual	O	O
understanding	O	O
from	O	O
pretest	O	O
to	O	O
posttest	O	O
than	O	O
students	O	O
in	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
,	O	O
and	O	O
students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
also	O	O
scored	O	O
higher	O	O
on	O	O
a	O	O
posttest	O	O
that	O	O
assessed	O	O
knowledge	O	O
about	O	O
inequality	O	O
symbols	O	O
and	O	O
inequality	O	O
problem	O	O
solving	O	O
.	O	O

Thus	O	O
,	O	O
they	O	O
learned	O	O
about	O	O
three	O	O
symbols	O	O
in	O	O
the	O	O
same	O	O
amount	O	O
of	O	O
time	O	O
as	O	O
other	O	O
students	O	O
learned	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
alone	O	O
or	O	O
not	O	O
at	O	O
all	O	O
.	O	O

Therefore	O	O
,	O	O
an	O	O
instructional	O	O
approach	O	O
involving	O	O
comparison	O	O
can	O	O
be	O	O
an	O	O
effective	O	O
tool	O	O
for	O	O
learning	O	O
about	O	O
concepts	O	O
in	O	O
mathematics	O	O
.	O	O

Shorter	O	O
treatment	O	O
for	O	O
vaginal	O	O
candidosis	O	O
:	O	O
comparison	O	O
between	O	O
single-dose	O	O
oral	O	O
fluconazole	Pharmacological	Pharmacological
and	O	O
three-day	O	O
treatment	O	O
with	O	O
local	O	O
miconazole	Pharmacological	O
.	Pharmacological	O

Fluconazole	Pharmacological	Pharmacological
is	O	O
an	O	O
effective	O	O
,	O	O
simple	O	O
and	O	O
safe	O	O
,	O	O
although	O	O
slightly	O	O
expensive	O	O
,	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	O	O
candidosis	O	O
.	O	O

Single-dose	O	O
fluconazole	Pharmacological	Pharmacological
(	O	Pharmacological
150	O	Pharmacological
mg	O	Pharmacological
)	O	Pharmacological
administered	O	O
orally	O	O
in	O	O
capsule	O	O
form	O	O
was	O	O
compared	O	O
with	O	O
three-day	O	O
local	O	O
treatment	O	O
with	O	O
miconazole	Pharmacological	Pharmacological
pessaries	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	O	O
candidosis	O	O
in	O	O
a	O	O
randomized	O	O
study	O	O
in	O	O
Finland	O	O
.	O	O

Cure	O	O
rates	O	O
were	O	O
good	O	O
(	O	O
>	O	O
80	O	O
%	O	O
)	O	O
in	O	O
randomized	O	O
patient	O	O
groups	O	O
assessed	O	O
both	O	O
clinically	O	O
and	O	O
by	O	O
the	O	O
results	O	O
of	O	O
yeast	O	O
cultures	O	O
.	O	O

Oral	O	O
administration	O	O
was	O	O
preferred	O	O
to	O	O
local	O	O
therapy	O	O
by	O	O
patients	O	O
in	O	O
both	O	O
the	O	O
miconazole	Pharmacological	O
and	O	O
fluconazole	Pharmacological	O
groups	O	O
.	O	O

For	O	O
the	O	O
time	O	O
being	O	O
,	O	O
fluconazole	Pharmacological	O
is	O	O
not	O	O
recommended	O	O
for	O	O
use	O	O
during	O	O
pregnancy	O	O
or	O	O
lactation	O	O
.	O	O

Maternal	O	O
breast-milk	O	O
and	O	O
intestinal	O	O
bifidobacteria	O	O
guide	O	O
the	O	O
compositional	O	O
development	O	O
of	O	O
the	O	O
Bifidobacterium	O	O
microbiota	O	O
in	O	O
infants	O	O
at	O	O
risk	O	O
of	O	O
allergic	O	O
disease	O	O
.	O	O

BACKGROUND	O	O
The	O	O
sources	O	O
and	O	O
the	O	O
impact	O	O
of	O	O
maternal	O	O
bacteria	O	O
on	O	O
the	O	O
initial	O	O
inoculum	O	O
of	O	O
the	O	O
intestinal	O	O
microflora	O	O
of	O	O
newborn	O	O
infants	O	O
remain	O	O
elusive	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
assess	O	O
the	O	O
association	O	O
between	O	O
maternal	O	O
breast-milk	O	O
and	O	O
fecal	O	O
bifidobacteria	O	O
and	O	O
infants	O	O
'	O	O
fecal	O	O
bifidobacteria	O	O
.	O	O

METHODS	O	O
Sixty-one	O	O
mother-infant	O	O
pairs	O	O
were	O	O
included	O	O
,	O	O
special	O	O
emphasis	O	O
being	O	O
placed	O	O
on	O	O
the	O	O
maternal	O	O
allergic	O	O
status	O	O
.	O	O

Bifidobacteria	O	O
were	O	O
analysed	O	O
by	O	O
a	O	O
direct	O	O
PCR	O	O
method	O	O
in	O	O
fecal	O	O
samples	O	O
from	O	O
mothers	O	O
at	O	O
30-35	O	O
weeks	O	O
of	O	O
gestation	O	O
and	O	O
from	O	O
infants	O	O
at	O	O
1	O	O
month	O	O
of	O	O
age	O	O
and	O	O
from	O	O
breast-milk	Physical	O
samples	Physical	O
1	O	O
month	O	O
post-partum	O	O
.	O	O

RESULTS	O	O
Fecal	O	O
Bifidobacterium	O	O
adolescentis	O	O
and	O	O
Bifidobacterium	O	O
bifidum	O	O
colonization	O	O
frequencies	O	O
and	O	O
counts	O	O
among	O	O
mother-infant	O	O
pairs	O	O
correlated	O	O
significantly	O	O
(	O	O
P=0.005	O	O
and	O	O
0.02	O	O
for	O	O
frequencies	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
P=0.002	O	O
and	O	O
0.01	O	O
for	O	O
counts	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Only	O	O
infants	O	O
of	O	O
allergic	O	O
,	O	O
atopic	O	O
mothers	O	O
were	O	O
colonized	O	O
with	O	O
B.	O	O
adolescentis	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
breast-milk	O	O
samples	O	O
contained	O	O
bifidobacteria	O	O
[	O	O
median	O	O
1.4	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
;	O	O
interquartile	O	O
range	O	O
(	O	O
IQR	O	O
)	O	O
48.7-3.8	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
]	O	O
.	O	O

Bifidobacterium	O	O
longum	O	O
was	O	O
the	O	O
most	O	O
frequently	O	O
detected	O	O
species	O	O
in	O	O
breast-milk	O	O
.	O	O

Allergic	O	O
mothers	O	O
had	O	O
significantly	O	O
lower	O	O
amounts	O	O
of	O	O
bifidobacteria	O	O
in	O	O
breast-milk	O	O
compared	O	O
with	O	O
non-allergic	O	O
mothers	O	O
[	O	O
median	O	O
1.3	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
(	O	O
IQR	O	O
22.4-3.0	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
)	O	O
vs.	O	O
5.6	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
(	O	O
1.8	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
-1.8	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
(	O	O
P=0.004	O	O
)	O	O
]	O	O
,	O	O
and	O	O
their	O	O
infants	O	O
had	O	O
concurrently	O	O
lower	O	O
counts	O	O
of	O	O
bifidobacteria	O	O
in	O	O
feces	O	O
[	O	O
3.9	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
bacterial	O	O
cells/g	O	O
(	O	O
IQR	O	O
6.5	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
-1.5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
)	O	O
in	O	O
infants	O	O
of	O	O
allergic	O	O
mothers	O	O
,	O	O
vs.	O	O
2.5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
bacterial	O	O
cells/g	O	O
(	O	O
6.5	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
-3.2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
)	O	O
in	O	O
infants	O	O
of	O	O
non-allergic	O	O
mothers	O	O
,	O	O
P=0.013	O	O
]	O	O
.	O	O

CONCLUSIONS	O	O
Breast-milk	O	O
contains	O	O
significant	O	O
numbers	O	O
of	O	O
bifidobacteria	O	O
and	O	O
the	O	O
maternal	O	O
allergic	O	O
status	O	O
further	O	O
deranges	O	O
the	O	O
counts	O	O
of	O	O
bifidobacteria	O	O
in	O	O
breast-milk	O	O
.	O	O

Maternal	O	O
fecal	O	O
and	O	O
breast-milk	O	O
bifidobacterial	O	O
counts	O	O
impacted	O	O
on	O	O
the	O	O
infants	O	O
'	O	O
fecal	O	O
Bifidobacterium	O	O
levels	O	O
.	O	O

Breast-milk	O	O
bacteria	O	O
should	O	O
thus	O	O
be	O	O
considered	O	O
an	O	O
important	O	O
source	O	O
of	O	O
bacteria	O	O
in	O	O
the	O	O
establishment	O	O
of	O	O
infantile	O	O
intestinal	O	O
microbiota	O	O
.	O	O

Hydrogen	Pharmacological	O
peroxide	Pharmacological	O
mouth	Pharmacological	O
rinse	Pharmacological	O
:	O	O
an	O	O
analgesic	O	O
post-tonsillectomy	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
analgesic	O	O
efficacy	O	O
of	O	O
hydrogen	Pharmacological	Pharmacological
peroxide	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
H2O2	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
mouth	Pharmacological	O
rinse	Pharmacological	O
with	O	O
control	Control	O
for	O	O
post-tonsillectomy	O	O
pain	O	O
management	O	O
.	O	O

DESIGN	O	O
Double-blinded	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
clinical	O	O
trial	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Thirty-seven	O	O
patients	O	O
from	O	O
5	O	O
to	O	O
14	O	O
years	O	O
old	O	O
undergoing	O	O
electrocautery	Surgical	O
tonsillectomy	Surgical	O
were	O	O
randomized	O	O
to	O	O
either	O	O
the	O	O
H2O2	Pharmacological	O
mouth	Pharmacological	O
rinse	Pharmacological	O
or	O	O
the	O	O
water	Control	O
rinse	Control	O
(	Control	O
control	Control	O
)	Control	O
group	Control	O
.	O	O

For	O	O
14	O	O
days	O	O
,	O	O
patients	O	O
recorded	O	O
pain	O	O
levels	O	O
twice	O	O
daily	O	O
using	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
.	O	O

Analgesic	O	O
uses	O	O
,	O	O
as	O	O
well	O	O
as	O	O
any	O	O
complications	O	O
,	O	O
were	O	O
also	O	O
noted	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

RESULTS	O	O
Thirty-seven	O	O
patients	O	O
completed	O	O
the	O	O
study	O	O
,	O	O
21	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
and	O	O
16	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Mean	O	O
postoperative	O	O
days	O	O
of	O	O
pain	O	O
were	O	O
10.3	O	O
and	O	O
8.3	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
differed	O	O
significantly	O	O
(	O	O
p	O	O
=	O	O
.008	O	O
)	O	O
.	O	O

Mean	O	O
postoperative	O	O
days	O	O
of	O	O
analgesic	O	O
use	O	O
were	O	O
9.0	O	O
and	O	O
6.7	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
differed	O	O
significantly	O	O
(	O	O
p	O	O
=	O	O
.005	O	O
)	O	O
.	O	O

Only	O	O
one	O	O
incidence	O	O
of	O	O
postoperative	O	O
hemorrhage	O	O
occurred	O	O
in	O	O
the	O	O
study	O	O
group	O	O
.	O	O

CONCLUSION	O	O
In	O	O
our	O	O
study	O	O
,	O	O
the	O	O
H2O2	Pharmacological	O
mouth	Pharmacological	O
rinse	Pharmacological	O
does	O	O
not	O	O
provide	O	O
a	O	O
better	O	O
analgesic	O	O
effect	O	O
than	O	O
the	O	O
water	O	O
rinse	O	O
for	O	O
post-tonsillectomy	O	O
pain	O	O
relief	O	O
.	O	O

Oral	O	O
health	O	O
impacts	O	O
on	O	O
daily	O	O
living	O	O
related	O	O
to	O	O
four	O	O
different	O	O
treatment	O	O
protocols	O	O
for	O	O
chronic	O	O
periodontitis	O	O
.	O	O

BACKGROUND	O	O
The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
evaluate	O	O
the	O	O
oral	O	O
health	O	O
impacts	O	O
perceived	O	O
by	O	O
patients	O	O
submitted	O	O
to	O	O
different	O	O
treatments	O	O
of	O	O
chronic	O	O
periodontitis	O	O
and	O	O
their	O	O
association	O	O
with	O	O
clinical	O	O
parameters	O	O
.	O	O

METHODS	O	O
Sixty	O	O
patients	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
the	O	O
following	O	O
therapeutic	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
treated	O	O
with	O	O
full-mouth	Physical	Physical
scaling	Physical	Physical
and	O	Physical
root	Physical	Physical
planing	Physical	Physical
(	Physical	Physical
SRP	Physical	Physical
)	Physical	Physical
;	O	O
test	O	O
1	O	O
,	O	O
treated	O	O
with	O	O
SRP	Surgical	Pharmacological
and	O	Pharmacological
400	O	Pharmacological
mg	O	Pharmacological
systemically	O	Pharmacological
administered	O	Pharmacological
metronidazole	Pharmacological	Pharmacological
(	O	O
MET	O	O
)	O	O
three	O	O
times	O	O
per	O	O
day	O	O
for	O	O
10	O	O
days	O	O
;	O	O
test	O	O
2	O	O
,	O	O
treated	O	O
with	O	O
SRP	Physical	O
and	O	O
professional	Physical	O
supragingival	Physical	O
plaque	Physical	O
removal	Physical	O
(	Physical	O
PP	Physical	O
)	Physical	O
every	O	O
week	O	O
for	O	O
3	O	O
months	O	O
;	O	O
and	O	O
test	O	O
3	O	O
,	O	O
treated	O	O
with	O	O
SRP	Surgical	O
and	O	O
MET	Pharmacological	O
plus	O	O
PP	O	O
.	O	O

Clinical	O	O
periodontal	O	O
measurements	O	O
and	O	O
data	O	O
regarding	O	O
patients	O	O
'	O	O
oral	O	O
health	O	O
impacts	O	O
(	O	O
perceived	O	O
impacts	O	O
on	O	O
bleeding	O	O
gums	O	O
,	O	O
gingival	O	O
recession	O	O
,	O	O
sensitivity	O	O
to	O	O
cold	O	O
,	O	O
packing	O	O
foods	O	O
,	O	O
aesthetics	O	O
,	O	O
bad	O	O
breath	O	O
,	O	O
and	O	O
tooth	O	O
mobility	O	O
)	O	O
were	O	O
collected	O	O
at	O	O
baseline	O	O
and	O	O
3	O	O
months	O	O
after	O	O
therapy	O	O
.	O	O

RESULTS	O	O
All	O	O
groups	O	O
presented	O	O
significant	O	O
improvement	O	O
in	O	O
oral	O	O
health	O	O
perceived	O	O
impacts	O	O
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
improvement	O	O
of	O	O
oral	O	O
health	O	O
impacts	O	O
among	O	O
groups	O	O
subjected	O	O
to	O	O
different	O	O
treatments	O	O
.	O	O

The	O	O
clinical	O	O
data	O	O
of	O	O
percentage	O	O
of	O	O
deep	O	O
probing	O	O
depth	O	O
,	O	O
deep	O	O
clinical	O	O
attachment	O	O
level	O	O
,	O	O
and	O	O
bleeding	O	O
on	O	O
probing	O	O
were	O	O
found	O	O
to	O	O
be	O	O
correlated	O	O
significantly	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

CONCLUSIONS	O	O
Periodontal	Physical	O
treatment	Physical	O
leads	O	O
to	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
self-perceived	O	O
impacts	O	O
regardless	O	O
of	O	O
the	O	O
non-surgical	O	O
treatment	O	O
protocol	O	O
employed	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
clinical	O	O
data	O	O
were	O	O
associated	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

Randomized	O	O
trial	O	O
of	O	O
fenretinide	Pharmacological	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
using	O	O
DNA	O	O
flow	O	O
cytometry	O	O
as	O	O
an	O	O
intermediate	O	O
end	O	O
point	O	O
.	O	O

Retinoids	O	O
have	O	O
shown	O	O
a	O	O
potential	O	O
activity	O	O
in	O	O
preventing	O	O
tumor	O	O
recurrence	O	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
synthetic	Pharmacological	O
retinoid	Pharmacological	O
fenretinide	Pharmacological	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
using	O	O
DNA	O	O
flow	O	O
cytometry	O	O
and	O	O
conventional	O	O
cytology	O	O
as	O	O
surrogate	O	O
biomarkers	O	O
.	O	O

A	O	O
total	O	O
of	O	O
99	O	O
subjects	O	O
with	O	O
resected	O	O
superficial	O	O
bladder	O	O
cancer	O	O
(	O	O
pTa	O	O
,	O	O
pT1	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
fenretinide	Pharmacological	O
(	O	O
200	O	O
mg	O	O
day	O	O
p.o	O	O
.	O	O

for	O	O
24	O	O
months	O	O
)	O	O
or	O	O
no	Control	Control
intervention	Control	Control
.	O	O

Cystoscopy	O	O
and	O	O
bladder	O	O
washing	O	O
for	O	O
DNA	O	O
flow	O	O
cytometry	O	O
end	O	O
points	O	O
(	O	O
proportion	O	O
of	O	O
DNA	O	O
aneuploid	O	O
histograms	O	O
,	O	O
hyperdiploid	O	O
fraction	O	O
,	O	O
and	O	O
percentage	O	O
of	O	O
apoptotic	O	O
cells	O	O
)	O	O
and	O	O
proportion	O	O
of	O	O
abnormal	O	O
cytological	O	O
examinations	O	O
were	O	O
repeated	O	O
every	O	O
4	O	O
months	O	O
for	O	O
up	O	O
to	O	O
36	O	O
months	O	O
.	O	O

The	O	O
primary	O	O
study	O	O
end	O	O
point	O	O
was	O	O
the	O	O
proportion	O	O
of	O	O
DNA	O	O
aneuploid	O	O
histograms	O	O
after	O	O
12	O	O
months	O	O
.	O	O

This	O	O
figure	O	O
was	O	O
48.9	O	O
%	O	O
in	O	O
the	O	O
fenretinide	Pharmacological	O
arm	O	O
and	O	O
41.9	O	O
%	O	O
in	O	O
the	O	O
control	O	O
arm	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
1.16	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.44-3.07	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
any	O	O
other	O	O
response	O	O
biomarker	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
up	O	O
to	O	O
36	O	O
months	O	O
,	O	O
nor	O	O
was	O	O
any	O	O
biomarker	O	O
able	O	O
to	O	O
predict	O	O
recurrence	O	O
risk	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
was	O	O
comparable	O	O
between	O	O
the	O	O
arms	O	O
(	O	O
27	O	O
events	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
versus	O	O
21	O	O
in	O	O
the	O	O
control	O	O
arm	O	O
;	O	O
P	O	O
=	O	O
0.36	O	O
)	O	O
.	O	O

Twelve	O	O
subjects	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
complained	O	O
of	O	O
diminished	O	O
dark	O	O
adaptability	O	O
,	O	O
and	O	O
nine	O	O
subjects	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
versus	O	O
one	O	O
control	O	O
subject	O	O
had	O	O
mild	O	O
dermatological	O	O
alterations	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
fenretinide	O	O
showed	O	O
a	O	O
lack	O	O
of	O	O
effect	O	O
on	O	O
the	O	O
DNA	O	O
content	O	O
distribution	O	O
and	O	O
the	O	O
morphology	O	O
of	O	O
urothelial	O	O
cells	O	O
obtained	O	O
in	O	O
serial	O	O
bladder	O	O
washings	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
was	O	O
comparable	O	O
between	O	O
groups	O	O
.	O	O

Because	O	O
our	O	O
data	O	O
are	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
predictivity	O	O
of	O	O
the	O	O
selected	O	O
biomarkers	O	O
,	O	O
additional	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
assess	O	O
the	O	O
activity	O	O
of	O	O
fenretinide	O	O
in	O	O
preventing	O	O
bladder	O	O
cancer	O	O
.	O	O

Partial	O	O
depletion	O	O
of	O	O
tissue	O	O
factor	O	O
pathway	O	O
inhibitor	O	O
during	O	O
subcutaneous	O	O
administration	O	O
of	O	O
unfractionated	O	O
heparin	Pharmacological	O
,	O	O
but	O	O
not	O	O
with	O	O
two	O	O
low	O	O
molecular	O	O
weight	O	O
heparins	O	O
.	O	O

Tissue	O	O
factor	O	O
pathway	O	O
inhibitor	O	O
(	O	O
TFPI	O	O
)	O	O
is	O	O
released	O	O
to	O	O
circulating	O	O
blood	O	O
after	O	O
intravenous	O	O
(	O	O
i.v	O	O
.	O	O

)	O	O
and	O	O
subcutaneous	O	O
(	O	O
s.c.	O	O
)	O	O
injections	O	O
of	O	O
heparins	O	O
,	O	O
and	O	O
may	O	O
thus	O	O
contribute	O	O
to	O	O
the	O	O
antithrombotic	O	O
effect	O	O
of	O	O
heparins	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
shown	O	O
that	O	O
total	O	O
TFPI	O	O
activity	O	O
,	O	O
plasma	O	O
free	O	O
TFPI	O	O
antigen	O	O
,	O	O
and	O	O
heparin	O	O
releasable	O	O
TFPI	O	O
were	O	O
partially	O	O
depleted	O	O
during	O	O
repeated	O	O
and	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
of	O	O
unfractionated	Pharmacological	O
heparin	Pharmacological	O
(	O	O
UFH	O	O
)	O	O
,	O	O
but	O	O
not	O	O
during	O	O
s.c.	O	O
treatment	O	O
with	O	O
a	O	O
low	O	O
molecular	O	O
weight	O	O
heparin	O	O
(	O	O
LMWH	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
may	O	O
be	O	O
attributed	O	O
to	O	O
a	O	O
different	O	O
mode	O	O
of	O	O
action	O	O
or	O	O
the	O	O
different	O	O
mode	O	O
of	O	O
administration	O	O
.	O	O

In	O	O
the	O	O
present	O	O
randomized	O	O
cross-over	O	O
study	O	O
,	O	O
s.c.	O	O
administration	O	O
of	O	O
therapeutic	O	O
doses	O	O
of	O	O
UFH	Pharmacological	O
was	O	O
compared	O	O
with	O	O
s.c.	O	O
administration	O	O
of	O	O
two	O	O
LMWHs	Pharmacological	O
.	O	O

12	O	O
healthy	O	O
male	O	O
volunteers	O	O
were	O	O
treated	O	O
for	O	O
3	O	O
d	O	O
with	O	O
UFH	Pharmacological	O
,	O	O
250	O	O
U/kg	O	O
twice	O	O
daily	O	O
,	O	O
dalteparin	Pharmacological	Pharmacological
,	O	O
200	O	O
U/kg	O	O
once	O	O
daily	O	O
,	O	O
and	O	O
enoxaparin	Pharmacological	Pharmacological
,	O	O
1.5	O	O
mg/kg	O	O
once	O	O
daily	O	O
.	O	O

Six	O	O
participants	O	O
were	O	O
also	O	O
treated	O	O
with	O	O
UFH	Pharmacological	O
,	O	O
300	O	O
U/kg	O	O
once	O	O
daily	O	O
.	O	O

On	O	O
day	O	O
5	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
either	O	O
drug	O	O
was	O	O
given	O	O
.	O	O

Peak	O	O
levels	O	O
of	O	O
total	O	O
TFPI	O	O
activity	O	O
and	O	O
free	O	O
TFPI	O	O
antigen	O	O
were	O	O
detected	O	O
1	O	O
h	O	O
after	O	O
injection	O	O
,	O	O
whereas	O	O
maximal	O	O
prolongation	O	O
of	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
time	O	O
(	O	O
APTT	O	O
)	O	O
and	O	O
peak	O	O
levels	O	O
of	O	O
anti-factor	O	O
Xa	O	O
activity	O	O
and	O	O
anti-factor	O	O
IIa	O	O
activity	O	O
were	O	O
detected	O	O
after	O	O
4	O	O
h.	O	O
On	O	O
UFH	Pharmacological	O
administered	O	O
twice	O	O
daily	O	O
,	O	O
free	O	O
TFPI	O	O
antigen	O	O
decreased	O	O
by	O	O
44	O	O
%	O	O
from	O	O
baseline	O	O
level	O	O
before	O	O
the	O	O
first	O	O
injection	O	O
on	O	O
day	O	O
1	O	O
to	O	O
pre-injection	O	O
level	O	O
on	O	O
day	O	O
5	O	O
.	O	O

On	O	O
UFH	Pharmacological	O
administered	O	O
once	O	O
daily	O	O
,	O	O
basal	O	O
free	O	O
TFPI	O	O
antigen	O	O
decreased	O	O
by	O	O
50	O	O
%	O	O
,	O	O
56	O	O
%	O	O
and	O	O
27	O	O
%	O	O
on	O	O
day	O	O
2	O	O
,	O	O
3	O	O
and	O	O
5	O	O
respectively	O	O
,	O	O
compared	O	O
with	O	O
day	O	O
1	O	O
.	O	O

Minimal	O	O
depletion	O	O
of	O	O
TFPI	O	O
was	O	O
detected	O	O
during	O	O
treatment	O	O
with	O	O
LMWHs	O	O
.	O	O

The	O	O
study	O	O
demonstrates	O	O
the	O	O
different	O	O
modes	O	O
of	O	O
action	O	O
of	O	O
LMWHs	Pharmacological	O
and	O	O
UFH	Pharmacological	O
and	O	O
may	O	O
help	O	O
to	O	O
explain	O	O
the	O	O
superior	O	O
antithrombotic	O	O
efficacy	O	O
of	O	O
LMWHs	O	O
.	O	O

Hip	Physical	O
protectors	Physical	O
improve	O	O
falls	O	O
self-efficacy	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
use	O	O
of	O	O
external	Physical	O
hip	Physical	O
protectors	Physical	O
on	O	O
subjects	O	O
'	O	O
fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
self-efficacy	O	O
(	O	O
belief	O	O
in	O	O
their	O	O
own	O	O
ability	O	O
to	O	O
avoid	O	O
falling	O	O
)	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Aged-care	O	O
health	O	O
services	O	O
in	O	O
Sydney	O	O
,	O	O
Australia	O	O
.	O	O

PARTICIPANTS	O	O
131	O	O
women	O	O
aged	O	O
75	O	O
years	O	O
or	O	O
older	O	O
,	O	O
who	O	O
had	O	O
two	O	O
or	O	O
more	O	O
falls	O	O
or	O	O
one	O	O
fall	O	O
requiring	O	O
hospital	O	O
admission	O	O
in	O	O
the	O	O
previous	O	O
year	O	O
and	O	O
who	O	O
live	O	O
at	O	O
home	O	O
.	O	O

Sixty-one	O	O
subjects	O	O
were	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
and	O	O
70	O	O
in	O	O
the	O	O
control	Control	O
group	O	O
.	O	O

INTERVENTION	O	O
Use	O	O
of	O	O
external	Physical	Physical
hip	Physical	Physical
protectors	Physical	Physical
and	O	O
encouragement	Physical	O
to	Physical	O
use	Physical	O
the	Physical	O
protectors	Physical	O
by	Physical	O
an	Physical	O
adherence	Physical	O
nurse	Physical	O
.	O	O

MEASUREMENTS	O	O
At	O	O
the	O	O
time	O	O
of	O	O
enrolment	O	O
into	O	O
a	O	O
wider	O	O
study	O	O
examining	O	O
the	O	O
effect	O	O
of	O	O
hip	Physical	O
protectors	Physical	O
on	O	O
hip	O	O
fractures	O	O
,	O	O
participants	O	O
recruited	O	O
at	O	O
home	O	O
completed	O	O
an	O	O
assessment	O	O
of	O	O
fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
efficacy	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
and	O	O
the	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
.	O	O

At	O	O
4-month	O	O
follow-up	O	O
,	O	O
these	O	O
scales	O	O
were	O	O
readministered	O	O
by	O	O
an	O	O
observer	O	O
who	O	O
was	O	O
not	O	O
aware	O	O
of	O	O
the	O	O
allocation	O	O
of	O	O
the	O	O
participant	O	O
to	O	O
intervention	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

RESULTS	O	O
Fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
self-efficacy	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
and	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scales	O	O
,	O	O
were	O	O
similar	O	O
at	O	O
baseline	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Fear	O	O
of	O	O
falling	O	O
was	O	O
present	O	O
at	O	O
follow-up	O	O
in	O	O
43	O	O
%	O	O
of	O	O
subjects	O	O
using	O	O
hip	O	O
protectors	O	O
and	O	O
57	O	O
%	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
chi2	O	O
=	O	O
2.58	O	O
,	O	O
P	O	O
=	O	O
0.11	O	O
)	O	O
.	O	O

Hip	Physical	O
protector	Physical	O
users	O	O
had	O	O
greater	O	O
improvement	O	O
in	O	O
falls	O	O
self-efficacy	O	O
at	O	O
follow-up	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
(	O	O
t	O	O
=	O	O
2.44	O	O
,	O	O
P	O	O
=	O	O
0.016	O	O
)	O	O
and	O	O
the	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
(	O	O
t	O	O
=	O	O
2.08	O	O
,	O	O
P	O	O
=	O	O
0.039	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Hip	Physical	O
protectors	Physical	O
improve	O	O
falls	O	O
self-efficacy	O	O
.	O	O

As	O	O
users	O	O
of	O	O
hip	Physical	O
protectors	Physical	O
feel	O	O
more	O	O
confident	O	O
that	O	O
they	O	O
can	O	O
complete	O	O
tasks	O	O
safely	O	O
,	O	O
they	O	O
may	O	O
become	O	O
more	O	O
physically	O	O
active	O	O
and	O	O
require	O	O
less	O	O
assistance	O	O
with	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
.	O	O

Relation	O	O
of	O	O
total	O	O
homocysteine	O	O
and	O	O
lipid	O	O
levels	O	O
in	O	O
children	O	O
to	O	O
premature	O	O
cardiovascular	O	O
death	O	O
in	O	O
male	O	O
relatives	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
relative	O	O
importance	O	O
of	O	O
lipid	O	O
,	O	O
apo	O	O
B	O	O
,	O	O
lipoprotein	O	O
(	O	O
a	O	O
)	O	O
[	O	O
Lp	O	O
(	O	O
a	O	O
)	O	O
]	O	O
,	O	O
and	O	O
total	O	O
homocysteine	O	O
(	O	O
tHcy	O	O
)	O	O
levels	O	O
in	O	O
children	O	O
in	O	O
relation	O	O
to	O	O
premature	O	O
cardiovascular	O	O
disease	O	O
in	O	O
family	O	O
members	O	O
.	O	O

Parents	O	O
of	O	O
381	O	O
girls	O	O
and	O	O
375	O	O
boys	O	O
age	O	O
8-12	O	O
y	O	O
completed	O	O
family	Other	O
history	Other	O
questionnaires	Other	O
.	Other	O

Nonfasting	O	O
serum	O	O
lipid	O	O
and	O	O
lipoproteins	O	O
and	O	O
plasma	O	O
tHcy	O	O
and	O	O
cysteine	O	O
levels	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
children	O	O
.	O	O

Serum	O	O
folate	O	O
and	O	O
vitamin	O	O
B12	O	O
levels	O	O
were	O	O
determined	O	O
in	O	O
a	O	O
random	O	O
subsample	O	O
of	O	O
23	O	O
%	O	O
of	O	O
the	O	O
children	O	O
,	O	O
who	O	O
participated	O	O
in	O	O
a	O	O
food	O	O
frequency	O	O
interview	O	O
.	O	O

Children	O	O
whose	O	O
parents	O	O
reported	O	O
hypercholesterolemia	O	O
had	O	O
higher	O	O
total	O	O
and	O	O
non-HDL	O	O
cholesterol	O	O
and	O	O
apo	O	O
B	O	O
levels	O	O
than	O	O
the	O	O
rest	O	O
,	O	O
but	O	O
these	O	O
levels	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	O	O
levels	O	O
were	O	O
similar	O	O
in	O	O
girls	O	O
and	O	O
boys	O	O
.	O	O

tHcy	O	O
was	O	O
higher	O	O
in	O	O
children	O	O
whose	O	O
father	O	O
,	O	O
grandfather	O	O
,	O	O
or	O	O
uncle	O	O
died	O	O
at	O	O
age	O	O
<	O	O
or	O	O
=	O	O
55	O	O
y	O	O
of	O	O
myocardial	O	O
infarction	O	O
or	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
than	O	O
in	O	O
control	O	O
children	O	O
[	O	O
5.92	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
of	O	O
5.47-6.36	O	O
)	O	O
versus	O	O
5.25	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5.16-5.34	O	O
)	O	O
]	O	O
,	O	O
also	O	O
after	O	O
adjustment	O	O
for	O	O
socioeconomic	O	O
group	O	O
.	O	O

Intake	O	O
and	O	O
serum	O	O
levels	O	O
of	O	O
vitamin	O	Pharmacological
B12	O	Pharmacological
and	O	O
folate	O	O
were	O	O
within	O	O
recommended	O	O
or	O	O
reference	O	O
ranges	O	O
.	O	O

In	O	O
a	O	O
stepwise	O	O
multiple	O	O
regression	O	O
analysis	O	O
,	O	O
serum	O	O
folate	O	O
(	O	O
negative	O	O
correlation	O	O
)	O	O
,	O	O
plasma	O	O
creatinine	O	O
,	O	O
and	O	O
sugar	O	O
intake	O	O
as	O	O
percent	O	O
of	O	O
dietary	O	O
energy	O	O
(	O	O
positive	O	O
correlations	O	O
)	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
tHcy	O	O
(	O	O
multiple	O	O
r	O	O
=	O	O
0.44	O	O
,	O	O
adjusted	O	O
r2	O	O
=	O	O
18	O	O
%	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5-30	O	O
%	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
a	O	O
modest	O	O
elevation	O	O
in	O	O
tHcy	O	O
in	O	O
children	O	O
was	O	O
related	O	O
to	O	O
premature	O	O
cardiovascular	O	O
death	O	O
in	O	O
their	O	O
male	O	O
relatives	O	O
and	O	O
may	O	O
partly	O	O
account	O	O
for	O	O
the	O	O
contribution	O	O
of	O	O
family	O	O
history	O	O
to	O	O
risk	O	O
of	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	O	O
may	O	O
be	O	O
modifiable	O	O
through	O	O
the	O	O
diet	O	O
,	O	O
even	O	O
in	O	O
children	O	O
with	O	O
apparently	O	O
adequate	O	O
vitamin	O	O
nutriture	O	O
.	O	O

Ten-year	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
and	O	O
prognosis	O	O
after	O	O
infarction	O	O
.	O	O

Department	O	O
of	O	O
Veterans	O	O
Affairs	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

BACKGROUND	O	O
The	O	O
10-year	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
(	O	O
fatal	O	O
and	O	O
nonfatal	O	O
)	O	O
and	O	O
the	O	O
prognosis	O	O
after	O	O
infarction	O	O
were	O	O
evaluated	O	O
in	O	O
686	O	O
patients	O	O
with	O	O
stable	O	O
angina	O	O
who	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
medical	Pharmacological	O
or	O	O
surgical	Surgical	O
treatment	O	O
in	O	O
the	O	O
Veterans	O	O
Administration	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Myocardial	O	O
infarction	O	O
was	O	O
defined	O	O
by	O	O
either	O	O
new	O	O
Q	O	O
wave	O	O
findings	O	O
or	O	O
clinical	O	O
symptoms	O	O
compatible	O	O
with	O	O
myocardial	O	O
infarction	O	O
accompanied	O	O
by	O	O
serum	O	O
enzyme	O	O
elevations	O	O
with	O	O
or	O	O
without	O	O
electrocardiographic	O	O
findings	O	O
.	O	O

Treatment	O	O
comparisons	O	O
were	O	O
made	O	O
according	O	O
to	O	O
original	O	O
treatment	O	O
assignment	O	O
;	O	O
35	O	O
%	O	O
of	O	O
the	O	O
medical	O	O
cohort	O	O
had	O	O
bypass	Surgical	O
surgery	Surgical	O
during	O	O
the	O	O
10-year	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
overall	O	O
cumulative	O	O
infarction	O	O
rate	O	O
was	O	O
somewhat	O	O
higher	O	O
in	O	O
patients	O	O
assigned	O	O
to	O	O
surgery	Surgical	O
(	O	O
36	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
31	O	O
%	O	O
)	O	O
(	O	O
p	O	O
=	O	O
0.13	O	O
)	O	O
due	O	O
to	O	O
perioperative	O	O
infarctions	O	O
(	O	O
13	O	O
%	O	O
)	O	O
and	O	O
an	O	O
accelerated	O	O
infarction	O	O
rate	O	O
after	O	O
the	O	O
fifth	O	O
year	O	O
of	O	O
follow-up	O	O
(	O	O
average	O	O
,	O	O
2.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
surgical	O	O
group	O	O
versus	O	O
1.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
medical	O	O
group	O	O
)	O	O
.	O	O

The	O	O
10-year	O	O
cumulative	O	O
incidence	O	O
of	O	O
death	O	O
or	O	O
myocardial	O	O
infarction	O	O
was	O	O
also	O	O
higher	O	O
in	O	O
surgical	O	O
(	O	O
54	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
(	O	O
49	O	O
%	O	O
)	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0.20	O	O
)	O	O
.	O	O

According	O	O
to	O	O
the	O	O
Cox	O	O
model	O	O
,	O	O
the	O	O
estimated	O	O
risk	O	O
of	O	O
death	O	O
after	O	O
infarction	O	O
was	O	O
59	O	O
%	O	O
lower	O	O
in	O	O
surgical	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
postinfarction	O	O
mortality	O	O
with	O	O
surgery	O	O
was	O	O
most	O	O
striking	O	O
in	O	O
the	O	O
first	O	O
month	O	O
after	O	O
the	O	O
event	O	O
:	O	O
99	O	O
%	O	O
in	O	O
the	O	O
first	O	O
month	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
and	O	O
49	O	O
%	O	O
subsequently	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
estimated	O	O
risk	O	O
of	O	O
death	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
infarction	O	O
was	O	O
nearly	O	O
identical	O	O
regardless	O	O
of	O	O
treatment	O	O
(	O	O
p	O	O
=	O	O
0.75	O	O
)	O	O
.	O	O

Exclusion	O	O
of	O	O
perioperative	O	O
infarctions	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
findings	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
surgery	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
overall	O	O
,	O	O
it	O	O
does	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
mortality	O	O
after	O	O
infarction	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
first	O	O
30	O	O
days	O	O
after	O	O
the	O	O
event	O	O
(	O	O
fatal	O	O
infarctions	O	O
)	O	O
.	O	O

Step-down	O	O
approach	O	O
using	O	O
either	O	O
cyclosporin	Pharmacological	Pharmacological
A	Pharmacological	Pharmacological
or	O	O
methotrexate	Pharmacological	Pharmacological
as	O	O
maintenance	O	O
therapy	O	O
in	O	O
early	O	O
rheumatoid	O	O
arthritis	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
feasibility	O	O
and	O	O
outcome	O	O
of	O	O
the	O	O
step-down	O	O
approach	O	O
using	O	O
either	O	O
cyclosporin	Pharmacological	Pharmacological
A	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
CSA	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
or	O	O
methotrexate	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
MTX	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
as	O	O
maintenance	O	O
therapy	O	O
following	O	O
6	O	O
months	O	O
treatment	O	O
with	O	O
these	O	O
2	O	O
agents	O	O
in	O	O
combination	O	O
in	O	O
early	O	O
,	O	O
nonerosive	O	O
rheumatoid	O	O
arthritis	O	O
(	O	O
RA	O	O
)	O	O
.	O	O

METHODS	O	O
Fifty-seven	O	O
patients	O	O
younger	O	O
than	O	O
65	O	O
years	O	O
with	O	O
early	O	O
,	O	O
nonerosive	O	O
RA	O	O
were	O	O
first	O	O
treated	O	O
with	O	O
CSA	Pharmacological	O
and	O	O
MTX	Pharmacological	Pharmacological
in	O	O
combination	O	O
for	O	O
6	O	O
months	O	O
.	O	O

They	O	O
were	O	O
then	O	O
randomly	O	O
stepped	O	O
down	O	O
to	O	O
single-agent	O	O
maintenance	O	O
treatment	O	O
for	O	O
another	O	O
18	O	O
months	O	O
.	O	O

Safety	O	O
,	O	O
clinical	O	O
efficacy	O	O
,	O	O
survival	O	O
on	O	O
treatment	O	O
,	O	O
and	O	O
radiographic	O	O
progression	O	O
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
When	O	O
being	O	O
treated	O	O
with	O	O
combination	O	O
therapy	O	O
,	O	O
7	O	O
of	O	O
the	O	O
57	O	O
patients	O	O
(	O	O
12.3	O	O
%	O	O
)	O	O
withdrew	O	O
because	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

Of	O	O
the	O	O
remaining	O	O
50	O	O
patients	O	O
,	O	O
42	O	O
(	O	O
84.0	O	O
%	O	O
)	O	O
were	O	O
American	O	O
College	O	O
of	O	O
Rheumatology	O	O
(	O	O
ACR	O	O
)	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
30	O	O
(	O	O
60.0	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
50	O	O
%	O	O
responders	O	O
,	O	O
and	O	O
23	O	O
(	O	O
46.0	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

At	O	O
month	O	O
6	O	O
,	O	O
22	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
CSA	Pharmacological	O
and	O	O
27	O	O
to	O	O
MTX	Pharmacological	Pharmacological
.	Pharmacological	O

During	O	O
this	O	O
trial	O	O
period	O	O
,	O	O
the	O	O
treatment	O	O
was	O	O
discontinued	O	O
by	O	O
16	O	O
patients	O	O
taking	O	O
CSA	Pharmacological	Pharmacological
(	O	O
mainly	O	O
because	O	O
of	O	O
loss	O	O
of	O	O
efficacy	O	O
)	O	O
and	O	O
by	O	O
4	O	O
taking	O	O
MTX	Pharmacological	Pharmacological
.	Pharmacological	O

At	O	O
month	O	O
24	O	O
,	O	O
the	O	O
probability	O	O
(	O	O
+/-	O	O
SEM	O	O
)	O	O
of	O	O
survival	O	O
on	O	O
treatment	O	O
was	O	O
0.273	O	O
+/-	O	O
0.09	O	O
for	O	O
CSA	Pharmacological	O
and	O	O
0.852	O	O
+/-	O	O
0.07	O	O
for	O	O
MTX	Pharmacological	O
.	Pharmacological	O

Of	O	O
the	O	O
6	O	O
CSA	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
trial	O	O
,	O	O
4	O	O
(	O	O
66.7	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
and	O	O
3	O	O
(	O	O
50	O	O
%	O	O
)	O	O
were	O	O
both	O	O
ACR	O	O
50	O	O
%	O	O
and	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

Of	O	O
the	O	O
23	O	O
completers	O	O
in	O	O
the	O	O
MTX	Pharmacological	O
arm	O	O
,	O	O
21	O	O
(	O	O
91.3	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
18	O	O
(	O	O
78.3	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
50	O	O
%	O	O
,	O	O
and	O	O
10	O	O
(	O	O
43.5	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

The	O	O
treatment	O	O
was	O	O
not	O	O
responsible	O	O
for	O	O
severe	O	O
adverse	O	O
events	O	O
.	O	O

Radiography	O	O
showed	O	O
a	O	O
slow	O	O
progression	O	O
in	O	O
the	O	O
damage	O	O
score	O	O
and	O	O
number	O	O
of	O	O
eroded	O	O
joints	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
Stepping	O	O
down	O	O
to	O	O
single	O	O
agent	O	O
maintenance	O	O
therapy	O	O
following	O	O
6	O	O
months	O	O
of	O	O
combination	O	O
treatment	O	O
with	O	O
CSA	Pharmacological	O
and	O	O
MTX	Pharmacological	O
in	O	O
early	O	O
RA	O	O
was	O	O
only	O	O
successful	O	O
with	O	O
MTX	Pharmacological	O
.	Pharmacological	O

Because	O	O
this	O	O
treatment	O	O
did	O	O
not	O	O
prevent	O	O
some	O	O
radiographic	O	O
progression	O	O
,	O	O
other	O	O
approaches	O	O
(	O	O
e.g.	O	O
,	O	O
step-up	O	O
approach	O	O
)	O	O
may	O	O
be	O	O
more	O	O
appropriate	O	O
in	O	O
early	O	O
RA	O	O
.	O	O

0.1	O	O
%	O	O
bupivacaine	Pharmacological	Pharmacological
does	O	O
not	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
infusion	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Although	O	O
local	O	Pharmacological
anesthesia	O	Pharmacological
has	O	O
been	O	O
demonstrated	O	O
to	O	O
potentiate	O	O
spinal	O	O
morphine	O	O
analgesia	O	O
in	O	O
animal	O	O
studies	O	O
,	O	O
results	O	O
comparing	O	O
epidural	O	O
local	O	O
anesthesia/opioid	O	O
mixtures	O	O
with	O	O
opioid	O	O
alone	O	O
are	O	O
contradictory	O	O
in	O	O
clinical	O	O
studies	O	O
.	O	O

The	O	O
hypothesis	O	O
was	O	O
that	O	O
,	O	O
although	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	Pharmacological	Pharmacological
(	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
to	O	O
minimize	O	O
its	O	O
adverse	O	O
effects	O	O
,	O	O
if	O	O
the	O	O
infusion	O	O
rate	O	O
of	O	O
a	O	O
fentanyl/bupivacaine	Pharmacological	O
solution	O	O
was	O	O
closely	O	O
adjusted	O	O
according	O	O
to	O	O
need	O	O
,	O	O
the	O	O
presence	O	O
bupivacaine	O	O
would	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
.	O	O

METHODS	O	O
Forty	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
fentanyl	Pharmacological	Pharmacological
(	O	O
10	O	O
micrograms/mL	O	O
)	O	O
or	O	O
a	O	O
fentanyl/bupivacaine	Pharmacological	O
(	O	O
0.1	O	O
%	O	O
)	O	O
mixture	O	O
epidurally	O	O
corresponding	O	O
to	O	O
the	O	O
dermatome	O	O
of	O	O
the	O	O
surgical	O	Surgical
incision	O	Surgical
in	O	O
a	O	O
double-blind	O	O
fashion	O	O
for	O	O
the	O	O
first	O	O
18	O	O
hours	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

The	O	O
infusion	O	O
was	O	O
titrated	O	O
for	O	O
each	O	O
patient	O	O
to	O	O
the	O	O
rate	O	O
required	O	O
for	O	O
pain	O	O
relief	O	O
during	O	O
forced	O	O
inspiration	O	O
(	O	O
pain	O	O
score	O	O
<	O	O
or	O	O
=	O	O
2	O	O
,	O	O
maximum	O	O
10	O	O
)	O	O
.	O	O

Pain	O	O
scores	O	O
,	O	O
the	O	O
fentanyl	O	O
doses	O	O
required	O	O
,	O	O
plasma	O	O
concentrations	O	O
of	O	O
fentanyl	O	O
at	O	O
18	O	O
hours	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
effects	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Patients	O	O
reported	O	O
similar	O	O
median	O	O
pain	O	O
scores	O	O
and	O	O
were	O	O
equally	O	O
satisfied	O	O
with	O	O
pain	O	O
relief	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
mean	O	O
required	O	O
post-operative	O	O
fentanyl	O	O
infusion	O	O
rate	O	O
(	O	O
57.7	O	O
+/-	O	O
19.5	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	O	O
concentrations	O	O
(	O	O
0.84	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl	O	O
group	O	O
were	O	O
comparable	O	O
to	O	O
the	O	O
infusion	O	O
rate	O	O
(	O	O
54.4	O	O
+/-	O	O
19.2	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	O	O
concentrations	O	O
(	O	O
0.86	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl/bupivacaine	O	O
group	O	O
.	O	O

Respiratory	O	O
and	O	O
cardiovascular	O	O
functions	O	O
were	O	O
preserved	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
nausea	O	O
,	O	O
pruritus	O	O
,	O	O
and	O	O
periods	O	O
of	O	O
drowsiness	O	O
or	O	O
sleep	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
low	O	O
concentrations	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
,	O	O
bupivacaine	Pharmacological	Pharmacological
did	O	O
not	O	O
reduce	O	O
the	O	O
titrated	O	O
dose	O	O
of	O	O
epidural	O	O
fentanyl	O	O
required	O	O
for	O	O
adequate	O	O
pain	O	O
relief	O	O
during	O	O
forced	O	O
inspiration	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

The	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
comparable	O	O
whether	O	O
or	O	O
not	O	O
low-dose	O	O
bupivacaine	Pharmacological	Pharmacological
infusion	O	O
was	O	O
used	O	O
.	O	O

The	O	O
ScanBrit	O	O
randomised	O	O
,	O	O
controlled	O	O
,	O	O
single-blind	O	O
study	O	O
of	O	O
a	O	O
gluten-	Other	O
and	Other	O
casein-free	Other	Educational
dietary	Other	Educational
intervention	Other	Educational
for	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

There	O	O
is	O	O
increasing	O	O
interest	O	O
in	O	O
the	O	O
use	O	O
of	O	O
gluten-	Other	O
and	Other	O
casein-free	Other	O
diets	Other	O
for	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
(	O	O
ASDs	O	O
)	O	O
.	O	O

We	O	O
report	O	O
results	O	O
from	O	O
a	O	O
two-stage	O	O
,	O	O
24-month	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
trial	O	O
incorporating	O	O
an	O	O
adaptive	O	O
'catch-up	O	O
'	O	O
design	O	O
and	O	O
interim	O	O
analysis	O	O
.	O	O

Stage	O	O
1	O	O
of	O	O
the	O	O
trial	O	O
saw	O	O
72	O	O
Danish	O	O
children	O	O
(	O	O
aged	O	O
4	O	O
years	O	O
to	O	O
10	O	O
years	O	O
11	O	O
months	O	O
)	O	O
assigned	O	O
to	O	O
diet	O	O
(	O	O
A	O	O
)	O	O
or	O	O
non-diet	Control	O
(	O	O
B	O	O
)	O	O
groups	O	O
by	O	O
stratified	O	O
randomisation	O	O
.	O	O

Autism	O	O
Diagnostic	O	O
Observation	O	O
Schedule	O	O
(	O	O
ADOS	O	O
)	O	O
and	O	O
the	O	O
Gilliam	O	O
Autism	O	O
Rating	O	O
Scale	O	O
(	O	O
GARS	O	O
)	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
core	O	O
autism	O	O
behaviours	O	O
,	O	O
Vineland	O	O
Adaptive	O	O
Behaviour	O	O
Scales	O	O
(	O	O
VABS	O	O
)	O	O
to	O	O
ascertain	O	O
developmental	O	O
level	O	O
,	O	O
and	O	O
Attention-Deficit	O	O
Hyperactivity	O	O
Disorder	O	O
-	O	O
IV	O	O
scale	O	O
(	O	O
ADHD-IV	O	O
)	O	O
to	O	O
determine	O	O
inattention	O	O
and	O	O
hyperactivity	O	O
.	O	O

Participants	O	O
were	O	O
tested	O	O
at	O	O
baseline	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
months	O	O
.	O	O

Based	O	O
on	O	O
per	O	O
protocol	O	O
repeated	O	O
measures	O	O
analysis	O	O
,	O	O
data	O	O
for	O	O
26	O	O
diet	O	O
children	O	O
and	O	O
29	O	O
controls	O	O
were	O	O
available	O	O
at	O	O
12	O	O
months	O	O
.	O	O

At	O	O
this	O	O
point	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
improvement	O	O
to	O	O
mean	O	O
diet	O	O
group	O	O
scores	O	O
(	O	O
time*treatment	O	O
interaction	O	O
)	O	O
on	O	O
sub-domains	O	O
of	O	O
ADOS	O	O
,	O	O
GARS	O	O
and	O	O
ADHD-IV	O	O
measures	O	O
.	O	O

Surpassing	O	O
of	O	O
predefined	O	O
statistical	O	O
thresholds	O	O
as	O	O
evidence	O	O
of	O	O
improvement	O	O
in	O	O
group	O	O
A	O	O
at	O	O
12	O	O
months	O	O
sanctioned	O	O
the	O	O
re-assignment	O	O
of	O	O
group	O	O
B	O	O
participants	O	O
to	O	O
active	O	O
dietary	O	O
treatment	O	O
.	O	O

Stage	O	O
2	O	O
data	O	O
for	O	O
18	O	O
group	O	O
A	O	O
and	O	O
17	O	O
group	O	O
B	O	O
participants	O	O
were	O	O
available	O	O
at	O	O
24	O	O
months	O	O
.	O	O

Multiple	O	O
scenario	O	O
analysis	O	O
based	O	O
on	O	O
inter-	O	O
and	O	O
intra-group	O	O
comparisons	O	O
showed	O	O
some	O	O
evidence	O	O
of	O	O
sustained	O	O
clinical	O	O
group	O	O
improvements	O	O
although	O	O
possibly	O	O
indicative	O	O
of	O	O
a	O	O
plateau	O	O
effect	O	O
for	O	O
intervention	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
dietary	Other	O
intervention	Other	O
may	O	O
positively	O	O
affect	O	O
developmental	O	O
outcome	O	O
for	O	O
some	O	O
children	O	O
diagnosed	O	O
with	O	O
ASD	O	O
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
placebo	Control	Control
condition	O	O
to	O	O
the	O	O
current	O	O
investigation	O	O
,	O	O
we	O	O
are	O	O
,	O	O
however	O	O
,	O	O
unable	O	O
to	O	O
disqualify	O	O
potential	O	O
effects	O	O
derived	O	O
from	O	O
intervention	O	O
outside	O	O
of	O	O
dietary	O	O
changes	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
ascertain	O	O
potential	O	O
best-	O	O
and	O	O
non-responders	O	O
to	O	O
intervention	O	O
.	O	O

The	O	O
study	O	O
was	O	O
registered	O	O
with	O	O
ClincialTrials.gov	O	O
,	O	O
number	O	O
NCT00614198	O	O
.	O	O

Niacin	Pharmacological	O
revisited	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
of	O	O
wax-matrix	O	O
sustained-release	O	O
niacin	Pharmacological	O
in	O	O
hypercholesterolemia	O	O
.	O	O

Two	O	O
hundred	O	O
one	O	O
male	O	O
and	O	O
female	O	O
subjects	O	O
,	O	O
aged	O	O
20	O	O
to	O	O
70	O	O
years	O	O
,	O	O
with	O	O
elevated	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
values	O	O
(	O	O
in	O	O
the	O	O
75th	O	O
to	O	O
95th	O	O
percentiles	O	O
)	O	O
,	O	O
participated	O	O
in	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
double-blind	O	O
study	O	O
using	O	O
a	O	O
new	O	O
form	O	O
of	O	O
niacin	Pharmacological	O
(	Pharmacological	O
Enduracin	Pharmacological	O
)	Pharmacological	O
,	O	O
which	O	O
employs	O	O
a	O	O
wax-matrix	O	O
vehicle	O	O
for	O	O
sustained	O	O
release	O	O
.	O	O

Four	O	O
niacin	Pharmacological	O
treatment	O	O
groups	O	O
(	O	O
daily	O	O
doses	O	O
of	O	O
2000	O	O
,	O	O
1500	O	O
,	O	O
1250	O	O
,	O	O
and	O	O
1000	O	O
mg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
placebo-	Control	O
and	O	O
diet-treated	Control	O
controls	Control	O
to	O	O
determine	O	O
side-effect	O	O
profile	O	O
and	O	O
optimal	O	O
range	O	O
of	O	O
efficacy	O	O
.	O	O

The	O	O
groups	O	O
given	O	O
2000	O	O
and	O	O
1500	O	O
mg	O	O
demonstrated	O	O
significant	O	O
reductions	O	O
in	O	O
values	O	O
of	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
(	O	O
-26	O	O
%	O	O
and	O	O
-19.3	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
total	O	O
cholesterol	O	O
(	O	O
-18.4	O	O
%	O	O
and	O	O
-13.3	O	O
%	O	O
)	O	O
,	O	O
and	O	O
total	O	O
cholesterol-high-density	O	O
lipoprotein	O	O
cholesterol	O	O
ratio	O	O
(	O	O
-20.4	O	O
%	O	O
and	O	O
-19.4	O	O
%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
diet-	O	O
and	O	O
placebo-treated	O	O
controls	O	O
.	O	O

Smaller	O	O
improvements	O	O
were	O	O
seen	O	O
in	O	O
high-density	O	O
lipoprotein	O	O
cholesterol	O	O
and	O	O
triglyceride	O	O
levels	O	O
.	O	O

Blood	O	O
chemistry	O	O
monitoring	O	O
indicated	O	O
that	O	O
reduction	O	O
in	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
level	O	O
strongly	O	O
correlated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
baseline	O	O
levels	O	O
of	O	O
some	O	O
enzymes	O	O
for	O	O
niacin-treated	O	O
subjects	O	O
.	O	O

The	O	O
improved	O	O
side-effect	O	O
profile	O	O
of	O	O
the	O	O
wax-matrix	O	O
form	O	O
of	O	O
niacin	Pharmacological	O
was	O	O
particularly	O	O
notable	O	O
.	O	O

The	O	O
dropout	O	O
rate	O	O
due	O	O
to	O	O
side	O	O
effects	O	O
was	O	O
only	O	O
3.4	O	O
%	O	O
and	O	O
was	O	O
coupled	O	O
with	O	O
good	O	O
medication	O	O
compliance	O	O
.	O	O

Aminocaproic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
versus	O	O
prednisone	Pharmacological	Pharmacological
for	O	O
the	O	O
treatment	O	O
of	O	O
traumatic	O	O
hyphema	O	O
.	O	O

A	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

One	O	O
hundred	O	O
twelve	O	O
patients	O	O
who	O	O
sustained	O	O
hyphema	O	O
after	O	O
blunt	O	O
trauma	O	O
were	O	O
enrolled	O	O
in	O	O
a	O	O
double-blind	O	O
randomized	O	O
clinical	O	O
trial	O	O
to	O	O
determine	O	O
the	O	O
relative	O	O
efficacies	O	O
of	O	O
aminocaproic	Pharmacological	O
acid	Pharmacological	O
(	Pharmacological	O
Amicar	Pharmacological	O
)	Pharmacological	O
and	O	O
systemic	Pharmacological	O
prednisone	Pharmacological	O
for	O	O
reducing	O	O
the	O	O
rate	O	O
of	O	O
secondary	O	O
hemorrhage	O	O
.	O	O

Fifty-six	O	O
patients	O	O
received	O	O
an	O	O
oral	O	Pharmacological
dosage	O	Pharmacological
of	O	Pharmacological
50	O	Pharmacological
mg/kg	O	Pharmacological
of	O	Pharmacological
aminocaproic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
every	O	O
4	O	O
hours	O	O
for	O	O
5	O	O
days	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
30	O	O
g	O	O
daily	O	O
,	O	O
and	O	O
56	O	O
patients	O	O
received	O	O
an	O	O
oral	O	Pharmacological
dosage	O	Pharmacological
of	O	Pharmacological
40	O	Pharmacological
mg	O	Pharmacological
of	O	Pharmacological
prednisone	Pharmacological	Pharmacological
daily	O	O
(	O	O
adjusted	O	O
for	O	O
weight	O	O
)	O	O
in	O	O
two	O	O
divided	O	O
doses	O	O
.	O	O

Placebo	Control	O
pills	O	O
and	O	O
liquids	O	O
were	O	O
given	O	O
to	O	O
each	O	O
patient	O	O
to	O	O
mask	O	O
the	O	O
treatment	O	O
schedules	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
patient	O	O
populations	O	O
for	O	O
any	O	O
demographic	O	O
or	O	O
clinical	O	O
characteristic	O	O
(	O	O
e.g.	O	O
,	O	O
visual	O	O
acuity	O	O
,	O	O
intraocular	O	O
pressure	O	O
[	O	O
IOP	O	O
]	O	O
,	O	O
initial	O	O
hyphema	O	O
size	O	O
)	O	O
measured	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Blacks	O	O
comprised	O	O
53	O	O
%	O	O
of	O	O
the	O	O
study	O	O
population	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
23.5	O	O
years	O	O
.	O	O

Four	O	O
patients	O	O
in	O	O
each	O	O
of	O	O
the	O	O
treatment	O	O
groups	O	O
experienced	O	O
a	O	O
secondary	O	O
hemorrhage	O	O
;	O	O
the	O	O
rebleed	O	O
rate	O	O
was	O	O
7.1	O	O
%	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Lactobacillus	Pharmacological	O
plantarum	Pharmacological	O
CECT7315	Pharmacological	O
and	Pharmacological	O
CECT7316	Pharmacological	O
stimulate	O	O
immunoglobulin	O	O
production	O	O
after	O	O
influenza	Pharmacological	O
vaccination	Pharmacological	O
in	O	O
elderly	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
effectiveness	O	O
of	O	O
influenza	Pharmacological	Pharmacological
vaccination	Pharmacological	Pharmacological
in	O	O
preventing	O	O
illness	O	O
is	O	O
lower	O	O
in	O	O
the	O	O
elderly	O	O
;	O	O
this	O	O
is	O	O
why	O	O
the	O	O
ability	O	O
of	O	O
Lactobacillus	Pharmacological	O
plantarum	Pharmacological	O
CECT	Pharmacological	O
7315/7316	Pharmacological	O
to	O	O
stimulate	O	O
the	O	O
response	O	O
to	O	O
influenza	Pharmacological	O
vaccination	Pharmacological	O
in	O	O
elderly	O	O
was	O	O
evaluated	O	O
.	O	O

RESEARCH	O	O
METHODS	O	O
AND	O	O
PROCEDURES	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	Control
human	O	O
trial	O	O
including	O	O
60	O	O
institutionalized	O	O
volunteers	O	O
aged	O	O
65-85	O	O
years	O	O
was	O	O
performed	O	O
.	O	O

All	O	O
the	O	O
volunteers	O	O
were	O	O
vaccinated	O	O
with	O	O
a	O	O
trivalent	Pharmacological	Pharmacological
influenza	Pharmacological	Pharmacological
vaccine	Pharmacological	Pharmacological
(	Pharmacological	O
A/Wisconsin/67/2005	Pharmacological	O
NYMC	Pharmacological	O
X-161B	Pharmacological	O
(	Pharmacological	O
H3N2	Pharmacological	O
)	Pharmacological	O
,	Pharmacological	O
A/Solomon	Pharmacological	O
Islands/3/2006	Pharmacological	O
(	Pharmacological	O
H1N1	Pharmacological	O
)	Pharmacological	O
and	Pharmacological	O
B/Malaysia/2506/2004	Pharmacological	O
)	Pharmacological	O
for	O	O
the	O	O
Spanish	O	O
vaccine	O	O
campaign	O	O
2006/2007	O	O
.	O	O

The	O	O
consumption	O	O
of	O	O
the	O	O
probiotic	O	O
began	O	O
between	O	O
three	O	O
and	O	O
four	O	O
months	O	O
after	O	O
the	O	O
vaccination	O	O
.	O	O

Volunteers	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
three	O	O
following	O	O
groups	O	O
:	O	O
group	O	O
A	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
9	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	Pharmacological	O
plantarum	Pharmacological	O
CECT	Pharmacological	Pharmacological
7315/7316	Pharmacological	Pharmacological
in	O	Pharmacological
20	O	Pharmacological
g	O	Pharmacological
powdered	O	Pharmacological
skim	O	Pharmacological
milk	O	Pharmacological
)	O	Pharmacological
,	O	O
group	O	O
B	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
8	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	Pharmacological	O
plantarum	Pharmacological	O
CECT	Pharmacological	Pharmacological
7315/7316	Pharmacological	Pharmacological
in	O	Pharmacological
20	O	Pharmacological
g	O	Pharmacological
powdered	O	Pharmacological
skim	O	Pharmacological
milk	O	Pharmacological
)	O	Pharmacological
and	O	O
group	O	O
C	O	O
or	O	O
placebo	Control	Control
(	O	O
20	O	O
g	O	O
powered	Control	O
skim	Control	O
milk	Control	O
)	Control	O
.	Control	O

The	O	O
participants	O	O
consumed	O	O
the	O	O
probiotic	O	O
during	O	O
3	O	O
months	O	O
.	O	O

RESULTS	O	O
The	O	O
consumption	O	O
of	O	O
L.	Pharmacological	O
plantarum	Pharmacological	O
CECT	Pharmacological	O
7315/7316	Pharmacological	O
during	O	O
3	O	O
months	O	O
after	O	O
influenza	Pharmacological	Pharmacological
vaccination	Pharmacological	Pharmacological
increased	O	O
the	O	O
levels	O	O
of	O	O
influenza-specific	O	O
IgA	O	O
and	O	O
IgG	O	O
antibodies	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
trend	O	O
towards	O	O
an	O	O
increase	O	O
in	O	O
influenza-specific	O	O
IgM	O	O
antibodies	O	O
was	O	O
also	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
L.	Pharmacological	O
plantarum	Pharmacological	O
CECT7315/7316	Pharmacological	Pharmacological
has	O	O
an	O	O
immunostimulating	O	O
effect	O	O
and	O	O
could	O	O
be	O	O
used	O	O
to	O	O
improve	O	O
the	O	O
response	O	O
to	O	O
influenza	Pharmacological	O
vaccination	Pharmacological	O
in	O	O
elderly	O	O
.	O	O

Effect	O	O
of	O	O
ranolazine	Pharmacological	O
on	O	O
A1C	O	O
and	O	O
glucose	O	O
levels	O	O
in	O	O
hyperglycemic	O	O
patients	O	O
with	O	O
non-ST	O	O
elevation	O	O
acute	O	O
coronary	O	O
syndrome	O	O
.	O	O

OBJECTIVE	O	O
We	O	O
determined	O	O
the	O	O
relationships	O	O
between	O	O
glycemia	O	O
at	O	O
randomization	O	O
,	O	O
concurrent	Pharmacological	O
antidiabetic	Pharmacological	O
therapy	Pharmacological	O
,	O	O
and	O	O
change	O	O
in	O	O
A1C	O	O
and	O	O
fasting	O	O
plasma	O	O
glucose	O	O
(	O	O
FPG	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
diabetes	O	O
receiving	O	O
standard	O	O
treatment	O	O
for	O	O
diabetes	O	O
and	O	O
randomized	O	O
to	O	O
ranolazine	Pharmacological	O
or	O	O
placebo	Control	Control
within	O	O
the	O	O
MERLIN-TIMI-36	O	O
(	O	O
MERLIN	O	O
)	O	O
study	O	O
.	O	O

Ranolazine	Pharmacological	Pharmacological
is	O	O
a	O	O
novel	O	O
first-in-class	O	O
drug	O	O
approved	O	O
for	O	O
treating	O	O
angina	O	O
pectoris	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
Randomization	O	O
and	O	O
4-month	O	O
glycemic	O	O
and	O	O
antidiabetes	Pharmacological	O
drug	Pharmacological	O
usage	O	O
data	O	O
from	O	O
MERLIN	O	O
were	O	O
analyzed	O	O
using	O	O
Spotfire	O	O
and	O	O
SAS	O	O
version	O	O
9.1	O	O
software	O	O
.	O	O

RESULTS	O	O
In	O	O
patients	O	O
with	O	O
diabetes	O	O
and	O	O
A1C	O	O
of	O	O
>	O	O
or=8-10	O	O
%	O	O
at	O	O
randomization	O	O
(	O	O
n	O	O
=	O	O
171	O	O
)	O	O
,	O	O
there	O	O
was	O	O
an	O	O
absolute	O	O
A1C	O	O
reduction	O	O
in	O	O
the	O	O
ranolazine	Pharmacological	O
group	O	O
of	O	O
1.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-1.4	O	O
to	O	O
-1.0	O	O
)	O	O
,	O	O
and	O	O
the	O	O
placebo-adjusted	Control	O
(	O	O
n	O	O
=	O	O
182	O	O
)	O	O
decrease	O	O
in	O	O
A1C	O	O
by	O	O
ranolazine	O	O
was	O	O
0.59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-0.99	O	O
to	O	O
-0.20	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
FPG	O	O
of	O	O
150-400	O	O
mg/dl	O	O
at	O	O
randomization	O	O
,	O	O
ranolazine	Pharmacological	O
(	O	O
n	O	O
=	O	O
131	O	O
)	O	O
compared	O	O
with	O	O
placebo	Control	Control
(	O	O
n	O	O
=	O	O
147	O	O
)	O	O
reduced	O	O
FPG	O	O
by	O	O
25.7	O	O
mg/dl	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-43.3	O	O
to	O	O
-8.1	O	O
,	O	O
P	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

When	O	O
changes	O	O
in	O	O
either	O	O
A1C	O	O
or	O	O
FPG	O	O
were	O	O
correlated	O	O
to	O	O
A1C	O	O
or	O	O
FPG	O	O
at	O	O
randomization	O	O
,	O	O
the	O	O
slopes	O	O
were	O	O
significantly	O	O
steeper	O	O
for	O	O
ranolazine	Pharmacological	O
than	O	O
placebo	Control	O
(	O	O
A1C	O	O
,	O	O
P	O	O
=	O	O
0.046	O	O
;	O	O
FPG	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
lowering	O	O
of	O	O
A1C	O	O
and	O	O
FPG	O	O
by	O	O
ranolazine	Pharmacological	O
is	O	O
related	O	O
to	O	O
hyperglycemia	O	O
at	O	O
randomization	O	O
.	O	O

Ranolazine	O	O
,	O	O
compared	O	O
with	O	O
placebo	O	Control
,	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
serious	O	O
hypoglycemic	O	O
events	O	O
,	O	O
associated	O	O
with	O	O
significant	O	O
changes	O	O
in	O	O
concurrent	O	O
antidiabetic	Pharmacological	O
therapy	Pharmacological	O
,	O	O
or	O	O
dependent	O	O
on	O	O
a	O	O
history	O	O
of	O	O
angina	O	O
.	O	O

CONCLUSIONS	O	O
Ranolazine	Pharmacological	O
,	O	O
when	O	O
added	O	O
to	O	O
concurrent	O	O
antidiabetes	O	O
treatment	O	O
,	O	O
lowers	O	O
FPG	O	O
and	O	O
A1C	O	O
in	O	O
patients	O	O
with	O	O
cardiovascular	O	O
disease	O	O
and	O	O
poorly	O	O
controlled	O	O
diabetes	O	O
.	O	O

Hyperbaric	Pharmacological	O
oxygen	Pharmacological	O
attenuation	O	O
of	O	O
lipopolysaccharide-induced	O	O
acute	O	O
lung	O	O
injury	O	O
involves	O	O
heme	O	O
oxygenase-1	O	O
.	O	O

BACKGROUND	O	O
Hyperbaric	Pharmacological	Physical
oxygen	Pharmacological	Physical
(	Pharmacological	O
HBO	Pharmacological	O
)	Pharmacological	O
attenuates	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-induced	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

This	O	O
beneficial	O	O
effect	O	O
of	O	O
HBO	O	O
involves	O	O
inhibition	O	O
of	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
(	O	O
iNOS	O	O
)	O	O
expression	O	O
and	O	O
subsequent	O	O
nitric	O	O
oxide	O	O
(	O	O
NO	O	O
)	O	O
biosynthesis	O	O
.	O	O

We	O	O
sought	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
(	O	O
HO-1	O	O
)	O	O
on	O	O
this	O	O
HBO	O	O
inhibition	O	O
of	O	O
iNOS	O	O
induction	O	O
and	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	O	O
rat	O	O
lungs	O	O
.	O	O

METHODS	O	O
Before	O	O
the	O	O
experiment	O	O
,	O	O
72	O	O
rats	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
HBO	Pharmacological	O
or	O	O
air	Pharmacological	O
treatment	Pharmacological	O
.	O	O

With	O	O
or	O	O
without	O	O
HBO	Pharmacological	Pharmacological
pre-treatment	O	O
,	O	O
the	O	O
rats	O	O
were	O	O
further	O	O
divided	O	O
into	O	O
the	O	O
following	O	O
subgroups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
:	O	O
(	O	O
i	O	O
)	O	O
LPS	Pharmacological	O
injection	Pharmacological	O
,	O	O
(	O	O
ii	O	O
)	O	O
normal	Control	O
saline	Control	O
(	Control	O
N/S	Control	O
)	Control	O
injection	Control	O
,	O	O
(	O	O
iii	O	O
)	O	O
hemin	Pharmacological	O
(	Pharmacological	O
a	Pharmacological	O
HO-1	Pharmacological	O
inducer	Pharmacological	O
)	Pharmacological	O
plus	Pharmacological	O
LPS	Pharmacological	O
,	O	O
(	O	O
iv	O	O
)	O	O
hemin	Pharmacological	O
alone	O	O
,	O	O
(	O	O
v	O	O
)	O	O
tin	Pharmacological	O
protoporphyrin	Pharmacological	O
(	Pharmacological	O
SnPP	Pharmacological	O
;	Pharmacological	O
a	Pharmacological	O
HO-1	Pharmacological	O
inhibitor	Pharmacological	O
)	Pharmacological	O
plus	Pharmacological	O
LPS	Pharmacological	O
,	O	O
and	O	O
(	O	O
vi	O	O
)	O	O
SnPP	Pharmacological	O
alone	O	O
.	O	O

All	O	O
rats	O	O
were	O	O
maintained	O	O
for	O	O
6	O	O
h	O	O
and	O	O
then	O	O
sacrificed	O	O
with	O	O
a	O	O
high-dose	Pharmacological	O
pentobarbital	Pharmacological	O
injection	Pharmacological	O
.	Pharmacological	O

Lung	O	O
injuries	O	O
and	O	O
relevant	O	O
enzymes	O	O
expression	O	O
were	O	O
thus	O	O
assayed	O	O
.	O	O

RESULTS	O	O
Histological	O	O
analysis	O	O
,	O	O
PMNs/alveoli	O	O
ratio	O	O
,	O	O
and	O	O
wet/dry	O	O
weight	O	O
ratio	O	O
measurements	O	O
demonstrated	O	O
that	O	O
LPS	O	O
caused	O	O
significant	O	O
lung	O	O
injury	O	O
and	O	O
HBO	O	O
and/or	O	O
hemin	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

Increased	O	O
pulmonary	O	O
iNOS	O	O
expression	O	O
and	O	O
NO	O	O
production	O	O
were	O	O
associated	O	O
with	O	O
lung	O	O
injury	O	O
.	O	O

Induction	O	O
of	O	O
HO-1	O	O
,	O	O
by	O	O
HBO	O	O
and/or	O	O
hemin	O	O
,	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	O
iNOS	O	O
expression	O	O
and	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

SnPP	O	O
,	O	O
on	O	O
the	O	O
contrary	O	O
,	O	O
offset	O	O
the	O	O
effects	O	O
of	O	O
HBO	Pharmacological	O
and	O	O
worsened	O	O
the	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

CONCLUSIONS	O	O
HBO	Pharmacological	O
may	O	O
act	O	O
through	O	O
inhibiting	O	O
pulmonary	O	O
iNOS	O	O
expression	O	O
to	O	O
attenuate	O	O
LPS-induced	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	O	O
rats	O	O
.	O	O

Furthermore	O	O
,	O	O
this	O	O
HBO	Pharmacological	O
attenuation	O	O
of	O	O
iNOS	O	O
expression	O	O
involves	O	O
HO-1	O	O
induction	O	O
.	O	O

Does	O	O
temporary	Surgical	O
clamping	Surgical	O
of	Surgical	O
drains	Surgical	O
following	O	O
knee	O	O
arthroplasty	O	O
reduce	O	O
blood	O	O
loss	O	O
?	O	O
A	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

In	O	O
a	O	O
randomised	O	O
,	O	O
blinded	O	O
study	O	O
76	O	O
patients	O	O
undergoing	O	O
primary	O	O
total	O	O
knee	O	O
arthroplasty	O	O
were	O	O
assigned	O	O
to	O	O
either	O	O
immediate	Surgical	O
drain	Surgical	O
opening	Surgical	O
(	O	O
n	O	O
=	O	O
45	O	O
)	O	O
or	O	O
drains	Surgical	O
opened	Surgical	O
at	Surgical	O
2	Surgical	O
h	Surgical	O
(	O	O
n	O	O
=	O	O
31	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
between	O	O
the	O	O
groups	O	O
for	O	O
the	O	O
volume	O	O
of	O	O
drained	O	O
blood	O	O
,	O	O
transfusion	O	O
requirements	O	O
,	O	O
knee	O	O
motion	O	O
or	O	O
wound	O	O
status	O	O
.	O	O

The	O	O
authors	O	O
conclude	O	O
that	O	O
the	O	O
practice	O	O
of	O	O
clamping	Surgical	O
drains	Surgical	O
has	O	O
no	O	O
benefit	O	O
in	O	O
routine	O	O
knee	O	O
arthroplasty	O	O
.	O	O

However	O	O
,	O	O
when	O	O
faced	O	O
with	O	O
immediate	O	O
brisk	O	O
blood	O	O
loss	O	O
,	O	O
the	O	O
results	O	O
suggest	O	O
that	O	O
drains	Surgical	O
can	O	O
be	O	O
clamped	O	O
without	O	O
any	O	O
excess	O	O
morbidity	O	O
.	O	O

In-hospital	O	O
costs	O	O
of	O	O
self-expanding	Surgical	Surgical
nitinol	Surgical	Surgical
stent	Surgical	Surgical
implantation	Surgical	Surgical
versus	O	O
balloon	Surgical	Physical
angioplasty	Surgical	Physical
in	O	O
the	O	O
femoropopliteal	O	O
artery	O	O
(	O	O
the	O	O
VascuCoil	O	O
Trial	O	O
)	O	O
.	O	O

PURPOSE	O	O
Although	O	O
several	O	O
prospective	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
stent	Surgical	O
placement	Surgical	O
for	O	O
femoropopliteal	O	O
arterial	O	O
disease	O	O
,	O	O
the	O	O
current	O	O
cost	O	O
of	O	O
these	O	O
procedures	O	O
is	O	O
unknown	O	O
.	O	O

To	O	O
estimate	O	O
and	O	O
compare	O	O
hospital	O	O
costs	O	O
associated	O	O
with	O	O
conventional	Surgical	Surgical
balloon	Surgical	Surgical
angioplasty	Surgical	Surgical
(	Surgical	Surgical
percutaneous	Surgical	Surgical
transluminal	Surgical	Surgical
angioplasty	Surgical	Surgical
[	Surgical	O
PTA	Surgical	O
]	Surgical	O
)	Surgical	O
and	O	O
stent	Surgical	O
placement	Surgical	O
for	O	O
patients	O	O
with	O	O
symptomatic	O	O
peripheral	O	O
arterial	O	O
disease	O	O
,	O	O
the	O	O
authors	O	O
performed	O	O
a	O	O
prospective	O	O
economic	O	O
evaluation	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Intracoil	O	O
Femoropopliteal	O	O
Stent	O	O
Trial	O	O
(	O	O
VascuCoil	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Between	O	O
May	O	O
1997	O	O
and	O	O
December	O	O
1999	O	O
,	O	O
266	O	O
patients	O	O
with	O	O
stenotic	O	O
or	O	O
occluded	O	O
superficial	O	O
femoral	O	O
or	O	O
popliteal	O	O
arteries	O	O
were	O	O
prospectively	O	O
randomized	O	O
to	O	O
treatment	O	O
with	O	O
the	O	O
IntraCoil	Surgical	O
stent	Surgical	O
or	O	O
PTA	Surgical	O
.	Surgical	O

Detailed	O	O
resource	O	O
use	O	O
and	O	O
cost	O	O
data	O	O
for	O	O
each	O	O
patient	O	O
's	O	O
initial	O	O
revascularization	O	O
procedure	O	O
and	O	O
ensuing	O	O
hospitalization	O	O
were	O	O
collected	O	O
and	O	O
analyzed	O	O
on	O	O
an	O	O
intention-to-treat	O	O
basis	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
conventional	Surgical	Physical
balloon	Surgical	Physical
angioplasty	Surgical	Physical
,	O	O
stent	Surgical	O
placement	Surgical	O
did	O	O
not	O	O
improve	O	O
clinical	O	O
outcomes	O	O
but	O	O
increased	O	O
procedure	O	O
duration	O	O
,	O	O
equipment	O	O
costs	O	O
,	O	O
and	O	O
physician	O	O
services	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
initial	O	O
hospital	O	O
costs	O	O
were	O	O
approximately	O	O
3,500	O	O
dollars	O	O
higher	O	O
for	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
IntraCoil	Surgical	O
stent	Surgical	O
,	O	O
compared	O	O
with	O	O
PTA	Surgical	O
(	O	O
8,435	O	O
dollars	O	O
vs	O	O
4,980	O	O
dollars	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
As	O	O
performed	O	O
in	O	O
the	O	O
VascuCoil	O	O
trial	O	O
,	O	O
primary	O	O
stent	O	O
placement	O	O
for	O	O
femoropopliteal	O	O
disease	O	O
did	O	O
not	O	O
improve	O	O
clinical	O	O
outcomes	O	O
but	O	O
increased	O	O
initial	O	O
treatment	O	O
costs	O	O
by	O	O
more	O	O
than	O	O
3,000	O	O
dollars	O	O
.	O	O

Because	O	O
there	O	O
were	O	O
no	O	O
substantial	O	O
differences	O	O
in	O	O
subsequent	O	O
clinical	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
treatments	O	O
,	O	O
it	O	O
is	O	O
unlikely	O	O
that	O	O
these	O	O
increased	O	O
initial	O	O
costs	O	O
would	O	O
be	O	O
offset	O	O
by	O	O
savings	O	O
in	O	O
follow-up	O	O
costs	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
a	O	O
strategy	O	O
of	O	O
routine	O	O
stent	Physical	O
implantation	O	O
for	O	O
patients	O	O
undergoing	O	O
femoropopliteal	O	O
PTA	Physical	O
is	O	O
not	O	O
optimal	O	O
on	O	O
economic	O	O
grounds	O	O
and	O	O
that	O	O
PTA	Physical	O
with	O	O
provisional	Physical	O
stent	Physical	O
implantation	Physical	O
is	O	O
preferred	O	O
.	O	O

Long-term	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
study	O	O
using	O	O
repetitive	O	O
education	O	O
at	O	O
six-month	O	O
intervals	O	O
and	O	O
monitoring	O	O
for	O	O
adherence	O	O
in	O	O
heart	O	O
failure	O	O
outpatients	O	O
:	O	O
the	O	O
REMADHE	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
effectiveness	O	O
of	O	O
heart	O	O
failure	O	O
disease	O	O
management	O	O
programs	O	O
in	O	O
patients	O	O
under	O	O
cardiologists	O	O
'	O	O
care	O	O
over	O	O
long-term	O	O
follow-up	O	O
is	O	O
not	O	O
established	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
disease	Other	O
management	Other	O
program	Other	O
with	Other	O
repetitive	Other	O
education	Other	O
and	O	O
telephone	Other	O
monitoring	Other	O
on	O	O
primary	O	O
(	O	O
combined	O	O
death	O	O
or	O	O
unplanned	O	O
first	O	O
hospitalization	O	O
and	O	O
quality-of-life	O	O
changes	O	O
)	O	O
and	O	O
secondary	O	O
end	O	O
points	O	O
(	O	O
hospitalization	O	O
,	O	O
death	O	O
,	O	O
and	O	O
adherence	O	O
)	O	O
.	O	O

The	O	O
REMADHE	O	O
[	O	O
Repetitive	O	O
Education	Other	O
and	Other	O
Monitoring	Other	O
for	O	O
ADherence	O	O
for	O	O
Heart	O	O
Failure	O	O
]	O	O
trial	O	O
is	O	O
a	O	O
long-term	O	O
randomized	O	O
,	O	O
prospective	O	O
,	O	O
parallel	O	O
trial	O	O
designed	O	O
to	O	O
compare	O	O
intervention	O	O
with	O	O
control	Control	O
.	Control	O

One	O	O
hundred	O	O
seventeen	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
usual	O	O
care	O	O
,	O	O
and	O	O
233	O	O
to	O	O
additional	O	O
intervention	O	O
.	O	O

The	O	O
mean	O	O
follow-up	O	O
was	O	O
2.47+/-1.75	O	O
years	O	O
,	O	O
with	O	O
54	O	O
%	O	O
adherence	O	O
to	O	O
the	O	O
program	O	O
.	O	O

In	O	O
the	O	O
intervention	O	O
group	O	O
,	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
composite	O	O
of	O	O
death	O	O
or	O	O
unplanned	O	O
hospitalization	O	O
was	O	O
reduced	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.64	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.43	O	O
to	O	O
0.88	O	O
;	O	O
P=0.008	O	O
)	O	O
,	O	O
driven	O	O
by	O	O
reduction	O	O
in	O	O
hospitalization	O	O
.	O	O

The	O	O
quality-of-life	O	O
questionnaire	O	O
score	O	O
improved	O	O
only	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.003	O	O
)	O	O
.	O	O

Mortality	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Number	O	O
of	O	O
hospitalizations	O	O
(	O	O
1.3+/-1.7	O	O
versus	O	O
0.8+/-1.3	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
total	O	O
hospital	O	O
days	O	O
during	O	O
the	O	O
follow-up	O	O
(	O	O
19.9+/-51	O	O
versus	O	O
11.1+/-24	O	O
days	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
and	O	O
the	O	O
need	O	O
for	O	O
emergency	O	O
visits	O	O
(	O	O
4.5+/-10.6	O	O
versus	O	O
1.6+/-2.4	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
were	O	O
lower	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
.	O	O

Beneficial	O	O
effects	O	O
were	O	O
homogeneous	O	O
for	O	O
sex	O	O
,	O	O
race	O	O
,	O	O
diabetes	O	O
and	O	O
no	O	O
diabetes	O	O
,	O	O
age	O	O
,	O	O
functional	O	O
class	O	O
,	O	O
and	O	O
etiology	O	O
.	O	O

CONCLUSIONS	O	O
For	O	O
a	O	O
longer	O	O
follow-up	O	O
period	O	O
than	O	O
in	O	O
previous	O	O
studies	O	O
,	O	O
this	O	O
heart	O	O
failure	O	O
disease	O	O
management	O	O
program	O	O
model	O	O
of	O	O
patients	O	O
under	O	O
the	O	O
supervision	O	O
of	O	O
a	O	O
cardiologist	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
unplanned	O	O
hospitalization	O	O
,	O	O
a	O	O
reduction	O	O
of	O	O
total	O	O
hospital	O	O
days	O	O
,	O	O
and	O	O
a	O	O
reduced	O	O
need	O	O
for	O	O
emergency	O	O
care	O	O
,	O	O
as	O	O
well	O	O
as	O	O
improved	O	O
quality	O	O
of	O	O
life	O	O
,	O	O
despite	O	O
modest	O	O
program	O	O
adherence	O	O
over	O	O
time	O	O
.	O	O

A	O	O
prospective	O	O
randomised	O	O
comparison	O	O
of	O	O
sublingual	Pharmacological	Pharmacological
and	Pharmacological	Pharmacological
vaginal	Pharmacological	Pharmacological
misoprostol	Pharmacological	Pharmacological
in	O	O
second	O	O
trimester	O	O
termination	O	O
of	O	O
pregnancy	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	O	O
,	O	O
side	O	O
effects	O	O
and	O	O
acceptability	O	O
of	O	O
sublingual	Pharmacological	Pharmacological
and	Pharmacological	Pharmacological
vaginal	Pharmacological	Pharmacological
misoprostol	Pharmacological	Pharmacological
for	O	O
second	O	O
trimester	O	O
medical	O	O
abortion	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Tertiary	O	O
referral	O	O
unit	O	O
and	O	O
a	O	O
teaching	O	O
hospital	O	O
.	O	O

POPULATION	O	O
Two	O	O
hundred	O	O
and	O	O
twenty-four	O	O
women	O	O
at	O	O
12	O	O
to	O	O
20	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O

METHODS	O	O
The	O	O
women	O	O
were	O	O
randomised	O	O
to	O	O
receive	O	O
either	O	O
sublingual	Pharmacological	Pharmacological
or	Pharmacological	Pharmacological
vaginal	Pharmacological	Pharmacological
misoprostol	Pharmacological	Pharmacological
400	Pharmacological	O
microg	Pharmacological	O
every	O	O
3	O	O
hours	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
five	O	O
doses	O	O
.	O	O

The	O	O
course	O	O
of	O	O
misoprostol	Pharmacological	Pharmacological
was	O	O
repeated	O	O
if	O	O
the	O	O
woman	O	O
did	O	O
not	O	O
abort	O	O
within	O	O
24	O	O
hours	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
The	O	O
success	O	O
rate	O	O
at	O	O
48	O	O
hours	O	O
,	O	O
induction-to-abortion	O	O
interval	O	O
and	O	O
the	O	O
side	O	O
effects	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
success	O	O
rate	O	O
at	O	O
48	O	O
hours	O	O
(	O	O
sublingual	O	O
:	O	O
91	O	O
%	O	O
;	O	O
vaginal	O	O
:	O	O
95	O	O
%	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
success	O	O
rate	O	O
at	O	O
24	O	O
hours	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
vaginal	O	O
group	O	O
(	O	O
85	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
the	O	O
sublingual	O	O
group	O	O
(	O	O
64	O	O
%	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
median	O	O
induction-to-abortion	O	O
interval	O	O
(	O	O
sublingual	O	O
:	O	O
13.8	O	O
hours	O	O
;	O	O
vaginal	O	O
:	O	O
12.0	O	O
hours	O	O
)	O	O
.	O	O

Significantly	O	O
more	O	O
women	O	O
in	O	O
the	O	O
sublingual	O	O
group	O	O
preferred	O	O
the	O	O
route	O	O
to	O	O
which	O	O
they	O	O
were	O	O
assigned	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
vaginal	O	O
group	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
fever	O	O
was	O	O
also	O	O
less	O	O
in	O	O
the	O	O
sublingual	O	O
group	O	O
.	O	O

CONCLUSION	O	O
The	O	O
use	O	O
of	O	O
vaginal	Pharmacological	Pharmacological
misoprostol	Pharmacological	Pharmacological
for	O	O
second	O	O
trimester	O	O
medical	O	O
abortion	O	O
resulted	O	O
in	O	O
a	O	O
higher	O	O
success	O	O
rate	O	O
than	O	O
sublingual	O	O
misoprostol	Pharmacological	O
at	O	O
24	O	O
hours	O	O
but	O	O
the	O	O
abortion	O	O
rate	O	O
was	O	O
similar	O	O
at	O	O
48	O	O
hours	O	O
.	O	O

Vaginal	Pharmacological	O
misoprostol	Pharmacological	Pharmacological
should	O	O
be	O	O
the	O	O
regimen	O	O
of	O	O
choice	O	O
but	O	O
sublingual	Pharmacological	Pharmacological
misoprostol	Pharmacological	Pharmacological
is	O	O
also	O	O
an	O	O
effective	O	O
alternative	O	O
.	O	O

Timing	O	O
for	O	O
delivering	O	O
individualized	Educational	O
patient	Educational	O
education	Educational	O
intervention	Educational	O
to	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Graft	O	O
patients	O	O
:	O	O
An	O	O
RCT	O	O
.	O	O

BACKGROUND	O	O
The	O	O
primary	O	O
focus	O	O
of	O	O
this	O	O
study	O	O
is	O	O
on	O	O
the	O	O
timing	O	O
of	O	O
the	O	O
delivery	O	O
of	O	O
education	O	O
to	O	O
patients	O	O
who	O	O
had	O	O
CABG	Surgical	O
surgery	Surgical	O
.	Surgical	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
an	O	O
individualized	Educational	Educational
telephone	Educational	Educational
patient	Educational	Educational
education	Educational	Educational
intervention	Educational	Educational
,	O	O
delivered	O	O
at	O	O
two	O	O
different	O	O
points	O	O
in	O	O
time	O	O
(	O	O
1-2	O	O
days	O	O
pre-discharge	O	O
versus	O	O
1-2	O	O
days	O	O
post-discharge	O	O
)	O	O
in	O	O
enhancing	O	O
the	O	O
CABG	O	O
patient	O	O
's	O	O
knowledge	O	O
of	O	O
self-care	O	O
behaviours	O	O
,	O	O
performance	O	O
of	O	O
self-care	O	O
behaviours	O	O
,	O	O
and	O	O
symptom	O	O
frequency	O	O
.	O	O

METHOD	O	O
A	O	O
randomized	O	O
clinical	O	O
trial	O	O
that	O	O
included	O	O
a	O	O
convenience	O	O
sample	O	O
of	O	O
first	O	O
time	O	O
CABG	O	O
patients	O	O
.	O	O

Individuals	O	O
who	O	O
received	O	O
education	Educational	O
pre-discharge	Educational	O
were	O	O
compared	O	O
to	O	O
individuals	O	O
who	O	O
received	O	O
education	O	O
post-discharge	O	O
on	O	O
the	O	O
outcomes	O	O
.	O	O

RESULTS	O	O
Results	O	O
indicated	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
time	O	O
points	O	O
.	O	O

As	O	O
well	O	O
,	O	O
anxiety	O	O
levels	O	O
were	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
pre-discharge	O	O
group	O	O
than	O	O
the	O	O
post-discharge	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
individualized	O	O
nature	O	O
of	O	O
the	O	O
educational	Educational	O
intervention	Educational	O
may	O	O
have	O	O
accounted	O	O
for	O	O
non-significant	O	O
findings	O	O
reported	O	O
in	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
time	O	O
points	O	O
.	O	O

PRACTICE	O	O
IMPLICATIONS	O	O
Nurses	O	O
may	O	O
consider	O	O
assessing	O	O
anxiety	O	O
levels	O	O
prior	O	O
to	O	O
delivery	O	O
of	O	O
educational	O	O
interventions	O	O
,	O	O
implement	O	O
interventions	O	O
aimed	O	O
at	O	O
reducing	O	O
anxiety	O	O
levels	O	O
,	O	O
and	O	O
provide	O	O
individualized	O	O
teaching	O	O
.	O	O

Moderate	Pharmacological	O
sodium	Pharmacological	O
restriction	Pharmacological	O
,	O	O
angiotensin	Pharmacological	O
converting	Pharmacological	O
enzyme	Pharmacological	O
inhibition	Pharmacological	O
,	O	O
and	O	O
thiazide	Pharmacological	O
diuretic	Pharmacological	O
in	O	O
the	O	O
management	O	O
of	O	O
essential	O	O
hypertension	O	O
.	O	O

Dietary	Physical	Pharmacological
sodium	Physical	Pharmacological
restriction	Physical	Pharmacological
alone	O	O
is	O	O
effective	O	O
in	O	O
lowering	O	O
blood	O	O
pressure	O	O
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
.	O	O

Homeostatic	O	O
mechanisms	O	O
,	O	O
including	O	O
activation	O	O
of	O	O
the	O	O
renin-aldosterone	O	O
system	O	O
,	O	O
may	O	O
counteract	O	O
the	O	O
effects	O	O
of	O	O
sodium	Physical	O
restriction	O	O
.	O	O

Angiotensin	Pharmacological	Pharmacological
converting	Pharmacological	Pharmacological
enzyme	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
ACE	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
inhibitors	Pharmacological	Pharmacological
are	O	O
also	O	O
effective	O	O
as	O	O
sole	O	O
therapy	O	O
in	O	O
many	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
,	O	O
but	O	O
may	O	O
be	O	O
less	O	O
effective	O	O
in	O	O
those	O	O
with	O	O
low-renin	O	O
hypertension	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
dietary	Pharmacological	O
sodium	Pharmacological	O
restriction	Pharmacological	O
with	O	O
blockade	O	O
of	O	O
the	O	O
renin	O	O
system	O	O
by	O	O
an	O	O
ACE	Pharmacological	O
inhibitor	Pharmacological	O
is	O	O
a	O	O
particularly	O	O
effective	O	O
way	O	O
to	O	O
improve	O	O
blood	O	O
pressure	O	O
control	O	O
.	O	O

Addition	O	O
of	O	O
a	O	O
thiazide	Pharmacological	O
diuretic	Pharmacological	O
will	O	O
reduce	O	O
pressure	O	O
further	O	O
.	O	O

Pegfilgrastim	Pharmacological	O
for	O	O
peripheral	O	O
CD34+	O	O
mobilization	O	O
in	O	O
patients	O	O
with	O	O
solid	O	O
tumours	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
pegfilgrastim+/-chemotherapy	Pharmacological	O
for	O	O
mobilizing	O	O
stem	O	O
cells	O	O
in	O	O
patients	O	O
with	O	O
solid	O	O
tumours	O	O
was	O	O
assessed	O	O
.	O	O

In	O	O
cycle	O	O
0	O	O
,	O	O
a	O	O
14-day	O	O
prechemotherapy	O	O
cycle	O	O
,	O	O
patients	O	O
(	O	O
N=61	O	O
)	O	O
were	O	O
randomized	O	O
open-label	O	O
to	O	O
single	O	O
doses	O	O
of	O	O
pegfilgrastim	Pharmacological	O
(	O	O
6	O	O
,	O	O
12	O	O
or	O	O
18	O	O
mg	O	O
)	O	O
on	O	O
day	O	O
1	O	O
,	O	O
or	O	O
daily	O	O
filgrastim	Pharmacological	O
(	O	O
10	O	O
microg/kg	O	O
)	O	O
for	O	O
<	O	O
or	O	O
=7	O	O
days	O	O
.	O	O

Mean	O	O
peak	O	O
peripheral	O	O
CD34+	O	O
cell	O	O
counts	O	O
increased	O	O
with	O	O
pegfilgrastim	Pharmacological	O
dose	O	O
,	O	O
but	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
filgrastim	Pharmacological	O
only	O	O
at	O	O
the	O	O
18	O	O
mg	O	O
dose	O	O
(	O	O
10.17	O	O
vs	O	O
4.96	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.014	O	O
)	O	O
.	O	O

In	O	O
the	O	O
clinically	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
3-7	O	O
,	O	O
both	O	O
12	O	O
and	O	O
18	O	O
mg	O	O
pegfilgrastim	Pharmacological	O
doses	O	O
produced	O	O
significantly	O	O
higher	O	O
peak	O	O
CD34+	O	O
counts	O	O
(	O	O
8.18	O	O
and	O	O
9.96	O	O
vs	O	O
4.51	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
for	O	O
filgrastim	Pharmacological	O
;	Pharmacological	O
P=0.034	O	O
and	O	O
0.006	O	O
)	O	O
.	O	O

In	O	O
cycle	O	O
1	O	O
,	O	O
patients	O	O
received	O	O
carboplatin/paclitaxel	Pharmacological	O
on	O	O
day	O	O
1	O	O
,	O	O
followed	O	O
from	O	O
day	O	O
2	O	O
by	O	O
pegfilgrastim	Pharmacological	O
6-18	O	O
mg	O	O
or	O	O
daily	O	O
filgrastim	Pharmacological	O
(	O	O
5	O	O
microg/kg/day	O	O
for	O	O
<	O	O
or	O	O
=14	O	O
days	O	O
)	O	O
as	O	O
per	O	O
randomization	O	O
in	O	O
cycle	O	O
0	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
mean	O	O
peak	O	O
CD34+	O	O
count	O	O
between	O	O
pegfilgrastim	Pharmacological	O
and	O	O
filgrastim	Pharmacological	O
,	O	O
but	O	O
there	O	O
was	O	O
an	O	O
advantage	O	O
for	O	O
pegfilgrastim	Pharmacological	O
18	O	O
mg	O	O
in	O	O
the	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
7-12	O	O
(	O	O
3.14	O	O
vs	O	O
1.19	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.043	O	O
)	O	O
.	O	O

A	O	O
single	O	O
pegfilgrastim	Pharmacological	O
dose	O	O
(	O	O
>	O	O
or	O	O
=6	O	O
mg	O	O
)	O	O
could	O	O
be	O	O
substituted	O	O
for	O	O
daily	O	O
filgrastim	Pharmacological	O
in	O	O
cytokine-only	O	O
peripheral	O	O
CD34+	O	O
cell	O	O
mobilization	O	O
.	O	O

Double-blind	O	O
comparison	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
trandolapril	Pharmacological	Pharmacological
2	O	Pharmacological
mg	O	Pharmacological
and	O	Pharmacological
hydrochlorothiazide	Pharmacological	Pharmacological
25	O	O
mg	O	O
in	O	O
patients	O	O
with	O	O
mild-to-moderate	O	O
essential	O	O
hypertension	O	O
.	O	O

Investigator	O	O
Study	O	O
Group	O	O
.	O	O

This	O	O
multicenter	O	O
international	O	O
trial	O	O
recruited	O	O
205	O	O
patients	O	O
from	O	O
16	O	O
investigators	O	O
.	O	O

After	O	O
a	O	O
4-week	O	O
,	O	O
single-blind	O	O
placebo	Control	O
run-in	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
16	O	O
weeks	O	O
of	O	O
trandolapril	Pharmacological	Pharmacological
2	O	Pharmacological
mg/day	O	Pharmacological
(	O	O
68	O	O
patients	O	O
)	O	O
,	O	O
hydrochlorothiazide	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
HCTZ	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
25	O	O
mg/day	O	O
(	O	O
68	O	O
patients	O	O
)	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
(	O	O
69	O	O
patients	O	O
)	O	O
.	O	O

Morning	O	O
predosing	O	O
supine	O	O
diastolic	O	O
blood	O	O
pressure	O	O
(	O	O
DBP	O	O
)	O	O
was	O	O
the	O	O
primary	O	O
efficacy	O	O
measurement	O	O
.	O	O

Intention-to-treat	O	O
analysis	O	O
showed	O	O
significant	O	O
decreases	O	O
in	O	O
all	O	O
three	O	O
groups	O	O
in	O	O
mean	O	O
(	O	O
+/-	O	O
SEM	O	O
)	O	O
supine	O	O
DBP	O	O
throughout	O	O
the	O	O
study	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
differences	O	O
at	O	O
week	O	O
16	O	O
between	O	O
trandolapril	O	O
(	O	O
-10.6	O	O
+/-	O	O
1.3	O	O
mm	O	O
Hg	O	O
)	O	O
and	O	O
HCTZ	O	O
(	O	O
-10.9	O	O
+/-	O	O
1.3	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
gave	O	O
a	O	O
significantly	O	O
greater	O	O
reduction	O	O
than	O	O
either	O	O
drug	O	O
alone	O	O
(	O	O
-15.1	O	O
+/-	O	O
1.13	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Blood	O	O
pressure	O	O
was	O	O
normalized	O	O
in	O	O
the	O	O
combination	O	O
group	O	O
in	O	O
67	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
a	O	O
significantly	O	O
higher	O	O
proportion	O	O
than	O	O
either	O	O
trandolapril	O	O
(	O	O
63	O	O
%	O	O
)	O	O
or	O	O
HCTZ	O	O
(	O	O
60	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
.	O	O

Each	O	O
treatment	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
adverse	O	O
events	O	O
was	O	O
similar	O	O
in	O	O
all	O	O
three	O	O
groups	O	O
.	O	O

Trandolapril	O	O
2	O	O
mg	O	O
once	O	O
daily	O	O
is	O	O
an	O	O
effective	O	O
antihypertensive	O	O
agent	O	O
,	O	O
comparable	O	O
to	O	O
HCTZ	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
was	O	O
shown	O	O
to	O	O
enhance	O	O
the	O	O
antihypertensive	O	O
effect	O	O
of	O	O
the	O	O
two	O	O
compounds	O	O
alone	O	O
.	O	O

Pilot	O	O
comparison	O	O
between	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
and	O	O
bipolar	Surgical	O
radiofrequency	Surgical	O
in	O	O
paediatric	O	O
tonsillectomy	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
compare	O	O
the	O	O
advantages	O	O
and	O	O
disadvantages	O	O
of	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
with	O	O
those	O	O
of	O	O
bipolar	Surgical	O
radiofrequency	Surgical	O
techniques	Surgical	O
,	O	O
in	O	O
paediatric	O	O
tonsillectomy	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Prospective	O	O
,	O	O
randomised	O	O
,	O	O
clinical	O	O
study	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
From	O	O
July	O	O
2004	O	O
to	O	O
April	O	O
2006	O	O
,	O	O
80	O	O
patients	O	O
aged	O	O
between	O	O
10	O	O
and	O	O
15	O	O
years	O	O
,	O	O
with	O	O
tonsillectomy	Surgical	O
planned	O	O
for	O	O
chronic	O	O
tonsillitis	O	O
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Children	O	O
were	O	O
prospectively	O	O
randomised	O	O
into	O	O
two	O	O
equal	O	O
groups	O	O
:	O	O
potassium	Surgical	Physical
titanyl	Surgical	Physical
phosphate	Surgical	Physical
laser	Surgical	Physical
tonsillectomy	Surgical	Physical
and	O	Physical
bipolar	Surgical	Physical
radiofrequency	Surgical	Physical
tonsillectomy	Surgical	Physical
.	O	O

Operative	O	O
time	O	O
and	O	O
intra-operative	O	O
blood	O	O
loss	O	O
were	O	O
recorded	O	O
.	O	O

Patients	O	O
were	O	O
scheduled	O	O
for	O	O
follow	O	O
up	O	O
during	O	O
the	O	O
first	O	O
,	O	O
second	O	O
and	O	O
fourth	O	O
post-operative	O	O
weeks	O	O
.	O	O

They	O	O
were	O	O
asked	O	O
to	O	O
record	O	O
their	O	O
pain	O	O
and	O	O
discomfort	O	O
on	O	O
a	O	O
standardised	O	O
visual	O	O
analogue	O	O
scale	O	O
,	O	O
from	O	O
zero	O	O
(	O	O
no	O	O
pain	O	O
)	O	O
to	O	O
10	O	O
(	O	O
severe	O	O
pain	O	O
)	O	O
.	O	O

Post-operative	O	O
complications	O	O
were	O	O
also	O	O
recorded	O	O
and	O	O
managed	O	O
.	O	O

RESULTS	O	O
The	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
group	Surgical	O
showed	O	O
a	O	O
slightly	O	O
longer	O	O
operative	O	O
time	O	O
(	O	O
mean	O	O
12	O	O
minutes	O	O
)	O	O
than	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
mean	O	O
10	O	O
minutes	O	O
)	O	O
.	O	O

Intra-operative	O	O
blood	O	O
loss	O	O
was	O	O
significantly	O	O
less	O	O
in	O	O
the	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
group	O	O
(	O	O
mean	O	O
21	O	O
cm3	O	O
)	O	O
than	O	O
in	O	O
the	O	O
bipolar	Surgical	O
radiofrequency	Surgical	O
group	Surgical	O
(	O	O
mean	O	O
30	O	O
cm3	O	O
)	O	O
.	O	O

In	O	O
the	O	O
first	O	O
week	O	O
,	O	O
post-operative	O	O
pain	O	O
scores	O	O
were	O	O
less	O	O
in	O	O
the	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
group	O	O
than	O	O
in	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
means	O	O
7.5	O	O
and	O	O
8.5	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
second	O	O
week	O	O
pain	O	O
scores	O	O
increased	O	O
more	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
than	O	O
in	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
means	O	O
8.5	O	O
and	O	O
6	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
the	O	O
fourth	O	O
week	O	O
,	O	O
both	O	O
groups	O	O
showed	O	O
equal	O	O
and	O	O
nearly	O	O
normal	O	O
pain	O	O
scores	O	O
.	O	O

No	O	O
case	O	O
of	O	O
reactionary	O	O
post-tonsillectomy	O	O
haemorrhage	O	O
was	O	O
recorded	O	O
in	O	O
either	O	O
group	O	O
.	O	O

Only	O	O
one	O	O
case	O	O
of	O	O
secondary	O	O
post-tonsillectomy	O	O
haemorrhage	O	O
was	O	O
recorded	O	O
,	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
(	O	O
2.5	O	O
per	O	O
cent	O	O
)	O	O
,	O	O
managed	O	O
conservatively	O	O
.	O	O

CONCLUSION	O	O
Both	O	O
the	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
and	O	O
the	O	O
bipolar	Surgical	O
radiofrequency	Surgical	O
techniques	Surgical	O
were	O	O
safe	O	O
and	O	O
easy	O	O
to	O	O
use	O	O
for	O	O
tonsillectomy	O	O
,	O	O
with	O	O
reduced	O	O
operative	O	O
time	O	O
,	O	O
blood	O	O
loss	O	O
and	O	O
complication	O	O
rates	O	O
and	O	O
better	O	O
post-operative	O	O
general	O	O
patient	O	O
condition	O	O
.	O	O

Potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
resulted	O	O
in	O	O
reduced	O	O
operative	O	O
bleeding	O	O
and	O	O
immediate	O	O
post-operative	O	O
pain	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
technique	O	O
.	O	O

However	O	O
,	O	O
potassium	Surgical	O
titanyl	Surgical	O
phosphate	Surgical	O
laser	Surgical	O
required	O	O
slightly	O	O
more	O	O
operative	O	O
time	O	O
and	O	O
caused	O	O
more	O	O
late	O	O
post-operative	O	O
pain	O	O
than	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
technique	O	O
.	O	O

The	O	O
low	O	O
rate	O	O
of	O	O
recorded	O	O
complications	O	O
showed	O	O
that	O	O
both	O	O
techniques	O	O
cause	O	O
little	O	O
damage	O	O
to	O	O
the	O	O
tonsillar	O	O
bed	O	O
during	O	O
dissection	O	O
,	O	O
thus	O	O
minimising	O	O
complications	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
time	O	O
required	O	O
to	O	O
administer	O	O
three	O	O
different	O	O
fluke	Pharmacological	O
and	Pharmacological	O
worm	Pharmacological	O
combination	Pharmacological	O
products	Pharmacological	O
to	O	O
commercial	O	O
beef	O	O
cattle	O	O
at	O	O
housing	O	O
.	O	O

Larger	O	O
livestock	O	O
units	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
the	O	O
farm	O	O
labor	O	O
force	O	O
,	O	O
animal	O	O
welfare	O	O
concerns	O	O
,	O	O
and	O	O
a	O	O
trend	O	O
toward	O	O
more	O	O
selective	O	O
use	O	O
of	O	O
drugs	O	O
have	O	O
increased	O	O
the	O	O
focus	O	O
on	O	O
animal	O	O
handling	O	O
,	O	O
time	O	O
management	O	O
,	O	O
convenience	O	O
,	O	O
and	O	O
compliance	O	O
in	O	O
administering	O	O
veterinary	O	O
therapeutics	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
quantify	O	O
and	O	O
compare	O	O
the	O	O
time	O	O
needed	O	O
to	O	O
treat	O	O
commercial	O	O
beef	O	O
cattle	O	O
with	O	O
three	Pharmacological	O
fluke	Pharmacological	O
and	Pharmacological	O
worm	Pharmacological	O
combination	Pharmacological	O
products	Pharmacological	O
with	O	O
different	O	O
administration	O	O
profiles	O	O
.	O	O

Young	O	O
beef	O	O
cattle	O	O
(	O	O
n	O	O
=	O	O
270	O	O
)	O	O
weighing	O	O
approximately	O	O
400	O	O
kg	O	O
were	O	O
allocated	O	O
to	O	O
batches	O	O
of	O	O
five	O	O
,	O	O
which	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
ivermectin	Pharmacological	Pharmacological
+	O	O
clorsulon	Pharmacological	O
injection	Pharmacological	O
,	O	O
ivermectin	Pharmacological	Pharmacological
+	O	O
closantel	Pharmacological	O
injection	Pharmacological	O
,	O	O
or	O	O
levamisole	Pharmacological	Pharmacological
+	O	Pharmacological
triclabendazole	Pharmacological	Pharmacological
oral	O	Pharmacological
drench	O	Pharmacological
.	O	O

The	O	O
mean	O	O
time	O	O
needed	O	O
to	O	O
administer	O	O
ivermectin	Pharmacological	Pharmacological
+	O	O
clorsulon	Pharmacological	O
(	O	O
single	O	O
injection	O	O
)	O	O
to	O	O
five	O	O
cattle	O	O
was	O	O
31	O	O
seconds	O	O
,	O	O
which	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
the	O	O
100	O	O
seconds	O	O
needed	O	O
for	O	O
ivermectin	Pharmacological	Pharmacological
+	O	O
closantel	Pharmacological	O
(	O	O
two	O	O
injections	O	O
)	O	O
and	O	O
the	O	O
126	O	O
seconds	O	O
needed	O	O
for	O	O
levamisole	Pharmacological	O
+	O	O
triclabendazole	Pharmacological	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Such	O	O
quantitative	O	O
data	O	O
can	O	O
allow	O	O
for	O	O
better	O	O
planning	O	O
and	O	O
selection	O	O
of	O	O
parasiticide	O	O
treatment	O	O
approaches	O	O
at	O	O
the	O	O
farm	O	O
level	O	O
.	O	O

18F-FDG	O	O
PET/CT	O	O
for	O	O
early	O	O
prediction	O	O
of	O	O
response	O	O
to	O	O
neoadjuvant	Pharmacological	O
lapatinib	Pharmacological	O
,	O	O
trastuzumab	Pharmacological	O
,	O	O
and	O	O
their	Pharmacological	O
combination	Pharmacological	O
in	O	O
HER2-positive	O	O
breast	O	O
cancer	O	O
:	O	O
results	O	O
from	O	O
Neo-ALTTO	O	O
.	O	O

UNLABELLED	O	O
Molecular	O	O
imaging	O	O
receives	O	O
increased	O	O
attention	O	O
for	O	O
selecting	O	O
patients	O	O
who	O	O
will	O	O
benefit	O	O
from	O	O
targeted	O	O
anticancer	O	O
therapies	O	O
.	O	O

Neo-ALTTO	O	O
(	O	O
Neoadjuvant	Pharmacological	O
Lapatinib	Pharmacological	O
and/or	O	O
Trastuzumab	Pharmacological	O
Treatment	O	O
Optimisation	O	O
)	O	O
enrolled	O	O
455	O	O
women	O	O
with	O	O
invasive	O	O
human	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
2	O	O
(	O	O
HER2	O	O
)	O	O
-positive	O	O
breast	O	O
cancer	O	O
and	O	O
compared	O	O
rates	O	O
of	O	O
pathologic	O	O
complete	O	O
response	O	O
(	O	O
pCR	O	O
)	O	O
to	O	O
neoadjuvant	Pharmacological	O
lapatinib	Pharmacological	O
,	O	O
trastuzumab	Pharmacological	O
,	O	O
and	O	O
their	O	O
combination	Pharmacological	O
.	O	O

Each	O	O
anti-HER2	Pharmacological	O
therapy	Pharmacological	O
was	O	O
given	O	O
alone	O	O
for	O	O
6	O	O
wk	O	O
,	O	O
followed	O	O
by	O	O
12	O	O
wk	O	O
of	O	O
the	O	O
same	O	O
therapy	O	O
plus	O	O
weekly	O	O
paclitaxel	Pharmacological	O
.	Pharmacological	O

The	O	O
early	O	O
metabolic	O	O
effects	O	O
of	O	O
the	O	O
anti-HER2	Pharmacological	Physical
therapies	Pharmacological	Physical
on	O	O
the	O	O
primary	O	O
tumors	O	O
and	O	O
their	O	O
predictive	O	O
values	O	O
for	O	O
pCR	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
patients	O	O
.	O	O

METHODS	O	O
Eighty-six	O	O
patients	O	O
underwent	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
at	O	O
baseline	O	O
and	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
of	O	O
anti-HER2	Pharmacological	O
treatment	Pharmacological	O
.	Pharmacological	O

An	O	O
imaging	O	O
core	O	O
laboratory	O	O
provided	O	O
central	O	O
validation	O	O
,	O	O
and	O	O
2	O	O
independent	O	O
reviewers	O	O
,	O	O
masked	O	O
to	O	O
assigned	O	O
treatment	O	O
arm	O	O
and	O	O
clinical	O	O
outcomes	O	O
,	O	O
performed	O	O
consensus	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
readings	O	O
.	O	O

Maximum	O	O
standardized	O	O
uptake	O	O
value	O	O
(	O	O
SUVmax	O	O
)	O	O
reductions	O	O
from	O	O
baseline	O	O
were	O	O
used	O	O
to	O	O
measure	O	O
metabolic	O	O
response	O	O
.	O	O

RESULTS	O	O
Seventy-seven	O	O
of	O	O
the	O	O
86	O	O
enrolled	O	O
patients	O	O
presented	O	O
an	O	O
evaluable	O	O
baseline	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
scan	O	O
;	O	O
of	O	O
these	O	O
,	O	O
68	O	O
and	O	O
66	O	O
were	O	O
evaluable	O	O
at	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
,	O	O
respectively	O	O
.	O	O

Metabolic	O	O
responses	O	O
in	O	O
the	O	O
primary	O	O
tumors	O	O
were	O	O
evident	O	O
after	O	O
2	O	O
wk	O	O
of	O	O
targeted	O	O
therapy	O	O
and	O	O
correlated	O	O
highly	O	O
with	O	O
metabolic	O	O
responses	O	O
at	O	O
week	O	O
6	O	O
(	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0.81	O	O
)	O	O
.	O	O

pCRs	O	O
were	O	O
associated	O	O
with	O	O
greater	O	O
SUVmax	O	O
reductions	O	O
at	O	O
both	O	O
time	O	O
points	O	O
.	O	O

Mean	O	O
SUVmax	O	O
reductions	O	O
for	O	O
pCR	O	O
and	O	O
non-pCR	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
54.3	O	O
%	O	O
versus	O	O
32.8	O	O
%	O	O
at	O	O
week	O	O
2	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
61.5	O	O
%	O	O
versus	O	O
34.1	O	O
%	O	O
at	O	O
week	O	O
6	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
metabolic	O	O
response	O	O
rates	O	O
at	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
were	O	O
71.6	O	O
%	O	O
and	O	O
60	O	O
%	O	O
,	O	O
respectively	O	O
using	O	O
European	O	O
Organization	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
criteria	O	O
;	O	O
pCR	O	O
rates	O	O
were	O	O
twice	O	O
as	O	O
high	O	O
for	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
responders	O	O
than	O	O
nonresponders	O	O
(	O	O
week	O	O
2	O	O
:	O	O
42	O	O
%	O	O
vs.	O	O
21	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.12	O	O
;	O	O
week	O	O
6	O	O
:	O	O
44	O	O
%	O	O
vs.	O	O
19	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Early	O	O
metabolic	O	O
assessment	O	O
using	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
can	O	O
identify	O	O
patients	O	O
with	O	O
an	O	O
increased	O	O
likelihood	O	O
of	O	O
pCR	O	O
after	O	O
neoadjuvant	Pharmacological	O
trastuzumab	Pharmacological	O
,	O	O
lapatinib	Pharmacological	O
,	O	O
or	O	O
their	O	O
combination	Pharmacological	O
when	O	O
given	O	O
with	O	O
chemotherapy	Pharmacological	Pharmacological
.	Pharmacological	O

Double-blind	O	O
comparison	O	O
of	O	O
doxepin	Pharmacological	O
versus	O	O
bupropion	Pharmacological	O
in	O	O
outpatients	O	O
with	O	O
a	O	O
major	O	O
depressive	O	O
disorder	O	O
.	O	O

A	O	O
double-blind	O	O
controlled	O	O
study	O	O
comparing	O	O
the	O	O
effects	O	O
of	O	O
bupropion	Pharmacological	O
to	O	O
doxepin	Pharmacological	O
in	O	O
outpatients	O	O
with	O	O
primary	O	O
depression	O	O
was	O	O
conducted	O	O
to	O	O
evaluate	O	O
efficacy	O	O
and	O	O
safety	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
drugs	O	O
.	O	O

Following	O	O
a	O	O
7-day	O	O
placebo	Control	O
washout	O	O
period	O	O
,	O	O
patients	O	O
could	O	O
be	O	O
treated	O	O
for	O	O
up	O	O
to	O	O
13	O	O
weeks	O	O
on	O	O
either	O	O
treatment	O	O
.	O	O

Antidepressant	O	O
response	O	O
was	O	O
assessed	O	O
by	O	O
the	O	O
Hamilton	O	O
Depression	O	O
and	O	O
Anxiety	O	O
Scales	O	O
,	O	O
Clinical	O	O
Global	O	O
Severity	O	O
and	O	O
Improvement	O	O
Ratings	O	O
,	O	O
and	O	O
the	O	O
Zung	O	O
Self-Rating	O	O
Depression	O	O
Scale	O	O
.	O	O

Comparable	O	O
efficacy	O	O
between	O	O
the	O	O
compounds	O	O
was	O	O
found	O	O
across	O	O
the	O	O
13-week	O	O
study	O	O
.	O	O

Doxepin	Pharmacological	O
differed	O	O
from	O	O
bupropion	Pharmacological	O
mainly	O	O
on	O	O
the	O	O
sleep	O	O
factor	O	O
of	O	O
the	O	O
Hamilton	O	O
Depression	O	O
Scale	O	O
,	O	O
with	O	O
doxepin	Pharmacological	O
improving	O	O
sleep	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
bupropion	Pharmacological	O
.	Pharmacological	O

Doxepin	Pharmacological	O
produced	O	O
a	O	O
greater	O	O
incidence	O	O
of	O	O
anticholinergic	O	O
side	O	O
effects	O	O
,	O	O
including	O	O
dry	O	O
mouth	O	O
,	O	O
constipation	O	O
,	O	O
sleepiness	O	O
,	O	O
and	O	O
tiredness	O	O
,	O	O
in	O	O
comparison	O	O
to	O	O
bupropion	Pharmacological	O
.	Pharmacological	O

Also	O	O
,	O	O
increased	O	O
appetite	O	O
and	O	O
weight	O	O
gain	O	O
were	O	O
consistent	O	O
side	O	O
effects	O	O
of	O	O
doxepin	Pharmacological	O
relative	O	O
to	O	O
bupropion	Pharmacological	O
.	Pharmacological	O

Controlled	O	O
clinical	O	O
trial	O	O
of	O	O
IV	O	O
cyclophosphamide	Pharmacological	Pharmacological
versus	O	O
IV	O	O
methylprednisolone	Pharmacological	Pharmacological
in	O	O
severe	O	O
neurological	O	O
manifestations	O	O
in	O	O
systemic	O	O
lupus	O	O
erythematosus	O	O
.	O	O

BACKGROUND	O	O
Severe	O	O
neurological	O	O
involvement	O	O
in	O	O
systemic	O	O
lupus	O	O
erythematosus	O	O
(	O	O
NPSLE	O	O
)	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
dreadful	O	O
complications	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
identify	O	O
the	O	O
best	O	O
drug	O	O
,	O	O
dose	O	O
,	O	O
and	O	O
treatment	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
The	O	O
study	O	O
was	O	O
a	O	O
controlled	O	O
clinical	O	O
trial	O	O
at	O	O
two	O	O
tertiary	O	O
care	O	O
centres	O	O
of	O	O
patients	O	O
with	O	O
SLE	O	O
according	O	O
to	O	O
the	O	O
ACR	O	O
criteria	O	O
,	O	O
with	O	O
incident	O	O
(	O	O
no	O	O
more	O	O
than	O	O
15	O	O
days	O	O
)	O	O
onset	O	O
of	O	O
severe	O	O
NP	O	O
manifestations	O	O
such	O	O
as	O	O
seizures	O	O
,	O	O
optic	O	O
neuritis	O	O
,	O	O
peripheral	O	O
or	O	O
cranial	O	O
neuropathy	O	O
,	O	O
coma	O	O
,	O	O
brainstem	O	O
disease	O	O
,	O	O
or	O	O
transverse	O	O
myelitis	O	O
.	O	O

Induction	O	O
treatment	O	O
with	O	O
3	O	O
g	O	O
of	O	O
IV	O	O
methylprednisolone	Pharmacological	O
(	O	O
MP	O	O
)	O	O
followed	O	O
by	O	O
either	O	O
IV	O	Pharmacological
monthly	O	Pharmacological
cyclophosphamide	Pharmacological	Pharmacological
(	O	Pharmacological
Cy	O	Pharmacological
)	O	Pharmacological
versus	O	O
IV	Pharmacological	O
MP	Pharmacological	O
bimonthly	Pharmacological	O
every	O	O
4	O	O
months	O	O
for	O	O
1	O	O
year	O	O
and	O	O
then	O	O
IV	O	O
Cy	O	O
or	O	O
IV	O	O
MP	O	O
every	O	O
3	O	O
months	O	O
for	O	O
another	O	O
year	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
response	O	O
to	O	O
treatment	O	O
:	O	O
at	O	O
least	O	O
20	O	O
%	O	O
improvement	O	O
from	O	O
basal	O	O
conditions	O	O
on	O	O
clinical	O	O
,	O	O
laboratory	O	O
,	O	O
or	O	O
specific	O	O
neurological	O	O
testing	O	O
variables	O	O
.	O	O

RESULTS	O	O
Overall	O	O
,	O	O
a	O	O
response	O	O
rate	O	O
of	O	O
75	O	O
%	O	O
was	O	O
observed	O	O
.	O	O

Of	O	O
the	O	O
32	O	O
patients	O	O
studied	O	O
,	O	O
18/19	O	O
receiving	O	O
Cy	O	O
and	O	O
7/13	O	O
receiving	O	O
MP	O	O
responded	O	O
to	O	O
treatment	O	O
(	O	O
p	O	O
<	O	O
0.03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Cy	O	O
seems	O	O
to	O	O
be	O	O
more	O	O
effective	O	O
than	O	O
MP	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
,	O	O
severe	O	O
NPSLE	O	O
.	O	O

[	O	O
Effect	O	O
of	O	O
liu	Pharmacological	Physical
wei	Pharmacological	Physical
di	Pharmacological	Physical
huang	Pharmacological	Physical
or	O	Physical
jin	Pharmacological	Physical
gui	Pharmacological	Physical
shen	Pharmacological	Physical
qi	Pharmacological	Physical
decoction	Pharmacological	Physical
as	O	O
on	O	O
adjuvant	O	O
treatment	O	O
in	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
]	O	O
.	O	O

Eighty-three	O	O
patients	O	O
with	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
were	O	O
randomized	O	O
with	O	O
or	O	O
without	O	O
using	O	O
a	O	O
traditional	Pharmacological	O
Chinese	Pharmacological	O
Kidney-tonifying	Pharmacological	O
decoction	Pharmacological	O
(	O	O
Liu	Pharmacological	O
Wei	Pharmacological	O
Di	Pharmacological	O
Huang	Pharmacological	O
or	O	O
Jin	Pharmacological	O
Gui	Pharmacological	O
Shen	Pharmacological	O
Qi	Pharmacological	O
medicinal	Pharmacological	O
decoction	Pharmacological	O
)	O	O
in	O	O
chemotherapy	O	Pharmacological
or	O	O
radiotherapy	O	O
courses	O	O
.	O	O

74	O	O
patients	O	O
were	O	O
availble	O	O
to	O	O
be	O	O
analysis	O	O
.	O	O

The	O	O
two	O	O
treatment	O	O
groups	O	O
were	O	O
well-matched	O	O
in	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
stage	O	O
and	O	O
performance	O	O
status	O	O
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
response	O	O
rate	O	O
and	O	O
the	O	O
median	O	O
survival	O	O
between	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
CR+PR	O	O
)	O	O
was	O	O
91.5	O	O
%	O	O
for	O	O
Chinese	Pharmacological	O
herb	Pharmacological	O
group	O	O
and	O	O
46.9	O	O
%	O	O
for	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
median	O	O
survival	O	O
was	O	O
16	O	O
months	O	O
for	O	O
the	O	O
traditional	O	O
Chinese	Pharmacological	O
Kidney-tonifying	Pharmacological	O
decoction	Pharmacological	O
group	O	O
,	O	O
and	O	O
10	O	O
months	O	O
for	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Survival	O	O
curve	O	O
(	O	O
Kaplan-meire	O	O
's	O	O
)	O	O
of	O	O
the	O	O
Chinese	O	Pharmacological
herb	O	Pharmacological
group	O	O
was	O	O
better	O	O
than	O	O
that	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

10	O	O
patients	O	O
of	O	O
Chinese	Pharmacological	Pharmacological
herb	Pharmacological	Pharmacological
group	O	O
was	O	O
alive	O	O
beyond	O	O
more	O	O
than	O	O
2	O	O
years	O	O
.	O	O

Until	O	O
now	O	O
,	O	O
4	O	O
patients	O	O
in	O	O
the	O	O
Chinese	Pharmacological	O
herb	Pharmacological	O
group	O	O
,	O	O
one	O	O
in	O	O
the	O	O
control	O	O
group	O	O
are	O	O
still	O	O
enjoying	O	O
their	O	O
disease-free	O	O
life	O	O
for	O	O
more	O	O
than	O	O
7	O	O
years	O	O
.	O	O

Hematologic	O	O
toxicities	O	O
were	O	O
observed	O	O
much	O	O
frequently	O	O
in	O	O
the	O	O
patients	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.005	O	O
and	O	O
0.01/WBC	O	O
and	O	O
BPC	O	O
)	O	O
.	O	O

Results	O	O
of	O	O
animal	O	O
experiments	O	O
with	O	O
the	O	O
same	O	O
traditional	O	O
medicinal	O	O
decoctions	O	O
as	O	O
used	O	O
in	O	O
clinic	O	O
have	O	O
showed	O	O
immuno-enhancement	O	O
activities	O	O
.	O	O

These	O	O
results	O	O
have	O	O
showed	O	O
that	O	O
the	O	O
traditional	Pharmacological	O
Chinese	Pharmacological	O
Kidney-tonifying	Pharmacological	O
decoction	Pharmacological	O
may	O	O
enhance	O	O
non-specific	O	O
immunology	O	O
activities	O	O
and	O	O
may	O	O
be	O	O
much	O	O
useful	O	O
for	O	O
solid	O	O
cancer	O	O
patients	O	O
as	O	O
an	O	O
adjuvant	O	O
treatment	O	O
.	O	O

Comparative	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
twice	O	O
daily	O	O
fluticasone	Pharmacological	Pharmacological
propionate	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
versus	O	O
placebo	Control	Control
in	O	O
the	O	O
treatment	O	O
of	O	O
moderate	O	O
asthma	O	O
.	O	O

BACKGROUND	O	O
Fluticasone	Pharmacological	O
propionate	Pharmacological	O
,	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
with	O	O
negligible	O	O
systemic	O	O
bioavailability	O	O
via	O	O
the	O	O
oral	O	O
route	O	O
,	O	O
is	O	O
efficacious	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
asthma	O	O
when	O	O
administered	O	O
via	O	O
metered-dose	O	O
inhaler	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
inhaled	Pharmacological	O
fluticasone	Pharmacological	Pharmacological
propionate	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
in	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
previously	O	O
treated	O	O
with	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	Control
,	O	O
parallel-group	O	O
,	O	O
multicenter	O	O
study	O	O
of	O	O
342	O	O
adolescent	O	O
and	O	O
adult	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
[	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
second	O	O
(	O	O
FEV1	O	O
)	O	O
between	O	O
50	O	O
%	O	O
and	O	O
80	O	O
%	O	O
of	O	O
predicted	O	O
]	O	O
treated	O	O
previously	O	O
by	O	O
beclomethasone	Pharmacological	O
dipropionate	Pharmacological	O
or	O	O
triamcinolone	Pharmacological	Pharmacological
acetonide	Pharmacological	Pharmacological
.	Pharmacological	O

Patients	O	O
received	O	O
fluticasone	Pharmacological	Pharmacological
propionate	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
50	O	Pharmacological
micrograms	O	Pharmacological
,	O	O
100	O	O
micrograms	O	O
,	O	O
250	O	O
micrograms	O	O
,	O	O
or	O	O
placebo	Control	Control
via	O	O
a	O	O
breath-actuated	O	O
inhalation	O	O
device	O	O
,	O	O
the	O	O
Diskhaler	O	O
,	O	O
twice	O	O
daily	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Patients	O	O
in	O	O
the	O	O
fluticasone	O	Pharmacological
propionate	O	Pharmacological
groups	O	O
experienced	O	O
a	O	O
mean	O	O
increase	O	O
from	O	O
baseline	O	O
to	O	O
endpoint	O	O
in	O	O
FEV1	O	O
ranging	O	O
from	O	O
0.43	O	O
L	O	O
to	O	O
0.47	O	O
L.	O	O
Patients	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
experienced	O	O
a	O	O
mean	O	O
decrease	O	O
from	O	O
baseline	O	O
of	O	O
0.22	O	O
L	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
probability	O	O
of	O	O
patients	O	O
remaining	O	O
in	O	O
the	O	O
study	O	O
over	O	O
time	O	O
without	O	O
developing	O	O
signs	O	O
of	O	O
exacerbating	O	O
asthma	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
fluticasone	O	Pharmacological
propionate	O	Pharmacological
groups	O	O
than	O	O
in	O	O
the	O	O
placebo	O	Control
group	O	O
(	O	O
P	O	O
=	O	O
.001	O	O
)	O	O
.	O	O

Asthma	O	O
symptom	O	O
scores	O	O
,	O	O
supplemental	O	O
rescue	O	O
albuterol	O	O
use	O	O
,	O	O
and	O	O
number	O	O
of	O	O
nighttime	O	O
awakenings	O	O
due	O	O
to	O	O
asthma	O	O
requiring	O	O
treatment	O	O
also	O	O
improved	O	O
significantly	O	O
with	O	O
all	O	O
fluticasone	O	Pharmacological
propionate	O	Pharmacological
treatment	O	O
regimens	O	O
compared	O	O
with	O	O
placebo	O	Control
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
at	O	O
endpoint	O	O
among	O	O
the	O	O
three	O	O
fluticasone	O	Pharmacological
propionate	O	Pharmacological
groups	O	O
.	O	O

No	O	O
serious	O	O
drug-related	O	O
adverse	O	O
events	O	O
occurred	O	O
.	O	O

CONCLUSIONS	O	O
Fluticasone	O	Pharmacological
propionate	O	Pharmacological
powder	O	Pharmacological
(	O	O
50	O	O
,	O	O
100	O	O
,	O	O
and	O	O
250	O	O
micrograms	O	O
)	O	O
was	O	O
well-tolerated	O	O
and	O	O
significantly	O	O
improved	O	O
lung	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
.	O	O

Factors	O	O
predictive	O	O
of	O	O
severe	O	O
hypoglycemia	O	O
in	O	O
type	O	O
1	O	O
diabetes	O	O
:	O	O
analysis	O	O
from	O	O
the	O	O
Juvenile	O	O
Diabetes	O	O
Research	O	O
Foundation	O	O
continuous	O	O
glucose	O	O
monitoring	O	O
randomized	O	O
control	O	O
trial	O	O
dataset	O	O
.	O	O

OBJECTIVE	O	O
Identify	O	O
factors	O	O
predictive	O	O
of	O	O
severe	O	O
hypoglycemia	O	O
(	O	O
SH	O	O
)	O	O
and	O	O
assess	O	O
the	O	O
clinical	O	O
utility	O	O
of	O	O
continuous	Other	O
glucose	Other	O
monitoring	Other	O
(	Other	O
CGM	Other	O
)	Other	O
to	O	O
warn	O	O
of	O	O
impending	O	O
SH	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
In	O	O
a	O	O
multicenter	O	O
randomized	O	O
clinical	O	O
trial	O	O
,	O	O
436	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
were	O	O
randomized	O	O
to	O	O
a	O	O
treatment	O	O
group	O	O
that	O	O
used	O	O
CGM	Other	O
(	O	O
N	O	O
=	O	O
224	O	O
)	O	O
,	O	O
or	O	O
a	O	O
control	Control	Physical
group	O	Physical
that	O	Physical
used	O	Physical
standard	Control	Physical
home	Control	Physical
blood	Control	Physical
glucose	Control	Physical
monitoring	Control	Physical
(	O	O
N	O	O
=	O	O
212	O	O
)	O	O
and	O	O
completed	O	O
12	O	O
months	O	O
of	O	O
follow-up	O	O
.	O	O

After	O	O
6	O	O
months	O	O
,	O	O
the	O	O
original	O	O
control	O	O
group	O	O
initiated	O	O
CGM	Other	O
while	O	O
the	O	O
treatment	O	O
group	O	O
continued	O	O
use	O	O
of	O	O
CGM	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Baseline	O	O
risk	O	O
factors	O	O
for	O	O
SH	O	O
were	O	O
evaluated	O	O
over	O	O
12	O	O
months	O	O
of	O	O
follow-up	O	O
using	O	O
proportional	O	O
hazards	O	O
regression	O	O
.	O	O

CGM-derived	O	O
indices	O	O
of	O	O
hypoglycemia	O	O
were	O	O
used	O	O
to	O	O
predict	O	O
episodes	O	O
of	O	O
SH	O	O
over	O	O
a	O	O
24-h	O	O
time	O	O
horizon	O	O
.	O	O

RESULTS	O	O
The	O	O
SH	O	O
rate	O	O
was	O	O
17.9	O	O
per	O	O
100	O	O
person-years	O	O
,	O	O
and	O	O
a	O	O
higher	O	O
rate	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
SH	O	O
in	O	O
the	O	O
prior	O	O
6	O	O
months	O	O
and	O	O
female	O	O
sex	O	O
.	O	O

SH	O	O
frequency	O	O
increased	O	O
eightfold	O	O
when	O	O
30	O	O
%	O	O
of	O	O
CGM	Other	O
values	O	O
were	O	O
?	O	O
70	O	O
mg/dL	O	O
on	O	O
the	O	O
prior	O	O
day	O	O
(	O	O
4.5	O	O
vs.	O	O
0.5	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
the	O	O
positive	O	O
predictive	O	O
value	O	O
(	O	O
PPV	O	O
)	O	O
was	O	O
low	O	O
(	O	O
<	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Results	O	O
were	O	O
similar	O	O
for	O	O
hypoglycemic	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
and	O	O
the	O	O
low	O	O
blood	O	O
glucose	O	O
index	O	O
calculated	O	O
by	O	O
CGM	Other	O
.	O	O

CONCLUSIONS	O	O
SH	O	O
in	O	O
the	O	O
6	O	O
months	O	O
prior	O	O
to	O	O
the	O	O
study	O	O
was	O	O
the	O	O
strongest	O	O
predictor	O	O
of	O	O
SH	O	O
during	O	O
the	O	O
study	O	O
.	O	O

CGM-measured	O	O
hypoglycemia	O	O
over	O	O
a	O	O
24-h	O	O
span	O	O
is	O	O
highly	O	O
associated	O	O
with	O	O
SH	O	O
the	O	O
following	O	O
day	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
the	O	O
PPV	O	O
is	O	O
low	O	O
.	O	O

Clofarabine	Pharmacological	O
?	Pharmacological	O
fludarabine	Pharmacological	O
with	O	O
once	O	O
daily	O	O
i.v	O	O
.	O	O

busulfan	O	Physical
as	O	Physical
pretransplant	O	Physical
conditioning	O	Physical
therapy	O	Physical
for	O	O
advanced	O	O
myeloid	O	O
leukemia	O	O
and	O	O
MDS	O	O
.	O	O

Although	O	O
a	O	O
combination	O	O
of	O	O
i.v	O	O
.	O	O

busulfan	O	O
(	O	O
Bu	O	O
)	O	O
and	O	O
fludarabine	Pharmacological	O
(	O	O
Flu	O	O
)	O	O
is	O	O
a	O	O
safe	O	O
,	O	O
reduced-toxicity	O	O
conditioning	O	O
program	O	O
for	O	O
acute	O	O
myelogenous	O	O
leukemia/myelodysplastic	O	O
syndromes	O	O
(	O	O
AML/MDS	O	O
)	O	O
,	O	O
recurrent	O	O
leukemia	O	O
posttransplantation	O	O
remains	O	O
a	O	O
problem	O	O
.	O	O

To	O	O
enhance	O	O
the	O	O
conditioning	O	O
regimen	O	O
's	O	O
antileukemic	O	O
effect	O	O
,	O	O
we	O	O
decided	O	O
to	O	O
supplant	O	O
Flu	O	O
with	O	O
clofarabine	Pharmacological	O
(	O	O
Clo	O	O
)	O	O
,	O	O
and	O	O
assayed	O	O
the	O	O
interactions	O	O
of	O	O
these	O	O
nucleoside	O	O
analogs	O	O
alone	O	O
and	O	O
in	O	O
combination	O	O
with	O	O
Bu	O	O
in	O	O
Bu-resistant	O	O
human	O	O
cell	O	O
lines	O	O
in	O	O
vitro	O	O
.	O	O

We	O	O
found	O	O
pronounced	O	O
synergy	O	O
between	O	O
each	O	O
nucleoside	O	O
and	O	O
the	O	O
alkylator	O	O
but	O	O
even	O	O
more	O	O
enhanced	O	O
cytotoxic	O	O
synergy	O	O
when	O	O
the	O	O
nucleoside	O	O
analogs	O	O
were	O	O
combined	O	O
prior	O	O
to	O	O
exposing	O	O
the	O	O
cells	O	O
to	O	O
Bu	O	O
.	O	O

We	O	O
then	O	O
designed	O	O
a	O	O
4-arm	O	O
clinical	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
myeloid	O	O
leukemia	O	O
undergoing	O	O
allogeneic	O	O
stem	O	O
cell	O	O
transplantation	O	O
(	O	O
allo-SCT	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
adaptively	O	O
randomized	O	O
as	O	O
follows	O	O
:	O	O
Arm	O	O
I-Clo	O	O
:	O	O
Flu	O	O
10:30	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
Arm	O	O
II-20:20	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
Arm	O	O
III-30:10	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
Arm	O	Pharmacological
IV-single-agent	O	Pharmacological
Clo	O	Pharmacological
at	O	O
40	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

The	O	O
nucleoside	O	O
analog	O	O
(	O	O
s	O	O
)	O	O
were/was	O	O
infused	O	O
over	O	O
1	O	O
hour	O	O
once	O	O
daily	O	O
for	O	O
4	O	O
days	O	O
,	O	O
followed	O	O
on	O	O
each	O	O
day	O	O
by	O	O
Bu	O	O
,	O	O
infused	O	O
over	O	O
3	O	O
hours	O	O
to	O	O
a	O	O
pharmacokinetically	O	O
targeted	O	O
daily	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
of	O	O
6000	O	O
?Mol-min	O	O
?	O	O
10	O	O
%	O	O
.	O	O

Fifty-one	O	O
patients	O	O
have	O	O
been	O	O
enrolled	O	O
with	O	O
a	O	O
minimum	O	O
follow-up	O	O
exceeding	O	O
100	O	O
days	O	O
.	O	O

There	O	O
were	O	O
32	O	O
males	O	O
and	O	O
19	O	O
females	O	O
,	O	O
with	O	O
a	O	O
median	O	O
age	O	O
of	O	O
45	O	O
years	O	O
(	O	O
range	O	O
:	O	O
6-59	O	O
)	O	O
.	O	O

Nine	O	O
patients	O	O
had	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
(	O	O
BC	O	O
:	O	O
2	O	O
,	O	O
second	O	O
AP	O	O
:	O	O
3	O	O
,	O	O
and	O	O
tyrosine-kinase	O	O
inhibitor	O	O
refractory	O	O
first	O	O
chronic	O	O
phase	O	O
[	O	O
CP	O	O
]	O	O
:	O	O
4	O	O
)	O	O
.	O	O

Forty-two	O	O
patients	O	O
had	O	O
AML	O	O
:	O	O
14	O	O
were	O	O
induction	O	O
failures	O	O
,	O	O
8	O	O
in	O	O
first	O	O
chemotherapy-refractory	O	O
relapse	O	O
,	O	O
7	O	O
in	O	O
untreated	O	O
relapse	O	O
,	O	O
3	O	O
in	O	O
second	O	O
or	O	O
subsequent	O	O
relapse	O	O
,	O	O
4	O	O
were	O	O
in	O	O
second	O	O
complete	O	O
remission	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
and	O	O
3	O	O
in	O	O
second	O	O
CR	O	O
without	O	O
platelet	O	O
recovery	O	O
(	O	O
CRp	O	O
)	O	O
,	O	O
2	O	O
were	O	O
in	O	O
high-risk	O	O
CR1	O	O
.	O	O

Finally	O	O
,	O	O
1	O	O
patient	O	O
was	O	O
in	O	O
first	O	O
CRp	O	O
.	O	O

Graft-versus-host	O	O
disease	O	O
(	O	O
GVHD	O	O
)	O	O
prophylaxis	O	O
was	O	O
tacrolimus	O	O
and	O	O
mini-methorexate	O	O
(	O	O
MTX	O	O
)	O	O
,	O	O
and	O	O
those	O	O
who	O	O
had	O	O
an	O	O
unrelated	O	O
or	O	O
1	O	O
antigen-mismatched	O	O
donor	O	O
received	O	O
low-dose	O	Pharmacological
rabbit-ATG	O	Pharmacological
(	O	Pharmacological
Thymoglobulin?	O	Pharmacological
)	O	Pharmacological
.	O	O

All	O	O
patients	O	O
engrafted	O	O
.	O	O

Forty-one	O	O
patients	O	O
had	O	O
active	O	O
leukemia	O	O
at	O	O
the	O	O
time	O	O
of	O	O
transplant	O	O
,	O	O
and	O	O
35	O	O
achieved	O	O
CR	O	O
(	O	O
85	O	O
%	O	O
)	O	O
.	O	O

Twenty	O	O
of	O	O
the	O	O
42	O	O
AML	O	O
patients	O	O
and	O	O
5	O	O
of	O	O
9	O	O
CML	O	O
patients	O	O
are	O	O
alive	O	O
with	O	O
a	O	O
projected	O	O
median	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
of	O	O
23	O	O
months	O	O
.	O	O

Marrow	O	O
and	O	O
blood	O	O
(	O	O
T	O	O
cell	O	O
)	O	O
chimerism	O	O
studies	O	O
at	O	O
day	O	O
+100	O	O
revealed	O	O
that	O	O
both	O	O
in	O	O
the	O	O
lower-dose	O	O
Clo	O	O
groups	O	O
(	O	O
groups	O	O
1+2	O	O
)	O	O
and	O	O
the	O	O
higher-dose	O	O
Clo	O	O
groups	O	O
(	O	O
groups	O	O
3+4	O	O
)	O	O
,	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
median	O	O
of	O	O
100	O	O
%	O	O
donor	O	O
(	O	O
T	O	O
cell	O	O
)	O	O
-derived	O	O
DNA	O	O
.	O	O

There	O	O
has	O	O
been	O	O
no	O	O
secondary	O	O
graft	O	O
failure	O	O
.	O	O

In	O	O
the	O	O
first	O	O
100	O	O
days	O	O
,	O	O
1	O	O
patient	O	O
died	O	O
of	O	O
pneumonia	O	O
,	O	O
and	O	O
1	O	O
of	O	O
liver	O	O
GVHD	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
(	O	O
1	O	O
)	O	O
Clo	O	O
?	O	O
Flu	O	O
with	O	O
i.v	O	O
.	O	O

Bu	O	O
as	O	O
pretransplant	O	O
conditioning	O	O
is	O	O
safe	O	O
in	O	O
high-risk	O	O
myeloid	O	O
leukemia	O	O
patients	O	O
;	O	O
(	O	O
2	O	O
)	O	O
clofarabine	O	O
is	O	O
sufficiently	O	O
immunosuppressive	O	O
to	O	O
support	O	O
allo-SCT	O	O
in	O	O
myeloid	O	O
leukemia	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
median	O	O
OS	O	O
of	O	O
23	O	O
months	O	O
in	O	O
this	O	O
high-risk	O	O
patient	O	O
population	O	O
is	O	O
encouraging	O	O
.	O	O

Additional	O	O
studies	O	O
to	O	O
evaluate	O	O
the	O	O
antileukemic	O	O
efficacy	O	O
of	O	O
Clo	O	O
?	O	O
Flu	O	O
with	O	O
i.v	O	O
.	O	O

Bu	O	O
as	O	O
pretransplant	O	O
conditioning	O	O
therapy	O	O
are	O	O
warranted	O	O
.	O	O

Genotyping	Other	O
of	Other	O
CYP21	Other	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
sex-specific	O	O
gene	O	O
in	O	O
neonatal	O	O
screening	O	O
for	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
feasibility	O	O
and	O	O
diagnostic	O	O
utility	O	O
of	O	O
genotyping	Other	O
9	Other	O
CYP21	Other	O
mutations	O	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
dimorphic	O	O
X-Y	O	O
marker	O	O
from	O	O
neonatal	O	O
screening	O	O
samples	O	O
.	O	O

Blood-impregnated	Other	O
filter	Other	O
papers	Other	O
(	O	O
Guthrie	O	O
cards	O	O
)	O	O
from	O	O
603	O	O
randomly	O	O
chosen	O	O
New	O	O
Zealand	O	O
neonates	O	O
were	O	O
genotyped	O	O
blind	O	O
to	O	O
17-hydroxyprogesterone	Other	O
(	O	O
17-OHP	O	O
)	O	O
levels	O	O
.	O	O

Another	O	O
50	O	O
samples	O	O
from	O	O
Swiss	O	O
and	O	O
North	O	O
American	O	O
infants	O	O
with	O	O
correlative	O	O
hormonal	O	O
data	O	O
were	O	O
also	O	O
genotyped	O	O
.	O	O

DNA	O	O
was	O	O
extracted	O	O
,	O	O
and	O	O
gene-specific	O	O
PCR	O	O
was	O	O
performed	O	O
.	O	O

CYP21	Other	Physical
PCR	Other	Physical
products	O	Physical
were	O	Physical
subjected	O	Physical
to	O	Physical
ligase	O	Physical
detection	O	Physical
reaction	O	Physical
,	O	O
simultaneously	O	O
analyzing	O	O
9	O	O
CYP21	O	O
mutations	O	O
;	O	O
PCR	O	O
products	O	O
of	O	O
other	O	O
genes	O	O
were	O	O
subjected	O	O
to	O	O
direct	O	O
gel	O	O
analysis	O	O
.	O	O

CYP21	Other	O
genotyping	O	O
indicated	O	O
a	O	O
heterozygote	O	O
rate	O	O
of	O	O
2.8	O	O
%	O	O
for	O	O
classic	O	O
mutations	O	O
(	O	O
excluding	O	O
CYP21	O	O
deletions	O	O
)	O	O
,	O	O
and	O	O
2.0	O	O
%	O	O
for	O	O
nonclassic	O	O
mutations	O	O
in	O	O
New	O	O
Zealanders	O	O
.	O	O

Ten	O	O
full-term	O	O
affected	O	O
neonates	O	O
showed	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
17-OHP	O	O
levels	O	O
(	O	O
15-1400	O	O
nmol/L	O	O
)	O	O
.	O	O

Sick	O	O
or	O	O
preterm	O	O
infants	O	O
or	O	O
infants	O	O
screened	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
life	O	O
with	O	O
high	O	O
17-OHP	O	O
proved	O	O
genetically	O	O
unaffected	O	O
.	O	O

Genetic	O	O
linkage	O	O
disequilibrium	O	O
was	O	O
found	O	O
between	O	O
two	O	O
CYP21	O	O
mutations	O	O
and	O	O
chromosome	O	O
6p	O	O
markers	O	O
.	O	O

Guthrie	O	O
cards	O	O
can	O	O
be	O	O
used	O	O
to	O	O
accurately	O	O
genotype	O	O
CYP21	O	O
and	O	O
other	O	O
relevant	O	O
markers	O	O
,	O	O
potentially	O	O
enhancing	O	O
the	O	O
specificity	O	O
and	O	O
sensitivity	O	O
of	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
screening	O	O
.	O	O

CYP21	Other	O
heterozygote	O	O
frequency	O	O
for	O	O
classic	O	O
mutations	O	O
is	O	O
higher	O	O
than	O	O
expected	O	O
based	O	O
on	O	O
genotype	O	O
compared	O	O
with	O	O
that	O	O
predicted	O	O
by	O	O
hormonal	O	O
newborn	O	O
screening	O	O
.	O	O

A	O	O
description	O	O
of	O	O
the	O	O
clinical	O	O
characteristics	O	O
at	O	O
baseline	O	O
of	O	O
patients	O	O
recruited	O	O
into	O	O
the	O	O
Carvedilol	Pharmacological	O
or	O	O
Metoprolol	Pharmacological	O
European	O	O
Trial	O	O
(	O	O
COMET	O	O
)	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
The	O	O
COMET	O	O
trial	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomised	O	O
trial	O	O
comparing	O	O
carvedilol	Pharmacological	Pharmacological
,	O	O
a	O	O
comprehensive	O	O
adrenergic	O	O
receptor	O	O
antagonist	Pharmacological	O
,	O	O
with	O	O
metoprolol	Pharmacological	Pharmacological
,	O	O
a	O	O
beta-1-selective	Pharmacological	O
agent	Pharmacological	O
in	O	O
patients	O	O
with	O	O
heart	O	O
failure	O	O
and	O	O
left	O	O
ventricular	O	O
systolic	O	O
dysfunction	O	O
.	O	O

The	O	O
trial	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
mortality	O	O
with	O	O
carvedilol	Pharmacological	O
that	O	O
was	O	O
consistent	O	O
across	O	O
subgroups	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
report	O	O
is	O	O
to	O	O
describe	O	O
in	O	O
greater	O	O
detail	O	O
the	O	O
heterogeneity	O	O
of	O	O
this	O	O
population	O	O
at	O	O
baseline	O	O
with	O	O
particular	O	O
reference	O	O
to	O	O
the	O	O
impact	O	O
of	O	O
symptomatic	O	O
severity	O	O
,	O	O
age	O	O
and	O	O
gender	O	O
on	O	O
patient	O	O
characteristics	O	O
.	O	O

METHODS	O	O
A	O	O
descriptive	O	O
report	O	O
using	O	O
data	O	O
entered	O	O
in	O	O
the	O	O
COMET	O	O
study	O	O
data-base	O	O
.	O	O

RESULTS	O	O
The	O	O
characteristics	O	O
of	O	O
the	O	O
population	O	O
studied	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
in	O	O
previous	O	O
trials	O	O
of	O	O
beta-blockers	O	O
.	O	O

Almost	O	O
all	O	O
patients	O	O
were	O	O
receiving	O	O
diuretics	Pharmacological	O
and	O	O
ACE	Pharmacological	Pharmacological
inhibitors	Pharmacological	Pharmacological
with	O	O
few	O	O
patients	O	O
taking	O	O
angiotensin	Pharmacological	O
receptor	Pharmacological	O
blockers	Pharmacological	O
.	Pharmacological	O

As	O	O
expected	O	O
,	O	O
older	O	O
patients	O	O
had	O	O
more	O	O
co-morbidity	O	O
.	O	O

Older	O	O
patients	O	O
and	O	O
women	O	O
reported	O	O
worse	O	O
symptoms	O	O
and	O	O
poorer	O	O
well-being	O	O
despite	O	O
similar	O	O
ventricular	O	O
dimensions	O	O
and	O	O
systolic	O	O
dysfunction	O	O
.	O	O

NT-proBNP	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
symptoms	O	O
and	O	O
older	O	O
patients	O	O
but	O	O
not	O	O
in	O	O
women	O	O
,	O	O
although	O	O
differences	O	O
in	O	O
NT-proBNP	O	O
may	O	O
have	O	O
been	O	O
confounded	O	O
by	O	O
differences	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

CONCLUSION	O	O
Age	O	O
and	O	O
gender	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
severity	O	O
of	O	O
cardiac	O	O
dysfunction	O	O
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
important	O	O
effect	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
heart	O	O
failure	O	O
symptoms	O	O
and	O	O
patient	O	O
'well-being	O	O
'	O	O
.	O	O

This	O	O
could	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
the	O	O
relationship	O	O
between	O	O
symptoms	O	O
and	O	O
prognosis	O	O
and	O	O
therefore	O	O
the	O	O
way	O	O
in	O	O
which	O	O
patients	O	O
are	O	O
selected	O	O
for	O	O
clinical	O	O
trials	O	O
and	O	O
the	O	O
goals	O	O
of	O	O
treatment	O	O
.	O	O

This	O	O
will	O	O
be	O	O
the	O	O
subject	O	O
of	O	O
further	O	O
analyses	O	O
.	O	O

Is	O	O
a	O	O
calculated	O	O
total	O	O
hip	O	O
BMD	O	O
of	O	O
clinical	O	O
use	O	O
?	O	O
The	O	O
diagnosis	O	O
of	O	O
osteoporosis	O	O
is	O	O
based	O	O
on	O	O
bone	O	O
mass	O	O
measurement	O	O
.	O	O

To	O	O
avoid	O	O
the	O	O
errors	O	O
associated	O	O
with	O	O
the	O	O
measurement	O	O
of	O	O
spinal	O	O
bone	O	O
density	O	O
the	O	O
total	O	O
hip	O	O
has	O	O
been	O	O
accepted	O	O
as	O	O
the	O	O
standard	O	O
measurement	O	O
site	O	O
.	O	O

This	O	O
information	O	O
is	O	O
not	O	O
available	O	O
for	O	O
many	O	O
early	O	O
measurements	O	O
.	O	O

We	O	O
have	O	O
assessed	O	O
whether	O	O
it	O	O
is	O	O
possible	O	O
to	O	O
derive	O	O
clinically	O	O
useful	O	O
information	O	O
about	O	O
total	Other	O
hip	Other	O
bone	Other	O
mineral	Other	O
density	Other	O
(	O	O
BMD	O	O
)	O	O
from	O	O
measurements	O	O
at	O	O
other	O	O
hip	O	O
sites	O	O
.	O	O

The	O	O
bone	O	O
mass	O	O
measurements	O	O
of	O	O
46	O	O
patients	O	O
participating	O	O
in	O	O
a	O	O
current	O	O
trial	O	O
of	O	O
therapy	O	O
for	O	O
osteoporosis	O	O
were	O	O
reviewed	O	O
.	O	O

The	O	O
total	O	O
hip	O	O
BMD	O	O
as	O	O
directly	O	O
measured	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
obtained	O	O
from	O	O
the	O	O
formula	O	O
:	O	O
Total	O	O
hip	O	O
BMD	O	O
=	O	O
0.48	O	O
x	O	O
Neck	O	O
BMD	O	O
+	O	O
0.62	O	O
x	O	O
Trochanteric	O	O
BMD	O	O
+	O	O
0.03	O	O
.	O	O

In	O	O
30	O	O
patients	O	O
with	O	O
follow-up	O	O
data	O	O
the	O	O
rate	O	O
of	O	O
change	O	O
in	O	O
hip	O	O
BMD	O	O
over	O	O
a	O	O
year	O	O
was	O	O
also	O	O
determined	O	O
by	O	O
both	O	O
methods	O	O
.	O	O

In	O	O
the	O	O
pretreatment	O	O
state	O	O
there	O	O
was	O	O
good	O	O
agreement	O	O
between	O	O
the	O	O
two	O	O
measures	O	O
(	O	O
r2	O	O
=	O	O
0.96	O	O
,	O	O
SEE	O	O
0.012	O	O
g/cm2	O	O
)	O	O
.	O	O

If	O	O
the	O	O
formula	O	O
was	O	O
used	O	O
to	O	O
compute	O	O
a	O	O
change	O	O
in	O	O
total	O	O
hip	O	O
BMD	O	O
,	O	O
the	O	O
agreement	O	O
between	O	O
both	O	O
methods	O	O
remained	O	O
good	O	O
.	O	O

However	O	O
,	O	O
the	O	O
standard	O	O
error	O	O
of	O	O
the	O	O
estimate	O	O
of	O	O
the	O	O
change	O	O
represented	O	O
59	O	O
%	O	O
of	O	O
the	O	O
observed	O	O
change	O	O
.	O	O

This	O	O
indicates	O	O
that	O	O
the	O	O
error	O	O
associated	O	O
with	O	O
this	O	O
estimate	O	O
is	O	O
too	O	O
great	O	O
to	O	O
allow	O	O
clinically	O	O
meaningful	O	O
conclusions	O	O
to	O	O
be	O	O
drawn	O	O
from	O	O
calculated	O	O
total	O	O
hip	O	O
BMD	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
,	O	O
whilst	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
obtain	O	O
reasonable	O	O
point	O	O
estimates	O	O
of	O	O
total	O	O
hip	O	O
BMD	O	O
from	O	O
other	O	O
measures	O	O
in	O	O
the	O	O
hip	O	O
,	O	O
these	O	O
estimates	O	O
are	O	O
too	O	O
imprecise	O	O
to	O	O
allow	O	O
conclusions	O	O
about	O	O
change	O	O
in	O	O
BMD	O	O
to	O	O
be	O	O
made	O	O
.	O	O

Changes	O	O
in	O	O
H	O	O
reflex	O	O
and	O	O
V	O	O
wave	O	O
following	O	O
short-term	Physical	O
endurance	Physical	O
and	O	O
strength	Physical	O
training	Physical	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
3	O	O
wk	O	O
of	O	O
either	O	O
endurance	Physical	Physical
or	O	O
strength	Physical	Physical
training	Physical	Physical
on	O	O
plasticity	O	O
of	O	O
the	O	O
neural	O	O
mechanisms	O	O
involved	O	O
in	O	O
the	O	O
soleus	O	O
H	O	O
reflex	O	O
and	O	O
V	O	O
wave	O	O
.	O	O

Twenty-five	O	O
sedentary	O	O
healthy	O	O
subjects	O	O
were	O	O
randomized	O	O
into	O	O
an	O	O
endurance	Physical	O
group	Physical	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
or	O	O
strength	Physical	O
group	Physical	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
.	O	O

Evoked	O	O
V-wave	O	O
,	O	O
H-reflex	O	O
,	O	O
and	O	O
M-wave	O	O
recruitment	O	O
curves	O	O
,	O	O
maximal	O	O
voluntary	O	O
contraction	O	O
(	O	O
MVC	O	O
)	O	O
,	O	O
and	O	O
time-to-task-failure	O	O
(	O	O
isometric	O	O
contraction	O	O
at	O	O
40	O	O
%	O	O
MVC	O	O
)	O	O
of	O	O
the	O	O
plantar	O	O
flexors	O	O
were	O	O
recorded	O	O
before	O	O
and	O	O
after	O	O
training	O	O
.	O	O

Following	O	O
strength	Physical	O
training	Physical	O
,	O	O
MVC	O	O
of	O	O
the	O	O
plantar	O	O
flexors	O	O
increased	O	O
by	O	O
14.4	O	O
?	O	O
5.2	O	O
%	O	O
in	O	O
the	O	O
strength	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
whereas	O	O
time-to-task-failure	O	O
was	O	O
prolonged	O	O
in	O	O
the	O	O
endurance	O	O
group	O	O
(	O	O
22.7	O	O
?	O	O
17.1	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
V	O	O
wave-to-maximal	O	O
M	O	O
wave	O	O
(	O	O
V/M	O	O
(	O	O
max	O	O
)	O	O
)	O	O
ratio	O	O
increased	O	O
significantly	O	O
(	O	O
55.1	O	O
?	O	O
28.3	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
following	O	O
strength	O	O
training	O	O
,	O	O
but	O	O
the	O	O
maximal	O	O
H	O	O
wave-to-maximal	O	O
M	O	O
wave	O	O
(	O	O
H	O	O
(	O	O
max	O	O
)	O	O
/M	O	O
(	O	O
max	O	O
)	O	O
)	O	O
ratio	O	O
remained	O	O
unchanged	O	O
.	O	O

Conversely	O	O
,	O	O
in	O	O
the	O	O
endurance	O	O
group	O	O
the	O	O
V/M	O	O
(	O	O
max	O	O
)	O	O
ratio	O	O
was	O	O
not	O	O
altered	O	O
,	O	O
whereas	O	O
the	O	O
H	O	O
(	O	O
max	O	O
)	O	O
/M	O	O
(	O	O
max	O	O
)	O	O
ratio	O	O
increased	O	O
by	O	O
30.8	O	O
?	O	O
21.7	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
endurance	Physical	O
training	Physical	O
group	O	O
also	O	O
displayed	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
H-reflex	O	O
excitability	O	O
threshold	O	O
while	O	O
the	O	O
H-reflex	O	O
amplitude	O	O
on	O	O
the	O	O
ascending	O	O
limb	O	O
of	O	O
the	O	O
recruitment	O	O
curve	O	O
increased	O	O
.	O	O

Strength	O	O
training	O	O
only	O	O
elicited	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
H-reflex	O	O
excitability	O	O
threshold	O	O
,	O	O
while	O	O
H-reflex	O	O
amplitudes	O	O
over	O	O
the	O	O
ascending	O	O
limb	O	O
remained	O	O
unchanged	O	O
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
H-reflex	O	O
pathway	O	O
is	O	O
strongly	O	O
involved	O	O
in	O	O
the	O	O
enhanced	O	O
endurance	O	O
resistance	O	O
that	O	O
occurs	O	O
following	O	O
endurance	Physical	O
training	Physical	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
the	O	O
improvements	O	O
in	O	O
MVC	O	O
following	O	O
strength	O	O
training	O	O
are	O	O
likely	O	O
attributed	O	O
to	O	O
increased	O	O
descending	O	O
drive	O	O
and/or	O	O
modulation	O	O
in	O	O
afferents	O	O
other	O	O
than	O	O
Ia	O	O
afferents	O	O
.	O	O

Comparison	O	O
of	O	O
patient-controlled	Pharmacological	Pharmacological
and	O	Pharmacological
nurse-administered	Pharmacological	Pharmacological
analgesia	Pharmacological	Pharmacological
using	O	Pharmacological
intravenous	O	Pharmacological
fentanyl	O	Pharmacological
during	O	O
labor	O	O
.	O	O

Preliminary	O	O
observations	O	O
have	O	O
shown	O	O
that	O	O
fentanyl	Pharmacological	O
citrate	Pharmacological	O
,	O	O
a	O	O
potent	O	O
narcotic	O	O
,	O	O
is	O	O
helpful	O	O
during	O	O
labor	O	O
without	O	O
undue	O	O
side	O	O
effects	O	O
.	O	O

This	O	O
randomized	O	O
prospective	O	O
investigation	O	O
compared	O	O
the	O	O
patient-controlled	Pharmacological	O
administration	Pharmacological	O
of	Pharmacological	O
fentanyl	Pharmacological	O
with	O	O
that	O	O
of	O	O
administration	Pharmacological	O
by	Pharmacological	O
nurses	Pharmacological	O
on	Pharmacological	O
request	Pharmacological	O
.	Pharmacological	O

Eighty	O	O
healthy	O	O
women	O	O
beginning	O	O
active	O	O
labor	O	O
(	O	O
cervical	O	O
dilation	O	O
4	O	O
cm	O	O
)	O	O
at	O	O
term	O	O
were	O	O
assigned	O	O
to	O	O
receive	O	O
fentanyl	Pharmacological	Pharmacological
intravenously	O	O
by	O	O
either	O	O
patient-controlled	Pharmacological	O
administration	O	O
(	O	O
n=37	O	O
)	O	O
or	O	O
nurse	Pharmacological	O
administration	Pharmacological	O
on	O	O
demand	O	O
(	O	O
n=43	O	O
)	O	O
.	O	O

Pain	O	O
intensity	O	O
measurements	O	O
during	O	O
early	O	O
and	O	O
late	O	O
labor	O	O
revealed	O	O
the	O	O
degree	O	O
of	O	O
analgesia	O	O
to	O	O
be	O	O
the	O	O
same	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
delay	O	O
in	O	O
setting	O	O
up	O	O
the	O	O
infusion	O	O
system	O	O
and	O	O
the	O	O
short	O	O
time	O	O
between	O	O
requesting	O	O
analgesia	O	O
and	O	O
vaginal	O	O
delivery	O	O
were	O	O
limitations	O	O
with	O	O
self-administration	O	O
.	O	O

Maternal	O	O
oversedation	O	O
and	O	O
vomiting	O	O
did	O	O
not	O	O
occur	O	O
.	O	O

Neonatal	O	Pharmacological
naloxone	O	Pharmacological
therapy	O	Pharmacological
was	O	O
used	O	O
infrequently	O	O
,	O	O
umbilical	O	O
serum	O	O
levels	O	O
of	O	O
fentanyl	O	O
were	O	O
the	O	O
same	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
and	O	O
postnatal	O	O
neuroadaptive	O	O
testing	O	O
revealed	O	O
comparable	O	O
results	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Despite	O	O
the	O	O
usefulness	O	O
of	O	O
fentanyl	O	O
during	O	O
labor	O	O
,	O	O
administration	Pharmacological	O
by	Pharmacological	O
the	Pharmacological	O
patient	Pharmacological	O
had	O	O
no	O	O
advantages	O	O
over	O	O
administration	Pharmacological	O
by	Pharmacological	O
the	Pharmacological	O
nurses	Pharmacological	O
in	O	O
significantly	O	O
reducing	O	O
drug	O	O
use	O	O
,	O	O
improving	O	O
pain	O	O
relief	O	O
,	O	O
or	O	O
avoiding	O	O
drowsiness	O	O
.	O	O

Nutritional	O	O
orientation	O	O
,	O	O
knowledge	O	O
and	O	O
quality	O	O
of	O	O
diet	O	O
in	O	O
heart	O	O
failure	O	O
:	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Non-pharmacological	O	O
measures	O	O
are	O	O
recommended	O	O
for	O	O
heart	O	O
failure	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
most	O	O
studies	O	O
evaluate	O	O
low	O	O
sodium	O	O
diet	O	O
,	O	O
while	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
effects	O	O
of	O	O
interventions	O	O
to	O	O
improve	O	O
adherence	O	O
and	O	O
knowledge	O	O
of	O	O
patients	O	O
about	O	O
diet	O	O
content	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
if	O	O
a	O	O
global	O	O
nutritional	Educational	O
orientation	Educational	O
could	O	O
affect	O	O
nutritional	O	O
knowledge	O	O
,	O	O
adherence	O	O
to	O	O
food	O	O
guidelines	O	O
,	O	O
anthropometrics	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
heart	O	O
failure	O	O
patients	O	O
.	O	O

METHODS	O	O
Forty	O	O
six	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
intervention	O	O
or	O	O
control	O	O
group	O	O
.	O	O

Both	O	O
groups	O	O
received	O	O
usual	Educational	Educational
care	Educational	Educational
with	Educational	Educational
medical	Educational	Educational
and	Educational	Educational
nursing	Educational	Educational
staff	Educational	Educational
;	Educational	O
the	Educational	O
intervention	Educational	O
group	Educational	O
received	Educational	O
additional	Educational	Other
nutritional	Educational	Other
guidance	Educational	Other
about	Educational	Other
diet	Educational	Other
and	Educational	O
its	Educational	O
relationship	Educational	O
with	Educational	O
disease	Educational	O
,	Educational	O
sources	Educational	O
of	Educational	O
nutrients	Educational	O
,	Educational	O
and	Educational	O
reduction	Educational	O
of	Educational	O
dietary	Educational	O
sodium	Educational	O
and	Educational	O
fats	Educational	O
.	Educational	O

Enforcement	Physical	O
of	Physical	O
the	Physical	O
nutritional	Physical	O
guidance	Physical	O
was	O	O
performed	O	O
after	O	O
4	O	O
weeks	O	O
.	O	O

Both	O	O
groups	O	O
were	O	O
evaluated	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
after	O	O
6	O	O
weeks	O	O
and	O	O
6	O	O
months	O	O
.	O	O

Evaluations	O	O
included	O	O
anthropometric	O	O
parameters	O	O
,	O	O
sodium	O	O
excretion	O	O
in	O	O
24-hour	O	O
urine	O	O
,	O	O
dietary	O	O
recall	O	O
,	O	O
nutrition	O	O
knowledge	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
questionnaires	O	O
.	O	O

RESULTS	O	O
Mean	O	O
age	O	O
of	O	O
included	O	O
patients	O	O
was	O	O
58	O	O
?	O	O
10	O	O
years	O	O
and	O	O
70	O	O
%	O	O
were	O	O
male	O	O
.	O	O

After	O	O
6	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
the	O	O
nutritional	O	O
knowledge	O	O
of	O	O
intervention	O	O
group	O	O
increased	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Caloric	O	O
,	O	O
fat	O	O
and	O	O
sodium	O	O
intake	O	O
decreased	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
seen	O	O
in	O	O
quality	O	O
of	O	O
life	O	O
or	O	O
anthropometric	O	O
parameters	O	O
.	O	O

CONCLUSIONS	O	O
Nutritional	Physical	O
orientation	Physical	O
was	O	O
effective	O	O
to	O	O
modify	O	O
1	O	O
)	O	O
knowledge	O	O
about	O	O
food	O	O
and	O	O
nutrition	O	O
,	O	O
and	O	O
2	O	O
)	O	O
quality	O	O
of	O	O
diet	O	O
in	O	O
outpatients	O	O
with	O	O
heart	O	O
failure	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
evaluate	O	O
the	O	O
benefits	O	O
on	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
prognosis	O	O
.	O	O

[	O	O
Long	O	O
term	O	O
observation	O	O
in	O	O
effects	O	O
of	O	O
potassium	Pharmacological	O
and	O	O
calcium	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
on	O	O
arterial	O	O
blood	O	O
pressure	O	O
and	O	O
sodium	O	O
metabolism	O	O
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
potassium	Pharmacological	O
and	O	O
calcium	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
in	O	O
table	O	O
salt	O	O
on	O	O
reduction	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
and	O	O
sodium	O	O
metabolism	O	O
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
.	O	O

METHODS	O	O
A	O	O
single	O	O
blind	O	O
placebo-controlled	Control	Control
trial	O	O
was	O	O
carried	O	O
out	O	O
for	O	O
two	O	O
years	O	O
in	O	O
220	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
,	O	O
aged	O	O
18	O	O
-	O	O
22	O	O
years	O	O
,	O	O
who	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
supplementary	O	Pharmacological
group	O	Pharmacological
(	O	O
n	O	O
=	O	O
110	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
110	O	O
)	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
subjects	O	O
in	O	O
the	O	O
supplementary	O	O
group	O	O
and	O	O
their	O	O
family	O	O
members	O	O
was	O	O
given	O	O
10	O	O
mmol	O	O
of	O	O
potassium	Pharmacological	O
and	O	O
10	O	O
mmol	O	O
of	O	O
calcium	Pharmacological	O
mixed	O	O
in	O	O
their	O	O
table	O	O
salt	O	O
daily	O	O
for	O	O
24	O	O
months	O	O
.	O	O

RESULTS	O	O
Night	O	O
urinary	O	O
sodium	O	O
and	O	O
potassium	O	O
excretion	O	O
increased	O	O
(	O	O
urinary	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
;	O	O
urinary	O	O
K	O	O
(	O	O
+	O	O
)	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
blood	O	O
pressure	O	O
lowered	O	O
by	O	O
5.3	O	O
mm	O	O
Hg/1.8	O	O
mm	O	O
Hg	O	O
in	O	O
average	O	O
from	O	O
the	O	O
baseline	O	O
in	O	O
the	O	O
supplementary	O	O
group	O	O
two	O	O
years	O	O
after	O	O
potassium	Pharmacological	O
and	O	O
calcium	Pharmacological	O
supplementation	Pharmacological	O
,	O	O
as	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
control	O	O
group	O	O
increased	O	O
by	O	O
(	O	O
1.3/1.7	O	O
)	O	O
mm	O	O
Hg	O	O
.	O	O

CONCLUSIONS	O	O
Adequate	O	O
supplement	Pharmacological	O
of	Pharmacological	O
potassium	Pharmacological	O
and	O	O
calcium	Pharmacological	O
in	O	O
daily	O	O
table	O	O
salt	O	O
intake	O	O
was	O	O
an	O	O
effective	O	O
way	O	O
to	O	O
prevent	O	O
form	O	O
hypertension	O	O
and	O	O
could	O	O
promote	O	O
their	O	O
urinary	O	O
sodium	O	O
excretion	O	O
and	O	O
reduction	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
.	O	O

Monitoring	O	O
tumour	O	O
cells	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
of	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
Flow	Other	O
cytometry	Other	O
was	O	O
used	O	O
to	O	O
enumerate	O	O
tumour	O	O
cells	O	O
in	O	O
longitudinal	O	O
studies	O	O
of	O	O
peripheral	O	O
blood	O	O
from	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
SCLC	O	O
)	O	O
patients	O	O
,	O	O
together	O	O
with	O	O
magnetic	O	O
bead	O	O
selection	O	O
to	O	O
isolate	O	O
and	O	O
identify	O	O
these	O	O
cells	O	O
.	O	O

As	O	O
part	O	O
of	O	O
a	O	O
trial	O	O
,	O	O
11	O	O
patients	O	O
received	O	O
either	O	O
standard	O	O
(	O	O
four	O	O
weekly	O	O
)	O	O
chemotherapy	Pharmacological	O
with	O	O
ifosfamide	Pharmacological	Pharmacological
,	O	Pharmacological
carboplatin	Pharmacological	Pharmacological
,	O	Pharmacological
and	O	Pharmacological
etoposide	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
ICE	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
or	O	O
accelerated	O	O
(	O	O
two	O	O
weekly	O	O
)	O	O
ICE	Pharmacological	O
with	Pharmacological	O
filgrastim	Pharmacological	O
(	Pharmacological	O
granulocyte	Pharmacological	O
colony-stimulating	Pharmacological	O
factor	Pharmacological	O
[	Pharmacological	O
G-CSF	Pharmacological	O
]	Pharmacological	O
)	Pharmacological	O
and	O	O
autologous	Pharmacological	Physical
stem	Pharmacological	Physical
cell	Pharmacological	Physical
support	Pharmacological	Physical
.	O	O

METHODS	O	O
Fresh	O	O
venous	O	O
blood	O	O
was	O	O
taken	O	O
throughout	O	O
treatment	O	O
and	O	O
follow-up	O	O
.	O	O

Aliquots	O	O
were	O	O
stained	O	O
with	O	O
a	O	O
tumour-specific	O	O
antibody	O	O
against	O	O
epithelial	O	O
tissue	O	O
(	O	O
Ber	O	O
EP4	O	O
)	O	O
,	O	O
verified	O	O
as	O	O
a	O	O
good	O	O
marker	O	O
of	O	O
SCLC	O	O
cells	O	O
by	O	O
immunohistochemistry	O	O
.	O	O

Matched	O	O
samples	O	O
labelled	O	O
with	O	O
Ber	O	O
EP4	O	O
were	O	O
separated	O	O
magnetically	O	O
by	O	O
adding	O	O
a	O	O
secondary	O	O
bead-antibody	O	O
conjugate	O	O
for	O	O
confirmation	O	O
of	O	O
tumour	O	O
cell	O	O
identity	O	O
.	O	O

RESULTS	O	O
Circulating	O	O
tumour	O	O
cells	O	O
were	O	O
detected	O	O
and	O	O
monitored	O	O
throughout	O	O
treatment	O	O
periods	O	O
.	O	O

An	O	O
initial	O	O
rise	O	O
in	O	O
circulating	O	O
cells	O	O
after	O	O
the	O	O
first	O	O
cycle	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
fall	O	O
in	O	O
both	O	O
treatment	O	O
arms	O	O
to	O	O
baseline	O	O
levels	O	O
set	O	O
by	O	O
normal	O	O
controls	O	O
.	O	O

This	O	O
was	O	O
achieved	O	O
by	O	O
week	O	O
12	O	O
in	O	O
the	O	O
accelerated	O	O
treatment	O	O
arm	O	O
and	O	O
by	O	O
week	O	O
24	O	O
in	O	O
the	O	O
standard	O	O
arm	O	O
.	O	O

CONCLUSIONS	O	O
Flow	O	O
cytometry	O	O
and	O	O
magnetic	O	O
bead	O	O
isolation	O	O
can	O	O
be	O	O
used	O	O
to	O	O
identify	O	O
changes	O	O
in	O	O
numbers	O	O
of	O	O
circulating	O	O
tumour	O	O
cells	O	O
in	O	O
patients	O	O
undergoing	O	O
chemotherapy	Pharmacological	O
for	O	O
SCLC	O	O
and	O	O
thereafter	O	O
during	O	O
follow-up	O	O
periods	O	O
.	O	O

Absence	O	O
of	O	O
tumour	O	O
cells	O	O
may	O	O
indicate	O	O
a	O	O
more	O	O
favourable	O	O
patient	O	O
group	O	O
who	O	O
would	O	O
benefit	O	O
from	O	O
a	O	O
more	O	O
intense	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O

Long-term	O	O
exposure	O	O
to	O	O
belatacept	O	O
in	O	O
recipients	O	O
of	O	O
extended	O	O
criteria	O	O
donor	O	O
kidneys	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
BENEFIT-EXT	O	O
study	O	O
received	O	O
extended	O	O
criteria	O	O
donor	O	O
kidneys	O	O
and	O	O
a	O	O
more	O	O
intensive	Pharmacological	O
(	Pharmacological	O
MI	Pharmacological	O
)	Pharmacological	O
or	Pharmacological	O
less	Pharmacological	O
intensive	Pharmacological	O
(	Pharmacological	O
LI	Pharmacological	O
)	Pharmacological	O
belatacept	Pharmacological	O
immunosuppression	Pharmacological	O
regimen	Pharmacological	O
,	O	O
or	O	O
cyclosporine	Pharmacological	Pharmacological
A	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
CsA	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
.	O	O

Patients	O	O
who	O	O
remained	O	O
on	O	O
assigned	O	O
therapy	O	O
through	O	O
year	O	O
3	O	O
were	O	O
eligible	O	O
to	O	O
enter	O	O
a	O	O
long-term	O	O
extension	O	O
(	O	O
LTE	O	O
)	O	O
study	O	O
.	O	O

Three	O	O
hundred	O	O
four	O	O
patients	O	O
entered	O	O
the	O	O
LTE	O	O
(	O	O
n	O	O
=	O	O
104	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
113	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
87	O	O
CsA	O	O
)	O	O
,	O	O
and	O	O
260	O	O
continued	O	O
treatment	O	O
through	O	O
year	O	O
5	O	O
(	O	O
n	O	O
=	O	O
91	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
100	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
69	O	O
CsA	O	O
)	O	O
.	O	O

Twenty	O	O
patients	O	O
died	O	O
during	O	O
the	O	O
LTE	O	O
(	O	O
n	O	O
=	O	O
5	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
9	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
6	O	O
CsA	O	O
)	O	O
,	O	O
and	O	O
eight	O	O
experienced	O	O
graft	O	O
loss	O	O
(	O	O
n	O	O
=	O	O
2	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
5	O	O
CsA	O	O
)	O	O
.	O	O

Three	O	O
patients	O	O
experienced	O	O
an	O	O
acute	O	O
rejection	O	O
episode	O	O
(	O	O
n	O	O
=	O	O
2	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
LI	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
rate	O	O
of	O	O
serious	O	O
adverse	O	O
events	O	O
,	O	O
viral	O	O
infections	O	O
and	O	O
fungal	O	O
infections	O	O
was	O	O
similar	O	O
across	O	O
groups	O	O
during	O	O
the	O	O
LTE	O	O
.	O	O

There	O	O
were	O	O
four	O	O
cases	O	O
of	O	O
posttransplant	O	O
lymphoproliferative	O	O
disorder	O	O
(	O	O
PTLD	O	O
)	O	O
from	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
LTE	O	O
to	O	O
year	O	O
5	O	O
(	O	O
n	O	O
=	O	O
3	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
CsA	O	O
)	O	O
;	O	O
two	O	O
of	O	O
three	O	O
PTLD	O	O
cases	O	O
in	O	O
the	O	O
LI	O	O
group	O	O
were	O	O
in	O	O
patients	O	O
who	O	O
were	O	O
seronegative	O	O
for	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
(	O	O
-	O	O
)	O	O
)	O	O
at	O	O
transplantation	O	O
.	O	O

Mean	O	O
?	O	O
SD	O	O
calculated	O	O
GFR	O	O
at	O	O
year	O	O
5	O	O
was	O	O
55.9	O	O
?	O	O
17.5	O	O
(	O	O
MI	O	O
)	O	O
,	O	O
59.0	O	O
?	O	O
29.1	O	O
(	O	O
LI	O	O
)	O	O
and	O	O
44.6	O	O
?	O	O
16.4	O	O
(	O	O
CsA	O	O
)	O	O
mL/min/1.73	O	O
m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

Continued	O	O
treatment	O	O
with	O	O
belatacept	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
consistent	O	O
safety	O	O
profile	O	O
and	O	O
sustained	O	O
improvement	O	O
in	O	O
renal	O	O
function	O	O
versus	O	O
CsA	O	O
over	O	O
time	O	O
.	O	O

The	O	O
costs	O	O
and	O	O
effects	O	O
of	O	O
a	O	O
nutritional	Educational	O
education	Educational	O
program	Educational	O
following	O	O
work-site	O	O
cholesterol	O	O
screening	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
costs	O	O
and	O	O
impact	O	O
of	O	O
a	O	O
nutrition	Educational	O
education	Educational	O
program	Educational	O
following	O	O
a	O	O
cholesterol	O	O
screening	O	O
.	O	O

METHODS	O	O
Forty	O	O
work-sites	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
educational	Educational	Educational
interventions	Educational	Educational
:	Educational	Educational
a	O	Educational
usual	Educational	Educational
intervention	Educational	Educational
of	Educational	O
5	Educational	O
minutes	Educational	O
of	Educational	O
counseling	Educational	O
,	Educational	O
or	Educational	O
a	Educational	O
special	Educational	O
intervention	Educational	O
of	Educational	O
2	Educational	O
hours	Educational	O
of	Educational	O
behaviorally	Educational	Educational
based	Educational	Educational
education	Educational	Educational
on	Educational	O
dietary	Educational	O
changes	Educational	O
to	Educational	O
lower	Educational	O
serum	Educational	O
cholesterol	Educational	O
.	Educational	O

Costs	O	O
were	O	O
monitored	O	O
,	O	O
and	O	O
cholesterol	O	O
levels	O	O
were	O	O
retested	O	O
6	O	O
and	O	O
12	O	O
months	O	O
later	O	O
.	O	O

RESULTS	O	O
The	O	O
total	O	O
per-person	O	O
cost	O	O
for	O	O
screening	O	O
and	O	O
the	O	O
educational	O	Educational
intervention	O	Educational
was	O	O
about	O	O
$	O	O
50	O	O
.	O	O

Cholesterol	O	O
levels	O	O
differed	O	O
little	O	O
between	O	O
the	O	O
two	O	O
intervention	O	O
groups	O	O
6	O	O
months	O	O
after	O	O
screening	O	O
,	O	O
but	O	O
after	O	O
12	O	O
months	O	O
those	O	O
in	O	O
the	O	O
special	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
6.5	O	O
%	O	O
drop	O	O
in	O	O
cholesterol	O	O
,	O	O
whereas	O	O
those	O	O
at	O	O
the	O	O
usual	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
drop	O	O
of	O	O
only	O	O
3.0	O	O
%	O	O
.	O	O

Hence	O	O
a	O	O
3.5	O	O
%	O	O
cholesterol	O	O
reduction	O	O
was	O	O
attributable	O	O
to	O	O
the	O	O
special	O	O
intervention	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
behaviorally	Educational	O
based	Educational	O
nutrition	Educational	O
education	Educational	O
program	Educational	O
following	O	O
cholesterol	O	O
screening	O	O
can	O	O
have	O	O
a	O	O
meaningful	O	O
impact	O	O
on	O	O
long-term	O	O
cholesterol	O	O
levels	O	O
at	O	O
a	O	O
low	O	O
cost	O	O
.	O	O

Nutrition	Educational	O
education	Educational	O
in	O	O
work-sites	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
useful	O	O
way	O	O
to	O	O
lower	O	O
the	O	O
risk	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
communities	O	O
.	O	O

A	O	O
comparative	O	O
study	O	O
of	O	O
methyldopa	Pharmacological	O
and	O	O
labetalol	Pharmacological	Pharmacological
in	O	O
the	O	O
treatment	O	O
of	O	O
hypertension	O	O
.	O	O

1	O	O
Twenty	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
completed	O	O
a	O	O
double-blind	O	O
,	O	O
dose-tritrated	O	O
,	O	O
cross-over	O	O
comparison	O	O
of	O	O
methyldopa	Pharmacological	O
and	O	O
labetalol	Pharmacological	Pharmacological
.	O	O

2	O	O
Average	O	O
lying	O	O
BPs	O	O
(	O	O
systolic/diastolic	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
28/15	O	O
mmHg	O	O
with	O	O
methyldopa	Pharmacological	O
and	O	O
by	O	O
23/15	O	O
mmHg	O	O
with	O	O
labetalol	Pharmacological	Pharmacological
.	Pharmacological	O

3	O	O
Average	O	O
standing	O	O
BPs	O	O
(	O	O
systolic/diastolic	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
29/14	O	O
mmHg	O	O
with	O	O
methyldopa	Pharmacological	O
and	O	O
by	O	O
29/15	O	O
mmHg	O	O
with	O	O
labetalol	Pharmacological	Pharmacological
.	Pharmacological	O

4	O	O
Both	O	O
lying	O	O
and	O	O
standing	O	O
heart	O	O
rates	O	O
were	O	O
reduced	O	O
with	O	O
labetalol	Pharmacological	Pharmacological
.	Pharmacological	O

5	O	O
It	O	O
is	O	O
concluded	O	O
that	O	O
the	O	O
antihypertensive	O	O
properties	O	O
of	O	O
labetalol	Pharmacological	Pharmacological
and	O	O
methyldopa	Pharmacological	O
are	O	O
similar	O	O
but	O	O
that	O	O
larger	O	O
patient	O	O
populations	O	O
are	O	O
needed	O	O
to	O	O
study	O	O
the	O	O
relative	O	O
incidence	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
.	O	O

Mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
effect	O	O
of	O	O
implantable	Surgical	Physical
cardioverter-defibrillator	Surgical	Physical
therapy	Surgical	Physical
on	O	O
mortality	O	O
in	O	O
high-risk	O	O
patients	O	O
with	O	O
recent	O	O
myocardial	O	O
infarction	O	O
:	O	O
insights	O	O
from	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

BACKGROUND	O	O
although	O	O
implantable	Surgical	Physical
cardioverter-defibrillators	Surgical	Physical
(	O	O
ICDs	O	O
)	O	O
lower	O	O
mortality	O	O
in	O	O
stable	O	O
patients	O	O
with	O	O
low	O	O
ejection	O	O
fraction	O	O
late	O	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
randomized	O	O
trials	O	O
of	O	O
ICD	Surgical	Pharmacological
versus	O	O
control	O	O
subjects	O	O
implanted	O	O
early	O	O
after	O	O
myocardial	O	O
infarction	O	O
do	O	O
not	O	O
show	O	O
mortality	O	O
benefit	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
investigate	O	O
possible	O	O
mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
mortality	O	O
benefit	O	O
in	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
this	O	O
is	O	O
a	O	O
secondary	O	O
analysis	O	O
of	O	O
the	O	O
prospective	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

Outpatients	O	O
with	O	O
recent	O	O
(	O	O
6	O	O
to	O	O
40	O	O
days	O	O
)	O	O
acute	O	O
myocardial	O	O
infarction	O	O
,	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
(	O	O
ejection	O	O
fraction	O	O
<	O	O
35	O	O
%	O	O
)	O	O
,	O	O
and	O	O
low	O	O
heart	O	O
rate	O	O
variability	O	O
were	O	O
randomized	O	O
to	O	O
ICD	Surgical	Pharmacological
(	O	O
n=311	O	O
)	O	O
or	O	O
to	O	O
standard	Control	O
medical	Control	O
therapy	Control	O
(	O	O
n=342	O	O
)	O	O
.	O	O

In	O	O
a	O	O
competing-risks	O	O
analysis	O	O
,	O	O
those	O	O
factors	O	O
that	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
arrhythmic	O	O
death	O	O
also	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
nonarrhythmic	O	O
deaths	O	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
these	O	O
factors	O	O
,	O	O
receiving	O	O
an	O	O
ICD	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
decreased	O	O
risk	O	O
of	O	O
arrhythmic	O	O
death	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.33	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.15	O	O
to	O	O
0.71	O	O
)	O	O
but	O	O
an	O	O
increase	O	O
in	O	O
nonarrhythmic	O	O
death	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
1.70	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.00	O	O
to	O	O
2.80	O	O
)	O	O
.	O	O

In	O	O
an	O	O
adjusted	O	O
time-dependent	O	O
analysis	O	O
,	O	O
patients	O	O
receiving	O	O
an	O	O
ICD	O	O
and	O	O
having	O	O
appropriate	O	O
ICD	O	O
therapy	O	O
had	O	O
a	O	O
15.1	O	O
%	O	O
yearly	O	O
hazard	O	O
of	O	O
mortality	O	O
compared	O	O
with	O	O
5.2	O	O
%	O	O
in	O	O
ICD	O	O
patients	O	O
with	O	O
no	O	O
appropriate	O	O
therapy	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
sudden	O	O
death	O	O
in	O	O
ICD	O	O
patients	O	O
was	O	O
completely	O	O
offset	O	O
by	O	O
increased	O	O
nonarrhythmic	O	O
deaths	O	O
,	O	O
which	O	O
were	O	O
greatest	O	O
in	O	O
patients	O	O
receiving	O	O
ICD	O	O
shock	O	O
therapy	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
6.0	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
2.8	O	O
to	O	O
12.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
in	O	O
patients	O	O
receiving	O	O
ICDs	O	O
early	O	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
those	O	O
factors	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
arrhythmia	O	O
requiring	O	O
ICD	O	O
therapy	O	O
are	O	O
also	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
nonsudden	O	O
death	O	O
,	O	O
negating	O	O
the	O	O
benefit	O	O
of	O	O
ICDs	O	O
in	O	O
this	O	O
setting	O	O
.	O	O

Predictors	O	O
of	O	O
postdischarge	O	O
outcomes	O	O
from	O	O
information	O	O
acquired	O	O
shortly	O	O
after	O	O
admission	O	O
for	O	O
acute	O	O
heart	O	O
failure	O	O
:	O	O
a	O	O
report	O	O
from	O	O
the	O	O
Placebo-Controlled	Control	O
Randomized	O	O
Study	O	O
of	O	O
the	O	O
Selective	O	O
A1	O	O
Adenosine	O	O
Receptor	O	O
Antagonist	O	O
Rolofylline	Pharmacological	O
for	O	O
Patients	O	O
Hospitalized	O	O
With	O	O
Acute	O	O
Decompensated	O	O
Heart	O	O
Failure	O	O
and	O	O
Volume	O	O
Overload	O	O
to	O	O
Assess	O	O
Treatment	O	O
Effect	O	O
on	O	O
Congestion	O	O
and	O	O
Renal	O	O
Function	O	O
(	O	O
PROTECT	O	O
)	O	O
Study	O	O
.	O	O

BACKGROUND	O	O
Acute	O	O
heart	O	O
failure	O	O
is	O	O
a	O	O
common	O	O
reason	O	O
for	O	O
admission	O	O
,	O	O
and	O	O
outcome	O	O
is	O	O
often	O	O
poor	O	O
.	O	O

Improved	O	O
prognostic	O	O
risk	O	O
stratification	O	O
may	O	O
assist	O	O
in	O	O
the	O	O
design	O	O
of	O	O
future	O	O
trials	O	O
and	O	O
in	O	O
patient	O	O
management	O	O
.	O	O

Using	O	O
data	O	O
from	O	O
a	O	O
large	O	O
randomized	O	O
trial	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
prognostic	O	O
value	O	O
of	O	O
clinical	O	O
variables	O	O
,	O	O
measured	O	O
at	O	O
hospital	O	O
admission	O	O
for	O	O
acute	O	O
heart	O	O
failure	O	O
,	O	O
to	O	O
determine	O	O
whether	O	O
a	O	O
few	O	O
selected	O	O
variables	O	O
were	O	O
inferior	O	O
to	O	O
an	O	O
extended	O	O
data	O	O
set	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
The	O	O
prognostic	O	O
model	O	O
included	O	O
37	O	O
clinical	O	O
characteristics	O	O
collected	O	O
at	O	O
baseline	O	O
in	O	O
PROTECT	O	O
,	O	O
a	O	O
study	O	O
comparing	O	O
rolofylline	Pharmacological	O
and	O	O
placebo	Control	Control
in	O	O
2033	O	O
patients	O	O
admitted	O	O
with	O	O
acute	O	O
heart	O	O
failure	O	O
.	O	O

Prespecified	O	O
outcomes	O	O
at	O	O
30	O	O
days	O	O
were	O	O
death	O	O
or	O	O
rehospitalization	O	O
for	O	O
any	O	O
reason	O	O
;	O	O
death	O	O
or	O	O
rehospitalization	O	O
for	O	O
cardiovascular	O	O
or	O	O
renal	O	O
reasons	O	O
;	O	O
and	O	O
,	O	O
at	O	O
both	O	O
30	O	O
and	O	O
180	O	O
days	O	O
,	O	O
all-cause	O	O
mortality	O	O
.	O	O

No	O	O
variable	O	O
had	O	O
a	O	O
c-index	O	O
>	O	O
0.70	O	O
,	O	O
and	O	O
few	O	O
had	O	O
values	O	O
>	O	O
0.60	O	O
;	O	O
c-indices	O	O
were	O	O
lower	O	O
for	O	O
composite	O	O
outcomes	O	O
than	O	O
for	O	O
mortality	O	O
.	O	O

Blood	O	O
urea	O	O
was	O	O
generally	O	O
the	O	O
strongest	O	O
single	O	O
predictor	O	O
.	O	O

Eighteen	O	O
variables	O	O
contributed	O	O
independent	O	O
prognostic	O	O
information	O	O
,	O	O
but	O	O
a	O	O
reduced	O	O
model	O	O
using	O	O
only	O	O
8	O	O
items	O	O
(	O	O
age	O	O
,	O	O
previous	O	O
heart	O	O
failure	O	O
hospitalization	O	O
,	O	O
peripheral	O	O
edema	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
,	O	O
serum	O	O
sodium	O	O
,	O	O
urea	O	O
,	O	O
creatinine	O	O
,	O	O
and	O	O
albumin	O	O
)	O	O
performed	O	O
similarly	O	O
.	O	O

For	O	O
prediction	O	O
of	O	O
all-cause	O	O
mortality	O	O
at	O	O
180	O	O
days	O	O
,	O	O
the	O	O
model	O	O
c-index	O	O
using	O	O
all	O	O
variables	O	O
was	O	O
0.72	O	O
and	O	O
for	O	O
the	O	O
simplified	O	O
model	O	O
,	O	O
also	O	O
0.72	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
few	O	O
simple	O	O
clinical	O	O
variables	O	O
measured	O	O
on	O	O
admission	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
heart	O	O
failure	O	O
predict	O	O
a	O	O
variety	O	O
of	O	O
adverse	O	O
outcomes	O	O
with	O	O
accuracy	O	O
similar	O	O
to	O	O
more	O	O
complex	O	O
models	O	O
.	O	O

However	O	O
,	O	O
predictive	O	O
models	O	O
were	O	O
of	O	O
only	O	O
moderate	O	O
accuracy	O	O
,	O	O
especially	O	O
for	O	O
outcomes	O	O
that	O	O
included	O	O
nonfatal	O	O
events	O	O
.	O	O

Better	O	O
methods	O	O
of	O	O
risk	O	O
stratification	O	O
are	O	O
required	O	O
.	O	O

CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
URL	O	O
:	O	O
http	O	O
:	O	O
//www.clinicaltrials.gov	O	O
.	O	O

Unique	O	O
identifiers	O	O
:	O	O
NCT00328692	O	O
and	O	O
NCT00354458	O	O
.	O	O

Online	Other	O
conductivity	Other	O
monitoring	Other	O
:	O	O
validation	O	O
and	O	O
usefulness	O	O
in	O	O
a	O	O
clinical	O	O
trial	O	O
of	O	O
reduced	Other	O
dialysate	Other	O
conductivity	Other	O
.	O	O

Relatively	Other	O
low	Other	O
dialysate	Other	O
conductivity	Other	O
(	Other	O
Cndi	Other	O
)	Other	O
may	O	O
improve	O	O
outcomes	O	O
by	O	O
reducing	O	O
the	O	O
overall	O	O
sodium	O	O
burden	O	O
in	O	O
dialysis	O	O
patients	O	O
.	O	O

Excess	O	O
sodium	O	O
removal	O	O
,	O	O
however	O	O
,	O	O
could	O	O
lead	O	O
to	O	O
hemodynamic	O	O
instability	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
of	O	O
reduction	Other	O
of	Other	O
Cndi	Other	O
.	Other	O

For	O	O
the	O	O
study	O	O
,	O	O
28	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
maintenance	O	O
of	O	O
Cndi	Other	O
at	O	O
13.6	O	O
mS/cm	O	O
(	O	O
equivalent	O	O
to	O	O
135	O	O
mmol/L	O	O
of	O	O
Na+	O	O
)	O	O
or	O	O
serial	O	O
reduction	O	O
of	O	O
Cndi	Other	O
in	O	O
steps	O	O
of	O	O
0.2	O	O
mS/cm	O	O
,	O	O
guided	O	O
by	O	O
symptoms	O	O
and	O	O
blood	O	O
pressure	O	O
.	O	O

Sodium	O	O
removal	O	O
estimated	O	O
from	O	O
pre-	O	O
and	O	O
postplasma	O	O
concentrations	O	O
correlated	O	O
well	O	O
with	O	O
removal	O	O
measured	O	O
by	O	O
conductivity	O	O
monitoring	O	O
as	O	O
ionic	O	O
mass	O	O
balance	O	O
(	O	O
R2	O	O
0.66	O	O
,	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
16	O	O
patients	O	O
randomized	O	O
to	O	O
reduction	Other	O
of	Other	O
Cndi	Other	O
,	O	O
6	O	O
achieved	O	O
Cndi	O	O
13.4	O	O
mS/cm	O	O
,	O	O
6	O	O
achieved	O	O
13.2	O	O
mS/cm	O	O
,	O	O
and	O	O
4	O	O
achieved	O	O
13.0	O	O
mS/cm	O	O
.	O	O

No	O	O
episodes	O	O
of	O	O
disequilibrium	O	O
occurred	O	O
.	O	O

Interdialytic	O	O
weight	O	O
gain	O	O
was	O	O
reduced	O	O
from	O	O
2.34	O	O
+/-	O	O
0.10	O	O
kg	O	O
to	O	O
1.57	O	O
+/-	O	O
0.11	O	O
kg	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Predialysis	O	O
systolic	O	O
blood	O	O
pressure	O	O
fell	O	O
from	O	O
144	O	O
+/-	O	O
3	O	O
mm	O	O
Hg	O	O
to	O	O
137	O	O
+/-	O	O
4	O	O
mm	O	O
Hg	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
convective	Physical	O
sodium	Physical	O
removal	Physical	O
was	O	O
balanced	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
diffusive	O	O
sodium	O	O
removal	O	O
(	O	O
95	O	O
+/-	O	O
9	O	O
mmol	O	O
cf	O	O
.	O	O

175	O	O
+/-	O	O
14	O	O
mmol	O	O
,	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Reduction	Other	O
in	Other	O
Cndi	Other	O
monitored	O	O
by	O	O
IMB	O	O
is	O	O
safe	O	O
and	O	O
practical	O	O
and	O	O
leads	O	O
to	O	O
improved	O	O
interdialytic	O	O
weight	O	O
gains	O	O
and	O	O
blood	O	O
pressure	O	O
control	O	O
,	O	O
while	O	O
avoiding	O	O
excessive	O	O
sodium	O	O
removal	O	O
.	O	O

[	O	O
Effects	O	O
of	O	O
small	Physical	Physical
needle-knife	Physical	Physical
comprehensive	Physical	Physical
therapy	Physical	Physical
on	O	O
pain	O	O
and	O	O
lumbar	O	O
flexion	O	O
range	O	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
observe	O	O
therapeutic	O	O
effect	O	O
of	O	O
small	Physical	O
needle-knife	Physical	O
comprehensive	Physical	O
therapy	Physical	O
on	O	O
pain	O	O
and	O	O
lumbar	O	O
flexion	O	O
range	O	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
.	O	O

METHODS	O	O
Three	O	O
hundred	O	O
and	O	O
five	O	O
cases	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
a	O	O
needle-knife	Physical	O
group	Physical	O
of	O	O
153	O	O
cases	O	O
and	O	O
a	O	O
physiotherapy	Physical	O
group	Physical	O
of	O	O
152	O	O
cases	O	O
.	O	O

The	O	O
needle-knife	Physical	O
group	O	O
were	O	O
treated	O	O
with	O	O
small	Physical	Physical
needle-knife	Physical	Physical
releasing	Physical	Physical
therapy	Physical	Physical
,	Physical	O
blocking	Physical	O
and	Physical	O
functional	Physical	O
training	Physical	O
.	Physical	O

The	O	O
physiotherapy	Physical	O
group	O	O
were	O	O
treated	O	O
with	O	O
ultra-short	Physical	O
wave	Physical	O
,	Physical	O
modulated	Physical	O
medium	Physical	O
frequency	Physical	O
current	Physical	O
,	Physical	O
massage	Physical	O
and	Physical	O
functional	Physical	O
training	Physical	O
.	Physical	O

Pain	O	O
was	O	O
assessed	O	O
by	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
and	O	O
the	O	O
lumbar	O	O
flexion	O	O
range	O	O
was	O	O
determined	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
.	O	O

RESULTS	O	O
After	O	O
treatment	O	O
,	O	O
the	O	O
pain	O	O
and	O	O
the	O	O
lumbar	O	O
flexion	O	O
range	O	O
were	O	O
significantly	O	O
improved	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
;	O	O
and	O	O
after	O	O
treatment	O	O
,	O	O
the	O	O
VAS	O	O
score	O	O
and	O	O
the	O	O
lumbar	O	O
flexion	O	O
range	O	O
were	O	O
(	O	O
1.60	O	O
+/-	O	O
0.38	O	O
)	O	O
points	O	O
and	O	O
(	O	O
65.76	O	O
+/-	O	O
15.11	O	O
)	O	O
cm	O	O
in	O	O
the	O	O
needle-knife	Physical	O
group	O	O
and	O	O
(	O	O
4.59	O	O
+/-	O	O
1.09	O	O
)	O	O
points	O	O
and	O	O
(	O	O
53.74	O	O
+/-	O	O
15.13	O	O
)	O	O
cm	O	O
in	O	O
the	O	O
physiotherapy	O	O
group	O	O
,	O	O
respectively	O	O
,	O	O
the	O	O
needle-knife	Physical	O
group	O	O
being	O	O
significantly	O	O
better	O	O
than	O	O
the	O	O
physiotherapy	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Follow-up	O	O
survey	O	O
of	O	O
6-36	O	O
months	O	O
showed	O	O
that	O	O
the	O	O
VAS	O	O
score	O	O
and	O	O
the	O	O
lumbar	O	O
flexion	O	O
range	O	O
in	O	O
the	O	O
needle-knife	Physical	O
group	O	O
were	O	O
superior	O	O
to	O	O
those	O	O
in	O	O
the	O	O
physiotherapy	Physical	O
group	O	O
.	O	O

CONCLUSION	O	O
Small	Physical	O
needle-knife	Physical	O
comprehensive	Physical	O
therapy	Physical	O
can	O	O
significantly	O	O
improve	O	O
pain	O	O
and	O	O
lumbar	O	O
flexion	O	O
range	O	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
,	O	O
with	O	O
a	O	O
stable	O	O
long-term	O	O
therapeutic	O	O
effect	O	O
.	O	O

Reactive	O	O
balance	O	O
adjustments	O	O
to	O	O
unexpected	Physical	O
perturbations	Physical	O
during	O	O
human	O	O
walking	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
unexpected	Physical	O
forward	Physical	O
perturbations	Physical	O
(	Physical	O
FP	Physical	O
)	Physical	O
during	O	O
gait	O	O
on	O	O
lower	O	O
extremity	O	O
joint	O	O
mechanics	O	O
and	O	O
muscle	O	O
Electromyographic	O	O
(	O	O
EMG	O	O
)	O	O
patterns	O	O
in	O	O
healthy	O	O
adults	O	O
.	O	O

The	O	O
muscles	O	O
surrounding	O	O
the	O	O
hip	O	O
were	O	O
found	O	O
to	O	O
be	O	O
most	O	O
important	O	O
in	O	O
maintaining	O	O
control	O	O
of	O	O
the	O	O
trunk	O	O
and	O	O
preventing	O	O
collapse	O	O
in	O	O
response	O	O
to	O	O
the	O	O
FP	O	O
.	O	O

Distinct	O	O
lower	O	O
extremity	O	O
joint	O	O
moment	O	O
and	O	O
power	O	O
patterns	O	O
were	O	O
observed	O	O
in	O	O
response	O	O
to	O	O
the	O	O
FP	Physical	O
but	O	O
an	O	O
overall	O	O
positive	O	O
moment	O	O
of	O	O
support	O	O
(	O	O
M	O	O
(	O	O
s	O	O
)	O	O
)	O	O
was	O	O
maintained	O	O
.	O	O

Therefore	O	O
,	O	O
reactive	O	O
balance	O	O
control	O	O
was	O	O
a	O	O
synchronized	O	O
effort	O	O
of	O	O
the	O	O
lower	O	O
extremity	O	O
joints	O	O
to	O	O
prevent	O	O
collapse	O	O
during	O	O
the	O	O
FP	Physical	O
.	Physical	O

The	O	O
prophylactic	O	O
effect	O	O
of	O	O
valproate	Pharmacological	Pharmacological
on	O	O
glyceryltrinitrate	O	O
induced	O	O
migraine	O	O
.	O	O

In	O	O
this	O	O
study	O	O
the	O	O
human	O	O
glyceryltrinitrate	O	O
(	O	O
GTN	O	O
)	O	O
model	O	O
of	O	O
migraine	O	O
was	O	O
for	O	O
the	O	O
first	O	O
time	O	O
used	O	O
to	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
prophylactic	O	O
drug	O	O
.	O	O

We	O	O
chose	O	O
to	O	O
test	O	O
valproate	Pharmacological	O
due	O	O
to	O	O
its	O	O
well	O	O
documented	O	O
effect	O	O
as	O	O
a	O	O
migraine	Pharmacological	O
prophylactic	Pharmacological	O
drug	Pharmacological	O
.	Pharmacological	O

Efficacy	O	O
of	O	O
this	O	O
compound	O	O
would	O	O
support	O	O
the	O	O
usefulness	O	O
of	O	O
the	O	O
model	O	O
in	O	O
prophylactic	O	O
antimigraine	O	O
drug	O	O
development	O	O
.	O	O

Twelve	O	O
patients	O	O
with	O	O
migraine	O	O
without	O	O
aura	O	O
were	O	O
included	O	O
in	O	O
a	O	O
randomized	O	O
double	O	O
blind	O	O
crossover	O	O
study	O	O
.	O	O

Valproate	Pharmacological	O
1000	O	O
mg	O	O
or	O	O
placebo	Control	Control
was	O	O
given	O	O
daily	O	O
,	O	O
each	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
13	O	O
days	O	O
.	O	O

On	O	O
the	O	O
last	O	O
treatment	O	O
day	O	O
of	O	O
each	O	O
arm	O	O
a	O	O
20	O	O
min	O	O
intravenous	O	O
infusion	O	O
of	O	O
GTN	Pharmacological	O
(	O	O
0.25	O	O
microg/kg/min	O	O
)	O	O
was	O	O
given	O	O
.	O	O

Headache	O	O
was	O	O
registered	O	O
for	O	O
12	O	O
h	O	O
after	O	O
the	O	O
infusion	O	O
and	O	O
headache	O	O
intensity	O	O
was	O	O
scored	O	O
on	O	O
a	O	O
scale	O	O
from	O	O
0	O	O
to	O	O
10	O	O
.	O	O

Fulfillment	O	O
of	O	O
IHS	O	O
criteria	O	O
was	O	O
recorded	O	O
for	O	O
24	O	O
h.	O	O
The	O	O
middle	O	O
cerebral	O	O
arteries	O	O
were	O	O
evaluated	O	O
by	O	O
transcranial	O	O
Doppler	O	O
and	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
superficial	O	O
temporal	O	O
and	O	O
radial	O	O
arteries	O	O
were	O	O
measured	O	O
with	O	O
high	O	O
frequency	O	O
ultrasound	O	O
.	O	O

GTN	Pharmacological	O
evoked	O	O
migraine	O	O
fulfilling	O	O
IHS	O	O
criteria	O	O
1.1	O	O
in	O	O
6	O	O
patients	O	O
after	O	O
placebo	Control	Control
and	O	O
in	O	O
2	O	O
patients	O	O
after	O	O
valproate	Pharmacological	O
(	O	O
P	O	O
=	O	O
0.125	O	O
)	O	O
.	O	O

Including	O	O
additionally	O	O
3	O	O
patients	O	O
on	O	O
placebo	Control	Control
and	O	O
1	O	O
patient	O	O
on	O	O
valproate	Pharmacological	O
who	O	O
felt	O	O
they	O	O
had	O	O
suffered	O	O
a	O	O
migraine	O	O
attack	O	O
,	O	O
but	O	O
who	O	O
had	O	O
as	O	O
associated	O	O
symptoms	O	O
only	O	O
photophobia	O	O
or	O	O
phonophobia	O	O
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
induced	O	O
migraine	O	O
after	O	O
valproate	Pharmacological	O
was	O	O
seen	O	O
(	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

Median	O	O
peak	O	O
headache	O	O
intensity	O	O
was	O	O
1	O	O
(	O	O
range	O	O
0-9	O	O
)	O	O
after	O	O
valproate	Pharmacological	Pharmacological
compared	O	O
to	O	O
4.5	O	O
(	O	O
range	O	O
0-8	O	O
)	O	O
after	O	O
placebo	Control	O
(	O	O
P	O	O
=	O	O
0.120	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
valproate	Pharmacological	Pharmacological
as	O	O
compared	O	O
to	O	O
placebo	Control	O
reduced	O	O
the	O	O
velocity	O	O
in	O	O
both	O	O
middle	O	O
cerebral	O	O
arteries	O	O
after	O	O
GTN	O	O
(	O	O
left	O	O
P	O	O
=	O	O
0.021	O	O
,	O	O
right	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
valproate	Pharmacological	Pharmacological
was	O	O
seen	O	O
in	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
superficial	O	O
temporal	O	O
artery	O	O
(	O	O
P	O	O
=	O	O
0.781	O	O
)	O	O
or	O	O
the	O	O
radial	O	O
artery	O	O
(	O	O
P	O	O
=	O	O
0.367	O	O
)	O	O
before	O	O
or	O	O
after	O	O
GTN	O	O
.	O	O

The	O	O
study	O	O
indicates	O	O
that	O	O
a	O	O
prophylactic	O	O
effect	O	O
of	O	O
valproate	Pharmacological	Pharmacological
may	O	O
be	O	O
demonstrated	O	O
using	O	O
the	O	O
GTN	Pharmacological	O
human	Pharmacological	O
migraine	Pharmacological	O
model	Pharmacological	O
.	Pharmacological	O

Although	O	O
,	O	O
all	O	O
headache	O	O
parameters	O	O
were	O	O
reduced	O	O
after	O	O
valproate	Pharmacological	Pharmacological
compared	O	O
to	O	O
placebo	Control	Control
,	O	O
only	O	O
one	O	O
parameter	O	O
was	O	O
statistically	O	O
significantly	O	O
reduced	O	O
probably	O	O
because	O	O
of	O	O
the	O	O
small	O	O
number	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
effect	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
valproate	O	Pharmacological
in	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
GTN	Pharmacological	O
model	Pharmacological	O
may	O	O
therefore	O	O
be	O	O
a	O	O
valid	O	O
tool	O	O
for	O	O
testing	O	O
new	O	O
prophylactic	O	O
antimigraine	O	O
drugs	O	O
.	O	O

Intravenous	Pharmacological	O
or	Pharmacological	O
intramuscular	Pharmacological	O
teicoplanin	Pharmacological	O
once	O	O
daily	O	O
for	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
.	O	O

Teicoplanin	Pharmacological	O
is	O	O
a	O	O
new	O	O
glycopeptide	O	O
antibiotic	O	O
with	O	O
potent	O	O
activity	O	O
against	O	O
gram-positive	O	O
bacteria	O	O
and	O	O
pharmacokinetics	O	O
that	O	O
allow	O	O
once	O	O
daily	O	O
administration	O	O
.	O	O

To	O	O
study	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
teicoplanin	Pharmacological	O
for	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
,	O	O
75	O	O
patients	O	O
received	O	O
teicoplanin	Pharmacological	O
intravenously	Pharmacological	O
(	Pharmacological	O
38	Pharmacological	O
)	Pharmacological	O
or	Pharmacological	O
intramuscularly	Pharmacological	O
(	O	O
37	O	O
,	O	O
of	O	O
which	O	O
16	O	O
were	O	O
outpatients	O	O
)	O	O
.	O	O

Of	O	O
62	O	O
clinically	O	O
evaluable	O	O
patients	O	O
,	O	O
97	O	O
percent	O	O
of	O	O
teicoplanin	Pharmacological	O
iv	O	O
and	O	O
93	O	O
percent	O	O
of	O	O
teicoplanin	Pharmacological	O
im	O	O
patients	O	O
were	O	O
cured	O	O
or	O	O
improved	O	O
.	O	O

All	O	O
teicoplanin	Pharmacological	O
iv	O	O
patients	O	O
and	O	O
64	O	O
percent	O	O
of	O	O
teicoplanin	Pharmacological	O
im	O	O
patients	O	O
were	O	O
cured	O	O
microbiologically	O	O
at	O	O
24-48	O	O
hours	O	O
posttherapy	O	O
.	O	O

Persistence	O	O
of	O	O
organisms	O	O
frequently	O	O
was	O	O
associated	O	O
with	O	O
skin	O	O
ulcers	O	O
or	O	O
abscess	O	O
cavities	O	O
and	O	O
usually	O	O
had	O	O
no	O	O
bearing	O	O
on	O	O
clinical	O	O
outcome	O	O
.	O	O

Possible	O	O
adverse	O	O
clinical	O	O
and	O	O
laboratory	O	O
reactions	O	O
caused	O	O
by	O	O
teicoplanin	Pharmacological	O
occurred	O	O
in	O	O
4	O	O
of	O	O
38	O	O
teicoplanin	O	O
iv	O	O
patients	O	O
(	O	O
11	O	O
percent	O	O
)	O	O
and	O	O
in	O	O
8	O	O
of	O	O
37	O	O
teicoplanin	Pharmacological	O
im	O	O
patients	O	O
(	O	O
22	O	O
percent	O	O
)	O	O
.	O	O

Reactions	O	O
were	O	O
mild	O	O
and	O	O
resolved	O	O
with	O	O
discontinuation	O	O
of	O	O
teicoplanin	Pharmacological	O
in	O	O
most	O	O
cases	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
teicoplanin	O	O
appeared	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
and	O	O
convenient	O	O
for	O	O
both	O	O
hospital	O	O
staff	O	O
and	O	O
patients	O	O
,	O	O
and	O	O
potentially	O	O
cost-effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
teicoplanin	Pharmacological	O
appears	O	O
to	O	O
be	O	O
appropriate	O	O
for	O	O
outpatient	O	O
parenteral	O	O
therapy	O	O
.	O	O

Cyclosporin	Pharmacological	Pharmacological
versus	O	O
cyclophosphamide	Pharmacological	Pharmacological
for	O	O
patients	O	O
with	O	O
steroid-dependent	O	O
and	O	O
frequently	O	O
relapsing	O	O
idiopathic	O	O
nephrotic	O	O
syndrome	O	O
:	O	O
a	O	O
multicentre	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	O	O
(	O	O
maintenance	O	O
of	O	O
remission	O	O
)	O	O
,	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
cyclosporin	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
CsA	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
with	O	O
those	O	O
of	O	O
cyclophosphamide	Pharmacological	Pharmacological
in	O	O
patients	O	O
with	O	O
steroid-dependent	O	O
or	O	O
frequently	O	O
relapsing	O	O
nephrotic	O	O
syndrome	O	O
(	O	O
NS	O	O
)	O	O
.	O	O

DESIGN	O	O
Open	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
multicentre	O	O
,	O	O
controlled	O	O
study	O	O
for	O	O
parallel	O	O
groups	O	O
,	O	O
stratified	O	O
for	O	O
adults	O	O
and	O	O
children	O	O
.	O	O

The	O	O
setting	O	O
was	O	O
in	O	O
nephrological	O	O
departments	O	O
in	O	O
Italy	O	O
.	O	O

SUBJECTS	O	O
AND	O	O
INTERVENTIONS	O	O
Seventy-three	O	O
patients	O	O
with	O	O
steroid-sensitive	O	O
idiopathic	O	O
NS	O	O
admitted	O	O
to	O	O
the	O	O
study	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
cyclophosphamide	Pharmacological	Pharmacological
(	O	O
2.5	O	O
mg/kg/day	O	O
)	O	O
for	O	O
8	O	O
weeks	O	O
or	O	O
CsA	Pharmacological	Pharmacological
(	O	O
5	O	O
mg/kg/day	O	O
in	O	O
adults	O	O
,	O	O
6	O	O
mg/kg/day	O	O
in	O	O
children	O	O
)	O	O
for	O	O
9	O	O
months	O	O
,	O	O
tapered	O	O
off	O	O
by	O	O
25	O	O
%	O	O
every	O	O
month	O	O
until	O	O
complete	O	O
discontinuation	O	O
at	O	O
month	O	O
12	O	O
.	O	O

Seven	O	O
patients	O	O
lost	O	O
to	O	O
follow	O	O
up	O	O
were	O	O
not	O	O
considered	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

The	O	O
remaining	O	O
66	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
for	O	O
3-24	O	O
months	O	O
after	O	O
randomization	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Relapse-free	O	O
survival	O	O
;	O	O
number	O	O
of	O	O
N.S	O	O
.	O	O

relapses/patient/year	O	O
;	O	O
cumulative	O	O
dose	O	O
of	O	O
prednisone/patient	O	O
;	O	O
laboratory	O	O
investigations	O	O
(	O	O
kidney	O	O
and	O	O
liver	O	O
functions	O	O
,	O	O
haematological	O	O
parameters	O	O
)	O	O
;	O	O
incidence	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

RESULTS	O	O
At	O	O
month	O	O
9	O	O
,	O	O
26	O	O
of	O	O
35	O	O
CsA-treated	O	O
patients	O	O
were	O	O
still	O	O
in	O	O
complete	O	O
remission	O	O
and	O	O
a	O	O
further	O	O
five	O	O
patients	O	O
were	O	O
in	O	O
partial	O	O
remission	O	O
;	O	O
18	O	O
of	O	O
28	O	O
cyclophosphamide-treated	Pharmacological	O
patients	O	O
were	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
one	O	O
in	O	O
partial	O	O
remission	O	O
(	O	O
P	O	O
=	O	O
NS	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
between	O	O
adults	O	O
and	O	O
children	O	O
was	O	O
seen	O	O
with	O	O
either	O	O
treatment	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
relapse	O	O
was	O	O
similar	O	O
between	O	O
frequent	O	O
relapsers	O	O
(	O	O
19	O	O
of	O	O
22	O	O
)	O	O
and	O	O
steroid-dependent	O	O
patients	O	O
(	O	O
8	O	O
of	O	O
14	O	O
)	O	O
given	O	O
CsA	O	Pharmacological
,	O	O
and	O	O
those	O	O
given	O	O
cyclophosphamide	Pharmacological	Pharmacological
(	O	O
5	O	O
of	O	O
15	O	O
and	O	O
6	O	O
of	O	O
15	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
number	O	O
of	O	O
relapses	O	O
per	O	O
year	O	O
and	O	O
the	O	O
mean	O	O
dose	O	O
of	O	O
prednisone	O	O
per	O	O
year	O	O
were	O	O
significantly	O	O
less	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
in	O	O
both	O	O
groups	O	O
for	O	O
the	O	O
experimental	O	O
year	O	O
than	O	O
for	O	O
the	O	O
year	O	O
before	O	O
randomization	O	O
.	O	O

At	O	O
2	O	O
years	O	O
,	O	O
25	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
given	O	O
CsA	Pharmacological	Pharmacological
(	O	O
50	O	O
%	O	O
adults	O	O
and	O	O
20	O	O
%	O	O
children	O	O
)	O	O
and	O	O
63	O	O
%	O	O
of	O	O
those	O	O
given	O	O
cyclophosphamide	Pharmacological	Pharmacological
(	O	O
40	O	O
%	O	O
adults	O	O
and	O	O
68	O	O
%	O	O
children	O	O
)	O	O
had	O	O
not	O	O
had	O	O
any	O	O
relapse	O	O
of	O	O
NS	O	O
.	O	O

Tolerance	O	O
to	O	O
the	O	O
two	O	O
drugs	O	O
was	O	O
generally	O	O
good	O	O
.	O	O

The	O	O
CsA-related	Pharmacological	O
side-effects	O	O
were	O	O
mild	O	O
and	O	O
disappeared	O	O
after	O	O
drug	O	O
discontinuation	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
both	O	O
treatments	O	O
are	O	O
effective	O	O
and	O	O
well	O	O
tolerated	O	O
;	O	O
more	O	O
patients	O	O
given	O	O
cyclophosphamide	Pharmacological	Pharmacological
had	O	O
stable	O	O
remissions	O	O
.	O	O

Pedantic	Psychological	O
speaking	Psychological	O
style	O	O
differentiates	O	O
Asperger	O	O
syndrome	O	O
from	O	O
high-functioning	O	O
autism	O	O
.	O	O

Asperger	O	O
syndrome	O	O
(	O	O
AS	O	O
)	O	O
is	O	O
a	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
recently	O	O
introduced	O	O
as	O	O
a	O	O
new	O	O
diagnostic	O	O
category	O	O
in	O	O
the	O	O
ICD-10	O	O
and	O	O
the	O	O
DSM-IV	O	O
.	O	O

Along	O	O
with	O	O
motor	O	O
clumsiness	O	O
,	O	O
pedantic	Psychological	O
speech	Psychological	O
has	O	O
been	O	O
proposed	O	O
as	O	O
a	O	O
clinical	O	O
feature	O	O
of	O	O
AS	O	O
.	O	O

However	O	O
,	O	O
few	O	O
attempts	O	O
have	O	O
been	O	O
made	O	O
to	O	O
define	O	O
and	O	O
measure	O	O
this	O	O
symptom	O	O
.	O	O

We	O	O
studied	O	O
17	O	O
patients	O	O
with	O	O
AS	O	O
(	O	O
ICD-10	O	O
;	O	O
14	O	O
male	O	O
,	O	O
3	O	O
female	O	O
;	O	O
mean	O	O
age	O	O
16.4	O	O
years	O	O
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
97	O	O
)	O	O
and	O	O
compared	O	O
them	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
normal-intelligence	O	O
autism	O	O
or	O	O
high-functioning	O	O
autism	O	O
(	O	O
HFA	O	O
)	O	O
(	O	O
ICD-10/DSM-III-R	O	O
;	O	O
12	O	O
male	O	O
,	O	O
1	O	O
female	O	O
;	O	O
mean	O	O
age	O	O
15.5	O	O
years	O	O
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
81.2	O	O
)	O	O
.	O	O

An	O	O
operational	O	O
definition	O	O
of	O	O
pedantic	O	O
speech	O	O
was	O	O
formulated	O	O
and	O	O
a	O	O
rating	O	O
scale	O	O
devised	O	O
.	O	O

13	O	O
(	O	O
76	O	O
%	O	O
)	O	O
of	O	O
the	O	O
AS	O	O
patients	O	O
were	O	O
rated	O	O
as	O	O
pedantic	Psychological	O
compared	O	O
to	O	O
4	O	O
(	O	O
31	O	O
%	O	O
)	O	O
of	O	O
the	O	O
HFA	O	O
group	O	O
(	O	O
chi	O	O
2	O	O
=	O	O
6.3	O	O
;	O	O
p	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

Results	O	O
suggest	O	O
that	O	O
pedantic	Psychological	O
speech	Psychological	O
is	O	O
common	O	O
in	O	O
AS	O	O
and	O	O
may	O	O
help	O	O
differentiate	O	O
AS	O	O
from	O	O
high-functioning	O	O
autism	O	O
.	O	O

Lack	O	O
of	O	O
effect	O	O
of	O	O
food	Physical	O
on	O	O
the	O	O
steady	O	O
state	O	O
pharmacokinetics	O	O
of	O	O
BMS-181101	O	O
,	O	O
an	O	O
antidepressant	O	O
,	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
food	O	O
on	O	O
the	O	O
pharmacokinetics	O	O
of	O	O
BMS-181101	Pharmacological	Pharmacological
,	O	O
a	O	O
new	O	O
anti-depressant	O	O
under	O	O
development	O	O
,	O	O
was	O	O
investigated	O	O
in	O	O
12	O	O
healthy	O	O
male	O	O
volunteers	O	O
at	O	O
steady	O	O
state	O	O
.	O	O

Each	O	O
subject	O	O
received	O	O
a	O	O
15	O	O
mg	O	O
oral	O	Pharmacological
dose	O	Pharmacological
of	O	Pharmacological
BMS-181101	Pharmacological	Pharmacological
twice	O	O
a	O	O
day	O	O
(	O	O
q	O	O
12	O	O
h	O	O
)	O	O
for	O	O
11	O	O
days	O	O
and	O	O
a	O	O
morning	O	O
dose	O	O
of	O	O
BMS-181101	Pharmacological	Pharmacological
on	O	O
day	O	O
12	O	O
.	O	O

Six	O	O
subjects	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
BMS-181101	Pharmacological	Pharmacological
under	O	O
fasted	O	O
conditions	O	O
from	O	O
days	O	O
1	O	O
to	O	O
6	O	O
and	O	O
then	O	O
crossed	O	O
over	O	O
to	O	O
fed	O	O
conditions	O	O
from	O	O
days	O	O
7	O	O
to	O	O
12	O	O
.	O	O

The	O	O
other	O	O
six	O	O
subjects	O	O
received	O	O
the	O	O
reverse	O	O
conditions	O	O
,	O	O
fed	O	O
for	O	O
days	O	O
1-6	O	O
and	O	O
fasted	O	O
for	O	O
days	O	O
7-12	O	O
.	O	O

Serial	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
up	O	O
to	O	O
12	O	O
h	O	O
on	O	O
days	O	O
6	O	O
and	O	O
12	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
trough	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
on	O	O
days	O	O
4	O	O
,	O	O
5	O	O
,	O	O
10	O	O
,	O	O
and	O	O
11	O	O
prior	O	O
to	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

Plasma	O	O
samples	O	O
were	O	O
analyzed	O	O
for	O	O
intact	O	O
BMS-181101	Pharmacological	O
using	O	O
a	O	O
validated	O	O
high-performance	O	O
liquid	O	O
chromatography	O	O
method	O	O
with	O	O
an	O	O
electrochemical	O	O
detector	O	O
.	O	O

BMS-181101	O	O
was	O	O
well	O	O
tolerated	O	O
both	O	O
with	O	O
and	O	O
without	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

The	O	O
statistical	O	O
evaluation	O	O
of	O	O
the	O	O
Cmin	O	O
values	O	O
indicated	O	O
that	O	O
steady	O	O
state	O	O
of	O	O
BMS-181101	Pharmacological	Pharmacological
was	O	O
achieved	O	O
by	O	O
the	O	O
fourth	O	O
day	O	O
of	O	O
dosing	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
subject	O	O
was	O	O
fasted	O	O
or	O	O
fed	O	O
.	O	O

When	O	O
BMS-181101	O	O
was	O	O
administered	O	O
with	O	O
food	O	O
,	O	O
Cmax	O	O
was	O	O
reduced	O	O
by	O	O
about	O	O
25	O	O
%	O	O
and	O	O
tmax	O	O
was	O	O
prolonged	O	O
by	O	O
1	O	O
h.	O	O
However	O	O
,	O	O
AUCtau	O	O
,	O	O
t1/2	O	O
,	O	O
and	O	O
time	O	O
to	O	O
attain	O	O
steady	O	O
state	O	O
of	O	O
BMS-181101	O	O
were	O	O
not	O	O
altered	O	O
by	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
BMS-181101	Pharmacological	Pharmacological
can	O	O
be	O	O
given	O	O
with	O	O
food	O	O
without	O	O
adversely	O	O
impacting	O	O
the	O	O
safety	O	O
or	O	O
pharmacokinetic	O	O
profiles	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Salbutamol	Pharmacological	Pharmacological
or	O	O
mist	Pharmacological	O
in	O	O
acute	O	O
bronchiolitis	O	O
.	O	O

BACKGROUND	O	O
The	O	O
role	O	O
of	O	O
bronchodilators	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
bronchiolitis	O	O
remains	O	O
controversial	O	O
.	O	O

METHODS	O	O
A	O	O
double-blind	O	O
,	O	O
placebo	O	Control
controlled	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	O	O
response	O	O
to	O	O
nebulized	O	O
salbutamol	Pharmacological	O
.	Pharmacological	O

One	O	O
hundred	O	O
and	O	O
fifty-six	O	O
infants	O	O
aged	O	O
between	O	O
7	O	O
weeks	O	O
and	O	O
24	O	O
months	O	O
who	O	O
had	O	O
had	O	O
an	O	O
episode	O	O
of	O	O
wheezing	O	O
and	O	O
other	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
bronchiolitis	O	O
were	O	O
randomized	O	O
to	O	O
three	O	O
groups	O	O
as	O	O
follows	O	O
:	O	O
(	O	O
i	O	O
)	O	O
nebulized	Pharmacological	O
salbutamol	Pharmacological	Pharmacological
was	O	O
administered	O	O
to	O	O
52	O	O
patients	O	O
in	O	O
group	O	O
I	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0.15	O	Pharmacological
mg/kg	O	Pharmacological
in	O	Pharmacological
2	O	Pharmacological
mL	O	Pharmacological
saline	Control	Pharmacological
;	Control	O
(	O	O
ii	O	O
)	O	O
saline	Control	O
was	O	O
nebulized	O	O
to	O	O
52	O	O
patients	O	O
in	O	O
group	O	O
II	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
in	O	O
group	O	O
III	O	O
52	O	O
patients	O	O
received	O	O
mist	Pharmacological	O
in	O	O
a	O	O
tent	O	O
.	O	O

All	O	O
three	O	O
groups	O	O
were	O	O
administered	O	O
oxygen	Pharmacological	O
during	O	O
the	O	O
procedures	O	O
.	O	O

Treatment	O	O
was	O	O
repeated	O	O
with	O	O
the	O	O
same	O	O
agent	O	O
after	O	O
30	O	O
min	O	O
if	O	O
the	O	O
respiratory	O	O
score	O	O
was	O	O
5	O	O
or	O	O
more	O	O
.	O	O

Respiratory	O	O
rate	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
oxygen	O	O
saturation	O	O
and	O	O
presence	O	O
of	O	O
cyanosis	O	O
,	O	O
wheezing	O	O
,	O	O
retractions	O	O
were	O	O
recorded	O	O
before	O	O
and	O	O
after	O	O
each	O	O
treatment	O	O
.	O	O

RESULTS	O	O
The	O	O
decrease	O	O
in	O	O
the	O	O
respiratory	O	O
score	O	O
was	O	O
5.2	O	O
+/-	O	O
1.8	O	O
,	O	O
0.82	O	O
+/-	O	O
2.4	O	O
and	O	O
1.7	O	O
+/-	O	O
1.3	O	O
in	O	O
group	O	O
I	O	O
,	O	O
II	O	O
and	O	O
III	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
group	O	O
I	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

Heart	O	O
rate	O	O
was	O	O
similar	O	O
between	O	O
groups	O	O
.	O	O

Oxygen	O	O
saturation	O	O
decreased	O	O
in	O	O
group	O	O
I	O	O
without	O	O
reaching	O	O
statistical	O	O
significance	O	O
.	O	O

CONCLUSIONS	O	O
Salbutamol	Pharmacological	Pharmacological
was	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
and	O	O
safe	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bronchiolitis	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
use	O	O
of	O	O
pyridostigmine	Pharmacological	Pharmacological
and	O	O
requirement	O	O
of	O	O
vecuronium	Pharmacological	Pharmacological
in	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
.	O	O

CONTEXT	O	O
Patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
receive	O	O
pyridostigmine	Pharmacological	Pharmacological
,	O	O
an	O	O
anticholinesterase	Pharmacological	O
agent	Pharmacological	O
,	O	O
as	O	O
a	O	O
part	O	O
of	O	O
therapy	O	O
.	O	O

These	O	O
patients	O	O
demonstrate	O	O
a	O	O
heightened	O	O
sensitivity	O	O
towards	O	O
non-depolarising	O	O
muscle	O	O
relaxants	O	O
.	O	O

Continuing	O	O
pyridostigmine	Pharmacological	O
till	O	O
the	O	O
day	O	O
of	O	O
the	O	O
surgery	O	O
or	O	O
omitting	O	O
it	O	O
on	O	O
the	O	O
night	O	O
before	O	O
surgery	O	O
could	O	O
provide	O	O
variable	O	O
results	O	O
with	O	O
regards	O	O
to	O	O
the	O	O
effect	O	O
of	O	O
vecuronium	Pharmacological	Pharmacological
.	Pharmacological	O

AIMS	O	O
Myographic	O	O
evaluation	O	O
of	O	O
a	O	O
dose	O	O
of	O	O
vecuronium	O	Pharmacological
in	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
on	O	O
pyridostigmine	O	O
therapy	O	O
.	O	O

SETTING	O	O
AND	O	O
DESIGN	O	O
A	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
clinical	O	O
study	O	O
conducted	O	O
in	O	O
a	O	O
teaching	O	O
hospital	O	O
.	O	O

SUBJECTS	O	O
AND	O	O
METHODS	O	O
Medically	O	O
(	Pharmacological	O
oral	Pharmacological	O
pyridostigmine	Pharmacological	O
)	Pharmacological	O
well-controlled	O	O
adult	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
who	O	O
were	O	O
posted	O	O
for	O	O
thymectomy	Surgical	O
,	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
two	O	O
groups	O	O
.	O	O

Patients	O	O
in	O	O
Group	O	O
1	O	O
received	O	O
their	O	O
last	O	O
dose	O	O
of	O	O
pyridostigmine	Pharmacological	Pharmacological
on	O	O
the	O	O
night	O	O
before	O	O
surgery	O	O
while	O	O
those	O	O
in	O	O
Group	O	O
2	O	O
received	O	O
even	O	O
the	O	O
morning	O	O
dose	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
the	O	O
day	O	O
of	O	O
surgery	O	O
.	O	O

Neostigmine	Pharmacological	O
(	O	O
1-2	O	O
mg	O	O
)	O	O
intravenously	O	O
was	O	O
used	O	O
as	O	O
rescue	O	O
medication	O	O
.	O	O

Vecuronium	Pharmacological	Pharmacological
(	O	O
0.01	O	O
mg/kg	O	O
)	O	O
was	O	O
used	O	O
for	O	O
intubation	O	O
and	O	O
muscle	O	O
relaxation	O	O
during	O	O
trans-sternal	Surgical	O
thymectomy	Surgical	O
and	O	O
its	O	O
effect	O	O
was	O	O
reversed	O	O
using	O	O
neostigmine	O	Pharmacological
and	O	O
atropine	O	O
.	O	O

RESULTS	O	O
Fourteen	O	O
patients	O	O
(	O	O
7	O	O
in	O	O
each	O	O
group	O	O
)	O	O
belonging	O	O
to	O	O
both	O	O
sexes	O	O
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
intubating	O	O
dose	O	O
of	O	O
vecuronium	O	Pharmacological
showed	O	O
quicker	O	O
onset	O	O
time	O	O
(	O	O
155	O	O
sec	O	O
or	O	O
2.7	O	O
min	O	O
approx	O	O
.	O	O

)	O	O
and	O	O
peak	O	O
effect	O	O
(	O	O
99	O	O
%	O	O
T1	O	O
suppression	O	O
)	O	O
in	O	O
patients	O	O
belonging	O	O
to	O	O
Group	O	O
1	O	O
,	O	O
and	O	O
3/7	O	O
(	O	O
43	O	O
%	O	O
)	O	O
complained	O	O
of	O	O
respiratory	O	O
discomfort	O	O
while	O	O
waiting	O	O
for	O	O
surgery	O	O
.	O	O

By	O	O
giving	O	O
the	O	O
morning	O	O
dose	O	O
of	O	O
pyridostigmine	Pharmacological	Pharmacological
(	O	O
Group	O	O
2	O	O
)	O	O
,	O	O
an	O	O
identical	O	O
intubating	O	O
dose	O	O
of	O	O
vecuronium	Pharmacological	Pharmacological
showed	O	O
relative	O	O
resistance	O	O
(	O	O
peak	O	O
effect-97	O	O
%	O	O
T1	O	O
suppression	O	O
)	O	O
and	O	O
delayed	O	O
onset	O	O
time	O	O
(	O	O
198	O	O
sec	O	O
approx.	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
reversal	O	O
was	O	O
complete	O	O
at	O	O
the	O	O
end	O	O
of	O	O
surgery	O	O
in	O	O
both	O	O
the	O	O
regimens	O	O
.	O	O

CONCLUSIONS	O	O
Omission	O	O
of	O	O
the	O	O
pyridostigmine	Pharmacological	O
dose	O	O
on	O	O
the	O	O
day	O	O
of	O	O
surgery	O	O
predisposed	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
respiratory	O	O
discomfort	O	O
and	O	O
sensitivity	O	O
to	O	O
vecuronium	Pharmacological	O
.	Pharmacological	O

Continued	O	O
administration	O	O
significantly	O	O
prolonged	O	O
the	O	O
onset	O	O
time	O	O
of	O	O
vecuronium	Pharmacological	Pharmacological
and	O	O
the	O	O
patients	O	O
required	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
vecuronium	Pharmacological	Pharmacological
.	Pharmacological	O

Pilot	O	O
study	O	O
of	O	O
Panax	Pharmacological	O
quinquefolius	Pharmacological	O
(	Pharmacological	O
American	Pharmacological	O
ginseng	Pharmacological	O
)	Pharmacological	O
to	O	O
improve	O	O
cancer-related	O	O
fatigue	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
dose-finding	O	O
evaluation	O	O
:	O	O
NCCTG	O	O
trial	O	O
N03CA	O	O
.	O	O

PURPOSE	O	O
This	O	O
pilot	O	O
trial	O	O
sought	O	O
to	O	O
investigate	O	O
whether	O	O
any	O	O
of	O	O
three	O	O
doses	O	O
of	O	O
American	Pharmacological	O
ginseng	Pharmacological	O
(	Pharmacological	O
Panax	Pharmacological	O
quinquefolius	Pharmacological	O
)	Pharmacological	O
might	O	O
help	O	O
cancer-related	O	O
fatigue	O	O
.	O	O

A	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
toxicity	O	O
.	O	O

METHODS	O	O
Eligible	O	O
adults	O	O
with	O	O
cancer	O	O
were	O	O
randomized	O	O
in	O	O
a	O	O
double-blind	O	O
manner	O	O
,	O	O
to	O	O
receive	O	O
American	Pharmacological	Pharmacological
ginseng	Pharmacological	Pharmacological
in	O	O
doses	O	O
of	O	O
750	O	O
,	O	O
1,000	O	O
,	O	O
or	O	O
2,000	O	O
mg/day	O	O
or	O	O
placebo	Control	Control
given	O	O
in	O	O
twice	O	O
daily	O	O
dosing	O	O
over	O	O
8	O	O
weeks	O	O
.	O	O

Outcome	O	O
measures	O	O
included	O	O
the	O	O
Brief	O	O
Fatigue	O	O
Inventory	O	O
,	O	O
vitality	O	O
subscale	O	O
of	O	O
the	O	O
Medical	O	O
Outcome	O	O
Scale	O	O
Short	O	O
Form-36	O	O
(	O	O
SF-36	O	O
)	O	O
,	O	O
and	O	O
the	O	O
Global	O	O
Impression	O	O
of	O	O
Benefit	O	O
Scale	O	O
at	O	O
4	O	O
and	O	O
8	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Two	O	O
hundred	O	O
ninety	O	O
patients	O	O
were	O	O
accrued	O	O
to	O	O
this	O	O
trial	O	O
.	O	O

Nonsignificant	O	O
trends	O	O
for	O	O
all	O	O
outcomes	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
doses	O	O
of	O	O
American	Pharmacological	O
ginseng	Pharmacological	O
.	Pharmacological	O

Area	O	O
under	O	O
the	O	O
curve	O	O
analysis	O	O
of	O	O
activity	O	O
interference	O	O
from	O	O
the	O	O
Brief	O	O
Fatigue	O	O
Inventory	O	O
was	O	O
460-467	O	O
in	O	O
the	O	O
placebo	Control	O
group	O	O
and	O	O
750	O	O
mg/day	O	O
group	O	O
versus	O	O
480-551	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
,	O	O
respectively	O	O
.	O	O

Change	O	O
from	O	O
baseline	O	O
in	O	O
the	O	O
vitality	O	O
subscale	O	O
of	O	O
the	O	O
SF-36	O	O
was	O	O
7.3-7.8	O	O
in	O	O
the	O	O
placebo	Control	O
and	O	O
the	O	O
750-mg/day	O	O
arm	O	O
,	O	O
versus	O	O
10.5-14.6	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
.	O	O

Over	O	O
twice	O	O
as	O	O
many	O	O
patients	O	O
on	O	O
ginseng	Pharmacological	O
perceived	O	O
a	O	O
benefit	O	O
and	O	O
were	O	O
satisfied	O	O
with	O	O
treatment	O	O
over	O	O
those	O	O
on	O	O
placebo	Control	Control
.	Control	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
any	O	O
measured	O	O
toxicities	O	O
between	O	O
any	O	O
of	O	O
the	O	O
arms	O	O
.	O	O

CONCLUSION	O	O
There	O	O
appears	O	O
to	O	O
be	O	O
some	O	O
activity	O	O
and	O	O
tolerable	O	O
toxicity	O	O
at	O	O
1,000-2,000	O	O
mg/day	O	O
doses	O	O
of	O	O
American	Pharmacological	O
ginseng	Pharmacological	O
with	O	O
regard	O	O
to	O	O
cancer-related	O	O
fatigue	O	O
.	O	O

Thus	O	O
,	O	O
further	O	O
study	O	O
of	O	O
American	Pharmacological	O
ginseng	Pharmacological	O
is	O	O
warranted	O	O
.	O	O

Extracorporeal	Physical	Physical
shock	Physical	Physical
wave	Physical	Physical
therapy	Physical	Physical
(	Physical	Physical
ESWT	Physical	Physical
)	Physical	Physical
in	O	O
patients	O	O
with	O	O
chronic	O	O
proximal	O	O
plantar	O	O
fasciitis	O	O
:	O	O
a	O	O
2-year	O	O
follow-up	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
extracorporeal	Physical	Physical
shock	Physical	Physical
wave	Physical	Physical
therapy	Physical	Physical
(	O	Physical
ESWT	O	Physical
)	O	Physical
in	O	O
patients	O	O
with	O	O
chronically	O	O
painful	O	O
proximal	O	O
plantar	O	O
fasciitis	O	O
with	O	O
a	O	O
further	O	O
conventional	O	O
conservative	O	O
treatment	O	O
.	O	O

Forty-seven	O	O
patients	O	O
(	O	O
49	O	O
feet	O	O
)	O	O
with	O	O
a	O	O
previously	O	O
unsuccessful	O	O
nonsurgical	O	O
treatment	O	O
of	O	O
at	O	O
least	O	O
6	O	O
months	O	O
were	O	O
randomized	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Heel	Physical	O
cups	Physical	O
had	O	O
to	O	O
be	O	O
worn	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Group	O	O
1	O	O
(	O	O
25	O	O
heels	O	O
)	O	O
was	O	O
treated	O	O
immediately	O	O
with	O	O
three	O	O
sessions	O	O
of	O	O
ESWT	Physical	O
(	O	O
3000	O	O
shock	O	O
waves/session	O	O
of	O	O
0.2	O	O
mJ/mm2	O	O
)	O	O
at	O	O
weekly	O	O
intervals	O	O
.	O	O

The	O	O
patients	O	O
of	O	O
group	O	O
2	O	O
(	O	O
24	O	O
heels	O	O
)	O	O
continued	O	O
nonsurgical	O	O
treatment	O	O
(	O	O
iontophoresis	Pharmacological	O
with	Pharmacological	O
diclofenac	Pharmacological	Pharmacological
and	O	O
an	O	O
oral	O	Pharmacological
nonsteroidal	Pharmacological	Pharmacological
anti-inflammatory	Pharmacological	Pharmacological
drug	Pharmacological	Pharmacological
)	O	Pharmacological
for	O	O
12	O	O
weeks	O	O
.	O	O

After	O	O
this	O	O
period	O	O
they	O	O
were	O	O
treated	O	O
using	O	O
the	O	O
protocol	O	O
of	O	O
group	O	O
1	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
of	O	O
pain	O	O
and	O	O
walking	O	O
time	O	O
after	O	O
further	O	O
nonsurgical	O	O
treatment	O	O
(	O	O
3	O	O
months	O	O
)	O	O
was	O	O
seen	O	O
in	O	O
group	O	O
2	O	O
.	O	O

At	O	O
12	O	O
weeks	O	O
after	O	O
ESWT	O	O
,	O	O
the	O	O
pain	O	O
estimation	O	O
on	O	O
the	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
for	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
diminished	O	O
significantly	O	O
by	O	O
62.9	O	O
%	O	O
in	O	O
group	O	O
1	O	O
and	O	O
by	O	O
63.0	O	O
%	O	O
in	O	O
group	O	O
2	O	O
.	O	O

The	O	O
comfortable	O	O
walking	O	O
time	O	O
had	O	O
increased	O	O
significantly	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Two	O	O
years	O	O
after	O	O
ESWT	O	O
,	O	O
pain	O	O
during	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
decreased	O	O
by	O	O
94	O	O
%	O	O
in	O	O
group	O	O
1	O	O
and	O	O
by	O	O
90	O	O
%	O	O
in	O	O
group	O	O
2	O	O
on	O	O
the	O	O
VAS	O	O
and	O	O
the	O	O
comfortable	O	O
walking	O	O
time	O	O
had	O	O
increased	O	O
significantly	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Sunbathing	O	O
and	O	O
sunbed	O	O
use	O	O
related	O	O
to	O	O
self-image	O	O
in	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
Swedish	O	O
adolescents	O	O
.	O	O

In	O	O
1996	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
4,020	O	O
Swedish	O	O
adolescents	O	O
from	O	O
three	O	O
birth	O	O
cohorts	O	O
were	O	O
sent	O	O
a	O	O
questionnaire	O	Educational
consisting	O	Educational
of	O	Educational
50	O	Educational
items	O	Educational
concerning	O	Educational
habitual	O	Educational
sun-related	O	Educational
behaviours	O	Educational
and	O	O
attitudes	O	O
,	O	O
knowledge	O	O
about	O	O
melanoma	O	O
,	O	O
risk	O	O
perception	O	O
and	O	O
self-image	O	O
.	O	O

A	O	O
total	O	O
of	O	O
2,615	O	O
questionnaires	O	O
were	O	O
returned	O	O
.	O	O

Girls	O	O
sunbathed	O	O
and	O	O
used	O	O
sunbeds	O	O
more	O	O
than	O	O
boys	O	O
at	O	O
all	O	O
ages	O	O
.	O	O

Sunbathing	O	O
and	O	O
sunbed	O	O
use	O	O
increased	O	O
with	O	O
age	O	O
.	O	O

Boys	O	O
who	O	O
were	O	O
most	O	O
satisfied	O	O
and	O	O
girls	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
sunbathed	O	O
most	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
used	O	O
sunbeds	O	O
most	O	O
frequently	O	O
.	O	O

Girls	O	O
reported	O	O
a	O	O
higher	O	O
perceived	O	O
susceptibility	O	O
to	O	O
melanoma	O	O
than	O	O
did	O	O
boys	O	O
.	O	O

The	O	O
perception	O	O
of	O	O
susceptibility	O	O
increased	O	O
with	O	O
age	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
reported	O	O
feeling	O	O
most	O	O
susceptible	O	O
.	O	O

The	O	O
overall	O	O
main	O	O
reason	O	O
for	O	O
sunbathing	O	O
was	O	O
appearance	O	O
,	O	O
both	O	O
for	O	O
own	O	O
sunbathing	O	O
,	O	O
and	O	O
to	O	O
an	O	O
even	O	O
higher	O	O
degree	O	O
,	O	O
as	O	O
a	O	O
supposed	O	O
reason	O	O
for	O	O
other	O	O
adolescents	O	O
'	O	O
behaviour	O	O
,	O	O
and	O	O
was	O	O
reported	O	O
most	O	O
frequently	O	O
by	O	O
girls	O	O
and	O	O
the	O	O
older	O	O
age	O	O
groups	O	O
.	O	O

The	O	O
second	O	O
most	O	O
'important	O	O
'	O	O
reason	O	O
for	O	O
sunbathing	O	O
was	O	O
'feeling	O	O
warm	O	O
and	O	O
comfortable	O	O
'	O	O
.	O	O

Preventive	O	O
programmes	O	O
aimed	O	O
at	O	O
a	O	O
change	O	O
of	O	O
sun	O	O
related	O	O
behaviours	O	O
among	O	O
Swedish	O	O
adolescents	O	O
have	O	O
to	O	O
be	O	O
tailored	O	O
to	O	O
the	O	O
climate	O	O
and	O	O
cultural	O	O
conditions	O	O
and	O	O
must	O	O
take	O	O
into	O	O
account	O	O
that	O	O
having	O	O
a	O	O
tan	O	O
,	O	O
and	O	O
the	O	O
warmth	O	O
of	O	O
the	O	O
sun	O	O
,	O	O
are	O	O
highly	O	O
valued	O	O
by	O	O
most	O	O
adolescents	O	O
.	O	O

Laser	Surgical	Physical
conization	Surgical	Physical
versus	O	Physical
cold	Surgical	Physical
knife	Surgical	Physical
conization	Surgical	Physical
.	Surgical	O

This	O	O
prospective	O	O
,	O	O
randomized	O	O
study	O	O
compares	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
measured	O	O
blood	O	O
loss	O	O
at	O	O
conization	O	O
and	O	O
within	O	O
24	O	O
hours	O	O
after	O	O
using	O	O
either	O	O
the	O	O
cold	Surgical	Physical
knife	Surgical	Physical
technique	Surgical	Physical
or	O	O
the	O	O
carbon	Surgical	Pharmacological
dioxide	Surgical	Pharmacological
laser	Surgical	Pharmacological
scalpel	Surgical	Pharmacological
.	O	O

One	O	O
hundred	O	O
and	O	O
ten	O	O
consecutive	O	O
patients	O	O
were	O	O
evaluated	O	O
.	O	O

The	O	O
median	O	O
blood	O	O
loss	O	O
in	O	O
the	O	O
laser	O	O
group	O	O
of	O	O
55	O	O
patients	O	O
was	O	O
4.6	O	O
milliliters	O	O
at	O	O
,	O	O
and	O	O
within	O	O
,	O	O
24	O	O
hours	O	O
after	O	O
operation	O	O
compared	O	O
with	O	O
30.1	O	O
milliliters	O	O
in	O	O
the	O	O
cold	Surgical	O
knife	Surgical	O
group	O	O
of	O	O
55	O	O
patients	O	O
.	O	O

More	O	O
important	O	O
,	O	O
however	O	O
,	O	O
is	O	O
that	O	O
the	O	O
corresponding	O	O
figures	O	O
for	O	O
the	O	O
range	O	O
of	O	O
bleeding	O	O
were	O	O
0.4	O	O
to	O	O
155.4	O	O
milliliters	O	O
and	O	O
5.6	O	O
to	O	O
1,570.9	O	O
milliliters	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
incidence	O	O
rate	O	O
for	O	O
bleeding	O	O
complications	O	O
requiring	O	O
surgical	O	O
intervention	O	O
was	O	O
1.8	O	O
per	O	O
cet	O	O
for	O	O
the	O	O
laser	O	O
group	O	O
and	O	O
14.6	O	O
per	O	O
cent	O	O
for	O	O
the	O	O
cold	Surgical	O
knife	Surgical	O
group	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.015	O	O
--	O	O
Fischer	O	O
's	O	O
exact	O	O
test	O	O
.	O	O

Conization	O	O
for	O	O
treatment	O	O
of	O	O
premalignant	O	O
changes	O	O
of	O	O
the	O	O
cervix	O	O
uteri	O	O
will	O	O
probably	O	O
remain	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
for	O	O
some	O	O
time	O	O
to	O	O
come	O	O
.	O	O

It	O	O
is	O	O
our	O	O
opinion	O	O
that	O	O
,	O	O
in	O	O
the	O	O
future	O	O
,	O	O
laser	Surgical	O
conization	O	O
will	O	O
replace	O	O
cold	Surgical	O
knife	Surgical	O
conization	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
acetylsalicylic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
on	O	O
B-thromboglobulin	O	O
and	O	O
platelet	O	O
factor	O	O
4	O	O
plasma	O	O
levels	O	O
in	O	O
patients	O	O
with	O	O
transient	O	O
ischaemic	O	O
attacks	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
acetylsalicylic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
ASA	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
versus	O	O
placebo	Control	Control
on	O	O
B-thromboglobulin	O	O
(	O	O
B-TG	O	O
)	O	O
and	O	O
platelet	O	O
factor	O	O
4	O	O
(	O	O
PF4	O	O
)	O	O
plasma	O	O
levels	O	O
and	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
in	O	O
25	O	O
male	O	O
patients	O	O
with	O	O
transient	O	O
ischaemic	O	O
attacks	O	O
(	O	O
TIA	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
allocated	O	O
randomly	O	O
to	O	O
two	O	O
groups	O	O
:	O	O
14	O	O
patients	O	O
received	O	O
oral	O	Pharmacological
treatment	O	Pharmacological
with	O	Pharmacological
ASA	Pharmacological	Pharmacological
500	O	O
mg	O	O
b.i.d	O	O
.	O	O

for	O	O
14	O	O
days	O	O
,	O	O
11	O	O
patients	O	O
placebo	Control	O
b.i.d	O	O
.	O	O

for	O	O
the	O	O
same	O	O
period	O	O
.	O	O

B-TG	O	O
and	O	O
PF4	O	O
plasma	O	O
levels	O	O
and	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
were	O	O
determined	O	O
in	O	O
basal	O	O
conditions	O	O
,	O	O
and	O	O
two	O	O
hours	O	O
,	O	O
and	O	O
seven	O	O
and	O	O
fourteen	O	O
days	O	O
after	O	O
starting	O	O
with	O	O
ASA	O	O
or	O	O
placebo	O	Control
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
same	O	O
parameters	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
20	O	O
healthy	O	O
males	O	O
of	O	O
matched	O	O
age	O	O
.	O	O

Basal	O	O
levels	O	O
of	O	O
plasma	O	O
B-TG	O	O
and	O	O
PF4	O	O
and	O	O
the	O	O
maximal	O	O
amplitude	O	O
of	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
were	O	O
abnormally	O	O
high	O	O
in	O	O
TIA	O	O
patients	O	O
.	O	O

ASA	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
B-TG	O	O
plasma	O	O
levels	O	O
in	O	O
TIA	O	O
patients	O	O
2	O	O
hours	O	O
after	O	O
the	O	O
first	O	O
administration	O	O
,	O	O
but	O	O
no	O	O
effect	O	O
was	O	O
observed	O	O
at	O	O
the	O	O
7th	O	O
and	O	O
14th	O	O
day	O	O
of	O	O
treatment	O	O
.	O	O

PF4	O	O
plasma	O	O
levels	O	O
were	O	O
unaffected	O	O
by	O	O
ASA	O	O
treatment	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
ASA	O	O
,	O	O
at	O	O
the	O	O
dose	O	O
conventionally	O	O
used	O	O
in	O	O
clinical	O	O
trials	O	O
,	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
release	O	O
of	O	O
two	O	O
alpha-granule	O	O
proteins	O	O
.	O	O

Computer-navigated	Surgical	O
versus	O	O
conventional	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
a	O	O
prospective	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
literature	O	O
lacks	O	O
studies	O	O
that	O	O
confirm	O	O
whether	O	O
the	O	O
improved	O	O
radiographic	O	O
alignment	O	O
that	O	O
can	O	O
be	O	O
achieved	O	O
with	O	O
computer-navigated	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
improves	O	O
patients?	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
or	O	O
the	O	O
durability	O	O
of	O	O
total	O	O
knee	O	O
prostheses	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
computer-navigated	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
improves	O	O
the	O	O
clinical	O	O
function	O	O
,	O	O
alignment	O	O
,	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
.	O	O

METHODS	O	O
We	O	O
prospectively	O	O
compared	O	O
the	O	O
results	O	O
of	O	O
520	O	O
patients	O	O
with	O	O
osteoarthritis	O	O
who	O	O
underwent	O	O
computer-navigated	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
for	O	O
one	O	O
knee	O	O
and	O	O
conventional	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
for	O	O
the	O	O
other	O	O
.	O	O

The	O	O
assignment	O	O
of	O	O
the	O	O
knee	O	O
to	O	O
navigation	O	O
or	O	O
not	O	O
was	O	O
done	O	O
randomly	O	O
.	O	O

There	O	O
were	O	O
452	O	O
women	O	O
(	O	O
904	O	O
knees	O	O
)	O	O
and	O	O
sixty-eight	O	O
men	O	O
(	O	O
136	O	O
knees	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
sixty-eight	O	O
years	O	O
(	O	O
range	O	O
,	O	O
forty-nine	O	O
to	O	O
eighty-eight	O	O
years	O	O
)	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
index	O	O
arthroplasty	O	O
.	O	O

The	O	O
mean	O	O
follow-up	O	O
period	O	O
was	O	O
10.8	O	O
years	O	O
(	O	O
range	O	O
,	O	O
ten	O	O
to	O	O
twelve	O	O
years	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assessed	O	O
clinically	O	O
and	O	O
radiographically	O	O
with	O	O
the	O	O
rating	O	O
system	O	O
of	O	O
the	O	O
Knee	O	O
Society	O	O
and	O	O
with	O	O
the	O	O
Western	O	O
Ontario	O	O
and	O	O
McMaster	O	O
Universities	O	O
Osteoarthritis	O	O
Index	O	O
(	O	O
WOMAC	O	O
)	O	O
score	O	O
at	O	O
three	O	O
months	O	O
,	O	O
one	O	O
year	O	O
,	O	O
and	O	O
annually	O	O
thereafter	O	O
.	O	O

RESULTS	O	O
Total	O	O
knee	O	O
scores	O	O
,	O	O
knee	O	O
function	O	O
scores	O	O
,	O	O
pain	O	O
scores	O	O
,	O	O
WOMAC	O	O
scores	O	O
,	O	O
knee	O	O
motion	O	O
,	O	O
and	O	O
activity	O	O
scores	O	O
did	O	O
not	O	O
show	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
preoperatively	O	O
or	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
final	O	O
follow-up	O	O
.	O	O

Alignment	O	O
and	O	O
the	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
Kaplan-Meier	O	O
survivorship	O	O
with	O	O
revision	O	O
as	O	O
the	O	O
end	O	O
point	O	O
at	O	O
10.8	O	O
years	O	O
was	O	O
98.8	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
computernavigated	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
group	O	O
and	O	O
99.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
conventional	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Our	O	O
data	O	O
demonstrated	O	O
no	O	O
difference	O	O
in	O	O
clinical	O	O
function	O	O
or	O	O
alignment	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
between	O	O
the	O	O
knees	O	O
that	O	O
underwent	O	O
computer-navigated	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
and	O	O
those	O	O
that	O	O
underwent	O	O
conventional	Surgical	O
total	Surgical	O
knee	Surgical	O
arthroplasty	Surgical	O
.	O	O

Creon	Pharmacological	O
10,000	Pharmacological	O
Minimicrospheres	Pharmacological	O
vs.	O	O
Creon	Pharmacological	O
8,000	Pharmacological	O
microspheres	Pharmacological	O
--	O	O
an	O	O
open	O	O
randomised	O	O
crossover	O	O
preference	O	O
study	O	O
.	O	O

Creon	Pharmacological	O
10,000	Pharmacological	O
Minimicrospherestrade	Pharmacological	O
mark	Pharmacological	O
(	Pharmacological	O
Creon	Pharmacological	O
)	Pharmacological	O
10,000	Pharmacological	O
MMS	Pharmacological	O
)	Pharmacological	O
is	O	O
a	O	O
pancreatic	O	O
enzyme	O	O
formulation	O	O
that	O	O
contains	O	O
smaller	O	O
spheres	O	O
of	O	O
pancreatin	O	O
in	O	O
a	O	O
50	O	O
%	O	O
smaller	O	O
capsule	O	O
than	O	O
conventional	O	O
microspheres	Pharmacological	O
(	Pharmacological	O
Creon	Pharmacological	O
)	Pharmacological	O
8,000	Pharmacological	O
)	Pharmacological	O
.	Pharmacological	O

This	O	O
three-centre	O	O
study	O	O
investigated	O	O
the	O	O
preference	O	O
of	O	O
cystic	O	O
fibrosis	O	O
(	O	O
CF	O	O
)	O	O
patients	O	O
for	O	O
these	O	O
products	O	O
.	O	O

In	O	O
one	O	O
centre	O	O
,	O	O
72	O	O
h	O	O
stool	O	O
fat	O	O
excretion	O	O
and	O	O
coefficient	O	O
of	O	O
fat	O	O
absorption	O	O
(	O	O
CFA	O	O
)	O	O
were	O	O
also	O	O
compared	O	O
.	O	O

Fifty-nine	O	O
patients	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
10	O	O
years	O	O
(	O	O
range	O	O
3-17	O	O
)	O	O
took	O	O
Creon	O	O
8,000	O	O
ms	O	O
for	O	O
14	O	O
days	O	O
and	O	O
were	O	O
then	O	O
randomised	O	O
to	O	O
28	O	O
days	O	O
of	O	O
Creon	Pharmacological	O
8,000	Pharmacological	O
ms	Pharmacological	O
followed	O	O
by	O	O
28	O	O
days	O	O
of	O	O
Creon	Pharmacological	O
10,000	Pharmacological	O
MMS	Pharmacological	O
,	O	O
or	O	O
vice	O	O
versa	O	O
.	O	O

Dosing	O	O
was	O	O
lipase	O	O
for	O	O
lipase	O	O
according	O	O
to	O	O
the	O	O
labelled	O	O
declaration	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
second	O	O
treatment	O	O
period	O	O
,	O	O
51	O	O
of	O	O
54	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
study	O	O
expressed	O	O
a	O	O
preference	O	O
,	O	O
with	O	O
a	O	O
statistically	O	O
significant	O	O
preference	O	O
in	O	O
favour	O	O
of	O	O
Creon	O	O
10,000	O	O
MMS	O	O
(	O	O
47/51	O	O
;	O	O
87	O	O
%	O	O
)	O	O
vs.	O	O
Creon	O	O
8,000	O	O
ms	O	O
(	O	O
4/51	O	O
;	O	O
7.4	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Stool	O	O
fat	O	O
(	O	O
g/day	O	O
)	O	O
and	O	O
CFA	O	O
(	O	O
%	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
24	O	O
patients	O	O
at	O	O
the	O	O
end	O	O
of	O	O
each	O	O
treatment	O	O
period	O	O
:	O	O
the	O	O
products	O	O
were	O	O
therapeutically	O	O
equivalent	O	O
(	O	O
Creon	Pharmacological	O
10,000	O	O
:	O	O
8.4	O	O
g/day	O	O
,	O	O
91.3	O	O
%	O	O
CFA	O	O
;	O	O
Creon	O	O
8,000	O	O
:	O	O
6.7	O	O
g/day	O	O
,	O	O
93.5	O	O
%	O	O
CFA	O	O
)	O	O
.	O	O

Both	O	O
products	O	O
were	O	O
well	O	O
tolerated	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
in	O	O
CF	O	O
children	O	O
we	O	O
found	O	O
a	O	O
clear	O	O
preference	O	O
for	O	O
Creon	O	O
10,000	O	O
MMS	O	O
compared	O	O
with	O	O
Creon	O	O
8,000	O	O
ms	O	O
with	O	O
no	O	O
difference	O	O
in	O	O
fat	O	O
absorption	O	O
between	O	O
the	O	O
two	O	O
products	O	O
.	O	O

Creon	Pharmacological	O
10,000s	O	O
smaller	O	O
capsules	O	O
are	O	O
easier	O	O
to	O	O
take	O	O
and	O	O
should	O	O
aid	O	O
patient	O	O
compliance	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
intermittent	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	Pharmacological	Pharmacological
with	O	O
continuous	O	O
dinoprostone	Pharmacological	O
for	O	O
cervical	O	O
ripening	O	O
and	O	O
labor	O	O
induction	O	O
.	O	O

OBJECTIVE	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	Pharmacological	Pharmacological
(	Pharmacological	O
Cytotec	Pharmacological	O
)	Pharmacological	O
with	O	O
that	O	O
of	O	O
dinoprostone	Pharmacological	O
(	Pharmacological	O
Cervidil	Pharmacological	O
)	Pharmacological	O
on	O	O
cervical	O	O
ripening	O	O
and	O	O
labor	O	O
induction	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Two	O	O
hundred	O	O
patients	O	O
with	O	O
indications	O	O
for	O	O
induction	O	O
of	O	O
labor	O	O
and	O	O
unfavorable	O	O
cervical	O	O
examinations	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
vaginally	O	O
administered	O	O
misoprostol	Pharmacological	Pharmacological
(	Pharmacological	O
prostaglandin	Pharmacological	O
E1	Pharmacological	O
)	Pharmacological	O
or	O	O
the	O	O
dinoprostone	Pharmacological	O
(	Pharmacological	O
prostaglandin	Pharmacological	O
E2	Pharmacological	O
)	Pharmacological	O
vaginal	O	O
insert	O	O
.	O	O

Twenty-five	O	O
microgram	O	O
tablets	O	O
of	O	O
misoprostol	Pharmacological	Pharmacological
were	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
fornix	O	O
every	O	O
4	O	O
hours	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
six	O	O
doses	O	O
.	O	O

Additional	O	O
misoprostol	Pharmacological	O
was	O	O
not	O	O
given	O	O
after	O	O
either	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
(	O	O
Bishop	O	O
score	O	O
of	O	O
>	O	O
or	O	O
=	O	O
8	O	O
or	O	O
cervical	O	O
dilatation	O	O
of	O	O
>	O	O
or	O	O
=	O	O
3	O	O
cm	O	O
)	O	O
,	O	O
or	O	O
beginning	O	O
of	O	O
active	O	O
labor	O	O
.	O	O

The	O	O
vaginal	O	O
insert	O	O
,	O	O
Cervidil	Pharmacological	O
,	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
dinoprostone	Pharmacological	O
in	O	O
a	O	O
timed-release	O	O
preparation	O	O
was	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
formix	O	O
for	O	O
a	O	O
maximum	O	O
period	O	O
of	O	O
24	O	O
hours	O	O
.	O	O

The	O	O
vaginal	O	O
insert	O	O
was	O	O
removed	O	O
for	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
entry	O	O
into	O	O
active	O	O
labor	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
,	O	O
or	O	O
abnormality	O	O
of	O	O
uterine	O	O
contractile	O	O
pattern	O	O
or	O	O
fetal	O	O
cardiac	O	O
activity	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
200	O	O
patients	O	O
enrolled	O	O
,	O	O
99	O	O
were	O	O
randomized	O	O
to	O	O
misoprostol	Pharmacological	Pharmacological
and	O	O
101	O	O
to	O	O
dinoprostone	Pharmacological	O
.	Pharmacological	O

The	O	O
average	O	O
interval	O	O
from	O	O
start	O	O
of	O	O
induction	O	O
to	O	O
vaginal	O	O
delivery	O	O
was	O	O
1	O	O
hour	O	O
shorter	O	O
in	O	O
the	O	O
misoprostol	Pharmacological	Pharmacological
group	O	O
(	O	O
1296.7	O	O
+/-	O	O
722.1	O	O
minutes	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	Pharmacological	O
group	O	O
(	O	O
1360.0	O	O
+/-	O	O
792.0	O	O
minutes	O	O
)	O	O
,	O	O
but	O	O
this	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0.97	O	O
)	O	O
.	O	O

Oxytocin	Pharmacological	Pharmacological
augmentation	O	O
of	O	O
labor	O	O
was	O	O
used	O	O
in	O	O
50	O	O
(	O	O
50.5	O	O
%	O	O
)	O	O
misoprostol-treated	Pharmacological	O
patients	O	O
and	O	O
43	O	O
(	O	O
43.5	O	O
%	O	O
)	O	O
dinoprostone-treated	Pharmacological	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
1.14	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.86	O	O
to	O	O
1.51	O	O
,	O	O
p	O	O
=	O	O
0.35	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
routes	O	O
of	O	O
delivery	O	O
with	O	O
misoprostol	Pharmacological	Pharmacological
or	O	O
dinoprostone	Pharmacological	O
.	Pharmacological	O

Overall	O	O
,	O	O
38	O	O
patients	O	O
(	O	O
19.3	O	O
%	O	O
)	O	O
had	O	O
cesarean	O	O
deliveries	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significantly	O	O
lower	O	O
prevalence	O	O
of	O	O
tachysystole	O	O
(	O	O
six	O	O
or	O	O
more	O	O
uterine	O	O
contractions	O	O
in	O	O
a	O	O
10-minute	O	O
window	O	O
for	O	O
two	O	O
consecutive	O	O
10-minute	O	O
periods	O	O
)	O	O
in	O	O
the	O	O
misoprostol	Pharmacological	Pharmacological
group	O	O
(	O	O
7.1	O	O
%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	Pharmacological	O
group	O	O
(	O	O
18.4	O	O
%	O	O
)	O	O
(	O	O
relative	O	O
risk	O	O
0.52	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.31	O	O
to	O	O
0.89	O	O
,	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
frequency	O	O
of	O	O
uterine	O	O
hyperstimulation	O	O
or	O	O
hypertonus	O	O
.	O	O

Abnormal	O	O
fetal	O	O
heart	O	O
rate	O	O
tracings	O	O
were	O	O
found	O	O
in	O	O
23	O	O
(	O	O
23.2	O	O
%	O	O
)	O	O
of	O	O
misoprostol-treated	Pharmacological	O
patients	O	O
and	O	O
35	O	O
(	O	O
35.7	O	O
%	O	O
)	O	O
of	O	O
dinoprostone-treated	Pharmacological	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
0.73	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.52	O	O
to	O	O
1.01	O	O
,	O	O
p	O	O
=	O	O
0.0546	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
meconium	O	O
passage	O	O
,	O	O
1-	O	O
or	O	O
5-minute	O	O
Apgar	O	O
scores	O	O
<	O	O
7	O	O
,	O	O
neonatal	O	O
resuscitations	O	O
,	O	O
or	O	O
admissions	O	O
to	O	O
the	O	O
neonatal	O	O
intensive	O	O
care	O	O
unit	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Vaginally	O	O
administered	O	O
misoprostol	Pharmacological	Pharmacological
is	O	O
as	O	O
effective	O	O
as	O	O
dinoprostone	O	O
for	O	O
cervical	O	O
ripening	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
labor	O	O
.	O	O

Mean	O	O
time	O	O
intervals	O	O
to	O	O
delivery	O	O
,	O	O
need	O	O
for	O	O
oxytocin	Pharmacological	O
augmentation	O	O
,	O	O
and	O	O
routes	O	O
of	O	O
delivery	O	O
were	O	O
similar	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Incidence	O	O
of	O	O
uterine	O	O
tachysystole	O	O
with	O	O
misoprostol	Pharmacological	O
every	O	O
4	O	O
hours	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
with	O	O
dinoprostone	Pharmacological	O
.	O	O

Acute	O	O
exposure	O	O
to	O	O
acid	O	O
fog	O	O
:	O	O
influence	O	O
of	O	O
breathing	O	O
pattern	O	O
on	O	O
effective	O	O
dose	O	O
.	O	O

Concern	O	O
about	O	O
the	O	O
possible	O	O
adverse	O	O
health	O	O
effects	O	O
of	O	O
acid	O	O
fog	O	O
has	O	O
been	O	O
fed	O	O
by	O	O
two	O	O
observations	O	O
:	O	O
air	O	O
pollution	O	O
disasters	O	O
earlier	O	O
in	O	O
this	O	O
century	O	O
were	O	O
typically	O	O
associated	O	O
with	O	O
fog	O	O
,	O	O
and	O	O
current	O	O
samples	O	O
of	O	O
fog	O	O
water	O	O
can	O	O
be	O	O
strongly	O	O
acid	O	O
.	O	O

To	O	O
study	O	O
the	O	O
acute	O	O
effects	O	O
of	O	O
acid	O	O
fog	O	O
on	O	O
the	O	O
lung	O	O
,	O	O
the	O	O
authors	O	O
generated	O	O
a	O	O
monodisperse	Pharmacological	O
10	Pharmacological	O
microM	Pharmacological	O
MMAD	Pharmacological	O
aerosol	Pharmacological	O
of	Pharmacological	O
H2SO4	Pharmacological	O
with	O	O
a	O	O
pH	O	O
of	O	O
2.0	O	O
and	O	O
a	O	O
nominal	O	O
concentration	O	O
of	O	O
500	O	O
micrograms/m3	O	O
.	O	O

They	O	O
exposed	O	O
seven	O	O
healthy	O	O
young	O	O
men	O	O
on	O	O
alternate	O	O
days	O	O
to	O	O
acid	Control	O
or	Control	O
control	Control	Pharmacological
equiosmolar	Control	Pharmacological
NaCl	Control	Pharmacological
aerosol	Control	Pharmacological
during	O	O
40	O	O
min	O	O
of	O	O
resting	O	O
ventilation	O	O
and	O	O
20	O	O
min	O	O
of	O	O
exercise	O	O
;	O	O
the	O	O
latter	O	O
was	O	O
sufficiently	O	O
intense	O	O
to	O	O
induce	O	O
oronasal	O	O
breathing	O	O
.	O	O

Exposure	O	O
was	O	O
by	O	O
means	O	O
of	O	O
a	O	O
head	O	O
dome	O	O
,	O	O
a	O	O
head-only	O	O
exposure	O	O
device	O	O
that	O	O
permitted	O	O
continuous	O	O
measurement	O	O
(	O	O
unfettered	O	O
breathing	O	O
)	O	O
of	O	O
Vr	O	O
,	O	O
f	O	O
,	O	O
VE	O	O
,	O	O
and	O	O
the	O	O
onset	O	O
and	O	O
persistence	O	O
of	O	O
oronasal	O	O
breathing	O	O
.	O	O

In	O	O
this	O	O
article	O	O
the	O	O
authors	O	O
compare	O	O
the	O	O
relative	O	O
importance	O	O
of	O	O
parameters	O	O
contributing	O	O
to	O	O
the	O	O
between-subject	O	O
variability	O	O
in	O	O
estimated	O	O
hydrogen	O	O
ion	O	O
dose	O	O
to	O	O
the	O	O
lower	O	O
airways	O	O
(	O	O
H+LAW	O	O
)	O	O
,	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
variance	O	O
.	O	O

Physiologic	O	O
parameters	O	O
accounted	O	O
for	O	O
70	O	O
%	O	O
of	O	O
the	O	O
variability	O	O
,	O	O
of	O	O
which	O	O
34	O	O
%	O	O
was	O	O
due	O	O
to	O	O
differences	O	O
in	O	O
duration	O	O
of	O	O
oronasal	O	O
breathing	O	O
(	O	O
tON	O	O
)	O	O
and	O	O
36	O	O
%	O	O
to	O	O
differences	O	O
in	O	O
ventilation	O	O
rate	O	O
during	O	O
oronasal	O	O
breathing	O	O
(	O	O
VE	O	O
(	O	O
ON	O	O
)	O	O
)	O	O
;	O	O
inhaled	O	O
hydrogen	O	O
ion	O	O
concentration	O	O
[	O	O
H+	O	O
]	O	O
,	O	O
the	O	O
environmental	O	O
parameter	O	O
,	O	O
contributed	O	O
only	O	O
30	O	O
%	O	O
.	O	O

Minute	O	O
ventilation	O	O
at	O	O
the	O	O
time	O	O
of	O	O
transition	O	O
from	O	O
nasal	O	O
to	O	O
oronasal	O	O
breathing	O	O
varied	O	O
significantly	O	O
among	O	O
subjects	O	O
even	O	O
if	O	O
normalized	O	O
to	O	O
FVC	O	O
,	O	O
an	O	O
index	O	O
of	O	O
lung	O	O
size	O	O
.	O	O

A	O	O
randomized	O	O
controlled	O	O
study	O	O
of	O	O
parent-assisted	Educational	O
Children	Educational	O
's	Educational	O
Friendship	Educational	O
Training	Educational	O
with	O	O
children	O	O
having	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
Children	Educational	O
's	Educational	O
Friendship	Educational	O
Training	Educational	O
(	Educational	O
CFT	Educational	O
)	Educational	O
,	Educational	O
a	Educational	O
manualized	Educational	Educational
parent-assisted	Educational	Educational
intervention	Educational	Educational
to	O	O
improve	O	O
social	O	O
skills	O	O
among	O	O
second	O	O
to	O	O
fifth	O	O
grade	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

Comparison	O	O
was	O	O
made	O	O
with	O	O
a	O	O
delayed	Educational	O
treatment	Educational	O
control	Educational	O
group	Educational	O
(	Educational	O
DTC	Educational	O
)	Educational	O
.	O	O

Targeted	O	O
skills	O	O
included	O	O
conversational	O	O
skills	O	O
,	O	O
peer	O	O
entry	O	O
skills	O	O
,	O	O
developing	O	O
friendship	O	O
networks	O	O
,	O	O
good	O	O
sportsmanship	O	O
,	O	O
good	O	O
host	O	O
behavior	O	O
during	O	O
play	O	O
dates	O	O
,	O	O
and	O	O
handling	O	O
teasing	O	O
.	O	O

At	O	O
post-testing	O	O
,	O	O
the	O	O
CFT	O	O
group	O	O
was	O	O
superior	O	O
to	O	O
the	O	O
DTC	O	O
group	O	O
on	O	O
parent	O	O
measures	O	O
of	O	O
social	O	O
skill	O	O
and	O	O
play	O	Educational
date	O	Educational
behavior	O	Educational
,	O	O
and	O	O
child	O	O
measures	O	O
of	O	O
popularity	O	O
and	O	O
loneliness	O	O
,	O	O
At	O	O
3-month	O	O
follow-up	O	O
,	O	O
parent	O	O
measures	O	O
showed	O	O
significant	O	O
improvement	O	O
from	O	O
baseline	O	O
.	O	O

Post-hoc	O	O
analysis	O	O
indicated	O	O
more	O	O
than	O	O
87	O	O
%	O	O
of	O	O
children	O	O
receiving	O	O
CFT	Educational	O
showed	O	O
reliable	O	O
change	O	O
on	O	O
at	O	O
least	O	O
one	O	O
measure	O	O
at	O	O
post-test	O	O
and	O	O
66.7	O	O
%	O	O
after	O	O
3	O	O
months	O	O
follow-up	O	O
.	O	O

Physostigmine	Pharmacological	O
reverses	O	O
propofol-induced	O	O
unconsciousness	O	O
and	O	O
attenuation	O	O
of	O	O
the	O	O
auditory	O	O
steady	O	O
state	O	O
response	O	O
and	O	O
bispectral	O	O
index	O	O
in	O	O
human	O	O
volunteers	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
postulated	O	O
that	O	O
alteration	O	O
of	O	O
central	O	O
cholinergic	O	O
transmission	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
anesthetics	O	O
produce	O	O
unconsciousness	O	O
.	O	O

The	O	O
authors	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
altering	O	O
central	O	O
cholinergic	O	O
transmission	O	O
,	O	O
by	O	O
physostigmine	Pharmacological	O
and	O	O
scopolamine	Pharmacological	O
,	O	O
on	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	Pharmacological
.	O	O

METHODS	O	O
Propofol	Pharmacological	Pharmacological
was	O	O
administered	O	O
to	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
physical	O	O
status	O	O
1	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
volunteers	O	O
with	O	O
use	O	O
of	O	O
a	O	O
computer-controlled	O	Pharmacological
infusion	O	Pharmacological
pump	O	Pharmacological
at	O	O
increasing	O	O
concentrations	O	O
until	O	O
unconsciousness	O	O
resulted	O	O
(	O	O
inability	O	O
to	O	O
respond	O	O
to	O	O
verbal	O	O
commands	O	O
,	O	O
abolition	O	O
of	O	O
spontaneous	O	O
movement	O	O
)	O	O
.	O	O

Central	O	O
nervous	O	O
system	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
use	O	O
of	O	O
the	O	O
Auditory	O	O
Steady	O	O
State	O	O
Response	O	O
(	O	O
ASSR	O	O
)	O	O
and	O	O
Bispectral	O	O
Index	O	O
(	O	O
BIS	O	O
)	O	O
analysis	O	O
of	O	O
electrooculogram	O	O
.	O	O

During	O	O
continuous	O	O
administration	O	O
of	O	O
propofol	O	Pharmacological
,	O	O
reversal	O	O
of	O	O
unconsciousness	O	O
produced	O	O
by	O	O
physostigmine	Pharmacological	O
(	O	O
28	O	O
microgram/kg	O	O
)	O	O
and	O	O
block	O	O
of	O	O
this	O	O
reversal	O	O
by	O	O
scopolamine	Pharmacological	Pharmacological
(	O	O
8.6	O	O
microgram/kg	O	O
)	O	O
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
Propofol	O	Pharmacological
produced	O	O
unconsciousness	O	O
at	O	O
a	O	O
plasma	O	O
concentration	O	O
of	O	O
3.2	O	O
+/-	O	O
0.8	O	O
(	O	O
+/-	O	O
SD	O	O
)	O	O
microgram/ml	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
.	O	O

Unconsciousness	O	O
was	O	O
associated	O	O
with	O	O
reductions	O	O
in	O	O
ASSR	O	O
(	O	O
0.10	O	O
+/-	O	O
0.08	O	O
microV	O	O
[	O	O
awake	O	O
baseline	O	O
0.32	O	O
+/-	O	O
0.18	O	O
microV	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
BIS	O	O
(	O	O
55.7	O	O
+/-	O	O
8.8	O	O
[	O	O
awake	O	O
baseline	O	O
92.4	O	O
+/-	O	O
3.9	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Physostigmine	O	O
restored	O	O
consciousness	O	O
in	O	O
9	O	O
of	O	O
11	O	O
subjects	O	O
,	O	O
with	O	O
concomitant	O	O
increases	O	O
in	O	O
ASSR	O	O
(	O	O
0.38	O	O
+/-	O	O
0.17	O	O
microV	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
BIS	O	O
(	O	O
75.3	O	O
+/-	O	O
8.3	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
all	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
scopolamine	O	O
blocked	O	O
the	O	O
physostigmine-induced	O	O
reversal	O	O
of	O	O
unconsciousness	O	O
and	O	O
the	O	O
increase	O	O
of	O	O
the	O	O
ASSR	O	O
and	O	O
BIS	O	O
(	O	O
ASSR	O	O
and	O	O
BIS	O	O
during	O	O
propofol-induced	O	O
unconsciousness	O	O
:	O	O
0.09	O	O
+/-	O	O
0.09	O	O
microV	O	O
and	O	O
58.2	O	O
+/-	O	O
7.5	O	O
,	O	O
respectively	O	O
;	O	O
ASSR	O	O
and	O	O
BIS	O	O
after	O	O
physostigmine	O	O
administration	O	O
:	O	O
0.08	O	O
+/-	O	O
0.06	O	O
microV	O	O
and	O	O
56.8	O	O
+/-	O	O
6.7	O	O
,	O	O
respectively	O	O
,	O	O
NS	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	O
is	O	O
mediated	O	O
at	O	O
least	O	O
in	O	O
part	O	O
via	O	O
interruption	O	O
of	O	O
central	O	O
cholinergic	O	O
muscarinic	O	O
transmission	O	O
.	O	O

Information	Educational	O
source	Educational	O
affects	O	O
peers	O	O
'	O	O
initial	O	O
attitudes	O	O
toward	O	O
autism	O	O
.	O	O

Authors	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
information	O	O
source	O	O
on	O	O
peers	O	O
'	O	O
cognitive	O	O
and	O	O
behavioral	O	O
attitudes	O	O
toward	O	O
an	O	O
unfamiliar	O	O
child	O	O
with	O	O
autism	O	O
.	O	O

Children	O	O
(	O	O
N=296	O	O
;	O	O
M	O	O
age=10.21	O	O
years	O	O
)	O	O
received	O	O
information	O	O
about	O	O
an	O	O
unfamiliar	O	O
child	O	O
with	O	O
autism	O	O
from	O	O
one	O	O
of	O	O
the	O	O
following	O	O
sources	O	O
:	O	O
(	O	O
a	O	O
)	O	O
videotape	Educational	O
,	O	O
(	O	O
b	O	O
)	O	O
teacher	Educational	O
,	O	O
(	O	O
c	O	O
)	O	O
hypothetical	Educational	O
mother	Educational	O
,	O	O
(	O	O
d	O	O
)	O	O
hypothetical	Educational	O
father	Educational	O
,	O	O
or	O	O
(	O	O
e	O	O
)	O	O
hypothetical	Educational	O
doctor	Educational	O
.	Educational	O

Interactive	O	O
effects	O	O
between	O	O
source	O	O
,	O	O
and	O	O
sex	O	O
and	O	O
grade	O	O
were	O	O
found	O	O
for	O	O
cognitive	O	O
and	O	O
behavioral	O	O
attitudes	O	O
.	O	O

Fifth-graders	O	O
reported	O	O
more	O	O
favorable	O	O
cognitive	O	O
and	O	O
behavioral	O	O
attitudes	O	O
when	O	O
information	O	O
was	O	O
provided	O	O
by	O	O
extra-familial	O	O
sources	O	O
(	O	O
i.e.	O	O
,	O	O
doctor	O	O
)	O	O
versus	O	O
parent	O	O
sources	O	O
.	O	O

Mother	O	O
yielded	O	O
more	O	O
persuasive	O	O
effects	O	O
on	O	O
behavioral	O	O
attitudes	O	O
for	O	O
third-graders	O	O
versus	O	O
fifth-graders	O	O
.	O	O

Attitudes	O	O
toward	O	O
autism	O	O
differ	O	O
depending	O	O
on	O	O
who	O	O
provides	O	O
information	O	O
about	O	O
the	O	O
disability	O	O
.	O	O

Persuasion	O	O
theory	O	O
appears	O	O
useful	O	O
to	O	O
guide	O	O
evaluation	O	O
of	O	O
educational	O	O
interventions	O	O
to	O	O
improve	O	O
attitudes	O	O
towards	O	O
autism	O	O
.	O	O

Implications	O	O
of	O	O
the	O	O
findings	O	O
,	O	O
study	O	O
limitations	O	O
,	O	O
and	O	O
recommendations	O	O
for	O	O
future	O	O
research	O	O
are	O	O
discussed	O	O
.	O	O

Brief	O	O
report	O	O
:	O	O
imitation	Psychological	O
effects	O	O
on	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

Twenty	O	O
children	O	O
with	O	O
autism	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
5	O	O
years	O	O
)	O	O
were	O	O
recruited	O	O
for	O	O
the	O	O
study	O	O
from	O	O
a	O	O
school	O	O
for	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

The	O	O
children	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
an	O	O
imitation	Psychological	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
or	O	O
contingently	Psychological	O
responsive	Psychological	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
interaction	O	O
group	O	O
based	O	O
on	O	O
a	O	O
stratification	O	O
table	O	O
for	O	O
gender	O	O
and	O	O
developmental	O	O
and	O	O
chronological	O	O
age	O	O
.	O	O

The	O	O
sessions	O	O
consisted	O	O
of	O	O
four	O	O
phases	O	O
,	O	O
with	O	O
each	O	O
phase	O	O
lasting	O	O
3	O	O
minutes	O	O
.	O	O

In	O	O
the	O	O
first	O	O
phase	O	O
,	O	O
the	O	O
child	O	O
walked	O	O
into	O	O
a	O	O
room	O	O
that	O	O
was	O	O
furnished	O	O
with	O	O
a	O	O
sofa	O	O
,	O	O
a	O	O
table	O	O
,	O	O
chairs	O	O
,	O	O
and	O	O
two	O	O
sets	O	O
of	O	O
identical	O	O
toys	O	O
.	O	O

An	O	O
adult	O	O
was	O	O
in	O	O
the	O	O
room	O	O
sitting	O	O
very	O	O
still	O	O
like	O	O
a	O	O
statue	O	O
(	O	O
first	O	O
still-face	O	O
condition	O	O
)	O	O
.	O	O

In	O	O
the	O	O
second	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
either	O	O
imitated	O	O
the	O	O
child	O	O
or	O	O
was	O	O
contingently	Psychological	O
responsive	Psychological	O
to	O	O
the	O	O
child	O	O
.	O	O

In	O	O
the	O	O
third	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
sat	O	O
still	O	O
again	O	O
(	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
and	O	O
in	O	O
the	O	O
fourth	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
engaged	O	O
in	O	O
a	O	O
spontaneous	O	O
interaction	O	O
.	O	O

During	O	O
the	O	O
third	O	O
phase	O	O
(	O	O
the	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
the	O	O
children	O	O
in	O	O
the	O	O
imitation	Psychological	O
group	O	O
spent	O	O
less	O	O
time	O	O
in	O	O
gross	O	O
motor	O	O
activity	O	O
and	O	O
more	O	O
time	O	O
touching	O	O
the	O	O
adult	O	O
,	O	O
as	O	O
if	O	O
attempting	O	O
to	O	O
initiate	O	O
an	O	O
interaction	O	O
.	O	O

The	O	O
contingency	Educational	O
condition	O	O
appeared	O	O
to	O	O
be	O	O
a	O	O
more	O	O
effective	O	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
distal	O	Educational
social	O	Educational
behavior	O	Educational
(	O	Educational
attention	O	Educational
)	O	Educational
,	O	O
whereas	O	O
the	O	O
imitative	Psychological	O
condition	O	O
was	O	O
a	O	O
more	O	O
effective	O	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
proximal	O	Educational
social	O	Educational
behavior	O	Educational
(	O	Educational
touching	O	Educational
)	O	Educational
.	O	O

[	O	O
Clinical	O	O
observation	O	O
on	O	O
different	O	O
acupuncture	Physical	Physical
and	O	Physical
moxibustion	Pharmacological	Physical
therapies	O	Physical
for	O	O
treatment	O	O
of	O	O
postsurgical	O	O
gastroparesis	O	O
syndrome	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
optimize	O	O
therapy	O	O
of	O	O
acupuncture	Physical	Physical
and	O	O
moxibustion	Pharmacological	O
for	O	O
postsurgical	O	O
gastroparesis	O	O
syndrome	O	O
(	O	O
PGS	O	O
)	O	O
.	O	O

METHODS	O	O
Forty-one	O	O
cases	O	O
of	O	O
PGS	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
3	O	O
groups	O	O
in	O	O
order	O	O
of	O	O
visiting	O	O
.	O	O

Group	O	O
A	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
were	O	O
treated	O	O
by	O	O
warming	O	Physical
needle	O	Physical
moxibustion	Pharmacological	Physical
,	O	O
group	O	O
B	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
by	O	O
acupuncture	Physical	Physical
plus	O	O
auricular	Physical	O
point	Physical	O
sticking	Physical	O
,	O	O
and	O	O
group	O	O
C	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
by	O	O
routine	Physical	O
acupuncture	Physical	Physical
.	Physical	O

Changes	O	O
of	O	O
gastric	O	O
drainage	O	O
volume	O	O
,	O	O
therapeutic	O	O
times	O	O
and	O	O
cured	O	O
rate	O	O
were	O	O
investigated	O	O
in	O	O
the	O	O
3	O	O
groups	O	O
.	O	O

RESULTS	O	O
All	O	O
the	O	O
3	O	O
therapeutic	O	O
methods	O	O
could	O	O
significantly	O	O
decrease	O	O
gastric	O	O
drainage	O	O
volume	O	O
.	O	O

The	O	O
cured	O	O
rate	O	O
was	O	O
100.0	O	O
%	O	O
and	O	O
the	O	O
therapeutic	O	O
times	O	O
was	O	O
(	O	O
7.24	O	O
+/-	O	O
3.87	O	O
)	O	O
in	O	O
the	O	O
group	O	O
A	O	O
,	O	O
66.7	O	O
%	O	O
,	O	O
(	O	O
9.83	O	O
+/-	O	O
4.60	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
B	O	O
and	O	O
75.0	O	O
%	O	O
,	O	O
(	O	O
15.25	O	O
+/-	O	O
3.81	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
C	O	O
,	O	O
with	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
cured	O	O
rate	O	O
and	O	O
the	O	O
therapeutic	O	O
times	O	O
among	O	O
the	O	O
3	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
warming	O	O
needle	O	O
moxibustion	Pharmacological	O
is	O	O
the	O	O
best	O	O
method	O	O
for	O	O
PGS	O	O
,	O	O
with	O	O
less	O	O
therapeutic	O	O
times	O	O
,	O	O
high	O	O
cured	O	O
rate	O	O
and	O	O
rapid	O	O
effect	O	O
.	O	O

Direct	Physical	O
trocar	Physical	O
insertion	Physical	O
vs.	O	O
Verres	Physical	O
needle	Physical	O
use	Physical	O
for	O	O
laparoscopic	O	O
sterilization	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
prospective	O	O
trial	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
direct	Physical	O
trocar	Physical	O
insertion	Physical	O
with	O	O
prior	O	O
peritoneal	O	O
insufflation	O	O
with	O	O
a	O	O
Verres	Physical	O
needle	Physical	O
for	O	O
laparoscopic	O	O
tubal	O	O
sterilization	O	O
.	O	O

Direct	Physical	O
trocar	Physical	O
insertion	Physical	O
resulted	O	O
in	O	O
fewer	O	O
instrument	O	O
insertions	O	O
(	O	O
21.8	O	O
%	O	O
vs.	O	O
7.8	O	O
%	O	O
)	O	O
and	O	O
use	O	O
of	O	O
smaller	O	O
volumes	O	O
of	O	O
CO2	O	O
(	O	O
2.67	O	O
vs.	O	O
2.32	O	O
L	O	O
)	O	O
.	O	O

Direct	Physical	O
trocar	Physical	O
use	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
operating	O	O
time	O	O
from	O	O
9	O	O
minutes	O	O
,	O	O
40	O	O
seconds	O	O
in	O	O
the	O	O
needle	O	O
group	O	O
to	O	O
7	O	O
minutes	O	O
,	O	O
30	O	O
seconds	O	O
in	O	O
the	O	O
trocar	O	O
group	O	O
.	O	O

Minor	O	O
omental	O	O
injuries	O	O
occurred	O	O
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
each	O	O
group	O	O
,	O	O
while	O	O
serious	O	O
complications	O	O
occurred	O	O
once	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Endometrial	O	O
cytodiagnosis	O	O
using	O	O
a	O	O
new	Other	O
softcyte	Other	O
versus	O	O
a	O	O
conventional	Other	O
endocyte	Other	O
.	O	O

A	O	O
new	O	O
endometrial	O	O
cytologic	O	O
sampling	O	O
device	O	O
,	O	O
softcyte	O	O
,	O	O
was	O	O
used	O	O
in	O	O
cytological	O	O
screening	O	O
for	O	O
endometrial	O	O
cancer	O	O
,	O	O
and	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
endocyte	Other	O
with	O	O
regard	O	O
to	O	O
manipulability	O	O
,	O	O
adverse	O	O
effects	O	O
(	O	O
including	O	O
pain	O	O
and	O	O
hemorrhage	O	O
)	O	O
,	O	O
and	O	O
cellular	O	O
findings	O	O
(	O	O
including	O	O
the	O	O
quantity	O	O
of	O	O
cells	O	O
collected	O	O
,	O	O
the	O	O
success	O	O
rate	O	O
,	O	O
cell	O	O
freshness	O	O
,	O	O
and	O	O
cellular	O	O
clumping	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
315	O	O
women	O	O
(	O	O
premenopause	O	O
251	O	O
,	O	O
postmenopause	O	O
64	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
two	O	O
groups	O	O
who	O	O
underwent	O	O
the	O	O
endometrial	Other	O
cytological	Other	O
screening	Other	O
with	Other	O
either	Other	O
the	Other	O
softcyte	Other	O
or	O	O
the	O	O
endocyte	Other	O
.	O	O

To	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
the	O	O
softcyte	Other	O
we	O	O
compared	O	O
it	O	O
with	O	O
the	O	O
endocyte	Other	O
.	Other	O

Endometrial	O	O
cytology	O	O
using	O	O
a	O	O
softcyte	Other	O
or	O	O
an	O	O
endocyte	Other	O
achieved	O	O
high	O	O
correct	O	O
diagnosis	O	O
rate	O	O
for	O	O
cancer	O	O
,	O	O
and	O	O
both	O	O
instruments	O	O
are	O	O
valuable	O	O
as	O	O
endometrial	O	O
cytologic	O	O
sample	O	O
devices	O	O
.	O	O

The	O	O
softcyte	O	O
causes	O	O
only	O	O
mild	O	O
pain	O	O
on	O	O
introduction	O	O
and	O	O
during	O	O
collection	O	O
,	O	O
and	O	O
a	O	O
large	O	O
quantity	O	O
of	O	O
cells	O	O
could	O	O
be	O	O
harvested	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
softcyte	O	O
is	O	O
a	O	O
useful	O	O
cytologic	O	O
sampling	O	O
device	O	O
in	O	O
screening	O	O
for	O	O
endometrial	O	O
cancer	O	O
.	O	O

Effects	O	O
of	O	O
three	O	O
oral	O	Pharmacological
analgesics	Pharmacological	Pharmacological
on	O	O
postoperative	O	O
pain	O	O
following	O	O
root	O	O
canal	O	O
preparation	O	O
:	O	O
a	O	O
controlled	O	O
clinical	O	O
trial	O	O
.	O	O

AIM	O	O
To	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
single	O	O
doses	O	O
of	O	O
three	O	O
oral	O	O
medications	O	O
on	O	O
postoperative	O	O
pain	O	O
following	O	O
instrumentation	O	O
of	O	O
root	O	O
canals	O	O
in	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
.	O	O

METHODOLOGY	O	O
In	O	O
this	O	O
double-blind	O	O
clinical	O	O
trial	O	O
,	O	O
100	O	O
patients	O	O
who	O	O
had	O	O
anterior	O	O
or	O	O
premolar	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
without	O	O
any	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	O
apical	O	O
periodontitis	O	O
and	O	O
moderate	O	O
to	O	O
severe	O	O
pain	O	O
were	O	O
divided	O	O
by	O	O
balanced	O	O
block	O	O
random	O	O
allocation	O	O
into	O	O
four	O	O
groups	O	O
of	O	O
25	O	O
each	O	O
,	O	O
a	O	O
control	Control	O
group	Control	O
receiving	O	O
a	O	O
placebo	Control	Control
medication	O	O
,	O	O
and	O	O
three	O	O
experimental	O	O
groups	O	O
receiving	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
either	O	O
Tramadol	Pharmacological	Pharmacological
(	O	O
100	O	O
mg	O	O
)	O	O
,	O	O
Novafen	Pharmacological	O
(	O	O
325	O	O
mg	O	O
of	O	O
paracetamol	Pharmacological	Pharmacological
,	O	O
200	O	O
mg	O	O
ibuprofen	Pharmacological	Pharmacological
and	O	O
40	O	O
mg	O	O
caffeine	Pharmacological	Pharmacological
anhydrous	Pharmacological	Pharmacological
)	O	Pharmacological
or	O	O
Naproxen	Pharmacological	Pharmacological
(	O	O
500	O	O
mg	O	O
)	O	O
immediately	O	O
after	O	O
the	O	O
first	O	O
appointment	O	O
where	O	O
the	O	O
pulp	O	O
was	O	O
removed	O	O
,	O	O
and	O	O
the	O	O
canals	O	O
were	O	O
fully	O	O
prepared	O	O
.	O	O

The	O	O
intensity	O	O
of	O	O
pain	O	O
was	O	O
scored	O	O
based	O	O
on	O	O
10-point	O	O
VAS	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
for	O	O
up	O	O
to	O	O
24	O	O
h	O	O
postoperatively	O	O
.	O	O

Data	O	O
were	O	O
submitted	O	O
to	O	O
repeated	O	O
analysis	O	O
of	O	O
variance	O	O
.	O	O

RESULTS	O	O
At	O	O
the	O	O
6	O	O
,	O	O
12	O	O
and	O	O
24	O	O
h	O	O
postoperative	O	O
intervals	O	O
after	O	O
drug	O	O
administration	O	O
,	O	O
the	O	O
intensity	O	O
of	O	O
pain	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
experimental	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
placebo	Pharmacological	Control
group	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Tramadol	Pharmacological	O
was	O	O
significantly	O	O
less	O	O
effective	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
than	O	O
Naproxen	Pharmacological	O
,	O	O
and	O	O
Novafen	Pharmacological	O
that	O	O
were	O	O
similar	O	O
to	O	O
each	O	O
other	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
A	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
Naproxen	Pharmacological	Pharmacological
,	O	O
Novafen	Pharmacological	O
and	O	O
Tramadol	Pharmacological	O
taken	O	O
immediately	O	O
after	O	O
treatment	O	O
reduced	O	O
postoperative	O	O
pain	O	O
following	O	O
pulpectomy	O	O
and	O	O
root	O	O
canal	O	O
preparation	O	O
of	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
.	O	O

Social	Educational	O
support	Educational	O
and	O	O
abstinence	Educational	O
from	O	O
opiates	O	O
and	O	O
cocaine	O	O
during	O	O
opioid	Pharmacological	O
maintenance	Pharmacological	O
treatment	Pharmacological	O
.	O	O

Social	Educational	O
support	Educational	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
helping	O	O
drug	O	O
users	O	O
achieve	O	O
abstinence	O	O
;	O	O
however	O	O
these	O	O
benefits	O	O
may	O	O
depend	O	O
on	O	O
the	O	O
type	O	O
of	O	O
support	O	O
experienced	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
observational	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
extent	O	O
to	O	O
which	O	O
general	Educational	O
and	Educational	O
abstinence-specific	Educational	O
support	Educational	O
,	Educational	O
both	Educational	O
structural	Educational	O
and	Educational	O
functional	Educational	O
,	O	O
predicted	O	O
opiate	O	O
and	O	O
cocaine	O	O
abstinence	O	O
in	O	O
128	O	O
opioid	O	O
maintenance	O	O
patients	O	O
receiving	O	O
either	O	O
methadone	Pharmacological	Pharmacological
or	O	O
LAAM	Pharmacological	O
.	O	O

A	O	O
new	O	O
multidimensional	O	O
self-report	O	O
instrument	O	O
assessing	O	O
abstinence-specific	Educational	O
functional	O	O
support	O	O
was	O	O
developed	O	O
for	O	O
the	O	O
study	O	O
.	O	O

Previously	O	O
validated	O	O
measures	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
remaining	O	O
types	O	O
of	O	O
support	O	O
.	O	O

With	O	O
baseline	O	O
abstinence	O	O
and	O	O
other	O	O
statistically	O	O
important	O	O
covariates	O	O
adjusted	O	O
,	O	O
hierarchical	O	O
logistic	O	O
regression	O	O
analyses	O	O
demonstrated	O	O
that	O	O
the	O	O
associations	O	O
between	O	O
social	O	O
support	O	O
at	O	O
study	O	O
baseline	O	O
and	O	O
biochemically	O	O
confirmed	O	O
abstinence	O	O
3	O	O
months	O	O
later	O	O
varied	O	O
by	O	O
type	O	O
of	O	O
support	O	O
and	O	O
by	O	O
drug	O	O
.	O	O

Greater	O	O
abstinence-specific	Educational	O
structural	O	O
support	O	O
(	O	O
operationalized	O	O
as	O	O
fewer	O	O
drug	O	O
users	O	O
in	O	O
the	O	O
social	O	O
network	O	O
)	O	O
and	O	O
decreases	O	O
in	O	O
three	O	O
types	O	O
of	O	O
negative	O	O
abstinence-specific	Educational	O
functional	O	O
support	O	O
(	O	O
Complaints	O	O
about	O	O
Drug	O	O
Use	O	O
,	O	O
Drug	O	O
Exposure	O	O
,	O	O
and	O	O
Demoralization	O	O
)	O	O
predicted	O	O
cocaine	O	O
,	O	O
but	O	O
not	O	O
opiate	O	O
abstinence	O	O
.	O	O

There	O	O
were	O	O
no	O	O
effects	O	O
for	O	O
general	O	O
support	O	O
,	O	O
whether	O	O
structural	O	O
or	O	O
functional	O	O
,	O	O
on	O	O
abstinence	O	O
from	O	O
either	O	O
drug	O	O
.	O	O

Interventions	O	O
that	O	O
focus	O	O
on	O	O
modifying	O	O
patients	O	O
'	O	O
abstinence-specific	Educational	O
support	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
reducing	O	O
the	O	O
high	O	O
rates	O	O
of	O	O
cocaine	O	O
use	O	O
disorders	O	O
in	O	O
this	O	O
population	O	O
.	O	O

Recombinant	Pharmacological	Pharmacological
human	Pharmacological	Pharmacological
erythropoietin	Pharmacological	Pharmacological
therapy	Pharmacological	Pharmacological
for	O	O
anemic	O	O
cancer	O	O
patients	O	O
on	O	O
combination	O	O
chemotherapy	O	O
.	O	O

BACKGROUND	O	O
Patients	O	O
with	O	O
advanced	O	O
cancer	O	O
frequently	O	O
experience	O	O
clinically	O	O
significant	O	O
anemia	O	O
,	O	O
which	O	O
is	O	O
often	O	O
exacerbated	O	O
by	O	O
myelosuppressive	O	Pharmacological
chemotherapy	O	Pharmacological
.	O	O

Consistent	O	O
with	O	O
the	O	O
anemia	O	O
of	O	O
chronic	O	O
disease	O	O
,	O	O
studies	O	O
have	O	O
documented	O	O
serum	O	O
erythropoietin	O	O
levels	O	O
that	O	O
are	O	O
inappropriately	O	O
low	O	O
for	O	O
the	O	O
degree	O	O
of	O	O
anemia	O	O
in	O	O
cancer	O	O
patients	O	O
.	O	O

Myelosuppressive	O	O
chemotherapy	O	O
impairs	O	O
erythropoiesis	O	O
,	O	O
which	O	O
may	O	O
not	O	O
fully	O	O
recover	O	O
between	O	O
treatment	O	O
cycles	O	O
.	O	O

Recombinant	Pharmacological	Pharmacological
human	Pharmacological	Pharmacological
erythropoietin	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
rHuEPO	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
has	O	O
been	O	O
used	O	O
safely	O	O
and	O	O
effectively	O	O
to	O	O
treat	O	O
anemia	O	O
in	O	O
AIDS	O	O
patients	O	O
receiving	O	O
zidovudine	O	Pharmacological
(	O	Pharmacological
AZT	O	Pharmacological
)	O	Pharmacological
and	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
renal	O	O
failure	O	O
.	O	O

PURPOSE	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	O	O
role	O	O
of	O	O
rHuEPO	O	O
in	O	O
reducing	O	O
symptomatic	O	O
anemia	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
cancer	O	O
who	O	O
were	O	O
receiving	O	O
myelosuppressive	O	Pharmacological
chemotherapy	O	Pharmacological
(	O	Pharmacological
excluding	O	Pharmacological
cisplatin	O	Pharmacological
)	O	O
.	O	O

METHODS	O	O
We	O	O
studied	O	O
153	O	O
anemic	O	O
cancer	O	O
patients	O	O
receiving	O	O
cyclic	Pharmacological	O
combination	Pharmacological	O
chemotherapy	Pharmacological	O
in	O	O
a	O	O
prospective	O	O
multicenter	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
rHuEPO	Pharmacological	Pharmacological
(	O	O
150	O	O
U/kg	O	O
)	O	O
or	O	O
placebo	Control	Control
subcutaneously	O	O
three	O	O
times	O	O
a	O	O
week	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
12	O	O
weeks	O	O
or	O	O
until	O	O
the	O	O
hematocrit	O	O
level	O	O
increased	O	O
to	O	O
38	O	O
%	O	O
-40	O	O
%	O	O
.	O	O

If	O	O
the	O	O
hematocrit	O	O
reached	O	O
this	O	O
target	O	O
level	O	O
before	O	O
12	O	O
weeks	O	O
,	O	O
the	O	O
rHuEPO	Pharmacological	O
dose	O	O
could	O	O
be	O	O
reduced	O	O
to	O	O
maintain	O	O
the	O	O
hematocrit	O	O
at	O	O
that	O	O
level	O	O
for	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Response	O	O
to	O	O
rHuEPO	Pharmacological	O
therapy	O	O
was	O	O
assessed	O	O
by	O	O
measuring	O	O
changes	O	O
in	O	O
hematocrit	O	O
level	O	O
,	O	O
transfusion	O	O
requirements	O	O
,	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Quality-of-life	O	O
assessment	O	O
was	O	O
based	O	O
on	O	O
patients	O	O
'	O	O
responses	O	O
to	O	O
questionnaires	O	O
before	O	O
and	O	O
after	O	O
the	O	O
courses	O	O
of	O	O
therapy	O	O
.	O	O

RESULTS	O	O
The	O	O
increase	O	O
in	O	O
hematocrit	O	O
in	O	O
the	O	O
rHuEPO-treated	Pharmacological	O
group	O	O
compared	O	O
with	O	O
hematocrit	O	O
in	O	O
the	O	O
placebo-treated	Control	O
group	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
=	O	O
.0001	O	O
)	O	O
as	O	O
measured	O	O
by	O	O
percentage	O	O
point	O	O
of	O	O
change	O	O
from	O	O
baseline	O	O
to	O	O
final	O	O
evaluation	O	O
,	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
hematocrit	O	O
level	O	O
of	O	O
six	O	O
percentage	O	O
points	O	O
or	O	O
more	O	O
unrelated	O	O
to	O	O
transfusion	O	O
,	O	O
and	O	O
by	O	O
a	O	O
rise	O	O
in	O	O
hematocrit	O	O
level	O	O
to	O	O
38	O	O
%	O	O
or	O	O
more	O	O
unrelated	O	O
to	O	O
transfusion	O	O
.	O	O

There	O	O
was	O	O
a	O	O
trend	O	O
toward	O	O
the	O	O
reduction	O	O
in	O	O
mean	O	O
units	O	O
of	O	O
blood	O	O
transfused	O	O
per	O	O
patient	O	O
during	O	O
months	O	O
2	O	O
and	O	O
3	O	O
of	O	O
therapy	O	O
combined	O	O
in	O	O
rHuEPO-treated	Pharmacological	O
patients	O	O
compared	O	O
with	O	O
placebo-treated	O	Control
patients	O	O
(	O	O
0.91	O	O
U	O	O
versus	O	O
1.65	O	O
U	O	O
;	O	O
P	O	O
=	O	O
.056	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
rHuEPO-treated	Pharmacological	O
patients	O	O
experienced	O	O
a	O	O
statistically	O	O
significant	O	O
improvement	O	O
in	O	O
energy	O	O
level	O	O
and	O	O
ability	O	O
to	O	O
perform	O	O
daily	O	O
activities	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.05	O	O
)	O	O
.	O	O

The	O	O
two	O	O
treatment	O	O
groups	O	O
showed	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
toxic	O	O
effects	O	O
except	O	O
for	O	O
increased	O	O
incidence	O	O
of	O	O
diaphoresis	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
diarrhea	O	O
(	O	O
P	O	O
=	O	O
.05	O	O
)	O	O
in	O	O
the	O	O
rHuEPO-treated	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
conclude	O	O
that	O	O
rHuEPO	Pharmacological	O
is	O	O
safe	O	O
and	O	O
effective	O	O
for	O	O
reversing	O	O
anemia	O	O
related	O	O
to	O	O
advanced	O	O
cancer	O	O
or	O	O
to	O	O
chemotherapy	O	O
for	O	O
cancer	O	O
.	O	O

Warfarin	Pharmacological	O
for	O	O
atrial	O	O
fibrillation	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
perspective	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
minimal	O	O
clinically	O	O
important	O	O
difference	O	O
(	O	O
MCID	O	O
)	O	O
of	O	O
warfarin	Pharmacological	Pharmacological
therapy	O	Pharmacological
for	O	O
the	O	O
treatment	O	O
of	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
using	O	O
2	O	O
different	O	O
elicitation	O	O
methods	O	O
.	O	O

DESIGN	O	O
All	O	O
patients	O	O
completed	O	O
2	O	O
face-to-face	O	O
interviews	O	O
,	O	O
which	O	O
were	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

For	O	O
each	O	O
interview	O	O
,	O	O
they	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
1	O	O
of	O	O
2	O	O
elicitation	O	O
methods	O	O
:	O	O
ping-ponging	O	O
or	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
.	O	O

SETTING	O	O
The	O	O
practices	O	O
of	O	O
2	O	O
university-affiliated	O	O
family	O	O
medicine	O	O
centers	O	O
(	O	O
8	O	O
physicians	O	O
each	O	O
)	O	O
,	O	O
14	O	O
community-based	O	O
family	O	O
physicians	O	O
,	O	O
and	O	O
2	O	O
cardiologists	O	O
.	O	O

PATIENTS	O	O
Sixty-four	O	O
patients	O	O
with	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
who	O	O
were	O	O
initiated	O	O
with	O	O
warfarin	O	Pharmacological
therapy	O	Pharmacological
at	O	O
least	O	O
3	O	O
months	O	O
before	O	O
the	O	O
study	O	O
.	O	O

INTERVENTION	O	O
During	O	O
each	O	O
interview	O	O
,	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	O	O
were	O	O
determined	O	O
by	O	O
using	O	O
(	O	O
1	O	O
)	O	O
a	O	Educational
pictorial	O	Educational
flip	O	Educational
chart	O	Educational
to	O	O
describe	O	O
atrial	O	O
fibrillation	O	O
;	O	O
the	O	O
consequences	O	O
of	O	O
a	O	O
minor	O	O
stroke	O	O
,	O	O
a	O	O
major	O	O
stroke	O	O
,	O	O
and	O	O
a	O	O
major	O	O
bleeding	O	O
episode	O	O
;	O	O
the	O	O
chance	O	O
of	O	O
stroke	O	O
if	O	O
not	O	O
taking	O	O
warfarin	O	Pharmacological
;	O	O
the	O	O
chance	O	O
of	O	O
a	O	O
major	O	O
bleeding	O	O
episode	O	O
if	O	O
taking	O	O
warfarin	O	Pharmacological
;	O	O
examples	O	O
of	O	O
the	O	O
inconvenience	O	O
,	O	O
minor	O	O
side	O	O
effects	O	O
,	O	O
and	O	O
costs	O	O
of	O	O
warfarin	O	Pharmacological
therapy	O	Pharmacological
;	O	O
and	O	O
then	O	O
(	O	O
2	O	O
)	O	O
1	O	O
of	O	O
the	O	O
2	O	O
elicitation	O	O
methods	O	O
to	O	O
determine	O	O
their	O	O
MCIDs	O	O
(	O	O
the	O	O
smallest	O	O
reduction	O	O
in	O	O
stroke	O	O
risk	O	O
at	O	O
which	O	O
the	O	O
patients	O	O
were	O	O
willing	O	O
to	O	O
take	O	O
warfarin	O	O
)	O	O
.	O	O

Patients	O	O
'	O	O
knowledge	O	O
of	O	O
their	O	O
stroke	O	O
risk	O	O
,	O	O
acceptability	O	O
of	O	O
the	O	O
interview	O	O
process	O	O
,	O	O
and	O	O
factors	O	O
determining	O	O
their	O	O
preferences	O	O
were	O	O
also	O	O
assessed	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
Given	O	O
a	O	O
baseline	O	O
risk	O	O
of	O	O
having	O	O
a	O	O
stroke	O	O
in	O	O
the	O	O
next	O	O
2	O	O
years	O	O
,	O	O
if	O	O
not	O	O
taking	O	O
warfarin	Pharmacological	Pharmacological
,	O	O
of	O	O
10	O	O
of	O	O
100	O	O
,	O	O
the	O	O
mean	O	O
MCID	O	O
was	O	O
2.01	O	O
of	O	O
100	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.60-2.42	O	O
)	O	O
.	O	O

Fifty-two	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
would	O	O
take	O	O
warfarin	Pharmacological	Pharmacological
for	O	O
an	O	O
absolute	O	O
decrease	O	O
in	O	O
stroke	O	O
risk	O	O
of	O	O
1	O	O
%	O	O
over	O	O
2	O	O
years	O	O
.	O	O

Before	O	O
eliciting	O	O
their	O	O
MCIDs	O	O
,	O	O
patients	O	O
showed	O	O
poor	O	O
knowledge	O	O
of	O	O
their	O	O
stroke	O	O
risk	O	O
,	O	O
which	O	O
improved	O	O
afterward	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
was	O	O
well	O	O
accepted	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

The	O	O
MCID	O	O
using	O	O
the	O	O
ping-ponging	O	O
elicitation	O	O
method	O	O
was	O	O
1.015	O	O
of	O	O
100	O	O
smaller	O	O
compared	O	O
with	O	O
use	O	O
of	O	O
the	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
method	O	O
(	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
were	O	O
able	O	O
to	O	O
determine	O	O
the	O	O
MCID	O	O
of	O	O
warfarin	Pharmacological	Pharmacological
therapy	Pharmacological	Pharmacological
for	O	O
the	O	O
prevention	O	O
of	O	O
stroke	O	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
with	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
.	O	O

Their	O	O
MCIDs	O	O
were	O	O
much	O	O
smaller	O	O
than	O	O
those	O	O
that	O	O
have	O	O
been	O	O
implied	O	O
by	O	O
some	O	O
experts	O	O
and	O	O
clinicians	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
,	O	O
using	O	O
the	O	O
flip	O	O
chart	O	O
approach	O	O
,	O	O
appeared	O	O
to	O	O
improve	O	O
the	O	O
patients	O	O
'	O	O
knowledge	O	O
of	O	O
their	O	O
disease	O	O
and	O	O
its	O	O
consequences	O	O
and	O	O
treatment	O	O
.	O	O

The	O	O
method	O	O
used	O	O
to	O	O
elicit	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	O	O
can	O	O
have	O	O
a	O	O
clinically	O	O
important	O	O
effect	O	O
on	O	O
patient	O	O
responses	O	O
.	O	O

The	O	O
method	O	O
used	O	O
in	O	O
our	O	O
study	O	O
can	O	O
be	O	O
generalized	O	O
to	O	O
other	O	O
conditions	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
could	O	O
be	O	O
helpful	O	O
in	O	O
3	O	O
ways	O	O
:	O	O
(	O	O
1	O	O
)	O	O
from	O	O
a	O	O
clinical	O	O
decision-making	O	O
perspective	O	O
,	O	O
it	O	O
could	O	O
facilitate	O	O
patient-physician	O	O
communication	O	O
;	O	O
(	O	O
2	O	O
)	O	O
it	O	O
could	O	O
clarify	O	O
the	O	O
patient	O	O
perspective	O	O
when	O	O
interpreting	O	O
the	O	O
results	O	O
of	O	O
previously	O	O
completed	O	O
trials	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
it	O	O
could	O	O
be	O	O
used	O	O
to	O	O
derive	O	O
more	O	O
clinically	O	O
relevant	O	O
sample	O	O
sizes	O	O
for	O	O
randomized	O	O
treatment	O	O
trials	O	O
.	O	O

Echocardiographic	O	O
evaluation	O	O
of	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
treated	O	O
with	O	O
carvedilol	Pharmacological	O
.	Pharmacological	O

Echocardiography	Physical	O
is	O	O
used	O	O
to	O	O
measure	O	O
the	O	O
therapeutic	O	O
effectiveness	O	O
of	O	O
heart	O	O
failure	O	O
therapy	O	O
in	O	O
adults	O	O
and	O	O
children	O	O
.	O	O

The	O	O
purposes	O	O
of	O	O
this	O	O
study	O	O
were	O	O
(	O	O
1	O	O
)	O	O
to	O	O
assess	O	O
baseline	O	O
echocardiographic	O	O
predictors	O	O
of	O	O
clinical	O	O
outcome	O	O
,	O	O
(	O	O
2	O	O
)	O	O
to	O	O
investigate	O	O
changes	O	O
in	O	O
echocardiographic	O	O
parameters	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
to	O	O
compare	O	O
these	O	O
echocardiographic	O	O
changes	O	O
with	O	O
changes	O	O
in	O	O
plasma	O	O
levels	O	O
of	O	O
b-type	O	Pharmacological
natriuretic	O	Pharmacological
peptide	O	Pharmacological
(	O	Pharmacological
BNP	O	Pharmacological
)	O	Pharmacological
in	O	O
a	O	O
population	O	O
of	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
and	O	O
symptomatic	O	O
heart	O	O
failure	O	O
treated	O	O
with	O	O
carvedilol	Pharmacological	Pharmacological
or	O	O
placebo	Control	Control
.	O	O

All	O	O
available	O	O
baseline	O	O
and	O	O
6-month	O	O
echocardiograms	O	O
from	O	O
Pediatric	O	O
Carvedilol	O	O
Trial	O	O
(	O	O
PCT	O	O
)	O	O
participants	O	O
(	O	O
carvedilol	Pharmacological	O
n	O	O
=	O	O
161	O	O
;	O	O
placebo	Control	Control
n	O	O
=	O	O
55	O	O
)	O	O
were	O	O
reviewed	O	O
.	O	O

Systolic	O	O
and	O	O
diastolic	O	O
sphericity	O	O
index	O	O
(	O	O
SI	O	O
;	O	O
n	O	O
=	O	O
110	O	O
)	O	O
,	O	O
TEI	O	O
index	O	O
(	O	O
n	O	O
=	O	O
145	O	O
)	O	O
,	O	O
and	O	O
systemic	O	O
ventricular	O	O
dP/dt	O	O
(	O	O
n	O	O
=	O	O
70	O	O
)	O	O
were	O	O
measured	O	O
.	O	O

The	O	O
PCT	O	O
composite	O	O
definition	O	O
of	O	O
clinical	O	O
outcome	O	O
(	O	O
i.e.	O	O
,	O	O
worsened	O	O
,	O	O
improved	O	O
,	O	O
or	O	O
unchanged	O	O
)	O	O
was	O	O
used	O	O
.	O	O

For	O	O
all	O	O
patients	O	O
,	O	O
baseline	O	O
TEI	O	O
index	O	O
was	O	O
a	O	O
predictor	O	O
of	O	O
worsened	O	O
outcome	O	O
.	O	O

Only	O	O
children	O	O
treated	O	O
with	O	O
carvedilol	Pharmacological	Pharmacological
showed	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
systolic	O	O
SI	O	O
(	O	O
P	O	O
B	O	O
0.0001	O	O
)	O	O
,	O	O
diastolic	O	O
SI	O	O
(	O	O
P	O	O
B	O	O
0.0001	O	O
)	O	O
,	O	O
and	O	O
TEI	O	O
index	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

An	O	O
inverse	O	O
correlation	O	O
between	O	O
changes	O	O
in	O	O
BNP	O	O
and	O	O
changes	O	O
in	O	O
dP/dt	O	O
(	O	O
r	O	O
=	O	O
-0.45	O	O
,	O	O
P	O	O
=	O	O
0.04	O	O
)	O	O
was	O	O
found	O	O
only	O	O
in	O	O
the	O	O
carvedilol	Pharmacological	O
group	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
TEI	O	O
index	O	O
predicted	O	O
outcome	O	O
in	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
and	O	O
heart	O	O
failure	O	O
.	O	O

Carvedilol	Pharmacological	O
may	O	O
have	O	O
a	O	O
beneficial	O	O
effect	O	O
on	O	O
reversal	O	O
of	O	O
left	O	O
ventricular	O	O
remodeling	O	O
and	O	O
global	O	O
ventricular	O	O
function	O	O
in	O	O
pediatric	O	O
heart	O	O
failure	O	O
.	O	O

[	O	O
Radiotherapy	Surgical	O
of	O	O
malignant	O	O
brain	O	O
gliomas	O	O
using	O	O
teniposide	Pharmacological	O
]	O	O
.	O	O

Efficacy	O	O
of	O	O
radiochemotherapy	Pharmacological	O
of	O	O
malignantly-converted	O	O
brain	O	O
gliomas	O	O
using	O	O
teniposide	Pharmacological	Pharmacological
was	O	O
evaluated	O	O
in	O	O
a	O	O
randomized	O	O
prospective	O	O
study	O	O
.	O	O

Combined	O	Physical
use	O	Physical
of	O	Physical
cytostatics	Pharmacological	Physical
and	O	Physical
irradiation	Surgical	Physical
appeared	O	O
safe	O	O
,	O	O
tolerable	O	O
and	O	O
significantly	O	O
more	O	O
effective	O	O
than	O	O
radiotherapy	Surgical	Physical
alone	O	O
as	O	O
assessed	O	O
by	O	O
local	O	O
control	O	O
of	O	O
tumor	O	O
and	O	O
survival	O	O
.	O	O

Dose	O	O
response	O	O
effect	O	O
of	O	O
cyclical	Pharmacological	Pharmacological
medroxyprogesterone	Pharmacological	Pharmacological
on	O	O
blood	O	O
pressure	O	O
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

OBJECTIVE	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
with	O	O
placebo	Control	Control
the	O	O
dose-response	O	O
effect	O	O
of	O	O
cyclical	O	O
doses	O	O
of	O	O
the	O	O
C21	Pharmacological	O
progestogen	Pharmacological	O
,	O	O
medroxyprogesterone	Pharmacological	Pharmacological
acetate	Pharmacological	Pharmacological
(	O	Pharmacological
MPA	O	Pharmacological
)	O	Pharmacological
on	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
when	O	O
administered	O	O
to	O	O
normotensive	O	O
postmenopausal	O	O
women	O	O
receiving	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
conjugated	Pharmacological	Pharmacological
equine	Pharmacological	Pharmacological
oestrogen	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
CEE	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
.	Pharmacological	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Twenty	O	O
normotensive	O	O
postmenopausal	O	O
women	O	O
(	O	O
median	O	O
age	O	O
53	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
which	O	O
used	O	O
a	O	O
double-blind	O	O
crossover	O	O
design	O	O
.	O	O

There	O	O
were	O	O
four	O	O
randomised	O	O
treatment	O	O
phases	O	O
,	O	O
each	O	O
of	O	O
4	O	O
weeks	O	O
duration	O	O
.	O	O

The	O	O
four	O	O
blinded	O	O
treatments	O	O
were	O	O
MPA	Pharmacological	O
2.5	O	O
mg	O	O
,	O	O
MPA	Pharmacological	O
5	O	O
mg	O	O
,	O	O
MPA	Pharmacological	O
10	O	O
mg	O	O
and	O	O
matching	O	O
placebo	Control	Control
,	O	O
taken	O	O
for	O	O
the	O	O
last	O	O
14	O	O
days	O	O
of	O	O
each	O	O
28	O	O
day	O	O
treatment	O	O
cycle	O	O
.	O	O

CEE	O	O
0.625	O	O
mg	O	O
was	O	O
also	O	O
administered	O	O
once	O	O
daily	O	O
as	O	O
open	O	O
labelled	O	O
tablets	O	O
to	O	O
all	O	O
subjects	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Clinic	O	O
BP	O	O
was	O	O
measured	O	O
weekly	O	O
with	O	O
the	O	O
mean	O	O
values	O	O
of	O	O
weeks	O	O
3	O	O
and	O	O
4	O	O
of	O	O
each	O	O
phase	O	O
used	O	O
for	O	O
analysis	O	O
.	O	O

Ambulatory	O	O
BP	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
final	O	O
week	O	O
of	O	O
each	O	O
phase	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
the	O	O
placebo	O	Control
phase	O	O
,	O	O
end	O	O
of	O	O
phase	O	O
clinic	O	O
BP	O	O
was	O	O
unchanged	O	O
by	O	O
any	O	O
of	O	O
the	O	O
progestogen	O	O
treatments	O	O
.	O	O

There	O	O
was	O	O
a	O	O
dose-dependent	O	O
decrease	O	O
in	O	O
ambulatory	O	O
daytime	O	O
diastolic	O	O
and	O	O
mean	O	O
arterial	O	O
BP	O	O
with	O	O
the	O	O
progestogen	O	O
treatments	O	O
compared	O	O
with	O	O
placebo	O	Control
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
In	O	O
a	O	O
regimen	O	O
of	O	O
postmenopausal	O	O
hormone	O	O
replacement	O	O
therapy	O	O
with	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
CEE	O	O
combined	O	O
with	O	O
a	O	O
cyclical	O	O
regimen	O	O
of	O	O
a	O	O
C21	O	O
progestogen	O	O
spanning	O	O
the	O	O
current	O	O
clinical	O	O
dose	O	O
range	O	O
,	O	O
the	O	O
progestogen	Pharmacological	O
has	O	O
either	O	O
no	O	O
effect	O	O
or	O	O
a	O	O
small	O	O
dose-dependent	O	O
reduction	O	O
in	O	O
clinic	O	O
and	O	O
ambulatory	O	O
BPs	O	O
over	O	O
one	O	O
treatment	O	O
cycle	O	O
.	O	O

Double-blind	O	O
randomized	O	O
evaluation	O	O
of	O	O
intercostal	Pharmacological	O
nerve	Pharmacological	O
blocks	Pharmacological	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
subarachnoid	O	O
administered	O	O
morphine	Pharmacological	Pharmacological
for	O	O
post-thoracotomy	O	O
analgesia	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Thoracotomy	O	O
is	O	O
associated	O	O
with	O	O
pain	O	O
and	O	O
compromised	O	O
pulmonary	O	O
function	O	O
.	O	O

Intercostal	Pharmacological	O
nerve	Pharmacological	O
blocks	Pharmacological	O
(	Pharmacological	O
INB	Pharmacological	O
)	Pharmacological	O
and	O	O
subarachnoid	Pharmacological	Pharmacological
morphine	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
SM	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
act	O	O
on	O	O
different	O	O
portions	O	O
of	O	O
the	O	O
pain	O	O
pathway	O	O
.	O	O

Each	O	O
is	O	O
effective	O	O
for	O	O
post-thoracotomy	O	O
pain	O	O
relief	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
these	O	O
two	O	O
modalities	O	O
in	O	O
relieving	O	O
post-thoracotomy	O	O
pain	O	O
and	O	O
improving	O	O
postoperative	O	O
pulmonary	O	O
function	O	O
has	O	O
not	O	O
been	O	O
investigated	O	O
.	O	O

METHODS	O	O
In	O	O
a	O	O
double-blind	O	O
study	O	O
,	O	O
20	O	O
patients	O	O
undergoing	O	O
lateral	O	O
thoracotomy	Surgical	O
for	O	O
lung	O	O
resection	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	Pharmacological	O
preoperatively	O	O
and	O	O
INB	Pharmacological	O
with	O	O
bupivacaine	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
INB+	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
prior	O	O
to	O	O
wound	O	O
closure	O	O
or	O	O
0.5	O	O
mg	O	O
SM	Pharmacological	O
with	O	O
INB	Pharmacological	O
using	O	O
saline	Control	O
(	O	O
INB-	O	O
)	O	O
.	O	O

Visual	O	O
analog	O	O
scale	O	O
pain	O	O
scores	O	O
at	O	O
rest	O	O
,	O	O
with	O	O
cough	O	O
,	O	O
and	O	O
with	O	O
movement	O	O
of	O	O
the	O	O
ipsilateral	O	O
arm	O	O
,	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
second	O	O
(	O	O
FEV1	O	O
)	O	O
,	O	O
and	O	O
forced	O	O
vital	O	O
capacity	O	O
(	O	O
FVC	O	O
)	O	O
were	O	O
measured	O	O
at	O	O
4	O	O
,	O	O
24	O	O
,	O	O
48	O	O
,	O	O
and	O	O
72	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

Opioid	O	O
use	O	O
was	O	O
measured	O	O
during	O	O
the	O	O
initial	O	O
24	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

RESULTS	O	O
At	O	O
4	O	O
hours	O	O
,	O	O
the	O	O
INB+	Pharmacological	O
group	O	O
demonstrated	O	O
better	O	O
FEV1	O	O
(	O	O
56.6	O	O
%	O	O
vs.	O	O
40.4	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
FVC	O	O
values	O	O
(	O	O
54.6	O	O
%	O	O
vs.	O	O
39.6	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
less	O	O
resting	O	O
and	O	O
cough	O	O
pain	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
FEV1	O	O
continued	O	O
to	O	O
decline	O	O
in	O	O
the	O	O
INB+	Pharmacological	O
group	O	O
at	O	O
24	O	O
hours	O	O
to	O	O
lower	O	O
than	O	O
the	O	O
INB-	Pharmacological	O
group	O	O
although	O	O
pain	O	O
scores	O	O
were	O	O
similar	O	O
beyond	O	O
4	O	O
hours	O	O
.	O	O

Opioid	O	O
usage	O	O
during	O	O
the	O	O
first	O	O
24	O	O
hours	O	O
was	O	O
similar	O	O
(	Pharmacological	O
INB-	Pharmacological	O
,	O	O
16.7	O	O
mg	O	O
vs.	O	O
INB+	Pharmacological	O
,	O	O
13.2	O	O
mg	O	O
,	O	O
P	O	O
=	O	O
.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
postoperative	O	O
INB	Pharmacological	O
provided	O	O
modest	O	O
improvements	O	O
in	O	O
pain	O	O
and	O	O
pulmonary	O	O
function	O	O
when	O	O
used	O	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
0.5	O	O
mg	O	O
SM	Pharmacological	O
for	O	O
post-thoracotomy	O	O
analgesia	O	O
,	O	O
the	O	O
benefits	O	O
were	O	O
transient	O	O
.	O	O

The	O	O
authors	O	O
do	O	O
not	O	O
recommend	O	O
adding	O	O
INB	Pharmacological	O
for	O	O
patients	O	O
undergoing	O	O
lateral	O	O
thoracotomy	O	O
who	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	Pharmacological	O
.	Pharmacological	O

Clonidine	Pharmacological	O
increases	O	O
the	O	O
sweating	O	O
threshold	O	O
,	O	O
but	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
gain	O	O
of	O	O
sweating	O	O
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
clonidine	Pharmacological	O
produces	O	O
a	O	O
dose-dependent	O	O
increase	O	O
in	O	O
the	O	O
sweating	O	O
threshold	O	O
but	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
gain	O	O
of	O	O
sweating	O	O
.	O	O

Six	O	O
healthy	O	O
male	O	O
volunteers	O	O
were	O	O
evaluated	O	O
,	O	O
each	O	O
on	O	O
three	O	O
separate	O	O
days	O	O
in	O	O
random	O	O
order	O	O
.	O	O

In	O	O
one	O	O
,	O	O
saline	Control	Pharmacological
was	O	O
administered	O	O
;	O	O
in	O	O
another	O	O
,	O	O
a	O	O
2-micrograms/kg	O	O
bolus	O	O
of	O	O
clonidine	Pharmacological	Pharmacological
was	O	O
followed	O	O
by	O	O
an	O	O
infusion	O	O
at	O	O
2	O	O
micrograms.kg-1.h-1	O	O
,	O	O
and	O	O
on	O	O
a	O	O
third	O	O
day	O	O
,	O	O
a	O	O
4-micrograms/kg	O	O
bolus	O	O
was	O	O
followed	O	O
by	O	O
an	O	O
infusion	O	O
at	O	O
4	O	O
micrograms.kg-1.h-1	O	O
.	O	O

Core	O	O
temperature	O	O
was	O	O
measured	O	O
at	O	O
the	O	O
tympanic	O	O
membrane	O	O
and	O	O
mean	O	O
skin	O	O
temperature	O	O
was	O	O
determined	O	O
from	O	O
four	O	O
sites	O	O
.	O	O

A	O	O
chest	O	O
sweating	O	O
rate	O	O
of	O	O
40	O	O
g.m-2.h-1	O	O
was	O	O
considered	O	O
significant	O	O
.	O	O

The	O	O
core	O	O
temperature	O	O
triggering	O	O
sweating	O	O
,	O	O
adjusted	O	O
to	O	O
a	O	O
designated	O	O
mean	O	O
skin	O	O
temperature	O	O
of	O	O
34	O	O
degrees	O	O
C	O	O
,	O	O
identified	O	O
the	O	O
threshold	O	O
for	O	O
this	O	O
response	O	O
.	O	O

Gain	O	O
was	O	O
defined	O	O
by	O	O
the	O	O
adjusted	O	O
core	O	O
temperature	O	O
increase	O	O
required	O	O
to	O	O
augment	O	O
sweating	O	O
from	O	O
100	O	O
to	O	O
300	O	O
g.m-2.h-1	O	O
.	O	O

degree	O	O
C-1	O	O
.	O	O

Plasma	O	O
clonidine	O	O
concentrations	O	O
were	O	O
0.8	O	O
+/-	O	O
0.1	O	O
and	O	O
1.6	O	O
+/-	O	O
0.2	O	O
ng/mL	O	O
on	O	O
the	O	O
small-	O	O
and	O	O
large-dose	O	O
days	O	O
,	O	O
respectively	O	O
.	O	O

Clonidine	O	O
administration	O	O
increased	O	O
the	O	O
sweating	O	O
threshold	O	O
approximately	O	O
0.4	O	O
degree	O	O
C	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
the	O	O
increase	O	O
was	O	O
comparable	O	O
at	O	O
each	O	O
dose	O	O
.	O	O

The	O	O
gain	O	O
of	O	O
sweating	O	O
was	O	O
approximately	O	O
0.2	O	O
degree	O	O
C	O	O
and	O	O
was	O	O
not	O	O
influenced	O	O
by	O	O
clonidine	O	O
administration	O	O
.	O	O

The	O	O
thermoregulatory	O	O
effects	O	O
of	O	O
clonidine	O	O
thus	O	O
resemble	O	O
those	O	O
of	O	O
volatile	O	O
anesthetics	O	O
,	O	O
opioids	O	O
,	O	O
and	O	O
propofol	O	Pharmacological
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
antishivering	O	O
effect	O	O
of	O	O
clonidine	O	Pharmacological
results	O	O
from	O	O
central	O	O
thermoregulatory	O	O
inhibition	O	O
rather	O	O
than	O	O
a	O	O
specific	O	O
peripheral	O	O
action	O	O
on	O	O
thermogenic	O	O
muscular	O	O
activity	O	O
.	O	O

Unlike	O	O
other	O	O
sedatives	O	O
and	O	O
anesthetics	O	O
,	O	O
the	O	O
concentration-dependence	O	O
of	O	O
clonidine	O	O
demonstrates	O	O
a	O	O
ceiling	O	O
beyond	O	O
which	O	O
the	O	O
administration	O	O
of	O	O
an	O	O
additional	O	O
drug	O	O
fails	O	O
to	O	O
enhance	O	O
the	O	O
effect	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
thermoregulatory	O	O
effect	O	O
of	O	O
clonidine	O	Pharmacological
may	O	O
be	O	O
limited	O	O
,	O	O
even	O	O
at	O	O
high	O	O
plasma	O	O
concentrations	O	O
.	O	O

The	O	O
gain	O	O
of	O	O
sweating	O	O
was	O	O
well	O	O
preserved	O	O
indicating	O	O
that	O	O
this	O	O
response	O	O
remains	O	O
effective	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
sedatives	O	O
and	O	O
anesthetics	O	O
.	O	O

Acute	O	O
effects	O	O
of	O	O
decaffeinated	Pharmacological	O
coffee	Pharmacological	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	Pharmacological	O
acid	O	O
and	O	O
trigonelline	Pharmacological	O
on	O	O
glucose	O	O
tolerance	O	O
.	O	O

OBJECTIVE	O	O
Coffee	Pharmacological	O
consumption	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
lower	O	O
risk	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
acute	O	O
effects	O	O
of	O	O
decaffeinated	Pharmacological	O
coffee	Pharmacological	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
on	O	O
glucose	O	O
tolerance	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
We	O	O
conducted	O	O
a	O	O
randomized	O	O
crossover	O	O
trial	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
12	O	Pharmacological
g	O	Pharmacological
decaffeinated	Pharmacological	Pharmacological
coffee	Pharmacological	Pharmacological
,	O	Pharmacological
1	O	Pharmacological
g	O	Pharmacological
chlorogenic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
,	O	O
500	O	O
mg	O	O
trigonelline	Pharmacological	O
,	O	O
and	O	O
placebo	Control	O
(	O	O
1	O	O
g	O	O
mannitol	Pharmacological	O
)	Pharmacological	O
on	O	O
glucose	O	O
and	O	O
insulin	O	O
concentrations	O	O
during	O	O
a	O	O
2-h	O	O
oral	O	O
glucose	O	O
tolerance	O	O
test	O	O
(	O	O
OGTT	O	O
)	O	O
in	O	O
15	O	O
overweight	O	O
men	O	O
.	O	O

RESULTS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
ingestion	O	O
significantly	O	O
reduced	O	O
glucose	O	O
(	O	O
-0.7	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
,	O	O
and	O	O
-0.5	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.024	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
insulin	O	O
(	O	O
-73	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.038	O	O
,	O	O
and	O	O
-117	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
)	O	O
concentrations	O	O
15	O	O
min	O	O
following	O	O
an	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	O	Control
.	O	O

None	O	O
of	O	O
the	O	O
treatments	O	O
affected	O	O
insulin	O	O
or	O	O
glucose	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
values	O	O
during	O	O
the	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	Control	Control
.	Control	O

CONCLUSIONS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
reduced	O	O
early	O	O
glucose	O	O
and	O	O
insulin	O	O
responses	O	O
during	O	O
an	O	O
OGTT	O	O
.	O	O

[	O	O
Effects	O	O
of	O	O
transcutaneous	Physical	Physical
electrical	Physical	Physical
stimulation	Physical	Physical
of	Physical	Physical
auricular	Physical	Physical
Shenmen	Physical	Physical
point	Physical	Physical
on	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
and	O	O
patient-controlled	O	O
epidural	O	O
analgesia	O	O
in	O	O
cesarean	O	O
section	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
transcutaneous	O	Physical
electrical	O	Physical
stimulation	O	Physical
of	O	Physical
auricular	O	Physical
Shenmen	O	Physical
point	O	Physical
on	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
and	O	O
patient-controlled	O	O
epidural	O	O
analgesia	O	O
in	O	O
cesarean	O	O
section	O	O
.	O	O

METHODS	O	O
After	O	O
IRB	O	O
approval	O	O
and	O	O
informed	O	O
consent	O	O
,	O	O
one	O	O
hundred	O	O
and	O	O
eighty	O	O
singleton	O	O
primiparas	O	O
undergoing	O	O
elective	O	O
cesarean	O	O
section	O	O
,	O	O
in	O	O
Qingdao	O	O
Municipal	O	O
Hospital	O	O
,	O	O
and	O	O
Qingdao	O	O
Hiser	O	O
Medical	O	O
Center	O	O
,	O	O
from	O	O
November	O	O
2011	O	O
to	O	O
March	O	O
2012	O	O
,	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	O	O
groups	O	O
:	O	O
transcutaneous	Physical	Physical
electrical	Physical	Physical
stimulation	Physical	Physical
of	Physical	O
auricular	Physical	O
Shenmen	Physical	O
point	Physical	O
group	Physical	O
(	O	O
group	O	O
A	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
,	O	O
transcutaneous	Physical	O
electrical	Physical	O
stimulation	Physical	O
of	Physical	O
auricular	Physical	O
Eye	Physical	O
point	Physical	O
group	Physical	O
(	O	O
group	O	O
B	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
and	O	O
control	Control	O
group	Control	O
(	O	O
group	O	O
C	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
A	O	O
received	O	O
transcutaneous	Physical	Physical
electrical	Physical	Physical
stimulation	Physical	Physical
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
(	O	O
frequency	O	O
1.5	O	O
HZ	O	O
)	O	O
at	O	O
the	O	O
time	O	O
of	O	O
preoperation	O	O
,	O	O
4	O	O
,	O	O
10	O	O
and	O	O
22	O	O
hours	O	O
of	O	O
postoperation	O	O
for	O	O
30	O	O
minutes	O	O
.	O	O

The	O	O
strength	O	O
was	O	O
controlled	O	O
by	O	O
themselves	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
B	O	O
received	O	O
stimulation	O	O
of	O	O
auricular	O	O
Eye	O	O
point	O	O
as	O	O
group	O	O
A	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
C	O	O
received	O	O
pressurization	O	O
and	O	O
connected	O	O
line	O	O
were	O	O
the	O	O
same	O	O
with	O	O
group	O	O
A	O	O
,	O	O
but	O	Physical
without	O	Physical
electrical	Control	Physical
stimulation	Control	Physical
.	O	O

The	O	O
following	O	O
indexes	O	O
was	O	O
observed	O	O
:	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
(	O	O
PONV	O	O
)	O	O
for	O	O
48	O	O
hours	O	O
;	O	O
the	O	O
rate	O	O
of	O	O
metoclopramide	O	Pharmacological
;	O	O
the	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
score	O	O
of	O	O
rest	O	O
pain	O	O
,	O	O
uterine	O	O
contration	O	O
pain	O	O
and	O	O
dynamic	O	O
pain	O	O
at	O	O
the	O	O
time	O	O
of	O	O
postoperation	O	O
for	O	O
6	O	O
,	O	O
12	O	O
,	O	O
24	O	O
and	O	O
48	O	O
hours	O	O
(	O	O
T	O	O
(	O	O
1	O	O
)	O	O
-T	O	O
(	O	O
4	O	O
)	O	O
)	O	O
;	O	O
the	O	O
total	O	O
number	O	O
and	O	O
effective	O	O
compressions	O	O
number	O	O
of	O	O
patient-controlled	O	O
epidural	O	O
analgesia	O	O
(	O	O
PCEA	O	O
)	O	O
;	O	O
the	O	O
dose	O	Pharmacological
of	O	Pharmacological
analgesia	O	Pharmacological
mixture	O	Pharmacological
;	O	O
the	O	O
anal	O	O
exhaust	O	O
time	O	O
;	O	O
the	O	O
volume	O	O
of	O	O
postoperative	O	O
bleeding	O	O
for	O	O
6	O	O
hours	O	O
of	O	O
postoperation	O	O
and	O	O
the	O	O
other	O	O
side	O	O
effects	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
group	O	O
B	O	O
and	O	O
group	O	O
C	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
PONV	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
metoclopramide	O	O
,	O	O
the	O	O
VAS	O	O
score	O	O
at	O	O
the	O	O
time	O	O
T	O	O
(	O	O
1	O	O
)	O	O
-T	O	O
(	O	O
4	O	O
)	O	O
,	O	O
the	O	O
total	O	O
number	O	O
and	O	O
effective	O	O
compressions	O	O
number	O	O
of	O	O
PCEA	O	O
,	O	O
the	O	O
ratio	O	O
of	O	O
the	O	O
total	O	O
number	O	O
with	O	O
effective	O	O
compressions	O	O
number	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
analgesia	O	O
mixture	O	O
were	O	O
decreased	O	O
in	O	O
group	O	O
A	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
no	O	O
difference	O	O
compared	O	O
group	O	O
B	O	O
with	O	O
group	O	O
C	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
anal	O	O
exhaust	O	O
time	O	O
and	O	O
the	O	O
volume	O	O
of	O	O
postoperative	O	O
bleeding	O	O
for	O	O
6	O	O
hours	O	O
of	O	O
postoperation	O	O
were	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
three	O	O
groups	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
other	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
Transcutaneous	O	Physical
electrical	O	Physical
stimulation	O	Physical
of	O	Physical
auricular	O	Physical
Shenmen	O	Physical
point	O	Physical
can	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
PONV	O	O
and	O	O
improves	O	O
analgesia	O	O
effect	O	O
of	O	O
PCEA	O	O
in	O	O
postoperation	O	O
of	O	O
cesarean	O	O
section	O	O
.	O	O

Memantine	Pharmacological	O
add-on	O	O
to	O	O
risperidone	Pharmacological	Pharmacological
for	O	O
treatment	O	O
of	O	O
negative	O	O
symptoms	O	O
in	O	O
patients	O	O
with	O	O
stable	O	O
schizophrenia	O	O
:	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
memantine	Pharmacological	O
add-on	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
patients	O	O
with	O	O
stable	O	O
schizophrenia	O	O
.	O	O

In	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	Control
clinical	O	O
trial	O	O
,	O	O
40	O	O
patients	O	O
with	O	O
schizophrenia	O	O
(	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	O	O
Disorders	O	O
,	O	O
Fourth	O	O
Edition	O	O
)	O	O
who	O	O
were	O	O
stabilized	O	O
on	O	O
risperidone	Pharmacological	Pharmacological
for	O	O
a	O	O
minimum	O	O
of	O	O
8	O	O
weeks	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
memantine	Pharmacological	O
(	O	O
20	O	O
mg	O	O
)	O	O
or	O	O
placebo	Control	Control
in	O	O
addition	O	O
to	O	O
risperidone	Pharmacological	Pharmacological
,	O	O
6	O	O
mg/d	O	O
,	O	O
for	O	O
eight	O	O
weeks	O	O
.	O	O

Assessment	O	O
was	O	O
done	O	O
using	O	O
the	O	O
Positive	O	O
and	O	O
Negative	O	O
Syndrome	O	O
Scale	O	O
at	O	O
baseline	O	O
,	O	O
week	O	O
4	O	O
,	O	O
and	O	O
week	O	O
8	O	O
.	O	O

The	O	O
Hamilton	O	O
Depression	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Extrapyramidal	O	O
Symptom	O	O
Rating	O	O
Scale	O	O
at	O	O
baseline	O	O
and	O	O
week	O	O
8	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
depression	O	O
and	O	O
extrapyramidal	O	O
symptoms	O	O
,	O	O
respectively	O	O
.	O	O

All	O	O
40	O	O
patients	O	O
had	O	O
at	O	O
least	O	O
one	O	O
postbaseline	O	O
measurement	O	O
,	O	O
and	O	O
38	O	O
patients	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
memantine	O	O
group	O	O
showed	O	O
a	O	O
significantly	O	O
greater	O	O
improvement	O	O
on	O	O
negative	O	O
subscale	O	O
than	O	O
the	O	O
placebo	Control	O
group	O	O
at	O	O
end	O	O
point	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
same	O	O
effect	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
total	O	O
score	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
the	O	O
general	O	O
psychopathology	O	O
subscale	O	O
score	O	O
(	O	O
P	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
reduction	O	O
of	O	O
positive	O	O
symptoms	O	O
score	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
(	O	O
P	O	O
=	O	O
0.757	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
Hamilton	O	O
Depression	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Extrapyramidal	O	O
Symptom	O	O
Rating	O	O
Scale	O	O
scores	O	O
and	O	O
frequency	O	O
of	O	O
adverse	O	O
effects	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

Our	O	O
study	O	O
showed	O	O
that	O	O
memantine	O	O
is	O	O
a	O	O
tolerable	O	O
and	O	O
efficacious	O	O
add-on	O	O
treatment	O	O
for	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
schizophrenia	O	O
.	O	O

VLDL	O	O
,	O	O
apolipoproteins	O	O
B	O	O
,	O	O
CIII	O	O
,	O	O
and	O	O
E	O	O
,	O	O
and	O	O
risk	O	O
of	O	O
recurrent	O	O
coronary	O	O
events	O	O
in	O	O
the	O	O
Cholesterol	O	O
and	O	O
Recurrent	O	O
Events	O	O
(	O	O
CARE	O	O
)	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Plasma	O	O
triglyceride	O	O
concentration	O	O
has	O	O
been	O	O
an	O	O
inconsistent	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
coronary	O	O
heart	O	O
disease	O	O
,	O	O
perhaps	O	O
because	O	O
of	O	O
the	O	O
metabolic	O	O
heterogeneity	O	O
among	O	O
VLDL	O	O
particles	O	O
,	O	O
the	O	O
main	O	O
carriers	O	O
of	O	O
triglycerides	O	O
in	O	O
plasma	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
We	O	O
conducted	O	O
a	O	O
prospective	O	O
,	O	O
nested	O	O
case-control	O	O
study	O	O
in	O	O
the	O	O
Cholesterol	O	O
and	O	O
Recurrent	O	O
Events	O	O
(	O	O
CARE	O	O
)	O	O
trial	O	O
,	O	O
a	O	O
randomized	O	O
placebo-controlled	Control	Control
trial	O	O
of	O	O
pravastatin	Pharmacological	Pharmacological
in	O	O
4159	O	O
patients	O	O
with	O	O
myocardial	O	O
infarction	O	O
and	O	O
average	O	O
LDL	O	O
concentrations	O	O
at	O	O
baseline	O	O
(	O	O
115	O	O
to	O	O
174	O	O
mg/dL	O	O
,	O	O
mean	O	O
139	O	O
mg/dL	O	O
)	O	O
.	O	O

Baseline	O	O
concentrations	O	O
of	O	O
VLDL-apolipoprotein	O	O
(	O	O
apo	O	O
)	O	O
B	O	O
(	O	O
the	O	O
VLDL	O	O
particle	O	O
concentration	O	O
)	O	O
,	O	O
VLDL	O	O
lipids	O	O
,	O	O
and	O	O
apoCIII	O	O
and	O	O
apoE	O	O
in	O	O
VLDL+LDL	O	O
and	O	O
in	O	O
HDL	O	O
were	O	O
compared	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
either	O	O
a	O	O
myocardial	O	O
infarction	O	O
or	O	O
coronary	O	O
death	O	O
(	O	O
cases	O	O
,	O	O
n=418	O	O
)	O	O
with	O	O
those	O	O
in	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
have	O	O
a	O	O
cardiovascular	O	O
event	O	O
(	O	O
control	O	O
subjects	O	O
,	O	O
n=370	O	O
)	O	O
in	O	O
5	O	O
years	O	O
of	O	O
follow-up	O	O
.	O	O

VLDL-cholesterol	O	O
,	O	O
VLDL-triglyceride	O	O
,	O	O
VLDL-apoB	O	O
,	O	O
apoCIII	O	O
and	O	O
apoE	O	O
in	O	O
VLDL+LDL	O	O
and	O	O
apoE	O	O
in	O	O
HDL	O	O
were	O	O
all	O	O
interrelated	O	O
,	O	O
and	O	O
each	O	O
was	O	O
a	O	O
univariate	O	O
predictor	O	O
of	O	O
subsequent	O	O
coronary	O	O
events	O	O
.	O	O

The	O	O
significant	O	O
independent	O	O
predictors	O	O
were	O	O
VLDL-apoB	O	O
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
3.2	O	O
for	O	O
highest	O	O
to	O	O
lowest	O	O
quintiles	O	O
,	O	O
P	O	O
:	O	O
=0.04	O	O
)	O	O
,	O	O
apoCIII	O	O
in	O	O
VLDL+LDL	O	O
(	O	O
RR	O	O
2.3	O	O
,	O	O
P	O	O
:	O	O
=0.04	O	O
)	O	O
,	O	O
and	O	O
apoE	O	O
in	O	O
HDL	O	O
(	O	O
RR	O	O
1.8	O	O
,	O	O
P	O	O
:	O	O
=0.02	O	O
)	O	O
.	O	O

Plasma	O	O
triglycerides	O	O
,	O	O
a	O	O
univariate	O	O
predictor	O	O
of	O	O
coronary	O	O
events	O	O
(	O	O
RR	O	O
1.6	O	O
,	O	O
P	O	O
:	O	O
=0.03	O	O
)	O	O
,	O	O
was	O	O
not	O	O
related	O	O
to	O	O
coronary	O	O
events	O	O
(	O	O
RR	O	O
1.3	O	O
,	O	O
P	O	O
:	O	O
=0.6	O	O
)	O	O
when	O	O
apoCIII	O	O
in	O	O
VLDL+LDL	O	O
was	O	O
included	O	O
in	O	O
the	O	O
model	O	O
,	O	O
whereas	O	O
apoCIII	O	O
remained	O	O
significant	O	O
.	O	O

Adjustment	O	O
for	O	O
LDL-	O	O
and	O	O
HDL-cholesterol	O	O
did	O	O
not	O	O
affect	O	O
these	O	O
results	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
plasma	O	O
concentrations	O	O
of	O	O
VLDL	O	O
particles	O	O
and	O	O
apoCIII	O	O
in	O	O
VLDL	O	O
and	O	O
LDL	O	O
are	O	O
more	O	O
specific	O	O
measures	O	O
of	O	O
coronary	O	O
heart	O	O
disease	O	O
risk	O	O
than	O	O
plasma	O	O
triglycerides	O	O
perhaps	O	O
because	O	O
their	O	O
known	O	O
metabolic	O	O
properties	O	O
link	O	O
them	O	O
more	O	O
closely	O	O
to	O	O
atherosclerosis	O	O
.	O	O

Gastric	O	O
ulcer	O	O
treatment	O	O
with	O	O
intravenous	O	O
human	Pharmacological	O
epidermal	Pharmacological	O
growth	Pharmacological	O
factor	Pharmacological	O
:	Pharmacological	O
a	O	O
double-blind	O	O
controlled	O	O
clinical	O	O
study	O	O
.	O	O

We	O	O
introduced	O	O
a	O	O
double-blind	O	O
controlled	O	O
clinical	O	O
study	O	O
to	O	O
compare	O	O
intravenous	Pharmacological	O
human	Pharmacological	O
epidermal	Pharmacological	O
growth	Pharmacological	O
factor	Pharmacological	O
(	Pharmacological	O
hEGF	Pharmacological	O
)	Pharmacological	O
to	O	O
cetraxate	Pharmacological	O
hydrochloride	Pharmacological	O
(	Pharmacological	O
CH	Pharmacological	O
)	Pharmacological	O
,	O	O
an	O	O
antiulcer	O	O
drug	O	O
,	O	O
for	O	O
their	O	O
healing	O	O
effect	O	O
on	O	O
gastric	O	O
ulcers	O	O
.	O	O

We	O	O
also	O	O
prospected	O	O
an	O	O
oral	O	O
use	O	O
of	O	O
EGF	Pharmacological	O
on	O	O
the	O	O
basis	O	O
of	O	O
our	O	O
experimental	O	O
evidence	O	O
.	O	O

In	O	O
the	O	O
clinical	O	O
trial	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
ulcer	O	O
healing	O	O
within	O	O
8	O	O
weeks	O	O
was	O	O
77.9	O	O
%	O	O
(	O	O
67/86	O	O
)	O	O
in	O	O
patients	O	O
receiving	O	O
6	O	O
micrograms	O	O
EGF	Pharmacological	O
intravenously	O	O
twice	O	O
a	O	O
week	O	O
,	O	O
being	O	O
significantly	O	O
greater	O	O
than	O	O
51.7	O	O
%	O	O
(	O	O
45/87	O	O
)	O	O
in	O	O
those	O	O
given	O	O
CH	Pharmacological	O
.	Pharmacological	O

Taking	O	O
together	O	O
all	O	O
aspects	O	O
assessed	O	O
including	O	O
the	O	O
healing	O	O
rate	O	O
,	O	O
pain	O	O
relief	O	O
,	O	O
blood	O	O
examination	O	O
and	O	O
adverse	O	O
reactions	O	O
,	O	O
we	O	O
judged	O	O
the	O	O
hEGF	Pharmacological	O
to	O	O
be	O	O
a	O	O
useful	O	O
and	O	O
safe	O	O
anticuler	O	O
drug	O	O
.	O	O

In	O	O
rats	O	O
,	O	O
50	O	O
micrograms/kg	O	O
mouse	O	O
EGF	O	O
(	O	O
mEGF	O	O
)	O	O
and	O	O
2	O	O
%	O	O
hydroxypropyl	Pharmacological	O
cellulose	Pharmacological	O
(	O	O
HPC	O	O
)	O	O
or	O	O
1.0	O	O
g/kg	O	O
sucralfate	O	O
given	O	O
by	O	O
gastric	O	O
intubation	O	O
significantly	O	O
raised	O	O
the	O	O
residual	O	O
mEGF	O	O
levels	O	O
in	O	O
both	O	O
gastric	O	O
luminal	O	O
content	O	O
(	O	O
HPC	O	O
:	O	O
x	O	O
30	O	O
;	O	O
sucralfate	O	Pharmacological
:	O	O
x	O	O
300	O	O
as	O	O
high	O	O
as	O	O
those	O	O
in	O	O
EGF	O	O
alone	O	O
)	O	O
and	O	O
tissue	O	O
(	O	O
HPC	O	O
:	O	O
x	O	O
60	O	O
;	O	O
sucralfate	O	Pharmacological
:	O	O
x	O	O
100	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
combined	O	O
treatments	O	O
significantly	O	O
promoted	O	O
healing	O	O
of	O	O
rat	O	O
gastric	O	O
ulcers	O	O
whereas	O	O
each	O	O
agent	O	O
alone	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
as	O	O
compared	O	O
with	O	O
control	O	O
(	O	O
saline	O	O
)	O	O
.	O	O

This	O	O
indicated	O	O
the	O	O
beneficial	O	O
effect	O	O
on	O	O
ulcers	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
EGF	Pharmacological	O
with	O	O
agents	O	O
allowing	O	O
it	O	O
to	O	O
remain	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
the	O	O
stomach	O	O
,	O	O
whereas	O	O
most	O	O
reports	O	O
suggested	O	O
less	O	O
effect	O	O
of	O	O
oral	O	O
EGF	O	O
on	O	O
healing	O	O
of	O	O
gastroduodenal	O	O
ulcers	O	O
.	O	O

Subsequent	O	O
to	O	O
the	O	O
clinical	O	O
study	O	O
,	O	O
evaluation	O	O
of	O	O
oral	O	O
use	O	O
of	O	O
EGF	Pharmacological	O
may	O	O
be	O	O
expected	O	O
as	O	O
the	O	O
next	O	O
step	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
ulcers	O	O
.	O	O

The	O	O
experimental	O	O
evidence	O	O
above	O	O
would	O	O
possibly	O	O
be	O	O
a	O	O
guide	O	O
for	O	O
such	O	O
trial	O	O
.	O	O

Sodium	Pharmacological	O
bicarbonate	Pharmacological	O
,	O	O
N-acetylcysteine	Pharmacological	Pharmacological
,	O	O
and	O	O
saline	Control	Pharmacological
for	O	O
prevention	O	O
of	O	O
radiocontrast-induced	O	O
nephropathy	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
3	O	O
regimens	O	O
for	O	O
protecting	O	O
contrast-induced	O	O
nephropathy	O	O
in	O	O
patients	O	O
undergoing	O	O
coronary	Surgical	O
procedures	Surgical	O
.	Surgical	O

A	O	O
single-center	O	O
prospective	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Several	O	O
protective	O	O
therapies	O	O
have	O	O
been	O	O
developed	O	O
to	O	O
prevent	O	O
contrast-induced	O	O
nephropathy	O	O
(	O	O
CIN	O	O
)	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
efficacy	O	O
of	O	O
sodium	Pharmacological	O
bicarbonate	Pharmacological	O
by	O	O
comparing	O	O
2	O	O
other	O	O
regimens	O	O
,	O	O
including	O	O
combination	O	O
of	O	O
N-acetylcysteine	Surgical	Pharmacological
(	Surgical	Pharmacological
NAC	Surgical	Pharmacological
)	Surgical	Pharmacological
plus	O	O
sodium	Pharmacological	O
chloride	Pharmacological	O
and	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
alone	O	Pharmacological
,	O	O
to	O	O
prevent	O	O
CIN	O	O
in	O	O
patients	O	O
undergoing	O	O
cardiovascular	O	O
procedures	O	O
.	O	O

METHODS	O	O
We	O	O
prospectively	O	O
enrolled	O	O
264	O	O
patients	O	O
who	O	O
were	O	O
scheduled	O	O
for	O	O
cardiovascular	O	O
procedures	O	O
and	O	O
had	O	O
a	O	O
baseline	O	O
creatinine	O	O
level	O	O
>	O	O
1.2	O	O
mg/dL	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assigned	O	O
1	O	O
of	O	O
3	O	Pharmacological
prophylactic	O	Pharmacological
regimens	O	Pharmacological
:	O	Pharmacological
infusion	O	Pharmacological
of	O	Pharmacological
sodium	Pharmacological	Pharmacological
bicarbonate	Pharmacological	Pharmacological
,	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
,	O	Pharmacological
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
plus	O	Pharmacological
oral	O	Pharmacological
NAC	Pharmacological	Pharmacological
(	O	O
600	O	O
mg	O	O
bid	O	O
)	O	O
.	O	O

Contrast-induced	O	O
nephropathy	O	O
was	O	O
defined	O	O
as	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	O	O
level	O	O
>	O	O
25	O	O
%	O	O
or	O	O
0.5	O	O
mg/dL	O	O
after	O	O
48	O	O
hours	O	O
.	O	O

RESULTS	O	O
There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
among	O	O
groups	O	O
regarding	O	O
baseline	O	O
demographic	O	O
properties	O	O
and	O	O
nephropathy	O	O
risk	O	O
factors	O	O
.	O	O

The	O	O
change	O	O
in	O	O
creatinine	O	O
clearance	O	O
was	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
sodium	Pharmacological	O
bicarbonate	Pharmacological	O
group	O	O
than	O	O
other	O	O
2	O	O
groups	O	O
(	O	O
P	O	O
=	O	O
.007	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
CIN	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
sodium	Pharmacological	O
bicarbonate	Pharmacological	O
group	O	O
(	O	O
4.5	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
alone	O	Pharmacological
(	O	O
13.6	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.036	O	O
)	O	O
and	O	O
tended	O	O
to	O	O
be	O	O
lower	O	O
than	O	O
in	O	O
the	O	O
combination	O	O
group	O	O
(	O	O
12.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.059	O	O
)	O	O
.	O	O

After	O	O
adjusting	O	O
the	O	O
Mehran	O	O
nephropathy	O	O
risk	O	O
score	O	O
,	O	O
the	O	O
risk	O	O
of	O	O
CIN	O	O
significantly	O	O
reduced	O	O
with	O	O
sodium	Pharmacological	O
bicarbonate	Pharmacological	O
compared	O	O
with	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
alone	O	Pharmacological
(	O	O
adjusted	O	O
risk	O	O
ratio	O	O
0.29	O	O
,	O	O
P	O	O
=	O	O
.043	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Hydration	O	O
with	O	O
sodium	Pharmacological	O
bicarbonate	Pharmacological	O
provides	O	O
better	O	O
protection	O	O
against	O	O
CIN	O	O
than	O	O
the	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
infusion	Pharmacological	Pharmacological
does	O	Pharmacological
alone	O	Pharmacological
.	O	O

Combination	O	O
therapy	O	O
of	O	O
NAC	Pharmacological	O
plus	Pharmacological	O
sodium	Pharmacological	O
chloride	Pharmacological	O
did	O	O
not	O	O
offer	O	O
additional	O	O
benefit	O	O
over	O	O
hydration	O	O
with	O	O
sodium	Pharmacological	Pharmacological
chloride	Pharmacological	Pharmacological
alone	O	Pharmacological
.	O	O

Treatment	O	O
of	O	O
stable	O	O
angina	O	O
of	O	O
effort	O	O
with	O	O
verapamil	Pharmacological	Pharmacological
:	Pharmacological	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	Control
randomized	O	O
crossover	O	O
study	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
verapamil	Pharmacological	Pharmacological
were	O	O
assessed	O	O
in	O	O
26	O	O
patients	O	O
with	O	O
stable	O	O
exertional	O	O
angina	O	O
pectoris	O	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	Control
,	O	O
randomized	O	O
crossover	O	O
protocol	O	O
using	O	O
serial	O	O
treadmill	O	O
tests	O	O
.	O	O

Verapamil	Pharmacological	Pharmacological
,	O	O
480	O	O
mg/day	O	O
,	O	O
reduced	O	O
anginal	O	O
frequency	O	O
from	O	O
5.6	O	O
+/-	O	O
7.3	O	O
to	O	O
2.2	O	O
+/-	O	O
3.9	O	O
attacks	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
nitroglycerin	Pharmacological	O
consumption	O	O
from	O	O
3.4	O	O
+/-	O	O
4.9	O	O
to	O	O
1.2	O	O
+/-	O	O
2.5	O	O
tablets	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
compared	O	O
with	O	O
placebo	Control	Control
.	Control	O

Treadmill	O	O
time	O	O
increased	O	O
from	O	O
6.4	O	O
+/-	O	O
2.1	O	O
minutes	O	O
during	O	O
the	O	O
placebo	Control	Control
phase	O	O
to	O	O
7.5	O	O
+/-	O	O
1.8	O	O
minutes	O	O
during	O	O
the	O	O
verapamil	Pharmacological	O
phase	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	Pharmacological	O
's	Pharmacological	O
beneficial	O	O
effect	O	O
appeared	O	O
to	O	O
be	O	O
related	O	O
,	O	O
in	O	O
part	O	O
,	O	O
to	O	O
a	O	O
10	O	O
%	O	O
reduction	O	O
of	O	O
the	O	O
rate-pressure	O	O
product	O	O
at	O	O
rest	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
and	O	O
a	O	O
12	O	O
%	O	O
reduction	O	O
during	O	O
submaximal	O	O
exercise	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	Pharmacological	Pharmacological
also	O	O
caused	O	O
less	O	O
marked	O	O
ST-segment	O	O
depressions	O	O
at	O	O
peak	O	O
exercise	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
at	O	O
a	O	O
similar	O	O
rate-pressure	O	O
product	O	O
,	O	O
suggesting	O	O
a	O	O
favorable	O	O
redistribution	O	O
of	O	O
coronary	O	O
blood	O	O
flow	O	O
to	O	O
the	O	O
ischemic	O	O
zone	O	O
.	O	O

Side	O	O
effects	O	O
from	O	O
verapamil	Pharmacological	Pharmacological
were	O	O
minimal	O	O
,	O	O
consisting	O	O
mainly	O	O
of	O	O
constipation	O	O
(	O	O
six	O	O
patients	O	O
)	O	O
.	O	O

Verapamil	Pharmacological	Pharmacological
appears	O	O
to	O	O
be	O	O
a	O	O
safe	O	O
and	O	O
effective	O	O
drug	O	O
for	O	O
treating	O	O
angina	O	O
of	O	O
effort	O	O
.	O	O

Transdermal	O	Pharmacological
scopolamine	Pharmacological	Pharmacological
patch	O	Pharmacological
in	O	O
addition	O	O
to	O	O
ondansetron	Pharmacological	Pharmacological
for	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
prophylaxis	O	O
in	O	O
patients	O	O
undergoing	O	O
ambulatory	O	O
cosmetic	O	O
surgery	O	O
.	O	O

STUDY	O	O
OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
transdermal	O	Pharmacological
scopolamine	Pharmacological	Pharmacological
in	O	O
addition	O	O
to	O	O
ondansetron	Pharmacological	Pharmacological
in	O	O
decreasing	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
(	O	O
PONV	O	O
)	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Academic	O	O
hospital	O	O
.	O	O

PATIENTS	O	O
126	O	O
ASA	O	O
physical	O	O
status	O	O
I	O	O
and	O	O
II	O	O
patients	O	O
undergoing	O	O
outpatient	O	O
plastic	O	O
surgery	O	O
with	O	O
three	O	O
or	O	O
more	O	O
risk	O	O
factors	O	O
for	O	O
PONV	O	O
.	O	O

INTERVENTIONS	O	O
Patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
to	O	O
receive	O	O
(	O	O
Group	O	O
1	O	O
)	O	O
a	O	O
transdermal	O	O
scopolamine	Pharmacological	Pharmacological
(	O	Pharmacological
TDS	O	Pharmacological
)	O	Pharmacological
patch	O	Pharmacological
or	O	O
(	O	O
Group	O	O
2	O	O
)	O	O
,	O	O
a	O	O
placebo	Control	Control
patch	O	O
two	O	O
hours	O	O
before	O	O
surgery	O	O
.	O	O

MEASUREMENTS	O	O
Occurrence	O	O
of	O	O
vomiting	O	O
,	O	O
severity	O	O
of	O	O
nausea	O	O
using	O	O
a	O	O
visual	O	O
analog	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
,	O	O
rescue	O	O
medication	O	O
,	O	O
pain	O	O
intensity	O	O
and	O	O
pain	O	O
medications	O	O
,	O	O
and	O	O
side	O	O
effects	O	O
were	O	O
recorded	O	O
every	O	O
hour	O	O
until	O	O
discharge	O	O
from	O	O
hospital	O	O
,	O	O
then	O	O
every	O	O
4	O	O
hours	O	O
thereafter	O	O
for	O	O
a	O	O
total	O	O
of	O	O
24	O	O
hours	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
A	O	O
statistically	O	O
significant	O	O
reduction	O	O
in	O	O
postoperative	O	O
nausea	O	O
between	O	O
8	O	O
and	O	O
24	O	O
hours	O	O
in	O	O
patients	O	O
receiving	O	O
TDS	O	O
was	O	O
noted	O	O
.	O	O

CONCLUSIONS	O	O
Transdermal	O	Pharmacological
scopolamine	Pharmacological	Pharmacological
in	O	O
addition	O	O
to	O	O
ondansetron	O	O
benefits	O	O
patients	O	O
at	O	O
high	O	O
risk	O	O
for	O	O
PONV	O	O
undergoing	O	O
outpatient	O	O
plastic	O	O
surgery	O	O
for	O	O
up	O	O
to	O	O
20	O	O
hours	O	O
after	O	O
surgery	O	O
.	O	O

Effect	O	O
of	O	O
four	Physical	O
intermediate	Physical	O
layer	Physical	O
treatments	Physical	O
on	O	O
microleakage	O	O
of	O	O
Class	O	O
II	O	O
composite	O	O
restorations	O	O
.	O	O

This	O	O
in	O	O
vitro	O	O
study	O	O
examines	O	O
the	O	O
marginal	O	O
sealing	O	O
ability	O	O
of	O	O
four	Other	O
different	Other	O
intermediate	Other	O
materials	Other	O
applied	O	O
before	O	O
placement	O	O
of	O	O
a	O	O
condensable	Other	O
composite	Other	O
.	Other	O

Class	O	O
II	O	O
preparations	O	O
were	O	O
made	O	O
with	O	O
gingival	O	O
margins	O	O
placed	O	O
1.0	O	O
mm	O	O
apical	O	O
to	O	O
the	O	O
cementoenamel	O	O
junction	O	O
of	O	O
60	O	O
extracted	O	O
teeth	O	O
,	O	O
randomly	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
of	O	O
12	O	O
.	O	O

Following	O	O
restoration	O	O
,	O	O
teeth	O	O
were	O	O
thermocycled	O	O
,	O	O
soaked	O	O
in	O	O
0.5	O	O
%	O	O
basic	O	O
fuchsin	O	O
,	O	O
and	O	O
sectioned	O	O
longitudinally	O	O
.	O	O

The	O	O
resin-modified	Other	O
glass	Other	O
ionomer	Other	O
cement	Other	O
demonstrated	O	O
significantly	O	O
less	O	O
microleakage	O	O
than	O	O
the	O	O
use	O	O
of	O	O
a	O	O
dentin	Other	O
bonding	Other	O
agent	Other	O
alone	Other	O
or	O	O
in	O	O
combination	Other	O
with	Other	O
flowable	Other	O
composite	Other	O
,	O	O
flowable	O	O
compomer	O	O
,	O	O
or	O	O
autoploymerizing	O	O
composite	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
,	O	O
Dunn	O	O
's	O	O
test	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
use	O	O
of	O	O
the	O	O
glass	Physical	Physical
ionomer	Physical	Physical
open	Physical	Physical
sandwich	Physical	Physical
technique	Physical	Physical
in	O	O
deep	O	O
Class	O	O
II	O	O
direct	O	O
composite	O	O
restorations	O	O
.	O	O

Use	O	O
and	O	O
limitations	O	O
of	O	O
Holter	Physical	O
electrocardiography	Physical	O
in	O	O
assessing	O	O
drug	O	O
therapy	O	O
of	O	O
myocardial	O	O
ischemia	O	O
during	O	O
the	O	O
peri-PTCA	O	O
period	O	O
.	O	O

Incidence	O	O
and	O	O
pattern	O	O
of	O	O
myocardial	O	O
ischemia	O	O
during	O	O
the	O	O
peri-PTCA	O	O
(	O	O
percutaneous	O	Surgical
transluminal	O	Surgical
coronary	O	Surgical
angioplasty	O	Surgical
)	O	O
period	O	O
and	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
continuous	Pharmacological	Pharmacological
intravenous	Pharmacological	Pharmacological
isosorbide	Pharmacological	Pharmacological
dinitrate	Pharmacological	Pharmacological
in	O	O
its	O	O
prevention	O	O
were	O	O
examined	O	O
prospectively	O	O
in	O	O
30	O	O
patients	O	O
.	O	O

Holter	Physical	O
electrocardiographic	Physical	O
monitoring	Physical	O
was	O	O
performed	O	O
for	O	O
21	O	O
+/-	O	O
3	O	O
h	O	O
before	O	O
PTCA	O	O
and	O	O
continued	O	O
during	O	O
and	O	O
for	O	O
41	O	O
+/-	O	O
8	O	O
h	O	O
after	O	O
the	O	O
procedure	O	O
.	O	O

Before	O	O
PTCA	O	O
,	O	O
19	O	O
ischemic	O	O
episodes	O	O
were	O	O
present	O	O
in	O	O
10	O	O
(	O	O
33	O	O
%	O	O
)	O	O
of	O	O
30	O	O
patients	O	O
.	O	O

PTCA	O	O
produced	O	O
an	O	O
abrupt	O	O
decrease	O	O
in	O	O
number	O	O
(	O	O
p	O	O
=	O	O
0.015	O	O
)	O	O
and	O	O
duration	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
of	O	O
spontaneous	O	O
ischemic	O	O
episodes	O	O
.	O	O

The	O	O
rarity	O	O
of	O	O
recurrent	O	O
myocardial	O	O
ischemic	O	O
events	O	O
by	O	O
Holter	Physical	O
monitoring	Physical	O
after	O	O
PTCA	O	O
negated	O	O
any	O	O
attempt	O	O
at	O	O
assessing	O	O
the	O	O
efficacy	O	O
of	O	O
intravenous	O	O
isosorbide	Pharmacological	Pharmacological
dinitrate	Pharmacological	Pharmacological
in	O	O
their	O	O
prevention	O	O
.	O	O

Holter	Physical	O
monitoring	Physical	O
could	O	O
not	O	O
be	O	O
used	O	O
as	O	O
an	O	O
early	O	O
predictor	O	O
of	O	O
late	O	O
coronary	O	O
restenosis	O	O
.	O	O

Tetracaine	Pharmacological	O
(	Pharmacological	O
ametop	Pharmacological	O
)	Pharmacological	O
compared	O	O
to	O	O
placebo	O	Control
for	O	O
reducing	O	O
pain	O	O
associated	O	O
with	O	O
intramuscular	O	O
injection	O	O
of	O	O
palivizumab	O	O
(	O	O
synagis	O	O
)	O	O
.	O	O

Infants	O	O
receive	O	O
many	O	O
painful	O	O
immunizations	O	O
before	O	O
they	O	O
are	O	O
2	O	O
years	O	O
old	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
if	O	O
topical	Pharmacological	Pharmacological
tetracaine	Pharmacological	Pharmacological
reduces	O	O
the	O	O
pain	O	O
of	O	O
intramuscular	O	O
palivizumab	Pharmacological	O
compared	O	O
to	O	O
placebo	Control	Control
.	Control	O

There	O	O
were	O	O
two	O	O
study	O	O
injections	O	O
,	O	O
one	O	O
with	O	O
tetracaine	Pharmacological	O
and	O	O
one	O	O
with	O	O
placebo	Control	Control
.	Control	O

Pain	O	O
was	O	O
scored	O	O
by	O	O
their	O	O
parents	O	O
and	O	O
a	O	O
pediatric	O	O
nurse	O	O
.	O	O

Topical	O	O
tetracaine	Pharmacological	O
was	O	O
not	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
pain	O	O
score	O	O
,	O	O
although	O	O
it	O	O
did	O	O
lead	O	O
to	O	O
faster	O	O
recovery	O	O
times	O	O
.	O	O

Additional	O	O
pain-reduction	O	O
strategies	O	O
are	O	O
required	O	O
.	O	O

Low-dose	Pharmacological	O
aspirin	Pharmacological	Pharmacological
and	O	O
incidence	O	O
of	O	O
colorectal	O	O
tumors	O	O
in	O	O
a	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Laboratory	O	O
,	O	O
clinical	O	O
,	O	O
and	O	O
epidemiologic	O	O
studies	O	O
have	O	O
recently	O	O
suggested	O	O
that	O	O
regular	O	O
use	O	O
of	O	O
aspirin	Pharmacological	Pharmacological
can	O	O
reduce	O	O
colorectal	O	O
cancer	O	O
incidence	O	O
or	O	O
mortality	O	O
.	O	O

However	O	O
,	O	O
observational	O	O
epidemiologic	O	O
analyses	O	O
have	O	O
had	O	O
limited	O	O
opportunity	O	O
to	O	O
control	O	O
for	O	O
confounding	O	O
bias	O	O
or	O	O
to	O	O
specify	O	O
aspirin	Pharmacological	Pharmacological
doses	O	O
used	O	O
.	O	O

PURPOSE	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
regular	O	O
use	O	O
of	O	O
low-dose	Pharmacological	O
aspirin	Pharmacological	Pharmacological
and	O	O
incidence	O	O
of	O	O
invasive	O	O
and	O	O
noninvasive	O	O
colorectal	O	O
tumors	O	O
by	O	O
utilizing	O	O
data	O	O
from	O	O
the	O	O
Physicians	O	O
'	O	O
Health	O	O
Study	O	O
,	O	O
a	O	O
randomized	O	O
,	O	O
double-blinded	O	O
,	O	O
placebo-controlled	Control	Control
trial	O	O
of	O	O
aspirin	Pharmacological	Pharmacological
and	O	O
beta	Pharmacological	O
carotene	Pharmacological	O
.	O	O

We	O	O
also	O	O
attempted	O	O
to	O	O
determine	O	O
whether	O	O
invasive	O	O
cancers	O	O
among	O	O
aspirin	Pharmacological	O
users	O	O
were	O	O
associated	O	O
with	O	O
rectal	O	O
bleeding	O	O
and	O	O
early	O	O
stage	O	O
at	O	O
diagnosis	O	O
.	O	O

METHODS	O	O
The	O	O
Physicians	O	O
'	O	O
Health	O	O
Study	O	O
includes	O	O
22071	O	O
U.S.	O	O
male	O	O
physicians	O	O
.	O	O

The	O	O
aspirin	O	Pharmacological
arm	O	O
was	O	O
terminated	O	O
in	O	O
1988	O	O
after	O	O
a	O	O
mean	O	O
follow-up	O	O
of	O	O
5	O	O
years	O	O
.	O	O

Stage	O	O
at	O	O
diagnosis	O	O
and	O	O
signs	O	O
and/or	O	O
symptoms	O	O
during	O	O
presentation	O	O
were	O	O
abstracted	O	O
from	O	O
medical	O	O
records	O	O
.	O	O

Cox	O	O
proportional	O	O
hazards	O	O
models	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
relative	O	O
risk	O	O
(	O	O
RR	O	O
)	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
intervals	O	O
(	O	O
CIs	O	O
)	O	O
,	O	O
and	O	O
the	O	O
association	O	O
between	O	O
aspirin	O	Pharmacological
and	O	O
bleeding	O	O
.	O	O

Differences	O	O
between	O	O
aspirin	Pharmacological	Pharmacological
and	O	O
placebo	Control	O
groups	O	O
in	O	O
tumor	O	O
risk	O	O
over	O	O
time	O	O
were	O	O
visualized	O	O
with	O	O
Kaplan-Meier	O	O
curves	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
association	O	O
between	O	O
aspirin	O	Pharmacological
and	O	O
stage	O	O
at	O	O
diagnosis	O	O
with	O	O
a	O	O
Mann-Whitney	O	O
rank	O	O
sum	O	O
statistic	O	O
for	O	O
non-parametric	O	O
comparison	O	O
of	O	O
two	O	O
ordinal	O	O
distributions	O	O
.	O	O

RESULTS	O	O
The	O	O
RR	O	O
of	O	O
developing	O	O
colorectal	O	O
cancer	O	O
for	O	O
aspirin	O	Pharmacological
compared	O	O
with	O	O
placebo	O	Control
was	O	O
1.15	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
0.80-1.65	O	O
)	O	O
.	O	O

For	O	O
in	O	O
situ	O	O
cancers	O	O
and	O	O
polyps	O	O
,	O	O
the	O	O
RR	O	O
was	O	O
0.86	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
0.68-1.10	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
trend	O	O
for	O	O
decreasing	O	O
RR	O	O
by	O	O
year	O	O
of	O	O
follow-up	O	O
for	O	O
invasive	O	O
cancers	O	O
(	O	O
P	O	O
=	O	O
.09	O	O
)	O	O
or	O	O
noninvasive	O	O
tumors	O	O
(	O	O
P	O	O
=	O	O
.96	O	O
)	O	O
.	O	O

Aspirin	O	Pharmacological
and	O	O
placebo	O	Control
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
stage	O	O
or	O	O
prevalence	O	O
of	O	O
rectal	O	O
bleeding	O	O
at	O	O
diagnosis	O	O
.	O	O

CONCLUSIONS	O	O
Regular	O	O
aspirin	Pharmacological	O
use	O	O
,	O	O
at	O	O
a	O	O
dose	O	O
adequate	O	O
for	O	O
preventing	O	O
myocardial	O	O
infarction	O	O
,	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
a	O	O
substantial	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
colorectal	O	O
cancer	O	O
during	O	O
5	O	O
years	O	O
of	O	O
randomized	O	O
treatment	O	O
and	O	O
follow-up	O	O
.	O	O

A	O	O
small	O	O
decrease	O	O
in	O	O
polyps	O	O
in	O	O
the	O	O
aspirin	O	Pharmacological
group	O	O
could	O	O
not	O	O
be	O	O
reliably	O	O
distinguished	O	O
from	O	O
a	O	O
chance	O	O
association	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
among	O	O
low-dose	O	O
aspirin	Pharmacological	Pharmacological
users	O	O
,	O	O
(	O	O
a	O	O
)	O	O
colorectal	O	O
cancer	O	O
mortality	O	O
is	O	O
not	O	O
likely	O	O
to	O	O
be	O	O
reduced	O	O
by	O	O
earlier	O	O
detection	O	O
and	O	O
(	O	O
b	O	O
)	O	O
incidence	O	O
is	O	O
not	O	O
likely	O	O
to	O	O
be	O	O
increased	O	O
due	O	O
to	O	O
aspirin-induced	O	O
gastrointestinal	O	O
bleeding	O	O
.	O	O

IMPLICATIONS	O	O
The	O	O
potential	O	O
for	O	O
a	O	O
benefit	O	O
from	O	O
higher	O	O
doses	O	O
of	O	O
aspirin	O	Pharmacological
or	O	O
longer	O	O
duration	O	O
of	O	O
use	O	O
should	O	O
be	O	O
addressed	O	O
by	O	O
more	O	O
detailed	O	O
observational	O	O
epidemiologic	O	O
studies	O	O
and	O	O
prevention	O	O
trials	O	O
with	O	O
longer	O	O
follow-up	O	O
of	O	O
randomized	O	O
participants	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
vaginal	O	O
tolerance	O	O
to	O	O
Acidform	Pharmacological	O
,	Pharmacological	O
an	Pharmacological	O
acid-buffering	Pharmacological	O
,	Pharmacological	O
bioadhesive	Pharmacological	O
gel	Pharmacological	O
.	Pharmacological	O

Vaginal	O	O
tolerance	O	O
tests	O	O
were	O	O
performed	O	O
with	O	O
a	O	O
new	O	O
potential	O	O
microbicidal	O	O
and	O	O
spermicidal	O	O
product	O	O
,	O	O
an	O	O
acid-buffering	Pharmacological	Pharmacological
vaginal	Pharmacological	Pharmacological
gel	Pharmacological	Pharmacological
(	Pharmacological	O
Acidform	Pharmacological	O
)	Pharmacological	O
without	Pharmacological	O
or	Pharmacological	O
with	Pharmacological	O
nonoxynol-9	Pharmacological	O
(	Pharmacological	O
N-9	Pharmacological	O
)	Pharmacological	O
.	Pharmacological	O

The	O	O
potential	O	O
advantages	O	O
over	O	O
other	O	O
vaginal	O	O
products	O	O
include	O	O
keeping	O	O
a	O	O
low	O	O
pH	O	O
,	O	O
decrease	O	O
of	O	O
the	O	O
irritating	O	O
effect	O	O
of	O	O
N-9	Pharmacological	O
on	O	O
the	O	O
cervix	O	O
or	O	O
vaginal	O	O
mucosa	O	O
associated	O	O
with	O	O
greater	O	O
retention	O	O
of	O	O
the	O	O
product	O	O
after	O	O
application	O	O
,	O	O
and	O	O
decreasing	O	O
messiness	O	O
as	O	O
compared	O	O
to	O	O
other	O	O
vaginal	O	O
products	O	O
.	O	O

Three	O	O
groups	O	O
of	O	O
six	O	O
women	O	O
were	O	O
admitted	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
use	O	O
Acidform	Pharmacological	O
with	O	O
0	O	O
%	O	O
,	O	O
2.5	O	O
%	O	O
,	O	O
and	O	O
5	O	O
%	O	O
N-9	Pharmacological	O
.	Pharmacological	O

Colposcopic	O	O
evaluation	O	O
for	O	O
vulvar	O	O
,	O	O
vaginal	O	O
,	O	O
and	O	O
cervical	O	O
signs	O	O
of	O	O
irritation	O	O
was	O	O
performed	O	O
and	O	O
photographs	O	O
were	O	O
taken	O	O
,	O	O
following	O	O
a	O	O
specific	O	O
World	O	O
Health	O	O
Organization	O	O
protocol	O	O
,	O	O
at	O	O
time	O	O
0	O	O
,	O	O
and	O	O
after	O	O
24	O	O
h	O	O
and	O	O
6	O	O
days	O	O
of	O	O
application	O	O
of	O	O
the	O	O
gel	O	O
.	O	O

No	O	O
irritation	O	O
or	O	O
symptom	O	O
was	O	O
reported	O	O
by	O	O
users	O	O
of	O	O
Acidform	Pharmacological	O
without	Pharmacological	O
N-9	Pharmacological	O
.	Pharmacological	O

A	O	O
generalized	O	O
and	O	O
intense	O	O
erythema	O	O
in	O	O
cervix	O	O
was	O	O
observed	O	O
in	O	O
10	O	O
of	O	O
12	O	O
Acidform/N-9	Pharmacological	O
users	O	O
and	O	O
abrasion	O	O
occurred	O	O
in	O	O
nine	O	O
of	O	O
them	O	O
.	O	O

Vulvar	O	O
irritation	O	O
was	O	O
seen	O	O
in	O	O
seven	O	O
of	O	O
these	O	O
10	O	O
volunteers	O	O
.	O	O

N-9	O	O
concentration	O	O
in	O	O
the	O	O
gel	O	O
(	O	O
2.5	O	O
%	O	O
or	O	O
5.0	O	O
%	O	O
)	O	O
was	O	O
not	O	O
related	O	O
to	O	O
the	O	O
findings	O	O
.	O	O

No	O	O
ulcer	O	O
,	O	O
exulceration	O	O
,	O	O
or	O	O
de-epithelialization	O	O
was	O	O
observed	O	O
.	O	O

Acidform	Pharmacological	O
without	Pharmacological	O
N-9	Pharmacological	O
was	O	O
well	O	O
tolerated	O	O
by	O	O
volunteers	O	O
,	O	O
but	O	O
it	O	O
was	O	O
unable	O	O
to	O	O
protect	O	O
the	O	O
cervix	O	O
,	O	O
vagina	O	O
,	O	O
and	O	O
vulva	O	O
from	O	O
the	O	O
N-9	O	O
effects	O	O
.	O	O

Dissociation	O	O
between	O	O
cortical	O	O
activation	O	O
and	O	O
cognitive	O	O
performance	O	O
under	O	O
pharmacological	O	O
blood	O	O
pressure	O	O
elevation	O	O
in	O	O
chronic	O	O
hypotension	O	O
.	O	O

The	O	O
present	O	O
study	O	O
explored	O	O
the	O	O
impact	O	O
of	O	O
pharmacological	Pharmacological	O
blood	Pharmacological	O
pressure	Pharmacological	O
elevation	Pharmacological	O
on	O	O
cortical	O	O
activation	O	O
and	O	O
reaction	O	O
time	O	O
in	O	O
chronic	O	O
hypotension	O	O
.	O	O

Effects	O	O
of	O	O
the	O	O
sympathomimetic	O	O
etilefrine	O	O
were	O	O
investigated	O	O
in	O	O
50	O	O
hypotensive	O	O
persons	O	O
based	O	O
on	O	O
a	O	O
randomized	O	O
,	O	O
placebo-controlled	Control	Control
double	O	O
blind	O	O
design	O	O
.	O	O

As	O	O
an	O	O
indicator	O	O
of	O	O
cortical	O	O
excitability	O	O
,	O	O
the	O	O
contingent	O	O
negative	O	O
variation	O	O
(	O	O
CNV	O	O
)	O	O
,	O	O
induced	O	O
by	O	O
a	O	O
constant	O	O
foreperiod	O	O
reaction	O	O
time	O	O
task	O	O
,	O	O
was	O	O
assessed	O	O
at	O	O
frontal	O	O
(	O	O
F3	O	O
,	O	O
Fz	O	O
,	O	O
F4	O	O
)	O	O
and	O	O
central	O	O
(	O	O
C3	O	O
,	O	O
Cz	O	O
,	O	O
C4	O	O
)	O	O
scalp	O	O
sites	O	O
.	O	O

Etilefrine	Pharmacological	O
provoked	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
frontal	O	O
and	O	O
central	O	O
CNV	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
shorter	O	O
reaction	O	O
times	O	O
were	O	O
observed	O	O
following	O	O
drug	O	O
administration	O	O
.	O	O

The	O	O
degree	O	O
of	O	O
pharmacologically	O	O
induced	O	O
blood	O	O
pressure	O	O
elevation	O	O
was	O	O
correlated	O	O
to	O	O
CNV	O	O
attrition	O	O
as	O	O
well	O	O
as	O	O
to	O	O
performance	O	O
enhancement	O	O
.	O	O

Inhibitory	O	O
effects	O	O
of	O	O
baroreceptor	O	O
activation	O	O
on	O	O
cortical	O	O
excitability	O	O
and	O	O
enhanced	O	O
cerebral	O	O
blood	O	O
flow	O	O
are	O	O
considered	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
mediating	O	O
the	O	O
effects	O	O
of	O	O
blood	O	O
pressure	O	O
elevation	O	O
on	O	O
cerebral	O	O
functioning	O	O
.	O	O

Implications	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
hypotension	O	O
are	O	O
discussed	O	O
.	O	O

Secretin	Pharmacological	O
and	O	O
sleep	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
this	O	O
pilot	O	O
study	O	O
were	O	O
1	O	O
)	O	O
to	O	O
examine	O	O
possible	O	O
effects	O	O
of	O	O
secretin	Pharmacological	Pharmacological
infusions	O	Pharmacological
on	O	O
sleep-wake	O	O
state	O	O
organization	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
,	O	O
and	O	O
2	O	O
)	O	O
to	O	O
assess	O	O
the	O	O
feasibility	O	O
of	O	O
home	O	O
recordings	O	O
using	O	O
time-lapse	O	O
videosomnography	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

Participants	O	O
were	O	O
a	O	O
subset	O	O
of	O	O
subjects	O	O
from	O	O
two	O	O
double	O	O
blind	O	O
,	O	O
placebo-control	O	O
,	O	O
multi-center	O	O
clinical	O	O
trials	O	O
.	O	O

One	O	O
trial	O	O
,	O	O
the	O	O
UC	O	O
Irvine	O	O
study	O	O
,	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
porcine	Pharmacological	Pharmacological
secretin	Pharmacological	Pharmacological
vs.	Pharmacological	O
saline	Control	Pharmacological
infusions	Control	Pharmacological
on	O	O
children	O	O
's	O	O
behavior	O	O
,	O	O
language	O	O
and	O	O
IQ	O	O
.	O	O

The	O	O
UC	O	O
Davis	O	O
trial	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
synthetic	Pharmacological	Pharmacological
human	Pharmacological	Pharmacological
secretin	Pharmacological	Pharmacological
vs.	O	O
saline	Control	Pharmacological
infusions	Control	Pharmacological
on	O	O
behavior	O	O
,	O	O
language	O	O
and	O	O
gastrointestinal	O	O
function	O	O
.	O	O

The	O	O
sleep	O	O
study	O	O
enrolled	O	O
some	O	O
of	O	O
the	O	O
children	O	O
from	O	O
each	O	O
of	O	O
the	O	O
two	O	O
trials	O	O
to	O	O
observe	O	O
possible	O	O
secretin	O	O
effects	O	O
on	O	O
sleep	O	O
.	O	O

To	O	O
examine	O	O
sleep	O	O
,	O	O
the	O	O
UC	O	O
Irvine	O	O
trial	O	O
used	O	O
the	O	O
Children	O	O
's	O	O
Sleep	O	O
Habits	O	O
Questionnaire	O	O
and	O	O
daily	O	O
sleep	O	O
diaries	O	O
,	O	O
whereas	O	O
the	O	O
UC	O	O
Davis	O	O
study	O	O
used	O	O
home-recorded	O	O
time-lapse	O	O
videosomnography	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
small	O	O
sample	O	O
size	O	O
,	O	O
the	O	O
results	O	O
from	O	O
both	O	O
trials	O	O
are	O	O
preliminary	O	O
.	O	O

They	O	O
suggest	O	O
that	O	O
secretin	Pharmacological	Pharmacological
,	Pharmacological	O
porcine	Pharmacological	O
or	Pharmacological	O
synthetic	Pharmacological	O
,	O	O
does	O	O
not	O	O
improve	O	O
sleep-wake	O	O
state	O	O
organization	O	O
dramatically	O	O
.	O	O

Effect	O	O
of	O	O
a	O	O
multi-faceted	Physical	Educational
intervention	Physical	Educational
on	O	O
gingival	O	O
health	O	O
among	O	O
adults	O	O
with	O	O
systemic	O	O
sclerosis	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
adaptive	Surgical	O
oral	Surgical	O
hygiene	Surgical	O
devices	Surgical	O
and	O	O
orofacial	Physical	O
exercise	Physical	O
to	O	O
improve	O	O
gingival	O	O
health	O	O
among	O	O
adults	O	O
with	O	O
systemic	O	O
sclerosis	O	O
(	O	O
SSc	O	O
)	O	O
.	O	O

METHODS	O	O
Forty-eight	O	O
patients	O	O
with	O	O
SSc	O	O
were	O	O
assigned	O	O
randomly	O	O
to	O	O
the	O	O
multifaceted	Physical	Educational
oral	Physical	Educational
health	Physical	Educational
intervention	Physical	Educational
or	O	O
usual	Control	Control
dental	Control	Control
care	Control	Control
control	O	Control
group	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
received	O	O
a	O	O
rechargeable	O	O
,	O	O
powered	O	O
Oral-B?	Physical	O
oscillating-rotating-pulsating	Physical	O
toothbrush	Physical	O
and	O	O
a	O	O
Reach?	Physical	O
Access?	Physical	O
Flosser	Physical	O
that	O	O
has	O	O
a	O	O
toothbrush-like	O	O
handle	O	O
.	O	O

For	O	O
those	O	O
with	O	O
an	O	O
oral	O	O
aperture	O	O
of	O	O
less	O	O
than	O	O
40	O	O
mm	O	O
,	O	O
orofacial	O	O
exercises	O	O
were	O	O
taught	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
each	O	O
given	O	O
a	O	O
manual	O	Educational
toothbrush	O	Educational
and	O	Educational
dental	O	Educational
floss	O	Educational
.	O	O

Participants	O	O
in	O	O
both	O	O
groups	O	O
received	O	O
instructions	O	O
and	O	O
demonstration	O	O
on	O	O
the	O	O
use	O	O
of	O	O
the	O	O
devices	O	O
,	O	O
and	O	O
were	O	O
requested	O	O
to	O	O
perform	O	O
the	O	O
respective	O	O
intervention	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Evaluations	O	O
were	O	O
at	O	O
baseline	O	O
,	O	O
3-	O	O
,	O	O
and	O	O
6-months	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
gingival	O	O
index	O	O
(	O	O
GI	O	O
)	O	O
,	O	O
an	O	O
indicator	O	O
of	O	O
gingival	O	O
inflammation	O	O
.	O	O

RESULTS	O	O
Both	O	O
groups	O	O
showed	O	O
significant	O	O
reduction	O	O
in	O	O
GI	O	O
scores	O	O
at	O	O
6	O	O
months	O	O
(	O	O
ps	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

Reduction	O	O
in	O	O
GI	O	O
scores	O	O
of	O	O
the	O	O
intervention	O	O
group	O	O
at	O	O
6	O	O
months	O	O
was	O	O
20.8	O	O
%	O	O
which	O	O
is	O	O
considered	O	O
to	O	O
be	O	O
clinically	O	O
significant	O	O
.	O	O

Compared	O	O
to	O	O
the	O	O
control	O	O
group	O	O
,	O	O
the	O	O
intervention	O	O
group	O	O
showed	O	O
a	O	O
significant	O	O
and	O	O
larger	O	O
reduction	O	O
in	O	O
GI	O	O
score	O	O
by	O	O
8	O	O
%	O	O
at	O	O
6	O	O
months	O	O
(	O	O
p=0.0007	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Results	O	O
support	O	O
the	O	O
use	O	O
of	O	O
adaptive	Surgical	O
devices	Surgical	O
and	O	O
orofacial	Physical	O
exercise	Physical	O
to	O	O
improve	O	O
gingival	O	O
health	O	O
in	O	O
adults	O	O
with	O	O
SSc	O	O
when	O	O
compared	O	O
to	O	O
use	O	O
of	O	O
manual	Control	O
toothbrushing	Control	O
and	O	O
finger-held	Control	O
flossing	Control	O
.	O	O

Recommending	O	O
and	O	O
educating	O	O
patients	O	O
with	O	O
SSc	O	O
to	O	O
use	O	O
adaptive	O	O
devices	O	O
to	O	O
clean	O	O
the	O	O
tooth	O	O
surfaces	O	O
looks	O	O
promising	O	O
for	O	O
long-term	O	O
oral	O	O
health	O	O
improvement	O	O
.	O	O

Effects	O	O
of	O	O
long-term	Pharmacological	O
vitamin	Pharmacological	Pharmacological
E	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
on	O	O
cardiovascular	O	O
events	O	O
and	O	O
cancer	O	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

CONTEXT	O	O
Experimental	O	O
and	O	O
epidemiological	O	O
data	O	O
suggest	O	O
that	O	O
vitamin	Pharmacological	Pharmacological
E	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
may	O	O
prevent	O	O
cancer	O	O
and	O	O
cardiovascular	O	O
events	O	O
.	O	O

Clinical	O	O
trials	O	O
have	O	O
generally	O	O
failed	O	O
to	O	O
confirm	O	O
benefits	O	O
,	O	O
possibly	O	O
due	O	O
to	O	O
their	O	O
relatively	O	O
short	O	O
duration	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
whether	O	O
long-term	Pharmacological	O
supplementation	Pharmacological	O
with	Pharmacological	O
vitamin	Pharmacological	Pharmacological
E	Pharmacological	Pharmacological
decreases	O	O
the	O	O
risk	O	O
of	O	O
cancer	O	O
,	O	O
cancer	O	O
death	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
.	O	O

DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PATIENTS	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	Control
international	O	O
trial	O	O
(	O	O
the	O	O
initial	O	O
Heart	O	O
Outcomes	O	O
Prevention	O	O
Evaluation	O	O
[	O	O
HOPE	O	O
]	O	O
trial	O	O
conducted	O	O
between	O	O
December	O	O
21	O	O
,	O	O
1993	O	O
,	O	O
and	O	O
April	O	O
15	O	O
,	O	O
1999	O	O
)	O	O
of	O	O
patients	O	O
at	O	O
least	O	O
55	O	O
years	O	O
old	O	O
with	O	O
vascular	O	O
disease	O	O
or	O	O
diabetes	O	O
mellitus	O	O
was	O	O
extended	O	O
(	O	O
HOPE-The	O	O
Ongoing	O	O
Outcomes	O	O
[	O	O
HOPE-TOO	O	O
]	O	O
)	O	O
between	O	O
April	O	O
16	O	O
,	O	O
1999	O	O
,	O	O
and	O	O
May	O	O
26	O	O
,	O	O
2003	O	O
.	O	O

Of	O	O
the	O	O
initial	O	O
267	O	O
HOPE	O	O
centers	O	O
that	O	O
had	O	O
enrolled	O	O
9541	O	O
patients	O	O
,	O	O
174	O	O
centers	O	O
participated	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
.	O	O

Of	O	O
7030	O	O
patients	O	O
enrolled	O	O
at	O	O
these	O	O
centers	O	O
,	O	O
916	O	O
were	O	O
deceased	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
extension	O	O
,	O	O
1382	O	O
refused	O	O
participation	O	O
,	O	O
3994	O	O
continued	O	O
to	O	O
take	O	O
the	O	O
study	O	O
intervention	O	O
,	O	O
and	O	O
738	O	O
agreed	O	O
to	O	O
passive	O	O
follow-up	O	O
.	O	O

Median	O	O
duration	O	O
of	O	O
follow-up	O	O
was	O	O
7.0	O	O
years	O	O
.	O	O

INTERVENTION	O	O
Daily	O	O
dose	O	O
of	O	O
natural	Pharmacological	Pharmacological
source	Pharmacological	Pharmacological
vitamin	Pharmacological	Pharmacological
E	Pharmacological	Pharmacological
(	O	O
400	O	O
IU	O	O
)	O	O
or	O	O
matching	O	O
placebo	Control	Control
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Primary	O	O
outcomes	O	O
included	O	O
cancer	O	O
incidence	O	O
,	O	O
cancer	O	O
deaths	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
(	O	O
myocardial	O	O
infarction	O	O
,	O	O
stroke	O	O
,	O	O
and	O	O
cardiovascular	O	O
death	O	O
)	O	O
.	O	O

Secondary	O	O
outcomes	O	O
included	O	O
heart	O	O
failure	O	O
,	O	O
unstable	O	O
angina	O	O
,	O	O
and	O	O
revascularizations	O	O
.	O	O

RESULTS	O	O
Among	O	O
all	O	O
HOPE	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
primary	O	O
analysis	O	O
:	O	O
for	O	O
cancer	O	O
incidence	O	O
,	O	O
there	O	O
were	O	O
552	O	O
patients	O	O
(	O	O
11.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
vitamin	Pharmacological	O
E	Pharmacological	O
group	O	O
vs	O	O
586	O	O
(	O	O
12.3	O	O
%	O	O
)	O	O
in	O	O
the	O	O
placebo	Control	O
group	O	O
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
,	O	O
0.94	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.84-1.06	O	O
;	O	O
P	O	O
=	O	O
.30	O	O
)	O	O
;	O	O
for	O	O
cancer	O	O
deaths	O	O
,	O	O
156	O	O
(	O	O
3.3	O	O
%	O	O
)	O	O
vs	O	O
178	O	O
(	O	O
3.7	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
0.88	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.71-1.09	O	O
;	O	O
P	O	O
=	O	O
.24	O	O
)	O	O
;	O	O
and	O	O
for	O	O
major	O	O
cardiovascular	O	O
events	O	O
,	O	O
1022	O	O
(	O	O
21.5	O	O
%	O	O
)	O	O
vs	O	O
985	O	O
(	O	O
20.6	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
1.04	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96-1.14	O	O
;	O	O
P	O	O
=	O	O
.34	O	O
)	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
vitamin	Pharmacological	O
E	Pharmacological	O
group	O	O
had	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
heart	O	O
failure	O	O
(	O	O
RR	O	O
,	O	O
1.13	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.26	O	O
;	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
and	O	O
hospitalization	O	O
for	O	O
heart	O	O
failure	O	O
(	O	O
RR	O	O
,	O	O
1.21	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.00-1.47	O	O
;	O	O
P	O	O
=	O	O
.045	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
among	O	O
patients	O	O
enrolled	O	O
at	O	O
the	O	O
centers	O	O
participating	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
cancer	O	O
incidence	O	O
,	O	O
cancer	O	O
deaths	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
,	O	O
but	O	O
higher	O	O
rates	O	O
of	O	O
heart	O	O
failure	O	O
and	O	O
hospitalizations	O	O
for	O	O
heart	O	O
failure	O	O
.	O	O

CONCLUSION	O	O
In	O	O
patients	O	O
with	O	O
vascular	O	O
disease	O	O
or	O	O
diabetes	O	O
mellitus	O	O
,	O	O
long-term	Pharmacological	O
vitamin	Pharmacological	Pharmacological
E	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
does	O	O
not	O	O
prevent	O	O
cancer	O	O
or	O	O
major	O	O
cardiovascular	O	O
events	O	O
and	O	O
may	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
heart	O	O
failure	O	O
.	O	O

Effect	O	O
of	O	O
acute	Physical	O
exercise	Physical	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	O	O
with	O	O
attention	O	O
deficit	O	O
hyperactivity	O	O
disorder	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
acute	Physical	O
aerobic	Physical	O
exercise	Physical	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	O	O
with	O	O
attention	O	O
deficit	O	O
hyperactivity	O	O
disorder	O	O
(	O	O
ADHD	O	O
)	O	O
.	O	O

Forty	O	O
children	O	O
with	O	O
ADHD	O	O
were	O	O
randomly	O	O
assigned	O	O
into	O	O
exercise	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
performed	O	O
a	O	O
moderate	Physical	Physical
intensity	Physical	Physical
aerobic	Physical	Physical
exercise	Physical	Physical
for	Physical	O
30	Physical	O
min	Physical	O
,	O	O
whereas	O	O
the	O	O
control	O	O
group	O	O
watched	O	O
a	O	O
running/exercise-related	Other	O
video	Other	O
.	Other	O

Neuropsychological	O	O
tasks	O	O
,	O	O
the	O	O
Stroop	O	O
Test	O	O
and	O	O
the	O	O
Wisconsin	O	O
Card	O	O
Sorting	O	O
Test	O	O
(	O	O
WCST	O	O
)	O	O
,	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
each	O	O
treatment	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
acute	O	O
exercise	O	O
facilitated	O	O
performance	O	O
in	O	O
the	O	O
Stroop	O	O
Test	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
Stroop	O	O
Color-Word	O	O
condition	O	O
.	O	O

Additionally	O	O
,	O	O
children	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
demonstrated	O	O
improvement	O	O
in	O	O
specific	O	O
WCST	O	O
performances	O	O
in	O	O
Non-perseverative	O	O
Errors	O	O
and	O	O
Categories	O	O
Completed	O	O
,	O	O
whereas	O	O
no	O	O
influences	O	O
were	O	O
found	O	O
in	O	O
those	O	O
performances	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Tentative	O	O
explanations	O	O
for	O	O
the	O	O
exercise	O	O
effect	O	O
postulate	O	O
that	O	O
exercise	O	O
allocates	O	O
attention	O	O
resources	O	O
,	O	O
influences	O	O
the	O	O
dorsolateral	O	O
prefrontal	O	O
cortex	O	O
,	O	O
and	O	O
is	O	O
implicated	O	O
in	O	O
exercise-induced	O	O
dopamine	O	O
release	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
promising	O	O
and	O	O
additional	O	O
investigations	O	O
to	O	O
explore	O	O
the	O	O
efficacy	O	O
of	O	O
exercise	Physical	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	O	O
with	O	O
ADHD	O	O
are	O	O
encouraged	O	O
.	O	O

PROCLAIM	O	O
:	O	O
pilot	O	O
study	O	O
to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
clopidogrel	Pharmacological	Pharmacological
on	O	O
inflammatory	O	O
markers	O	O
in	O	O
patients	O	O
with	O	O
metabolic	O	O
syndrome	O	O
receiving	O	O
low-dose	O	Pharmacological
aspirin	Pharmacological	Pharmacological
.	Pharmacological	O

Metabolic	O	O
syndrome	O	O
is	O	O
associated	O	O
with	O	O
intravascular	O	O
inflammation	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
increased	O	O
levels	O	O
of	O	O
inflammatory	O	O
biomarkers	O	O
and	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
ischemic	O	O
atherothrombotic	O	O
events	O	O
.	O	O

Evidence	O	O
suggests	O	O
that	O	O
atherothrombosis	O	O
and	O	O
intravascular	O	O
inflammation	O	O
share	O	O
predictive	O	O
biomarkers	O	O
,	O	O
including	O	O
high-sensitivity	O	O
C-reactive	O	O
protein	O	O
,	O	O
CD40	O	O
ligand	O	O
,	O	O
P-selectin	O	O
,	O	O
and	O	O
N-terminal	O	O
pro-brain	O	O
natriuretic	O	O
peptide	O	O
.	O	O

Patients	O	O
who	O	O
had	O	O
metabolic	O	O
syndrome	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
clopidogrel	Pharmacological	Pharmacological
75	O	O
mg/day	O	O
plus	O	Pharmacological
aspirin	Pharmacological	Pharmacological
81	O	O
mg/day	O	O
(	O	O
n	O	O
=	O	O
89	O	O
)	O	O
or	O	O
placebo	Control	Control
plus	O	Control
aspirin	Pharmacological	Control
81	O	O
mg/day	O	O
(	O	O
n	O	O
=	O	O
92	O	O
)	O	O
for	O	O
9	O	O
weeks	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
of	O	O
each	O	O
treatment	O	O
in	O	O
suppression	O	O
of	O	O
inflammatory	O	O
markers	O	O
.	O	O

Change	O	O
from	O	O
baseline	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
high-sensitivity	O	O
C-reactive	O	O
protein	O	O
,	O	O
CD40	O	O
ligand	O	O
,	O	O
P-selectin	O	O
,	O	O
and	O	O
N-terminal	O	O
pro-brain	O	O
natriuretic	O	O
peptide	O	O
at	O	O
6	O	O
weeks	O	O
was	O	O
assessed	O	O
to	O	O
evaluate	O	O
each	O	O
treatment	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
at	O	O
Week	O	O
6	O	O
in	O	O
model-adjusted	O	O
CD40-ligand	O	O
levels	O	O
in	O	O
favor	O	O
of	O	O
clopidogrel	Pharmacological	Pharmacological
plus	O	O
aspirin	Pharmacological	Pharmacological
compared	O	O
with	O	O
placebo	Control	Control
plus	O	O
aspirin	Pharmacological	Pharmacological
in	O	O
both	O	O
the	O	O
intent-to-treat	O	O
population	O	O
(	O	O
difference	O	O
between	O	O
least-squares	O	O
means	O	O
=	O	O
-186.5	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-342.3	O	O
to	O	O
-30.8	O	O
;	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
the	O	O
per-protocol	O	O
population	O	O
(	O	O
P	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
treatment	O	O
arms	O	O
for	O	O
high-sensitivity	O	O
C-reactive	O	O
protein	O	O
,	O	O
P-selectin	O	O
,	O	O
and	O	O
N-terminal	O	O
pro-brain	O	O
natriuretic	O	O
peptide	O	O
.	O	O

There	O	O
were	O	O
no	O	O
deaths	O	O
or	O	O
serious	O	O
adverse	O	O
events	O	O
in	O	O
either	O	O
treatment	O	O
arm	O	O
.	O	O

Data	O	O
from	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
clopidogrel	Pharmacological	Pharmacological
can	O	O
decrease	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
CD40-ligand	O	O
biomarker	O	O
.	O	O

Morphological	O	O
onset	O	O
and	O	O
early	O	O
diagnosis	O	O
in	O	O
apical	O	O
hypertrophic	O	O
cardiomyopathy	O	O
:	O	O
a	O	O
long	O	O
term	O	O
analysis	O	O
with	O	O
nuclear	Other	O
magnetic	Other	O
resonance	Other	O
imaging	Other	O
.	Other	O

OBJECTIVES	O	O
A	O	O
long-term	O	O
follow-up	O	O
study	O	O
with	O	O
nuclear	Other	O
magnetic	Other	O
resonance	Other	O
(	Other	O
NMR	Other	O
)	Other	O
imaging	Other	O
was	O	O
undertaken	O	O
to	O	O
detect	O	O
the	O	O
morphological	O	O
onset	O	O
and	O	O
to	O	O
establish	O	O
the	O	O
early	O	O
diagnosis	O	O
in	O	O
apical	O	O
hypertrophic	O	O
cardiomyopathy	O	O
(	O	O
HCM	O	O
)	O	O
.	O	O

BACKGROUND	O	O
A	O	O
spadelike	O	O
configuration	O	O
on	O	O
left	O	O
ventriculogram	O	O
(	O	O
LVG	O	O
)	O	O
is	O	O
regarded	O	O
as	O	O
a	O	O
diagnostic	O	O
criterion	O	O
for	O	O
the	O	O
classical	O	O
apical	O	O
HCM	O	O
.	O	O

There	O	O
also	O	O
exists	O	O
a	O	O
segmented	O	O
hypertrophy	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
without	O	O
indicating	O	O
the	O	O
spadelike	O	O
features	O	O
(	O	O
a	O	O
nonspade	O	O
configuration	O	O
)	O	O
.	O	O

To	O	O
detect	O	O
the	O	O
hypertrophied	O	O
myocardium	O	O
of	O	O
the	O	O
nonspade	O	O
configuration	O	O
,	O	O
circumferential	O	O
scrutiny	O	O
of	O	O
the	O	O
apex	O	O
is	O	O
required	O	O
.	O	O

Although	O	O
both	O	O
configurations	O	O
can	O	O
be	O	O
underlying	O	O
causes	O	O
of	O	O
giant	O	O
negative	O	O
T	O	O
waves	O	O
,	O	O
etiological	O	O
relationship	O	O
between	O	O
the	O	O
two	O	O
is	O	O
not	O	O
clarified	O	O
.	O	O

METHODS	O	O
The	O	O
criteria	O	O
for	O	O
the	O	O
spadelike	O	O
configuration	O	O
defined	O	O
on	O	O
left	O	O
ventricular	O	O
short-axis	O	O
NMR	Other	O
images	Other	O
were	O	O
as	O	O
follows	O	O
:	O	O
(	O	O
apical	O	O
maximal	O	O
thickness	O	O
>	O	O
or	O	O
=	O	O
15	O	O
mm	O	O
)	O	O
,	O	O
(	O	O
apical	O	O
anterior	O	O
thickness	O	O
over	O	O
basal	O	O
anterior	O	O
thickness	O	O
>	O	O
or	O	O
=	O	O
1.3	O	O
)	O	O
and	O	O
(	O	O
apical	O	O
posterior	O	O
thickness	O	O
over	O	O
basal	O	O
posterior	O	O
thickness	O	O
>	O	O
or	O	O
=1.3	O	O
)	O	O
.	O	O

Thirteen	O	O
patients	O	O
who	O	O
had	O	O
predominant	O	O
hypertrophy	O	O
(	O	O
>	O	O
or	O	O
=	O	O
15	O	O
mm	O	O
)	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
without	O	O
the	O	O
spadelike	O	O
configuration	O	O
underwent	O	O
NMR	Other	Physical
imaging	Other	Physical
twice	O	Physical
before	O	Physical
and	O	O
after	O	O
54+/-10	O	O
months	O	O
'	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
Apical	O	O
hypertrophy	O	O
that	O	O
had	O	O
been	O	O
confined	O	O
to	O	O
the	O	O
lateral	O	O
wall	O	O
in	O	O
four	O	O
,	O	O
the	O	O
anterior-lateral	O	O
wall	O	O
in	O	O
two	O	O
,	O	O
and	O	O
the	O	O
septal-anterior	O	O
wall	O	O
in	O	O
one	O	O
developed	O	O
to	O	O
become	O	O
circumferential	O	O
hypertrophy	O	O
that	O	O
fulfilled	O	O
the	O	O
criteria	O	O
for	O	O
the	O	O
spadelike	O	O
configuration	O	O
after	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
spadelike	O	O
configuration	O	O
can	O	O
begin	O	O
with	O	O
the	O	O
nonspade	O	O
configuration	O	O
and	O	O
therefore	O	O
,	O	O
both	O	O
can	O	O
constitute	O	O
a	O	O
single	O	O
disease	O	O
entity	O	O
of	O	O
apical	O	O
HCM	O	O
.	O	O

The	O	O
early	O	O
diagnosis	O	O
of	O	O
apical	O	O
HCM	O	O
can	O	O
be	O	O
achieved	O	O
by	O	O
identifying	O	O
the	O	O
hypertrophy	O	O
frequently	O	O
confined	O	O
to	O	O
the	O	O
lateral	O	O
wall	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
.	O	O

The	O	O
dipeptidyl	Pharmacological	Pharmacological
peptidase-4	Pharmacological	Pharmacological
inhibitor	Pharmacological	Pharmacological
PHX1149	Pharmacological	Pharmacological
improves	O	O
blood	O	O
glucose	O	O
control	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
mellitus	O	O
.	O	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
PHX1149	Pharmacological	O
,	O	O
a	O	O
novel	O	O
dipeptidyl	O	Pharmacological
peptidase-4	O	Pharmacological
(	O	Pharmacological
DPP4	O	Pharmacological
)	O	Pharmacological
inhibitor	O	Pharmacological
,	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

METHODS	O	O
This	O	O
is	O	O
a	O	O
multicentre	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	Control
,	O	O
4-week	O	O
study	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
suboptimal	O	O
metabolic	O	O
control	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
baseline	O	O
haemoglobin	O	O
A	O	O
(	O	O
1c	O	O
)	O	O
(	O	O
HbA	O	O
(	O	O
1c	O	O
)	O	O
)	O	O
of	O	O
7.3	O	O
to	O	O
11.0	O	O
%	O	O
were	O	O
randomized	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
to	O	O
receive	O	O
once-daily	O	O
oral	O	Pharmacological
therapy	O	Pharmacological
with	O	O
either	O	O
PHX1149	Pharmacological	O
(	O	O
100	O	O
,	O	O
200	O	Pharmacological
or	O	Pharmacological
400	O	Pharmacological
mg	O	Pharmacological
)	O	Pharmacological
or	O	O
placebo	Control	Control
;	O	O
patients	O	O
were	O	O
on	O	O
a	O	O
constant	O	O
background	O	O
therapy	O	O
of	O	O
either	O	O
metformin	O	Pharmacological
alone	O	O
or	O	O
metformin	O	Pharmacological
plus	O	O
a	O	O
glitazone	O	O
.	O	O

RESULTS	O	O
Treatment	O	O
with	O	O
100	O	O
,	O	O
200	O	O
or	O	O
400	O	O
mg	O	O
of	O	O
PHX1149	O	O
significantly	O	O
decreased	O	O
postprandial	O	O
glucose	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
AUC	O	O
(	O	O
0-2	O	O
h	O	O
)	O	O
by	O	O
approximately	O	O
20	O	O
%	O	O
(	O	O
+0.11	O	O
+/-	O	O
0.50	O	O
,	O	O
-2.08	O	O
+/-	O	O
0.51	O	O
,	O	O
-1.73	O	O
+/-	O	O
0.49	O	O
and	O	O
-1.88	O	O
+/-	O	O
0.48	O	O
mmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.002	O	O
,	O	O
0.008	O	O
and	O	O
0.004	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Postprandial	O	O
AUC	O	O
(	O	O
0-2	O	O
h	O	O
)	O	O
of	O	O
intact	O	O
glucagon-like	O	O
peptide-1	O	O
,	O	O
the	O	O
principal	O	O
mediator	O	O
of	O	O
the	O	O
biological	O	O
effects	O	O
of	O	O
DPP4	O	O
inhibitors	O	O
,	O	O
was	O	O
increased	O	O
by	O	O
3.90	O	O
+/-	O	O
2.83	O	O
,	O	O
11.63	O	O
+/-	O	O
2.86	O	O
,	O	O
16.42	O	O
+/-	O	O
2.72	O	O
and	O	O
15.75	O	O
+/-	O	O
2.71	O	O
pmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.053	O	O
,	O	O
0.001	O	O
and	O	O
0.002	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Mean	O	O
HbA	O	O
(	O	O
1c	O	O
)	O	O
was	O	O
lower	O	O
in	O	O
all	O	O
dose	O	O
groups	O	O
;	O	O
the	O	O
placebo-corrected	O	O
change	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
400	O	O
mg	O	O
PHX1149	O	O
was	O	O
-0.28	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

DPP4	O	O
inhibition	O	O
on	O	O
day	O	O
28	O	O
was	O	O
53	O	O
,	O	O
73	O	O
and	O	O
78	O	O
%	O	O
at	O	O
24	O	O
h	O	O
postdose	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
PHX1149	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
adverse	O	O
events	O	O
between	O	O
PHX1149-treated	O	Pharmacological
and	O	O
placebo	O	Control
subjects	O	O
.	O	O

CONCLUSIONS	O	O
Addition	O	O
of	O	O
the	O	O
DPP4	O	O
inhibitor	O	O
PHX1149	O	O
to	O	O
a	O	O
stable	O	O
regimen	O	O
of	O	O
metformin	O	Pharmacological
or	O	O
metformin	O	Pharmacological
plus	O	O
a	O	O
glitazone	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
improved	O	O
blood	O	O
glucose	O	O
control	O	O
.	O	O

Glibenclamide	Pharmacological	O
vs	O	O
gliclazide	Pharmacological	O
in	O	O
reducing	O	O
oxidative	O	O
stress	O	O
in	O	O
patients	O	O
of	O	O
noninsulin	O	O
dependent	O	O
diabetes	O	O
mellitus	O	O
--	O	O
a	O	O
double	O	O
blind	O	O
randomized	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
Parameters	O	O
of	O	O
oxidative	O	O
stress	O	O
were	O	O
quantitated	O	O
in	O	O
50	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
mellitus	O	O
in	O	O
uncontrolled	O	O
state	O	O
and	O	O
after	O	O
control	O	O
using	O	O
oral	O	Pharmacological
glibenclamide	Pharmacological	Pharmacological
or	O	O
gliclazide	Pharmacological	O
.	O	O

The	O	O
estimates	O	O
were	O	O
further	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
irrespective	O	O
of	O	O
drug	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
difference	O	O
,	O	O
if	O	O
any	O	O
.	O	O

METHODS	O	O
The	O	O
study	O	O
was	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
uncontrolled	O	O
,	O	O
noncrossover	O	O
and	O	O
randomized	O	O
trial	O	O
.	O	O

Fifty	O	O
patients	O	O
of	O	O
uncontrolled	O	O
type	O	O
2	O	O
diabetes	O	O
were	O	O
divided	O	O
in	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Group	O	O
I	O	O
(	O	O
25	O	O
patients	O	O
)	O	O
received	O	O
capsule	O	Pharmacological
A	O	Pharmacological
(	O	Pharmacological
glibenclamide	Pharmacological	Pharmacological
)	O	O
while	O	O
Group	O	O
II	O	O
(	O	O
25	O	O
patients	O	O
)	O	O
received	O	O
capsule	O	O
B	O	O
(	O	O
gliclazide	Pharmacological	O
)	O	O
.	O	O

The	O	O
parameters	O	O
studied	O	O
were	O	O
Superoxide	O	O
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
,	O	O
malonyl-dialdehyde	O	O
(	O	O
MDA	O	O
)	O	O
and	O	O
reduced	O	O
glutathione	O	O
(	O	O
GSH	O	O
)	O	O
.	O	O

They	O	O
were	O	O
done	O	O
at	O	O
(	O	O
a	O	O
)	O	O
uncontrolled	O	O
stage	O	O
(	O	O
FBS	O	O
--	O	O
165	O	O
+/-	O	O
16.7	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
240	O	O
+/-	O	O
30.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
10.5	O	O
+/-	O	O
0.9	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
150	O	O
+/-	O	O
15.8	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
246	O	O
+/-	O	O
29.1	O	O
mg/dl	O	O
HbA1	O	O
10.6	O	O
+/-	O	O
0.8	O	O
%	O	O
in	O	O
group	O	O
II	O	O
)	O	O
and	O	O
during	O	O
controlled	O	O
stage	O	O
at	O	O
12	O	O
weeks	O	O
(	O	O
FBS	O	O
--	O	O
120	O	O
+/-	O	O
18.5	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
180	O	O
+/-	O	O
19.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.4	O	O
+/-	O	O
0.29	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
118	O	O
+/-	O	O
17.6	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
176	O	O
+/-	O	O
20.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.5	O	O
+/-	O	O
0.39	O	O
%	O	O
in	O	O
group	O	O
II	O	O
patients	O	O
)	O	O
.	O	O

RESULTS	O	O
The	O	O
significantly	O	O
raised	O	O
levels	O	O
of	O	O
MDA	O	O
and	O	O
SOD	O	O
,	O	O
and	O	O
decreased	O	O
levels	O	O
of	O	O
reduced	O	O
glutathione	O	O
(	O	O
GSH	O	O
)	O	O
during	O	O
uncontrolled	O	O
stage	O	O
of	O	O
diabetes	O	O
indicated	O	O
free	O	O
radical	O	O
stress	O	O
induced	O	O
lipid	O	O
peroxidation	O	O
.	O	O

The	O	O
significant	O	O
fall	O	O
of	O	O
MDA	O	O
and	O	O
SOD	O	O
and	O	O
increased	O	O
levels	O	O
of	O	O
GSH	O	O
in	O	O
blood	O	O
in	O	O
both	O	O
groups	O	O
after	O	O
control	O	O
revealed	O	O
beneficial	O	O
effects	O	O
of	O	O
glycemic	O	O
control	O	O
on	O	O
oxidative	O	O
stress	O	O
.	O	O

The	O	O
levels	O	O
were	O	O
not	O	O
normalized	O	O
and	O	O
stayed	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
controls	O	O
.	O	O

On	O	O
intergroup	O	O
comparison	O	O
;	O	O
the	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	Pharmacological	O
(	O	O
group	O	O
II	O	O
)	O	O
showed	O	O
improvement	O	O
in	O	O
oxidative	O	O
stress	O	O
(	O	O
MDA	O	O
,	O	O
GSH	O	O
)	O	O
better	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
than	O	O
glibenclamide	Pharmacological	Pharmacological
(	O	O
group	O	O
I	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Oxidative	O	O
stress	O	O
in	O	O
uncontrolled	O	O
diabetes	O	O
is	O	O
decreased	O	O
with	O	O
glycemic	O	O
control	O	O
.	O	O

The	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	Pharmacological	O
reduced	O	O
oxidative	O	O
stress	O	O
more	O	O
than	O	O
glibenclamide	Pharmacological	O
,	O	O
indicating	O	O
higher	O	O
antioxidant	O	O
properties	O	O
of	O	O
gliclazide	O	O
.	O	O

Normalization	O	O
of	O	O
oxidative	O	O
stress	O	O
was	O	O
not	O	O
achieved	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
see	O	O
long-term	O	O
effect	O	O
of	O	O
drug	O	Pharmacological
therapy	O	Pharmacological
in	O	O
combating	O	O
oxidative	O	O
stress	O	O
after	O	O
achieving	O	O
acceptable	O	O
control	O	O
of	O	O
diabetes	O	O
.	O	O

Effects	O	O
of	O	O
sibutramine	Pharmacological	O
on	O	O
thermogenesis	O	O
in	O	O
obese	O	O
patients	O	O
assessed	O	O
via	O	O
immersion	O	O
calorimetry	O	O
.	O	O

Glucose	O	O
utilization	O	O
studies	O	O
show	O	O
that	O	O
sibutramine-induced	Pharmacological	O
thermogenesis	O	O
is	O	O
mediated	O	O
via	O	O
selective	O	O
sympathetic	O	O
activation	O	O
of	O	O
brown	O	O
adipose	O	O
tissue	O	O
.	O	O

The	O	O
goal	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
use	O	O
a	O	O
new	O	O
calorimetry	O	O
method	O	O
in	O	O
which	O	O
resting	O	O
metabolic	O	O
rate	O	O
is	O	O
enhanced	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
sibutramine	Pharmacological	O
treatment	O	O
on	O	O
thermogenesis	O	O
.	O	O

Sixty	O	O
obese	O	O
women	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Subjects	O	O
were	O	O
divided	O	O
into	O	O
2	O	O
equal	O	O
groups-the	O	O
placebo	Control	O
and	O	O
sibutramine	Pharmacological	O
treatment	O	O
groups	O	O
.	O	O

The	O	O
sibutramine	Pharmacological	O
group	O	O
was	O	O
given	O	O
sibutramine	Pharmacological	O
10	O	O
mg	O	O
daily	O	O
for	O	O
12	O	O
wk	O	O
.	O	O

At	O	O
baseline	O	O
and	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
12-wk	O	O
treatment	O	O
period	O	O
,	O	O
thermogenic	O	O
measurements	O	O
were	O	O
taken	O	O
with	O	O
the	O	O
use	O	O
of	O	O
water	O	O
immersion	O	O
calorimetry	O	O
.	O	O

Subjects	O	O
were	O	O
examined	O	O
at	O	O
weeks	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
of	O	O
treatment	O	O
to	O	O
identify	O	O
adverse	O	O
effects	O	O
.	O	O

Body	O	O
mass	O	O
index	O	O
,	O	O
measured	O	O
at	O	O
31.5+/-2.05	O	O
kg/m2	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
decreased	O	O
to	O	O
30.4+/-2.94	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
after	O	O
12	O	O
wk	O	O
(	O	O
P=.07	O	O
)	O	O
.	O	O

In	O	O
the	O	O
sibutramine	Pharmacological	O
group	O	O
,	O	O
it	O	O
decreased	O	O
from	O	O
33.5+/-4.1	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
to	O	O
30.9+/-4.8	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

In	O	O
the	O	O
sibutramine	Pharmacological	O
group	O	O
,	O	O
mean	O	O
thermogenic	O	O
response	O	O
changed	O	O
from	O	O
a	O	O
baseline	O	O
value	O	O
of	O	O
1.27+/-0.29	O	O
kcal/kg/h	O	O
to	O	O
1.44+/-0.13	O	O
kcal/kg/h	O	O
after	O	O
12	O	O
wk	O	O
of	O	O
treatment	O	O
.	O	O

In	O	O
the	O	O
placebo	O	Control
group	O	O
,	O	O
the	O	O
baseline	O	O
value	O	O
was	O	O
1.56+/-0.27	O	O
kcal/kg/h	O	O
;	O	O
it	O	O
changed	O	O
to	O	O
1.33+/-0.36	O	O
kcal/kg/h	O	O
at	O	O
the	O	O
end	O	O
of	O	O
12	O	O
wk	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
sibutramine	O	O
treatment	O	O
promotes	O	O
thermogenesis	O	O
,	O	O
thus	O	O
facilitating	O	O
weight	O	O
loss	O	O
.	O	O

Calorimetry	O	O
enhances	O	O
resting	O	O
metabolism	O	O
through	O	O
more	O	O
efficient	O	O
heat	O	O
transfer	O	O
from	O	O
the	O	O
body	O	O
.	O	O

1999	O	O
WHO/ISH	O	O
Guidelines	O	O
applied	O	O
to	O	O
a	O	O
1999	O	O
MONICA	O	O
sample	O	O
from	O	O
northern	O	O
Sweden	O	O
.	O	O

BACKGROUND	O	O
Treating	O	O
hypertension	O	O
with	O	O
drugs	O	O
is	O	O
so	O	O
far	O	O
the	O	O
most	O	O
cost-effective	O	O
way	O	O
to	O	O
reduce	O	O
this	O	O
important	O	O
risk	O	O
factor	O	O
for	O	O
cardiovascular	O	O
disease	O	O
(	O	O
CVD	O	O
)	O	O
.	O	O

It	O	O
is	O	O
,	O	O
however	O	O
,	O	O
important	O	O
to	O	O
determine	O	O
absolute	O	O
risk	O	O
,	O	O
and	O	O
thereby	O	O
estimate	O	O
indication	O	O
for	O	O
drug	O	O
treatment	O	O
,	O	O
in	O	O
order	O	O
to	O	O
maintain	O	O
a	O	O
cost-effective	O	O
drug	O	O
treatment	O	O
.	O	O

WHO/ISH	O	O
Hypertension	O	O
Guidelines	O	O
from	O	O
1999	O	O
propose	O	O
a	O	O
risk	O	O
stratification	O	O
for	O	O
estimating	O	O
absolute	O	O
risk	O	O
for	O	O
CVD	O	O
based	O	O
on	O	O
blood	O	O
pressure	O	O
and	O	O
additional	O	O
risk	O	O
factors	O	O
,	O	O
target	O	O
organ	O	O
damage	O	O
(	O	O
TOD	O	O
)	O	O
and	O	O
CVD	O	O
.	O	O

OBJECTIVES	O	O
We	O	O
studied	O	O
the	O	O
consequences	O	O
of	O	O
applying	O	O
the	O	O
recent	O	O
WHO/ISH	Pharmacological	O
risk	Pharmacological	O
stratification	Pharmacological	O
scheme	Pharmacological	O
to	O	O
a	O	O
MONICA	O	O
sample	O	O
of	O	O
6000	O	O
subjects	O	O
from	O	O
a	O	O
geographically	O	O
defined	O	O
population	O	O
in	O	O
northern	O	O
Sweden	O	O
,	O	O
regarding	O	O
indications	O	O
for	O	O
treatment	O	O
,	O	O
target	O	O
blood	O	O
pressure	O	O
and	O	O
risk	O	O
distribution	O	O
.	O	O

METHODS	O	O
We	O	O
have	O	O
risk-classified	O	O
each	O	O
of	O	O
these	O	O
patients	O	O
using	O	O
a	O	O
computer	Other	O
program	Other	O
,	O	O
according	O	O
to	O	O
the	O	O
WHO/ISH	O	O
scheme	O	O
.	O	O

Data	O	O
on	O	O
TOD	O	O
were	O	O
not	O	O
available	O	O
.	O	O

RESULTS	O	O
In	O	O
all	O	O
,	O	O
917	O	O
(	O	O
15	O	O
%	O	O
)	O	O
had	O	O
drug-treated	O	O
hypertension	O	O
.	O	O

Three-quarters	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
were	O	O
inadequately	O	O
treated	O	O
,	O	O
with	O	O
blood	O	O
pressure	O	O
levels	O	O
at	O	O
or	O	O
above	O	O
140	O	O
or	O	O
90	O	O
mmHg	O	O
.	O	O

1773	O	O
(	O	O
30	O	O
%	O	O
of	O	O
5997	O	O
)	O	O
untreated	O	O
subjects	O	O
had	O	O
a	O	O
blood	O	O
pressure	O	O
of	O	O
140/90	O	O
or	O	O
above	O	O
;	O	O
16	O	O
%	O	O
in	O	O
the	O	O
low-	O	O
,	O	O
62	O	O
%	O	O
in	O	O
the	O	O
medium-	O	O
,	O	O
8	O	O
%	O	O
in	O	O
the	O	O
high-	O	O
,	O	O
and	O	O
14	O	O
%	O	O
in	O	O
the	O	O
very-high-risk	O	O
group	O	O
.	O	O

The	O	O
corresponding	O	O
risk-group	O	O
pattern	O	O
for	O	O
the	O	O
inadequately	O	O
treated	O	O
hypertensives	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
was	O	O
5.5	O	O
,	O	O
48.3	O	O
,	O	O
11.1	O	O
and	O	O
35.2	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

If	O	O
we	O	O
shifted	O	O
the	O	O
target	O	O
blood	O	O
pressure	O	O
from	O	O
below	O	O
140/90	O	O
to	O	O
below	O	O
130/85	O	O
for	O	O
drug-treated	O	O
subjects	O	O
under	O	O
60	O	O
(	O	O
n	O	O
=	O	O
278	O	O
)	O	O
the	O	O
number	O	O
of	O	O
inadequately	O	O
treated	O	O
subjects	O	O
increased	O	O
by	O	O
34	O	O
(	O	O
12.2	O	O
%	O	O
of	O	O
278	O	O
)	O	O
;	O	O
14	O	O
in	O	O
the	O	O
low-risk	O	O
group	O	O
,	O	O
15	O	O
in	O	O
the	O	O
medium-risk	O	O
group	O	O
,	O	O
and	O	O
only	O	O
five	O	O
in	O	O
the	O	O
high-	O	O
or	O	O
very-high-risk	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Only	O	O
one-fifth	O	O
of	O	O
the	O	O
drug-treated	O	O
hypertensives	O	O
were	O	O
well	O	O
controlled	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
newly	O	O
detected	O	O
blood	O	O
pressure	O	O
elevation	O	O
was	O	O
high	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
younger	O	O
subjects	O	O
with	O	O
high	O	O
blood	O	O
pressure	O	O
had	O	O
low	O	O
risk	O	O
,	O	O
but	O	O
in	O	O
those	O	O
aged	O	O
45-54	O	O
this	O	O
had	O	O
already	O	O
risen	O	O
to	O	O
a	O	O
medium	O	O
risk	O	O
.	O	O

Changing	O	O
the	O	O
target	O	O
blood	O	O
pressure	O	O
to	O	O
below	O	O
130/85	O	O
,	O	O
for	O	O
subjects	O	O
aged	O	O
below	O	O
60	O	O
,	O	O
as	O	O
recommended	O	O
by	O	O
WHO/ISH	O	O
,	O	O
affects	O	O
predominantly	O	O
low-	O	O
and	O	O
medium-risk	O	O
groups	O	O
.	O	O

Sex	O	O
risk	O	O
behavior	O	O
among	O	O
adolescent	O	O
and	O	O
young	O	O
adult	O	O
children	O	O
of	O	O
opiate	O	O
addicts	O	O
:	O	O
outcomes	O	O
from	O	O
the	O	O
focus	O	O
on	O	O
families	O	O
prevention	O	O
trial	O	O
and	O	O
an	O	O
examination	O	O
of	O	O
childhood	O	O
and	O	O
concurrent	O	O
predictors	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
.	O	O

This	O	O
study	O	O
reports	O	O
on	O	O
rates	O	O
and	O	O
predictors	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
among	O	O
a	O	O
sample	O	O
of	O	O
adolescent	O	O
and	O	O
young	O	O
adult	O	O
children	O	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	Pharmacological	O
treatment	O	O
for	O	O
opiate	O	O
addiction	O	O
.	O	O

Data	O	O
are	O	O
from	O	O
151	O	O
participants	O	O
(	O	O
80	O	O
males	O	O
,	O	O
71	O	O
females	O	O
)	O	O
in	O	O
the	O	O
Focus	O	O
on	O	O
Families	O	O
(	O	O
FOF	O	O
)	O	O
project	O	O
,	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
a	O	O
family	Educational	Physical
intervention	Educational	Physical
and	O	O
a	O	O
study	O	O
of	O	O
the	O	O
development	O	O
of	O	O
at-risk	O	O
children	O	O
.	O	O

The	O	O
study	O	O
participants	O	O
are	O	O
children	O	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	Pharmacological	O
treatment	O	O
between	O	O
1990	O	O
and	O	O
1993	O	O
.	O	O

Participants	O	O
were	O	O
interviewed	O	O
in	O	O
2005	O	O
when	O	O
they	O	O
ranged	O	O
in	O	O
age	O	O
from	O	O
15	O	O
to	O	O
29	O	O
years	O	O
.	O	O

In	O	O
the	O	O
year	O	O
prior	O	O
to	O	O
the	O	O
follow-up	O	O
,	O	O
79	O	O
%	O	O
of	O	O
the	O	O
males	O	O
and	O	O
83	O	O
%	O	O
of	O	O
females	O	O
were	O	O
sexually	O	O
active	O	O
,	O	O
26	O	O
%	O	O
of	O	O
males	O	O
and	O	O
10	O	O
%	O	O
of	O	O
females	O	O
had	O	O
more	O	O
than	O	O
one	O	O
partner	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
,	O	O
and	O	O
34	O	O
%	O	O
of	O	O
males	O	O
and	O	O
24	O	O
%	O	O
of	O	O
females	O	O
reported	O	O
having	O	O
sex	O	O
outside	O	O
of	O	O
a	O	O
committed	O	O
relationship	O	O
.	O	O

Twenty-four	O	O
percent	O	O
of	O	O
males	O	O
and	O	O
17	O	O
%	O	O
of	O	O
females	O	O
met	O	O
criteria	O	O
for	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
,	O	O
reporting	O	O
casual	O	O
or	O	O
multiple	O	O
partners	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
and	O	O
inconsistent	O	O
condom	O	O
use	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	Other	O
and	O	O
control	Control	O
conditions	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
in	O	O
terms	O	O
of	O	O
any	O	O
measure	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
examined	O	O
.	O	O

None	O	O
of	O	O
the	O	O
measures	O	O
of	O	O
parent	O	O
behavior	O	O
and	O	O
family	O	O
processes	O	O
derived	O	O
from	O	O
data	O	O
at	O	O
baseline	O	O
of	O	O
the	O	O
FOF	O	O
study	O	O
predicted	O	O
whether	O	O
participants	O	O
engaged	O	O
in	O	O
high-risk	O	O
sex	O	O
.	O	O

Among	O	O
measures	O	O
derived	O	O
from	O	O
data	O	O
collected	O	O
at	O	O
long-term	O	O
follow-up	O	O
,	O	O
however	O	O
,	O	O
having	O	O
ever	O	O
met	O	O
criteria	O	O
for	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
predicted	O	O
greater	O	O
likelihood	O	O
of	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
,	O	O
and	O	O
being	O	O
married	O	O
or	O	O
being	O	O
in	O	O
a	O	O
romantic	O	O
relationship	O	O
was	O	O
associated	O	O
with	O	O
lower	O	O
likelihood	O	O
of	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
.	O	O

The	O	O
findings	O	O
point	O	O
to	O	O
the	O	O
important	O	O
role	O	O
of	O	O
committed	O	O
relationships	O	O
in	O	O
regulating	O	O
sex	O	O
risk	O	O
behavior	O	O
among	O	O
this	O	O
population	O	O
,	O	O
as	O	O
well	O	O
as	O	O
heightened	O	O
levels	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
associated	O	O
with	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
.	O	O

Effects	O	O
of	O	O
tonabersat	Pharmacological	O
on	O	O
migraine	O	O
with	O	O
aura	O	O
:	O	O
a	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Migraine	O	O
with	O	O
aura	O	O
is	O	O
thought	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
cortical	O	O
spreading	O	O
depression	O	O
(	O	O
CSD	O	O
)	O	O
.	O	O

Tonabersat	Pharmacological	O
inhibits	O	O
CSD	O	O
,	O	O
and	O	O
we	O	O
therefore	O	O
investigated	O	O
whether	O	O
tonabersat	O	O
has	O	O
a	O	O
preventive	O	O
effect	O	O
in	O	O
migraine	O	O
with	O	O
aura	O	O
.	O	O

METHODS	O	O
In	O	O
this	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
trial	O	O
,	O	O
40	O	O
mg	O	O
tonabersat	Pharmacological	O
once	O	O
daily	O	O
was	O	O
compared	O	O
with	O	O
matched	O	O
placebo	Control	Control
in	O	O
patients	O	O
who	O	O
had	O	O
at	O	O
least	O	O
one	O	O
aura	O	O
attack	O	O
per	O	O
month	O	O
during	O	O
the	O	O
past	O	O
3	O	O
months	O	O
.	O	O

Randomisation	O	O
was	O	O
by	O	O
computer-generated	O	O
list	O	O
.	O	O

Patients	O	O
kept	O	O
a	O	O
detailed	O	O
diary	O	O
to	O	O
enable	O	O
objective	O	O
diagnosis	O	O
of	O	O
each	O	O
attack	O	O
as	O	O
migraine	O	O
with	O	O
aura	O	O
,	O	O
migraine	O	O
without	O	O
aura	O	O
,	O	O
or	O	O
other	O	O
type	O	O
of	O	O
headache	O	O
.	O	O

Primary	O	O
endpoints	O	O
were	O	O
a	O	O
reduction	O	O
in	O	O
aura	O	O
attacks	O	O
with	O	O
or	O	O
without	O	O
headache	O	O
and	O	O
a	O	O
reduction	O	O
in	O	O
migraine	O	O
headache	O	O
days	O	O
with	O	O
or	O	O
without	O	O
an	O	O
aura	O	O
.	O	O

Analysis	O	O
was	O	O
per	O	O
protocol	O	O
.	O	O

This	O	O
trial	O	O
is	O	O
registered	O	O
,	O	O
number	O	O
NCT00332007	O	O
.	O	O

FINDINGS	O	O
39	O	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
of	O	O
whom	O	O
31	O	O
were	O	O
included	O	O
in	O	O
the	O	O
statistical	O	O
analysis	O	O
of	O	O
efficacy	O	O
.	O	O

Median	O	O
(	O	O
IQR	O	O
)	O	O
attacks	O	O
of	O	O
aura	O	O
were	O	O
reduced	O	O
from	O	O
3.2	O	O
(	O	O
1.0-5.0	O	O
)	O	O
per	O	O
12	O	O
weeks	O	O
on	O	O
placebo	Control	O
to	O	O
1.0	O	O
(	O	O
0-3.0	O	O
)	O	O
on	O	O
tonabersat	O	O
(	O	O
p=0.01	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
other	O	O
primary	O	O
outcome	O	O
measure	O	O
,	O	O
median	O	O
migraine	O	O
headache	O	O
days	O	O
with	O	O
or	O	O
without	O	O
aura	O	O
,	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
placebo	Control	Control
and	O	O
tonabersat	Pharmacological	O
groups	O	O
(	O	O
3.0	O	O
days	O	O
in	O	O
each	O	O
group	O	O
;	O	O
p=0.09	O	O
)	O	O
.	O	O

Tonabersat	O	O
was	O	O
well	O	O
tolerated	O	O
but	O	O
overall	O	O
had	O	O
more	O	O
side-effects	O	O
than	O	O
placebo	O	O
.	O	O

INTERPRETATION	O	O
Tonabersat	Pharmacological	O
showed	O	O
a	O	O
preventive	O	O
effect	O	O
on	O	O
attacks	O	O
of	O	O
migraine	O	O
aura	O	O
but	O	O
no	O	O
efficacy	O	O
on	O	O
non-aura	O	O
attacks	O	O
,	O	O
in	O	O
keeping	O	O
with	O	O
its	O	O
known	O	O
inhibitory	O	O
effect	O	O
on	O	O
CSD	O	O
.	O	O

The	O	O
results	O	O
support	O	O
the	O	O
theory	O	O
that	O	O
auras	O	O
are	O	O
caused	O	O
by	O	O
CSD	O	O
and	O	O
that	O	O
this	O	O
phenomenon	O	O
is	O	O
not	O	O
involved	O	O
in	O	O
attacks	O	O
without	O	O
aura	O	O
.	O	O

FUNDING	O	O
Minster	O	O
Pharmaceuticals	O	O
;	O	O
Lundbeck	O	O
Foundation	O	O
.	O	O

Whole-body	Other	O
CT	Other	O
screening	Other	O
:	O	O
scan	O	O
delay	O	O
and	O	O
contrast	Pharmacological	O
injection	Pharmacological	O
duration	O	O
for	O	O
optimal	O	O
enhancement	O	O
of	O	O
abdominal	O	O
organs	O	O
and	O	O
deep	O	O
vessels	O	O
.	O	O

PURPOSE	O	O
To	O	O
assess	O	O
the	O	O
optimal	O	O
scan	O	O
delays	O	O
and	O	O
contrast	O	O
injection	O	O
durations	O	O
for	O	O
contrast-enhanced	Other	O
whole-body	Other	O
computed	Other	O
tomography	Other	O
(	Other	O
CT	Other	O
)	Other	O
.	Other	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
One	O	O
hundred	O	O
forty-two	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
protocol	O	O
A-scan	O	O
delay	O	O
of	O	O
65	O	O
s	O	O
after	O	O
starting	O	O
contrast	Pharmacological	O
injection	Pharmacological	O
over	O	O
30	O	O
s	O	O
;	O	O
protocol	O	O
B-105	O	O
and	O	O
70	O	O
s	O	O
;	O	O
and	O	O
protocol	O	O
C-145	O	O
and	O	O
110	O	O
s	O	O
,	O	O
respectively	O	O
.	O	O

Contrast	O	O
enhancement	O	O
and	O	O
diagnostic	O	O
acceptability	O	O
were	O	O
assessed	O	O
.	O	O

RESULTS	O	O
Qualitative	O	O
assessment	O	O
was	O	O
subtle	O	O
among	O	O
the	O	O
three	O	O
protocols	O	O
.	O	O

Homogenous	O	O
enhancement	O	O
of	O	O
deep	O	O
veins	O	O
was	O	O
more	O	O
assuredly	O	O
achieved	O	O
with	O	O
protocol	O	O
C.	O	O
CONCLUSION	O	O
With	O	O
protocol	O	O
C	O	O
,	O	O
qualitatively	O	O
acceptable	O	O
enhancement	O	O
can	O	O
be	O	O
obtained	O	O
in	O	O
whole-body	Other	O
CT	Other	O
.	Other	O

A	O	O
randomized	O	O
comparison	O	O
of	O	O
the	O	O
Endeavor	Physical	Physical
zotarolimus-eluting	Physical	Physical
stent	Physical	Physical
versus	O	O
the	O	O
TAXUS	Physical	Physical
paclitaxel-eluting	Physical	Physical
stent	Physical	Physical
in	O	O
de	O	O
novo	O	O
native	O	O
coronary	O	O
lesions	O	O
12-month	O	O
outcomes	O	O
from	O	O
the	O	O
ENDEAVOR	O	O
IV	O	O
trial	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
ENDEAVOR	O	O
IV	O	O
(	O	O
Randomized	O	O
Comparison	O	O
of	O	O
Zotarolimus-Eluting	Physical	O
and	O	O
Paclitaxel-Eluting	Physical	O
Stents	Physical	O
in	O	O
Patients	O	O
with	O	O
Coronary	O	O
Artery	O	O
Disease	O	O
)	O	O
trial	O	O
evaluated	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
the	O	O
zotarolimus-eluting	Physical	Physical
stent	Physical	Physical
(	Physical	Physical
ZES	Physical	Physical
)	Physical	Physical
compared	O	O
with	O	O
the	O	O
paclitaxel-eluting	Physical	Physical
stent	Physical	Physical
(	Physical	Physical
PES	Physical	Physical
)	Physical	Physical
.	O	O

BACKGROUND	O	O
First-generation	O	O
drug-eluting	O	O
stents	O	O
have	O	O
reduced	O	O
angiographic	O	O
and	O	O
clinical	O	O
restenosis	O	O
,	O	O
but	O	O
long-term	O	O
safety	O	O
remains	O	O
controversial	O	O
.	O	O

A	O	O
second-generation	O	O
drug-eluting	O	O
stent	O	O
,	O	O
which	O	O
delivers	O	O
zotarolimus	Pharmacological	O
,	O	O
a	O	O
potent	O	O
antiproliferative	O	O
agent	O	O
,	O	O
via	O	O
a	O	O
biocompatible	O	O
phosphorylcholine	O	O
polymer	O	O
on	O	O
a	O	O
cobalt	O	O
alloy	O	O
thin-strut	O	O
stent	O	O
has	O	O
shown	O	O
promising	O	O
experimental	O	O
and	O	O
early	O	O
clinical	O	O
results	O	O
.	O	O

METHODS	O	O
This	O	O
is	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
(	O	O
1:1	O	O
)	O	O
,	O	O
single-blind	O	O
,	O	O
controlled	O	O
trial	O	O
comparing	O	O
outcomes	O	O
of	O	O
patients	O	O
with	O	O
single	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
treated	O	O
with	O	O
ZES	O	O
or	O	O
PES	O	Physical
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
noninferiority	O	O
of	O	O
9-month	O	O
target	O	O
vessel	O	O
failure	O	O
defined	O	O
as	O	O
cardiac	O	O
death	O	O
,	O	O
myocardial	O	O
infarction	O	O
,	O	O
or	O	O
target	O	O
vessel	O	O
revascularization	O	O
.	O	O

RESULTS	O	O
Among	O	O
a	O	O
total	O	O
of	O	O
1,548	O	O
patients	O	O
assigned	O	O
to	O	O
ZES	Physical	O
(	O	O
n	O	O
=	O	O
773	O	O
)	O	O
or	O	O
PES	O	Physical
(	O	O
n	O	O
=	O	O
775	O	O
)	O	O
,	O	O
at	O	O
9	O	O
months	O	O
,	O	O
ZES	O	O
was	O	O
noninferior	O	O
to	O	O
PES	O	Physical
with	O	O
rates	O	O
of	O	O
target	O	O
vessel	O	O
failure	O	O
6.6	O	O
%	O	O
versus	O	O
7.1	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
(	O	O
noninferiority	O	O
)	O	O
<	O	O
or	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
fewer	O	O
periprocedural	O	O
myocardial	O	O
infarctions	O	O
with	O	O
ZES	Physical	O
(	O	O
0.5	O	O
%	O	O
vs.	O	O
2.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.007	O	O
)	O	O
,	O	O
whereas	O	O
at	O	O
12	O	O
months	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
in	O	O
rates	O	O
of	O	O
cardiac	O	O
death	O	O
,	O	O
myocardial	O	O
infarction	O	O
,	O	O
target	O	O
vessel	O	O
revascularization	O	O
,	O	O
or	O	O
stent	O	O
thrombosis	O	O
.	O	O

Although	O	O
incidence	O	O
of	O	O
8-month	O	O
binary	O	O
angiographic	O	O
in-segment	O	O
restenosis	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
ZES	Physical	O
versus	O	O
PES	O	O
(	O	O
15.3	O	O
%	O	O
vs.	O	O
10.4	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.284	O	O
)	O	O
,	O	O
rates	O	O
of	O	O
12-month	O	O
target	O	O
lesion	O	O
revascularization	O	O
were	O	O
similar	O	O
(	O	O
4.5	O	O
%	O	O
vs.	O	O
3.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.228	O	O
)	O	O
,	O	O
especially	O	O
in	O	O
patients	O	O
without	O	O
planned	O	O
angiographic	O	O
follow-up	O	O
(	O	O
3.6	O	O
%	O	O
vs.	O	O
3.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.756	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
demonstrate	O	O
that	O	O
ZES	Physical	O
has	O	O
similar	O	O
clinical	O	O
safety	O	O
and	O	O
efficacy	O	O
compared	O	O
with	O	O
PES	Physical	Physical
in	O	O
simple	O	O
and	O	O
medium	O	O
complexity	O	O
single	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
.	O	O

(	O	O
ENDEAVOR	O	O
IV	O	O
Clinical	O	O
Trial	O	O
;	O	O
NCT00217269	O	O
)	O	O
.	O	O

Effect	O	O
of	O	O
cigarette	O	O
smoking	O	O
on	O	O
gastric	O	O
emptying	O	O
of	O	O
solids	O	O
in	O	O
Japanese	O	O
smokers	O	O
:	O	O
a	O	O
crossover	O	O
study	O	O
using	O	O
the	O	O
13C-octanoic	O	O
acid	O	O
breath	O	O
test	O	O
.	O	O

BACKGROUND	O	O
Cigarette	O	O
smoking	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
peptic	O	O
ulcer	O	O
and	O	O
gastroesophageal	O	O
reflux	O	O
disease	O	O
.	O	O

Gastric	O	O
emptying	O	O
disorders	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
these	O	O
upper	O	O
gastrointestinal	O	O
diseases	O	O
.	O	O

Thus	O	O
,	O	O
studies	O	O
examining	O	O
a	O	O
link	O	O
between	O	O
smoking	O	O
and	O	O
gastric	O	O
emptying	O	O
disorders	O	O
have	O	O
clinical	O	O
relevance	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
smoking	O	O
on	O	O
gastric	O	O
emptying	O	O
of	O	O
solids	O	O
in	O	O
Japanese	O	O
smokers	O	O
.	O	O

METHODS	O	O
The	O	O
(	Other	O
13	Other	O
)	Other	O
C-octanoic	Other	O
acid	Other	O
breath	Other	O
test	Other	O
was	O	O
performed	O	O
in	O	O
eight	O	O
male	O	O
habitual	O	O
smokers	O	O
on	O	O
two	O	O
randomized	O	O
occasions	O	O
(	O	O
either	O	O
sham	O	O
smoking	O	O
or	O	O
actively	O	O
smoking	O	O
)	O	O
.	O	O

The	O	O
time	O	O
vs	O	O
(	O	O
13	O	O
)	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
excretion	O	O
rate	O	O
curve	O	O
was	O	O
mathematically	O	O
fitted	O	O
to	O	O
a	O	O
conventional	O	O
formula	O	O
of	O	O
y	O	O
(	O	O
t	O	O
)	O	O
=	O	O
m*k*beta*e	O	O
(	O	O
-k*t	O	O
)	O	O
*	O	O
(	O	O
1	O	O
-	O	O
e	O	O
(	O	O
-k*t	O	O
)	O	O
)	O	O
(	O	O
beta-1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
parameters	O	O
of	O	O
k	O	O
and	O	O
beta	O	O
were	O	O
determined	O	O
:	O	O
under	O	O
the	O	O
crossover	O	O
protocol	O	O
,	O	O
a	O	O
larger	O	O
(	O	O
smaller	O	O
)	O	O
beta	O	O
indicates	O	O
slower	O	O
(	O	O
faster	O	O
)	O	O
emptying	O	O
in	O	O
the	O	O
early	O	O
phase	O	O
,	O	O
and	O	O
a	O	O
larger	O	O
(	O	O
smaller	O	O
)	O	O
k	O	O
indicates	O	O
faster	O	O
(	O	O
slower	O	O
)	O	O
emptying	O	O
in	O	O
the	O	O
later	O	O
phase	O	O
.	O	O

The	O	O
half	O	O
(	O	O
13	O	O
)	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
excretion	O	O
time	O	O
(	O	O
t	O	O
(	O	O
1/2b	O	O
)	O	O
=	O	O
-	O	O
[	O	O
ln	O	O
(	O	O
1	O	O
-	O	O
2	O	O
(	O	O
-1/beta	O	O
)	O	O
)	O	O
]	O	O
/k	O	O
)	O	O
and	O	O
the	O	O
time	O	O
of	O	O
maximal	O	O
(	O	O
13	O	O
)	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
excretion	O	O
rate	O	O
(	O	O
t	O	O
(	O	O
max	O	O
)	O	O
=	O	O
[	O	O
lnbeta	O	O
]	O	O
/k	O	O
)	O	O
were	O	O
also	O	O
calculated	O	O
.	O	O

Between	O	O
the	O	O
two	O	O
occasions	O	O
,	O	O
k	O	O
,	O	O
beta	O	O
,	O	O
t	O	O
(	O	O
1/2b	O	O
)	O	O
,	O	O
and	O	O
t	O	O
(	O	O
max	O	O
)	O	O
were	O	O
compared	O	O
by	O	O
the	O	O
Wilcoxon	O	O
signed-rank	O	O
test	O	O
.	O	O

RESULTS	O	O
After	O	O
smoking	O	O
,	O	O
k	O	O
was	O	O
significantly	O	O
increased	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
beta	O	O
,	O	O
t	O	O
(	O	O
1/2	O	O
)	O	O
,	O	O
and	O	O
t	O	O
(	O	O
max	O	O
)	O	O
between	O	O
the	O	O
two	O	O
occasions	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
increase	O	O
in	O	O
k	O	O
suggests	O	O
the	O	O
acceleration	O	O
of	O	O
gastric	O	O
emptying	O	O
in	O	O
the	O	O
later	O	O
phase	O	O
.	O	O

For	O	O
the	O	O
first	O	O
time	O	O
,	O	O
this	O	O
study	O	O
has	O	O
revealed	O	O
that	O	O
acute	O	O
smoking	O	O
speeds	O	O
the	O	O
gastric	O	O
emptying	O	O
of	O	O
solids	O	O
in	O	O
Japanese	O	O
habitual	O	O
smokers	O	O
.	O	O

Effects	O	O
of	O	O
bifidobacterium	Pharmacological	Pharmacological
breve	Pharmacological	Pharmacological
supplementation	O	Pharmacological
on	O	O
intestinal	O	O
flora	O	O
of	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
known	O	O
that	O	O
the	O	O
bifidobacteria	O	O
flora	O	O
play	O	O
important	O	O
roles	O	O
in	O	O
mucosal	O	O
host	O	O
defense	O	O
and	O	O
can	O	O
prevent	O	O
infectious	O	O
diseases	O	O
.	O	O

Because	O	O
bacterial	O	O
populations	O	O
develop	O	O
during	O	O
the	O	O
first	O	O
day	O	O
of	O	O
life	O	O
,	O	O
the	O	O
authors	O	O
examined	O	O
whether	O	O
the	O	O
early	O	O
administration	O	O
of	O	O
bifidobacteria	O	O
has	O	O
a	O	O
positive	O	O
effect	O	O
on	O	O
the	O	O
health	O	O
of	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
.	O	O

METHODS	O	O
The	O	O
effects	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
Bifidobacterium	Pharmacological	Pharmacological
breve	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
B.	Pharmacological	Pharmacological
breve	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
supplements	Pharmacological	Pharmacological
were	O	O
studied	O	O
in	O	O
a	O	O
controlled	O	O
trial	O	O
with	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
(	O	O
average	O	O
birth	O	O
weight	O	O
1489	O	O
g	O	O
)	O	O
.	O	O

The	O	O
infants	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
Group	O	O
A	O	O
and	O	O
B	O	O
received	O	O
a	O	O
dose	O	O
of	O	O
1.6	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
cells	O	O
of	O	O
B.	O	O
breve	O	O
supplement	O	O
twice	O	O
a	O	O
day	O	O
,	O	O
commencing	O	O
either	O	O
from	O	O
several	O	O
hours	O	O
after	O	O
birth	O	O
(	O	O
group	O	O
A	O	O
)	O	O
or	O	O
24	O	O
h	O	O
after	O	O
birth	O	O
(	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Group	O	O
C	O	O
,	O	O
the	O	O
control	Control	O
group	Control	O
,	O	O
received	O	O
no	O	O
supplement	O	O
.	O	O

RESULTS	O	O
There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
birth	O	O
weight	O	O
,	O	O
treatment	O	O
with	O	O
antibiotics	O	Pharmacological
,	O	O
and	O	O
the	O	O
starting	O	O
time	O	O
of	O	O
breast-feeding	O	O
among	O	O
the	O	O
three	O	O
groups	O	O
.	O	O

A	O	O
Bifidobacterium-predominant	O	O
flora	O	O
was	O	O
formed	O	O
at	O	O
an	O	O
average	O	O
of	O	O
2	O	O
weeks	O	O
after	O	O
birth	O	O
in	O	O
group	O	O
A	O	O
and	O	O
at	O	O
an	O	O
average	O	O
of	O	O
4	O	O
weeks	O	O
after	O	O
birth	O	O
in	O	O
group	O	O
B	O	O
,	O	O
while	O	O
no	O	O
Bifidobacterium	O	O
was	O	O
isolated	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
10	O	O
infants	O	O
in	O	O
group	O	O
C	O	O
during	O	O
the	O	O
observation	O	O
period	O	O
of	O	O
7	O	O
weeks	O	O
.	O	O

In	O	O
comparison	O	O
between	O	O
group	O	O
A	O	O
and	O	O
B	O	O
,	O	O
Bifidobacterium	O	O
was	O	O
detected	O	O
significantly	O	O
earlier	O	O
in	O	O
group	O	O
A	O	O
,	O	O
and	O	O
the	O	O
number	O	O
of	O	O
Enterobacteriaceae	O	O
present	O	O
in	O	O
the	O	O
infants	O	O
at	O	O
2	O	O
weeks	O	O
after	O	O
birth	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
A	O	O
.	O	O

CONCLUSION	O	O
The	O	O
results	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
very	O	O
early	O	O
administration	O	O
of	O	O
B.	O	O
breve	O	O
to	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
is	O	O
useful	O	O
in	O	O
promoting	O	O
the	O	O
colonization	O	O
of	O	O
the	O	O
Bifidobacterium	O	O
and	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
normal	O	O
intestinal	O	O
flora	O	O
.	O	O

Teacher	O	O
and	O	O
child	O	O
predictors	O	O
of	O	O
achieving	O	O
IEP	Educational	O
goals	O	O
of	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

It	O	O
is	O	O
encouraging	O	O
that	O	O
children	O	O
with	O	O
autism	O	O
show	O	O
a	O	O
strong	O	O
response	O	O
to	O	O
early	O	O
intervention	O	O
,	O	O
yet	O	O
more	O	O
research	O	O
is	O	O
needed	O	O
for	O	O
understanding	O	O
the	O	O
variability	O	O
in	O	O
responsiveness	O	O
to	O	O
specialized	O	O
programs	O	O
.	O	O

Treatment	O	O
predictor	O	O
variables	O	O
from	O	O
47	O	O
teachers	O	O
and	O	O
children	O	O
who	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
the	O	O
COMPASS	Educational	Educational
intervention	Educational	Educational
(	O	O
Ruble	O	O
et	O	O
al	O	O
.	O	O

in	O	O
The	O	O
collaborative	O	O
model	O	O
for	O	O
promoting	O	O
competence	O	O
and	O	O
success	O	O
for	O	O
students	O	O
with	O	O
ASD	O	O
.	O	O

Springer	O	O
,	O	O
New	O	O
York	O	O
,	O	O
2012a	O	O
)	O	O
were	O	O
analyzed	O	O
.	O	O

Predictors	O	O
evaluated	O	O
against	O	O
child	O	O
IEP	O	O
goal	O	O
attainment	O	O
included	O	O
child	O	O
,	O	O
teacher	O	O
,	O	O
intervention	O	O
practice	O	O
,	O	O
and	O	O
implementation	O	O
practice	O	O
variables	O	O
based	O	O
on	O	O
an	O	O
implementation	O	O
science	O	O
framework	O	O
(	O	O
Dunst	O	O
and	O	O
Trivette	O	O
in	O	O
J	O	O
Soc	O	O
Sci	O	O
8:143-148	O	O
,	O	O
2012	O	O
)	O	O
.	O	O

Findings	O	O
revealed	O	O
one	O	O
child	O	O
(	O	O
engagement	O	O
)	O	O
,	O	O
one	O	O
teacher	O	O
(	O	O
exhaustion	O	O
)	O	O
,	O	O
two	O	O
intervention	O	O
quality	O	O
(	O	O
IEP	O	O
quality	O	O
for	O	O
targeted	O	O
and	O	O
not	O	O
targeted	O	O
elements	O	O
)	O	O
,	O	O
and	O	O
no	O	O
implementation	O	O
quality	O	O
variables	O	O
accounted	O	O
for	O	O
variance	O	O
in	O	O
child	O	O
outcomes	O	O
when	O	O
analyzed	O	O
separately	O	O
.	O	O

When	O	O
the	O	O
four	O	O
significant	O	O
variables	O	O
were	O	O
compared	O	O
against	O	O
each	O	O
other	O	O
in	O	O
a	O	O
single	O	O
regression	O	O
analysis	O	O
,	O	O
IEP	Educational	O
quality	O	O
accounted	O	O
for	O	O
one	O	O
quarter	O	O
of	O	O
the	O	O
variance	O	O
in	O	O
child	O	O
outcomes	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
gonadotropin-releasing	Pharmacological	Pharmacological
hormone	Pharmacological	Pharmacological
analog	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
Diphereline	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
and	O	O
Cabergoline	Pharmacological	O
(	Pharmacological	O
Dostinex	Pharmacological	O
)	Pharmacological	O
treatment	O	O
on	O	O
uterine	O	O
myoma	O	O
regression	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
cabergoline	Pharmacological	O
(	Pharmacological	O
Dostinex	Pharmacological	O
,	Pharmacological	O
a	Pharmacological	O
dopamine	Pharmacological	Pharmacological
agonist	Pharmacological	Pharmacological
)	Pharmacological	O
on	O	O
the	O	O
myoma	O	O
growth	O	O
compared	O	O
to	O	O
Diphereline	Pharmacological	O
(	Pharmacological	O
a	Pharmacological	O
gonadotropin-releasing	Pharmacological	O
hormone	Pharmacological	O
agonist	Pharmacological	O
)	Pharmacological	O
.	Pharmacological	O

METHODS	O	O
This	O	O
study	O	O
took	O	O
place	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
of	O	O
Tabriz	O	O
University	O	O
of	O	O
Medical	O	O
Sciences	O	O
,	O	O
Tabriz	O	O
,	O	O
Iran	O	O
from	O	O
July	O	O
2004	O	O
to	O	O
December	O	O
2005	O	O
.	O	O

Fifty	O	O
women	O	O
with	O	O
uterine	O	O
myoma	O	O
,	O	O
who	O	O
met	O	O
the	O	O
criteria	O	O
of	O	O
the	O	O
study	O	O
thoroughly	O	O
,	O	O
were	O	O
randomly	O	O
allocated	O	O
into	O	O
2	O	O
equal	O	O
groups	O	O
to	O	O
take	O	O
either	O	O
Diphereline	Pharmacological	Pharmacological
or	O	O
Cabergoline	Pharmacological	O
.	Pharmacological	O

The	O	O
first	O	O
Group	O	O
took	O	O
3.75	O	O
mg	O	O
of	O	O
Diphereline	Pharmacological	O
4	O	O
times	O	O
every	O	O
28	O	O
days	O	O
and	O	O
the	O	O
second	O	O
group	O	O
took	O	O
0.5	O	O
mg	O	O
of	O	O
Cabergoline	Pharmacological	O
once	O	O
a	O	O
week	O	O
for	O	O
6	O	O
weeks	O	O
.	O	O

RESULTS	O	O
The	O	O
Cabergoline	Pharmacological	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
fewer	O	O
adverse	O	O
effects	O	O
were	O	O
noted	O	O
.	O	O

The	O	O
tumor	O	O
regressed	O	O
significantly	O	O
and	O	O
volume	O	O
reduction	O	O
rate	O	O
of	O	O
individual	O	O
tumor	O	O
nodule	O	O
varied	O	O
from	O	O
46-53	O	O
%	O	O
.	O	O

The	O	O
gonadotropin	Pharmacological	Pharmacological
releasing	Pharmacological	Pharmacological
hormone	Pharmacological	Pharmacological
agonist	Pharmacological	Pharmacological
group	O	O
all	O	O
responded	O	O
to	O	O
the	O	O
treatment	O	O
,	O	O
and	O	O
volume	O	O
reduction	O	O
rate	O	O
of	O	O
the	O	O
individual	O	O
tumor	O	O
nodule	O	O
varied	O	O
from	O	O
21-97	O	O
%	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
tumor	O	O
shrinkage	O	O
was	O	O
positively	O	O
correlated	O	O
to	O	O
the	O	O
number	O	O
of	O	O
nodules	O	O
(	O	O
p=0.881	O	O
,	O	O
p	O	O
<	O	O
0.005	O	O
and	O	O
0.701	O	O
,	O	O
p	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

CONCLUSION	O	O
In	O	O
light	O	O
of	O	O
therapeutic	O	O
efficacy	O	O
and	O	O
few	O	O
adverse	O	O
effects	O	O
,	O	O
the	O	O
dopamine	Pharmacological	O
agonists	Pharmacological	O
may	O	O
hold	O	O
promise	O	O
as	O	O
novel	O	O
treatment	O	O
modalities	O	O
for	O	O
leiomyoma	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
warranted	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
strategy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
leiomyoma	O	O
through	O	O
these	O	O
agents	O	O
.	O	O

Perioperative	O	O
fever	O	O
and	O	O
outcome	O	O
in	O	O
surgical	O	O
patients	O	O
with	O	O
aneurysmal	O	O
subarachnoid	O	O
hemorrhage	O	O
.	O	O

OBJECTIVE	O	O
We	O	O
examined	O	O
the	O	O
incidence	O	O
of	O	O
perioperative	O	O
fever	O	O
and	O	O
its	O	O
relationship	O	O
to	O	O
outcome	O	O
among	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
Intraoperative	O	O
Hypothermia	O	O
for	O	O
Aneurysm	O	O
Surgery	O	O
Trial	O	O
.	O	O

METHODS	O	O
One	O	O
thousand	O	O
patients	O	O
with	O	O
initial	O	O
World	O	O
Federation	O	O
of	O	O
Neurological	O	O
Surgeons	O	O
grades	O	O
of	O	O
I	O	O
to	O	O
III	O	O
undergoing	O	O
clipping	O	O
of	O	O
intracranial	O	O
aneurysms	O	O
after	O	O
subarachnoid	O	O
hemorrhage	O	O
were	O	O
randomized	O	O
to	O	O
intraoperative	Other	O
normothermia	Other	O
(	O	O
36	O	O
degrees	O	O
C-37	O	O
degrees	O	O
C	O	O
)	O	O
or	O	O
hypothermia	Other	O
(	O	O
32.5	O	O
degrees	O	O
C-33.5	O	O
degrees	O	O
C	O	O
)	O	O
.	O	O

Fever	O	O
(	O	O
>	O	O
or	O	O
=38.5	O	O
degrees	O	O
C	O	O
)	O	O
and	O	O
other	O	O
complications	O	O
(	O	O
including	O	O
infections	O	O
)	O	O
occurring	O	O
between	O	O
admission	O	O
and	O	O
discharge	O	O
(	O	O
or	O	O
death	O	O
)	O	O
were	O	O
recorded	O	O
.	O	O

Functional	O	O
and	O	O
neuropsychologic	O	O
outcomes	O	O
were	O	O
assessed	O	O
3	O	O
months	O	O
postoperatively	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
variable	O	O
for	O	O
the	O	O
trial	O	O
was	O	O
dichotomized	O	O
Glasgow	O	O
Outcome	O	O
Scale	O	O
(	O	O
good	O	O
outcome	O	O
versus	O	O
all	O	O
others	O	O
)	O	O
.	O	O

RESULTS	O	O
Fever	O	O
was	O	O
reported	O	O
in	O	O
41	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

In	O	O
97	O	O
%	O	O
of	O	O
these	O	O
,	O	O
fever	O	O
occurred	O	O
in	O	O
the	O	O
postoperative	O	O
period	O	O
.	O	O

The	O	O
median	O	O
time	O	O
from	O	O
surgery	O	O
to	O	O
first	O	O
fever	O	O
was	O	O
3	O	O
days	O	O
.	O	O

All	O	O
measures	O	O
of	O	O
outcome	O	O
were	O	O
worse	O	O
in	O	O
patients	O	O
who	O	O
developed	O	O
fever	O	O
,	O	O
even	O	O
in	O	O
those	O	O
without	O	O
infections	O	O
or	O	O
who	O	O
were	O	O
World	O	O
Federation	O	O
of	O	O
Neurological	O	O
Surgeons	O	O
grade	O	O
I.	O	O
Logistic	O	O
regression	O	O
analyses	O	O
were	O	O
performed	O	O
to	O	O
adjust	O	O
for	O	O
differences	O	O
in	O	O
preoperative	O	O
factors	O	O
(	O	O
e.g.	O	O
,	O	O
age	O	O
,	O	O
Fisher	O	O
grade	O	O
,	O	O
initial	O	O
neurological	O	O
status	O	O
)	O	O
.	O	O

This	O	O
demonstrated	O	O
that	O	O
fever	O	O
continued	O	O
to	O	O
be	O	O
significantly	O	O
associated	O	O
with	O	O
most	O	O
outcome	O	O
measures	O	O
,	O	O
even	O	O
when	O	O
infection	O	O
was	O	O
added	O	O
to	O	O
the	O	O
model	O	O
.	O	O

An	O	O
alternative	O	O
stepwise	O	O
model	O	O
selection	O	O
process	O	O
including	O	O
all	O	O
fever-related	O	O
measures	O	O
from	O	O
the	O	O
preoperative	O	O
and	O	O
intraoperative	O	O
period	O	O
(	O	O
e.g.	O	O
,	O	O
hydrocephalus	O	O
,	O	O
duration	O	O
of	O	O
surgery	O	O
,	O	O
intraoperative	O	O
blood	O	O
loss	O	O
)	O	O
resulted	O	O
in	O	O
the	O	O
loss	O	O
of	O	O
significance	O	O
for	O	O
dichotomized	O	O
Glasgow	O	O
Outcome	O	O
Scale	O	O
,	O	O
but	O	O
significant	O	O
associations	O	O
between	O	O
fever	O	O
and	O	O
several	O	O
other	O	O
outcome	O	O
measures	O	O
remained	O	O
.	O	O

After	O	O
adding	O	O
postoperative	O	O
delayed	O	O
ischemic	O	O
neurological	O	O
deficits	O	O
to	O	O
the	O	O
model	O	O
,	O	O
only	O	O
worsened	O	O
National	O	O
Institutes	O	O
of	O	O
Health	O	O
Stroke	O	O
Scale	O	O
score	O	O
,	O	O
Barthel	O	O
Activities	O	O
of	O	O
Daily	O	O
Living	O	O
index	O	O
,	O	O
and	O	O
discharge	O	O
destination	O	O
(	O	O
home	O	O
versus	O	O
other	O	O
)	O	O
remained	O	O
independently	O	O
associated	O	O
with	O	O
fever	O	O
.	O	O

CONCLUSION	O	O
These	O	O
findings	O	O
suggest	O	O
that	O	O
fever	O	O
is	O	O
associated	O	O
with	O	O
worsened	O	O
outcome	O	O
in	O	O
surgical	O	O
subarachnoid	O	O
hemorrhage	O	O
patients	O	O
,	O	O
although	O	O
,	O	O
because	O	O
the	O	O
association	O	O
between	O	O
fever	O	O
and	O	O
the	O	O
primary	O	O
outcome	O	O
measure	O	O
for	O	O
the	O	O
trial	O	O
is	O	O
dependent	O	O
on	O	O
the	O	O
covariates	O	O
used	O	O
in	O	O
the	O	O
analysis	O	O
(	O	O
particularly	O	O
operative	O	O
events	O	O
and	O	O
delayed	O	O
ischemic	O	O
neurological	O	O
deficits	O	O
)	O	O
,	O	O
we	O	O
can	O	O
not	O	O
rule	O	O
out	O	O
the	O	O
possibility	O	O
that	O	O
fever	O	O
is	O	O
a	O	O
marker	O	O
for	O	O
other	O	O
events	O	O
.	O	O

Only	O	O
a	O	O
formal	O	O
trial	O	O
of	O	O
fever	O	O
treatment	O	O
or	O	O
prevention	O	O
can	O	O
address	O	O
this	O	O
issue	O	O
.	O	O

Effects	O	O
of	O	O
weight-bearing	Physical	Pharmacological
versus	O	O
nonweight-bearing	Physical	Physical
exercise	Physical	Physical
on	O	O
function	O	O
,	O	O
walking	O	O
speed	O	O
,	O	O
and	O	O
position	O	O
sense	O	O
in	O	O
participants	O	O
with	O	O
knee	O	O
osteoarthritis	O	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
whether	O	O
weight-bearing	Physical	Physical
(	Physical	Physical
WB	Physical	Physical
)	Physical	Physical
exercise	Physical	Physical
enhances	O	O
functional	O	O
capacity	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
nonweight-bearing	Physical	O
(	Physical	O
NWB	Physical	O
)	Physical	O
exercise	Physical	O
in	O	O
participants	O	O
with	O	O
knee	O	O
osteoarthritis	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Kinesiology	O	O
laboratory	O	O
.	O	O

PARTICIPANTS	O	O
Participants	O	O
(	O	O
N=106	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
WB	Physical	Physical
exercise	Physical	Physical
,	O	Physical
NWB	Physical	Physical
exercise	Physical	Physical
,	O	O
or	O	O
a	O	O
control	Control	Control
group	Control	Control
(	Control	Control
no	Control	Control
exercise	Control	Control
)	Control	Control
.	O	O

INTERVENTION	O	O
WB	Physical	Physical
exercise	Physical	Physical
and	O	O
NWB	Physical	O
exercise	Physical	O
groups	Physical	O
underwent	O	O
an	O	O
8-week	Physical	O
knee	Physical	O
extension-flexion	Physical	Physical
exercise	Physical	Physical
program	Physical	Physical
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Western	O	O
Ontario	O	O
and	O	O
McMaster	O	O
Universities	O	O
Osteoarthritis	O	O
Index	O	O
(	O	O
WOMAC	O	O
)	O	O
function	O	O
scale	O	O
,	O	O
walking	O	O
speed	O	O
,	O	O
muscle	O	O
torque	O	O
,	O	O
and	O	O
knee	O	O
reposition	O	O
error	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
intervention	O	O
.	O	O

RESULTS	O	O
Equally	O	O
significant	O	O
improvements	O	O
were	O	O
apparent	O	O
for	O	O
all	O	O
outcomes	O	O
after	O	O
WB	O	Physical
exercise	O	Physical
and	O	O
NWB	O	O
exercise	O	O
,	O	O
except	O	O
for	O	O
reposition	O	O
error	O	O
,	O	O
for	O	O
which	O	O
improvement	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
WB	Physical	O
exercise	Physical	O
group	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
there	O	O
were	O	O
no	O	O
improvements	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Simple	O	O
knee	O	O
flexion	O	O
and	O	O
extension	O	O
exercises	O	O
(	Physical	O
WB	Physical	O
and	O	O
NWB	Physical	O
)	O	O
performed	O	O
over	O	O
8	O	O
weeks	O	O
resulted	O	O
in	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
WOMAC	O	O
function	O	O
scale	O	O
and	O	O
knee	O	O
strength	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

NWB	Physical	O
exercise	Physical	O
alone	O	O
may	O	O
be	O	O
sufficient	O	O
enough	O	O
to	O	O
improve	O	O
function	O	O
and	O	O
muscle	O	O
strength	O	O
.	O	O

The	O	O
additional	O	O
benefit	O	O
of	O	O
WB	Physical	O
exercise	Physical	O
was	O	O
improved	O	O
position	O	O
sense	O	O
,	O	O
which	O	O
may	O	O
enhance	O	O
complex	O	O
walking	O	O
tasks	O	O
(	O	O
walking	O	O
on	O	O
figure	O	O
of	O	O
8	O	O
route	O	O
and	O	O
spongy	O	O
surface	O	O
)	O	O
.	O	O

Phytase	Pharmacological	O
and	O	O
1alpha-hydroxycholecalciferol	Pharmacological	O
supplementation	Pharmacological	O
of	O	O
broiler	O	O
chickens	O	O
during	O	O
the	O	O
starting	O	O
and	O	O
growing/finishing	O	O
phases	O	O
.	O	O

Supplemental	O	O
1alpha-hydroxycholecalciferol	O	O
(	O	O
1alpha-OHD3	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
qualitatively	O	O
similar	O	O
and	O	O
quantitatively	O	O
additive	O	O
effects	O	O
to	O	O
exogenous	O	O
phytase	O	O
.	O	O

Two	O	O
experiments	O	O
were	O	O
conducted	O	O
from	O	O
0	O	O
to	O	O
35	O	O
d	O	O
in	O	O
floor	O	O
pens	O	O
to	O	O
determine	O	O
the	O	O
additive	O	O
effect	O	O
of	O	O
phytase	Pharmacological	O
and	O	O
1alpha-OHD3	Pharmacological	O
when	O	O
supplemented	O	O
to	O	O
Ca-	Pharmacological	O
and	Pharmacological	O
P-deficient	Pharmacological	O
diets	Pharmacological	O
.	O	O

In	O	O
both	O	O
experiments	O	O
,	O	O
at	O	O
least	O	O
4	O	O
replicates	O	O
per	O	O
treatment	O	O
(	O	O
50	O	O
chicks	O	O
per	O	O
replicate	O	O
)	O	O
were	O	O
used	O	O
.	O	O

Corn-soybean-meal-and	Other	O
soybean-oil-based	Other	O
diets	Other	O
were	O	O
fed	O	O
and	O	O
birds	O	O
were	O	O
raised	O	O
in	O	O
a	O	O
house	O	O
impervious	O	O
to	O	O
ultraviolet	O	O
light	O	O
.	O	O

During	O	O
the	O	O
starter	O	O
phase	O	O
(	O	O
ST	O	O
)	O	O
,	O	O
from	O	O
0	O	O
to	O	O
18	O	O
d	O	O
,	O	O
chicks	O	O
were	O	O
fed	O	O
a	O	O
23	O	O
%	O	O
CP	O	Pharmacological
diet	O	Pharmacological
containing	O	O
0.60	O	O
%	O	O
Ca	O	O
and	O	O
0.47	O	O
%	O	O
total	O	O
P	O	O
(	O	O
tP	O	O
)	O	O
.	O	O

During	O	O
the	O	O
grower/finisher	O	O
phase	O	O
(	O	O
GF	O	O
)	O	O
,	O	O
from	O	O
19	O	O
to	O	O
35	O	O
d	O	O
,	O	O
birds	O	O
were	O	O
fed	O	O
a	O	O
19	O	O
%	O	O
CP	O	Pharmacological
diet	O	Pharmacological
containing	O	Pharmacological
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
1,000	O	O
phytase	O	O
units/kg	O	O
of	O	O
Natuphos	O	O
phytase	O	O
and	O	O
5	O	O
microg/kg	O	O
of	O	O
1alpha-OHD3	O	Pharmacological
(	O	Pharmacological
P+1A	O	Pharmacological
)	O	Pharmacological
was	O	O
supplemented	O	O
to	O	O
some	O	O
of	O	O
the	O	O
feed	O	O
during	O	O
the	O	O
ST	O	O
and	O	O
GF	O	O
.	O	O

Diets	O	O
containing	O	O
adequate	O	O
Ca	O	O
and	O	O
P	O	O
were	O	O
also	O	O
fed	O	O
during	O	O
the	O	O
ST	O	O
(	O	O
0.90	O	O
%	O	O
Ca	O	O
,	O	O
0.68	O	O
%	O	O
tP	O	O
)	O	O
and	O	O
GF	O	O
(	O	O
0.80	O	O
%	O	O
Ca	O	O
,	O	O
0.67	O	O
%	O	O
tP	O	O
)	O	O
.	O	O

Performance	O	O
characteristics	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
rickets	O	O
and	O	O
tibial	O	O
dyschondroplasia	O	O
were	O	O
measured	O	O
at	O	O
18	O	O
and	O	O
35	O	O
d.	O	O
In	O	O
experiment	O	O
1	O	O
,	O	O
unsupplemented	O	O
chicks	O	O
performed	O	O
well	O	O
but	O	O
had	O	O
considerable	O	O
leg	O	O
problems	O	O
.	O	O

Chicks	O	O
fed	O	O
P+1A	O	O
during	O	O
the	O	O
ST	O	O
or	O	O
GF	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
as	O	O
birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
.	O	O

Birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
performed	O	O
as	O	O
well	O	O
birds	O	O
fed	O	O
the	O	O
adequate	O	O
diets	O	O
without	O	O
any	O	O
indication	O	O
of	O	O
leg	O	O
problems	O	O
.	O	O

In	O	O
experiment	O	O
2	O	O
,	O	O
unsupplemented	O	O
birds	O	O
performed	O	O
similarly	O	O
to	O	O
unsupplemented	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
.	O	O

However	O	O
,	O	O
chicks	O	O
fed	O	O
the	O	O
supplements	O	O
or	O	O
the	O	O
control	O	O
diets	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
or	O	O
accumulate	O	O
as	O	O
much	O	O
bone	O	O
ash	O	O
as	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
,	O	O
although	O	O
the	O	O
diets	O	O
were	O	O
formulated	O	O
identically	O	O
in	O	O
both	O	O
experiments	O	O
.	O	O

Diets	O	O
with	O	O
as	O	O
little	O	O
as	O	O
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
appear	O	O
to	O	O
be	O	O
adequate	O	O
for	O	O
broilers	O	O
older	O	O
than	O	O
18	O	O
d	O	O
if	O	O
supplemented	O	O
with	O	O
the	O	O
correct	O	O
amounts	O	O
of	O	O
phytase	O	O
and	O	O
1alpha-OHD3	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
unknown	O	O
variables	O	O
that	O	O
may	O	O
limit	O	O
the	O	O
potential	O	O
of	O	O
broilers	O	O
in	O	O
terms	O	O
of	O	O
bone	O	O
mineralization	O	O
and	O	O
bone	O	O
pathology	O	O
,	O	O
even	O	O
when	O	O
adequate	O	O
diets	O	O
are	O	O
fed	O	O
.	O	O

The	O	O
acute	O	O
effects	O	O
of	O	O
fluid	O	O
intake	O	O
on	O	O
urine	O	O
specific	O	O
gravity	O	O
and	O	O
fluid	O	O
retention	O	O
in	O	O
a	O	O
mildly	O	O
dehydrated	O	O
state	O	O
.	O	O

Many	O	O
athletes	O	O
arrive	O	O
at	O	O
training	O	O
sessions	O	O
and	O	O
competitions	O	O
in	O	O
a	O	O
mildly	O	O
hypohydrated	O	O
(	O	O
HYPO	O	O
)	O	O
state	O	O
and	O	O
are	O	O
instructed	O	O
to	O	O
drink	O	O
fluids	O	O
before	O	O
exercise	O	O
to	O	O
reach	O	O
a	O	O
euhydrated	O	O
(	O	O
HYD	O	O
)	O	O
state	O	O
.	O	O

Ten	O	O
recreational	O	O
athletes	O	O
(	O	O
6	O	O
women	O	O
,	O	O
4	O	O
men	O	O
;	O	O
71.9	O	O
?	O	O
4.6	O	O
kg	O	O
,	O	O
25.2	O	O
?	O	O
0.9	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
studies	O	O
to	O	O
examine	O	O
(	O	O
a	O	O
)	O	O
the	O	O
day-to-day	O	O
variability	O	O
of	O	O
morning	O	O
urine	O	O
specific	O	O
gravity	O	O
(	O	O
USG	O	O
)	O	O
,	O	O
(	O	O
b	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
600	Educational	O
ml	Educational	O
of	Educational	O
water	Educational	Pharmacological
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYD	O	O
and	O	O
HYPO	O	O
(	O	O
USG	O	O
>	O	O
1.020	O	O
)	O	O
subjects	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
water	Educational	O
(	Educational	O
W	Educational	O
)	Educational	O
,	O	O
salt-water	Educational	O
(	Educational	O
SW	O	O
,	O	O
40	O	O
mM	O	O
Na	O	O
)	O	O
,	O	O
a	O	O
carbohydrate-electrolyte	Educational	Pharmacological
solution	Educational	Pharmacological
with	Educational	Pharmacological
3	Educational	Pharmacological
%	Educational	Pharmacological
or	Educational	Pharmacological
light	Educational	Pharmacological
carbohydrate	Educational	Pharmacological
(	Educational	Pharmacological
CES-L	O	Pharmacological
,	O	O
20	O	O
mM	O	O
Na	O	O
)	O	O
or	O	O
a	O	O
CES	Educational	Pharmacological
with	Educational	Pharmacological
6	Educational	Pharmacological
%	Educational	Pharmacological
carbohydrate	Educational	Pharmacological
(	Educational	Pharmacological
CES	O	Pharmacological
,	O	Pharmacological
20	O	Pharmacological
mM	O	Pharmacological
Na	O	Pharmacological
)	O	Pharmacological
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYPO	O	O
subjects	O	O
.	O	O

The	O	O
hydration	O	O
status	O	O
was	O	O
assessed	O	O
with	O	O
USG	O	O
and	O	O
body	O	O
mass	O	O
measures	O	O
and	O	O
urine	O	O
volume	O	O
collections	O	O
.	O	O

The	O	O
day-to-day	O	O
variability	O	O
in	O	O
morning	O	O
USG	O	O
(	O	O
coefficient	O	O
of	O	O
variation	O	O
=	O	O
0.2	O	O
?	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
and	O	O
the	O	O
responses	O	O
to	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
ingestion	O	O
were	O	O
repeatable	O	O
.	O	O

Pretrial	O	O
USG	O	O
was	O	O
1.022	O	O
?	O	O
0.001	O	O
in	O	O
the	O	O
HYPO	O	O
trial	O	O
and	O	O
decreased	O	O
<	O	O
1.020	O	O
by	O	O
45	O	O
minutes	O	O
(	O	O
1.013	O	O
?	O	O
0.003	O	O
)	O	O
.	O	O

In	O	O
the	O	O
CES	O	O
study	O	O
,	O	O
HYPO	O	O
subjects	O	O
reached	O	O
HYD	O	O
status	O	O
at	O	O
45	O	O
minutes	O	O
in	O	O
all	O	O
conditions	O	O
(	O	O
W	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
SW	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
CES-L	O	O
1.011	O	O
?	O	O
0.003	O	O
,	O	O
CES	O	O
1.017	O	O
?	O	O
0.004	O	O
)	O	O
because	O	O
salt	O	O
or	O	O
CES	O	O
ingestion	O	O
did	O	O
not	O	O
affect	O	O
fluid	O	O
retention	O	O
(	O	O
W	O	O
68	O	O
%	O	O
,	O	O
SW	O	O
72	O	O
%	O	O
,	O	O
CES-L	O	O
68	O	O
%	O	O
,	O	O
CES	O	O
76	O	O
%	O	O
)	O	O
.	O	O

This	O	O
study	O	O
demonstrated	O	O
that	O	O
mildly	O	O
HYPO	O	O
subjects	O	O
could	O	O
reach	O	O
euhydration	O	O
within	O	O
45	O	O
minutes	O	O
of	O	O
the	O	O
ingestion	O	O
of	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
salt	O	O
and	O	O
CES	O	O
solutions	O	O
.	O	O

Following	O	O
this	O	O
practice	O	O
will	O	O
minimize	O	O
the	O	O
incidence	O	O
of	O	O
starting	O	O
a	O	O
practice	O	O
or	O	O
competition	O	O
hypohydrated	O	O
.	O	O

Allogeneic	Pharmacological	Surgical
marrow	Pharmacological	Surgical
transplantation	Pharmacological	Surgical
in	O	O
patients	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
two	O	O
irradiation	O	O
regimens	O	O
.	O	O

A	O	O
randomized	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
compare	O	O
two	O	O
regimens	O	O
of	O	O
total	Other	Physical
body	Other	Physical
irradiation	Other	Physical
in	O	O
patients	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
treated	O	O
by	O	O
allogeneic	Pharmacological	O
marrow	Pharmacological	O
transplantation	Pharmacological	O
while	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
cyclophosphamide	Pharmacological	Pharmacological
120	O	Pharmacological
mg/kg	O	Pharmacological
followed	O	Pharmacological
by	O	Pharmacological
total	Other	Physical
body	Other	Physical
irradiation	Other	Physical
and	O	O
marrow	Pharmacological	O
from	Pharmacological	O
HLA-identical	Pharmacological	O
siblings	Pharmacological	O
.	O	O

Cyclosporine	Pharmacological	Pharmacological
and	O	O
methotrexate	Pharmacological	Pharmacological
were	O	O
used	O	O
for	O	O
prophylaxis	O	O
against	O	O
acute	O	O
graft-versus-host	O	O
disease	O	O
.	O	O

Fifty-seven	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.0	O	O
Gy	O	O
fractions	O	O
of	O	O
irradiation	Other	O
daily	O	O
for	O	O
6	O	O
days	O	O
and	O	O
59	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.25	O	O
Gy	O	O
fractions	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

The	O	O
probabilities	O	O
of	O	O
relapse	O	O
at	O	O
4	O	O
years	O	O
were	O	O
0.25	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.00	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.008	O	O
)	O	O
.	O	O

The	O	O
actuarial	O	O
probabilities	O	O
of	O	O
survival	O	O
and	O	O
relapse-free	O	O
survival	O	O
at	O	O
4	O	O
years	O	O
were	O	O
0.60	O	O
and	O	O
0.58	O	O
among	O	O
the	O	O
patients	O	O
who	O	O
received	O	O
12.0	O	O
Gy	O	O
compared	O	O
with	O	O
0.66	O	O
and	O	O
0.66	O	O
for	O	O
those	O	O
who	O	O
received	O	O
15.75	O	O
Gy	O	O
.	O	O

The	O	O
4-year	O	O
probabilities	O	O
of	O	O
transplant-related	O	O
mortality	O	O
were	O	O
0.24	O	O
and	O	O
0.34	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
.13	O	O
)	O	O
while	O	O
the	O	O
probability	O	O
of	O	O
moderate	O	O
to	O	O
severe	O	O
acute	O	O
graft-versus-host	O	O
disease	O	O
was	O	O
0.33	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.44	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.15	O	O
)	O	O
.	O	O

The	O	O
lower	O	O
relapse	O	O
probability	O	O
in	O	O
the	O	O
patients	O	O
receiving	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
total	Other	O
body	Other	O
irradiation	Other	O
did	O	O
not	O	O
result	O	O
in	O	O
improved	O	O
survival	O	O
because	O	O
mortality	O	O
from	O	O
causes	O	O
other	O	O
than	O	O
relapse	O	O
was	O	O
increased	O	O
.	O	O

Short-	O	O
and	O	O
long-term	O	O
effects	O	O
of	O	O
tactile	Physical	O
massage	Physical	O
on	O	O
salivary	O	O
cortisol	O	O
concentrations	O	O
in	O	O
Parkinson	O	O
's	O	O
disease	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
pilot	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Parkinson	O	O
's	O	O
disease	O	O
(	O	O
PD	O	O
)	O	O
is	O	O
a	O	O
chronic	O	O
neurodegenerative	O	O
disorder	O	O
with	O	O
limited	O	O
knowledge	O	O
about	O	O
the	O	O
normal	O	O
function	O	O
and	O	O
effects	O	O
of	O	O
non-pharmacological	Other	O
therapies	Other	O
on	O	O
the	O	O
hypothalamic-pituitary-adrenal	O	O
(	O	O
HPA	O	O
)	O	O
axis	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
analyse	O	O
the	O	O
basal	O	O
diurnal	O	O
and	O	O
total	O	O
secretion	O	O
of	O	O
salivary	O	O
cortisol	O	O
in	O	O
short-	O	O
and	O	O
long-term	O	O
aspects	O	O
of	O	O
tactile	Physical	O
massage	Physical	O
(	Physical	O
TM	Physical	O
)	Physical	O
.	Other	O

METHODS	O	O
DESIGN	O	O
Prospective	O	O
,	O	O
Controlled	O	O
and	O	O
Randomised	O	O
Multicentre	O	O
Trial	O	O
.	O	O

SETTING	O	O
AND	O	O
INTERVENTIONS	O	O
Forty-five	O	O
women	O	O
and	O	O
men	O	O
,	O	O
aged	O	O
50-79	O	O
years	O	O
,	O	O
were	O	O
recruited	O	O
.	O	O

Twenty-nine	O	O
of	O	O
them	O	O
were	O	O
blindly	O	O
randomised	O	O
to	O	O
tactile	Other	O
massage	Other	O
(	Other	O
TM	Other	O
)	Other	O
and	O	O
16	O	O
of	O	O
them	O	O
to	O	O
the	O	O
control	Control	O
group	O	O
,	O	O
rest	Control	O
to	Control	O
music	Control	O
(	Control	O
RTM	Control	O
)	Control	O
.	Control	O

Ten	O	O
interventions	O	O
were	O	O
given	O	O
during	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
26	O	O
weeks	O	O
of	O	O
follow	O	O
up	O	O
.	O	O

Salivary	O	O
cortisol	O	O
was	O	O
collected	O	O
at	O	O
8	O	O
am	O	O
,	O	O
1	O	O
pm	O	O
,	O	O
8	O	O
pm	O	O
,	O	O
and	O	O
8	O	O
am	O	O
the	O	O
next	O	O
day	O	O
,	O	O
on	O	O
five	O	O
occasions	O	O
.	O	O

With	O	O
the	O	O
first	O	O
and	O	O
eighth	O	O
interventions	O	O
,	O	O
it	O	O
was	O	O
collected	O	O
immediately	O	O
before	O	O
and	O	O
after	O	O
intervention	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
The	O	O
primary	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
and	O	O
compare	O	O
cortisol	O	O
concentrations	O	O
before	O	O
and	O	O
immediately	O	O
after	O	O
intervention	O	O
and	O	O
also	O	O
during	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
impact	O	O
of	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
body	O	O
mass	O	O
index	O	O
(	O	O
BMI	O	O
)	O	O
,	O	O
duration	O	O
and	O	O
severity	O	O
of	O	O
PD	O	O
,	O	O
effects	O	O
of	O	O
interventional	O	O
time-point	O	O
of	O	O
the	O	O
day	O	O
,	O	O
and	O	O
levodopa	O	O
doses	O	O
on	O	O
cortisol	O	O
concentration	O	O
.	O	O

RESULTS	O	O
The	O	O
median	O	O
cortisol	O	O
concentrations	O	O
for	O	O
all	O	O
participants	O	O
were	O	O
16.0	O	O
,	O	O
5.8	O	O
,	O	O
2.8	O	O
,	O	O
and	O	O
14.0	O	O
nmol/L	O	O
at	O	O
baseline	O	O
,	O	O
later	O	O
reproduced	O	O
four	O	O
times	O	O
without	O	O
significant	O	O
differences	O	O
.	O	O

Cortisol	O	O
concentrations	O	O
decreased	O	O
significantly	O	O
after	O	O
TM	Physical	O
intervention	O	O
but	O	O
no	O	O
change	O	O
in	O	O
diurnal	O	O
salivary	O	O
cortisol	O	O
pattern	O	O
was	O	O
found	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
reduced	O	O
salivary	O	O
cortisol	O	O
concentrations	O	O
immediately	O	O
after	O	O
the	O	O
interventions	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
previous	O	O
studies	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
TM	Physical	O
and	O	O
control	O	O
groups	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
correlations	O	O
between	O	O
cortisol	O	O
concentrations	O	O
and	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
BMI	O	O
,	O	O
time-point	O	O
for	O	O
intervention	O	O
,	O	O
time	O	O
interval	O	O
between	O	O
anti-parkinson	O	O
pharmacy	O	O
intake	O	O
and	O	O
sampling	O	O
,	O	O
levodopa	O	O
doses	O	O
,	O	O
duration	O	O
,	O	O
or	O	O
severity	O	O
of	O	O
PD	O	O
.	O	O

CONCLUSIONS	O	O
Diurnal	O	O
salivary	O	O
cortisol	O	O
rhythm	O	O
was	O	O
normal	O	O
.	O	O

Salivary	O	O
cortisol	O	O
concentrations	O	O
were	O	O
significantly	O	O
reduced	O	O
after	O	O
the	O	O
TM	Physical	O
intervention	O	O
and	O	O
after	O	O
RTM	Control	O
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
and	O	O
no	O	O
sustained	O	O
long-term	O	O
effect	O	O
.	O	O

No	O	O
associations	O	O
were	O	O
seen	O	O
between	O	O
salivary	O	O
cortisol	O	O
concentration	O	O
and	O	O
clinical	O	O
and/or	O	O
pharmacological	O	O
characteristics	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrial.gov	O	O
,	O	O
NCT01734876	O	O
and	O	O
FoU	O	O
Sweden	O	O
108881	O	O
.	O	O

Long-term	O	O
evaluation	O	O
of	O	O
tamsulosin	Pharmacological	O
in	O	O
benign	O	O
prostatic	O	O
hyperplasia	O	O
:	O	O
placebo-controlled	Control	Control
,	O	O
double-blind	O	O
extension	O	O
of	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

Tamsulosin	O	O
Investigator	O	O
Group	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
evaluate	O	O
the	O	O
long-term	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
once-daily	O	O
tamsulosin	Pharmacological	O
(	O	O
0.4	O	O
and	O	O
0.8	O	O
mg	O	O
)	O	O
,	O	O
a	O	O
unique	O	O
selective	O	O
alpha1A-adrenoceptor	O	O
antagonist	O	O
in	O	O
patients	O	O
with	O	O
benign	O	O
prostatic	O	O
hyperplasia	O	O
(	O	O
BPH	O	O
)	O	O
.	O	O

METHODS	O	O
This	O	O
trial	O	O
extended	O	O
a	O	O
13-week	O	O
,	O	O
Phase	O	O
III	O	O
multicenter	O	O
placebo-controlled	O	O
,	O	O
double-blind	O	O
outpatient	O	O
trial	O	O
for	O	O
an	O	O
additional	O	O
40	O	O
weeks	O	O
.	O	O

Of	O	O
618	O	O
patients	O	O
,	O	O
418	O	O
(	O	O
68	O	O
%	O	O
)	O	O
continued	O	O
into	O	O
the	O	O
extension	O	O
phase	O	O
on	O	O
the	O	O
same	O	O
double-blind	O	O
medication	O	O
and	O	O
dose	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
parameters	O	O
were	O	O
total	O	O
American	O	O
Urological	O	O
Association	O	O
(	O	O
AUA	O	O
)	O	O
symptom	O	O
score	O	O
and	O	O
maximum	O	O
urinary	O	O
flow	O	O
(	O	O
Qmax	O	O
)	O	O
.	O	O

RESULTS	O	O
The	O	O
mean	O	O
changes	O	O
in	O	O
AUA	O	O
symptom	O	O
score	O	O
from	O	O
baseline	O	O
to	O	O
end	O	O
point	O	O
were	O	O
statistically	O	O
significant	O	O
in	O	O
all	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Significant	O	O
improvements	O	O
were	O	O
observed	O	O
in	O	O
Qmax	O	O
for	O	O
both	O	O
tamsulosin	Pharmacological	O
groups	O	O
but	O	O
not	O	O
for	O	O
the	O	O
placebo	Control	O
group	O	O
.	O	O

The	O	O
statistically	O	O
significant	O	O
improvements	O	O
from	O	O
baseline	O	O
in	O	O
efficacy	O	O
parameters	O	O
observed	O	O
for	O	O
each	O	O
tamsulosin	Pharmacological	O
group	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
13-week	O	O
Phase	O	O
III	O	O
trial	O	O
were	O	O
maintained	O	O
during	O	O
the	O	O
long-term	O	O
extension	O	O
phase	O	O
.	O	O

Tamsulosin	O	O
at	O	O
both	O	O
dosages	O	O
was	O	O
well	O	O
tolerated	O	O
as	O	O
maintenance	O	O
therapy	O	O
.	O	O

Clinically	O	O
significant	O	O
orthostatic	O	O
hypotension	O	O
was	O	O
not	O	O
observed	O	O
.	O	O

Vital	O	O
sign	O	O
changes	O	O
in	O	O
either	O	O
hypertensive	O	O
or	O	O
normotensive	O	O
patients	O	O
were	O	O
not	O	O
clinically	O	O
significantly	O	O
different	O	O
across	O	O
the	O	O
three	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Tamsulosin	Pharmacological	O
once-daily	O	O
at	O	O
0.4	O	O
or	O	O
0.8	O	O
mg	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
safe	O	O
,	O	O
and	O	O
well	O	O
tolerated	O	O
in	O	O
the	O	O
target	O	O
BPH	O	O
population	O	O
during	O	O
long-term	O	O
use	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
evaluator-blind	O	O
,	O	O
multicenter	O	O
comparison	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
Perlane	Pharmacological	Pharmacological
versus	O	O
Zyplast	Pharmacological	Pharmacological
in	O	O
the	O	O
correction	O	O
of	O	O
nasolabial	O	O
folds	O	O
.	O	O

Bovine	Pharmacological	O
collagen	Pharmacological	O
is	O	O
widely	O	O
used	O	O
as	O	O
a	O	O
dermal	O	O
filler	O	O
for	O	O
facial	O	O
soft-tissue	O	O
augmentation	O	O
,	O	O
but	O	O
it	O	O
provides	O	O
only	O	O
temporary	O	O
cosmetic	O	O
improvement	O	O
.	O	O

Nonanimal	Pharmacological	Pharmacological
stabilized	Pharmacological	Pharmacological
hyaluronic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
has	O	O
reduced	O	O
potential	O	O
for	O	O
immunogenicity	O	O
and	O	O
hypersensitivity	O	O
and	O	O
may	O	O
provide	O	O
a	O	O
more	O	O
durable	O	O
aesthetic	O	O
result	O	O
.	O	O

Sixty-eight	O	O
patients	O	O
with	O	O
prominent	O	O
nasolabial	O	O
folds	O	O
were	O	O
randomized	O	O
to	O	O
intradermal	O	O
treatment	O	O
with	O	O
nonanimal	Pharmacological	Pharmacological
stabilized	Pharmacological	Pharmacological
hyaluronic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
gel	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
Perlane	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
and	O	O
bovine	Pharmacological	O
collagen	Pharmacological	O
(	Pharmacological	O
Zyplast	Pharmacological	O
)	Pharmacological	O
on	O	O
contralateral	O	O
sides	O	O
of	O	O
the	O	O
face	O	O
.	O	O

On	O	O
achievement	O	O
of	O	O
optimal	O	O
cosmetic	O	O
result	O	O
(	O	O
baseline	O	O
)	O	O
,	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
for	O	O
6	O	O
months	O	O
;	O	O
bilateral	O	O
retreatment	O	O
with	O	O
Perlane	Pharmacological	O
was	O	O
offered	O	O
at	O	O
6	O	O
or	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
.	O	O

Responses	O	O
were	O	O
evaluated	O	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
9	O	O
,	O	O
and	O	O
12	O	O
months	O	O
after	O	O
baseline	O	O
.	O	O

Investigator-based	O	O
and	O	O
patient-based	O	O
ratings	O	O
indicated	O	O
that	O	O
Perlane	Pharmacological	O
was	O	O
more	O	O
effective	O	O
than	O	O
Zyplast	Pharmacological	O
in	O	O
maintaining	O	O
cosmetic	O	O
correction	O	O
.	O	O

According	O	O
to	O	O
investigator-based	O	O
Wrinkle	O	O
Severity	O	O
Rating	O	O
Scale	O	O
assessments	O	O
at	O	O
6	O	O
and	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
,	O	O
Perlane	Pharmacological	O
was	O	O
superior	O	O
in	O	O
50.0	O	O
percent	O	O
and	O	O
48.8	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
Zyplast	Pharmacological	O
was	O	O
superior	O	O
in	O	O
10.3	O	O
percent	O	O
and	O	O
14.0	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
<	O	O
0.0004	O	O
)	O	O
.	O	O

Investigator-based	O	O
Global	O	O
Aesthetic	O	O
Improvement	O	O
Scale	O	O
assessment	O	O
at	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
indicated	O	O
that	O	O
Perlane	Pharmacological	O
was	O	O
superior	O	O
in	O	O
48.8	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
whereas	O	O
Zyplast	Pharmacological	O
was	O	O
superior	O	O
in	O	O
14.0	O	O
percent	O	O
of	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0.0025	O	O
)	O	O
.	O	O

Optimal	O	O
cosmetic	O	O
result	O	O
was	O	O
achieved	O	O
with	O	O
a	O	O
smaller	O	O
volume	O	O
of	O	O
Perlane	Pharmacological	O
than	O	O
Zyplast	Pharmacological	O
(	O	O
mean	O	O
,	O	O
1.2	O	O
ml	O	O
versus	O	O
2.1	O	O
ml	O	O
)	O	O
.	O	O

Local	O	O
injection-site	O	O
reactions	O	O
(	O	O
redness	O	O
,	O	O
swelling	O	O
,	O	O
pruritus	O	O
,	O	O
and	O	O
induration	O	O
)	O	O
were	O	O
less	O	O
frequent	O	O
with	O	O
Perlane	Pharmacological	O
than	O	O
with	O	O
Zyplast	Pharmacological	O
.	Pharmacological	O

Delayed-onset	O	O
reactions	O	O
were	O	O
rare	O	O
and	O	O
did	O	O
not	O	O
reoccur	O	O
after	O	O
Perlane	Pharmacological	O
retreatment	O	O
.	O	O

Perlane	Pharmacological	O
has	O	O
acceptable	O	O
long-term	O	O
safety	O	O
and	O	O
offers	O	O
a	O	O
longer-lasting	O	O
aesthetic	O	O
improvement	O	O
than	O	O
Zyplast	Pharmacological	O
.	Pharmacological	O

Perioperative	O	O
myocardial	O	O
infarctions	O	O
are	O	O
common	O	O
and	O	O
often	O	O
unrecognized	O	O
in	O	O
patients	O	O
undergoing	O	O
hip	O	O
fracture	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
prospective	O	O
cohort	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
incidence	O	O
and	O	O
characteristics	O	O
of	O	O
acute	O	O
myocardial	O	O
infarction	O	O
in	O	O
patients	O	O
undergoing	O	O
surgery	O	O
for	O	O
acute	O	O
hip	O	O
fracture	O	O
.	O	O

METHODS	O	O
A	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
200	O	O
,	O	O
68	O	O
men	O	O
)	O	O
referred	O	O
to	O	O
acute	Surgical	O
surgical	Surgical	O
correction	Surgical	O
of	Surgical	O
hip	Surgical	O
fracture	Surgical	O
was	O	O
studied	O	O
.	O	O

Troponin	Other	O
T	Other	O
(	Other	O
TnT	Other	O
)	Other	O
measurements	Other	O
and	O	O
electrocardiographic	Other	O
(	Other	O
ECG	Other	O
)	Other	O
recordings	Other	O
were	O	O
performed	O	O
at	O	O
admission	O	O
,	O	O
before	O	O
operation	O	O
,	O	O
and	O	O
on	O	O
the	O	O
first	O	O
and	O	O
2nd	O	O
postoperative	O	O
days	O	O
,	O	O
which	O	O
were	O	O
used	O	O
for	O	O
diagnosis	O	O
.	O	O

RESULTS	O	O
The	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
ranged	O	O
from	O	O
32	O	O
to	O	O
98	O	O
years	O	O
(	O	O
mean	O	O
,	O	O
80.8	O	O
years	O	O
)	O	O
,	O	O
and	O	O
65	O	O
patients	O	O
had	O	O
a	O	O
history	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

A	O	O
significant	O	O
rise	O	O
in	O	O
TnT	O	O
as	O	O
a	O	O
sign	O	O
of	O	O
myocardial	O	O
infarction	O	O
was	O	O
observed	O	O
in	O	O
71	O	O
patients	O	O
(	O	O
35.5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
25	O	O
of	O	O
them	O	O
had	O	O
a	O	O
TnT	O	O
elevation	O	O
exceeding	O	O
five	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

TnT	O	O
elevation	O	O
was	O	O
observed	O	O
in	O	O
36	O	O
patients	O	O
(	O	O
51	O	O
%	O	O
)	O	O
already	O	O
before	O	O
surgery	O	O
.	O	O

Seven	O	O
patients	O	O
(	O	O
10	O	O
%	O	O
)	O	O
had	O	O
ST	O	O
elevation	O	O
myocardial	O	O
infarction	O	O
,	O	O
23	O	O
patients	O	O
(	O	O
32	O	O
%	O	O
)	O	O
had	O	O
new	O	O
ST	O	O
depressions	O	O
,	O	O
and	O	O
21	O	O
patients	O	O
(	O	O
30	O	O
%	O	O
)	O	O
had	O	O
no	O	O
new	O	O
ST	O	O
segment	O	O
changes	O	O
in	O	O
the	O	O
serial	O	O
electrocardiographic	O	O
recordings	O	O
.	O	O

In	O	O
40	O	O
patients	O	O
(	O	O
56	O	O
%	O	O
)	O	O
,	O	O
the	O	O
perioperative	O	O
myocardial	O	O
infarction	O	O
was	O	O
the	O	O
first	O	O
manifestation	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

Multivariate	O	O
logistic	O	O
regression	O	O
revealed	O	O
that	O	O
old	O	O
age	O	O
(	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
,	O	O
1.06	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
1.02-1.10	O	O
;	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
,	O	O
earlier	O	O
revascularization	O	O
(	O	O
OR	O	O
,	O	O
3.29	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.12-9.73	O	O
;	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
and	O	O
heart	O	O
failure	O	O
(	O	O
OR	O	O
,	O	O
2.42	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.04-5.61	O	O
;	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
were	O	O
independent	O	O
predictors	O	O
of	O	O
TnT	O	O
elevation	O	O
.	O	O

Majority	O	O
of	O	O
myocardial	O	O
infarctions	O	O
were	O	O
asymptomatic	O	O
or	O	O
unrecognized	O	O
.	O	O

Evidence-based	O	O
medications	O	O
of	O	O
myocardial	O	O
infarction	O	O
were	O	O
seldom	O	O
started	O	O
and	O	O
cardiologist	O	O
was	O	O
consulted	O	O
in	O	O
12	O	O
patients	O	O
(	O	O
16.9	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Patients	O	O
with	O	O
hip	O	O
fracture	O	O
often	O	O
develop	O	O
asymptomatic	O	O
and	O	O
clinically	O	O
unrecognized	O	O
perioperative	O	O
myocardial	O	O
infarctions	O	O
.	O	O

Earlier	O	O
diagnosis	O	O
and	O	O
appropriate	O	O
treatment	O	O
of	O	O
cardiac	O	O
infarction	O	O
may	O	O
improve	O	O
survival	O	O
of	O	O
hip	O	O
fracture	O	O
patients	O	O
.	O	O

LEVEL	O	O
OF	O	O
EVIDENCE	O	O
Epidemiologic	O	O
study	O	O
,	O	O
level	O	O
III	O	O
.	O	O

Effect	O	O
of	O	O
testosterone	Pharmacological	Pharmacological
and	O	O
a	O	O
nutritional	Pharmacological	O
supplement	Pharmacological	O
,	O	O
alone	O	O
and	O	O
in	O	O
combination	O	O
,	O	O
on	O	O
hospital	O	O
admissions	O	O
in	O	O
undernourished	O	O
older	O	O
men	O	O
and	O	O
women	O	O
.	O	O

BACKGROUND	O	O
In	O	O
older	O	O
people	O	O
,	O	O
undernutrition	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
hospitalization	O	O
rates	O	O
and	O	O
mortality	O	O
.	O	O

Because	O	O
weight	O	O
loss	O	O
in	O	O
older	O	O
people	O	O
often	O	O
reflects	O	O
a	O	O
disproportionate	O	O
reduction	O	O
of	O	O
skeletal	O	O
muscle	O	O
,	O	O
anabolic	O	O
treatments	O	O
may	O	O
be	O	O
beneficial	O	O
.	O	O

OBJECTIVE	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
hypothesis	O	O
that	O	O
testosterone	Pharmacological	Pharmacological
treatment	O	Pharmacological
and	O	O
a	O	O
nutritional	Pharmacological	O
supplement	Pharmacological	O
have	O	O
additive	O	O
benefits	O	O
.	O	O

DESIGN	O	O
Oral	O	O
testosterone	Pharmacological	Pharmacological
undecanoate	Pharmacological	Pharmacological
(	O	O
40	O	O
mg	O	O
daily	O	O
for	O	O
women	O	O
,	O	O
80	O	O
mg	O	O
twice	O	O
daily	O	O
for	O	O
men	O	O
)	O	O
and	O	O
an	O	O
oral	O	Pharmacological
nutritional	Pharmacological	Pharmacological
supplement	Pharmacological	Pharmacological
(	O	O
475	O	O
kcal/d	O	O
)	O	O
were	O	O
administered	O	O
,	O	O
alone	O	O
or	O	O
combined	O	O
,	O	O
for	O	O
1	O	O
y	O	O
to	O	O
49	O	O
community-dwelling	O	O
,	O	O
undernourished	O	O
people	O	O
[	O	O
Mini	O	O
Nutritional	O	O
Assessment	O	O
score	O	O
<	O	O
24	O	O
and	O	O
low	O	O
body	O	O
weight	O	O
(	O	O
body	O	O
mass	O	O
index	O	O
,	O	O
in	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
:	O	O
<	O	O
22	O	O
)	O	O
or	O	O
recent	O	O
weight	O	O
loss	O	O
(	O	O
>	O	O
7.5	O	O
%	O	O
over	O	O
3	O	O
mo	O	O
)	O	O
]	O	O
aged	O	O
>	O	O
65	O	O
y	O	O
(	O	O
mean	O	O
age	O	O
:	O	O
77	O	O
y	O	O
;	O	O
26	O	O
women	O	O
and	O	O
23	O	O
men	O	O
)	O	O
.	O	O

Hospital	O	O
admissions	O	O
and	O	O
other	O	O
variables	O	O
were	O	O
assessed	O	O
.	O	O

RESULTS	O	O
In	O	O
subjects	O	O
receiving	O	O
combined	O	Pharmacological
testosterone	Pharmacological	Pharmacological
and	O	Pharmacological
nutritional	Pharmacological	Pharmacological
supplements	Pharmacological	Pharmacological
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
hospital	O	O
admissions	O	O
,	O	O
whereas	O	O
there	O	O
were	O	O
9	O	O
admissions	O	O
(	O	O
2	O	O
elective	O	O
)	O	O
in	O	O
13	O	O
subjects	O	O
in	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
4	O	O
in	O	O
the	O	O
testosterone-treated	Pharmacological	O
group	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
and	O	O
5	O	O
in	O	O
the	O	O
supplement-treated	Pharmacological	O
group	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0.06	O	O
with	O	O
no-treatment	O	O
compared	O	O
with	O	O
combined	O	O
treatment	O	O
.	O	O

When	O	O
compared	O	O
with	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
the	O	O
combined-treatment	Pharmacological	O
group	O	O
had	O	O
significantly	O	O
fewer	O	O
subjects	O	O
admitted	O	O
to	O	O
hospital	O	O
(	O	O
0	O	O
compared	O	O
with	O	O
5	O	O
,	O	O
P	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
fewer	O	O
days	O	O
in	O	O
hospital	O	O
(	O	O
0	O	O
compared	O	O
with	O	O
74	O	O
,	O	O
P	O	O
=	O	O
0.041	O	O
)	O	O
,	O	O
and	O	O
a	O	O
longer	O	O
time	O	O
to	O	O
hospital	O	O
admission	O	O
(	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
undernourished	O	O
older	O	O
people	O	O
,	O	O
combined	O	O
treatment	O	O
with	O	O
testosterone	Pharmacological	O
and	O	O
nutritional	Pharmacological	O
supplementation	Pharmacological	O
reduced	O	O
the	O	O
number	O	O
of	O	O
people	O	O
hospitalized	O	O
and	O	O
the	O	O
duration	O	O
of	O	O
hospital	O	O
admissions	O	O
,	O	O
which	O	O
are	O	O
important	O	O
endpoints	O	O
in	O	O
this	O	O
group	O	O
.	O	O

Larger	O	O
,	O	O
confirmatory	O	O
studies	O	O
are	O	O
now	O	O
needed	O	O
.	O	O

This	O	O
trial	O	O
was	O	O
registered	O	O
before	O	O
commencement	O	O
at	O	O
clinical	O	O
trials.gov	O	O
as	O	O
NCT00117000	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
therapeutic	O	O
effects	O	O
of	O	O
a	O	O
hippotherapy	Physical	O
simulator	Physical	O
in	O	O
children	O	O
with	O	O
cerebral	O	O
palsy	O	O
:	O	O
a	O	O
stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
whether	O	O
hippotherapy	Physical	O
(	Physical	O
when	Physical	O
applied	Physical	O
by	Physical	O
a	Physical	O
simulator	Physical	O
)	Physical	O
improves	O	O
postural	O	O
control	O	O
and	O	O
balance	O	O
in	O	O
children	O	O
with	O	O
cerebral	O	O
palsy	O	O
.	O	O

DESIGN	O	O
Stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
with	O	O
an	O	O
independent	O	O
assessor	O	O
.	O	O

Stratification	O	O
was	O	O
made	O	O
by	O	O
gross	O	O
motor	O	O
function	O	O
classification	O	O
system	O	O
levels	O	O
,	O	O
and	O	O
allocation	O	O
was	O	O
concealed	O	O
.	O	O

SUBJECTS	O	O
Children	O	O
between	O	O
4	O	O
and	O	O
18	O	O
years	O	O
old	O	O
with	O	O
cerebral	O	O
palsy	O	O
.	O	O

INTERVENTIONS	O	O
Participants	O	O
were	O	O
randomized	O	O
to	O	O
an	O	O
intervention	Physical	Educational
(	Physical	Educational
simulator	Physical	Educational
ON	Physical	Educational
)	Physical	Educational
or	O	O
control	Control	Control
(	Control	Control
simulator	Control	Control
OFF	Control	Control
)	Control	Control
group	O	O
after	O	O
getting	O	O
informed	O	O
consent	O	O
.	O	O

Treatment	O	O
was	O	O
provided	O	O
once	O	O
a	O	O
week	O	O
(	O	O
15	O	O
minutes	O	O
)	O	O
for	O	O
10	O	O
weeks	O	O
.	O	O

MAIN	O	O
MEASURES	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
(	O	O
dimension	O	O
B	O	O
for	O	O
balance	O	O
and	O	O
the	O	O
Total	O	O
Score	O	O
)	O	O
and	O	O
Sitting	O	O
Assessment	O	O
Scale	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
baseline	O	O
(	O	O
prior	O	O
to	O	O
randomization	O	O
)	O	O
,	O	O
end	O	O
of	O	O
intervention	O	O
and	O	O
12	O	O
weeks	O	O
after	O	O
completing	O	O
the	O	O
intervention	O	O
.	O	O

RESULTS	O	O
Thirty-eight	O	O
children	O	O
participated	O	O
.	O	O

The	O	O
groups	O	O
were	O	O
balanced	O	O
at	O	O
baseline	O	O
.	O	O

Sitting	O	O
balance	O	O
(	O	O
measured	O	O
by	O	O
dimension	O	O
B	O	O
of	O	O
the	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
)	O	O
improved	O	O
significantly	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.36	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.01-0.71	O	O
)	O	O
and	O	O
the	O	O
effect	O	O
size	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
severely	O	O
disabled	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.80	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.13-1.47	O	O
)	O	O
.	O	O

The	O	O
improvements	O	O
in	O	O
sitting	O	O
balance	O	O
were	O	O
not	O	O
maintained	O	O
over	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
total	O	O
score	O	O
of	O	O
the	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
and	O	O
the	O	O
Sitting	O	O
Assessment	O	O
Scale	O	O
were	O	O
not	O	O
significant	O	O
.	O	O

CONCLUSION	O	O
Hippotherapy	Physical	O
with	O	O
a	O	O
simulator	O	O
can	O	O
improve	O	O
sitting	O	O
balance	O	O
in	O	O
cerebral	O	O
palsy	O	O
children	O	O
who	O	O
have	O	O
higher	O	O
levels	O	O
of	O	O
disability	O	O
.	O	O

However	O	O
,	O	O
this	O	O
did	O	O
not	O	O
lead	O	O
to	O	O
a	O	O
change	O	O
in	O	O
the	O	O
overall	O	O
function	O	O
of	O	O
these	O	O
children	O	O
(	O	O
Gross	O	O
Motor	O	O
Function	O	O
Classification	O	O
System	O	O
level	O	O
V	O	O
)	O	O
.	O	O

Randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	O
trial	O	O
of	O	O
oral	O	O
sirolimus	O	Pharmacological
for	O	O
restenosis	O	O
prevention	O	O
in	O	O
patients	O	O
with	O	O
in-stent	O	O
restenosis	O	O
:	O	O
the	O	O
Oral	O	O
Sirolimus	Pharmacological	O
to	O	O
Inhibit	O	O
Recurrent	O	O
In-stent	O	O
Stenosis	O	O
(	O	O
OSIRIS	O	O
)	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Despite	O	O
recent	O	O
advances	O	O
in	O	O
interventional	O	O
cardiology	O	O
,	O	O
including	O	O
the	O	O
introduction	O	O
of	O	O
drug-eluting	O	Pharmacological
stents	O	Pharmacological
for	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
,	O	O
the	O	O
treatment	O	O
of	O	O
in-stent	O	O
restenosis	O	O
(	O	O
ISR	O	O
)	O	O
remains	O	O
a	O	O
challenging	O	O
clinical	O	O
issue	O	O
.	O	O

Given	O	O
the	O	O
efficacy	O	O
of	O	O
systemic	O	O
sirolimus	O	O
administration	O	O
to	O	O
prevent	O	O
neointimal	O	O
hyperplasia	O	O
in	O	O
animal	O	O
models	O	O
and	O	O
to	O	O
halt	O	O
and	O	O
even	O	O
reverse	O	O
the	O	O
progression	O	O
of	O	O
allograft	O	O
vasculopathy	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	Control
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
a	O	O
10-day	O	O
oral	O	O
sirolimus	O	O
treatment	O	O
with	O	O
2	O	O
different	O	O
loading	O	O
regimens	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
recurrent	O	O
restenosis	O	O
in	O	O
patients	O	O
with	O	O
ISR	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Three	O	O
hundred	O	O
symptomatic	O	O
patients	O	O
with	O	O
ISR	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
1	O	O
of	O	O
3	O	O
treatment	O	O
arms	O	O
:	O	O
placebo	Control	Control
or	O	O
usual-dose	O	O
or	O	O
high-dose	O	O
sirolimus	Pharmacological	O
.	O	O

Patients	O	O
received	O	O
a	O	O
cumulative	O	O
loading	O	O
dose	O	O
of	O	O
0	O	O
,	O	O
8	O	O
,	O	O
or	O	O
24	O	O
mg	O	O
of	O	O
sirolimus	O	O
2	O	O
days	O	O
before	O	O
and	O	O
the	O	O
day	O	O
of	O	O
repeat	O	O
intervention	O	O
followed	O	O
by	O	O
maintenance	O	O
therapy	O	O
of	O	O
2	O	O
mg/d	O	O
for	O	O
7	O	O
days	O	O
.	O	O

Angiographic	O	O
restenosis	O	O
at	O	O
6-month	O	O
angiography	O	O
was	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Restenosis	O	O
was	O	O
significantly	O	O
reduced	O	O
from	O	O
42.2	O	O
%	O	O
to	O	O
38.6	O	O
%	O	O
and	O	O
to	O	O
22.1	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
sirolimus	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.005	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
the	O	O
need	O	O
for	O	O
target	O	O
vessel	O	O
revascularization	O	O
was	O	O
reduced	O	O
from	O	O
25.5	O	O
%	O	O
to	O	O
24.2	O	O
%	O	O
and	O	O
to	O	O
15.2	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.08	O	O
)	O	O
.	O	O

The	O	O
sirolimus	O	O
blood	O	O
concentration	O	O
on	O	O
the	O	O
day	O	O
of	O	O
the	O	O
procedure	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
late	O	O
lumen	O	O
loss	O	O
at	O	O
follow-up	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
patients	O	O
with	O	O
ISR	O	O
,	O	O
an	O	O
oral	O	Pharmacological
adjunctive	O	Pharmacological
sirolimus	O	Pharmacological
treatment	O	O
with	O	O
an	O	O
intensified	O	O
loading	O	O
regimen	O	O
before	O	O
coronary	O	O
intervention	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
angiographic	O	O
parameters	O	O
of	O	O
restenosis	O	O
.	O	O

Comparison	O	O
of	O	O
neodymium-doped	Surgical	Physical
yttrium	Surgical	Physical
aluminum	Surgical	Physical
garnet	Surgical	Physical
laser	Surgical	Physical
treatment	Surgical	Physical
with	O	Physical
cold	Surgical	Physical
knife	Surgical	Physical
endoscopic	Surgical	Physical
incision	Surgical	Physical
of	O	O
urethral	O	O
strictures	O	O
in	O	O
male	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
assess	O	O
the	O	O
effectiveness	O	O
of	O	O
visual	Surgical	Physical
laser	Surgical	Physical
ablation	Surgical	Physical
treatment	Surgical	Physical
with	Surgical	Physical
neodymium-doped	Surgical	Physical
yttrium	Surgical	Physical
aluminum	Surgical	Physical
garnet	Surgical	Physical
(	Surgical	Physical
Nd	Surgical	Physical
:	Surgical	Physical
YAG	Surgical	Physical
)	Surgical	Physical
laser	O	Physical
in	O	O
male	O	O
patients	O	O
with	O	O
urethral	O	O
strictures	O	O
and	O	O
to	O	O
compare	O	O
the	O	O
effects	O	O
with	O	O
those	O	O
obtained	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
Sachse	O	O
's	O	O
optical	O	O
urethrotomy	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Fifty	O	O
patients	O	O
aged	O	O
22	O	O
to	O	O
83	O	O
(	O	O
mean	O	O
age	O	O
61.8	O	O
)	O	O
with	O	O
primary	O	O
(	O	O
n	O	O
=	O	O
26	O	O
,	O	O
52	O	O
%	O	O
)	O	O
and	O	O
recurrent	O	O
(	O	O
n	O	O
=	O	O
24	O	O
,	O	O
48	O	O
%	O	O
)	O	O
urethral	O	O
strictures	O	O
0.3	O	O
to	O	O
2.4	O	O
cm	O	O
long	O	O
qualified	O	O
for	O	O
the	O	O
study	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
30	O	O
men	O	O
treated	O	O
using	O	O
visual	Surgical	O
laser	Surgical	O
ablation	Surgical	O
of	Surgical	O
urethral	Surgical	O
strictures	Surgical	O
(	Surgical	O
VLASU	Surgical	O
)	Surgical	O
with	Surgical	O
Nd	Surgical	O
:	Surgical	O
YAGlaser	Surgical	O
and	O	O
20	O	O
men	O	O
treated	O	O
by	O	O
correction	O	O
of	O	O
urethral	O	O
strictures	O	O
using	O	O
Sachse	Surgical	O
's	Surgical	O
optical	Surgical	O
urethrotomy	Surgical	O
.	O	O

RESULTS	O	O
At	O	O
12-month	O	O
follow-up	O	O
,	O	O
seven	O	O
(	O	O
35	O	O
%	O	O
)	O	O
patients	O	O
who	O	O
underwent	O	O
optical	Surgical	O
urethrotomy	Surgical	O
and	O	O
21	O	O
(	O	O
70	O	O
%	O	O
)	O	O
in	O	O
the	O	O
VLASU	Surgical	O
group	O	O
did	O	O
not	O	O
require	O	O
repetition	O	O
of	O	O
the	O	O
procedure	O	O
.	O	O

The	O	O
choice	O	O
of	O	O
VLASU	Surgical	Pharmacological
as	O	O
a	O	O
method	O	O
of	O	O
treatment	O	O
significantly	O	O
decreased	O	O
the	O	O
probability	O	O
of	O	O
therapeutic	O	O
failure	O	O
and	O	O
recurrence	O	O
of	O	O
urethral	O	O
strictures	O	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
VLASU	Surgical	O
can	O	O
be	O	O
used	O	O
as	O	O
a	O	O
method	O	O
of	O	O
treatment	O	O
of	O	O
this	O	O
disorder	O	O
.	O	O

It	O	O
is	O	O
an	O	O
effective	O	O
,	O	O
modern	O	O
,	O	O
low-invasive	O	O
,	O	O
and	O	O
repeatable	O	O
technique	O	O
and	O	O
is	O	O
technically	O	O
simple	O	O
and	O	O
easy	O	O
to	O	O
master	O	O
.	O	O

It	O	O
can	O	O
be	O	O
used	O	O
in	O	O
cases	O	O
in	O	O
which	O	O
introduction	O	O
of	O	O
a	O	O
22	O	O
Char	O	O
optical	O	O
urethrotome	O	O
into	O	O
the	O	O
stricture	O	O
site	O	O
is	O	O
impossible	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
treatment	O	O
of	O	O
multiple	O	O
strictures	O	O
during	O	O
one	O	O
procedure	O	O
.	O	O

Co-administration	O	O
of	O	O
pethidine	Pharmacological	Pharmacological
and	O	O
clonidine	Pharmacological	O
:	O	O
a	O	O
spinal	O	O
anaesthetic	O	O
technique	O	O
for	O	O
total	Surgical	O
hip	Surgical	O
replacement	Surgical	O
.	Surgical	O

Co-administration	O	O
of	O	O
pethidine	Pharmacological	Pharmacological
0.75	O	O
mg	O	O
kg-1	O	O
and	O	O
clonidine	Pharmacological	O
75	O	O
micrograms	O	O
intrathecally	O	O
provided	O	O
good	O	O
intraoperative	O	O
anaesthesia	O	O
for	O	O
total	Surgical	O
hip	Surgical	O
replacement	Surgical	O
,	O	O
similar	O	O
to	O	O
that	O	O
obtained	O	O
using	O	O
0.5	Pharmacological	O
%	Pharmacological	O
isobaric	Pharmacological	O
bupivacaine	Pharmacological	O
.	Pharmacological	O

Sensory	O	O
and	O	O
motor	O	O
block	O	O
were	O	O
of	O	O
shorter	O	O
duration	O	O
than	O	O
that	O	O
after	O	O
0.5	O	O
%	O	O
isobaric	Pharmacological	O
bupivacaine	Pharmacological	Pharmacological
and	O	O
0.5	O	O
%	O	O
isobaric	Pharmacological	O
bupivacaine	Pharmacological	Pharmacological
with	O	Pharmacological
morphine	Pharmacological	Pharmacological
0.5	O	O
mg	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
sensory	O	O
block	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
motor	O	O
block	O	O
)	O	O
.	O	O

Postoperative	O	O
morphine	Pharmacological	O
consumption	O	O
,	O	O
measured	O	O
using	O	O
a	O	O
patient-controlled	O	O
system	O	O
,	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
in	O	O
patients	O	O
in	O	O
the	O	O
bupivacaine	Pharmacological	Pharmacological
only	O	O
group	O	O
(	O	O
pethidine-clonidine	Pharmacological	O
:	O	O
median	O	O
39	O	O
mg/24	O	O
h	O	O
;	O	O
bupivacaine	Pharmacological	Pharmacological
:	O	O
median	O	O
34	O	O
mg/24	O	O
h	O	O
)	O	O
but	O	O
greater	O	O
than	O	O
that	O	O
in	O	O
the	O	O
bupivacaine-morphine	Pharmacological	O
group	O	O
(	O	O
median	O	O
8	O	O
mg/24	O	O
h	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Visual	O	O
analogue	O	O
pain	O	O
scores	O	O
after	O	O
operation	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
with	O	O
bupivacaine	Pharmacological	Pharmacological
alone	Pharmacological	O
at	O	O
all	O	O
but	O	O
one	O	O
of	O	O
the	O	O
recording	O	O
times	O	O
but	O	O
were	O	O
greater	O	O
than	O	O
those	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
bupivacaine	Pharmacological	Pharmacological
and	O	O
morphine	Pharmacological	Pharmacological
at	O	O
4	O	O
,	O	O
6	O	O
and	O	O
10	O	O
h	O	O
after	O	O
operation	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
,	O	O
P	O	O
<	O	O
0.04	O	O
,	O	O
P	O	O
<	O	O
0.02	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
did	O	O
not	O	O
offer	O	O
any	O	O
major	O	O
advantage	O	O
over	O	O
conventional	O	O
agents	O	O
.	O	O

Effect	O	O
of	O	O
a	O	O
vitamin/mineral	Pharmacological	Pharmacological
supplement	Pharmacological	Pharmacological
on	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
.	O	O

BACKGROUND	O	O
Vitamin/mineral	Pharmacological	O
supplements	Pharmacological	O
are	O	O
among	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
treatments	O	O
for	O	O
autism	O	O
,	O	O
but	O	O
the	O	O
research	O	O
on	O	O
their	O	O
use	O	O
for	O	O
treating	O	O
autism	O	O
has	O	O
been	O	O
limited	O	O
.	O	O

METHOD	O	O
This	O	O
study	O	O
is	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	Control
three	O	O
month	O	O
vitamin/mineral	Pharmacological	O
treatment	Pharmacological	O
study	Pharmacological	O
.	Pharmacological	O

The	O	O
study	O	O
involved	O	O
141	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
,	O	O
and	O	O
pre	O	O
and	O	O
post	O	O
symptoms	O	O
of	O	O
autism	O	O
were	O	O
assessed	O	O
.	O	O

None	O	O
of	O	O
the	O	O
participants	O	O
had	O	O
taken	O	O
a	O	O
vitamin/mineral	Pharmacological	O
supplement	Pharmacological	O
in	O	O
the	O	O
two	O	O
months	O	O
prior	O	O
to	O	O
the	O	O
start	O	O
of	O	O
the	O	O
study	O	O
.	O	O

For	O	O
a	O	O
subset	O	O
of	O	O
the	O	O
participants	O	O
(	O	O
53	O	O
children	O	O
ages	O	O
5-16	O	O
)	O	O
pre	O	O
and	O	O
post	O	O
measurements	O	O
of	O	O
nutritional	O	O
and	O	O
metabolic	O	O
status	O	O
were	O	O
also	O	O
conducted	O	O
.	O	O

RESULTS	O	O
The	O	O
vitamin/mineral	Pharmacological	O
supplement	Pharmacological	O
was	O	O
generally	O	O
well-tolerated	O	O
,	O	O
and	O	O
individually	O	O
titrated	O	O
to	O	O
optimum	O	O
benefit	O	O
.	O	O

Levels	O	O
of	O	O
many	O	O
vitamins	O	O
,	O	O
minerals	O	O
,	O	O
and	O	O
biomarkers	O	O
improved/increased	O	O
showing	O	O
good	O	O
compliance	O	O
and	O	O
absorption	O	O
.	O	O

Statistically	O	O
significant	O	O
improvements	O	O
in	O	O
metabolic	O	O
status	O	O
were	O	O
many	O	O
including	O	O
:	O	O
total	O	O
sulfate	O	O
(	O	O
+17	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
,	O	O
S-adenosylmethionine	O	O
(	O	O
SAM	O	O
;	O	O
+6	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.003	O	O
)	O	O
,	O	O
reduced	O	O
glutathione	O	O
(	O	O
+17	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.0008	O	O
)	O	O
,	O	O
ratio	O	O
of	O	O
oxidized	O	O
glutathione	O	O
to	O	O
reduced	O	O
glutathione	O	O
(	O	O
GSSG	O	O
:	O	O
GSH	O	O
;	O	O
-27	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
,	O	O
nitrotyrosine	O	O
(	O	O
-29	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
,	O	O
ATP	O	O
(	O	O
+25	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.000001	O	O
)	O	O
,	O	O
NADH	O	O
(	O	O
+28	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.0002	O	O
)	O	O
,	O	O
and	O	O
NADPH	O	O
(	O	O
+30	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

Most	O	O
of	O	O
these	O	O
metabolic	O	O
biomarkers	O	O
improved	O	O
to	O	O
normal	O	O
or	O	O
near-normal	O	O
levels.The	O	O
supplement	Pharmacological	O
group	O	O
had	O	O
significantly	O	O
greater	O	O
improvements	O	O
than	O	O
the	O	O
placebo	Control	O
group	O	O
on	O	O
the	O	O
Parental	O	O
Global	O	O
Impressions-Revised	O	O
(	O	O
PGI-R	O	O
,	O	O
Average	O	O
Change	O	O
,	O	O
p	O	O
=	O	O
0.008	O	O
)	O	O
,	O	O
and	O	O
on	O	O
the	O	O
subscores	O	O
for	O	O
Hyperactivity	O	O
(	O	O
p	O	O
=	O	O
0.003	O	O
)	O	O
,	O	O
Tantrumming	O	O
(	O	O
p	O	O
=	O	O
0.009	O	O
)	O	O
,	O	O
Overall	O	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
,	O	O
and	O	O
Receptive	O	O
Language	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
.	O	O

For	O	O
the	O	O
other	O	O
three	O	O
assessment	O	O
tools	O	O
the	O	O
difference	O	O
between	O	O
treatment	O	O
group	O	O
and	O	O
placebo	O	Control
group	O	O
was	O	O
not	O	O
statistically	O	O
significant.Regression	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
degree	O	O
of	O	O
improvement	O	O
on	O	O
the	O	O
Average	O	O
Change	O	O
of	O	O
the	O	O
PGI-R	O	O
was	O	O
strongly	O	O
associated	O	O
with	O	O
several	O	O
biomarkers	O	O
(	O	O
adj	O	O
.	O	O

R2	O	O
=	O	O
0.61	O	O
,	O	O
p	O	O
<	O	O
0.0005	O	O
)	O	O
with	O	O
the	O	O
initial	O	O
levels	O	O
of	O	O
biotin	O	O
and	O	O
vitamin	O	O
K	O	O
being	O	O
the	O	O
most	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
;	O	O
both	O	O
biotin	O	O
and	O	O
vitamin	O	O
K	O	O
are	O	O
made	O	O
by	O	O
beneficial	O	O
intestinal	O	O
flora	O	O
.	O	O

CONCLUSIONS	O	O
Oral	O	O
vitamin/mineral	Pharmacological	Pharmacological
supplementation	Pharmacological	Pharmacological
is	O	O
beneficial	O	O
in	O	O
improving	O	O
the	O	O
nutritional	O	O
and	O	O
metabolic	O	O
status	O	O
of	O	O
children	O	O
with	O	O
autism	O	O
,	O	O
including	O	O
improvements	O	O
in	O	O
methylation	O	O
,	O	O
glutathione	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
sulfation	O	O
,	O	O
ATP	O	O
,	O	O
NADH	O	O
,	O	O
and	O	O
NADPH	O	O
.	O	O

The	O	O
supplement	Pharmacological	O
group	O	O
had	O	O
significantly	O	O
greater	O	O
improvements	O	O
than	O	O
did	O	O
the	O	O
placebo	Control	Control
group	O	O
on	O	O
the	O	O
PGI-R	O	O
Average	O	O
Change	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
a	O	O
vitamin/mineral	Pharmacological	O
supplement	Pharmacological	O
is	O	O
a	O	O
reasonable	O	O
adjunct	O	O
therapy	O	O
to	O	O
consider	O	O
for	O	O
most	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
NUMBER	O	O
NCT01225198	O	O
.	O	O

Combined	Pharmacological	O
typhoid	Pharmacological	O
fever	Pharmacological	O
and	Pharmacological	O
hepatitis	Pharmacological	O
A	Pharmacological	O
vaccine	Pharmacological	O
:	Pharmacological	O
comparison	O	O
of	O	O
immunogenicity	O	O
and	O	O
safety	O	O
to	O	O
concomitant	O	Pharmacological
monovalent	O	Pharmacological
vaccine	O	Pharmacological
over	O	O
3	O	O
years	O	O
.	O	O

BACKGROUND	O	O
The	O	O
safety	O	O
and	O	O
immunogenicity	O	O
of	O	O
Viatim	Pharmacological	O
,	O	O
a	O	O
combined	Pharmacological	O
hepatitis	Pharmacological	O
A	Pharmacological	O
(	Pharmacological	O
HA	Pharmacological	O
)	Pharmacological	O
and	Pharmacological	O
typhoid	Pharmacological	O
fever	Pharmacological	O
(	Pharmacological	O
Vi	Pharmacological	O
)	Pharmacological	O
vaccine	Pharmacological	O
,	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
monovalent	Pharmacological	O
component	Pharmacological	O
vaccines	Pharmacological	O
up	O	O
to	O	O
and	O	O
1	O	O
month	O	O
after	O	O
a	O	O
booster	O	O
dose	O	O
at	O	O
3	O	O
years	O	O
.	O	O

METHODS	O	O
Healthy	O	O
,	O	O
adult	O	O
volunteers	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
Viatim	Pharmacological	Pharmacological
(	O	O
group	O	O
A	O	O
,	O	O
n	O	O
=	O	O
179	O	O
)	O	O
or	O	O
separate	Pharmacological	Pharmacological
HA	Pharmacological	Pharmacological
and	Pharmacological	Pharmacological
Vi	Pharmacological	Pharmacological
vaccines	Pharmacological	Pharmacological
(	O	O
group	O	O
B	O	O
,	O	O
n	O	O
=	O	O
181	O	O
)	O	O
;	O	O
subgroups	O	O
were	O	O
boosted	O	O
after	O	O
3	O	O
years	O	O
with	O	O
Viatim	Pharmacological	Pharmacological
(	O	O
groups	O	O
C	O	O
and	O	O
D	O	O
,	O	O
n	O	O
=	O	O
56	O	O
and	O	O
46	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Local	O	O
and	O	O
systemic	O	O
reactions	O	O
were	O	O
recorded	O	O
for	O	O
28	O	O
days	O	O
postvaccination	O	O
.	O	O

Seroconversion	O	O
and	O	O
seroprotection	O	O
rates	O	O
and	O	O
geometric	O	O
mean	O	O
antibody	O	O
concentrations	O	O
were	O	O
measured	O	O
at	O	O
14	O	O
and	O	O
28	O	O
days	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postvaccination	O	O
,	O	O
and	O	O
28	O	O
days	O	O
after	O	O
the	O	O
booster	O	O
dose	O	O
.	O	O

RESULTS	O	O
Local	O	O
and	O	O
systemic	O	O
safety	O	O
profiles	O	O
were	O	O
equivalent	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Immediate	O	O
local	O	O
reactions	O	O
were	O	O
infrequent	O	O
(	O	O
1	O	O
in	O	O
group	O	O
A	O	O
and	O	O
2	O	O
in	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Local	O	O
reactions	O	O
,	O	O
consisting	O	O
mostly	O	O
of	O	O
mild	O	O
or	O	O
moderate	O	O
pain	O	O
,	O	O
were	O	O
least	O	O
frequent	O	O
with	O	O
monovalent	O	Pharmacological
HA	O	Pharmacological
.	O	O

Antibody	O	O
concentrations	O	O
to	O	O
both	O	O
antigens	O	O
were	O	O
similar	O	O
in	O	O
groups	O	O
A	O	O
and	O	O
B	O	O
,	O	O
in	O	O
which	O	O
HA	O	O
seroprotection	O	O
rates	O	O
(	O	O
>	O	O
or	O	O
=	O	O
20	O	O
mIU/mL	O	O
)	O	O
were	O	O
respectively	O	O
,	O	O
98.7	O	O
%	O	O
and	O	O
100	O	O
%	O	O
at	O	O
day	O	O
28	O	O
,	O	O
and	O	O
99.1	O	O
%	O	O
and	O	O
99.0	O	O
%	O	O
after	O	O
3	O	O
years	O	O
,	O	O
achieving	O	O
100	O	O
%	O	O
after	O	O
the	O	O
booster	O	O
.	O	O

Vi	O	O
seroprotection	O	O
rates	O	O
(	O	O
>	O	O
or	O	O
=	O	O
1	O	O
microg/mL	O	O
)	O	O
of	O	O
85.2	O	O
%	O	O
and	O	O
84.9	O	O
%	O	O
after	O	O
28	O	O
days	O	O
fell	O	O
to	O	O
32.1	O	O
%	O	O
and	O	O
35.6	O	O
%	O	O
after	O	O
3	O	O
years	O	O
,	O	O
increasing	O	O
to	O	O
67.3	O	O
%	O	O
and	O	O
69.8	O	O
%	O	O
after	O	O
the	O	O
booster	O	O
dose	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
combined	Pharmacological	O
HA/Vi	Pharmacological	O
vaccine	Pharmacological	O
,	Pharmacological	O
Viatim	Pharmacological	O
,	O	O
had	O	O
equivalent	O	O
tolerability	O	O
and	O	O
safety	O	O
and	O	O
was	O	O
as	O	O
rapidly	O	O
immunogenic	O	O
as	O	O
its	O	O
component	O	O
monovalent	O	O
vaccines	O	O
when	O	O
given	O	O
concurrently	O	O
.	O	O

A	O	O
booster	O	O
dose	O	O
after	O	O
3	O	O
years	O	O
significantly	O	O
increased	O	O
antibody	O	O
levels	O	O
with	O	O
some	O	O
evidence	O	O
of	O	O
relative	O	O
hyporesponsiveness	O	O
of	O	O
the	O	O
typhoid	O	O
response	O	O
.	O	O

Menopausal	O	O
quality	O	O
of	O	O
life	O	O
:	O	O
RCT	O	O
of	O	O
yoga	Physical	Physical
,	O	Physical
exercise	Physical	Physical
,	O	O
and	O	O
omega-3	Pharmacological	O
supplements	Pharmacological	O
.	O	O

OBJECTIVE	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
3	O	O
nonhormonal	O	O
therapies	O	O
for	O	O
the	O	O
improvement	O	O
of	O	O
menopause-related	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
women	O	O
with	O	O
vasomotor	O	O
symptoms	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
We	O	O
conducted	O	O
a	O	O
12-week	O	O
3	O	O
?	O	O
2	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
factorial	O	O
design	O	O
trial	O	O
.	O	O

Peri-	O	O
and	O	O
postmenopausal	O	O
women	O	O
,	O	O
40-62	O	O
years	O	O
old	O	O
,	O	O
were	O	O
assigned	O	O
randomly	O	O
to	O	O
yoga	Physical	Physical
(	O	Physical
n	O	Physical
=	O	Physical
107	O	Physical
)	O	Physical
,	O	Physical
exercise	O	Physical
(	O	O
n	O	O
=	O	O
106	O	O
)	O	O
,	O	O
or	O	O
usual	Control	O
activity	Control	O
(	O	O
n	O	O
=	O	O
142	O	O
)	O	O
and	O	O
also	O	O
assigned	O	O
randomly	O	O
to	O	O
a	O	O
double-blind	O	O
comparison	O	O
of	O	O
omega-3	Pharmacological	O
(	O	O
n	O	O
=	O	O
177	O	O
)	O	O
or	O	O
placebo	Control	Control
(	O	O
n	O	O
=	O	O
178	O	O
)	O	O
capsules	O	O
.	O	O

We	O	O
performed	O	O
the	O	O
following	O	O
interventions	O	O
:	O	O
(	O	O
1	O	O
)	O	O
weekly	O	O
90-minute	O	O
yoga	O	O
classes	O	O
with	O	O
daily	O	O
at-home	O	O
practice	O	O
,	O	O
(	O	O
2	O	O
)	O	O
individualized	O	Physical
facility-based	O	Physical
aerobic	O	Physical
exercise	O	Physical
training	O	Physical
3	O	Physical
times/week	O	Physical
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
0.615	O	O
g	O	O
omega-3	Pharmacological	O
supplement	Pharmacological	O
,	O	O
3	O	O
times/day	O	O
.	O	O

The	O	O
outcomes	O	O
were	O	O
assessed	O	O
with	O	O
the	O	O
following	O	O
scores	O	O
:	O	O
Menopausal	O	O
Quality	O	O
of	O	O
Life	O	O
Questionnaire	O	O
(	O	O
MENQOL	O	O
)	O	O
total	O	O
and	O	O
domain	O	O
(	O	O
vasomotor	O	O
symptoms	O	O
,	O	O
psychosocial	O	O
,	O	O
physical	O	O
and	O	O
sexual	O	O
)	O	O
.	O	O

RESULTS	O	O
Among	O	O
355	O	O
randomly	O	O
assigned	O	O
women	O	O
who	O	O
average	O	O
age	O	O
was	O	O
54.7	O	O
years	O	O
,	O	O
338	O	O
women	O	O
(	O	O
95	O	O
%	O	O
)	O	O
completed	O	O
12-week	O	O
assessments	O	O
.	O	O

Mean	O	O
baseline	O	O
vasomotor	O	O
symptoms	O	O
frequency	O	O
was	O	O
7.6/day	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
baseline	O	O
total	O	O
MENQOL	O	O
score	O	O
was	O	O
3.8	O	O
(	O	O
range	O	O
,	O	O
1-8	O	O
from	O	O
better	O	O
to	O	O
worse	O	O
)	O	O
with	O	O
no	O	O
between-group	O	O
differences	O	O
.	O	O

For	O	O
yoga	O	O
compared	O	O
to	O	O
usual	O	O
activity	O	O
,	O	O
baseline	O	O
to	O	O
12-week	O	O
improvements	O	O
were	O	O
seen	O	O
for	O	O
MENQOL	O	O
total	O	O
-0.3	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-0.6	O	O
to	O	O
0	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
,	O	O
vasomotor	O	O
symptom	O	O
domain	O	O
(	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
,	O	O
and	O	O
sexuality	O	O
domain	O	O
(	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
scores	O	O
.	O	O

For	O	O
women	O	O
who	O	O
underwent	O	O
exercise	Physical	O
and	O	O
omega-3	Pharmacological	O
therapy	Pharmacological	O
compared	O	O
with	O	O
control	O	O
subjects	O	O
,	O	O
improvements	O	O
in	O	O
baseline	O	O
to	O	O
12-week	O	O
total	O	O
MENQOL	O	O
scores	O	O
were	O	O
not	O	O
observed	O	O
.	O	O

Exercise	O	O
showed	O	O
benefit	O	O
in	O	O
the	O	O
MENQOL	O	O
physical	O	O
domain	O	O
score	O	O
at	O	O
12	O	O
weeks	O	O
(	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
All	O	O
women	O	O
become	O	O
menopausal	O	O
,	O	O
and	O	O
many	O	O
of	O	O
them	O	O
seek	O	O
medical	O	O
advice	O	O
on	O	O
ways	O	O
to	O	O
improve	O	O
quality	O	O
of	O	O
life	O	O
;	O	O
little	O	O
evidence-based	O	O
information	O	O
exists	O	O
.	O	O

We	O	O
found	O	O
that	O	O
,	O	O
among	O	O
healthy	O	O
sedentary	O	O
menopausal	O	O
women	O	O
,	O	O
yoga	O	O
appears	O	O
to	O	O
improve	O	O
menopausal	O	O
quality	O	O
of	O	O
life	O	O
;	O	O
the	O	O
clinical	O	O
significance	O	O
of	O	O
our	O	O
finding	O	O
is	O	O
uncertain	O	O
because	O	O
of	O	O
the	O	O
modest	O	O
effect	O	O
.	O	O

Prophylactic	Pharmacological	O
vs	Pharmacological	O
therapeutic	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
for	O	O
obstetric	O	O
patients	O	O
with	O	O
accidental	O	O
dural	O	O
puncture	O	O
--	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

Epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
is	O	O
a	O	O
standard	O	O
treatment	O	O
for	O	O
obstetric	O	O
patients	O	O
experiencing	O	O
a	O	O
severe	O	O
post-dural	O	O
puncture	O	O
headache	O	O
.	O	O

Patients	O	O
who	O	O
sustained	O	O
an	O	O
accidental	O	O
dural	O	O
puncture	O	O
during	O	O
establishment	O	O
of	O	O
epidural	O	O
analgesia	O	O
during	O	O
labour	O	O
or	O	O
at	O	O
caesarean	O	O
delivery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
a	O	O
prophylactic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
or	O	O
conservative	Pharmacological	O
treatment	Pharmacological	O
with	Pharmacological	O
a	Pharmacological	O
therapeutic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
if	O	O
required	O	O
.	O	O

Eleven	O	O
of	O	O
60	O	O
(	O	O
18.3	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
prophylactic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
group	O	O
developed	O	O
a	O	O
post-dural	O	O
puncture	O	O
headache	O	O
compared	O	O
with	O	O
39	O	O
of	O	O
49	O	O
(	O	O
79.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
therapeutic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
group	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

A	O	O
blood	O	O
patch	O	O
was	O	O
performed	O	O
in	O	O
36	O	O
(	O	O
73.4	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
therapeutic	O	O
group	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
needed	O	O
a	O	O
second	O	O
blood	O	O
patch	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
:	O	O
6	O	O
(	O	O
10.0	O	O
%	O	O
)	O	O
for	O	O
prophylactic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
and	O	O
4	O	O
(	O	O
11.1	O	O
%	O	O
)	O	O
for	O	O
therapeutic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	Pharmacological	O
.	Pharmacological	O

We	O	O
conclude	O	O
that	O	O
prophylactic	Pharmacological	O
epidural	Pharmacological	O
blood	Pharmacological	O
patch	O	O
is	O	O
an	O	O
effective	O	O
method	O	O
to	O	O
reduce	O	O
the	O	O
development	O	O
of	O	O
post-dural	O	O
puncture	O	O
headache	O	O
in	O	O
obstetric	O	O
patients	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
breast	O	O
size	O	O
on	O	O
late	O	O
radiation	O	O
effects	O	O
and	O	O
association	O	O
with	O	O
radiotherapy	O	Physical
dose	O	O
inhomogeneity	O	O
.	O	O

A	O	O
prospective	O	O
assessment	O	O
of	O	O
late	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
in	O	O
559	O	O
patients	O	O
after	O	O
tumour	Surgical	O
excision	Surgical	O
and	O	O
radiotherapy	Physical	O
for	O	O
early	O	O
breast	O	O
cancer	O	O
noted	O	O
a	O	O
strong	O	O
association	O	O
with	O	O
breast	O	O
size	O	O
.	O	O

Only	O	O
3/48	O	O
(	O	O
6	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
small	O	O
breasts	O	O
developed	O	O
moderate	O	O
or	O	O
severe	O	O
late	O	O
changes	O	O
compared	O	O
with	O	O
94/423	O	O
(	O	O
22	O	O
%	O	O
)	O	O
with	O	O
medium	O	O
sized	O	O
breasts	O	O
and	O	O
34/88	O	O
(	O	O
39	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
large	O	O
breasts	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

One	O	O
possibility	O	O
is	O	O
that	O	O
greater	O	O
radiation	O	O
changes	O	O
are	O	O
related	O	O
to	O	O
greater	O	O
dose	O	O
inhomogeneity	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

To	O	O
explore	O	O
this	O	O
hypothesis	O	O
,	O	O
radiation	O	O
dose	O	O
distributions	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
37	O	O
women	O	O
in	O	O
whom	O	O
three-level	O	O
transverse	O	O
computer	O	O
tomographic	O	O
images	O	O
of	O	O
the	O	O
breast	O	O
in	O	O
the	O	O
treatment	O	O
position	O	O
were	O	O
available	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
breast	O	O
size	O	O
and	O	O
dose	O	O
inhomogeneity	O	O
which	O	O
may	O	O
account	O	O
for	O	O
the	O	O
marked	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
reported	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

Epirubicin	Pharmacological	O
and	O	O
cyclophosphamide	Pharmacological	Pharmacological
versus	O	O
epirubicin	Pharmacological	Pharmacological
and	O	O
docetaxel	Pharmacological	Pharmacological
as	O	O
first-line	O	O
therapy	O	O
for	O	O
women	O	O
with	O	O
metastatic	O	O
breast	O	O
cancer	O	O
:	O	O
final	O	O
results	O	O
of	O	O
a	O	O
randomised	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
This	O	O
randomised	O	O
phase	O	O
III	O	O
trial	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
epirubicin	Pharmacological	Pharmacological
and	O	O
cyclophosphamide	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
EC	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
with	O	Pharmacological
epirubicin	Pharmacological	Pharmacological
and	O	O
docetaxel	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
Taxotere	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
ED	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
as	O	O
first-line	O	O
chemotherapy	O	O
for	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Patients	O	O
(	O	O
n	O	O
=	O	O
240	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
ED	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
epirubicin	Pharmacological	Pharmacological
75	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
docetaxel	Pharmacological	O
75	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
or	O	O
EC	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
epirubicin	Pharmacological	Pharmacological
90	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
cyclophosphamide	Pharmacological	Pharmacological
600	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
objective	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
.	O	O

Secondary	O	O
end	O	O
points	O	O
were	O	O
progression-free	O	O
survival	O	O
(	O	O
PFS	O	O
)	O	O
,	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
,	O	O
and	O	O
safety	O	O
.	O	O

RESULTS	O	O
ORR	O	O
for	O	O
patients	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
EC	Pharmacological	O
and	O	O
ED	Pharmacological	O
were	O	O
42	O	O
%	O	O
and	O	O
47	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
0.63	O	O
)	O	O
.	O	O

Median	O	O
PFS	O	O
[	O	O
10.1	O	O
versus	O	O
10.3	O	O
months	O	O
;	O	O
hazard	O	O
ratio	O	O
(	O	O
HR	O	O
)	O	O
0.98	O	O
;	O	O
log-rank	O	O
P	O	O
=	O	O
0.38	O	O
]	O	O
and	O	O
OS	O	O
(	O	O
19.9	O	O
versus	O	O
30.0	O	O
months	O	O
;	O	O
HR	O	O
0.663	O	O
;	O	O
log-rank	O	O
P	O	O
=	O	O
0.21	O	O
)	O	O
were	O	O
comparable	O	O
in	O	O
both	O	O
arms	O	O
.	O	O

Although	O	O
grade	O	O
3/4	O	O
leucopenia	O	O
occurred	O	O
more	O	O
frequently	O	O
with	O	O
ED	Pharmacological	O
(	O	O
81	O	O
%	O	O
versus	O	O
73	O	O
%	O	O
;	O	O
P	O	O
=	O	O
0.01	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
febrile	O	O
neutropenia	O	O
and	O	O
grade	O	O
3/4	O	O
infections	O	O
.	O	O

Grade	O	O
3/4	O	O
non-haematologic	O	O
toxicity	O	O
was	O	O
infrequent	O	O
in	O	O
both	O	O
arms	O	O
.	O	O

Congestive	O	O
heart	O	O
failure	O	O
was	O	O
observed	O	O
in	O	O
one	O	O
patient	O	O
in	O	O
each	O	O
arm	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
randomised	O	O
trial	O	O
,	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
efficacy	O	O
study	O	O
end	O	O
points	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
arms	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
body	O	O
positioning	O	O
upon	O	O
maximal	Pharmacological	O
oxygenation	Pharmacological	O
of	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
.	O	O

A	O	O
quasi-experimental	O	O
,	O	O
repeated-measures	O	O
cross-over	O	O
design	O	O
study	O	O
on	O	O
the	O	O
effect	O	O
of	O	O
body	O	O
position	O	O
on	O	O
oxygenation	Pharmacological	O
(	Pharmacological	O
SaO2	Pharmacological	O
)	Pharmacological	O
blood	O	O
pressure	O	O
,	O	O
respiration	O	O
and	O	O
pulse	O	O
in	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
was	O	O
conducted	O	O
.	O	O

Previous	O	O
research	O	O
strongly	O	O
suggests	O	O
that	O	O
positioning	O	O
with	O	O
the	O	O
healthy	O	O
(	O	O
unaffected	O	O
)	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
(	O	O
down	O	O
)	O	O
position	O	O
is	O	O
related	O	O
to	O	O
improved	O	O
oxygenation	O	O
,	O	O
but	O	O
knowledge	O	O
about	O	O
whether	O	O
this	O	O
effect	O	O
is	O	O
maintained	O	O
over	O	O
time	O	O
is	O	O
lacking	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
:	O	O
(	O	O
1	O	O
)	O	O
Is	O	O
positioning	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
position	O	O
related	O	O
to	O	O
increased	O	O
arterial	O	O
blood	O	O
saturation	O	O
levels	O	O
and	O	O
decreased	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
and	O	O
respiration	O	O
?	O	O
(	O	O
2	O	O
)	O	O
What	O	O
is	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
dependent	O	O
variables	O	O
--	O	O
oxygenation	O	O
saturation	O	O
levels	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
and	O	O
respiration	O	O
--	O	O
and	O	O
the	O	O
independent	O	O
variables	O	O
--	O	O
body	O	O
position	O	O
and	O	O
time	O	O
in	O	O
the	O	O
position	O	O
?	O	O
Thirty-nine	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
were	O	O
positioned	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
down	O	O
,	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
affected	O	O
lung	O	O
down	O	O
,	O	O
and	O	O
also	O	O
in	O	O
semi-Fowler	O	O
's	O	O
position	O	O
.	O	O

Arterial	Physical	O
(	Physical	O
SaO2	Physical	O
)	Physical	O
blood	Physical	O
saturation	Physical	O
and	O	O
vital	Physical	O
signs	Physical	O
were	O	O
measured	O	O
at	O	O
baseline	O	O
0	O	O
,	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
relationship	O	O
between	O	O
oxygenation	O	O
level	O	O
or	O	O
systolic	O	O
blood	O	O
pressure	O	O
.	O	O

Diastolic	O	O
blood	O	O
pressure	O	O
,	O	O
respiration	O	O
and	O	O
pulse	O	O
did	O	O
vary	O	O
significantly	O	O
with	O	O
position	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
physical	Psychological	O
and	Psychological	O
emotional	Psychological	O
status	Psychological	O
on	O	O
adherence	O	O
to	O	O
a	O	O
low-fat	Other	O
dietary	Other	O
pattern	Other	O
in	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
examine	O	O
whether	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
adherance	O	O
to	O	O
a	O	O
low-fat	Educational	O
(	Educational	O
20	Educational	O
%	Educational	O
energy	Educational	O
)	Educational	O
dietary	Educational	O
pattern	Educational	O
are	O	O
mediated	O	O
by	O	O
participation	O	O
in	O	O
an	O	O
intervention	Educational	Educational
program	Educational	Educational
(	Educational	Educational
attending	Educational	Educational
sessions	Educational	Educational
and	Educational	Educational
self-monitoring	Educational	Educational
)	Educational	Educational
.	Educational	O

DESIGN	O	O
The	O	O
Baron	O	O
and	O	O
Kenny	O	O
mediator	O	O
model	O	O
,	O	O
a	O	O
series	O	O
of	O	O
4	O	O
regression	O	O
analyses	O	O
,	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
whether	O	O
:	O	O
a	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
predicted	O	O
program	O	O
participation	O	O
,	O	O
b	O	O
)	O	O
program	O	O
participation	O	O
predicted	O	O
dietary	O	O
adherence	O	O
,	O	O
c	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
factors	O	O
predicted	O	O
dietary	Other	O
adherence	Other	O
,	O	O
and	O	O
,	O	O
ultimately	O	O
d	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
dietary	O	O
adherence	O	O
were	O	O
mediated	O	O
by	O	O
program	O	O
participation	O	O
.	O	O

SUBJECTS/SETTING	O	O
Data	O	O
from	O	O
13,277	O	O
postmenopausal	O	O
women	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	Educational	O
intervention	Educational	O
arm	O	O
of	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
Dietary	O	O
Modification	O	O
Trial	O	O
.	O	O

INTERVENTION	O	O
The	O	O
nutrition	O	O
goals	O	O
for	O	O
women	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	Educational	O
intervention	Educational	O
were	O	O
to	O	O
reduce	Educational	O
total	Educational	O
fat	Educational	O
intake	Educational	O
to	Educational	O
20	Educational	O
%	Educational	O
or	Educational	O
less	Educational	O
of	Educational	O
energy	Educational	O
from	Educational	O
fat	Educational	O
and	Educational	O
to	Educational	O
consume	Educational	O
5	Educational	O
or	Educational	O
more	Educational	O
fruit/vegetable	Educational	O
servings	Educational	O
daily	Educational	O
and	Educational	O
6	Educational	O
or	Educational	O
more	Educational	O
grain	Educational	O
servings	Educational	O
daily	Educational	O
.	Educational	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Year	O	O
1	O	O
program	O	O
participation	O	O
(	O	O
degree	O	O
of	O	O
attending	O	O
group	O	O
sessions	O	O
and	O	O
submitting	O	O
fat	O	O
scores	O	O
)	O	O
and	O	O
adherence	O	O
to	O	O
the	O	O
low-fat	Educational	O
dietary	Educational	O
pattern	Educational	O
(	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
)	O	O
as	O	O
predicted	O	O
by	O	O
baseline	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
(	O	O
eight	O	O
SF-36	O	O
Health	O	O
Survey	O	O
subscales	O	O
)	O	O
.	O	O

RESULTS	O	O
Participating	O	O
in	O	O
the	O	O
dietary	Educational	O
intervention	Educational	O
program	Educational	O
reduced	O	O
(	O	O
mediated	O	O
)	O	O
the	O	O
negative	O	O
effect	O	O
of	O	O
poorer	O	O
mental	O	O
health	O	O
on	O	O
dietary	O	O
adherence	O	O
by	O	O
15	O	O
%	O	O
.	O	O

Additional	O	O
findings	O	O
included	O	O
that	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
physical	O	O
functioning	O	O
increased	O	O
session	O	O
attendance	O	O
by	O	O
0.4	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
and	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
mental	O	O
health	O	O
predicted	O	O
a	O	O
decrease	O	O
in	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
of	O	O
0.3	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Program	O	O
participation	O	O
had	O	O
a	O	O
marked	O	O
effect	O	O
on	O	O
dietary	O	O
adherence	O	O
:	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
session	O	O
attendance	O	O
predicted	O	O
a	O	O
1.2	O	O
%	O	O
decrease	O	O
in	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

APPLICATIONS/CONCLUSIONS	O	O
Understanding	O	O
and	O	O
using	O	O
instruments	O	O
to	O	O
assess	O	O
the	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
of	O	O
a	O	O
target	O	O
population	O	O
will	O	O
help	O	O
dietetic	O	O
professionals	O	O
promote	O	O
healthful	O	O
dietary	O	O
change	O	O
and	O	O
maintenance	O	O
.	O	O

Induction	Pharmacological	Physical
chemotherapy	Pharmacological	Physical
in	O	O
head	O	O
and	O	O
neck	O	O
cancer	O	O
:	O	O
results	O	O
of	O	O
a	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

Between	O	O
December	O	O
1982	O	O
and	O	O
October	O	O
1986	O	O
,	O	O
131	O	O
patients	O	O
with	O	O
stage	O	O
II-III-IV	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
of	O	O
the	O	O
oropharynx	O	O
or	O	O
oral	O	O
cavity	O	O
were	O	O
randomized	O	O
to	O	O
induction	O	Pharmacological
chemotherapy	Pharmacological	Pharmacological
,	O	O
consisting	O	O
of	O	O
bleomycin	Pharmacological	Pharmacological
(	O	Pharmacological
10	O	Pharmacological
mg/m2/day	O	Pharmacological
in	O	O
continuous	O	O
infusion	O	O
from	O	O
day	O	O
1	O	O
to	O	O
day	O	O
5	O	O
)	O	O
,	O	O
methotrexate	Pharmacological	Pharmacological
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
followed	O	O
by	O	O
folinic	Pharmacological	Pharmacological
acid	Pharmacological	Pharmacological
,	O	Pharmacological
5-fluorouracil	Pharmacological	Pharmacological
(	O	Pharmacological
5	O	Pharmacological
FU	O	Pharmacological
)	O	Pharmacological
(	O	O
600	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
,	O	O
and	O	O
cisplatin	Pharmacological	Pharmacological
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
4	O	O
)	O	O
every	O	O
4	O	O
weeks	O	O
for	O	O
a	O	O
total	O	O
of	O	O
three	O	O
cycles	O	O
followed	O	O
by	O	O
definitive	O	O
locoregional	O	O
treatment	O	O
versus	O	O
locoregional	O	O
treatment	O	O
alone	O	O
.	O	O

The	O	O
modalities	O	O
of	O	O
definitive	O	O
treatment	O	O
(	O	O
radiotherapy	Surgical	O
+/-	O	O
surgery	Surgical	O
)	O	O
were	O	O
chosen	O	O
prior	O	O
to	O	O
randomization	O	O
.	O	O

A	O	O
total	O	O
of	O	O
116	O	O
patients	O	O
were	O	O
evaluable	O	O
.	O	O

Of	O	O
55	O	O
patients	O	O
in	O	O
the	O	O
chemotherapy	Pharmacological	O
arm	O	O
,	O	O
four	O	O
(	O	O
7	O	O
%	O	O
)	O	O
had	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
and	O	O
23	O	O
(	O	O
42	O	O
%	O	O
)	O	O
a	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
following	O	O
the	O	O
induction	O	O
regimen	O	O
.	O	O

At	O	O
the	O	O
completion	O	O
of	O	O
locoregional	O	O
treatment	O	O
,	O	O
76	O	O
%	O	O
(	O	O
42	O	O
of	O	O
55	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
were	O	O
in	O	O
CR	O	O
compared	O	O
to	O	O
89	O	O
%	O	O
(	O	O
54	O	O
of	O	O
61	O	O
)	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
survival	O	O
,	O	O
cause-specific	O	O
survival	O	O
,	O	O
and	O	O
pattern	O	O
of	O	O
relapse	O	O
between	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
median	O	O
survival	O	O
was	O	O
22	O	O
months	O	O
in	O	O
the	O	O
chemotherapy	O	O
group	O	O
and	O	O
29	O	O
months	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Responders	O	O
to	O	O
chemotherapy	O	O
did	O	O
not	O	O
fare	O	O
better	O	O
than	O	O
nonresponders	O	O
.	O	O

Chemotherapy-related	O	O
toxicities	O	O
were	O	O
few	O	O
and	O	O
most	O	O
of	O	O
them	O	O
related	O	O
to	O	O
cisplatin	O	Pharmacological
which	O	O
was	O	O
reduced	O	O
to	O	O
100	O	O
mg/m2	O	O
for	O	O
35	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
treatment-related	O	O
deaths	O	O
and	O	O
,	O	O
in	O	O
the	O	O
experimental	O	O
arm	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
no	O	O
increased	O	O
morbidity	O	O
from	O	O
locoregional	O	O
treatment	O	O
.	O	O

This	O	O
induction	O	O
regimen	O	O
does	O	O
not	O	O
offer	O	O
any	O	O
advantages	O	O
over	O	O
standard	O	O
treatment	O	O
.	O	O

Effect	O	O
of	O	O
upper	O	O
arm	O	O
brachial	O	O
basilic	O	O
and	O	O
prosthetic	O	O
forearm	O	O
arteriovenous	O	O
fistula	O	O
on	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
.	O	O

BACKGROUND	O	O
Creation	O	O
of	O	O
an	O	O
arteriovenous	O	O
fistula	O	O
(	O	O
AVF	O	O
)	O	O
may	O	O
increase	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
in	O	O
the	O	O
hemodialysis	O	O
population	O	O
.	O	O

Aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
brachial-basilic	Physical	O
(	Physical	O
BB	Physical	O
)	Physical	O
AVF	Physical	O
and	O	O
the	O	O
prosthetic	Physical	O
brachial-antecubital	Physical	Surgical
forearm	Physical	Surgical
loop	Physical	Surgical
access	Physical	Surgical
(	O	Surgical
PTFE	O	Surgical
)	O	Surgical
on	O	O
cardiac	O	O
performance	O	O
.	O	O

METHODS	O	O
Patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
BB-AVF	Physical	Pharmacological
or	Physical	O
prosthetic	Physical	O
brachial-antecubital	Physical	O
forearm	Physical	O
loop	Physical	O
access	Physical	O
.	Physical	O

Before	O	O
and	O	O
three	O	O
months	O	O
after	O	O
AVF	O	O
creation	O	O
patients	O	O
underwent	O	O
an	O	O
echocardiographic	O	O
examination	O	O
.	O	O

Mann-Whitney	O	O
U-test	O	O
was	O	O
used	O	O
to	O	O
compare	O	O
relative	O	O
increase	O	O
between	O	O
the	O	O
measured	O	O
cardiac	O	O
parameters	O	O
for	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Twenty-seven	O	O
patients	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
relative	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
parameters	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Only	O	O
left	O	O
ventricular	O	O
end-diastolic	O	O
diameter	O	O
tended	O	O
to	O	O
be	O	O
of	O	O
significance	O	O
.	O	O

Mean	O	O
blood	O	O
flow	O	O
through	O	O
the	O	O
brachial	O	O
artery	O	O
was	O	O
1680+/-156	O	O
and	O	O
1450+/-221	O	O
mL/min	O	O
three	O	O
months	O	O
after	O	O
surgery	O	O
for	O	O
the	O	O
PTFE	O	O
and	O	O
the	O	O
BB-AVF	O	O
group	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
After	O	O
three	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
changes	O	O
in	O	O
cardiac	O	O
structure	O	O
were	O	O
comparable	O	O
between	O	O
patients	O	O
with	O	O
BB	O	O
and	O	O
PTFE	O	O
AVFs	O	O
.	O	O

Also	O	O
access	O	O
flow	O	O
was	O	O
comparable	O	O
at	O	O
this	O	O
time	O	O
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
creation	O	O
of	O	O
a	O	O
fistula	O	O
on	O	O
LV	O	O
structure	O	O
were	O	O
limited	O	O
.	O	O

Longer	O	O
follow	O	O
up	O	O
time	O	O
may	O	O
be	O	O
needed	O	O
to	O	O
explore	O	O
the	O	O
long	O	O
term	O	O
effects	O	O
of	O	O
different	O	O
vascular	O	O
accesses	O	O
on	O	O
cardiac	O	O
function	O	O
.	O	O

Long	Surgical	O
pediatric	Surgical	O
colonoscope	Surgical	O
versus	O	O
intermediate	Surgical	O
length	Surgical	O
adult	Surgical	O
colonoscope	Surgical	O
for	O	O
colonoscopy	O	O
.	O	O

BACKGROUND	O	O
Controversy	O	O
exists	O	O
on	O	O
how	O	O
the	O	O
length	O	O
and	O	O
diameter	O	O
of	O	O
colonoscopes	O	O
affect	O	O
the	O	O
quality	O	O
of	O	O
colonoscopy	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
a	O	O
long	Surgical	O
pediatric	Surgical	O
colonoscope	Surgical	O
with	O	O
an	O	O
intermediate	Surgical	O
length	Surgical	O
adult	Surgical	O
colonoscope	Surgical	O
with	O	O
regards	O	O
to	O	O
completion	O	O
rate	O	O
and	O	O
cecal	O	O
intubation	O	O
time	O	O
.	O	O

Whether	O	O
either	O	O
scope	O	O
may	O	O
be	O	O
more	O	O
efficient	O	O
in	O	O
any	O	O
subgroups	O	O
was	O	O
also	O	O
investigated	O	O
.	O	O

METHODS	O	O
Asymptomatic	O	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
physical	O	O
check-up	O	O
department	O	O
of	O	O
Buddhist	O	O
Dalin	O	O
Tzu	O	O
Chi	O	O
General	O	O
Hospital	O	O
were	O	O
included	O	O
.	O	O

A	O	O
single	O	O
endoscopist	O	O
performed	O	O
all	O	O
of	O	O
the	O	O
colonoscopic	Physical	O
examinations	Physical	O
under	O	O
sedation	O	O
.	O	O

Consecutive	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
undergo	O	O
colonoscopy	Surgical	O
with	Surgical	O
either	Surgical	O
intermediate	Surgical	O
length	Surgical	O
adult	Surgical	O
colonoscope	Surgical	O
(	Surgical	O
CF-240I	Surgical	O
)	Surgical	O
or	O	O
long	Surgical	O
pediatric	Surgical	O
colonoscope	Surgical	O
(	Surgical	O
PCF-240L	Surgical	O
)	Surgical	O
.	O	O

The	O	O
success	O	O
rate	O	O
and	O	O
time	O	O
required	O	O
to	O	O
reach	O	O
cecum	O	O
were	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Between	O	O
April	O	O
2005	O	O
and	O	O
February	O	O
2006	O	O
,	O	O
a	O	O
total	O	O
of	O	O
918	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Incomplete	O	O
colonoscopy	O	O
occurred	O	O
in	O	O
21	O	O
(	O	O
2.3	O	O
%	O	O
)	O	O
cases	O	O
(	O	O
14	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
and	O	O
seven	O	O
in	O	O
the	O	O
PCF-240L	O	O
group	O	O
,	O	O
P	O	O
>	O	O
0.1	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
cecal	O	O
mean	O	O
insertion	O	O
time	O	O
was	O	O
6.00	O	O
+/-	O	O
3.66	O	O
min	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
CF-240I	Surgical	O
and	O	O
PCF	Surgical	O
240L	Surgical	O
groups	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
cecal	O	O
intubation	O	O
rate	O	O
(	O	O
96.9	O	O
%	O	O
vs	O	O
98.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.18	O	O
)	O	O
,	O	O
the	O	O
need	O	O
for	O	O
abdominal	O	O
pressure	O	O
(	O	O
71.7	O	O
%	O	O
vs	O	O
73.4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.55	O	O
)	O	O
and	O	O
change	O	O
of	O	O
position	O	O
(	O	O
13.5	O	O
%	O	O
vs	O	O
11.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.37	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
cecal	O	O
intubation	O	O
time	O	O
was	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
(	O	O
5.75	O	O
+/-	O	O
3.18	O	O
vs	O	O
6.26	O	O
+/-	O	O
3.30	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

Subgroup	O	O
analysis	O	O
by	O	O
sex	O	O
,	O	O
age	O	O
,	O	O
and	O	O
body	O	O
mass	O	O
index	O	O
showed	O	O
comparable	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
except	O	O
that	O	O
the	O	O
cecal	O	O
intubation	O	O
times	O	O
were	O	O
significantly	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
when	O	O
only	O	O
men	O	O
(	O	O
4.78	O	O
+/-	O	O
2.57	O	O
vs	O	O
5.50	O	O
+/-	O	O
2.93	O	O
min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
or	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
(	O	O
5.50	O	O
+/-	O	O
2.90	O	O
vs	O	O
6.25	O	O
+/-	O	O
3.68	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
were	O	O
considered	O	O
.	O	O

CONCLUSION	O	O
Cecal	O	O
intubation	O	O
time	O	O
is	O	O
shorter	O	O
in	O	O
patients	O	O
examined	O	O
with	O	O
an	O	O
intermediate	Surgical	O
length	Surgical	O
adult	Surgical	O
colonoscope	Surgical	O
,	O	O
mainly	O	O
in	O	O
the	O	O
subgroups	O	O
of	O	O
men	O	O
and	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Migration	O	O
of	O	O
the	O	O
acetabular	O	O
component	O	O
:	O	O
effect	O	O
of	O	O
cement	Physical	O
pressurization	Physical	O
and	O	O
significance	O	O
of	O	O
early	O	O
radiolucency	O	O
:	O	O
a	O	O
randomized	O	O
5-year	O	O
study	O	O
using	O	O
radiostereometry	Other	O
.	Other	O

BACKGROUND	O	O
Cementing	O	O
technique	O	O
is	O	O
a	O	O
crucial	O	O
factor	O	O
in	O	O
prosthesis	O	O
fixation	O	O
.	O	O

No	O	O
randomized	O	O
studies	O	O
have	O	O
been	O	O
published	O	O
,	O	O
however	O	O
,	O	O
comparing	O	O
the	O	O
outcome	O	O
of	O	O
conventional	O	O
fingerpacking	O	O
with	O	O
the	O	O
outcome	O	O
of	O	O
pressurization	O	O
of	O	O
the	O	O
cement	O	O
prior	O	O
to	O	O
cup	O	O
insertion	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
We	O	O
randomized	O	O
50	O	O
THAs	O	O
to	O	O
either	O	O
fingerpacking	Other	O
or	O	O
sequential	Physical	O
pressurization	Physical	O
(	Other	O
including	Other	O
individual	Other	O
pressurization	Other	O
of	Other	O
each	Other	O
anchorage	Other	O
hole	Other	O
)	Other	O
and	O	O
followed	O	O
the	O	O
patients	O	O
with	O	O
RSA	Other	O
for	O	O
5	O	O
years	O	O
.	O	O

The	O	O
penetration	O	O
of	O	O
cement	O	O
into	O	O
the	O	O
anchorage	O	O
holes	O	O
was	O	O
measured	O	O
on	O	O
digital	O	O
radiographs	O	O
.	O	O

Postoperative	O	O
radiolucent	O	O
lines	O	O
around	O	O
the	O	O
cup	O	O
were	O	O
correlated	O	O
to	O	O
later	O	O
RSA	O	O
results	O	O
.	O	O

For	O	O
clinical	O	O
evaluation	O	O
,	O	O
we	O	O
used	O	O
SF-36	O	O
and	O	O
HHS	O	O
.	O	O

RESULTS	O	O
The	O	O
pressurized	O	O
group	O	O
of	O	O
THAs	O	O
was	O	O
more	O	O
stable	O	O
regarding	O	O
changes	O	O
in	O	O
inclination	O	O
.	O	O

We	O	O
found	O	O
no	O	O
other	O	O
difference	O	O
in	O	O
the	O	O
migratory	O	O
behavior	O	O
.	O	O

The	O	O
cement	O	O
penetration	O	O
into	O	O
the	O	O
anchorage	O	O
holes	O	O
was	O	O
deeper	O	O
with	O	O
the	O	O
pressurization	O	O
technique	O	O
than	O	O
with	O	O
fingerpacking	O	O
.	O	O

For	O	O
the	O	O
whole	O	O
group	O	O
taken	O	O
together	O	O
,	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
relation	O	O
between	O	O
the	O	O
presence	O	O
of	O	O
radiolucent	O	O
lines	O	O
as	O	O
measured	O	O
on	O	O
the	O	O
postoperative	O	O
radiograph	O	O
and	O	O
later	O	O
migration	O	O
observed	O	O
by	O	O
RSA	O	O
at	O	O
2	O	O
and	O	O
5	O	O
years	O	O
.	O	O

INTERPRETATION	O	O
Pressurization	O	O
of	O	O
the	O	O
cement	O	O
produced	O	O
better	O	O
cement	O	O
penetration	O	O
and	O	O
increased	O	O
the	O	O
cup	O	O
stability	O	O
in	O	O
terms	O	O
of	O	O
changes	O	O
in	O	O
inclination	O	O
.	O	O

Early	O	O
findings	O	O
of	O	O
radiolucent	O	O
lines	O	O
can	O	O
predict	O	O
later	O	O
unfavorable	O	O
cup	O	O
migration	O	O
.	O	O

B-domain	Pharmacological	Pharmacological
deleted	Pharmacological	Pharmacological
recombinant	Pharmacological	Pharmacological
factor	Pharmacological	Pharmacological
VIII	Pharmacological	Pharmacological
preparations	Pharmacological	O
are	O	O
bioequivalent	O	O
to	O	O
a	O	O
monoclonal	O	O
antibody	O	O
purified	O	O
plasma-derived	O	O
factor	O	O
VIII	O	O
concentrate	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
three-way	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Deletion	O	O
of	O	O
the	O	O
B-domain	O	O
of	O	O
recombinant	O	O
blood	O	O
coagulation	O	O
factor	O	O
VIII	O	O
(	O	O
BDDrFVIII	O	O
)	O	O
increases	O	O
the	O	O
manufacturing	O	O
yield	O	O
of	O	O
the	O	O
product	O	O
but	O	O
does	O	O
not	O	O
impair	O	O
in	O	O
vitro	O	O
or	O	O
in	O	O
vivo	O	O
functionality	O	O
.	O	O

BDDrFVIII	O	O
(	O	O
ReFacto	O	O
)	O	O
has	O	O
been	O	O
developed	O	O
with	O	O
the	O	O
additional	O	O
benefit	O	O
of	O	O
being	O	O
formulated	O	O
without	O	O
human	O	O
albumin	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
three-way	O	O
crossover-design	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
pharmacokinetic	O	O
(	O	O
PK	O	O
)	O	O
parameters	O	O
of	O	O
two	O	O
BDDrFVIII	Pharmacological	O
formulations	Pharmacological	O
(	O	O
one	O	O
reconstituted	O	O
with	O	O
5	O	Pharmacological
mL	O	Pharmacological
of	O	Pharmacological
sterile	O	Pharmacological
water	O	Pharmacological
,	O	O
the	O	O
other	O	O
reconstituted	O	O
with	O	O
4	O	O
mL	O	O
sodium	O	Pharmacological
chloride	O	Pharmacological
0.9	O	Pharmacological
%	O	Pharmacological
USP	O	Pharmacological
)	O	Pharmacological
with	O	O
those	O	O
of	O	O
a	O	O
plasma-derived	O	O
,	O	O
full-length	Pharmacological	O
FVIII	Pharmacological	O
preparation	Pharmacological	O
(	Pharmacological	O
Hemofil	Pharmacological	O
M	Pharmacological	O
)	Pharmacological	O
in	O	O
patients	O	O
with	O	O
haemophilia	O	O
A	O	O
to	O	O
determine	O	O
bioequivalence	O	O
.	O	O

METHODS	O	O
A	O	O
series	O	O
of	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
over	O	O
a	O	O
period	O	O
of	O	O
48	O	O
h	O	O
after	O	O
i.v	O	O
.	O	O

administration	O	O
of	O	O
each	O	O
of	O	O
the	O	O
FVIII	Pharmacological	O
preparations	Pharmacological	O
.	Pharmacological	O

Plasma	O	O
FVIII	O	O
activity	O	O
was	O	O
determined	O	O
using	O	O
a	O	O
validated	O	O
chromogenic	O	O
substrate	O	O
assay	O	O
.	O	O

Plasma	O	O
FVIII	O	O
activity	O	O
vs.	O	O
time	O	O
curves	O	O
was	O	O
characterized	O	O
for	O	O
a	O	O
standard	O	O
set	O	O
of	O	O
PK	O	O
parameter	O	O
estimates	O	O
.	O	O

Two	O	O
parameter	O	O
estimates	O	O
,	O	O
the	O	O
maximum	O	O
plasma	O	O
concentration	O	O
(	O	O
Cmax	O	O
)	O	O
and	O	O
the	O	O
area	O	O
under	O	O
plasma	O	O
concentration	O	O
vs.	O	O
time	O	O
curves	O	O
(	O	O
AUCs	O	O
)	O	O
,	O	O
were	O	O
used	O	O
to	O	O
evaluate	O	O
bioequivalence	O	O
.	O	O

The	O	O
two	O	O
preparations	O	O
were	O	O
considered	O	O
bioequivalent	O	O
if	O	O
the	O	O
90	O	O
%	O	O
confidence	O	O
intervals	O	O
for	O	O
the	O	O
ratio	O	O
of	O	O
geometric	O	O
means	O	O
for	O	O
Cmax	O	O
and	O	O
AUCs	O	O
fell	O	O
within	O	O
the	O	O
bioequivalence	O	O
window	O	O
of	O	O
80	O	O
%	O	O
to	O	O
125	O	O
%	O	O
.	O	O

RESULTS/CONCLUSION	O	O
Results	O	O
show	O	O
that	O	O
each	O	O
BDDrFVIII	Pharmacological	O
formulation	Pharmacological	O
is	O	O
bioequivalent	O	O
to	O	O
Hemofil	O	O
M	O	O
and	O	O
the	O	O
two	O	O
formulations	O	O
of	O	O
BDDrFVIII	O	O
are	O	O
bioequivalent	O	O
to	O	O
each	O	O
other	O	O
.	O	O

Short-term	O	O
studies	O	O
on	O	O
the	O	O
use	O	O
of	O	O
glycerol	Pharmacological	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
glycerol	Pharmacological	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
two	O	O
different	O	O
concentrations	O	O
(	O	O
92	O	O
mmol/l	O	O
and	O	O
272	O	O
mmol/l	O	O
)	O	O
in	O	O
peritoneal	O	O
dialysis	O	O
fluid	O	O
was	O	O
investigated	O	O
over	O	O
3	O	O
days	O	O
in	O	O
six	O	O
patients	O	O
on	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
and	O	O
compared	O	O
with	O	O
two	O	O
concentrations	O	O
of	O	O
glucose	Control	O
(	O	O
76	O	O
mmol/l	O	O
and	O	O
215	O	O
mmol/l	O	O
)	O	O
in	O	O
the	O	O
same	O	O
patients	O	O
.	O	O

The	O	O
calorific	O	O
value	O	O
of	O	O
the	O	O
absorbed	O	O
osmotic	O	O
agent	O	O
was	O	O
lower	O	O
,	O	O
by	O	O
19	O	O
%	O	O
with	O	O
isotonic	O	O
and	O	O
22	O	O
%	O	O
with	O	O
hypertonic	O	O
solutions	O	O
,	O	O
when	O	O
glycerol	Pharmacological	O
was	O	O
used	O	O
in	O	O
place	O	O
of	O	O
glucose	Control	O
.	O	O

However	O	O
,	O	O
glycerol	O	O
provided	O	O
significantly	O	O
lower	O	O
total	O	O
ultrafiltration	O	O
than	O	O
glucose	O	O
at	O	O
each	O	O
concentration	O	O
,	O	O
despite	O	O
a	O	O
higher	O	O
initial	O	O
osmotic	O	O
pressure	O	O
of	O	O
the	O	O
glycerol-based	O	O
solutions	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
higher	O	O
concentration	O	O
of	O	O
glycerol	O	O
required	O	O
to	O	O
provide	O	O
equal	O	O
ultrafiltration	O	O
may	O	O
offset	O	O
any	O	O
calorific	O	O
advantage	O	O
.	O	O

Equilibration	O	O
of	O	O
creatinine	O	O
and	O	O
urea	O	O
was	O	O
slower	O	O
and	O	O
creatinine	O	O
clearance	O	O
lower	O	O
with	O	O
glycerol	Pharmacological	O
.	O	O

Solutions	O	O
containing	O	O
glycerol	Pharmacological	O
were	O	O
initially	O	O
less	O	O
acid	O	O
(	O	O
pH	O	O
6.5	O	O
)	O	O
than	O	O
those	O	O
containing	O	O
glucose	O	O
(	O	O
pH	O	O
5.1	O	O
)	O	O
.	O	O

Blood	O	O
glycerol	O	O
levels	O	O
,	O	O
which	O	O
were	O	O
in	O	O
the	O	O
physiological	O	O
range	O	O
with	O	O
glucose	O	O
as	O	O
the	O	O
osmotic	O	O
agent	O	O
,	O	O
reached	O	O
a	O	O
peak	O	O
80-fold	O	O
greater	O	O
at	O	O
4.3	O	O
+/-	O	O
0.8	O	O
mmol/l	O	O
during	O	O
dialysis	O	O
with	O	O
fluid	O	O
containing	O	O
glycerol	Pharmacological	O
at	O	O
272	O	O
mmol/l	O	O
and	O	O
eightfold	O	O
higher	O	O
at	O	O
0.42	O	O
+/-	O	O
0.09	O	O
mmol/l	O	O
with	O	O
glycerol	Pharmacological	O
at	O	O
92	O	O
mmol/l	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
haemolysis	O	O
or	O	O
other	O	O
toxic	O	O
effect	O	O
despite	O	O
these	O	O
levels	O	O
.	O	O

The	O	O
rise	O	O
in	O	O
blood	O	O
glucose	O	O
and	O	O
insulin	O	O
noted	O	O
during	O	O
the	O	O
use	O	O
of	O	O
glucose-based	O	O
solutions	O	O
was	O	O
not	O	O
found	O	O
with	O	O
glycerol	Pharmacological	O
.	O	O

Circulating	O	O
levels	O	O
of	O	O
lactate	O	O
,	O	O
pyruvate	O	O
,	O	O
alanine	O	O
,	O	O
non-esterified	O	O
fatty	O	O
acids	O	O
and	O	O
the	O	O
ketone	O	O
bodies	O	O
were	O	O
similar	O	O
with	O	O
the	O	O
two	O	O
agents	O	O
.	O	O

Although	O	O
these	O	O
short-term	O	O
studies	O	O
have	O	O
shown	O	O
no	O	O
conclusive	O	O
advantage	O	O
of	O	O
glycerol	Pharmacological	O
over	O	O
glucose	Control	O
,	O	O
long-term	O	O
effects	O	O
of	O	O
glycerol	Pharmacological	O
,	O	O
particularly	O	O
on	O	O
circulating	O	O
lipid	O	O
levels	O	O
,	O	O
will	O	O
determine	O	O
its	O	O
future	O	O
role	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

Motion	Physical	Pharmacological
style	Physical	Pharmacological
acupuncture	Physical	Pharmacological
treatment	Physical	Pharmacological
(	Physical	Pharmacological
MSAT	Physical	Pharmacological
)	Physical	Pharmacological
for	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
with	O	O
severe	O	O
disability	O	O
:	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
protocol	O	O
.	O	O

BACKGROUND	O	O
Acupuncture	O	Physical
is	O	O
widely-used	O	O
to	O	O
treat	O	O
patients	O	O
with	O	O
low	O	O
back	O	O
pain	O	O
,	O	O
despite	O	O
insufficient	O	O
evidence	O	O
of	O	O
the	O	O
technique	O	O
's	O	O
efficacy	O	O
for	O	O
acute	O	O
back	O	O
pain	O	O
.	O	O

Motion	Physical	Physical
style	Physical	Physical
acupuncture	Physical	Physical
treatment	Physical	O
(	Physical	O
MSAT	Physical	O
)	Physical	O
is	O	O
a	O	O
non-traditional	O	Physical
acupuncture	O	Physical
treatment	O	O
requiring	O	O
a	O	O
patient	O	O
to	O	O
exercise	O	O
while	O	O
receiving	O	O
acupuncture	O	Physical
.	O	O

In	O	O
Korea	O	O
,	O	O
MSAT	O	O
is	O	O
used	O	O
to	O	O
reduce	O	O
musculoskeletal	O	O
pain	O	O
and	O	O
improve	O	O
functional	O	O
status	O	O
.	O	O

The	O	O
study	O	O
aims	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
MSAT	O	O
on	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
with	O	O
severe	O	O
disability	O	O
.	O	O

METHODS/DESIGN	O	O
This	O	O
study	O	O
is	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
active-controlled	O	O
trial	O	O
with	O	O
two	O	O
parallel	O	O
arms	O	O
.	O	O

Participants	O	O
with	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
and	O	O
severe	O	O
functional	O	O
disability	O	O
,	O	O
defined	O	O
as	O	O
an	O	O
Oswestry	O	O
Disability	O	O
Index	O	O
(	O	O
ODI	O	O
)	O	O
value	O	O
>	O	O
60	O	O
%	O	O
,	O	O
will	O	O
be	O	O
randomly	O	O
allocated	O	O
to	O	O
the	O	O
acupuncture	Physical	Physical
group	O	O
and	O	O
the	O	O
nonsteroidal	Pharmacological	O
anti-inflammatory	Pharmacological	O
drug	Pharmacological	O
(	Pharmacological	O
NSAID	Pharmacological	O
)	Pharmacological	O
injection	Pharmacological	O
group	Pharmacological	O
.	O	O

The	O	O
acupuncture	O	O
group	O	O
will	O	O
receive	O	O
MSAT	Physical	O
and	O	O
the	O	O
NSAID	Pharmacological	O
injection	Pharmacological	O
group	Pharmacological	O
will	O	O
receive	O	O
an	O	O
intramuscular	O	Pharmacological
injection	O	Pharmacological
of	O	Pharmacological
diclofenac	Pharmacological	Pharmacological
.	Pharmacological	O

All	O	O
procedures	O	O
will	O	O
be	O	O
limited	O	O
to	O	O
one	O	O
session	O	O
and	O	O
the	O	O
symptoms	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
will	O	O
be	O	O
measured	O	O
by	O	O
assessors	O	O
blinded	O	O
to	O	O
treatment	O	O
allocation	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
will	O	O
be	O	O
measured	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
treatment	O	O
using	O	O
the	O	O
numerical	O	O
rating	O	O
scale	O	O
(	O	O
NRS	O	O
)	O	O
of	O	O
low	O	O
back	O	O
pain	O	O
while	O	O
the	O	O
patient	O	O
is	O	O
moving	O	O
.	O	O

Secondary	O	O
outcomes	O	O
will	O	O
be	O	O
measured	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
treatment	O	O
using	O	O
the	O	O
NRS	O	O
of	O	O
leg	O	O
pain	O	O
,	O	O
ODI	O	O
,	O	O
patient	O	O
global	O	O
impression	O	O
of	O	O
change	O	O
,	O	O
range	O	O
of	O	O
motion	O	O
(	O	O
ROM	O	O
)	O	O
of	O	O
the	O	O
lumbar	O	O
spine	O	O
,	O	O
and	O	O
degrees	O	O
of	O	O
straight	O	O
leg	O	O
raising	O	O
(	O	O
SLR	O	O
)	O	O
.	O	O

Post-treatment	O	O
follow-up	O	O
will	O	O
be	O	O
performed	O	O
to	O	O
measure	O	O
primary	O	O
and	O	O
secondary	O	O
outcomes	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
ROM	O	O
and	O	O
SLR	O	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
24	O	O
weeks	O	O
after	O	O
treatment	O	O
.	O	O

DISCUSSION	O	O
The	O	O
results	O	O
of	O	O
this	O	O
trial	O	O
will	O	O
be	O	O
discussed	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrial.gov	O	O
NCT01315561	O	O
.	O	O

B-type	Other	O
natriuretic	Other	O
peptide	Other	O
in	O	O
the	O	O
evaluation	O	O
and	O	O
management	O	O
of	O	O
dyspnoea	O	O
in	O	O
primary	O	O
care	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
rapid	O	O
and	O	O
accurate	O	O
diagnosis	O	O
of	O	O
heart	O	O
failure	O	O
in	O	O
primary	O	O
care	O	O
is	O	O
a	O	O
major	O	O
unmet	O	O
clinical	O	O
need	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
additional	O	O
use	O	O
of	O	O
B-type	Other	O
natriuretic	Other	O
peptide	Other	O
(	Other	O
BNP	Other	O
)	Other	O
levels	O	O
.	O	O

DESIGN	O	O
A	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Twenty-nine	O	O
primary	O	O
care	O	O
physicians	O	O
in	O	O
Switzerland	O	O
and	O	O
Germany	O	O
coordinated	O	O
by	O	O
the	O	O
University	O	O
Hospital	O	O
Basel	O	O
,	O	O
Switzerland	O	O
.	O	O

SUBJECTS	O	O
A	O	O
total	O	O
of	O	O
323	O	O
consecutive	O	O
patients	O	O
presenting	O	O
with	O	O
dyspnoea	O	O
.	O	O

INTERVENTIONS	O	O
Assignment	O	O
in	O	O
a	O	O
1	O	O
:	O	O
1	O	O
ratio	O	O
to	O	O
a	O	O
diagnostic	Other	O
strategy	Other	O
including	Other	O
point-of-care	Other	O
measurement	Other	O
of	Other	O
BNP	Other	O
(	O	O
n	O	O
=	O	O
163	O	O
)	O	O
or	O	O
standard	Control	O
assessment	Control	O
without	Control	O
BNP	Control	O
(	O	O
n	O	O
=	O	O
160	O	O
)	O	O
.	O	O

The	O	O
total	O	O
medical	O	O
cost	O	O
at	O	O
3	O	O
months	O	O
was	O	O
the	O	O
primary	O	O
end-point	O	O
.	O	O

Secondary	O	O
end-points	O	O
were	O	O
diagnostic	O	O
certainty	O	O
,	O	O
time	O	O
to	O	O
appropriate	O	O
therapy	O	O
,	O	O
functional	O	O
capacity	O	O
,	O	O
hospitalization	O	O
and	O	O
mortality	O	O
.	O	O

The	O	O
final	O	O
diagnosis	O	O
was	O	O
adjudicated	O	O
by	O	O
a	O	O
physician	O	O
blinded	O	O
to	O	O
the	O	O
BNP	O	O
levels	O	O
.	O	O

RESULTS	O	O
Heart	O	O
failure	O	O
was	O	O
the	O	O
final	O	O
diagnosis	O	O
in	O	O
34	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
number	O	O
of	O	O
hospitalizations	O	O
,	O	O
functional	O	O
status	O	O
and	O	O
total	O	O
medical	O	O
cost	O	O
at	O	O
3	O	O
months	O	O
[	O	O
median	O	O
$	O	O
1655	O	O
,	O	O
interquartile	O	O
range	O	O
(	O	O
IQR	O	O
)	O	O
,	O	O
850-3331	O	O
vs.	O	O
$	O	O
1541	O	O
,	O	O
IQR	O	O
859-2827	O	O
;	O	O
P	O	O
=	O	O
0.68	O	O
]	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

BNP	O	O
increased	O	O
diagnostic	O	O
certainty	O	O
as	O	O
defined	O	O
by	O	O
the	O	O
need	O	O
for	O	O
further	O	O
diagnostic	O	O
work-up	O	O
(	O	O
33	O	O
%	O	O
vs.	O	O
45	O	O
%	O	O
;	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
accelerated	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
appropriate	O	O
treatment	O	O
(	O	O
13	O	O
days	O	O
vs.	O	O
25	O	O
days	O	O
;	O	O
P	O	O
=	O	O
0.01	O	O
)	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
receiver-operating	O	O
characteristics	O	O
curve	O	O
for	O	O
BNP	O	O
to	O	O
identify	O	O
heart	O	O
failure	O	O
was	O	O
0.87	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.81-0.93	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
use	O	O
of	O	O
BNP	Other	O
levels	Other	O
in	O	O
primary	O	O
care	O	O
did	O	O
not	O	O
reduce	O	O
total	O	O
medical	O	O
cost	O	O
,	O	O
but	O	O
improved	O	O
some	O	O
of	O	O
the	O	O
secondary	O	O
end-points	O	O
including	O	O
diagnostic	O	O
certainty	O	O
and	O	O
time	O	O
to	O	O
initiation	O	O
of	O	O
appropriate	O	O
treatment	O	O
.	O	O

[	O	O
Methodologic	O	O
comparison	O	O
of	O	O
the	O	O
polyfrequency	Physical	O
oscillation	Physical	O
method	Physical	O
,	O	O
transcutaneous	O	O
oxygen	O	O
pressure	O	O
measurement	O	O
and	O	O
body	O	O
plethysmography	O	O
in	O	O
bronchial	O	O
provocation	O	O
with	O	O
methacholine	Pharmacological	O
]	O	O
.	O	O

A	O	O
bronchial	O	O
provocation	O	O
challenge	O	O
test	O	O
was	O	O
conducted	O	O
with	O	O
30	O	O
subjects	O	O
using	O	O
metacholin	Pharmacological	O
.	Pharmacological	O

In	O	O
randomised	O	O
sequence	O	O
lung	O	O
function	O	O
analysis	O	O
tests	O	O
were	O	O
carried	O	O
out	O	O
with	O	O
the	O	O
bodyplethysmograph	Physical	O
(	O	O
Raw	O	O
,	O	O
FEV1	O	O
)	O	O
and	O	O
the	O	O
polyfrequent	O	O
oscillation	O	O
method	O	O
(	O	O
resistance	O	O
,	O	O
reactance	O	O
between	O	O
2	O	O
and	O	O
52	O	O
Hz	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
transcutaneous	Pharmacological	O
oxygen	Pharmacological	O
pressure	Pharmacological	O
(	O	O
tc-PO2	O	O
)	O	O
was	O	O
measured	O	O
continuously	O	O
.	O	O

Correlations	O	O
between	O	O
the	O	O
various	O	O
parameters	O	O
,	O	O
the	O	O
change	O	O
of	O	O
the	O	O
values	O	O
at	O	O
PD60	O	O
sGaw	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
initial	O	O
values	O	O
,	O	O
the	O	O
interindividual	O	O
variability	O	O
and	O	O
the	O	O
reactivity	O	O
were	O	O
determined	O	O
.	O	O

Medium	O	O
correlations	O	O
were	O	O
found	O	O
for	O	O
the	O	O
oscillatory	O	O
parameters	O	O
and	O	O
Raw	O	O
,	O	O
whereas	O	O
for	O	O
tc-PO2	O	O
and	O	O
Raw	O	O
the	O	O
correlation	O	O
was	O	O
markedly	O	O
lower	O	O
.	O	O

In	O	O
terms	O	O
of	O	O
percentage	O	O
the	O	O
greatest	O	O
change	O	O
was	O	O
found	O	O
in	O	O
reactance	O	O
,	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
initial	O	O
value	O	O
,	O	O
followed	O	O
by	O	O
Raw	O	O
and	O	O
FEV1	O	O
.	O	O

The	O	O
interindividual	O	O
variability	O	O
resulted	O	O
in	O	O
the	O	O
highest	O	O
values	O	O
for	O	O
the	O	O
reactance	O	O
,	O	O
followed	O	O
by	O	O
Raw	O	O
and	O	O
FEV1	O	O
.	O	O

Interindividual	O	O
variability	O	O
showed	O	O
the	O	O
highest	O	O
values	O	O
for	O	O
the	O	O
reactance	O	O
before	O	O
oscillatory	O	O
resistance	O	O
and	O	O
Raw	O	O
.	O	O

In	O	O
respect	O	O
of	O	O
reactivity	O	O
,	O	O
reactance	O	O
also	O	O
had	O	O
the	O	O
highest	O	O
values	O	O
.	O	O

Overall	O	O
evaluation	O	O
showed	O	O
that	O	O
bodyplethysmography	Physical	O
and	O	O
the	O	O
polyfrequent	Physical	O
oscillation	Physical	O
method	Physical	O
(	O	O
reactance	O	O
or	O	O
resonance	O	O
frequency	O	O
)	O	O
are	O	O
comparably	O	O
sensitive	O	O
.	O	O

Immunologic	O	O
response	O	O
after	O	O
laparoscopic	O	O
colon	O	O
cancer	O	O
operation	O	O
within	O	O
an	O	O
enhanced	O	O
recovery	O	O
program	O	O
.	O	O

OBJECTIVE	O	O
It	O	O
has	O	O
been	O	O
demonstrated	O	O
that	O	O
colon	O	O
operation	O	O
combined	O	O
with	O	O
fast-track	O	Surgical
(	O	Surgical
FT	O	Surgical
)	O	Surgical
surgery	O	Surgical
and	O	Surgical
laparoscopic	O	Surgical
technique	O	Surgical
can	O	O
shorten	O	O
the	O	O
length	O	O
of	O	O
hospital	O	O
stay	O	O
,	O	O
accelerate	O	O
recovery	O	O
of	O	O
intestinal	O	O
function	O	O
,	O	O
and	O	O
reduce	O	O
the	O	O
occurrence	O	O
of	O	O
post-operative	O	O
complications	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O	O
regarding	O	O
the	O	O
combined	O	O
effects	O	O
of	O	O
FT	O	Physical
colon	O	Physical
operation	O	Physical
and	O	Physical
laparoscopic	O	Physical
technique	O	Physical
on	O	O
humoral	O	O
inflammatory	O	O
cellular	O	O
immunity	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
controlled	O	O
study	O	O
.	O	O

One	O	O
hundred	O	O
sixty-three	O	O
colon	O	O
cancer	O	O
patients	O	O
underwent	O	O
the	O	O
traditional	Surgical	Physical
protocol	Surgical	Physical
and	Surgical	Physical
open	Surgical	Physical
operation	Surgical	Physical
(	O	Physical
traditional	O	Physical
open	O	Physical
group	O	Physical
,	O	O
n=42	O	O
)	O	O
,	O	O
the	O	O
traditional	Surgical	O
protocol	Surgical	O
and	Surgical	O
laparoscopic	Surgical	Surgical
operation	Surgical	Surgical
(	O	Surgical
traditional	O	Surgical
laparoscopic	O	Surgical
group	O	O
,	O	O
n=40	O	O
)	O	O
,	O	O
the	O	O
FT	Surgical	O
protocol	Surgical	O
and	Surgical	O
open	Surgical	Surgical
operation	Surgical	Surgical
(	O	Surgical
FT	O	Surgical
open	O	Surgical
group	O	O
,	O	O
n=41	O	O
)	O	O
,	O	O
or	O	O
the	O	O
FT	Surgical	O
protocol	Surgical	O
and	Surgical	O
laparoscopic	Surgical	Surgical
operation	Surgical	Surgical
(	O	Surgical
FT	O	Surgical
laparoscopic	O	Surgical
group	O	O
,	O	O
n=40	O	O
)	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
taken	O	O
prior	O	O
to	O	O
operation	O	O
as	O	O
well	O	O
as	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
after	O	O
operation	O	O
.	O	O

The	O	O
number	O	O
of	O	O
lymphocyte	O	O
subpopulations	O	O
was	O	O
determined	O	O
by	O	O
flow	O	O
cytometry	O	O
,	O	O
and	O	O
serum	O	O
interleukin-6	O	O
and	O	O
C-reactive	O	O
protein	O	O
levels	O	O
were	O	O
measured	O	O
.	O	O

Post-operative	O	O
hospital	O	O
stay	O	O
,	O	O
post-operative	O	O
morbidity	O	O
,	O	O
readmission	O	O
rate	O	O
,	O	O
and	O	O
in-hospital	O	O
mortality	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
open	O	Surgical
operation	O	Surgical
,	O	Surgical
laparoscopic	O	Surgical
colon	O	Surgical
operation	O	Surgical
effectively	O	Surgical
inhibited	O	O
the	O	O
release	O	O
of	O	O
post-operative	O	O
inflammatory	O	O
factors	O	O
and	O	O
yielded	O	O
good	O	O
protection	O	O
via	O	O
post-operative	O	O
cell	O	O
immunity	O	O
.	O	O

FT	O	O
surgery	O	O
had	O	O
a	O	O
better	O	O
protective	O	O
role	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
compared	O	O
with	O	O
traditional	O	O
peri-operative	O	O
care	O	O
.	O	O

Inflammatory	O	O
reactions	O	O
,	O	O
based	O	O
on	O	O
interleukin-6	O	O
and	O	O
C-reactive	O	O
protein	O	O
levels	O	O
,	O	O
were	O	O
less	O	O
intense	O	O
following	O	O
FT	O	Surgical
laparoscopic	O	Surgical
operation	O	Surgical
compared	O	Surgical
to	O	Surgical
FT	O	Surgical
open	O	Surgical
operation	O	Surgical
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
specific	O	O
immunity	O	O
(	O	O
CD3+	O	O
and	O	O
CD4+	O	O
counts	O	O
,	O	O
and	O	O
the	O	O
CD4+/CD8+	O	O
ratio	O	O
)	O	O
during	O	O
these	O	O
two	O	O
types	O	O
of	O	O
surgical	O	O
procedures	O	O
.	O	O

Post-operative	O	O
hospital	O	O
stay	O	O
in	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
FT	O	O
laparoscopic	O	O
group	O	O
was	O	O
significantly	O	O
shorter	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Post-operative	O	O
complications	O	O
in	O	O
patients	O	O
who	O	O
underwent	O	O
FT	O	Physical
laparoscopic	O	Physical
treatment	O	Physical
were	O	O
less	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
four	O	O
treatment	O	O
groups	O	O
regarding	O	O
readmission	O	O
rate	O	O
and	O	O
in-hospital	O	O
mortality	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
laparoscopic	O	O
technique	O	O
and	O	O
FT	O	O
surgery	O	O
rehabilitation	O	O
program	O	O
effectively	O	O
inhibited	O	O
release	O	O
of	O	O
post-operative	O	O
inflammatory	O	O
factors	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
peri-operative	O	O
trauma	O	O
and	O	O
stress	O	O
,	O	O
which	O	O
together	O	O
played	O	O
a	O	O
protective	O	O
role	O	O
on	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
.	O	O

Combining	O	O
two	O	O
treatment	O	O
measures	O	O
during	O	O
colon	O	O
operation	O	O
produced	O	O
better	O	O
protective	O	O
effects	O	O
via	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

The	O	O
beneficial	O	O
clinical	O	O
effects	O	O
support	O	O
that	O	O
the	O	O
better-preserved	O	O
post-operative	O	O
immune	O	O
system	O	O
may	O	O
also	O	O
contribute	O	O
to	O	O
the	O	O
improvement	O	O
of	O	O
post-operative	O	O
results	O	O
in	O	O
FT	O	O
laparoscopic	O	O
patients	O	O
.	O	O

Enhancing	O	O
the	O	O
self-esteem	O	O
of	O	O
inpatient	O	O
alcoholics	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
pairing	O	O
inpatient	O	O
alcoholics	O	O
with	O	O
nursing	Other	O
home	Other	O
residents	Other	O
(	Other	O
NHRs	Other	O
)	Other	O
on	O	O
the	O	O
alcoholics	O	O
'	O	O
self-esteem	O	O
.	O	O

In	O	O
this	O	O
PALS	O	O
program	O	O
,	O	O
the	O	O
alcoholic	O	O
inpatients	O	O
assumed	O	O
a	O	O
helping-companion	O	O
relationship	O	O
with	O	O
the	O	O
NHRs	O	O
for	O	O
2	O	O
hr	O	O
per	O	O
day	O	O
during	O	O
their	O	O
last	O	O
2	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Fifty	O	O
alcoholic	O	O
inpatients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
PALS	Psychological	Educational
program	Psychological	Educational
(	O	O
n	O	O
=	O	O
25	O	O
)	O	O
or	O	O
to	O	O
the	O	O
library	Psychological	O
for	Psychological	O
free	Psychological	O
reading	Psychological	O
time	Psychological	O
(	O	O
n	O	O
=	O	O
25	O	O
)	O	O
.	O	O

The	O	O
Tennessee	O	O
Self-Concept	O	O
Scale	O	O
(	O	O
TSCS	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
all	O	O
subjects	O	O
in	O	O
both	O	O
groups	O	O
before	O	O
and	O	O
after	O	O
the	O	O
interventions	O	O
.	O	O

Of	O	O
the	O	O
nine	O	O
TSCS	O	O
scales	O	O
,	O	O
the	O	O
improvement	O	O
on	O	O
the	O	O
Moral-Ethical	O	O
scale	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
PALS	O	O
group	O	O
.	O	O

Because	O	O
the	O	O
alcoholic	O	O
inpatients	O	O
in	O	O
the	O	O
PALS	O	O
group	O	O
engaged	O	O
in	O	O
altruistic	O	O
(	O	O
moral	O	O
)	O	O
behavior	O	O
,	O	O
this	O	O
study	O	O
provides	O	O
a	O	O
logical	O	O
link	O	O
between	O	O
the	O	O
intervention	O	O
and	O	O
the	O	O
outcome	O	O
,	O	O
which	O	O
has	O	O
been	O	O
a	O	O
prevalent	O	O
weakness	O	O
in	O	O
previous	O	O
studies	O	O
of	O	O
self-esteem	O	O
in	O	O
alcoholics	O	O
.	O	O

Transurethral	Surgical	O
prostate	Surgical	O
resection	Surgical	O
and	O	O
bleeding	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
placebo	Control	Control
controlled	O	O
trial	O	O
of	O	O
role	O	O
of	O	O
finasteride	Pharmacological	O
for	O	O
decreasing	O	O
operative	O	O
blood	O	O
loss	O	O
.	O	O

PURPOSE	O	O
Bleeding	O	O
associated	O	O
with	O	O
transurethral	O	O
prostate	O	O
resection	O	O
can	O	O
often	O	O
be	O	O
significant	O	O
and	O	O
lead	O	O
to	O	O
increased	O	O
morbidity	O	O
and	O	O
occasionally	O	O
mortality	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
finasteride	Pharmacological	O
decreases	O	O
bleeding	O	O
in	O	O
patients	O	O
with	O	O
hematuria	O	O
of	O	O
prostatic	O	O
origin	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
bleeding	O	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	O	O
prostate	O	O
resection	O	O
could	O	O
be	O	O
decreased	O	O
by	O	O
giving	O	O
finasteride	Pharmacological	O
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
70	O	O
patients	O	O
scheduled	O	O
to	O	O
undergo	O	O
elective	O	Surgical
transurethral	O	Surgical
prostate	O	Surgical
resection	O	Surgical
were	O	O
randomized	O	O
to	O	O
receive	O	O
5	Pharmacological	Pharmacological
mg.	Pharmacological	Pharmacological
finasteride	Pharmacological	Pharmacological
daily	Pharmacological	Pharmacological
or	O	O
placebo	Control	Control
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

Serum	O	O
hemoglobin	O	O
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
surgery	O	O
,	O	O
and	O	O
the	O	O
following	O	O
day	O	O
.	O	O

The	O	O
volume	O	O
of	O	O
irrigation	O	O
fluid	O	O
used	O	O
and	O	O
its	O	O
hemoglobin	O	O
concentration	O	O
as	O	O
well	O	O
as	O	O
resected	O	O
prostate	O	O
weight	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
68	O	O
patients	O	O
who	O	O
underwent	O	O
transurethral	O	Surgical
prostate	O	Surgical
resection	O	Surgical
2	O	Surgical
were	O	Surgical
withdrawn	O	Surgical
before	O	Surgical
surgery	O	Surgical
,	O	O
and	O	O
so	O	O
32	O	O
received	O	O
finasteride	Pharmacological	O
and	O	O
36	O	O
received	O	O
placebo	Control	Control
.	O	O

There	O	O
was	O	O
significantly	O	O
less	O	O
mean	O	O
blood	O	O
loss	O	O
in	O	O
irrigation	O	O
fluid	O	O
in	O	O
the	O	O
finasteride	Pharmacological	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
43.6	O	O
versus	O	O
69.3	O	O
gm	O	O
.	O	O

hemoglobin	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
difference	O	O
was	O	O
more	O	O
significant	O	O
when	O	O
blood	O	O
loss	O	O
per	O	O
gm	O	O
.	O	O

resected	O	O
prostate	O	O
was	O	O
calculated	O	O
(	O	O
2.65	O	O
versus	O	O
4.65	O	O
gm	O	O
.	O	O

hemoglobin	O	O
per	O	O
gm	O	O
.	O	O

prostate	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
finasteride	Pharmacological	O
given	O	O
for	O	O
2	O	O
weeks	O	O
preoperatively	O	O
decreases	O	O
bleeding	O	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	O	Surgical
prostate	O	Surgical
resection	O	Surgical
.	O	O

Further	O	O
study	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
timing	O	O
and	O	O
dose	O	O
duration	O	O
to	O	O
minimize	O	O
blood	O	O
loss	O	O
and	O	O
identify	O	O
how	O	O
relevant	O	O
such	O	O
a	O	O
decrease	O	O
in	O	O
bleeding	O	O
is	O	O
in	O	O
clinical	O	O
practice	O	O
.	O	O

Immunogenicity	O	O
and	O	O
safety	O	O
of	O	O
a	O	O
plasma-derived	Pharmacological	O
heat-inactivated	Pharmacological	O
hepatitis	Pharmacological	O
B	Pharmacological	O
vaccine	Pharmacological	O
(	Pharmacological	O
CLB	Pharmacological	O
)	Pharmacological	O
.	O	O

Studies	O	O
in	O	O
volunteers	O	O
at	O	O
a	O	O
low	O	O
risk	O	O
of	O	O
infection	O	O
with	O	O
hepatitis	O	O
B	O	O
virus	O	O
.	O	O

The	O	O
safety	O	O
and	O	O
immunogenicity	O	O
of	O	O
a	O	O
plasma-derived	Pharmacological	O
heat-inactivated	Pharmacological	O
hepatitis	Pharmacological	O
B	Pharmacological	O
vaccine	Pharmacological	O
(	Pharmacological	O
CLB	Pharmacological	O
)	Pharmacological	O
were	O	O
evaluated	O	O
in	O	O
471	O	O
healthy	O	O
human	O	O
volunteers	O	O
,	O	O
who	O	O
,	O	O
both	O	O
in	O	O
their	O	O
occupations	O	O
and	O	O
in	O	O
their	O	O
private	O	O
lives	O	O
,	O	O
had	O	O
been	O	O
at	O	O
minimal	O	O
risk	O	O
of	O	O
being	O	O
infected	O	O
with	O	O
hepatitis	O	O
B	O	O
virus	O	O
.	O	O

The	O	O
first	O	O
202	O	O
individuals	O	O
received	O	O
three	O	O
3-micrograms	O	O
doses	O	O
of	O	O
heat-inactivated	Pharmacological	O
hepatitis	Pharmacological	O
B	Pharmacological	O
surface	Pharmacological	O
antigen	Pharmacological	O
(	Pharmacological	O
HBsAg	Pharmacological	O
)	Pharmacological	O
at	O	O
one-month	O	O
intervals	O	O
(	O	O
trial	O	O
A	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
42	O	O
%	O	O
one	O	O
month	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
,	O	O
84	O	O
%	O	O
after	O	O
two	O	O
months	O	O
,	O	O
and	O	O
93	O	O
%	O	O
after	O	O
five	O	O
months	O	O
had	O	O
become	O	O
anti-HBs	O	O
(	O	O
antibody	O	O
to	O	O
hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
)	O	O
positive	O	O
.	O	O

In	O	O
a	O	O
second	O	O
randomized	O	O
study	O	O
(	O	O
trial	O	O
B	O	O
)	O	O
,	O	O
the	O	O
immunogenicity	O	O
of	O	O
five	O	O
different	O	O
dosages	O	O
of	O	O
the	O	O
vaccine	O	O
was	O	O
compared	O	O
in	O	O
269	O	O
volunteers	O	O
.	O	O

When	O	O
the	O	O
dose	O	O
of	O	O
HBsAg	O	O
was	O	O
diminished	O	O
from	O	O
3	O	O
micrograms	O	O
to	O	O
1.5	O	O
,	O	O
0.6	O	O
,	O	O
and	O	O
0.25	O	O
microgram	O	O
,	O	O
no	O	O
decrease	O	O
of	O	O
the	O	O
anti-HBs	O	O
response	O	O
was	O	O
observed	O	O
.	O	O

However	O	O
,	O	O
when	O	O
the	O	O
dose	O	O
was	O	O
diminished	O	O
to	O	O
0.1	O	O
microgram	O	O
of	O	O
HBsAg	O	O
,	O	O
the	O	O
anti-HBs	O	O
response	O	O
dropped	O	O
significantly	O	O
to	O	O
63	O	O
%	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
recipients	O	O
of	O	O
all	O	O
five	O	O
vaccine	O	O
dosages	O	O
,	O	O
no	O	O
influence	O	O
of	O	O
sex	O	O
and	O	O
age	O	O
was	O	O
found	O	O
on	O	O
the	O	O
anti-HBs	O	O
conversion	O	O
rates	O	O
.	O	O

During	O	O
the	O	O
eight-month	O	O
observation	O	O
period	O	O
,	O	O
none	O	O
of	O	O
the	O	O
vaccinees	O	O
became	O	O
HBsAg	O	O
and/or	O	O
anti-HBc	O	O
(	O	O
antibody	O	O
to	O	O
hepatitis	O	O
B	O	O
core	O	O
antigen	O	O
)	O	O
positive	O	O
,	O	O
and	O	O
none	O	O
developed	O	O
antibodies	O	O
associated	O	O
with	O	O
autoimmune	O	O
liver	O	O
disease	O	O
.	O	O

No	O	O
serious	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

An	O	O
open	O	O
and	O	O
randomized	O	O
study	O	O
comparing	O	O
the	O	O
efficacy	O	O
of	O	O
standard	Pharmacological	O
danazol	Pharmacological	O
and	O	O
modified	Pharmacological	O
triptorelin	Pharmacological	O
regimens	Pharmacological	O
for	O	O
postoperative	O	O
disease	O	O
management	O	O
of	O	O
moderate	O	O
to	O	O
severe	O	O
endometriosis	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
danazol	Pharmacological	O
and	O	O
triptorelin	Pharmacological	O
(	O	O
Decapeptyl	O	O
CR	O	O
,	O	O
Ferring	O	O
,	O	O
Kiel	O	O
,	O	O
Germany	O	O
)	O	O
in	O	O
the	O	O
management	O	O
of	O	O
moderate	O	O
and	O	O
severe	O	O
endometriosis	O	O
in	O	O
terms	O	O
of	O	O
symptom	O	O
control	O	O
and	O	O
revised	O	O
American	O	O
Fertility	O	O
Society	O	O
(	O	O
AFS	O	O
)	O	O
score	O	O
reduction	O	O
,	O	O
and	O	O
to	O	O
evaluate	O	O
the	O	O
hormonal	O	O
profile	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
triptorelin	Pharmacological	O
every	O	O
6	O	O
weeks	O	O
.	O	O

DESIGN	O	O
Open	O	O
and	O	O
randomized	O	O
trial	O	O
.	O	O

SETTING	O	O
Kwong	O	O
Wah	O	O
Hospital	O	O
,	O	O
a	O	O
large	O	O
public	O	O
hospital	O	O
in	O	O
an	O	O
urban	O	O
location	O	O
(	O	O
Hong	O	O
Kong	O	O
)	O	O
.	O	O

PATIENT	O	O
(	O	O
S	O	O
)	O	O
Forty	O	O
patients	O	O
after	O	O
their	O	O
first	O	O
conservative	O	O
operation	O	O
for	O	O
endometriosis	O	O
,	O	O
with	O	O
surgical	O	O
confirmation	O	O
of	O	O
revised	O	O
AFS	O	O
stage	O	O
III	O	O
or	O	O
IV	O	O
endometriosis	O	O
.	O	O

INTERVENTION	O	O
(	O	O
S	O	O
)	O	O
Postoperative	O	O
6	O	O
months	O	O
'	O	O
therapy	O	O
of	O	O
danazol	Pharmacological	O
or	O	O
triptorelin	Pharmacological	O
every	O	O
6	O	O
weeks	O	O
,	O	O
postmedical	O	O
therapy	O	O
second-look	O	O
laparoscopy	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURE	O	O
(	O	O
S	O	O
)	O	O
Symptom	O	O
control	O	O
and	O	O
patients	O	O
'	O	O
tolerance	O	O
during	O	O
medical	O	O
therapy	O	O
,	O	O
posttherapy	O	O
revised	O	O
AFS	O	O
score	O	O
,	O	O
hormonal	O	O
profile	O	O
during	O	O
triptorelin	O	Pharmacological
therapy	O	Pharmacological
.	O	O

RESULT	O	O
(	O	O
S	O	O
)	O	O
Pain	O	O
control	O	O
was	O	O
similar	O	O
between	O	O
danazol	Pharmacological	O
and	O	O
triptorelin	Pharmacological	O
therapy	O	O
.	O	O

There	O	O
was	O	O
less	O	O
breakthrough	O	O
bleeding	O	O
with	O	O
triptorelin	Pharmacological	O
.	Pharmacological	O

More	O	O
patients	O	O
failed	O	O
to	O	O
complete	O	O
the	O	O
whole	O	O
course	O	O
of	O	O
danazol	Pharmacological	O
because	O	O
of	O	O
its	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
revised	O	O
AFS	O	O
score	O	O
at	O	O
second-look	O	O
laparoscopy	O	O
did	O	O
not	O	O
show	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O	O
medications	O	O
.	O	O

Adequate	O	O
pituitary	O	O
suppression	O	O
was	O	O
observed	O	O
with	O	O
injection	O	O
of	O	O
triptorelin	Pharmacological	O
every	O	O
6	O	O
weeks	O	O
.	O	O

CONCLUSION	O	O
(	O	O
S	O	O
)	O	O
Lengthening	O	O
of	O	O
triptorelin	Pharmacological	O
administration	O	O
intervals	O	O
from	O	O
4	O	O
weeks	O	O
to	O	O
6	O	O
weeks	O	O
is	O	O
effective	O	O
in	O	O
maintaining	O	O
a	O	O
hypoestrogenic	O	O
state	O	O
.	O	O

Patients	O	O
were	O	O
more	O	O
compliant	O	O
with	O	O
triptorelin	Pharmacological	O
than	O	O
danazol	Pharmacological	O
.	Pharmacological	O

Thus	O	O
,	O	O
triptorelin	Pharmacological	O
injection	O	O
every	O	O
6	O	O
weeks	O	O
is	O	O
more	O	O
cost-effective	O	O
than	O	O
conventional	O	O
regimens	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
release	O	O
of	O	O
digoxin	Pharmacological	Pharmacological
from	O	O
four	O	O
different	O	O
soft	O	O
gelatin	O	O
capsule	Pharmacological	O
formulations	Pharmacological	O
.	Pharmacological	O

A	O	O
blinded	O	O
,	O	O
four-treatment	O	O
crossover	O	O
study	O	O
in	O	O
16	O	O
normal	O	O
adult	O	O
male	O	O
volunteers	O	O
compared	O	O
plasma	O	O
concentrations	O	O
and	O	O
urinary	O	O
excretion	O	O
of	O	O
digoxin	Pharmacological	O
,	O	O
measured	O	O
by	O	O
radioimmunoassay	O	O
,	O	O
after	O	O
oral	O	O
administration	O	O
of	O	O
soft	Pharmacological	O
gelatin	Pharmacological	O
capsule	Pharmacological	O
formulations	Pharmacological	O
of	Pharmacological	O
digoxin	Pharmacological	Pharmacological
.	Pharmacological	O

Four	O	O
0.4-mg	O	O
formulations	O	O
with	O	O
different	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
and	O	O
dissolution	O	O
rates	O	O
were	O	O
administered	O	O
,	O	O
with	O	O
2-week	O	O
intervals	O	O
between	O	O
treatments	O	O
.	O	O

The	O	O
two	O	O
capsules	O	O
with	O	O
lowest	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
(	O	O
2.9	O	O
and	O	O
16	O	O
min	O	O
)	O	O
gave	O	O
comparable	O	O
in	O	O
vivo	O	O
results	O	O
.	O	O

The	O	O
other	O	O
two	O	O
capsules	O	O
,	O	O
with	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
of	O	O
62	O	O
and	O	O
229	O	O
min	O	O
,	O	O
produced	O	O
significant	O	O
delays	O	O
in	O	O
digoxin	O	O
absorption	O	O
.	O	O

In	O	O
vitro-in	O	O
vivo	O	O
correlations	O	O
were	O	O
obtained	O	O
by	O	O
comparing	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
burst	O	O
time	O	O
with	O	O
time	O	O
to	O	O
peak	O	O
plasma	O	O
level	O	O
and	O	O
the	O	O
time	O	O
to	O	O
the	O	O
first	O	O
measurable	O	O
plasma	O	O
level	O	O
(	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

05	O	O
ng/ml	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
mean	O	O
time	O	O
to	O	O
peak	O	O
plasma	O	O
level	O	O
correlated	O	O
with	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
time	O	O
required	O	O
to	O	O
release	O	O
either	O	O
50	O	O
%	O	O
or	O	O
85	O	O
%	O	O
of	O	O
the	O	O
digoxin	O	Pharmacological
in	O	O
vitro	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
digoxin	Pharmacological	O
absorbed	O	O
from	O	O
each	O	O
capsule	O	O
as	O	O
determined	O	O
by	O	O
urinary	O	O
excretion	O	O
or	O	O
AUC0-infinity	O	O
.	O	O

Transcutaneous	Physical	Physical
electrical	Physical	Physical
nerve	Physical	Physical
stimulation	Physical	Physical
following	O	O
appendicectomy	O	O
:	O	O
the	O	O
placebo	O	O
effect	O	O
.	O	O

A	O	O
controlled	O	O
trial	O	O
was	O	O
undertaken	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
transcutaneous	Physical	Physical
electrical	Physical	Physical
nerve	Physical	Physical
stimulation	Physical	Physical
(	Physical	Physical
TENS	Physical	Physical
)	Physical	Physical
with	O	O
standard	O	O
intramuscular	O	O
opiate	Pharmacological	Pharmacological
analgesia	Pharmacological	Pharmacological
in	O	O
the	O	O
management	O	O
of	O	O
postoperative	O	O
pain	O	O
following	O	O
appendicectomy	O	O
.	O	O

Consecutive	O	O
patients	O	O
undergoing	O	O
emergency	Surgical	O
appendicectomy	Surgical	O
were	O	O
randomised	O	O
into	O	O
control	O	O
,	O	O
sham	Physical	Physical
TENS	Physical	Physical
and	O	O
active	Physical	O
TENS	Physical	O
groups	Physical	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
pain	O	O
severity	O	O
and	O	O
analgesic	O	O
intake	O	O
in	O	O
both	O	O
active	Physical	O
and	Physical	O
sham	Physical	Physical
TENS	Physical	Physical
groups	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	Control	O
group	Control	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
was	O	O
demonstrated	O	O
in	O	O
pain	O	O
severity	O	O
between	O	O
active	Physical	O
and	Physical	O
sham	Physical	Physical
TENS	Physical	Physical
groups	O	O
but	O	O
the	O	O
active	Physical	O
TENS	Physical	O
group	O	O
required	O	O
slightly	O	O
less	O	O
analgesia	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
major	O	O
benefit	O	O
of	O	O
TENS	Physical	O
in	O	O
the	O	O
postappendicectomy	O	O
patient	O	O
is	O	O
due	O	O
to	O	O
its	O	O
'placebo	O	O
effect	O	O
'	O	O
and	O	O
its	O	O
use	O	O
in	O	O
this	O	O
situation	O	O
can	O	O
not	O	O
be	O	O
recommended	O	O
.	O	O

Concurrent	O	O
alcohol	Educational	O
dependence	Educational	O
among	O	O
methadone-maintained	O	O
cocaine	O	O
abusers	O	O
is	O	O
associated	O	O
with	O	O
greater	O	O
abstinence	O	O
.	O	O

Concurrent	Educational	O
alcohol	Educational	O
dependence	Educational	O
(	Educational	O
AD	Educational	O
)	Educational	O
among	O	O
polysubstance	O	O
abusers	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
negative	O	O
consequences	O	O
,	O	O
although	O	O
it	O	O
may	O	O
not	O	O
necessarily	O	O
lead	O	O
to	O	O
poor	O	O
treatment	O	O
outcomes	O	O
.	O	O

One	O	O
of	O	O
the	O	O
most	O	O
efficacious	O	O
treatments	O	O
for	O	O
cocaine	O	O
abuse	O	O
is	O	O
contingency	Educational	O
management	Educational	O
(	Educational	O
CM	Educational	O
)	Educational	O
,	O	O
but	O	O
little	O	O
research	O	O
has	O	O
explored	O	O
the	O	O
impact	O	O
of	O	O
AD	Educational	O
on	O	O
abstinence	O	O
outcomes	O	O
,	O	O
particularly	O	O
among	O	O
patients	O	O
in	O	O
methadone	O	O
maintenance	O	O
.	O	O

Using	O	O
data	O	O
from	O	O
three	O	O
trials	O	O
of	O	O
CM	O	Pharmacological
for	O	O
cocaine	O	O
use	O	O
,	O	O
we	O	O
compared	O	O
baseline	O	O
characteristics	O	O
and	O	O
posttreatment	O	O
and	O	O
follow-up	O	O
cocaine	O	O
outcomes	O	O
between	O	O
methadone-maintained	Pharmacological	O
,	O	O
cocaine-dependent	Pharmacological	O
patients	O	O
(	O	O
N	O	O
=	O	O
193	O	O
)	O	O
with	Educational	O
and	Educational	O
without	Educational	O
concurrent	Educational	O
AD	Educational	O
,	Educational	O
randomized	Educational	O
to	Educational	O
standard	Educational	Educational
care	Educational	Educational
(	Educational	Educational
SC	Educational	Educational
)	Educational	Educational
with	Educational	Educational
or	Educational	Educational
without	Educational	Educational
CM	Educational	Educational
.	Educational	O

Patients	O	O
with	Educational	O
and	Educational	O
without	Educational	O
concurrent	Educational	O
AD	Educational	O
had	O	O
similar	O	O
baseline	O	O
characteristics	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
that	O	O
AD	Educational	O
patients	O	O
reported	O	O
more	O	O
alcohol	O	O
use	O	O
.	O	O

AD	Educational	O
patients	O	O
achieved	O	O
longer	O	O
durations	O	O
of	O	O
cocaine	O	O
abstinence	O	O
and	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
submit	O	O
a	O	O
cocaine-negative	O	O
sample	O	O
at	O	O
follow-up	O	O
than	O	O
non-AD	Educational	O
patients	O	O
.	O	O

Patients	O	O
randomized	O	O
to	O	O
CM	Educational	O
achieved	O	O
better	O	O
outcomes	O	O
than	O	O
those	O	O
randomized	O	O
to	O	O
SC	Educational	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
interaction	O	O
between	O	O
treatment	O	O
condition	O	O
and	O	O
AD	Educational	O
status	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
cocaine-using	O	O
methadone	O	O
patients	O	O
with	O	O
AD	Educational	O
achieve	O	O
greater	O	O
cocaine	O	O
abstinence	O	O
than	O	O
their	O	O
non-AD	Educational	O
counterparts	O	O
and	O	O
should	O	O
not	O	O
necessarily	O	O
be	O	O
viewed	O	O
as	O	O
more	O	O
difficult	O	O
to	O	O
treat	O	O
.	O	O

A	O	O
randomized	O	O
trial	O	O
of	O	O
radiation	Surgical	Physical
therapy	Surgical	Physical
compared	O	O
to	O	O
split	Surgical	Physical
course	Surgical	Physical
radiation	Surgical	Physical
therapy	Surgical	Physical
combined	O	O
with	O	O
mitomycin	Pharmacological	O
C	Pharmacological	O
and	O	O
5	Pharmacological	O
fluorouracil	Pharmacological	O
as	O	O
initial	O	O
treatment	O	O
for	O	O
advanced	O	O
laryngeal	O	O
and	O	O
hypopharyngeal	O	O
squamous	O	O
carcinoma	O	O
.	O	O

Two	O	O
hundred	O	O
and	O	O
twelve	O	O
patients	O	O
with	O	O
previously	O	O
untreated	O	O
advanced	O	O
squamous	O	O
carcinoma	O	O
of	O	O
the	O	O
larynx	O	O
or	O	O
hypopharynx	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
initial	O	O
treatment	O	O
with	O	O
radiotherapy	Surgical	Physical
,	O	O
50	O	O
Gy	O	O
in	O	O
20	O	O
fractions	O	O
in	O	O
28	O	O
days	O	O
or	O	O
split	Surgical	O
course	Surgical	O
radiotherapy	Surgical	O
and	O	O
concurrent	Pharmacological	Pharmacological
chemotherapy	Pharmacological	Pharmacological
,	O	O
25	O	O
Gy	O	O
in	O	O
10	O	O
fractions	O	O
in	O	O
14	O	O
days	O	O
followed	O	O
by	O	O
a	O	O
4	O	O
week	O	O
rest	O	O
and	O	O
a	O	O
further	O	O
25	O	O
Gy	O	O
in	O	O
10	O	O
fractions	O	O
in	O	O
14	O	O
days	O	O
starting	O	O
on	O	O
day	O	O
43	O	O
;	O	O
Mitomycin	Pharmacological	O
C	Pharmacological	O
was	O	O
given	O	O
on	O	O
day	O	O
1	O	O
and	O	O
day	O	O
43	O	O
and	O	O
5FU	Pharmacological	Pharmacological
continuous	O	Pharmacological
infusions	O	Pharmacological
on	O	O
days	O	O
1	O	O
--	O	O
4	O	O
and	O	O
days	O	O
43	O	O
--	O	O
46	O	O
.	O	O

Surgery	O	O
was	O	O
reserved	O	O
for	O	O
persistent	O	O
or	O	O
recurrent	O	O
disease	O	O
.	O	O

Two	O	O
hundred	O	O
and	O	O
nine	O	O
of	O	O
the	O	O
212	O	O
patients	O	O
randomized	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analyses	O	O
.	O	O

Outcome	O	O
analyses	O	O
were	O	O
performed	O	O
at	O	O
a	O	O
median	O	O
follow-up	O	O
interval	O	O
of	O	O
4.4	O	O
years	O	O
.	O	O

No	O	O
patients	O	O
were	O	O
lost	O	O
to	O	O
follow-up	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
found	O	O
between	O	O
the	O	O
two	O	O
arms	O	O
for	O	O
the	O	O
end	O	O
points	O	O
of	O	O
local	O	O
relapse-free	O	O
rate	O	O
(	O	O
p	O	O
=	O	O
0.91	O	O
)	O	O
,	O	O
regional	O	O
relapse-free	O	O
rate	O	O
(	O	O
p	O	O
=	O	O
0.17	O	O
,	O	O
adjusted	O	O
)	O	O
or	O	O
overall	O	O
survival	O	O
(	O	O
p	O	O
=	O	O
0.86	O	O
)	O	O
.	O	O

Eight-eight	O	O
patients	O	O
had	O	O
attempted	O	Surgical
surgical	O	Surgical
resection	O	Surgical
following	O	Surgical
radiotherapy	Surgical	Surgical
failure	O	Surgical
.	O	O

The	O	O
contribution	O	O
of	O	O
salvage	O	O
surgery	O	O
to	O	O
overall	O	O
survival	O	O
was	O	O
similar	O	O
for	O	O
both	O	O
arms	O	O
of	O	O
the	O	O
study	O	O
as	O	O
was	O	O
the	O	O
surgical	O	O
complication	O	O
rate	O	O
.	O	O

Serious	O	O
late	O	O
radiation	O	O
toxicity	O	O
was	O	O
minimal	O	O
(	O	O
3	O	O
%	O	O
in	O	O
the	O	O
RT	O	O
group	O	O
,	O	O
0	O	O
%	O	O
in	O	O
the	O	O
radiation	O	Physical
therapy	O	Physical
plus	O	Physical
chemotherapy	O	Physical
group	O	O
)	O	O
.	O	O

The	O	O
result	O	O
of	O	O
the	O	O
trial	O	O
shows	O	O
no	O	O
advantage	O	O
in	O	O
terms	O	O
of	O	O
local	O	O
control	O	O
or	O	O
survival	O	O
for	O	O
the	O	O
experimental	O	O
treatment	O	O
arm	O	O
of	O	O
split	O	O
course	O	O
radiotherapy	Surgical	O
and	O	O
concurrent	Pharmacological	Pharmacological
chemotherapy	Pharmacological	Pharmacological
with	O	O
Mitomycin	Pharmacological	O
C	Pharmacological	O
and	O	O
5	Pharmacological	O
Fluorouracil	Pharmacological	Pharmacological
compared	O	O
to	O	O
radiotherapy	O	O
alone	O	O
.	O	O

[	O	O
Dose-reduced	O	O
antihypertensive	Pharmacological	O
agents	Pharmacological	O
--	O	O
use	O	O
in	O	O
complex	O	O
nonmedicamentous	Pharmacological	O
therapy	O	O
of	O	O
hypertension	O	O
]	O	O
.	O	O

In	O	O
order	O	O
to	O	O
estimate	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
non-medicamentous	Pharmacological	O
therapy	Pharmacological	O
(	Pharmacological	O
CNT	Pharmacological	O
)	Pharmacological	O
on	O	O
the	O	O
consumption	O	O
of	O	O
medicaments	O	O
and	O	O
coronary	O	O
risk	O	O
in	O	O
high	O	O
blood	O	O
pressure	O	O
73	O	O
hypertensives	O	O
of	O	O
a	O	O
medicamentously	O	O
stabilized	O	O
CNT-group	O	O
were	O	O
examined	O	O
in	O	O
comparison	O	O
to	O	O
a	O	O
group	O	O
of	O	O
the	O	O
same	O	O
size	O	O
of	O	O
patients	O	O
with	O	O
hypertension	O	O
who	O	O
were	O	O
managed	O	O
exclusively	O	O
medicamentously	O	O
for	O	O
behaviour	O	O
of	O	O
blood	O	O
pressure	O	O
,	O	O
need	O	O
of	O	O
antihypertensive	Pharmacological	O
drugs	Pharmacological	O
and	O	O
changes	O	O
of	O	O
hypertension-associated	O	O
risk	O	O
factors	O	O
.	O	O

After	O	O
an	O	O
exactly	O	O
controlled	O	O
6-month	O	O
treatment	O	O
hypertensives	O	O
with	O	O
additionally	O	O
recommended	O	O
far-reaching	O	O
CNT	O	O
showed	O	O
an	O	O
economization	O	O
of	O	O
medicaments	O	O
by	O	O
scarcely	O	O
the	O	O
half	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
reference	O	O
group	O	O
.	O	O

By	O	O
means	O	O
of	O	O
suitable	O	O
control	O	O
methods	O	O
a	O	O
causal	O	O
non-medicamentously	Pharmacological	O
conditioned	O	O
decrease	O	O
of	O	O
blood	O	O
pressure	O	O
could	O	O
be	O	O
excluded	O	O
.	O	O

A	O	O
different	O	O
need	O	O
of	O	O
antihypertensive	Pharmacological	O
drugs	Pharmacological	O
was	O	O
simulated	O	O
by	O	O
the	O	O
exacter	O	O
intake	O	O
of	O	O
medicaments	O	O
in	O	O
the	O	O
index-patients	O	O
.	O	O

Notwithstanding	O	O
the	O	O
metabolic	O	O
effects	O	O
of	O	O
the	O	O
additional	O	O
therapy	O	O
have	O	O
induced	O	O
a	O	O
positive	O	O
change	O	O
of	O	O
atherogenic	O	O
lipids	O	O
.	O	O

The	O	O
examinations	O	O
indicate	O	O
in	O	O
general	O	O
the	O	O
difficulty	O	O
of	O	O
the	O	O
judgement	O	O
of	O	O
efficacy	O	O
of	O	O
non-medicamentous	Pharmacological	O
therapeutic	Pharmacological	O
measures	O	O
in	O	O
connection	O	O
with	O	O
a	O	O
rational	O	O
dose-reduced	O	O
long-term	O	O
therapy	O	O
with	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
dietary	Pharmacological	O
fibre	Pharmacological	O
source	Pharmacological	O
and	O	O
gender	O	O
on	O	O
the	O	O
postprandial	O	O
glucose	O	O
and	O	O
lipid	O	O
response	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

BACKGROUND	O	O
Consumption	O	O
of	O	O
soluble	Pharmacological	O
dietary	Pharmacological	O
fibre	Pharmacological	O
is	O	O
correlated	O	O
with	O	O
decreased	O	O
postprandial	O	O
glucose	O	O
and	O	O
insulin	O	O
responses	O	O
and	O	O
hence	O	O
has	O	O
beneficial	O	O
effects	O	O
on	O	O
the	O	O
metabolic	O	O
syndrome	O	O
.	O	O

AIM	O	O
OF	O	O
THE	O	O
STUDY	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
on	O	O
postprandial	O	O
glucose	O	O
,	O	O
insulin	O	O
and	O	O
triglyceride	O	O
concentrations	O	O
of	O	O
meals	O	O
enriched	O	O
with	O	O
soluble	O	O
dietary	O	O
fibres	O	O
from	O	O
oats	O	O
,	O	O
rye	O	O
bran	O	O
,	O	O
sugar	O	Pharmacological
beet	O	Pharmacological
fibre	O	Pharmacological
or	O	O
a	O	O
mixture	O	O
of	O	O
these	O	O
three	O	O
fibres	O	O
.	O	O

METHODS	O	O
Thirteen	O	O
healthy	O	O
human	O	O
volunteers	O	O
(	O	O
6	O	O
men	O	O
and	O	O
7	O	O
women	O	O
,	O	O
aged	O	O
20-28	O	O
years	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
subjects	O	O
came	O	O
to	O	O
the	O	O
study	O	O
centre	O	O
once	O	O
a	O	O
week	O	O
after	O	O
an	O	O
overnight	O	O
fast	O	O
to	O	O
ingest	O	O
test	O	O
meals	Pharmacological	O
and	O	O
a	O	O
control	O	O
meal	O	O
in	O	O
random	O	O
order	O	O
.	O	O

The	O	O
meals	O	O
contained	O	O
either	O	O
oat	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
(	O	O
62	O	O
g	O	O
,	O	O
of	O	O
which	O	Pharmacological
2.7	O	Pharmacological
soluble	O	Pharmacological
fibre	O	Pharmacological
)	O	Pharmacological
,	O	O
rye	Pharmacological	O
bran	Pharmacological	O
(	O	O
31	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	Pharmacological
fibre	O	Pharmacological
)	O	Pharmacological
,	O	O
sugar	Pharmacological	O
beet	Pharmacological	O
fibre	Pharmacological	O
(	O	O
19	O	O
g	O	O
,	O	O
of	O	O
which	O	Pharmacological
5	O	Pharmacological
g	O	Pharmacological
soluble	O	Pharmacological
fibre	O	Pharmacological
)	O	Pharmacological
,	O	O
a	O	O
mixture	Other	O
of	O	O
these	O	O
three	O	O
fibres	O	O
(	O	O
74	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	O
fibre	O	O
from	O	O
each	O	O
source	O	O
,	O	O
giving	O	Pharmacological
5	O	Pharmacological
g	O	Pharmacological
soluble	O	Pharmacological
fibre	O	Pharmacological
)	O	Pharmacological
or	O	O
no	O	Control
added	Control	Control
fibre	Control	Control
(	Control	Control
control	Control	Control
)	Control	O
and	O	O
were	O	O
all	O	O
adjusted	O	O
to	O	O
contain	O	O
the	O	O
same	O	O
total	O	O
amount	O	O
of	O	O
available	O	O
carbohydrates	Other	O
.	Other	O

Blood	O	O
samples	O	O
were	O	O
drawn	O	O
before	O	O
and	O	O
every	O	O
30	O	O
min	O	O
up	O	O
to	O	O
180	O	O
min	O	O
after	O	O
the	O	O
meals	O	O
.	O	O

RESULTS	O	O
Meals	Pharmacological	O
with	Pharmacological	O
rye	Pharmacological	O
bran	Pharmacological	O
gave	O	O
a	O	O
lower	O	O
postprandial	O	O
glucose	O	O
peak	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	O	O
,	O	O
and	O	O
this	O	O
effect	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
women	O	O
compared	O	O
to	O	O
men	O	O
.	O	O

Oat	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
,	O	Pharmacological
containing	O	Pharmacological
a	O	Pharmacological
low	O	Pharmacological
amount	O	Pharmacological
of	O	Pharmacological
total	O	Pharmacological
fibre	O	Pharmacological
and	O	O
a	O	O
high	O	O
amount	O	O
of	O	O
carbohydrates	O	O
in	O	O
liquid	O	O
matrix	O	O
,	O	O
gave	O	O
a	O	O
higher	O	O
incremental	O	O
glucose	O	O
peak	O	O
concentration	O	O
compared	O	O
to	O	O
rye	O	O
bran	O	O
and	O	O
sugar	O	O
beet	O	O
fibre	O	O
and	O	O
higher	O	O
insulin	O	O
incremental	O	O
area	O	O
under	O	O
curve	O	O
compared	O	O
to	O	O
control	O	O
.	O	O

The	O	O
oat	Pharmacological	Pharmacological
powder	Pharmacological	Pharmacological
also	O	O
influenced	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
mixed	O	O
meal	O	O
,	O	O
diminishing	O	O
the	O	O
glucose-lowering	O	O
effects	O	O
.	O	O

Postprandial	O	O
triglyceride	O	O
levels	O	O
tended	O	O
to	O	O
be	O	O
higher	O	O
after	O	O
all	O	O
fibre-rich	O	O
meals	O	O
,	O	O
but	O	O
only	O	O
significant	O	O
for	O	O
oat	O	O
powder	O	O
and	O	O
the	O	O
mixed	O	O
meal	Pharmacological	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	Control	O
.	Pharmacological	O

CONCLUSIONS	O	O
Postprandial	O	O
glucose	O	O
,	O	O
insulin	O	O
and	O	O
triglyceride	O	O
concentrations	O	O
are	O	O
influenced	O	O
by	O	O
dietary	Pharmacological	O
fibre-rich	Pharmacological	O
meals	Pharmacological	O
,	O	O
depending	O	O
on	O	O
fibre	O	O
source	O	O
,	O	O
dose	O	O
of	O	O
soluble	O	O
and	O	O
total	O	O
fibre	O	O
and	O	O
possibly	O	O
gender	O	O
.	O	O

Comparative	O	O
drug	O	O
effects	O	O
and	O	O
abuse	O	O
liability	O	O
of	O	O
lorazepam	Pharmacological	Pharmacological
,	O	O
buspirone	Pharmacological	Pharmacological
,	O	O
and	O	O
secobarbital	Pharmacological	O
in	O	O
nondependent	O	O
subjects	O	O
.	O	O

The	O	O
pharmacologic	O	O
effects	O	O
of	O	O
lorazepam	Pharmacological	Pharmacological
(	O	Pharmacological
2	O	Pharmacological
mg	O	Pharmacological
)	O	Pharmacological
,	O	Pharmacological
buspirone	Pharmacological	Pharmacological
(	O	O
20	O	O
mg	O	O
,	O	O
10	O	O
mg	O	O
)	O	O
,	O	O
secobarbital	Pharmacological	O
(	O	O
100	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
placebo	Control	Control
were	O	O
compared	O	O
in	O	O
15	O	O
male	O	O
,	O	O
experienced	O	O
,	O	O
intermittent	O	O
nontherapeutic	O	O
drug	O	O
users	O	O
.	O	O

All	O	O
drugs	O	O
produced	O	O
a	O	O
drug	O	O
effect	O	O
,	O	O
however	O	O
,	O	O
buspirone	Pharmacological	O
20	O	O
mg	O	O
was	O	O
significantly	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
lorazepam	Pharmacological	O
,	O	O
secobarbital	Pharmacological	O
,	O	O
or	O	O
buspirone	Pharmacological	Pharmacological
10	O	O
mg	O	O
(	O	O
p	O	O
less	O	O
than	O	O
.05	O	O
)	O	O
but	O	O
not	O	O
placebo	Control	Control
.	Control	O

Lorazepam	Pharmacological	O
was	O	O
liked	O	O
better	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
only	O	O
at	O	O
1	O	O
hour	O	O
and	O	O
only	O	O
compared	O	O
with	O	O
buspirone	Pharmacological	Pharmacological
20	O	O
and	O	O
placebo	Control	O
.	Control	O

Compared	O	O
with	O	O
other	O	O
drugs	O	O
,	O	O
lorazepam	Pharmacological	O
drug	O	O
effects	O	O
were	O	O
greater	O	O
and	O	O
resulted	O	O
in	O	O
more	O	O
prolonged	O	O
impairment	O	O
of	O	O
a	O	O
motor	O	O
tracking	O	O
task	O	O
,	O	O
standing	O	O
steadiness	O	O
,	O	O
and	O	O
memory	O	O
.	O	O

Buspirone	Pharmacological	O
20	O	O
mg	O	O
significantly	O	O
impaired	O	O
memory	O	O
at	O	O
1	O	O
hour	O	O
compared	O	O
with	O	O
placebo	Pharmacological	O
.	Pharmacological	O

Subjects	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
identify	O	O
buspirone	Pharmacological	O
as	O	O
unfamiliar	O	O
.	O	O

Because	O	O
buspirone	Pharmacological	O
20	O	O
mg	O	O
was	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
,	O	O
dose	O	O
escalation	O	O
as	O	O
part	O	O
of	O	O
drug	O	O
abuse	O	O
is	O	O
not	O	O
likely	O	O
to	O	O
occur	O	O
.	O	O

Lorazepam	Pharmacological	O
also	O	O
was	O	O
not	O	O
particularly	O	O
liked	O	O
and	O	O
was	O	O
not	O	O
different	O	O
from	O	O
placebo	Control	O
on	O	O
most	O	O
subjective	O	O
abuse-relevant	O	O
measures	O	O
.	O	O

Effects	O	O
of	O	O
interaction	O	O
of	O	O
RRR-alpha-tocopheryl	Pharmacological	O
acetate	Pharmacological	O
and	O	O
fish	Pharmacological	O
oil	Pharmacological	O
on	O	O
low-density-lipoprotein	O	O
oxidation	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
and	O	O
without	O	O
hormone-replacement	Pharmacological	O
therapy	Pharmacological	O
.	Pharmacological	O

We	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
RRR-alpha-tocpheryl	Pharmacological	Pharmacological
acetate	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
alpha-tocopheryl	Pharmacological	Pharmacological
acetate	Pharmacological	Pharmacological
)	Pharmacological	O
and	O	O
hormone-replacement	Pharmacological	Pharmacological
therapy	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
HRT	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
on	O	O
the	O	O
oxidative	O	O
susceptibility	O	O
of	O	O
low-density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
in	O	O
postmenopausal	O	O
women	O	O
consuming	O	O
a	O	O
fish	Pharmacological	Pharmacological
oil	Pharmacological	Pharmacological
supplement	Pharmacological	Pharmacological
.	Pharmacological	O

The	O	O
independent	O	O
effect	O	O
of	O	O
fish	O	O
oil	O	O
was	O	O
also	O	O
assessed	O	O
.	O	O

Forty-eight	O	O
women	O	O
,	O	O
equally	O	O
divided	O	O
between	O	O
women	O	O
using	O	O
and	O	O
not	O	O
using	O	O
HRT	Pharmacological	O
,	O	O
participated	O	O
in	O	O
a	O	O
double-blind	O	O
crossover	O	O
trial	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
four	O	O
periods	O	O
lasted	O	O
5	O	O
wk	O	O
and	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
4-wk	O	O
washout	O	O
interval	O	O
.	O	O

During	O	O
each	O	O
period	O	O
all	O	O
subjects	O	O
were	O	O
given	O	O
a	O	O
15-g	O	O
supplement	O	O
of	O	O
fish	O	O
oil	O	O
and	O	O
either	O	O
0	O	O
(	O	O
placebo	Control	O
)	O	O
,	O	O
100	O	O
,	O	O
200	O	O
,	O	O
or	O	O
400	O	Pharmacological
mg	O	Pharmacological
alpha-tocopheryl	Pharmacological	Pharmacological
acetate	Pharmacological	Pharmacological
daily	O	O
.	O	O

LDL	O	O
resistance	O	O
to	O	O
oxidative	O	O
modification	O	O
was	O	O
assessed	O	O
by	O	O
calculating	O	O
lag	O	O
time	O	O
,	O	O
propagation	O	O
rate	O	O
,	O	O
and	O	O
maximum	O	O
production	O	O
of	O	O
conjugated	O	O
dienes	O	O
.	O	O

Supplementation	O	O
with	O	O
fish	O	Pharmacological
oil	O	Pharmacological
and	O	O
placebo	Control	Control
shortened	O	O
lag	O	O
time	O	O
and	O	O
slowed	O	O
propagation	O	O
rate	O	O
in	O	O
women	O	O
both	O	O
using	O	O
and	O	O
not	O	O
using	O	O
HRT	O	Pharmacological
.	O	O

After	O	O
subjects	O	O
consumed	O	O
fish	O	O
oil	O	O
,	O	O
supplementation	O	O
with	O	O
alpha-tocopheryl	O	Pharmacological
acetate	O	Pharmacological
increased	O	O
plasma	O	O
and	O	O
LDL	O	O
alpha-tocopherol	O	O
contents	O	O
significantly	O	O
and	O	O
lengthened	O	O
lag	O	O
time	O	O
(	O	O
at	O	O
even	O	O
the	O	O
lowest	O	O
concentration	O	O
)	O	O
but	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
propagation	O	O
rate	O	O
or	O	O
maximum	O	O
production	O	O
compared	O	O
with	O	O
values	O	O
measured	O	O
after	O	O
consumption	O	O
of	O	O
fish	O	O
oil	O	O
alone	O	O
.	O	O

Women	O	O
not	O	O
using	O	O
HRT	O	O
had	O	O
faster	O	O
propagation	O	O
rates	O	O
and	O	O
higher	O	O
maximum	O	O
production	O	O
than	O	O
women	O	O
using	O	O
HRT	O	O
;	O	O
after	O	O
supplementation	O	O
with	O	O
fish	O	O
oil	O	O
and	O	O
alpha-tocopheryl	Pharmacological	O
acetate	O	O
these	O	O
differences	O	O
prevailed	O	O
.	O	O

Supplements	O	O
as	O	O
low	O	O
as	O	O
100	O	O
mg	O	O
alpha-tocopheryl	O	O
acetate/d	O	O
increase	O	O
the	O	O
resistance	O	O
of	O	O
LDL	O	O
to	O	O
oxidation	O	O
when	O	O
fish	O	O
oil	O	O
supplements	O	O
are	O	O
used	O	O
.	O	O

HRT	O	Pharmacological
and	O	O
fish	O	O
oil	O	O
supplements	O	O
may	O	O
independently	O	O
affect	O	O
LDL	O	O
oxidative	O	O
susceptibility	O	O
.	O	O

Failure	O	O
of	O	O
naltrexone	Pharmacological	Pharmacological
hydrochloride	Pharmacological	Pharmacological
to	O	O
reduce	O	O
self-injurious	O	O
and	O	O
autistic	O	O
behavior	O	O
in	O	O
mentally	O	O
retarded	O	O
adults	O	O
.	O	O

Double-blind	O	O
placebo-controlled	Control	O
studies	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
hypothesized	O	O
that	O	O
self-injurious	O	O
behavior	O	O
(	O	O
SIB	O	O
)	O	O
and	O	O
symptoms	O	O
of	O	O
autism	O	O
may	O	O
be	O	O
due	O	O
to	O	O
overactivity	O	O
in	O	O
some	O	O
opioid	O	O
systems	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
naltrexone	Pharmacological	Pharmacological
hydrochloride	Pharmacological	Pharmacological
,	O	O
an	O	O
opioid	O	Pharmacological
antagonist	O	Pharmacological
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
SIB	O	O
and	O	O
autism	O	O
in	O	O
mentally	O	O
retarded	O	O
adults	O	O
.	O	O

METHOD	O	O
Thirty-three	O	O
mentally	O	O
retarded	O	O
adults	O	O
with	O	O
autism	O	O
and/or	O	O
SIB	O	O
participated	O	O
in	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	Control
crossover	O	O
studies	O	O
.	O	O

Active	O	O
treatment	O	O
was	O	O
first	O	O
a	O	O
single	O	O
100-mg	O	O
dose	O	O
of	O	O
naltrexone	Pharmacological	Pharmacological
hydrochloride	Pharmacological	Pharmacological
.	Pharmacological	O

Subsequently	O	O
,	O	O
19	O	O
subjects	O	O
were	O	O
treated	O	O
with	O	O
50	O	O
mg/d	O	O
and	O	O
14	O	O
with	O	O
150	O	O
mg/d	O	O
of	O	O
naltrexone	Pharmacological	Pharmacological
hydrochloride	Pharmacological	Pharmacological
for	O	O
4	O	O
weeks	O	O
.	O	O

The	O	O
outcome	O	O
was	O	O
assessed	O	O
by	O	O
means	O	O
of	O	O
direct	O	O
observations	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
and	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
scores	O	O
on	O	O
a	O	O
list	O	O
of	O	O
target	O	O
behaviors	O	O
,	O	O
the	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
,	O	O
and	O	O
the	O	O
Clinical	O	O
Global	O	O
Impression	O	O
Scale	O	O
.	O	O

RESULTS	O	O
Thirty-two	O	O
subjects	O	O
(	O	O
seven	O	O
with	O	O
autism	O	O
,	O	O
16	O	O
with	O	O
autism	O	O
and	O	O
SIB	O	O
,	O	O
and	O	O
nine	O	O
with	O	O
SIB	O	O
)	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Naltrexone	Pharmacological	Pharmacological
treatment	O	O
failed	O	O
to	O	O
have	O	O
therapeutic	O	O
effects	O	O
on	O	O
SIB	O	O
and	O	O
autism	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
naltrexone	Pharmacological	O
increased	O	O
the	O	O
incidence	O	O
of	O	O
stereotypic	O	O
behavior	O	O
on	O	O
the	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
,	O	O
and	O	O
the	O	O
care	O	O
staff	O	O
evaluated	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
50-mg/d	O	O
treatment	O	O
as	O	O
being	O	O
significantly	O	O
worse	O	O
than	O	O
that	O	O
of	O	O
the	O	O
placebo	O	O
treatment	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Clinical	O	O
Global	O	O
Impression	O	O
Scale	O	O
.	O	O

CONCLUSION	O	O
Our	O	O
findings	O	O
suggest	O	O
that	O	O
naltrexone	O	Pharmacological
has	O	O
no	O	O
clinical	O	O
value	O	O
for	O	O
a	O	O
broad	O	O
group	O	O
of	O	O
mentally	O	O
retarded	O	O
subjects	O	O
with	O	O
SIB	O	O
and/or	O	O
autism	O	O
.	O	O

Junctional	O	O
ectopic	O	O
tachycardia	O	O
after	O	O
congenital	O	Surgical
heart	O	Surgical
surgery	O	Surgical
in	O	Surgical
the	O	Surgical
current	O	Surgical
surgical	O	Surgical
era	O	Surgical
.	O	O

To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
junctional	O	O
ectopic	O	O
tachycardia	O	O
(	O	O
JET	O	O
)	O	O
in	O	O
a	O	O
modern	O	O
cohort	O	O
of	O	O
pediatric	O	O
patients	O	O
,	O	O
evaluate	O	O
possible	O	O
risk	O	O
factors	O	O
for	O	O
JET	O	O
,	O	O
and	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
JET	O	O
on	O	O
postoperative	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

JET	O	O
is	O	O
common	O	O
after	O	O
congenital	O	O
heart	O	O
surgery	O	O
.	O	O

JET-related	O	O
mortality	O	O
has	O	O
been	O	O
a	O	O
rare	O	O
event	O	O
at	O	O
our	O	O
center	O	O
,	O	O
which	O	O
is	O	O
different	O	O
from	O	O
previous	O	O
reports	O	O
.	O	O

We	O	O
reviewed	O	O
records	O	O
for	O	O
pediatric	O	O
patients	O	O
who	O	O
had	O	O
postoperative	O	O
arrhythmias	O	O
between	O	O
January	O	O
2006	O	O
and	O	O
June	O	O
2010	O	O
at	O	O
a	O	O
large	O	O
tertiary-care	O	O
children	O	O
's	O	O
hospital	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
matched	O	O
case-control	O	O
study	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
for	O	O
JET	O	O
and	O	O
a	O	O
matched-cohort	O	O
study	O	O
to	O	O
compare	O	O
outcomes	O	O
between	O	O
patients	O	O
and	O	O
controls	O	O
.	O	O

Whenever	O	O
possible	O	O
,	O	O
each	O	O
JET	O	O
case	O	O
was	O	O
randomly	O	O
matched	O	O
to	O	O
two	O	O
controls	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
lesion	O	O
,	O	O
repair	O	O
,	O	O
and	O	O
surgical	O	O
period	O	O
.	O	O

We	O	O
identified	O	O
54	O	O
patients	O	O
with	O	O
JET	O	O
(	O	O
incidence	O	O
=	O	O
1.4	O	O
%	O	O
)	O	O
.	O	O

After	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
,	O	O
low	O	O
operative	O	O
weight	O	O
,	O	O
cardiopulmonary	O	O
bypass	O	O
(	O	O
CPB	O	O
)	O	O
duration	O	O
>	O	O
100	O	O
min	O	O
,	O	O
and	O	O
immediate	O	O
postoperative	O	O
serum	O	O
lactic	O	O
acid	O	O
level	O	O
>	O	O
20	O	O
mg/dl	O	O
were	O	O
associated	O	O
with	O	O
increased	O	O
odds	O	O
of	O	O
developing	O	O
JET	O	O
.	O	O

Patients	O	O
with	O	O
JET	O	O
had	O	O
longer	O	O
mechanical	O	O
ventilation	O	O
time	O	O
,	O	O
cardiac	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
CICU	O	O
)	O	O
stay	O	O
,	O	O
and	O	O
hospital	O	O
stay	O	O
.	O	O

There	O	O
was	O	O
only	O	O
one	O	O
death	O	O
in	O	O
JET	O	O
group	O	O
(	O	O
1.8	O	O
%	O	O
)	O	O
with	O	O
no	O	O
significant	O	O
difference	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

JET	O	O
remains	O	O
a	O	O
relatively	O	O
common	O	O
postoperative	O	O
arrhythmia	O	O
,	O	O
but	O	O
it	O	O
is	O	O
less	O	O
frequent	O	O
than	O	O
previously	O	O
reported	O	O
.	O	O

JET	O	O
occurs	O	O
more	O	O
commonly	O	O
in	O	O
smaller	O	O
patients	O	O
with	O	O
longer	O	O
CPB	O	O
runs	O	O
and	O	O
significant	O	O
postoperative	O	O
lactic	O	O
acidosis	O	O
levels	O	O
.	O	O

Mortality	O	O
associated	O	O
with	O	O
JET	O	O
is	O	O
lower	O	O
than	O	O
historically	O	O
reported	O	O
,	O	O
but	O	O
morbidity	O	O
remains	O	O
high	O	O
.	O	O

Observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
outcome	O	O
in	O	O
traumatic	O	O
brain	O	O
injury	O	O
:	O	O
experience	O	O
from	O	O
a	O	O
multicenter	O	O
,	O	O
international	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
Accurate	O	O
and	O	O
consistent	O	O
outcome	O	O
assessment	O	O
is	O	O
essential	O	O
to	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
explore	O	O
observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
outcome	O	O
in	O	O
a	O	O
recently	O	O
completed	O	O
trial	O	O
of	O	O
dexanabinol	Pharmacological	O
in	O	O
head	O	O
injury	O	O
and	O	O
to	O	O
consider	O	O
steps	O	O
to	O	O
reduce	O	O
such	O	O
variation	O	O
.	O	O

METHODS	O	O
Eight	O	O
hundred	O	O
sixty-one	O	O
patients	O	O
with	O	O
severe	O	O
traumatic	O	O
brain	O	O
injury	O	O
who	O	O
were	O	O
admitted	O	O
to	O	O
86	O	O
centers	O	O
were	O	O
included	O	O
in	O	O
a	O	O
multicenter	O	O
,	O	O
placebo-controlled	Control	O
,	O	O
Phase	O	O
III	O	O
trial	O	O
.	O	O

Outcome	O	O
was	O	O
assessed	O	O
at	O	O
3	O	O
and	O	O
6	O	O
months	O	O
postinjury	O	O
using	O	O
the	O	O
extended	O	O
Glasgow	O	O
Outcome	O	O
Scale	O	O
;	O	O
standardized	O	O
assessment	O	O
was	O	O
facilitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
a	O	O
structured	O	O
interview	O	O
.	O	O

Before	O	O
initiation	O	O
of	O	O
trial	O	O
centers	O	O
,	O	O
outcome	O	O
ratings	O	O
were	O	O
obtained	O	O
for	O	O
sample	O	O
cases	O	O
to	O	O
establish	O	O
initial	O	O
levels	O	O
of	O	O
agreement	O	O
.	O	O

Training	O	O
sessions	O	O
in	O	O
outcome	O	O
assessment	O	O
were	O	O
held	O	O
,	O	O
and	O	O
problems	O	O
in	O	O
assigning	O	O
outcome	O	O
were	O	O
investigated	O	O
.	O	O

During	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
process	O	O
of	O	O
central	O	O
review	O	O
was	O	O
established	O	O
to	O	O
monitor	O	O
performance	O	O
.	O	O

Interobserver	O	O
variation	O	O
was	O	O
analyzed	O	O
using	O	O
the	O	O
kappa	O	O
statistic	O	O
.	O	O

RESULTS	O	O
Substantial	O	O
observer	O	O
variation	O	O
was	O	O
found	O	O
in	O	O
the	O	O
rating	O	O
of	O	O
sample	O	O
cases	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.72	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.68-0.75	O	O
)	O	O
and	O	O
in	O	O
assigning	O	O
outcome	O	O
based	O	O
on	O	O
completed	O	O
structured	O	O
interviews	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.61	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.57-0.64	O	O
)	O	O
.	O	O

In	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
relatively	O	O
large	O	O
number	O	O
of	O	O
discrepancies	O	O
(	O	O
29-37	O	O
%	O	O
)	O	O
were	O	O
identified	O	O
on	O	O
central	O	O
review	O	O
.	O	O

This	O	O
number	O	O
declined	O	O
as	O	O
the	O	O
trial	O	O
progressed	O	O
and	O	O
coincided	O	Physical
with	O	Physical
investigator	O	Physical
training	O	Physical
and	O	O
feedback	O	O
from	O	O
central	O	O
review	O	O
.	O	O

Centers	O	O
with	O	O
higher	O	O
enrollment	O	O
rates	O	O
showed	O	O
better	O	O
performance	O	O
.	O	O

CONCLUSION	O	O
Observer	O	O
variation	O	O
in	O	O
outcome	O	O
assessment	O	O
is	O	O
a	O	O
significant	O	O
problem	O	O
for	O	O
head	O	O
injury	O	O
trials	O	O
.	O	O

Consistency	O	O
can	O	O
be	O	O
improved	O	O
by	O	O
standardizing	O	O
procedures	O	O
,	O	O
training	O	O
assessors	O	O
,	O	O
and	O	O
monitoring	O	O
the	O	O
quality	O	O
of	O	O
assessments	O	O
and	O	O
providing	O	O
feedback	O	O
to	O	O
interviewers	O	O
.	O	O

Small	O	O
but	O	O
important	O	O
errors	O	O
in	O	O
cardiovascular	O	O
risk	O	O
calculation	O	O
by	O	O
practice	O	O
nurses	O	O
:	O	O
a	O	O
cross-sectional	O	O
study	O	O
in	O	O
randomised	O	O
trial	O	O
setting	O	O
.	O	O

BACKGROUND	O	O
Practice	O	O
nurses	O	O
play	O	O
an	O	O
increasingly	O	O
important	O	O
role	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
diseases	O	O
but	O	O
we	O	O
do	O	O
not	O	O
have	O	O
evidence	O	O
about	O	O
the	O	O
accuracy	O	O
of	O	O
their	O	O
cardiovascular	O	O
risk	O	O
assessments	O	O
during	O	O
real	O	O
practice	O	O
consultations	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
examine	O	O
how	O	O
nurses	O	O
perform	O	O
with	O	O
regard	O	O
to	O	O
absolute	O	O
10-year	O	O
cardiovascular	O	O
risk	O	O
assessment	O	O
in	O	O
actual	O	O
practice	O	O
.	O	O

DESIGN	O	O
Cross-sectional	O	O
study	O	O
.	O	O

SETTING	O	O
This	O	O
study	O	O
was	O	O
nested	O	O
in	O	O
the	O	O
IMPALA	O	O
study	O	O
,	O	O
a	O	O
clustered	O	O
randomised	O	O
controlled	O	O
trial	O	O
involving	O	O
24	O	O
general	O	O
practices	O	O
in	O	O
The	O	O
Netherlands	O	O
.	O	O

PARTICIPANTS	O	O
24	O	O
practice	O	O
nurses	O	O
,	O	O
trained	O	O
in	O	O
10-year	O	O
cardiovascular	O	O
risk	O	O
assessment	O	O
,	O	O
calculated	O	O
the	O	O
risk	O	O
of	O	O
a	O	O
total	O	O
of	O	O
421	O	O
patients	O	O
without	O	O
established	O	O
cardiovascular	O	O
diseases	O	O
but	O	O
eligible	O	O
for	O	O
cardiovascular	O	O
risk	O	O
assessment	O	O
.	O	O

METHODS	O	O
The	O	O
main	O	O
outcome	O	O
measure	O	O
was	O	O
the	O	O
accuracy	Other	O
of	Other	O
risk	Other	O
assessments	Other	O
,	O	O
defined	O	O
as	O	O
(	O	O
1	O	O
)	O	O
the	O	O
difference	O	O
between	O	O
the	O	O
10-year	O	O
cardiovascular	O	O
risk	O	O
percentage	O	O
calculated	O	O
by	O	O
nurses	Other	O
and	O	O
an	O	O
independent	O	O
assessor	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
agreement	O	O
between	O	O
the	O	O
treatment	O	O
categories	O	O
assigned	O	O
by	O	O
the	O	O
nurses	Other	O
(	O	O
low	O	O
,	O	O
moderate	O	O
or	O	O
high	O	O
risk	O	O
)	O	O
and	O	O
those	O	O
assigned	O	O
by	O	O
the	O	O
independent	O	O
assessor	O	O
.	O	O

RESULTS	O	O
Thirty-one	O	O
(	O	O
7.4	O	O
%	O	O
)	O	O
of	O	O
the	O	O
calculated	O	O
risk	O	O
percentages	O	O
differed	O	O
by	O	O
more	O	O
than	O	O
our	O	O
preset	O	O
limits	O	O
,	O	O
25	O	O
(	O	O
81	O	O
%	O	O
)	O	O
being	O	O
underestimations	O	O
.	O	O

Elderly	O	O
patients	O	O
(	O	O
OR	O	O
1.1	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.0-1.1	O	O
)	O	O
,	O	O
male	O	O
patients	O	O
(	O	O
vs.	O	O
female	O	O
OR	O	O
3.1	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.2-7.3	O	O
)	O	O
,	O	O
and	O	O
smoking	O	O
patients	O	O
(	O	O
vs.	O	O
non-smoking	O	O
OR	O	O
3.8	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.7-8.9	O	O
)	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
their	O	O
cardiovascular	O	O
risk	O	O
miscalculated	O	O
.	O	O

Ten	O	O
(	O	O
28	O	O
%	O	O
)	O	O
of	O	O
the	O	O
36	O	O
patients	O	O
who	O	O
should	O	O
be	O	O
assigned	O	O
to	O	O
the	O	O
high-risk	O	O
treatment	O	O
category	O	O
according	O	O
to	O	O
the	O	O
independent	O	O
calculation	O	O
,	O	O
were	O	O
missed	O	O
as	O	O
high-risk	O	O
patients	O	O
by	O	O
the	O	O
practice	O	O
nurses	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
overall	O	O
standard	O	O
of	O	O
accuracy	O	O
of	O	O
cardiovascular	Other	O
risk	Other	O
assessment	Other	O
by	O	O
trained	O	O
practice	O	O
nurses	O	O
in	O	O
actual	O	O
practice	O	O
is	O	O
high	O	O
.	O	O

However	O	O
,	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
high-risk	O	O
patients	O	O
were	O	O
misclassified	O	O
,	O	O
with	O	O
the	O	O
probability	O	O
that	O	O
it	O	O
led	O	O
to	O	O
missed	O	O
opportunities	O	O
for	O	O
risk-reducing	O	O
interventions	O	O
.	O	O

As	O	O
cardiovascular	O	O
risk	O	O
assessments	O	O
are	O	O
frequently	O	O
done	O	O
by	O	O
nurses	O	O
in	O	O
general	O	O
practice	O	O
,	O	O
further	O	O
specific	O	O
training	O	O
should	O	O
be	O	O
considered	O	O
to	O	O
prevent	O	O
undertreatment	O	O
.	O	O

Cytokine	O	O
levels	O	O
and	O	O
systemic	O	O
toxicity	O	O
in	O	O
patients	O	O
undergoing	O	O
isolated	Pharmacological	O
limb	Pharmacological	O
perfusion	Pharmacological	O
with	O	O
high-dose	Pharmacological	O
tumor	Pharmacological	O
necrosis	Pharmacological	O
factor	Pharmacological	O
,	O	O
interferon	Pharmacological	O
gamma	Pharmacological	O
,	O	O
and	O	O
melphalan	Pharmacological	O
.	O	O

PURPOSE	O	O
Isolated	Pharmacological	O
limb	Pharmacological	O
perfusion	Pharmacological	O
(	Pharmacological	O
ILP	Pharmacological	O
)	Pharmacological	O
with	O	O
tumor	Pharmacological	O
necrosis	Pharmacological	O
factor	Pharmacological	O
(	Pharmacological	O
TNF	Pharmacological	O
)	Pharmacological	O
,	O	O
interferon	Pharmacological	Pharmacological
gamma	Pharmacological	Pharmacological
,	O	O
and	O	O
melphalan	Pharmacological	O
(	Pharmacological	O
M	Pharmacological	O
)	Pharmacological	O
has	O	O
been	O	O
reported	O	O
to	O	O
result	O	O
in	O	O
high	O	O
response	O	O
rates	O	O
for	O	O
extremity	O	O
melanoma	O	O
and	O	O
sarcoma	O	O
.	O	O

We	O	O
have	O	O
evaluated	O	O
the	O	O
relationship	O	O
of	O	O
systemic	O	O
TNF	O	O
exposure	O	O
to	O	O
induction	O	O
of	O	O
several	O	O
secondary	O	O
mediators	O	O
and	O	O
incidence	O	O
of	O	O
systemic	O	O
toxicity	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Nineteen	O	O
patients	O	O
with	O	O
extremity	O	O
melanoma	O	O
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
or	O	O
sarcoma	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
underwent	O	O
90-minute	O	O
ILP	Pharmacological	O
with	Pharmacological	O
TNF-alpha	Pharmacological	O
,	O	O
interferon	Pharmacological	O
gamma	Pharmacological	O
(	O	O
0.2	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
M	Pharmacological	O
(	O	O
10	O	O
to	O	O
13	O	O
mg/L	O	O
of	O	O
limb	O	O
volume	O	O
)	O	O
(	Pharmacological	O
TNF/IFN/M	Pharmacological	O
)	Pharmacological	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
or	O	O
M	Pharmacological	O
alone	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

Continuous	O	O
intraoperative	O	O
monitoring	O	O
(	O	O
CIM	O	O
)	O	O
for	O	O
systemic	O	O
leak	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
was	O	O
performed	O	O
using	O	O
radioactive	O	O
iodine-131	Pharmacological	O
albumin	Pharmacological	O
.	Pharmacological	O

Cytokine	O	O
levels	O	O
in	O	O
the	O	O
perfusate	O	O
and	O	O
systemic	O	O
circulation	O	O
during	O	O
and	O	O
after	O	O
ILP	O	O
were	O	O
measured	O	O
by	O	O
enzyme-linked	Pharmacological	O
immunosorbent	Pharmacological	O
assay	Pharmacological	O
.	Pharmacological	O

RESULTS	O	O
Systemic	O	O
leaks	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
occurred	O	O
in	O	O
six	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
and	O	O
in	O	O
four	O	O
who	O	O
received	O	O
M	O	O
alone	O	O
.	O	O

Hypotension	O	O
that	O	O
required	O	O
vasopressor	O	O
support	O	O
occurred	O	O
in	O	O
six	O	O
of	O	O
six	O	O
patients	O	O
with	O	O
evidence	O	O
of	O	O
a	O	O
leak	O	O
(	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
)	O	O
and	O	O
zero	O	O
of	O	O
six	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
<	O	O
1	O	O
%	O	O
)	O	O
.	O	O

These	O	O
six	O	O
patients	O	O
had	O	O
significantly	O	O
higher	O	O
peak	O	O
systemic	O	O
TNF	O	O
levels	O	O
during	O	O
and	O	O
after	O	O
perfusion	O	O
than	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
2.8	O	O
and	O	O
8.2	O	O
ng/mL	O	O
v	O	O
0.7	O	O
and	O	O
2.0	O	O
ng/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
had	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
systemic	O	O
interleukin-6	O	O
(	O	O
IL-6	O	O
)	O	O
levels	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
M	O	O
alone	O	O
(	O	O
12,395	O	O
+/-	O	O
10,374	O	O
pg/mL	O	O
v	O	O
79.4	O	O
+/-	O	O
7.2	O	O
pg/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Intracellular	O	O
adhesion	O	O
molecule	O	O
(	O	O
ICAM	O	O
)	O	O
,	O	O
IL-8	O	O
,	O	O
and	O	O
TNF-R	O	O
levels	O	O
were	O	O
also	O	O
increased	O	O
after	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
.	O	O

CONCLUSION	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
can	O	O
be	O	O
safely	O	O
performed	O	O
,	O	O
as	O	O
I131	O	O
albumin	O	O
provides	O	O
a	O	O
sensitive	O	O
measure	O	O
of	O	O
systemic	O	O
leakage	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
measured	O	O
leak	O	O
of	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
develop	O	O
mild	O	O
and	O	O
transient	O	O
postoperative	O	O
hypotension	O	O
with	O	O
significantly	O	O
higher	O	O
systemic	O	O
TNF	O	O
levels	O	O
and	O	O
lower	O	O
perfusate	O	O
TNF	O	O
levels	O	O
than	O	O
in	O	O
patients	O	O
without	O	O
leaks	O	O
.	O	O

Bitewing	O	O
film	O	O
quality	O	O
:	O	O
a	O	O
clinical	O	O
comparison	O	O
of	O	O
the	O	O
loop	Surgical	O
vs.	O	O
holder	Surgical	O
techniques	Surgical	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
in	O	O
vivo	O	O
bitewing	O	O
film	O	O
quality	O	O
using	O	O
the	O	O
holder	Surgical	O
versus	Surgical	O
the	Surgical	O
paper	Surgical	O
loop	Surgical	O
technique	Surgical	O
.	O	O

METHOD	O	O
AND	O	O
MATERIALS	O	O
Four	O	O
bitewing	O	O
films	O	O
were	O	O
taken	O	O
from	O	O
the	O	O
right	O	O
and	O	O
left	O	O
premolar	O	O
and	O	O
molar	O	O
regions	O	O
of	O	O
45	O	O
dental	O	O
students	O	O
using	O	O
both	O	O
the	O	O
bitewing	O	O
holder	Surgical	O
and	Surgical	O
paper	Surgical	O
loop	Surgical	O
techniques	Surgical	O
.	O	O

A	O	O
total	O	O
of	O	O
360	O	O
films	O	O
were	O	O
taken	O	O
and	O	O
assessed	O	O
by	O	O
an	O	O
experienced	O	O
practitioner	O	O
not	O	O
apprised	O	O
of	O	O
the	O	O
bitewing	Surgical	O
technique	Surgical	O
used	O	O
.	O	O

Of	O	O
interest	O	O
were	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
number	O	O
of	O	O
overlaps	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
teeth	O	O
showing	O	O
the	O	O
alveolar	O	O
crest	O	O
;	O	O
(	O	O
2	O	O
)	O	O
proper	O	Physical
film	O	Physical
positioning	O	Physical
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
percentage	O	O
of	O	O
cone	O	O
cutting	O	O
.	O	O

A	O	O
Poisson	O	O
regression	O	O
using	O	O
generalized	O	O
estimating	O	O
equations	O	O
(	O	O
GEEs	O	O
)	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
difference	O	O
in	O	O
overlap	O	O
between	O	O
the	O	O
two	O	O
techniques	O	O
.	O	O

For	O	O
proper	O	O
positioning	O	O
and	O	O
cone	O	O
cutting	O	O
,	O	O
logistic	O	O
regressions	O	O
using	O	O
GEEs	O	O
were	O	O
used	O	O
.	O	O

RESULTS	O	O
The	O	O
average	O	O
number	O	O
of	O	O
horizontal	O	O
overlaps	O	O
for	O	O
the	O	O
loop	Surgical	O
and	O	O
holder	Surgical	O
techniques	Surgical	O
at	O	O
the	O	O
right	O	O
premolar	O	O
,	O	O
right	O	O
molar	O	O
,	O	O
left	O	O
premolar	O	O
,	O	O
and	O	O
left	O	O
molar	O	O
were	O	O
1.64	O	O
,	O	O
2.11	O	O
,	O	O
2.16	O	O
,	O	O
2.78	O	O
,	O	O
and	O	O
1.64	O	O
,	O	O
2.00	O	O
,	O	O
2.00	O	O
,	O	O
2.18	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
loop	Surgical	O
technique	Surgical	O
was	O	O
1.11	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
cause	O	O
overlapping	O	O
than	O	O
the	O	O
holder	Surgical	O
technique	Surgical	O
.	Surgical	O

The	O	O
highest	O	O
percentage	O	O
of	O	O
teeth	O	O
showing	O	O
the	O	O
alveolar	O	O
crest	O	O
by	O	O
the	O	O
loop	Surgical	O
technique	Surgical	O
was	O	O
97.8	O	O
%	O	O
in	O	O
the	O	O
mandibular	O	O
second	O	O
premolar	O	O
and	O	O
first	O	O
molar	O	O
.	O	O

With	O	O
respect	O	O
to	O	O
film	O	O
positioning	O	O
,	O	O
the	O	O
loop	Surgical	O
technique	Surgical	O
was	O	O
1.12	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
cause	O	O
improper	O	O
positioning	O	O
than	O	O
the	O	O
holder	Surgical	O
technique	Surgical	O
.	Surgical	O

Both	O	O
techniques	O	O
demonstrated	O	O
minimal	O	O
cone	O	O
cutting	O	O
(	O	O
1	O	O
in	O	O
the	O	O
loop	O	O
versus	O	O
0	O	O
in	O	O
the	O	O
holder	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
quality	O	O
of	O	O
bitewing	O	O
films	O	O
taken	O	O
by	O	O
the	O	O
loop	Surgical	O
and	Surgical	O
holder	Surgical	O
techniques	Surgical	O
was	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

Smoking	O	O
cessation	O	O
with	O	O
smokeless	Other	O
tobacco	Other	O
and	O	O
group	Educational	O
therapy	Educational	O
:	Other	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
.	O	O

Smokeless	Other	O
tobacco	Other	O
might	O	O
be	O	O
effective	O	O
as	O	O
an	O	O
adjunct	O	O
for	O	O
smoking	O	O
cessation	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
efficacy	O	O
of	O	O
smokeless	Other	O
tobacco	Other	O
and	O	O
group	Educational	O
support	Educational	O
for	O	O
smoking	O	O
cessation	O	O
in	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
study	O	O
that	O	O
compared	O	O
smokeless	Other	O
tobacco	Other	O
plus	O	O
group	Educational	O
support	Educational	O
versus	O	O
group	Other	O
support	Other	O
only	Educational	O
.	O	O

The	O	O
study	O	O
enrolled	O	O
263	O	O
healthy	O	O
smokers	O	O
(	O	O
M	O	O
(	O	O
age	O	O
)	O	O
=	O	O
49	O	O
years	O	O
)	O	O
who	O	O
smoked	O	O
a	O	O
mean	O	O
of	O	O
24	O	O
cigarettes/day	O	O
,	O	O
with	O	O
a	O	O
mean	O	O
of	O	O
31	O	O
pack-years	O	O
.	O	O

Smokeless	Other	O
tobacco	Other	O
was	O	O
provided	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
or	O	O
up	O	O
to	O	O
12	O	O
)	O	O
,	O	O
combined	O	Educational
with	O	Educational
eight	O	Educational
group	Educational	Educational
support	Educational	Educational
visits	Educational	Educational
provided	Educational	Educational
by	Educational	Educational
nurses	Educational	Educational
.	O	O

The	O	O
control	Control	O
group	Control	O
received	O	O
group	Other	O
support	Other	O
only	Educational	O
.	O	O

Smoking	O	O
cessation	O	O
rates	O	O
were	O	O
statistically	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
smokeless	O	O
tobacco	O	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
during	O	O
the	O	O
first	O	O
7	O	O
weeks	O	O
.	O	O

Point-prevalence	O	O
abstinence	O	O
rates	O	O
at	O	O
7	O	O
weeks	O	O
were	O	O
36.4	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
2.52	O	O
,	O	O
p	O	O
=	O	O
.001	O	O
)	O	O
,	O	O
respectively	O	O
;	O	O
and	O	O
continuous	O	O
abstinence	O	O
rates	O	O
from	O	O
weeks	O	O
4	O	O
to	O	O
7	O	O
were	O	O
31.5	O	O
%	O	O
versus	O	O
19.2	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
1.94	O	O
,	O	O
p	O	O
=	O	O
.023	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
primary	O	O
outcomes	O	O
(	O	O
i.e.	O	O
,	O	O
6-month	O	O
point	O	O
prevalence	O	O
)	O	O
were	O	O
23.1	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
OR	O	O
=	O	O
1.31	O	O
,	O	O
ns	O	O
)	O	O
.	O	O

Smokeless	Other	O
tobacco	Other	O
was	O	O
relatively	O	O
well	O	O
tolerated	O	O
,	O	O
although	O	O
15	O	O
subjects	O	O
(	O	O
11.2	O	O
%	O	O
)	O	O
stopped	O	O
use	O	O
due	O	O
to	O	O
adverse	O	O
events	O	O
.	O	O

A	O	O
total	O	O
of	O	O
25	O	O
subjects	O	O
(	O	O
17.5	O	O
%	O	O
)	O	O
were	O	O
still	O	O
using	O	O
smokeless	O	O
tobacco	O	O
after	O	O
6	O	O
months	O	O
.	O	O

This	O	O
trial	O	O
demonstrated	O	O
short-term	O	O
efficacy	O	O
of	O	O
smokeless	Other	O
tobacco	Other	O
in	O	O
combination	O	O
with	O	O
group	O	O
support	O	O
for	O	O
smoking	O	O
cessation	O	O
but	O	O
no	O	O
long-term	O	O
efficacy	O	O
.	O	O

Efficacy	O	O
of	O	O
a	O	O
family	Educational	Educational
practice-based	Educational	Educational
lifestyle	Educational	Educational
intervention	Educational	Educational
program	Educational	Educational
to	O	Educational
increase	O	Educational
physical	O	Educational
activity	O	Educational
and	O	O
reduce	O	O
clinical	O	O
and	O	O
physiological	O	O
markers	O	O
of	O	O
vascular	O	O
health	O	O
in	O	O
patients	O	O
with	O	O
high	O	O
normal	O	O
blood	O	O
pressure	O	O
and/or	O	O
high	O	O
normal	O	O
blood	O	O
glucose	O	O
(	O	O
SNAC	O	O
)	O	O
:	O	O
study	O	O
protocol	O	O
for	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Previous	O	O
interventions	O	O
to	O	O
increase	O	O
physical	O	O
activity	O	O
and	O	O
reduce	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
have	O	O
been	O	O
targeted	O	O
at	O	O
individuals	O	O
with	O	O
established	O	O
disease	O	O
;	O	O
less	O	O
attention	O	O
has	O	O
been	O	O
given	O	O
to	O	O
intervention	O	O
among	O	O
individuals	O	O
with	O	O
high	O	O
risk	O	O
for	O	O
disease	O	O
nor	O	O
has	O	O
there	O	O
been	O	O
determination	O	O
of	O	O
the	O	O
influence	O	O
of	O	O
setting	O	O
in	O	O
which	O	O
the	O	O
intervention	O	O
is	O	O
provided	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
family	O	O
practice	O	O
represents	O	O
an	O	O
ideal	O	O
setting	O	O
for	O	O
the	O	O
provision	O	O
and	O	O
long-term	O	O
maintenance	O	O
of	O	O
lifestyle	O	O
interventions	O	O
for	O	O
patients	O	O
at	O	O
risk	O	O
(	O	O
ie	O	O
high-normal	O	O
blood	O	O
pressure	O	O
or	O	O
impaired	O	O
glucose	O	O
tolerance	O	O
)	O	O
.	O	O

METHODS/DESIGN	O	O
The	O	O
Staged	O	O
Nutrition	O	O
and	O	O
Activity	O	O
Counseling	O	O
(	O	O
SNAC	O	O
)	O	O
study	O	O
is	O	O
a	O	O
randomized	O	O
clustered	O	O
design	O	O
clinical	O	O
trial	O	O
that	O	O
will	O	O
investigate	O	O
the	O	O
effectiveness	O	O
and	O	O
efficacy	O	O
of	O	O
a	O	O
multi-component	Educational	Educational
lifestyle	Educational	Educational
intervention	Educational	Educational
on	O	O
cardiovascular	O	O
disease	O	O
risk	O	O
factors	O	O
and	O	O
vascular	O	O
function	O	O
in	O	O
patients	O	O
at	O	O
risk	O	O
in	O	O
primary	O	O
care	O	O
.	O	O

Patients	O	O
will	O	O
be	O	O
randomized	O	O
by	O	O
practice	O	O
to	O	O
either	O	O
a	O	O
standard	Educational	Educational
of	Educational	Educational
care	Educational	Educational
lifestyle	Educational	Educational
intervention	Educational	Educational
or	O	O
a	O	O
behaviourally-based	Educational	O
,	Educational	O
matched	Educational	O
prescriptive	Educational	O
physical	Educational	O
activity	Educational	O
and	Educational	O
diet	Educational	O
change	Educational	O
program	Educational	O
.	O	O

The	O	O
primary	O	O
goal	O	O
is	O	O
to	O	O
increase	O	O
physical	O	O
activity	O	O
and	O	O
improve	O	O
dietary	O	O
intake	O	O
according	O	O
to	O	O
Canada	O	O
's	O	O
Guides	O	O
to	O	O
Physical	O	O
Activity	O	O
Healthy	O	O
Eating	O	O
over	O	O
24	O	O
months	O	O
.	O	O

The	O	O
primary	O	O
intention	O	O
to	O	O
treat	O	O
analysis	O	O
will	O	O
compare	O	O
behavioral	O	O
,	O	O
physiological	O	O
and	O	O
metabolic	O	O
outcomes	O	O
at	O	O
6	O	O
,	O	O
12	O	O
and	O	O
24	O	O
months	O	O
post-randomization	O	O
including	O	O
estimation	O	O
of	O	O
incident	O	O
hypertension	O	O
and/or	O	O
diabetes	O	O
.	O	O

DISCUSSION	O	O
The	O	O
design	O	O
features	O	O
of	O	O
our	O	O
trial	O	O
,	O	O
and	O	O
the	O	O
practical	O	O
problems	O	O
(	O	O
and	O	O
solutions	O	O
)	O	O
associated	O	O
with	O	O
implementing	O	O
these	O	O
design	O	O
features	O	O
,	O	O
particularly	O	O
those	O	O
that	O	O
result	O	O
in	O	O
potential	O	O
delay	O	O
between	O	O
recruitment	O	O
,	O	O
baseline	O	O
data	O	O
collection	O	O
,	O	O
randomization	O	O
,	O	O
intervention	O	O
,	O	O
and	O	O
assessment	O	O
will	O	O
be	O	O
discussed	O	O
.	O	O

Results	O	O
of	O	O
the	O	O
SNAC	O	O
trial	O	O
will	O	O
provide	O	O
scientific	O	O
rationale	O	O
for	O	O
the	O	O
implementation	O	O
of	O	O
this	O	O
lifestyle	O	Educational
intervention	O	Educational
in	O	O
primary	O	O
care	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ISRCTN	O	O
:	O	O
ISRCTN:42921300	O	O
.	O	O

Autism-Spectrum	Other	O
Quotient-Japanese	Other	O
version	O	O
and	O	O
its	O	O
short	O	O
forms	O	O
for	O	O
screening	O	O
normally	O	O
intelligent	O	O
persons	O	O
with	O	O
pervasive	O	O
developmental	O	O
disorders	O	O
.	O	O

A	O	O
Japanese	Other	O
version	Other	O
of	Other	O
the	Other	O
Autism	Other	O
Spectrum	Other	O
Quotient	Other	O
(	Other	O
AQ	Other	O
)	Other	O
,	Other	O
AQ-J	Other	O
was	O	O
administered	O	O
to	O	O
25	O	O
normally	O	O
intelligent	O	O
high-functioning	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
(	O	O
HPDD	O	O
)	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
24.2	O	O
years	O	O
;	O	O
24	O	O
male	O	O
,	O	O
one	O	O
female	O	O
)	O	O
and	O	O
215	O	O
controls	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
30.4	O	O
years	O	O
;	O	O
86	O	O
male	O	O
,	O	O
129	O	O
female	O	O
)	O	O
randomly	O	O
selected	O	O
from	O	O
the	O	O
general	O	O
population	O	O
.	O	O

The	O	O
AQ-J	Other	O
had	O	O
satisfactory	O	O
internal	O	O
consistency	O	O
reliability	O	O
(	O	O
Cronbach	O	O
's	O	O
alpha	O	O
>	O	O
0.70	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
)	O	O
,	O	O
test-retest	O	O
reliability	O	O
,	O	O
and	O	O
discriminant	O	O
validity	O	O
[	O	O
i.e	O	O
.	O	O

the	O	O
AQ-J	O	O
score	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
HPDD	O	O
(	O	O
mean	O	O
,	O	O
29.6	O	O
)	O	O
than	O	O
controls	O	O
(	O	O
mean	O	O
,	O	O
22.2	O	O
)	O	O
]	O	O
.	O	O

At	O	O
a	O	O
cut-off	O	O
of	O	O
26	O	O
,	O	O
the	O	O
AQ-J	Other	O
had	O	O
satisfactory	O	O
sensitivity	O	O
,	O	O
specificity	O	O
,	O	O
and	O	O
negative	O	O
predictive	O	O
value	O	O
,	O	O
but	O	O
it	O	O
had	O	O
low	O	O
positive	O	O
predictive	O	O
value	O	O
(	O	O
0.24	O	O
)	O	O
possibly	O	O
due	O	O
to	O	O
the	O	O
facts	O	O
that	O	O
the	O	O
25	O	O
mild	O	O
HPDD	O	O
patients	O	O
scored	O	O
lower	O	O
and	O	O
the	O	O
controls	O	O
scored	O	O
higher	O	O
on	O	O
the	O	O
AQ-J	Other	O
than	O	O
British	O	O
counterparts	O	O
on	O	O
the	O	O
AQ	O	O
.	O	O

The	O	O
AQ-J-21	Other	O
(	O	O
consisting	O	O
of	O	O
21	O	O
items	O	O
significantly	O	O
associated	O	O
with	O	O
HPDD	O	O
diagnosis	O	O
)	O	O
and	O	O
the	O	O
AQ-J-10	Other	O
(	O	O
consisting	O	O
of	O	O
10	O	O
of	O	O
the	O	O
21	O	O
items	O	O
with	O	O
an	O	O
effect	O	O
size	O	O
>	O	O
0.17	O	O
)	O	O
had	O	O
higher	O	O
,	O	O
although	O	O
not	O	O
satisfactory	O	O
,	O	O
positive	O	O
predictive	O	O
values	O	O
of	O	O
0.35	O	O
and	O	O
0.46	O	O
at	O	O
cut-offs	O	O
of	O	O
12	O	O
and	O	O
7	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
the	O	O
AQ-J	Other	O
.	Other	O

The	O	O
AQ-J	Other	O
and	O	O
two	O	O
short	O	O
forms	O	O
are	O	O
useful	O	O
not	O	O
to	O	O
predict	O	O
but	O	O
to	O	O
rule	O	O
out	O	O
mild	O	O
HPDD	O	O
,	O	O
the	O	O
most	O	O
difficult	O	O
part	O	O
of	O	O
HPDD	O	O
to	O	O
be	O	O
distinguished	O	O
from	O	O
non-PDD	O	O
conditions	O	O
,	O	O
in	O	O
persons	O	O
scoring	O	O
under	O	O
the	O	O
cut-offs	O	O
and	O	O
to	O	O
consider	O	O
professionals	O	O
'	O	O
examination	O	O
of	O	O
HPDD	O	O
in	O	O
persons	O	O
scoring	O	O
over	O	O
them	O	O
,	O	O
because	O	O
their	O	O
negative	O	O
predictive	O	O
values	O	O
were	O	O
satisfactory	O	O
.	O	O

Coagulation	Pharmacological	O
factor	Pharmacological	O
concentrate	Pharmacological	O
in	O	O
the	O	O
treatment	O	O
of	O	O
the	O	O
haemorrhagic	O	O
diathesis	O	O
of	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
clotting	Pharmacological	Pharmacological
factor	Pharmacological	Pharmacological
concentrate	Pharmacological	Pharmacological
infusions	Pharmacological	Pharmacological
in	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
,	O	O
a	O	O
controlled	O	O
trial	O	O
was	O	O
performed	O	O
in	O	O
which	O	O
nine	O	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
treatment	O	O
with	O	O
either	O	O
concentrate	Pharmacological	Pharmacological
alone	Pharmacological	Pharmacological
or	Pharmacological	O
concentrate	Pharmacological	Pharmacological
plus	Pharmacological	Pharmacological
heparin	Pharmacological	Pharmacological
.	Pharmacological	O

The	O	O
five	O	O
patients	O	O
receiving	O	O
concentrate	Pharmacological	O
alone	O	O
all	O	O
died	O	O
,	O	O
with	O	O
major	O	O
bleeding	O	O
as	O	O
the	O	O
direct	O	O
cause	O	O
of	O	O
death	O	O
in	O	O
three	O	O
,	O	O
whereas	O	O
in	O	O
the	O	O
four	O	O
receiving	O	O
heparin	Pharmacological	O
as	O	O
well	O	O
there	O	O
was	O	O
only	O	O
one	O	O
instance	O	O
of	O	O
bleeding	O	O
and	O	O
one	O	O
patient	O	O
survived	O	O
.	O	O

Clinical	O	O
evidence	O	O
of	O	O
intravascular	O	O
coagulation	O	O
appeared	O	O
in	O	O
two	O	O
patients	O	O
treated	O	O
with	O	O
concentrate	Pharmacological	O
alone	O	O
and	O	O
the	O	O
laboratory	O	O
evidence	O	O
of	O	O
this	O	O
progressed	O	O
during	O	O
the	O	O
period	O	O
of	O	O
infusions	O	O
in	O	O
all	O	O
patients	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
in	O	O
those	O	O
receiving	O	O
heparin	Pharmacological	O
.	Pharmacological	O

Additional	O	O
evidence	O	O
for	O	O
intravascular	O	O
coagulation	O	O
came	O	O
from	O	O
the	O	O
changes	O	O
observed	O	O
in	O	O
factor	O	O
VIII	O	O
levels	O	O
which	O	O
,	O	O
although	O	O
initially	O	O
high	O	O
in	O	O
all	O	O
patients	O	O
,	O	O
fell	O	O
subsequently	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
given	O	O
concentrate	Pharmacological	O
alone	O	O
.	O	O

There	O	O
was	O	O
some	O	O
improvement	O	O
in	O	O
the	O	O
prothrombin	O	O
ratio	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
patients	O	O
but	O	O
not	O	O
complete	O	O
correction	O	O
,	O	O
and	O	O
serial	O	O
assays	O	O
of	O	O
clotting	O	O
factors	O	O
showed	O	O
that	O	O
although	O	O
factor	O	O
II	O	O
rose	O	O
to	O	O
high	O	O
levels	O	O
during	O	O
treatment	O	O
,	O	O
factors	O	O
IX	O	O
and	O	O
X	O	O
showed	O	O
little	O	O
response	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
use	O	O
of	O	O
concentrate	O	O
of	O	O
factor	O	O
IX	O	O
in	O	O
this	O	O
trial	O	O
,	O	O
as	O	O
well	O	O
as	O	O
potentiating	O	O
intravascular	O	O
coagulation	O	O
,	O	O
was	O	O
inadequate	O	O
as	O	O
replacement	O	O
for	O	O
the	O	O
clotting	O	O
factor	O	O
deficiencies	O	O
.	O	O

Comparison	O	O
of	O	O
thiopentone/guaifenesin	Pharmacological	Pharmacological
,	O	Pharmacological
ketamine/guaifenesin	Pharmacological	Pharmacological
and	O	O
ketamine/midazolam	Pharmacological	Pharmacological
for	O	O
the	O	O
induction	O	O
of	O	O
horses	O	O
to	O	O
be	O	O
anaesthetised	O	O
with	O	O
isoflurane	O	Pharmacological
.	O	O

Forty-eight	O	O
horses	O	O
subjected	O	O
to	O	O
elective	O	O
surgery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	O	O
groups	O	O
of	O	O
16	O	O
horses	O	O
.	O	O

After	O	O
premedication	O	O
with	O	O
0.1	O	Pharmacological
mg/kg	O	Pharmacological
acepromazine	Pharmacological	Pharmacological
intramuscularly	O	Pharmacological
and	O	O
0.6	O	O
mg/kg	O	O
xylazine	Pharmacological	O
intravenously	O	O
,	O	O
anaesthesia	O	O
was	O	O
induced	O	O
either	O	O
with	O	O
2	O	O
g	O	O
thiopentone	Pharmacological	Pharmacological
in	O	Pharmacological
500	O	Pharmacological
ml	O	Pharmacological
of	O	Pharmacological
a	O	Pharmacological
10	O	Pharmacological
per	O	Pharmacological
cent	O	Pharmacological
guaifenesin	Pharmacological	Pharmacological
solution	O	Pharmacological
,	O	O
given	O	O
intravenously	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
ml/kg	O	O
(	O	O
group	O	O
TG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
100	O	O
mg/kg	O	O
guaifenesin	Pharmacological	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	Pharmacological	Pharmacological
given	O	O
intravenously	O	O
(	O	O
group	O	O
KG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
0.06	O	O
mg/kg	O	O
midazolam	Pharmacological	Pharmacological
,	O	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	Pharmacological	Pharmacological
given	O	O
intravenously	O	O
(	O	O
group	O	O
KM	O	O
)	O	O
.	O	O

Anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
isoflurane	Pharmacological	Pharmacological
.	Pharmacological	O

The	O	O
mean	O	O
(	O	O
sd	O	O
)	O	O
end	O	O
tidal	O	O
isoflurane	Pharmacological	O
concentration	O	O
(	O	O
per	O	O
cent	O	O
)	O	O
needed	O	O
to	O	O
maintain	O	O
a	O	O
light	O	O
surgical	O	O
anaesthesia	O	O
(	O	O
stage	O	O
III	O	O
,	O	O
plane	O	O
2	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KM	O	O
(	O	O
0.91	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TG	O	O
(	O	O
1.11	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
and	O	O
KG	O	O
(	O	O
1.14	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
(	O	O
sd	O	O
)	O	O
arterial	O	O
pressure	O	O
(	O	O
mmHg	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KG	O	O
(	O	O
67.4	O	O
[	O	O
2.07	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TC	O	O
(	O	O
75.6	O	O
[	O	O
2.23	O	O
]	O	O
)	O	O
and	O	O
KM	O	O
(	O	O
81.0	O	O
[	O	O
2.16	O	O
]	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
,	O	O
recovery	O	O
time	O	O
or	O	O
quality	O	O
of	O	O
recovery	O	O
between	O	O
the	O	O
three	O	O
induction	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
pronounced	O	O
ataxia	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
horses	O	O
of	O	O
group	O	O
KM	O	O
,	O	O
especially	O	O
after	O	O
periods	O	O
of	O	O
anaesthesia	O	O
lasting	O	O
less	O	O
than	O	O
75	O	O
minutes	O	O
.	O	O

Parents	O	O
'	O	O
state	O	O
and	O	O
trait	O	O
anxiety	O	O
:	O	O
relationships	O	O
with	O	O
anxiety	O	O
severity	O	O
and	O	O
treatment	O	O
response	O	O
in	O	O
adolescents	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

Comorbid	O	O
anxiety	O	O
is	O	O
common	O	O
among	O	O
children	O	O
with	O	O
Autism	O	O
Spectrum	O	O
Disorder	O	O
(	O	O
ASD	O	O
)	O	O
,	O	O
and	O	O
parents	O	O
of	O	O
children	O	O
with	O	O
ASD	O	O
are	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
anxiety	O	O
disorders	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
parents	Psychological	O
'	Psychological	O
state	Psychological	O
and	Psychological	O
trait	Psychological	O
anxiety	Psychological	O
and	O	O
parent-reported	Educational	O
internalizing	Educational	O
and	Other	O
externalizing	Educational	O
symptoms	Educational	O
among	O	O
adolescents	O	O
(	O	O
n	O	O
=	O	O
30	O	O
)	O	O
with	O	O
ASD	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
relationship	O	O
of	O	O
parents	O	O
'	O	O
anxiety	O	O
symptoms	O	O
and	O	O
adolescent	O	O
treatment	O	O
response	O	O
in	O	O
the	O	O
context	O	O
of	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

Parental	O	O
state	O	O
anxiety	O	O
correlated	O	O
with	O	O
severity	O	O
of	O	O
adolescent	O	O
anxiety	O	O
,	O	O
and	O	O
trait	O	O
anxiety	O	O
in	O	O
parents	O	O
correlated	O	O
with	O	O
parent-reported	O	O
adolescent	O	O
internalizing	O	O
and	O	O
externalizing	O	O
symptoms	O	O
.	O	O

Also	O	O
,	O	O
parents	O	O
of	O	O
adolescent	O	O
treatment	O	O
responders	O	O
experienced	O	O
a	O	O
decrease	O	O
in	O	O
their	O	O
own	O	O
trait	O	O
anxiety	O	O
.	O	O

Findings	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
considering	O	O
parental	O	O
anxiety	O	O
when	O	O
targeting	O	O
anxiety	O	O
among	O	O
youth	O	O
with	O	O
ASD	O	O
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
Org	Pharmacological	Pharmacological
2766	Pharmacological	Pharmacological
,	O	O
a	O	O
synthetic	O	O
analog	O	O
of	O	O
the	O	O
adrenocorticotrophic	O	O
hormone	O	O
(	O	O
4-9	O	O
)	O	O
,	O	O
in	O	O
14	O	O
outpatient	O	O
autistic	O	O
children	O	O
.	O	O

Fourteen	O	O
children	O	O
(	O	O
12	O	O
infantile	O	O
autism	O	O
full	O	O
syndrome	O	O
present	O	O
,	O	O
2	O	O
atypical	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
)	O	O
between	O	O
5	O	O
and	O	O
13	O	O
years	O	O
of	O	O
age	O	O
participated	O	O
in	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	Control
cross-over	O	O
trial	O	O
.	O	O

Each	O	O
child	O	O
received	O	O
20	O	Pharmacological
mg	O	Pharmacological
Org	Pharmacological	Pharmacological
2766	Pharmacological	Pharmacological
(	O	O
synthetic	O	O
analog	O	O
of	O	O
ACTH	O	O
4-9	O	O
)	O	O
/day	O	O
during	O	O
4	O	O
weeks	O	O
,	O	O
or	O	O
placebo	O	Control
in	O	O
a	O	O
randomly	O	O
assigned	O	O
sequence	O	O
.	O	O

Drug	O	O
effects	O	O
were	O	O
monitored	O	O
by	O	O
ethological	O	O
playroom	O	O
observation	O	O
and	O	O
by	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
ratings	O	O
by	O	O
parents	O	O
and	O	O
teachers	O	O
.	O	O

Data	O	O
of	O	O
the	O	O
playroom	O	O
observation	O	O
pointed	O	O
to	O	O
an	O	O
activating	O	O
influence	O	O
of	O	O
Org	O	O
2766	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
a	O	O
significant	O	O
decrease	O	O
of	O	O
stereotypic	O	O
behavior	O	O
and	O	O
significant	O	O
increases	O	O
in	O	O
change	O	O
toys	O	O
,	O	O
locomote	O	O
,	O	O
and	O	O
talk	O	O
.	O	O

Checklist	O	O
ratings	O	O
did	O	O
not	O	O
show	O	O
significant	O	O
changes	O	O
.	O	O

The	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
hypoxemia	O	O
on	O	O
cardiac	O	O
output	O	O
.	O	O

A	O	O
dose-response	O	O
curve	O	O
.	O	O

To	O	O
establish	O	O
a	O	O
dose-response	O	O
curve	O	O
for	O	O
the	O	O
effects	O	O
of	O	O
isocapnic	O	O
hypoxemia	O	O
on	O	O
cardiac	O	O
output	O	O
(	O	O
CO	O	O
)	O	O
,	O	O
we	O	O
studied	O	O
20	O	O
healthy	O	O
men	O	O
,	O	O
aged	O	O
20	O	O
to	O	O
34	O	O
years	O	O
,	O	O
using	O	O
a	O	O
tight-fitting	Other	O
face	Other	O
mask	Other	O
and	Other	O
an	Other	O
isocapnic	Other	O
partial	Other	O
rebreathing	Other	O
system	Other	O
(	O	O
a	O	O
modified	O	O
anesthesia	O	O
machine	O	O
)	O	O
.	O	O

We	O	O
blended	O	O
oxygen	Other	O
and	O	O
hypoxic	Other	O
gas	Other	O
to	O	O
achieve	O	O
arterial	O	O
oxygen	O	O
saturations	O	O
(	O	O
SaO2	O	O
)	O	O
of	O	O
80	O	O
,	O	O
85	O	O
,	O	O
and	O	O
90	O	O
percent	O	O
;	O	O
subjects	O	O
also	O	O
breathed	O	O
100	Other	O
percent	Other	O
oxygen	Other	O
and	O	O
room	Other	O
air	Other	O
(	O	O
RA	O	O
)	O	O
.	O	O

Target	O	O
SaO2	O	O
and	O	O
end-tidal	O	O
carbon	O	O
dioxide	O	O
were	O	O
continuously	O	O
monitored	O	O
using	O	O
an	O	O
ear	O	O
oximeter	O	O
and	O	O
CO2	O	O
gas	O	O
analyzer	O	O
.	O	O

Subjects	O	O
experienced	O	O
the	O	O
five	O	O
SaO2	O	O
measurements	O	O
in	O	O
random	O	O
order	O	O
.	O	O

CO	O	O
was	O	O
measured	O	O
noninvasively	O	O
at	O	O
approximately	O	O
two-minute	O	O
intervals	O	O
,	O	O
using	O	O
continuous-wave	O	O
Doppler	O	O
echocardiography	O	O
.	O	O

Mean	O	O
cardiac	O	O
output	O	O
increased	O	O
with	O	O
increasing	O	O
hypoxemia	O	O
from	O	O
6.84	O	O
L/min	O	O
at	O	O
FIo2	O	O
1.0	O	O
to	O	O
8.44	O	O
L/min	O	O
at	O	O
SaO2	O	O
80	O	O
percent	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0005	O	O
)	O	O
;	O	O
the	O	O
increase	O	O
was	O	O
entirely	O	O
due	O	O
to	O	O
increased	O	O
heart	O	O
rate	O	O
.	O	O

We	O	O
concluded	O	O
that	O	O
cardiac	O	O
output	O	O
increases	O	O
significantly	O	O
in	O	O
a	O	O
dose-response	O	O
manner	O	O
in	O	O
response	O	O
to	O	O
acute	O	O
isocapnic	O	O
hypoxemia	O	O
in	O	O
normal	O	O
persons	O	O
.	O	O

Is	O	O
chronic	Pharmacological	O
sildenafil	Pharmacological	O
therapy	Pharmacological	O
safe	O	O
and	O	O
clinically	O	O
beneficial	O	O
in	O	O
patients	O	O
with	O	O
systolic	O	O
heart	O	O
failure	O	O
?	O	O
Sildenafil	Pharmacological	O
is	O	O
a	O	O
selective	O	O
phosphodiesterase-5	O	O
inhibitor	O	O
and	O	O
causes	O	O
vasodilatation	O	O
,	O	O
particularly	O	O
in	O	O
pulmonary	O	O
circulation	O	O
.	O	O

Since	O	O
left	O	O
heart	O	O
failure	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
out	O	O
of	O	O
proportion	O	O
to	O	O
left	O	O
heart	O	O
disease	O	O
,	O	O
sildenafil	Pharmacological	O
may	O	O
have	O	O
beneficial	O	O
effect	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

The	O	O
present	O	O
investigation	O	O
was	O	O
designed	O	O
as	O	O
a	O	O
12-week	O	O
,	O	O
single-center	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	Control	Control
study	O	O
evaluating	O	O
the	O	O
effects	O	O
of	O	O
sildenafil	Pharmacological	Pharmacological
on	O	O
mean	O	O
blood	O	O
pressure	O	O
(	O	O
primary	O	O
endpoint	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
left	O	O
systolic	O	O
heart	O	O
failure	O	O
.	O	O

Secondary	O	O
endpoints	O	O
included	O	O
exercise	O	O
capacity	O	O
assessed	O	O
by	O	O
6-minute	O	O
walk	O	O
test	O	O
.	O	O

A	O	O
total	O	O
of	O	O
106	O	O
patients	O	O
were	O	O
randomized	O	O
1:1	O	O
to	O	O
sildenafil	Pharmacological	Pharmacological
(	O	O
n=53	O	O
)	O	O
or	O	O
placebo	Control	Control
(	O	O
n=53	O	O
)	O	O
.	O	O

Patients	O	O
received	O	O
sildenafil	Pharmacological	Pharmacological
25	O	O
mg	O	O
twice	O	O
a	O	O
day	O	O
or	O	O
matching	O	O
placebo	Control	Control
for	O	O
the	O	O
first	O	O
2	O	O
weeks	O	O
and	O	O
50	O	O
mg	O	O
3	O	O
times	O	O
a	O	O
week	O	O
for	O	O
the	O	O
remainder	O	O
of	O	O
the	O	O
trial	O	O
.	O	O

The	O	O
placebo-corrected	O	O
effect	O	O
on	O	O
mean	O	O
blood	O	O
pressure	O	O
was	O	O
1.16	O	O
mm	O	O
Hg	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-1.6	O	O
to	O	O
5.1	O	O
,	O	O
P	O	O
>	O	O
.05	O	O
)	O	O
,	O	O
demonstrating	O	O
that	O	O
sildenafil	O	Pharmacological
did	O	O
not	O	O
decrease	O	O
mean	O	O
blood	O	O
pressure	O	O
.	O	O

Compared	O	O
with	O	O
placebo	O	Control
,	O	O
sildenafil	Pharmacological	O
increased	O	O
the	O	O
6-minute	O	O
walk	O	O
test	O	O
by	O	O
a	O	O
nonsignificant	O	O
treatment	O	O
effect	O	O
of	O	O
14	O	O
m	O	O
(	O	O
P=.67	O	O
)	O	O
.	O	O

Adverse	O	O
effects	O	O
occurred	O	O
in	O	O
a	O	O
comparable	O	O
proportion	O	O
of	O	O
patients	O	O
taking	O	O
sildenafil	Pharmacological	Pharmacological
and	O	O
placebo	O	Control
,	O	O
and	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
needed	O	O
to	O	O
discontinue	O	O
therapy	O	O
.	O	O

Sildenafil	O	O
is	O	O
well	O	O
tolerated	O	O
in	O	O
left	O	O
heart	O	O
failure	O	O
patients	O	O
and	O	O
does	O	O
not	O	O
decrease	O	O
blood	O	O
pressure	O	O
.	O	O

It	O	O
can	O	O
be	O	O
safely	O	O
added	O	O
to	O	O
standard	O	O
heart	O	O
failure	O	O
therapy	O	O
.	O	O

The	O	O
aging	O	O
motor	O	O
system	O	O
as	O	O
a	O	O
model	O	O
for	O	O
plastic	O	O
changes	O	O
of	O	O
GABA-mediated	O	O
intracortical	O	O
inhibition	O	O
and	O	O
their	O	O
behavioral	O	O
relevance	O	O
.	O	O

Since	O	O
GABAA-mediated	O	O
intracortical	O	O
inhibition	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
underlie	O	O
plastic	O	O
changes	O	O
throughout	O	O
the	O	O
lifespan	O	O
from	O	O
development	O	O
to	O	O
aging	O	O
,	O	O
here	O	O
,	O	O
the	O	O
aging	O	O
motor	O	O
system	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
to	O	O
analyze	O	O
the	O	O
interdependence	O	O
of	O	O
plastic	O	O
alterations	O	O
within	O	O
the	O	O
inhibitory	O	O
motorcortical	O	O
network	O	O
and	O	O
level	O	O
of	O	O
behavioral	O	O
performance	O	O
.	O	O

Double-pulse	Physical	Physical
transcranial	Physical	Physical
magnetic	Physical	Physical
stimulation	Physical	Physical
(	Physical	Physical
dpTMS	Physical	Physical
)	Physical	Physical
was	Physical	O
used	Physical	O
to	Physical	O
examine	Physical	O
inhibition	Physical	O
by	Physical	O
means	Physical	O
of	Physical	O
short-interval	Physical	O
intracortical	Physical	O
inhibition	Physical	O
(	Physical	O
SICI	Physical	O
)	Physical	O
of	Physical	O
the	Physical	O
contralateral	Physical	O
primary	Physical	O
motor	Physical	O
cortex	Physical	O
in	O	O
a	O	O
sample	O	O
of	O	O
64	O	O
healthy	O	O
right-handed	O	O
human	O	O
subjects	O	O
covering	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
the	O	O
adult	O	O
lifespan	O	O
(	O	O
age	O	O
range	O	O
20-88	O	O
years	O	O
,	O	O
mean	O	O
47.6	O	O
?	O	O
20.7	O	O
,	O	O
34	O	O
female	O	O
)	O	O
.	O	O

SICI	O	O
was	O	O
evaluated	O	O
during	O	O
resting	O	O
state	O	O
and	O	O
in	O	O
an	O	O
event-related	O	O
condition	O	O
during	O	O
movement	O	O
preparation	O	O
in	O	O
a	O	O
visually	O	O
triggered	O	O
simple	O	O
reaction	O	O
time	O	O
task	O	O
.	O	O

In	O	O
a	O	O
subgroup	O	O
(	O	O
N	O	O
=	O	O
23	O	O
)	O	O
,	O	O
manual	O	O
motor	O	O
performance	O	O
was	O	O
tested	O	O
with	O	O
tasks	O	O
of	O	O
graded	O	O
dexterous	O	O
demand	O	O
.	O	O

Weak	O	O
resting-state	O	O
inhibition	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
overall	O	O
lower	O	O
manual	O	O
motor	O	O
performance	O	O
.	O	O

Better	O	O
event-related	O	O
modulation	O	O
of	O	O
inhibition	O	O
correlated	O	O
with	O	O
better	O	O
performance	O	O
in	O	O
more	O	O
demanding	O	O
tasks	O	O
,	O	O
in	O	O
which	O	O
fast	O	O
alternating	O	O
activation	O	O
of	O	O
cortical	O	O
representations	O	O
are	O	O
necessary	O	O
.	O	O

Declining	O	O
resting-state	O	O
inhibition	O	O
was	O	O
associated	O	O
with	O	O
weakened	O	O
event-related	O	O
modulation	O	O
of	O	O
inhibition	O	O
.	O	O

Therefore	O	O
,	O	O
reduced	O	O
resting-state	O	O
inhibition	O	O
might	O	O
lead	O	O
to	O	O
a	O	O
subsequent	O	O
loss	O	O
of	O	O
modulatory	O	O
capacity	O	O
,	O	O
possibly	O	O
reflecting	O	O
malfunctioning	O	O
precision	O	O
in	O	O
GABAAergic	O	O
neurotransmission	O	O
;	O	O
the	O	O
consequence	O	O
is	O	O
an	O	O
inevitable	O	O
decline	O	O
in	O	O
motor	O	O
function	O	O
.	O	O

Effect	O	O
of	O	O
hydrochlorothiazide	Pharmacological	Pharmacological
therapy	Pharmacological	Pharmacological
on	O	O
cardiac	O	O
arrhythmias	O	O
in	O	O
African-American	O	O
men	O	O
with	O	O
systemic	O	O
hypertension	O	O
and	O	O
moderate	O	O
to	O	O
severe	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
hydrochlorothiazide	Pharmacological	Physical
therapy	Pharmacological	Physical
on	O	O
ventricular	O	O
arrhythmias	O	O
was	O	O
studied	O	O
in	O	O
45	O	O
hypertensive	O	O
African-American	O	O
men	O	O
with	O	O
moderate	O	O
to	O	O
severe	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
hypertrophy	O	O
.	O	O

After	O	O
medication	O	O
washout	O	O
,	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
placebo	Control	Control
followed	O	O
by	O	O
hydrochlorothiazide	Pharmacological	O
.	O	O

Clinical	O	O
,	O	O
biochemical	O	O
,	O	O
and	O	O
48-hour	O	O
ambulatory	O	O
electrocardiographic	O	O
data	O	O
was	O	O
collected	O	O
after	O	O
each	O	O
treatment	O	O
phase	O	O
.	O	O

Signal-averaged	O	O
electrocardiograms	O	O
were	O	O
recorded	O	O
in	O	O
a	O	O
subgroup	O	O
of	O	O
24	O	O
patients	O	O
.	O	O

Average	O	O
LV	O	O
posterior	O	O
wall	O	O
thickness	O	O
was	O	O
15	O	O
+/-	O	O
1.1	O	O
mm	O	O
,	O	O
septum	O	O
16	O	O
+/-	O	O
2	O	O
mm	O	O
,	O	O
LV	O	O
mass	O	O
420	O	O
+/-	O	O
90	O	O
g	O	O
,	O	O
and	O	O
LV	O	O
mass	O	O
index	O	O
212	O	O
=	O	O
51	O	O
g/m2	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
was	O	O
168	O	O
+/-	O	O
18	O	O
mm	O	O
Hg	O	O
after	O	O
the	O	O
placebo	O	Control
phase	O	O
and	O	O
146	O	O
+/-	O	O
15	O	O
mm	O	O
Hg	O	O
after	O	O
hydrochlorothiazide	O	O
;	O	O
diastolic	O	O
BP	O	O
was	O	O
103	O	O
+/-	O	O
6	O	O
mm	O	O
Hg	O	O
and	O	O
89	O	O
+/-	O	O
9	O	O
mm	O	O
Hg	O	O
,	O	O
respectively	O	O
.	O	O

Serum	O	O
potassium	O	O
decreased	O	O
significantly	O	O
from	O	O
4.2	O	O
+/-	O	O
0.4	O	O
mmol/L	O	O
to	O	O
3.7	O	O
+/-	O	O
0.6	O	O
mmol/L	O	O
after	O	O
hydrochlorothiazide	Pharmacological	O
therapy	Pharmacological	O
.	Pharmacological	O

The	O	O
average	O	O
hourly	O	O
incidence	O	O
of	O	O
ventricular	O	O
premature	O	O
contractions	O	O
was	O	O
22	O	O
with	O	O
placebo	Control	Control
and	O	O
25	O	O
with	O	O
hydrochlorothiazide	Pharmacological	Pharmacological
.	Pharmacological	O

There	O	O
were	O	O
3	O	O
and	O	O
1	O	O
couplets	O	O
and	O	O
0.2	O	O
and	O	O
0.2	O	O
runs	O	O
of	O	O
ventricular	O	O
tachycardia	O	O
per	O	O
patient	O	O
per	O	O
hour	O	O
,	O	O
respectively	O	O
.	O	O

Variables	O	O
of	O	O
signal-averaged	O	O
electrocardiography	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
2	O	O
treatments	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
hypertensive	O	O
African-American	O	O
men	O	O
with	O	O
moderate	O	O
to	O	O
severe	O	O
LV	O	O
hypertrophy	O	O
,	O	O
hydrochlorothiazide	Pharmacological	O
does	O	O
not	O	O
worsen	O	O
ventricular	O	O
arrhythmias	O	O
or	O	O
signal-averaged	O	O
electrocardiographic	O	O
variables	O	O
.	O	O

Reduced	O	O
platelet	O	O
thromboxane	O	O
formation	O	O
after	O	O
long-term	O	O
administration	O	O
of	O	O
a	O	O
dihydropyridine	Pharmacological	Pharmacological
calcium	Pharmacological	Pharmacological
channel	Pharmacological	Pharmacological
blocker	Pharmacological	Pharmacological
:	O	O
a	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
with	O	O
nitrendipine	Pharmacological	O
in	O	O
borderline	O	O
hypertensive	O	O
patients	O	O
with	O	O
IDDM-type	O	O
diabetes	O	O
mellitus	O	O
.	O	O

Twenty-nine	O	O
IDDM	O	O
patients	O	O
with	O	O
borderline	O	O
hypertension	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
placebo	Control	Control
or	O	O
nitrendipine	Pharmacological	O
treatment	O	O
.	O	O

Nitrendipine	Pharmacological	O
was	O	O
given	O	O
orally	O	O
at	O	O
a	O	O
dosage	O	O
of	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
over	O	O
4	O	O
weeks	O	O
.	O	O

Stimulated	O	O
platelet	O	O
thromboxane	O	O
formation	O	O
at	O	O
rest	O	O
and	O	O
after	O	O
standardized	O	O
,	O	O
non	O	O
exhausting	O	O
exercise	O	O
was	O	O
measured	O	O
by	O	O
standard	O	O
methods	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
plasma	O	O
levels	O	O
of	O	O
platelet	O	O
factor	O	O
4	O	O
and	O	O
aggregation	O	O
responses	O	O
to	O	O
collagen	O	O
and	O	O
ADP	O	O
were	O	O
determined	O	O
.	O	O

In	O	O
the	O	O
treatment	O	O
group	O	O
thromboxane	O	O
formation	O	O
after	O	O
stimulation	O	O
with	O	O
collagen	O	O
(	O	O
0.3	O	O
and	O	O
1.0	O	O
micrograms/ml	O	O
)	O	O
and	O	O
1	O	O
mM	O	O
arachidonic	O	O
acid	O	O
(	O	O
AA	O	O
)	O	O
was	O	O
reduced	O	O
in	O	O
the	O	O
resting	O	O
state	O	O
.	O	O

Exercise	O	O
induced	O	O
change	O	O
of	O	O
thromboxane	O	O
synthesis	O	O
in	O	O
response	O	O
to	O	O
1.0	O	O
micrograms/ml	O	O
collagen	O	O
was	O	O
significantly	O	O
lower	O	O
as	O	O
compared	O	O
to	O	O
placebo	Control	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
PF4	O	O
plasma	O	O
levels	O	O
were	O	O
significantly	O	O
lowered	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Whole	O	O
blood	O	O
aggregation	O	O
after	O	O
collagen	O	O
stimulation	O	O
(	O	O
1.0	O	O
micrograms/ml	O	O
)	O	O
was	O	O
reduced	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
nitrendipine	Pharmacological	O
treatment	O	O
,	O	O
but	O	O
ADP	O	O
(	O	O
5	O	O
microM	O	O
)	O	O
induced	O	O
aggregation	O	O
was	O	O
not	O	O
.	O	O

These	O	O
effects	O	O
of	O	O
nitrendipine	Pharmacological	O
were	O	O
not	O	O
seen	O	O
in	O	O
platelet	O	O
rich	O	O
plasma	O	O
.	O	O

In	O	O
conclusion	O	O
long-term	O	O
nitrendipine	Pharmacological	O
treatment	O	O
may	O	O
inhibit	O	O
collagen	O	O
dependent	O	O
platelet	O	O
activation	O	O
in	O	O
the	O	O
blood	O	O
of	O	O
diabetic	O	O
patients	O	O
with	O	O
borderline	O	O
hypertension	O	O
.	O	O

Effects	O	O
of	O	O
20	O	O
mg	O	O
rosuvastatin	Pharmacological	O
on	O	O
VLDL1-	O	O
,	O	O
VLDL2-	O	O
,	O	O
IDL-	O	O
and	O	O
LDL-ApoB	O	O
kinetics	O	O
in	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

AIMS/HYPOTHESIS	O	O
In	O	O
addition	O	O
to	O	O
its	O	O
efficacy	O	O
in	O	O
reducing	O	O
LDL-cholesterol	O	O
,	O	O
rosuvastatin	Pharmacological	O
has	O	O
been	O	O
shown	O	O
to	O	O
significantly	O	O
decrease	O	O
plasma	O	O
triacylglycerol	O	O
.	O	O

The	O	O
use	O	O
of	O	O
rosuvastatin	Pharmacological	O
may	O	O
be	O	O
beneficial	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
,	O	O
who	O	O
usually	O	O
have	O	O
increased	O	O
triacylglycerol	O	O
levels	O	O
.	O	O

However	O	O
,	O	O
its	O	O
effects	O	O
on	O	O
the	O	O
metabolism	O	O
of	O	O
triacylglycerol-rich	O	O
lipoproteins	O	O
in	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
remains	O	O
unknown	O	O
.	O	O

METHODS	O	O
We	O	O
performed	O	O
a	O	O
randomised	O	O
double-blind	O	O
crossover	O	O
trial	O	O
of	O	O
6-week	O	O
treatment	O	O
with	O	O
placebo	Control	Control
or	O	O
rosuvastatin	Pharmacological	O
20	O	O
mg	O	O
in	O	O
eight	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
who	O	O
were	O	O
being	O	O
treated	O	O
with	O	O
oral	O	Pharmacological
glucose-lowering	O	Pharmacological
agents	O	Pharmacological
.	O	Pharmacological

In	O	O
each	O	O
patient	O	O
,	O	O
an	O	O
in	O	O
vivo	O	O
kinetic	O	O
study	O	O
of	O	O
apolipoprotein	O	O
B	O	O
(	O	O
ApoB	O	O
)	O	O
-containing	O	O
lipoproteins	O	O
with	O	O
[	O	O
13C	O	O
]	O	O
leucine	O	O
was	O	O
performed	O	O
at	O	O
the	O	O
end	O	O
of	O	O
each	O	O
treatment	O	O
period	O	O
.	O	O

A	O	O
central	O	O
randomisation	O	O
centre	O	O
used	O	O
computer-generated	O	O
tables	O	O
to	O	O
allocate	O	O
treatments	O	O
.	O	O

Participants	O	O
,	O	O
caregivers	O	O
and	O	O
those	O	O
assessing	O	O
the	O	O
outcomes	O	O
were	O	O
blinded	O	O
to	O	O
group	O	O
assignment	O	O
.	O	O

RESULTS	O	O
Rosuvastatin	Pharmacological	O
20	O	O
mg	O	O
significantly	O	O
reduced	O	O
plasma	O	O
LDL-cholesterol	O	O
,	O	O
triacylglycerol	O	O
and	O	O
total	O	O
ApoB	O	O
.	O	O

It	O	O
also	O	O
significantly	O	O
reduced	O	O
ApoB	O	O
pool	O	O
sizes	O	O
of	O	O
larger	O	O
triacylglycerol-rich	O	O
VLDL	O	O
particles	O	O
(	O	O
VLDL1	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
smaller	O	O
VLDL	O	O
particles	O	O
(	O	O
VLDL2	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
intermediate	O	O
density	O	O
lipoprotein	O	O
(	O	O
IDL	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
and	O	O
LDL	O	O
(	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

This	O	O
reduction	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
total	O	O
fractional	O	O
catabolic	O	O
rate	O	O
of	O	O
VLDL1-ApoB	O	O
(	O	O
6.70	O	O
+/-	O	O
3.24	O	O
vs	O	O
4.52	O	O
+/-	O	O
2.34	O	O
pool/day	O	O
,	O	O
p	O	O
=	O	O
0.049	O	O
)	O	O
,	O	O
VLDL2-ApoB	O	O
(	O	O
8.72	O	O
+/-	O	O
3.37	O	O
vs	O	O
5.36	O	O
+/-	O	O
2.64	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
IDL-ApoB	O	O
(	O	O
7.06	O	O
+/-	O	O
1.68	O	O
vs	O	O
4.21	O	O
+/-	O	O
1.51	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
and	O	O
LDL-ApoB	O	O
(	O	O
1.02	O	O
+/-	O	O
0.27	O	O
vs	O	O
0.59	O	O
+/-	O	O
0.13	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

Rosuvastatin	Pharmacological	O
did	O	O
not	O	O
change	O	O
the	O	O
production	O	O
rates	O	O
of	O	O
VLDL2-	O	O
,	O	O
IDL-	O	O
or	O	O
LDL-	O	O
,	O	O
but	O	O
did	O	O
reduce	O	O
VLDL1-ApoB	O	O
production	O	O
rate	O	O
(	O	O
12.4	O	O
+/-	O	O
4.5	O	O
vs	O	O
19.5	O	O
+/-	O	O
8.4	O	O
mg	O	O
kg	O	O
(	O	O
-1	O	O
)	O	O
day	O	O
(	O	O
-1	O	O
)	O	O
,	O	O
p	O	O
=	O	O
0.035	O	O
)	O	O
.	O	O

No	O	O
side	O	O
effects	O	O
of	O	O
rosuvastatin	O	O
were	O	O
observed	O	O
during	O	O
the	O	O
study	O	O
.	O	O

CONCLUSIONS/INTERPRETATION	O	O
In	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
rosuvastatin	Pharmacological	O
20	O	O
mg	O	O
not	O	O
only	O	O
induces	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
LDL-ApoB	O	O
catabolism	O	O
(	O	O
73	O	O
%	O	O
)	O	O
,	O	O
but	O	O
also	O	O
has	O	O
favourable	O	O
effects	O	O
on	O	O
the	O	O
catabolism	O	O
of	O	O
triacylglycerol-rich	O	O
lipoproteins	O	O
,	O	O
e.g	O	O
.	O	O

a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
catabolism	O	O
of	O	O
VLDL1-ApoB	O	O
(	O	O
48	O	O
%	O	O
)	O	O
,	O	O
VLDL2-ApoB	O	O
(	O	O
63	O	O
%	O	O
)	O	O
and	O	O
IDL-ApoB	O	O
(	O	O
68	O	O
%	O	O
)	O	O
,	O	O
and	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
production	O	O
rate	O	O
of	O	O
VLDL1-ApoB	O	O
(	O	O
-36	O	O
%	O	O
)	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
rosuvastatin	Pharmacological	O
on	O	O
the	O	O
metabolism	O	O
of	O	O
triacylglycerol-rich	O	O
lipoproteins	O	O
may	O	O
be	O	O
beneficial	O	O
for	O	O
prevention	O	O
of	O	O
atherosclerosis	O	O
in	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
.	O	O

How	O	O
does	O	O
Cash	Other	O
and	O	O
Counseling	Other	O
affect	O	O
costs	O	O
?	O	O
OBJECTIVE	O	O
To	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
consumer-directed	O	O
model	O	O
(	O	O
Cash	Other	O
and	O	O
Counseling	Other	O
)	O	O
of	O	O
Medicaid	O	O
personal	O	O
care	O	O
services	O	O
(	O	O
PCS	O	O
)	O	O
or	O	O
home-	O	O
and	O	O
community-based	O	O
waiver	O	O
services	O	O
(	O	O
HCBS	O	O
)	O	O
on	O	O
the	O	O
cost	O	O
of	O	O
Medicaid	O	O
services	O	O
.	O	O

DATA	O	O
SOURCES/STUDY	O	O
SETTING	O	O
Medicaid	O	O
claims	O	O
data	O	O
were	O	O
collected	O	O
for	O	O
all	O	O
enrollees	O	O
in	O	O
the	O	O
Cash	O	O
and	O	O
Counseling	O	O
demonstration	O	O
.	O	O

Demonstration	O	O
enrollees	O	O
included	O	O
those	O	O
eligible	O	O
for	O	O
PCS	O	O
(	O	O
in	O	O
Arkansas	O	O
)	O	O
,	O	O
those	O	O
assessed	O	O
to	O	O
receive	O	O
such	O	O
services	O	O
(	O	O
in	O	O
New	O	O
Jersey	O	O
)	O	O
,	O	O
and	O	O
recipients	O	O
of	O	O
Medicaid	O	O
HCBS	O	O
(	O	O
in	O	O
Florida	O	O
)	O	O
.	O	O

Enrollment	O	O
occurred	O	O
from	O	O
December	O	O
1998	O	O
through	O	O
April	O	O
2001	O	O
.	O	O

The	O	O
follow-up	O	O
period	O	O
covered	O	O
up	O	O
to	O	O
24	O	O
months	O	O
after	O	O
enrollment	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Demonstration	O	O
volunteers	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
have	O	O
the	O	O
option	O	O
to	O	O
participate	O	O
in	O	O
Cash	Other	O
and	O	O
Counseling	Other	O
(	O	O
the	O	O
treatment	O	O
group	O	O
)	O	O
,	O	O
or	O	O
to	O	O
receive	O	O
Medicaid	Control	O
services	Control	O
as	Control	O
usual	Control	O
from	Control	O
an	Control	O
agency	Control	O
(	O	O
the	O	O
control	O	O
group	O	O
)	O	O
.	O	O

Ordinary	O	O
least	O	O
squares	O	O
regressions	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
program	O	O
on	O	O
costs	O	O
for	O	O
Medicaid	O	O
PCS/waiver	O	O
services	O	O
and	O	O
other	O	O
Medicaid	O	O
services	O	O
,	O	O
while	O	O
controlling	O	O
for	O	O
consumers	O	O
'	O	O
preenrollment	O	O
characteristics	O	O
and	O	O
preenrollment	O	O
Medicaid	O	O
spending	O	O
.	O	O

Models	O	O
were	O	O
estimated	O	O
separately	O	O
for	O	O
nonelderly	O	O
and	O	O
elderly	O	O
adults	O	O
in	O	O
each	O	O
state	O	O
and	O	O
for	O	O
children	O	O
in	O	O
Florida	O	O
.	O	O

DATA	O	O
EXTRACTION	O	O
METHODS	O	O
Each	O	O
state	O	O
supplied	O	O
claims	O	O
data	O	O
for	O	O
demonstration	O	O
enrollees	O	O
.	O	O

PRINCIPAL	O	O
FINDINGS	O	O
Largely	O	O
because	O	O
the	O	O
program	O	O
increased	O	O
consumers	O	O
'	O	O
ability	O	O
to	O	O
get	O	O
the	O	O
authorized	O	O
amount	O	O
of	O	O
paid	O	O
care	O	O
,	O	O
expenditures	O	O
for	O	O
personal	O	O
care/waiver	O	O
services	O	O
were	O	O
higher	O	O
for	O	O
the	O	O
treatment	O	O
group	O	O
than	O	O
for	O	O
the	O	O
control	O	O
group	O	O
in	O	O
each	O	O
state	O	O
and	O	O
age	O	O
group	O	O
,	O	O
except	O	O
among	O	O
the	O	O
elderly	O	O
in	O	O
Florida	O	O
.	O	O

Higher	O	O
costs	O	O
for	O	O
personal	O	O
care/waiver	O	O
services	O	O
were	O	O
partially	O	O
offset	O	O
by	O	O
savings	O	O
in	O	O
other	O	O
Medicaid	O	O
services	O	O
,	O	O
particularly	O	O
those	O	O
related	O	O
to	O	O
long-term	O	O
care	O	O
.	O	O

During	O	O
year	O	O
1	O	O
,	O	O
total	O	O
Medicaid	O	O
costs	O	O
were	O	O
generally	O	O
higher	O	O
for	O	O
the	O	O
treatment	O	O
group	O	O
than	O	O
for	O	O
the	O	O
control	O	O
group	O	O
,	O	O
with	O	O
treatment-control	O	O
cost	O	O
differences	O	O
ranging	O	O
from	O	O
1	O	O
percent	O	O
(	O	O
and	O	O
statistically	O	O
insignificant	O	O
)	O	O
for	O	O
the	O	O
elderly	O	O
in	O	O
Florida	O	O
to	O	O
17	O	O
percent	O	O
for	O	O
the	O	O
elderly	O	O
in	O	O
Arkansas	O	O
.	O	O

In	O	O
year	O	O
2	O	O
,	O	O
these	O	O
cost	O	O
differences	O	O
were	O	O
generally	O	O
greater	O	O
than	O	O
in	O	O
year	O	O
1	O	O
.	O	O

Only	O	O
in	O	O
Arkansas	O	O
did	O	O
the	O	O
treatment-control	O	O
difference	O	O
in	O	O
total	O	O
cost	O	O
shrink	O	O
over	O	O
time-to	O	O
less	O	O
than	O	O
5	O	O
percent	O	O
(	O	O
and	O	O
statistically	O	O
insignificant	O	O
)	O	O
in	O	O
year	O	O
2	O	O
.	O	O

CONCLUSIONS	O	O
Medicaid	O	O
costs	O	O
were	O	O
generally	O	O
higher	O	O
under	O	O
Cash	Other	O
and	O	O
Counseling	Other	O
because	O	O
those	O	O
in	O	O
the	O	O
traditional	O	O
system	O	O
did	O	O
not	O	O
get	O	O
the	O	O
services	O	O
they	O	O
were	O	O
entitled	O	O
to	O	O
.	O	O

Compared	O	O
with	O	O
the	O	O
treatment	O	O
group	O	O
,	O	O
(	O	O
1	O	O
)	O	O
control	O	O
group	O	O
members	O	O
were	O	O
less	O	O
likely	O	O
to	O	O
receive	O	O
any	O	O
services	O	O
at	O	O
all	O	O
(	O	O
despite	O	O
being	O	O
authorized	O	O
for	O	O
them	O	O
)	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
service	O	O
recipients	O	O
received	O	O
a	O	O
lower	O	O
proportion	O	O
of	O	O
the	O	O
amount	O	O
of	O	O
care	O	O
that	O	O
was	O	O
authorized	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
flaw	O	O
in	O	O
Florida	O	O
's	O	O
reassessment	O	O
procedures	O	O
led	O	O
to	O	O
treatment	O	O
group	O	O
members	O	O
receiving	O	O
more	O	O
generous	O	O
benefit	O	O
amounts	O	O
than	O	O
control	O	O
group	O	O
members	O	O
.	O	O

To	O	O
keep	O	O
total	O	O
Medicaid	O	O
costs	O	O
per	O	O
recipient	O	O
at	O	O
the	O	O
level	O	O
incurred	O	O
under	O	O
the	O	O
traditional	O	O
system	O	O
,	O	O
consumer-directed	O	O
programs	O	O
need	O	O
to	O	O
be	O	O
carefully	O	O
designed	O	O
and	O	O
closely	O	O
monitored	O	O
.	O	O

Comparing	O	O
the	O	O
effectiveness	O	O
of	O	O
peer	Educational	O
mentoring	Educational	O
and	O	O
student	Educational	O
mentoring	Educational	O
in	O	O
a	O	O
35-week	O	O
fitness	O	O
program	O	O
for	O	O
older	O	O
adults	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
applicability	O	O
and	O	O
effectiveness	O	O
of	O	O
a	O	O
peer-mentored	Physical	Educational
exercise	Physical	Educational
program	Physical	Educational
,	O	O
this	O	O
study	O	O
compared	O	O
the	O	O
retention	O	O
and	O	O
participation	O	O
rates	O	O
,	O	O
and	O	O
physical	O	O
improvements	O	O
of	O	O
older	O	O
adults	O	O
trained	O	O
by	O	O
peer	Physical	O
mentors	Physical	O
(	Physical	O
PM	Physical	O
)	Physical	O
to	O	O
a	O	O
group	O	O
trained	O	O
by	O	O
young	Physical	O
qualified	Physical	O
student	Physical	O
mentors	Physical	O
(	Physical	O
SM	Physical	O
)	Physical	O
.	O	O

A	O	O
group	O	O
of	O	O
older	O	O
adults	O	O
were	O	O
prepared	O	O
as	O	O
peer	O	O
mentors	O	O
through	O	O
a	O	O
30-week	O	O
preparation	O	O
program	O	O
.	O	O

Later	O	O
,	O	O
60	O	O
older	O	O
adults	O	O
(	O	O
mean	O	O
?	O	O
SD	O	O
age	O	O
:	O	O
68.7	O	O
?	O	O
6.1	O	O
years	O	O
)	O	O
were	O	O
recruited	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
either	O	O
the	O	O
PM	O	O
or	O	O
SM	O	O
group	O	O
.	O	O

Both	O	O
groups	O	O
completed	O	O
an	O	O
identical	O	Educational
35-week	O	Educational
fitness	O	Educational
program	O	Educational
.	O	O

Pre-	O	O
,	O	O
midterm-	O	O
and	O	O
post-training	O	O
assessments	O	O
of	O	O
fitness	O	O
were	O	O
completed	O	O
and	O	O
rates	O	O
of	O	O
participation	O	O
and	O	O
retention	O	O
were	O	O
documented	O	O
.	O	O

The	O	O
same	O	O
retention	O	O
rates	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
but	O	O
SM	O	O
group	O	O
had	O	O
higher	O	O
participation	O	O
.	O	O

Both	O	O
groups	O	O
improved	O	O
significantly	O	O
in	O	O
all	O	O
measures	O	O
of	O	O
fitness	O	O
and	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
post-test	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
in	O	O
the	O	O
fitness	O	O
measures	O	O
.	O	O

Findings	O	O
suggest	O	O
that	O	O
the	O	O
peer	O	O
mentor	O	O
model	O	O
is	O	O
applicable	O	O
in	O	O
an	O	O
older	O	O
adult	O	O
exercise	O	O
program	O	O
and	O	O
may	O	O
be	O	O
as	O	O
effective	O	O
as	O	O
a	O	O
program	O	O
mentored	O	O
by	O	O
young	O	O
professionals	O	O
.	O	O

Comparison	O	O
of	O	O
rectal	O	Pharmacological
midazolam	Pharmacological	Pharmacological
and	O	O
diazepam	Pharmacological	Pharmacological
for	O	O
premedication	O	O
in	O	O
pediatric	O	O
dental	O	O
patients	O	O
.	O	O

Rectally	O	Pharmacological
administered	O	Pharmacological
midazolam	Pharmacological	Pharmacological
(	O	O
0.35	O	O
mg/kg	O	O
)	O	O
and	O	O
diazepam	Pharmacological	Pharmacological
(	O	O
0.70	O	O
mg/kg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
each	O	O
other	O	O
and	O	O
with	O	O
placebo	Control	Control
for	O	O
preanesthetic	O	O
medication	O	O
in	O	O
children	O	O
undergoing	O	O
dental	O	O
extractions	O	O
.	O	O

All	O	O
rectal	Pharmacological	O
medications	Pharmacological	O
were	O	O
very	O	O
well	O	O
accepted	O	O
,	O	O
but	O	O
mask	O	O
acceptance	O	O
,	O	O
improvement	O	O
in	O	O
anxiety	O	O
,	O	O
and	O	O
sedation	O	O
were	O	O
best	O	O
in	O	O
the	O	O
midazolam	Pharmacological	Pharmacological
group	O	O
.	O	O

Improvement	O	O
in	O	O
anxiety	O	O
and	O	O
sedation	O	O
were	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
two	O	O
drug	O	O
groups	O	O
than	O	O
in	O	O
those	O	O
patients	O	O
who	O	O
had	O	O
received	O	O
placebo	Control	Control
.	Control	O

Thirty	O	O
minutes	O	O
after	O	O
rectal	O	O
administration	O	O
of	O	O
midazolam	Pharmacological	Pharmacological
,	O	O
patients	O	O
showed	O	O
a	O	O
decrease	O	O
in	O	O
both	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
.	O	O

Although	O	O
these	O	O
decreases	O	O
differed	O	O
significantly	O	O
from	O	O
the	O	O
premedication	O	O
values	O	O
,	O	O
they	O	O
were	O	O
probably	O	O
of	O	O
little	O	O
clinical	O	O
importance	O	O
.	O	O

Only	O	O
minor	O	O
adverse	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Overall	O	O
rectally	O	O
administered	O	O
midazolam	Pharmacological	Pharmacological
appeared	O	O
to	O	O
be	O	O
somewhat	O	O
more	O	O
efficacious	O	O
than	O	O
diazepam	Pharmacological	O
.	Pharmacological	O

The	O	O
additional	O	O
value	O	O
of	O	O
a	O	O
night	Physical	Physical
splint	Physical	Physical
to	O	Physical
eccentric	Physical	Physical
exercises	Physical	Physical
in	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

AIM	O	O
To	O	O
assess	O	O
whether	O	O
the	O	O
use	O	O
of	O	O
a	O	O
night	Physical	O
splint	Physical	O
is	O	O
of	O	O
added	O	O
benefit	O	O
on	O	O
functional	O	O
outcome	O	O
in	O	O
treating	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
single-blind	O	O
,	O	O
prospective	O	O
,	O	O
single	O	O
centre	O	O
,	O	O
randomised	O	O
controlled	O	O
trial	O	O
set	O	O
in	O	O
the	O	O
Sports	O	O
Medical	O	O
Department	O	O
,	O	O
The	O	O
Hague	O	O
Medical	O	O
Centre	O	O
,	O	O
The	O	O
Netherlands	O	O
.	O	O

Inclusion	O	O
criteria	O	O
were	O	O
:	O	O
age	O	O
18-70	O	O
years	O	O
,	O	O
active	O	O
participation	O	O
in	O	O
sports	O	O
,	O	O
and	O	O
tendon	O	O
pain	O	O
localised	O	O
at	O	O
2-7	O	O
cm	O	O
from	O	O
distal	O	O
insertion	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
:	O	O
insertional	O	O
disorders	O	O
,	O	O
partial	O	O
or	O	O
complete	O	O
ruptures	O	O
,	O	O
or	O	O
systemic	O	O
illness	O	O
.	O	O

70	O	O
tendons	O	O
were	O	O
included	O	O
and	O	O
randomised	O	O
into	O	O
one	O	O
of	O	O
two	O	O
treatment	O	O
groups	O	O
:	O	O
eccentric	Physical	Physical
exercises	Physical	Physical
with	Physical	Physical
a	Physical	Physical
night	Physical	Physical
splint	Physical	Physical
(	O	Physical
night	O	Physical
splint	O	Physical
group	O	Physical
,	O	Physical
n	O	Physical
=	O	Physical
36	O	Physical
)	O	Physical
or	O	O
eccentric	Physical	Physical
exercises	Physical	Physical
only	Physical	Physical
(	O	O
eccentric	O	O
group	O	O
,	O	O
n	O	O
=	O	O
34	O	O
)	O	O
.	O	O

INTERVENTIONS	O	O
Both	O	O
groups	O	O
completed	O	O
a	O	O
12-week	O	O
heavy-load	Physical	Physical
eccentric	Physical	Physical
training	Physical	Physical
programme	Physical	Physical
.	Physical	O

One	O	O
group	O	O
received	O	O
a	O	O
night	Physical	Physical
splint	Physical	Physical
in	O	Physical
addition	O	Physical
to	O	Physical
eccentric	Physical	Physical
exercises	Physical	Physical
.	O	O

At	O	O
baseline	O	O
and	O	O
follow-up	O	O
at	O	O
12	O	O
weeks	O	O
,	O	O
patient	O	O
satisfaction	O	O
,	O	O
Victorian	O	O
Institute	O	O
of	O	O
Sport	O	O
Assessment-Achilles	O	O
questionnaire	O	O
(	O	O
VISA-A	O	O
)	O	O
score	O	O
and	O	O
reported	O	O
compliance	O	O
were	O	O
recorded	O	O
by	O	O
a	O	O
single-blind	O	O
trained	O	O
researcher	O	O
who	O	O
was	O	O
blinded	O	O
to	O	O
the	O	O
treatment	O	O
.	O	O

RESULTS	O	O
After	O	O
12	O	O
weeks	O	O
,	O	O
patient	O	O
satisfaction	O	O
in	O	O
the	O	O
eccentric	O	O
group	O	O
was	O	O
63	O	O
%	O	O
compared	O	O
with	O	O
48	O	O
%	O	O
in	O	O
the	O	O
night	Physical	O
splint	Physical	O
group	O	O
.	O	O

The	O	O
VISA-A	O	O
score	O	O
significantly	O	O
improved	O	O
in	O	O
both	O	O
groups	O	O
;	O	O
in	O	O
the	O	O
eccentric	O	O
group	O	O
from	O	O
50.1	O	O
to	O	O
68.8	O	O
(	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
and	O	O
in	O	O
the	O	O
night	O	O
splint	O	O
group	O	O
from	O	O
49.4	O	O
to	O	O
67.0	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
in	O	O
VISA-A	O	O
score	O	O
(	O	O
p	O	O
=	O	O
0.815	O	O
)	O	O
and	O	O
patient	O	O
satisfaction	O	O
(	O	O
p	O	O
=	O	O
0.261	O	O
)	O	O
.	O	O

CONCLUSION	O	O
A	O	O
night	Physical	O
splint	Physical	O
is	O	O
not	O	O
beneficial	O	O
in	O	O
addition	O	O
to	O	O
eccentric	O	O
exercises	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
.	O	O

LNH-84	O	O
regimen	O	O
:	O	O
a	O	O
multicenter	O	O
study	O	O
of	O	O
intensive	O	Pharmacological
chemotherapy	O	Pharmacological
in	O	O
737	O	O
patients	O	O
with	O	O
aggressive	O	O
malignant	O	O
lymphoma	O	O
.	O	O

From	O	O
July	O	O
1984	O	O
to	O	O
September	O	O
1987	O	O
,	O	O
737	O	O
patients	O	O
with	O	O
aggressive	O	O
malignant	O	O
lymphoma	O	O
(	O	O
ML	O	O
)	O	O
were	O	O
treated	O	O
by	O	O
an	O	O
intensive	Pharmacological	O
regimen	Pharmacological	O
(	Pharmacological	O
LNH-84	Pharmacological	O
)	Pharmacological	O
comprising	O	O
three	O	O
or	O	O
four	O	O
courses	O	O
of	O	O
doxorubicin	Pharmacological	Pharmacological
,	O	O
75	O	O
mg/m2	O	O
;	O	O
cyclophosphamide	Pharmacological	Pharmacological
,	O	Pharmacological
1,200	O	Pharmacological
mg/m2	O	Pharmacological
;	O	Pharmacological
vindesine	Pharmacological	Pharmacological
,	O	O
2	O	O
mg/m2	O	O
x	O	O
2	O	O
;	O	O
bleomycin	Pharmacological	Pharmacological
,	O	Pharmacological
10	O	Pharmacological
mg	O	Pharmacological
x	O	Pharmacological
2	O	Pharmacological
;	O	Pharmacological
and	O	Pharmacological
prednisolone	Pharmacological	Pharmacological
,	O	O
60	O	O
mg/m2	O	O
x	O	O
5	O	O
(	O	O
ACVB	O	O
)	O	O
,	O	O
consolidation	O	O
with	O	O
high-dose	O	O
methotrexate	Pharmacological	Pharmacological
,	O	O
ifosfamide	Pharmacological	Pharmacological
,	O	O
etoposide	Pharmacological	Pharmacological
,	O	O
asparaginase	Pharmacological	O
,	O	O
and	O	O
cytarabine	Pharmacological	Pharmacological
,	O	O
and	O	O
a	O	O
randomized	O	O
late	O	O
intensification	O	O
with	O	O
two	O	O
courses	O	O
of	O	O
cytarabine	Pharmacological	Pharmacological
,	O	O
cyclophosphamide	Pharmacological	Pharmacological
,	O	O
teniposide	Pharmacological	Pharmacological
,	O	O
bleomycin	Pharmacological	Pharmacological
,	O	O
and	O	O
prednisone	Pharmacological	Pharmacological
(	O	O
AraCVmB	O	O
)	O	O
.	O	O

Four	O	O
hundred	O	O
forty-two	O	O
patients	O	O
had	O	O
intermediate-grade	O	O
ML	O	O
,	O	O
221	O	O
highgrade	O	O
ML	O	O
,	O	O
and	O	O
74	O	O
unclassified	O	O
ML	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
advanced	O	O
disease	O	O
:	O	O
stage	O	O
IIE	O	O
(	O	O
23	O	O
%	O	O
)	O	O
,	O	O
III	O	O
(	O	O
13	O	O
%	O	O
)	O	O
,	O	O
or	O	O
IV	O	O
(	O	O
47	O	O
%	O	O
)	O	O
;	O	O
38	O	O
%	O	O
disseminated	O	O
nodes	O	O
;	O	O
38	O	O
%	O	O
two	O	O
or	O	O
more	O	O
extranodal	O	O
sites	O	O
;	O	O
and	O	O
41	O	O
%	O	O
a	O	O
tumoral	O	O
mass	O	O
greater	O	O
than	O	O
10	O	O
cm	O	O
.	O	O

Five	O	O
hundred	O	O
fifty-three	O	O
patients	O	O
(	O	O
75	O	O
%	O	O
)	O	O
went	O	O
into	O	O
complete	O	O
remission	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
63	O	O
(	O	O
9	O	O
%	O	O
)	O	O
into	O	O
partial	O	O
remission	O	O
,	O	O
62	O	O
(	O	O
8	O	O
%	O	O
)	O	O
failed	O	O
to	O	O
respond	O	O
,	O	O
and	O	O
59	O	O
(	O	O
8	O	O
%	O	O
)	O	O
died	O	O
during	O	O
ACVB	O	O
courses	O	O
,	O	O
17	O	O
of	O	O
them	O	O
from	O	O
progression	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow-up	O	O
of	O	O
23	O	O
months	O	O
,	O	O
the	O	O
estimated	O	O
2-year	O	O
overall	O	O
survival	O	O
time	O	O
to	O	O
failure	O	O
(	O	O
TTF	O	O
)	O	O
,	O	O
and	O	O
time	O	O
to	O	O
relapse	O	O
(	O	O
TTR	O	O
)	O	O
survival	O	O
are	O	O
67	O	O
%	O	O
,	O	O
56	O	O
%	O	O
,	O	O
and	O	O
67	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Patients	O	O
receiving	O	O
a	O	O
late	O	O
intensification	O	O
had	O	O
the	O	O
same	O	O
relapse	O	O
rate	O	O
as	O	O
the	O	O
other	O	O
patients	O	O
.	O	O

A	O	O
persistent	O	O
fibronecrotic	O	O
mass	O	O
was	O	O
found	O	O
in	O	O
150	O	O
patients	O	O
(	O	O
20	O	O
%	O	O
)	O	O
and	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
relapse	O	O
rate	O	O
.	O	O

Toxicity	O	O
was	O	O
mainly	O	O
neutropenia	O	O
and	O	O
infection	O	O
during	O	O
the	O	O
ACVB	O	O
courses	O	O
,	O	O
with	O	O
40	O	O
patients	O	O
(	O	O
5	O	O
%	O	O
)	O	O
dying	O	O
from	O	O
septic	O	O
complications	O	O
while	O	O
responding	O	O
to	O	O
treatment	O	O
.	O	O

Fifty-three	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
neutropenia	O	O
less	O	O
than	O	O
0.500	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/L	O	O
,	O	O
58	O	O
%	O	O
fever	O	O
(	O	O
6	O	O
%	O	O
grade	O	O
4	O	O
)	O	O
,	O	O
and	O	O
49	O	O
%	O	O
a	O	O
documented	O	O
infection	O	O
(	O	O
8	O	O
%	O	O
grade	O	O
4	O	O
)	O	O
.	O	O

These	O	O
results	O	O
obtained	O	O
with	O	O
the	O	O
LNH-84	O	O
regimen	O	O
demonstrate	O	O
that	O	O
this	O	O
therapeutic	O	O
scheme	O	O
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
aggressive	O	O
ML	O	O
.	O	O

Randomized	O	O
trial	O	O
of	O	O
tailored	O	O
skin	O	O
cancer	O	O
prevention	O	O
for	O	O
children	O	O
:	O	O
the	O	O
Project	O	O
SCAPE	O	O
family	O	O
study	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
a	O	O
tailored	Educational	Educational
intervention	Educational	Educational
to	O	O
promote	Physical	O
sun	Physical	O
protection	Physical	O
in	O	O
parents	O	O
and	O	O
their	O	O
children	O	O
,	O	O
hypothesizing	O	O
that	O	O
the	O	O
tailored	O	Educational
intervention	O	Educational
would	O	O
lead	O	O
to	O	O
improved	O	O
skin	O	O
cancer	O	O
prevention	O	O
behaviors	O	O
compared	O	O
to	O	O
generic	O	O
materials	O	O
.	O	O

Families	O	O
were	O	O
recruited	O	O
through	O	O
schools	O	O
and	O	O
community	O	O
centers	O	O
and	O	O
were	O	O
included	O	O
if	O	O
there	O	O
was	O	O
1	O	O
child	O	O
in	O	O
Grades	O	O
1-3	O	O
at	O	O
moderate	O	O
to	O	O
high	O	O
risk	O	O
for	O	O
skin	O	O
cancer	O	O
.	O	O

Participants	O	O
were	O	O
randomized	O	O
into	O	O
one	O	O
of	O	O
two	O	O
intervention	O	O
groups	O	O
:	O	O
a	O	O
tailored	Educational	Educational
intervention	Educational	Educational
,	Educational	O
in	Educational	O
which	Educational	O
they	Educational	O
received	Educational	O
personalized	Educational	O
skin	Educational	O
cancer	Educational	O
education	Educational	O
through	Educational	O
the	Educational	O
mail	Educational	O
;	Educational	O
or	Educational	O
a	Educational	O
control	Educational	O
group	Educational	O
who	Educational	O
received	Educational	O
generic	Educational	O
skin	Educational	O
cancer	Educational	O
information	Educational	O
materials	Educational	O
.	Educational	O

Before	O	O
and	O	O
after	O	O
intervention	O	O
,	O	O
parents	O	O
completed	O	O
questionnaires	O	O
about	O	O
their	O	O
and	O	O
their	O	O
children	O	O
's	O	O
skin	O	O
cancer	O	O
risk	O	O
and	O	O
prevention	O	O
knowledge	O	O
and	O	O
behaviors	O	O
.	O	O

Parents	O	O
also	O	O
completed	O	O
4-day	O	Educational
sun	O	Educational
exposure	O	Educational
and	O	Educational
protection	O	Educational
diaries	O	Educational
for	O	O
their	O	O
child	O	O
and	O	O
themselves	O	O
.	O	O

Tailored	O	O
group	O	O
participants	O	O
demonstrated	O	O
significantly	O	O
greater	O	O
positive	O	O
changes	O	O
in	O	O
prevention	O	O
behavior	O	O
after	O	O
the	O	O
intervention	O	O
,	O	O
including	O	O
children	O	O
's	O	O
use	O	O
of	O	O
sunscreen	O	O
,	O	O
shirts	O	O
,	O	O
and	O	O
hats	O	O
,	O	O
and	O	O
parents	O	O
'	O	O
use	O	O
of	O	O
shade	O	O
,	O	O
and	O	O
skin	O	O
examinations	O	O
.	O	O

Effect	O	O
sizes	O	O
were	O	O
small	O	O
and	O	O
perceived	O	O
benefits	O	O
and	O	O
social	O	O
norms	O	O
mediated	O	O
intervention	O	O
effects	O	O
.	O	O

Findings	O	O
from	O	O
this	O	O
study	O	O
support	O	O
the	O	O
efficacy	O	O
of	O	O
focusing	O	O
tailored	O	O
communications	O	O
to	O	O
families	O	O
in	O	O
order	O	O
to	O	O
change	O	O
skin	O	O
cancer	O	O
prevention	O	O
practices	O	O
in	O	O
young	O	O
children	O	O
.	O	O

Chemotherapy	O	O
of	O	O
large	O	O
bowel	O	O
carcinoma	O	O
--	O	O
fluorouracil	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
FU	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
+	O	Pharmacological
hydroxyurea	Pharmacological	Pharmacological
(	Pharmacological	Pharmacological
HU	Pharmacological	Pharmacological
)	Pharmacological	Pharmacological
vs.	O	Pharmacological
methyl-CCNU	Pharmacological	Pharmacological
,	O	O
oncovin	Pharmacological	O
,	O	O
fluorouracil	Pharmacological	O
,	O	O
and	O	O
streptozotocin	Pharmacological	O
(	Pharmacological	O
MOF-Strep	Pharmacological	O
)	Pharmacological	O
.	O	O

An	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
study	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
randomized	O	O
study	O	O
of	O	O
initial	O	O
chemotherapy	O	O
for	O	O
advanced	O	O
measurable	O	O
metastatic	O	O
large	O	O
bowel	O	O
carcinoma	O	O
,	O	O
the	O	O
response	O	O
rate	O	O
was	O	O
6/32	O	O
(	O	O
19	O	O
%	O	O
)	O	O
for	O	O
FU	O	O
+	O	O
HU	O	O
and	O	O
5/32	O	O
(	O	O
16	O	O
%	O	O
)	O	O
for	O	O
MOF-Strep	O	O
;	O	O
the	O	O
estimated	O	O
median	O	O
survival	O	O
is	O	O
43	O	O
weeks	O	O
for	O	O
both	O	O
treatments	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
MOF-Strep	O	O
experienced	O	O
substantially	O	O
greater	O	O
vomiting	O	O
and	O	O
hematologic	O	O
toxicity	O	O
than	O	O
patients	O	O
who	O	O
received	O	O
FU	O	O
+	O	O
HU	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Mechanical	O	O
efficiency	O	O
and	O	O
propulsion	O	O
technique	O	O
after	O	O
7	O	O
weeks	O	O
of	O	O
low-intensity	O	O
wheelchair	O	O
training	O	O
.	O	O

BACKGROUND	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
7-week	O	O
low-intensity	O	O
hand	O	O
rim	O	O
wheelchair	O	O
training	O	O
on	O	O
the	O	O
submaximal	O	O
metabolic	O	O
cost	O	O
,	O	O
mechanical	O	O
efficiency	O	O
and	O	O
propulsion	O	O
technique	O	O
in	O	O
able-bodied	O	O
participants	O	O
.	O	O

METHODS	O	O
Participants	O	O
were	O	O
randomly	O	O
divided	O	O
over	O	O
an	O	O
experimental	O	O
group	O	O
(	O	O
n=14	O	O
)	O	O
and	O	O
a	O	O
control	O	Control
group	O	Control
(	O	O
n=7	O	O
)	O	O
.	O	O

The	O	O
experimental	O	O
group	O	O
received	O	O
7	O	O
weeks	O	O
wheelchair	Physical	Physical
training	Physical	Physical
(	O	O
3	O	O
week	O	O
(	O	O
-1	O	O
)	O	O
,	O	O
70	O	O
min	O	O
)	O	O
at	O	O
a	O	O
low	O	O
intensity	O	O
(	O	O
30	O	O
%	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
reserve	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
control	Educational	O
group	O	O
did	Educational	O
not	Educational	O
receive	Educational	O
training	Educational	O
.	O	O

During	O	O
pre-	O	O
and	O	O
post-tests	O	O
,	O	O
submaximal	O	O
exercise	O	O
was	O	O
performed	O	O
on	O	O
a	O	O
stationary	O	O
wheelchair	Physical	O
ergometer	O	O
at	O	O
fixed	O	O
levels	O	O
of	O	O
power	O	O
output	O	O
.	O	O

Mechanical	O	O
efficiency	O	O
,	O	O
oxygen	O	O
uptake	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
timing	O	O
parameters	O	O
and	O	O
stroke	O	O
angles	O	O
were	O	O
measured	O	O
.	O	O

Video	O	O
recordings	O	O
were	O	O
made	O	O
to	O	O
determine	O	O
the	O	O
stroke	O	O
pattern	O	O
.	O	O

FINDINGS	O	O
Mechanical	O	O
efficiency	O	O
increased	O	O
and	O	O
metabolic	O	O
cost	O	O
decreased	O	O
significantly	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Push	O	O
time	O	O
increased	O	O
and	O	O
cycle	O	O
frequency	O	O
decreased	O	O
as	O	O
a	O	O
result	O	O
of	O	O
training	O	O
.	O	O

The	O	O
stroke	O	O
angle	O	O
increased	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
during	O	O
the	O	O
training	O	O
period	O	O
.	O	O

The	O	O
experimental	O	O
group	O	O
preferred	O	O
double-looping	O	O
over	O	O
propulsion	O	O
,	O	O
while	O	O
the	O	O
control	O	O
group	O	O
mainly	O	O
used	O	O
single-looping	O	O
over	O	O
propulsion	O	O
patterns	O	O
during	O	O
the	O	O
post-test	O	O
.	O	O

INTERPRETATION	O	O
A	O	O
low-intensity	O	O
,	O	O
7-week	O	O
training	O	O
protocol	O	O
has	O	O
a	O	O
beneficial	O	O
effect	O	O
on	O	O
the	O	O
mechanical	O	O
efficiency	O	O
and	O	O
metabolic	O	O
cost	O	O
of	O	O
wheelchair	O	O
propulsion	O	O
in	O	O
able-bodied	O	O
participants	O	O
.	O	O

The	O	O
improved	O	O
mechanical	O	O
efficiency	O	O
seems	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
changes	O	O
in	O	O
propulsion	O	O
technique	O	O
that	O	O
were	O	O
found	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
amino	O	Pharmacological
acid	O	Pharmacological
and	O	O
ketoacid	O	O
on	O	O
protein	O	O
metabolism	O	O
in	O	O
humans	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
insulin	O	O
,	O	O
amino	O	O
acid	O	O
(	O	O
AA	O	O
)	O	O
,	O	O
and	O	O
branched-chain	O	O
ketoacid	O	O
(	O	O
KA	O	O
)	O	O
availability	O	O
on	O	O
leucine	O	O
kinetics	O	O
in	O	O
eight	O	O
healthy	O	O
volunteers	O	O
(	O	O
age	O	O
=	O	O
22	O	O
+/-	O	O
2	O	O
y	O	O
,	O	O
body	O	O
mass	O	O
index	O	O
=	O	O
24	O	O
+/-	O	O
1	O	O
kg	O	O
)	O	O
by	O	O
using	O	O
the	O	O
euglycemic	Surgical	O
insulin	Surgical	O
clamp	Surgical	O
and	Surgical	O
[	Surgical	O
1-14C	Surgical	O
]	Surgical	O
leucine	Surgical	O
turnover	Surgical	O
techniques	Surgical	O
.	Surgical	O

Four	O	O
experimental	O	O
conditions	O	O
were	O	O
studied	O	O
:	O	O
study	O	O
I	O	O
,	O	O
hyperinsulinemia	O	O
;	O	O
study	O	O
II	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
maintenance	O	O
of	O	O
basal	O	O
plasma	O	O
AA	O	O
and	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
study	O	O
III	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
hyperaminoacidemia	O	O
and	O	O
basal	O	O
plasma	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
and	O	O
study	O	O
IV	O	O
,	O	O
hyperinsulinemia	O	O
plus	O	O
basal	O	O
plasma	O	O
AA	O	O
concentrations	O	O
and	O	O
elevated	O	O
branched-chain	O	O
KA	O	O
levels	O	O
.	O	O

Basal	O	O
endogenous	O	O
leucine	O	O
flux	O	O
(	O	O
ELF	O	O
)	O	O
averaged	O	O
1.20	O	O
+/-	O	O
0.05	O	O
(	O	O
mumol.kg-1.min-1	O	O
,	O	O
mean	O	O
+/-	O	O
SE	O	O
)	O	O
;	O	O
basal	O	O
leucine	O	O
oxidation	O	O
(	O	O
LOX	O	O
)	O	O
was	O	O
0.25	O	O
+/-	O	O
0.01	O	O
;	O	O
and	O	O
basal	O	O
non-oxidative	O	O
leucine	O	O
disposal	O	O
(	O	O
NOLD	O	O
)	O	O
was	O	O
0.95	O	O
+/-	O	O
0.04	O	O
.	O	O

ELF	O	O
significantly	O	O
decreased	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.77	O	O
+/-	O	O
0.06	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

When	O	O
plasma	O	O
AA	O	O
and	O	O
branched-chain	O	O
KA	O	O
were	O	O
either	O	O
maintained	O	O
at	O	O
their	O	O
basal	O	O
levels	O	O
(	O	O
study	O	O
II	O	O
)	O	O
or	O	O
increased	O	O
above	O	O
baseline	O	O
values	O	O
(	O	O
studies	O	O
III	O	O
and	O	O
IV	O	O
)	O	O
,	O	O
ELF	O	O
declined	O	O
further	O	O
(	O	O
0.64	O	O
+/-	O	O
0.05	O	O
,	O	O
0.66	O	O
+/-	O	O
0.02	O	O
,	O	O
and	O	O
0.66	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
;	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
and	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
study	O	O
I	O	O
)	O	O
.	O	O

LOX	O	O
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.12	O	O
+/-	O	O
0.02	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
but	O	O
increased	O	O
significantly	O	O
in	O	O
studies	O	O
II	O	O
,	O	O
III	O	O
,	O	O
and	O	O
IV	O	O
(	O	O
0.31	O	O
+/-	O	O
0.04	O	O
,	O	O
0.37	O	O
+/-	O	O
0.03	O	O
,	O	O
and	O	O
0.40	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
,	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
IV	O	O
versus	O	O
study	O	O
II	O	O
,	O	O
and	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
III	O	O
versus	O	O
study	O	O
II	O	O
)	O	O
.	O	O

NOLD	O	O
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.65	O	O
+/-	O	O
0.05	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
,	O	O
whereas	O	O
neither	O	O
the	O	O
maintenance	O	O
of	O	O
basal	O	O
plasma	O	O
AA/branched-chain	O	O
KA	O	O
levels	O	O
(	O	O
study	O	O
II	O	O
;	O	O
0.89	O	O
+/-	O	O
0.2	O	O
mumol.kg-1.min-1	O	O
)	O	O
nor	O	O
the	O	O
elevation	O	O
of	O	O
plasma	O	O
branched-chain	O	O
KA	O	O
concentration	O	O
(	O	O
study	O	O
IV	O	O
;	O	O
0.96	O	O
+/-	O	O
0.1	O	O
mumol.kg-1.min-1	O	O
)	O	O
increased	O	O
NOLD	O	O
above	O	O
baseline	O	O
level	O	O
.	O	O

A	O	O
stimulation	O	O
of	O	O
NOLD	O	O
was	O	O
observed	O	O
only	O	O
when	O	O
plasma	O	O
AA	O	O
levels	O	O
were	O	O
increased	O	O
(	O	O
study	O	O
III	O	O
;	O	O
1.23	O	O
+/-	O	O
0.03	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
present	O	O
data	O	O
do	O	O
not	O	O
support	O	O
the	O	O
concept	O	O
of	O	O
a	O	O
direct	O	O
anabolic	O	O
action	O	O
of	O	O
ketoanalogs	O	O
but	O	O
do	O	O
provide	O	O
additional	O	O
evidence	O	O
for	O	O
the	O	O
pivotal	O	O
role	O	O
of	O	O
AA	O	O
availability	O	O
in	O	O
the	O	O
stimulation	O	O
of	O	O
whole-body	O	O
protein	O	O
synthesis	O	O
.	O	O

Effect	O	O
of	O	O
patient	O	O
withdrawal	O	O
on	O	O
a	O	O
study	O	O
evaluating	O	O
pharmacist	Other	O
management	Other	O
of	Other	O
hypertension	Other	O
.	O	O

STUDY	O	O
OBJECTIVES	O	O
To	O	O
examine	O	O
potential	O	O
threats	O	O
to	O	O
internal	O	O
and	O	O
external	O	O
study	O	O
validity	O	O
caused	O	O
by	O	O
differential	O	O
patient	O	O
withdrawal	O	O
from	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
evaluating	O	O
pharmacist	O	O
management	O	O
of	O	O
hypertension	O	O
,	O	O
to	O	O
compare	O	O
the	O	O
characteristics	O	O
of	O	O
patients	O	O
who	O	O
withdrew	O	O
with	O	O
those	O	O
of	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
study	O	O
,	O	O
and	O	O
to	O	O
identify	O	O
characteristics	O	O
that	O	O
predispose	O	O
patients	O	O
to	O	O
withdraw	O	O
from	O	O
hypertension	O	O
management	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
comparative	O	O
study	O	O
.	O	O

SETTING	O	O
Network	O	O
of	O	O
primary	O	O
care	O	O
clinics	O	O
.	O	O

PATIENTS	O	O
Four	O	O
hundred	O	O
sixty-three	O	O
patients	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
hypertension	O	O
and	O	O
a	O	O
last	O	O
documented	O	O
systolic	O	O
blood	O	O
pressure	O	O
of	O	O
160	O	O
mm	O	O
Hg	O	O
or	O	O
greater	O	O
and/or	O	O
diastolic	O	O
blood	O	O
pressure	O	O
of	O	O
100	O	O
mm	O	O
Hg	O	O
or	O	O
greater	O	O
.	O	O

INTERVENTION	O	O
Patients	O	O
were	O	O
randomly	O	Educational
allocated	O	Educational
to	O	Educational
the	O	Educational
pharmacist	Other	Educational
intervention	Other	Educational
or	O	O
usual-care	Control	O
(	Control	O
control	Control	O
)	Control	O
group	Other	O
.	O	O

Those	O	O
in	O	O
the	O	O
pharmacist	O	Educational
intervention	O	Educational
group	O	Educational
were	O	Educational
collaboratively	O	Educational
managed	Other	Educational
by	Other	Educational
a	Other	Educational
primary	Other	Educational
care	Other	Educational
clinical	Other	Educational
pharmacy	Other	Educational
specialist	Other	Educational
and	Other	O
their	Other	O
primary	Other	O
care	Other	O
provider	Other	O
.	O	O

Patients	O	O
in	O	O
the	O	O
control	O	O
group	O	O
received	O	O
usual	Control	Educational
care	Control	Educational
from	O	Educational
only	O	Educational
their	O	Educational
primary	Other	Educational
care	Other	Educational
provider	Other	Educational
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
Of	O	O
the	O	O
463	O	O
patients	O	O
,	O	O
191	O	O
(	O	O
41	O	O
%	O	O
)	O	O
withdrew	O	O
from	O	O
the	O	O
study	O	O
after	O	O
randomization	O	O
and	O	O
272	O	O
(	O	O
59	O	O
%	O	O
)	O	O
completed	O	O
the	O	O
study	O	O
.	O	O

Patients	O	O
who	O	O
withdrew	O	O
from	O	O
the	O	O
pharmacist	Other	O
intervention	Other	O
group	O	O
were	O	O
similar	O	O
to	O	O
patients	O	O
who	O	O
withdrew	O	O
from	O	O
the	O	O
usual-care	O	O
group	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
insurance	O	O
status	O	O
,	O	O
and	O	O
chronic	O	O
conditions	O	O
.	O	O

Patients	O	O
who	O	O
smoked	O	O
or	O	O
had	O	O
commercial	O	O
insurance	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
withdraw	O	O
from	O	O
the	O	O
study	O	O
than	O	O
the	O	O
other	O	O
participants	O	O
.	O	O

However	O	O
,	O	O
multivariate	O	O
analysis	O	O
of	O	O
all	O	O
variables	O	O
,	O	O
when	O	O
adjusted	O	O
for	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
intervention	O	O
,	O	O
revealed	O	O
that	O	O
insurance	O	O
status	O	O
was	O	O
the	O	O
only	O	O
variable	O	O
associated	O	O
with	O	O
a	O	O
heightened	O	O
probability	O	O
of	O	O
withdrawal	O	O
(	O	O
p=0.002	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Although	O	O
this	O	O
study	O	O
had	O	O
a	O	O
high	O	O
withdrawal	O	O
rate	O	O
,	O	O
between-group	O	O
patient	O	O
characteristics	O	O
remained	O	O
balanced	O	O
.	O	O

Therefore	O	O
,	O	O
internal	O	O
validity	O	O
was	O	O
preserved	O	O
,	O	O
and	O	O
outcomes	O	O
from	O	O
the	O	O
study	O	O
groups	O	O
could	O	O
be	O	O
reliably	O	O
compared	O	O
.	O	O

A	O	O
lack	O	O
of	O	O
significant	O	O
differences	O	O
between	O	O
patients	O	O
who	O	O
withdrew	O	O
versus	O	O
those	O	O
who	O	O
completed	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
insurance	O	O
status	O	O
,	O	O
suggests	O	O
that	O	O
external	O	O
validity	O	O
was	O	O
not	O	O
jeopardized	O	O
.	O	O

Effectiveness	O	O
and	O	O
safety	O	O
of	O	O
the	O	O
Levitan	Physical	O
FPS	Physical	O
Scope?	Physical	O
for	O	O
tracheal	O	O
intubation	O	O
under	O	O
general	O	O
anesthesia	O	O
with	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

PURPOSE	O	O
Studies	O	O
show	O	O
that	O	O
the	O	O
Levitan	Physical	O
FPS	Physical	O
(	Physical	O
first	Physical	O
pass	Physical	O
success	Physical	O
)	Physical	O
Scope?	Physical	O
(	Physical	O
LFS	Physical	O
)	Physical	O
is	O	O
analogous	O	O
to	O	O
a	O	O
bougie	O	O
in	O	O
simulated	O	O
difficult	O	O
airways	O	O
with	O	O
comparable	O	O
tracheal	O	O
intubation	O	O
success	O	O
rates	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
tracheal	O	O
intubation	O	O
with	O	O
the	O	O
LFS	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
the	O	O
Macintosh	O	O
laryngoscope	O	O
utilizing	O	O
manual	O	O
in-line	O	O
stabilization	O	O
(	O	O
MILS	O	O
)	O	O
to	O	O
simulate	O	O
difficult	O	O
airways	O	O
.	O	O

METHODS	O	O
Ninety-four	O	O
subjects	O	O
successfully	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Manual	O	O
in-line	O	O
stabilization	O	O
of	O	O
the	O	O
cervical	O	O
spine	O	O
was	O	O
applied	O	O
and	O	O
the	O	O
initial	O	O
laryngoscopy	O	O
was	O	O
performed	O	O
using	O	O
either	O	O
the	O	O
Macintosh	Physical	O
or	O	O
the	O	O
LFS	Physical	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	O	O
.	O	O

Following	O	O
the	O	O
initial	O	O
grading	O	O
,	O	O
a	O	O
second	O	O
laryngoscopy	O	O
was	O	O
repeated	O	O
using	O	O
the	O	O
second	O	O
randomized	O	O
technique	O	O
.	O	O

Cormack-Lehane	O	O
grades	O	O
,	O	O
percentage	O	O
of	O	O
glottic	O	O
opening	O	O
(	O	O
POGO	O	O
)	O	O
scores	O	O
,	O	O
time	O	O
to	O	O
intubate	O	O
,	O	O
number	O	O
of	O	O
intubation	O	O
attempts	O	O
,	O	O
and	O	O
the	O	O
use	O	O
of	O	O
alternate	O	O
techniques	O	O
were	O	O
recorded	O	O
.	O	O

The	O	O
anesthesiologist	O	O
rated	O	O
the	O	O
subjective	O	O
difficulty	O	O
in	O	O
using	O	O
each	O	O
technique	O	O
with	O	O
a	O	O
numeric	O	O
rating	O	O
scale	O	O
and	O	O
a	O	O
visual	O	O
rating	O	O
scale	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
outcome	O	O
good	O	O
laryngoscopic	O	O
views	O	O
(	O	O
Cormack-Lehane	O	O
grade	O	O
1	O	O
and	O	O
2	O	O
)	O	O
compared	O	O
with	O	O
poor	O	O
laryngoscopic	O	O
views	O	O
(	O	O
Cormack-Lehane	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
)	O	O
between	O	O
the	O	O
LFS	O	O
and	O	O
the	O	O
Macintosh	O	O
.	O	O

There	O	O
were	O	O
higher	O	O
POGO	O	O
scores	O	O
with	O	O
the	O	O
LFS	O	O
compared	O	O
with	O	O
the	O	O
Macintosh	O	O
(	O	O
80	O	O
%	O	O
vs	O	O
20	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
but	O	O
this	O	O
did	O	O
not	O	O
translate	O	O
to	O	O
easier	O	O
intubations	O	O
,	O	O
as	O	O
documented	O	O
by	O	O
the	O	O
need	O	O
for	O	O
an	O	O
alternate	O	O
intubation	O	O
technique	O	O
or	O	O
time	O	O
to	O	O
intubate	O	O
(	O	O
<	O	O
30	O	O
and	O	O
<	O	O
60	O	O
sec	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
mucosal	O	O
trauma	O	O
,	O	O
sore	O	O
throat	O	O
,	O	O
and	O	O
hemodynamic	O	O
responses	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
techniques	O	O
.	O	O

CONCLUSION	O	O
The	O	O
LFS	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	Physical	O
laryngoscope	O	O
does	O	O
not	O	O
improve	O	O
the	O	O
efficacy	O	O
or	O	O
safety	O	O
of	O	O
tracheal	O	O
intubation	O	O
in	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

Enhanced	Educational	O
small	Educational	O
group	Educational	O
instruction	Educational	O
using	Educational	O
choral	Educational	O
responding	Educational	O
and	Educational	O
student	Educational	O
interaction	Educational	O
for	O	O
children	O	O
with	O	O
autism	O	O
and	O	O
developmental	O	O
disabilities	O	O
.	O	O

The	O	O
use	O	O
of	O	O
effective	Educational	O
instructional	Educational	O
strategies	Educational	O
in	O	O
small	O	O
groups	O	O
was	O	O
investigated	O	O
to	O	O
determine	O	O
learning	O	O
effects	O	O
for	O	O
24	O	O
elementary	O	O
age	O	O
students	O	O
with	O	O
autism	O	O
and	O	O
developmental	O	O
disabilities	O	O
.	O	O

Effective	O	O
strategies	O	O
included	O	O
(	O	O
a	O	O
)	O	O
the	Educational	O
use	Educational	O
of	Educational	O
choral	Educational	O
responding	Educational	O
;	Educational	O
(	O	O
b	O	O
)	O	O
the	Educational	O
use	Educational	O
of	Educational	O
student-to-student	Educational	O
responding	Educational	O
;	Educational	O
(	O	O
c	O	O
)	O	O
the	Educational	O
rotation	Educational	O
of	Educational	O
materials	Educational	O
every	Educational	O
5	Educational	O
minutes	Educational	O
during	Educational	O
the	Educational	O
30-minute	Educational	Educational
group	Educational	Educational
while	Educational	Educational
teaching	Educational	Educational
2	Educational	Educational
to	Educational	Educational
3	Educational	Educational
concepts	Educational	Educational
;	Educational	O
and	Educational	O
(	O	O
d	O	O
)	O	O
the	Educational	O
use	Educational	O
of	Educational	O
random	Educational	O
,	Educational	O
unpredictable	Educational	O
trials	Educational	O
for	Educational	O
student	Educational	O
responding	Educational	O
.	Educational	O

Thirty-minute	O	Educational
language	O	Educational
groups	O	Educational
were	O	Educational
targeted	O	Educational
to	O	Educational
teach	O	Educational
receptive	O	Educational
and	O	Educational
expressive	O	Educational
skills	O	Educational
using	O	Educational
pictures	O	Educational
and	O	O
common	O	O
objects	O	O
across	O	O
five	O	O
categories	O	O
(	O	O
e.g.	O	O
,	O	O
household	O	O
items	O	O
,	O	O
foods	O	O
)	O	O
.	O	O

Results	O	O
showed	O	O
increased	O	O
opportunities	O	O
to	O	O
respond	O	O
,	O	O
increased	O	O
levels	O	O
of	O	O
responding	O	O
and	O	O
academic	O	O
engagement	O	O
,	O	O
higher	O	O
gains	O	O
on	O	O
weekly	O	O
criterion-referenced	O	O
pre-	O	O
and	O	O
posttests	O	O
,	O	O
and	O	O
decreased	O	O
passive	O	O
and	O	O
inappropriate	O	O
student	O	O
behavior	O	O
during	O	O
interventions	O	O
.	O	O

Immunological	O	O
changes	O	O
after	O	O
minimally	Surgical	O
invasive	Surgical	O
or	O	O
conventional	Surgical	O
esophageal	Surgical	O
resection	Surgical	O
for	O	O
cancer	O	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
This	O	O
study	O	O
was	O	O
performed	O	O
as	O	O
a	O	O
substudy	O	O
analysis	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
conventional	Surgical	Surgical
open	Surgical	Surgical
esophagectomy	Surgical	Surgical
[	O	Surgical
open	O	Surgical
surgical	O	Surgical
technique	O	Surgical
(	O	O
OE	O	O
)	O	O
]	O	O
by	O	O
thoracotomy	Surgical	O
and	O	O
laparotomy	Surgical	O
with	O	O
minimally	Surgical	Surgical
invasive	Surgical	Surgical
esophagectomy	Surgical	Surgical
[	O	Surgical
minimally	O	Surgical
invasive	O	Surgical
procedure	O	Surgical
(	O	O
MIE	O	O
)	O	O
]	O	O
by	O	O
thoracoscopy	Surgical	O
and	O	O
laparoscopy	Surgical	O
.	O	O

This	O	O
additional	O	O
analysis	O	O
focuses	O	O
on	O	O
the	O	O
immunological	O	O
changes	O	O
and	O	O
surgical	O	O
stress	O	O
response	O	O
in	O	O
these	O	O
two	O	O
randomized	O	O
groups	O	O
of	O	O
a	O	O
single	O	O
center	O	O
.	O	O

METHODS	O	O
Patients	O	O
with	O	O
a	O	O
resectable	O	O
esophageal	O	O
cancer	O	O
were	O	O
randomized	O	O
to	O	O
OE	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
or	O	O
MIE	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
neoadjuvant	Pharmacological	Pharmacological
chemoradiotherapy	Pharmacological	Pharmacological
.	Pharmacological	O

The	O	O
immunological	O	O
response	O	O
was	O	O
measured	O	O
by	O	O
means	O	O
of	O	O
leukocyte	O	O
counts	O	O
,	O	O
HLA-DR	O	O
expression	O	O
on	O	O
monocytes	O	O
,	O	O
the	O	O
acute-phase	O	O
response	O	O
by	O	O
means	O	O
of	O	O
C-reactive	O	O
protein	O	O
(	O	O
CRP	O	O
)	O	O
,	O	O
interleukin-6	O	O
(	O	O
IL-6	O	O
)	O	O
,	O	O
and	O	O
interleukin-8	O	O
(	O	O
IL-8	O	O
)	O	O
,	O	O
and	O	O
the	O	O
stress	O	O
response	O	O
was	O	O
measured	O	O
by	O	O
cortisol	O	O
,	O	O
growth	O	O
hormone	O	O
,	O	O
and	O	O
prolactin	O	O
.	O	O

All	O	O
parameters	O	O
were	O	O
determined	O	O
at	O	O
baseline	O	O
(	O	O
preoperatively	O	O
)	O	O
and	O	O
24	O	O
,	O	O
72	O	O
,	O	O
96	O	O
,	O	O
and	O	O
168	O	O
h	O	O
postoperatively	O	O
.	O	O

RESULTS	O	O
Significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
MIE	O	O
group	O	O
with	O	O
regard	O	O
to	O	O
leukocyte	O	O
counts	O	O
,	O	O
IL-8	O	O
,	O	O
and	O	O
prolactin	O	O
at	O	O
168	O	O
h	O	O
(	O	O
1	O	O
week	O	O
)	O	O
postoperatively	O	O
.	O	O

For	O	O
HLA-DR	O	O
expression	O	O
,	O	O
IL-6	O	O
,	O	O
and	O	O
CRP	O	O
levels	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
clear	O	O
rise	O	O
in	O	O
levels	O	O
upon	O	O
operation	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
substudy	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
minimally	O	Surgical
invasive	O	Surgical
and	O	O
conventional	O	Physical
open	O	Physical
esophagectomies	O	Physical
for	O	O
cancer	O	O
,	O	O
significantly	O	O
better	O	O
preserved	O	O
leukocyte	O	O
counts	O	O
and	O	O
IL-8	O	O
levels	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
open	O	O
group	O	O
.	O	O

Both	O	O
findings	O	O
can	O	O
be	O	O
related	O	O
to	O	O
fewer	O	O
respiratory	O	O
infections	O	O
found	O	O
postoperatively	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
.	O	O

Moreover	O	O
,	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
prolactin	O	O
levels	O	O
at	O	O
168	O	O
h	O	O
after	O	O
surgery	O	O
imply	O	O
that	O	O
the	O	O
stress	O	O
response	O	O
is	O	O
better	O	O
preserved	O	O
in	O	O
the	O	O
MIE	Surgical	O
group	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
less	O	O
surgical	O	O
trauma	O	O
could	O	O
lead	O	O
to	O	O
better	O	O
preserved	O	O
acute-phase	O	O
and	O	O
stress	O	O
responses	O	O
and	O	O
fewer	O	O
clinical	O	O
manifestations	O	O
of	O	O
respiratory	O	O
infections	O	O
.	O	O

Treatment	O	O
with	O	O
metformin	Pharmacological	O
of	O	O
non-diabetic	O	O
men	O	O
with	O	O
hypertension	O	O
,	O	O
hypertriglyceridaemia	O	O
and	O	O
central	O	O
fat	O	O
distribution	O	O
:	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
In	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
,	O	O
one	O	O
year	O	O
of	O	O
treatment	O	O
with	O	O
metformin	Pharmacological	Pharmacological
in	O	O
non-diabetic	O	O
obese	O	O
subjects	O	O
with	O	O
a	O	O
central	O	O
fat	O	O
distribution	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
fasting	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
or	O	O
on	O	O
blood	O	O
pressure	O	O
despite	O	O
a	O	O
decrease	O	O
in	O	O
weight	O	O
,	O	O
fasting	O	O
plasma	O	O
insulin	O	Pharmacological
and	O	O
glucose	O	O
concentrations	O	O
.	O	O

To	O	O
re-evaluate	O	O
the	O	O
effect	O	O
of	O	O
metformin	Pharmacological	Pharmacological
on	O	O
fasting	O	O
triglyceride	O	O
concentration	O	O
and	O	O
on	O	O
blood	O	O
pressure	O	O
,	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
included	O	O
non-diabetic	O	O
men	O	O
(	O	O
n=168	O	O
)	O	O
with	O	O
a	O	O
fasting	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
>	O	O
or	O	O
=1.7	O	O
and	O	O
<	O	O
or	O	O
=6.5	O	O
mmol/l	O	O
,	O	O
high	O	O
blood	O	O
pressure	O	O
(	O	O
systolic	O	O
>	O	O
or	O	O
=140	O	O
and	O	O
<	O	O
or	O	O
=180	O	O
and/or	O	O
diastolic	O	O
>	O	O
or	O	O
=90	O	O
and	O	O
<	O	O
or	O	O
=105	O	O
mmHg	O	O
,	O	O
or	O	O
treatment	O	O
for	O	O
hypertension	O	O
)	O	O
and	O	O
a	O	O
waist-to-hip	O	O
ratio	O	O
>	O	O
or	O	O
=0.95	O	O
.	O	O

METHODS	O	O
A	O	O
randomised	O	O
double-blind	O	O
trial	O	O
comparing	O	O
metformin	Pharmacological	Pharmacological
treatment	O	O
(	O	O
850	O	O
mg	O	O
bid	O	O
)	O	O
with	O	O
placebo	Control	Control
.	O	O

RESULTS	O	O
Metformin	Pharmacological	Pharmacological
had	O	O
no	O	O
significant	O	O
effect	O	O
either	O	O
on	O	O
blood	O	O
pressure	O	O
or	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
placebo	Control	O
group	O	O
,	O	O
fasting	O	O
plasma	O	O
insulin	O	O
(	O	O
p	O	O
<	O	O
0.04	O	O
)	O	O
,	O	O
total	O	O
cholesterol	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
and	O	O
Apo	O	O
B	O	O
(	O	O
p	O	O
<	O	O
0.008	O	O
)	O	O
concentrations	O	O
decreased	O	O
more	O	O
in	O	O
the	O	O
metformin	O	O
group	O	O
in	O	O
the	O	O
BIGPRO	O	O
1	O	O
.	O	O

2	O	O
trial	O	O
,	O	O
confirming	O	O
most	O	O
of	O	O
the	O	O
previous	O	O
results	O	O
of	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
.	O	O

Tissue	O	O
plasminogen	O	O
activator	O	O
antigen	O	O
concentration	O	O
decreased	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
only	O	O
in	O	O
the	O	O
metformin	Pharmacological	O
group	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
the	O	O
placebo	Control	Control
group	O	O
(	O	O
p	O	O
<	O	O
0.12	O	O
)	O	O
;	O	O
further	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
change	O	O
in	O	O
plasminogen	O	O
activator	O	O
inhibitor	O	O
1	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
consistency	O	O
of	O	O
the	O	O
two	O	O
BIGPRO	O	O
trials	O	O
supports	O	O
the	O	O
conclusion	O	O
that	O	O
metformin	Pharmacological	O
affects	O	O
several	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
favourably	O	O
in	O	O
non-diabetic	O	O
subjects	O	O
with	O	O
a	O	O
central	O	O
fat	O	O
distribution	O	O
.	O	O

Psychoeducational	Educational	O
group	Educational	O
intervention	Educational	O
for	O	O
wives	O	O
of	O	O
men	O	O
with	O	O
prostate	O	O
cancer	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
effects	O	O
of	O	O
a	O	O
6-week	O	Educational
psychoeducational	Educational	Educational
group	Educational	Educational
intervention	Educational	Educational
on	O	O
the	O	O
distress	O	O
,	O	O
coping	O	O
,	O	O
personal	O	O
growth	O	O
,	O	O
and	O	O
marital	O	O
communication	O	O
of	O	O
wives	O	O
of	O	O
men	O	O
diagnosed	O	O
with	O	O
prostate	O	O
cancer	O	O
were	O	O
evaluated	O	O
using	O	O
a	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

METHODS	O	O
Sixty	O	O
wives	O	O
completed	O	O
measures	O	O
prior	O	O
to	O	O
random	O	O
assignment	O	O
to	O	O
either	O	O
the	O	O
psychoeducational	Control	O
group	Control	O
intervention	Control	O
or	O	O
a	O	O
no-treatment	Control	Control
control	Control	Control
group	Control	O
,	O	O
and	O	O
1	O	O
month	O	O
after	O	O
completion	O	O
of	O	O
the	O	O
group	O	O
.	O	O

RESULTS	O	O
No	O	O
differences	O	O
with	O	O
regard	O	O
to	O	O
wives	O	O
'	O	O
general	O	O
distress	O	O
or	O	O
cancer-specific	O	O
distress	O	O
were	O	O
noted	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
participants	O	O
receiving	O	O
the	O	O
intervention	O	O
perceived	O	O
that	O	O
having	O	O
a	O	O
spouse	O	O
with	O	O
prostate	O	O
cancer	O	O
had	O	O
made	O	O
positive	O	O
contributions	O	O
to	O	O
their	O	O
lives	O	O
,	O	O
reported	O	O
gains	O	O
in	O	O
the	O	O
use	O	O
of	O	O
positive	O	O
reappraisal	O	O
coping	O	O
and	O	O
reductions	O	O
in	O	O
denial	O	O
coping	O	O
.	O	O

CONCLUSION	O	O
Although	O	O
the	O	O
psychoeducational	Educational	O
intervention	Educational	O
did	O	O
not	O	O
result	O	O
in	O	O
changes	O	O
in	O	O
psychological	O	O
distress	O	O
,	O	O
improvements	O	O
in	O	O
adaptive	O	O
coping	O	O
and	O	O
indicators	O	O
of	O	O
psychological	O	O
growth	O	O
were	O	O
found	O	O
.	O	O

The	O	O
utility	O	O
of	O	O
group	O	O
interventions	O	O
for	O	O
spouses	O	O
of	O	O
men	O	O
with	O	O
prostate	O	O
cancer	O	O
is	O	O
discussed	O	O
.	O	O

Clinically	O	O
relevant	O	O
improvement	O	O
of	O	O
recurrence-free	O	O
survival	O	O
with	O	O
5-aminolevulinic	Pharmacological	O
acid	Pharmacological	O
induced	O	O
fluorescence	O	O
diagnosis	O	O
in	O	O
patients	O	O
with	O	O
superficial	O	O
bladder	O	O
tumors	O	O
.	O	O

PURPOSES	O	O
Fluorescence	O	O
diagnosis	O	O
induced	O	O
by	O	O
5-aminolevulinic	Pharmacological	O
acid	Pharmacological	O
enables	O	O
more	O	O
thorough	O	O
transurethral	O	O
resection	O	O
of	O	O
superficial	O	O
bladder	O	O
carcinoma	O	O
compared	O	O
with	O	O
conventional	O	Physical
white	O	Physical
light	O	Physical
.	O	O

We	O	O
performed	O	O
a	O	O
prospective	O	O
,	O	O
single	O	O
institution	O	O
,	O	O
randomized	O	O
trial	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
and	O	O
long-term	O	O
tumor	O	O
recurrence	O	O
can	O	O
be	O	O
decreased	O	O
by	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
of	O	O
301	O	O
patients	O	O
underwent	O	O
transurethral	Surgical	Physical
resection	Surgical	Physical
of	O	Physical
bladder	O	Physical
tumors	O	Physical
with	O	Physical
white	O	Physical
light	O	Physical
or	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

Transurethral	Surgical	O
resection	Surgical	O
was	O	O
repeated	O	O
5	O	O
to	O	O
6	O	O
weeks	O	O
later	O	O
to	O	O
evaluate	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
.	O	O

To	O	O
determine	O	O
recurrence-free	O	O
survival	O	O
patient	O	O
followup	O	O
was	O	O
performed	O	O
every	O	O
3	O	O
months	O	O
by	O	O
white	O	Physical
light	O	Physical
cystoscopy	O	Physical
and	O	O
urine	O	O
cytology	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
was	O	O
analyzed	O	O
via	O	O
Kaplan-Meier	O	O
methods	O	O
and	O	O
multivariable	O	O
Cox	O	O
regression	O	O
analysis	O	O
.	O	O

RESULTS	O	O
A	O	O
total	O	O
of	O	O
191	O	O
patients	O	O
with	O	O
superficial	O	O
bladder	O	O
carcinoma	O	O
were	O	O
available	O	O
for	O	O
efficacy	O	O
analysis	O	O
.	O	O

The	O	O
residual	O	O
tumor	O	O
rate	O	O
was	O	O
25.2	O	O
%	O	O
in	O	O
the	O	O
white	O	O
light	O	O
arm	O	O
versus	O	O
4.5	O	O
%	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Median	O	O
followup	O	O
in	O	O
the	O	O
white	O	Physical
light	O	Physical
arm	O	O
in	O	O
103	O	O
cases	O	O
was	O	O
21.2	O	O
months	O	O
(	O	O
range	O	O
4	O	O
to	O	O
40	O	O
)	O	O
compared	O	O
with	O	O
20.5	O	O
(	O	O
range	O	O
3	O	O
to	O	O
40	O	O
)	O	O
in	O	O
the	O	O
88	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
group	O	O
was	O	O
89.6	O	O
%	O	O
after	O	O
12	O	O
and	O	O
24	O	O
months	O	O
compared	O	O
with	O	O
73.8	O	O
%	O	O
and	O	O
65.9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
white	O	O
light	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
.	O	O

This	O	O
superiority	O	O
proved	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
risk	O	O
group	O	O
.	O	O

The	O	O
adjusted	O	O
hazard	O	O
ratio	O	O
of	O	O
fluorescence	O	O
diagnosis	O	O
versus	O	O
white	O	Physical
light	O	Physical
transurethral	O	Physical
resection	O	Physical
was	O	O
0.33	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.16	O	O
to	O	O
0.67	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Fluorescence	O	O
diagnosis	O	O
is	O	O
significantly	O	O
superior	O	O
to	O	O
conventional	O	Physical
white	O	Physical
light	O	Physical
transurethral	O	Physical
resection	O	Physical
with	O	O
respect	O	O
to	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
and	O	O
recurrence-free	O	O
survival	O	O
.	O	O

The	O	O
differences	O	O
in	O	O
recurrence-free	O	O
survival	O	O
imply	O	O
that	O	O
fluorescence	O	O
diagnosis	O	O
is	O	O
a	O	O
clinically	O	O
relevant	O	O
procedure	O	O
for	O	O
decreasing	O	O
the	O	O
number	O	O
of	O	O
tumor	O	O
recurrences	O	O
.	O	O

The	O	O
relationship	O	O
between	O	O
repetitive	O	O
behaviors	O	O
and	O	O
growth	O	O
hormone	O	O
response	O	O
to	O	O
sumatriptan	Pharmacological	O
challenge	O	O
in	O	O
adult	O	O
autistic	O	O
disorder	O	O
.	O	O

Autism	O	O
is	O	O
heterogeneous	O	O
with	O	O
respect	O	O
to	O	O
clinical	O	O
symptoms	O	O
and	O	O
etiology	O	O
.	O	O

To	O	O
sort	O	O
out	O	O
this	O	O
heterogeneity	O	O
in	O	O
autism	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
specific	O	O
neurobiological	O	O
markers	O	O
vary	O	O
in	O	O
parallel	O	O
to	O	O
core	O	O
symptomatology	O	O
.	O	O

Specifically	O	O
,	O	O
we	O	O
assessed	O	O
growth	O	O
hormone	O	O
response	O	O
to	O	O
the	O	O
5-HT	Pharmacological	O
1d	Pharmacological	O
agonist	Pharmacological	O
,	Pharmacological	O
sumatriptan	Pharmacological	O
,	O	O
and	O	O
linked	O	O
this	O	O
measure	O	O
of	O	O
serotonergic	O	O
function	O	O
to	O	O
the	O	O
severity	O	O
of	O	O
repetitive	O	O
behaviors	O	O
in	O	O
adult	O	O
autistic	O	O
patients	O	O
.	O	O

Eleven	O	O
adult	O	O
patients	O	O
with	O	O
autism	O	O
or	O	O
Asperger	O	O
's	O	O
disorder	O	O
were	O	O
randomized	O	O
to	O	O
single	O	O
dose	O	O
sumatriptan	Pharmacological	O
(	O	O
6	O	O
mg	O	O
SQ	O	O
)	O	O
and	O	O
placebo	Control	Control
challenges	O	O
,	O	O
separated	O	O
by	O	O
a	O	O
one-week	O	O
interval	O	O
.	O	O

In	O	O
adult	O	O
autistic	O	O
disorders	O	O
,	O	O
severity	O	O
of	O	O
repetitive	O	O
behaviors	O	O
at	O	O
baseline	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
YBOCS-compulsion	O	O
score	O	O
,	O	O
significantly	O	O
positively	O	O
correlated	O	O
with	O	O
both	O	O
peak	O	O
delta	O	O
growth	O	O
hormone	O	O
response	O	O
and	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
growth	O	O
hormone	O	O
response	O	O
to	O	O
sumatriptan	Pharmacological	O
.	Pharmacological	O

Thus	O	O
,	O	O
the	O	O
severity	O	O
of	O	O
a	O	O
specific	O	O
behavioral	O	O
dimension	O	O
in	O	O
autism	O	O
(	O	O
repetitive	O	O
behaviors	O	O
)	O	O
parallels	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
5-HT	Pharmacological	O
1d	Pharmacological	O
receptor	Pharmacological	O
,	O	O
as	O	O
manifest	O	O
by	O	O
sumatriptan	Pharmacological	O
elicited	O	O
GH	O	O
response	O	O
.	O	O

Anxiety	O	O
sensitivity	O	O
as	O	O
an	O	O
incremental	O	O
predictor	O	O
of	O	O
later	O	O
anxiety	O	O
symptoms	O	O
and	O	O
syndromes	O	O
.	O	O

Although	O	O
anxiety	O	O
sensitivity	O	O
(	O	O
AS	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
predict	O	O
anxiety	O	O
symptoms	O	O
and	O	O
panic	O	O
,	O	O
this	O	O
literature	O	O
is	O	O
limited	O	O
in	O	O
regard	O	O
to	O	O
evaluating	O	O
AS	O	O
as	O	O
an	O	O
incremental	O	O
predictor	O	O
of	O	O
anxiety	Psychological	O
psychopathology	Psychological	O
relative	O	O
to	O	O
other	O	O
established	O	O
risk	O	O
factors	O	O
including	O	O
sex	O	O
and	O	O
negative	O	O
affect	O	O
.	O	O

The	O	O
present	O	O
report	O	O
prospectively	O	O
evaluated	O	O
whether	O	O
AS	O	O
was	O	O
predictive	O	O
of	O	O
later	O	O
changes	O	O
in	O	O
anxiety	O	O
symptoms	O	O
after	O	O
controlling	Other	O
for	Other	O
potential	Other	O
confounding	Other	O
factors	Other	O
.	Other	O

Consistent	O	O
with	O	O
hypothesis	O	O
,	O	O
AS	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
significant	O	O
,	O	O
incremental	O	O
predictor	O	O
of	O	O
anxiety	O	O
symptoms	O	O
over	O	O
time	O	O
,	O	O
even	O	O
after	O	O
controlling	O	O
for	O	O
sex	O	O
and	O	O
negative	O	O
affectivity	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
novel	O	O
evidence	O	O
for	O	O
the	O	O
unique	O	O
association	O	O
between	O	O
AS	O	O
of	O	O
the	O	O
development	O	O
of	O	O
anxiety	O	O
symptoms	O	O
.	O	O

A	O	O
double-blind	O	O
randomized	O	O
clinical	O	O
evaluation	O	O
of	O	O
enamel	Pharmacological	O
matrix	Pharmacological	O
derivative	Pharmacological	O
proteins	Pharmacological	O
for	O	O
the	O	O
treatment	O	O
of	O	O
proximal	O	O
class-II	O	O
furcation	O	O
involvements	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
randomized	O	O
,	O	O
double-blind	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	O	O
response	O	O
of	O	O
proximal	O	O
furcations	O	O
treated	O	O
with	O	O
enamel	Pharmacological	O
matrix	Pharmacological	O
derivative	Pharmacological	O
proteins	Pharmacological	O
(	Pharmacological	O
EMD	Pharmacological	O
)	Pharmacological	O
.	Pharmacological	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
Fifteen	O	O
patients	O	O
,	O	O
each	O	O
with	O	O
a	O	O
pair	O	O
of	O	O
contralateral	O	O
class-II	O	O
proximal	O	O
furcation	O	O
involvements	O	O
,	O	O
presenting	O	O
probing	O	O
depths	O	O
(	O	O
PDs	O	O
)	O	O
>	O	O
/=5	O	O
mm	O	O
and	O	O
bleeding	O	O
on	O	O
probing	O	O
(	O	O
BOP	O	O
)	O	O
were	O	O
selected	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
:	O	O
control	Control	Control
group	Control	O
(	O	O
n=15	O	O
)	O	O
-	O	O
open	Control	O
flap	Control	O
debridement	Control	O
(	Control	O
OFD	Control	O
)	Control	O
+24	Control	O
%	Control	O
ethylenediaminetetraacetic	Control	O
acid	Control	O
(	Control	O
EDTA	Control	O
)	Control	O
conditioning	Control	O
;	Pharmacological	O
test	O	O
group	O	O
(	O	O
n=15	O	O
)	O	O
-	O	O
OFD+24	Pharmacological	O
%	Pharmacological	O
EDTA	Pharmacological	O
conditioning+EMD	Pharmacological	O
application	Pharmacological	O
.	Pharmacological	O

Plaque	O	O
index	O	O
(	O	O
PI	O	O
)	O	O
,	O	O
BOP	O	O
,	O	O
PD	O	O
,	O	O
gingival	O	O
margin	O	O
position	O	O
(	O	O
GMP	O	O
)	O	O
,	O	O
relative	O	O
vertical	O	O
and	O	O
horizontal	O	O
clinical	O	O
attachment	O	O
level	O	O
(	O	O
RVCAL	O	O
and	O	O
RHCAL	O	O
)	O	O
,	O	O
vertical	O	O
and	O	O
horizontal	O	O
bone	O	O
level	O	O
(	O	O
VBL	O	O
and	O	O
HBL	O	O
)	O	O
and	O	O
furcation	O	O
closure	O	O
were	O	O
evaluated	O	O
immediately	O	O
before	O	O
and	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
months	O	O
after	O	O
the	O	O
surgeries	O	O
.	O	O

RESULTS	O	O
At	O	O
6	O	O
months	O	O
,	O	O
the	O	O
RVCAL	O	O
gains	O	O
of	O	O
the	O	O
control	O	O
and	O	O
test	O	O
group	O	O
were	O	O
0.39	O	O
+/-	O	O
1.00	O	O
and	O	O
0.54	O	O
+/-	O	O
0.95	O	O
mm	O	O
,	O	O
while	O	O
the	O	O
RHCAL	O	O
gains	O	O
were	O	O
1.21	O	O
+/-	O	O
2.28	O	O
and	O	O
1.36	O	O
+/-	O	O
1.26	O	O
mm	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
VBL	O	O
and	O	O
HBL	O	O
gains	O	O
of	O	O
the	O	O
control	O	O
group	O	O
were	O	O
1.04	O	O
+/-	O	O
1.12	O	O
and	O	O
1.00	O	O
+/-	O	O
1.79	O	O
mm	O	O
,	O	O
and	O	O
0.82	O	O
+/-	O	O
1.82	O	O
and	O	O
1.17	O	O
+/-	O	O
1.38	O	O
mm	O	O
for	O	O
the	O	O
test	O	O
group	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
statistical	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
number	O	O
of	O	O
the	O	O
remaining	O	O
class-II	O	O
furcations	O	O
between	O	O
the	O	O
test	O	O
and	O	O
control	O	O
groups	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
in	O	O
this	O	O
period	O	O
.	O	O

CONCLUSION	O	O
It	O	O
may	O	O
be	O	O
concluded	O	O
that	O	O
the	O	O
use	O	O
of	O	O
EMD	Pharmacological	O
in	O	O
proximal	O	O
furcations	O	O
did	O	O
not	O	O
promote	O	O
a	O	O
superior	O	O
reduction	O	O
in	O	O
PD	O	O
or	O	O
a	O	O
gain	O	O
in	O	O
clinical	O	O
and	O	O
osseous	O	O
attachment	O	O
levels	O	O
,	O	O
but	O	O
resulted	O	O
in	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
class-II	O	O
to	O	O
class-I	O	O
furcation	O	O
conversion	O	O
.	O	O

Psychosocial	Psychological	O
nursing	Psychological	O
therapy	Psychological	O
following	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
:	O	O
impact	O	O
on	O	O
two-year	O	O
survival	O	O
.	O	O

BACKGROUND	O	O
Although	O	O
psychosocial	Psychological	O
therapy	Psychological	O
has	O	O
been	O	O
shown	O	O
to	O	O
reduce	O	O
mortality	O	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
it	O	O
is	O	O
unknown	O	O
whether	O	O
the	O	O
benefits	O	O
of	O	O
psychosocial	Psychological	O
therapy	Psychological	O
on	O	O
mortality	O	O
reduction	O	O
extend	O	O
to	O	O
out-of-hospital	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
,	O	O
a	O	O
main	O	O
cause	O	O
of	O	O
cardiovascular	O	O
mortality	O	O
.	O	O

OBJECTIVE	O	O
Describe	O	O
efficacy	O	O
of	O	O
psychosocial	Psychological	O
therapy	Psychological	O
on	O	O
two-year	O	O
cardiovascular	O	O
mortality	O	O
in	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
survivors	O	O
.	O	O

METHOD	O	O
Survivors	O	O
of	O	O
out-of-hospital	O	O
ventricular	O	O
fibrillation	O	O
or	O	O
asystole	O	O
(	O	O
N	O	O
=	O	O
129	O	O
)	O	O
,	O	O
documented	O	O
by	O	O
electrocardiograms	O	O
from	O	O
registries	O	O
of	O	O
a	O	O
citywide	O	O
Medic	O	O
One	O	O
unit	O	O
and	O	O
two	O	O
countywide	O	O
emergency	O	O
units	O	O
,	O	O
were	O	O
randomized	O	O
into	O	O
a	O	O
two	O	O
group	O	O
,	O	O
experimental	O	O
,	O	O
longitudinal	O	O
design	O	O
.	O	O

The	O	O
intervention	O	O
consisted	O	O
of	O	O
11	O	O
individual	O	O
sessions	O	O
,	O	O
implementing	O	O
three	O	O
components	O	O
:	O	O
physiologic	O	Physical
relaxation	O	Physical
with	O	Physical
biofeedback	O	Physical
training	O	Physical
focused	O	Physical
on	O	O
altering	O	O
autonomic	O	O
tone	O	O
;	O	O
cognitive	Psychological	O
behavioral	Psychological	O
therapy	Psychological	O
aimed	O	O
at	O	O
self-management	O	O
and	O	O
coping	O	O
strategies	O	O
for	O	O
depression	O	O
,	O	O
anxiety	O	O
,	O	O
and	O	O
anger	O	O
;	O	O
and	O	O
cardiovascular	O	O
health	O	O
education	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
measure	O	O
was	O	O
cardiovascular	O	O
mortality	O	O
.	O	O

RESULTS	O	O
Risk	O	O
of	O	O
cardiovascular	O	O
death	O	O
was	O	O
significantly	O	O
reduced	O	O
86	O	O
%	O	O
by	O	O
psychosocial	O	O
therapy	O	O
,	O	O
p	O	O
=	O	O
.03	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
seven	O	O
cardiovascular	O	O
deaths	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
caused	O	O
by	O	O
ventricular	O	O
arrhythmias	O	O
.	O	O

The	O	O
cardiovascular	O	O
death	O	O
in	O	O
the	O	O
therapy	O	O
group	O	O
was	O	O
due	O	O
to	O	O
stroke	O	O
.	O	O

Controlling	O	O
for	O	O
depression	O	O
,	O	O
previous	O	O
myocardial	O	O
infarction	O	O
,	O	O
low	O	O
ejection	O	O
fraction	O	O
,	O	O
decreased	O	O
heart	O	O
rate	O	O
variability	O	O
,	O	O
and	O	O
ventricular	O	O
ectopic	O	O
beats	O	O
had	O	O
little	O	O
impact	O	O
on	O	O
estimated	O	O
treatment	O	O
effect	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
all-cause	O	O
mortality	O	O
was	O	O
reduced	O	O
by	O	O
62	O	O
%	O	O
in	O	O
the	O	O
therapy	O	O
group	O	O
,	O	O
p	O	O
=	O	O
.13	O	O
.	O	O

There	O	O
were	O	O
a	O	O
total	O	O
of	O	O
three	O	O
deaths	O	O
in	O	O
the	O	O
therapy	O	O
group	O	O
and	O	O
eight	O	O
deaths	O	O
in	O	O
the	O	O
control	Control	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Psychosocial	Psychological	O
therapy	Psychological	O
significantly	O	O
reduced	O	O
the	O	O
risk	O	O
of	O	O
cardiovascular	O	O
death	O	O
in	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
survivors	O	O
.	O	O

